<SEC-DOCUMENT>0001213900-25-029464.txt : 20250407
<SEC-HEADER>0001213900-25-029464.hdr.sgml : 20250407
<ACCEPTANCE-DATETIME>20250407165810
ACCESSION NUMBER:		0001213900-25-029464
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		98
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250407
DATE AS OF CHANGE:		20250407

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroSense Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001875091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41084
		FILM NUMBER:		25818843

	BUSINESS ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
		BUSINESS PHONE:		972-9-9531142

	MAIL ADDRESS:	
		STREET 1:		11 HAMENOFIM ST.
		STREET 2:		BUILDING B
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4672562
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>ea0237295-20f_neuro.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 07 20:27:38 UTC 2025 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nrsn="http://www.neurosensetx.com/20241231" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-18771">20-F</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentRegistrationStatement" id="ixv-18772">&#9744;</ix:nonNumeric> REGISTRATION STATEMENT PURSUANT TO SECTION
12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="ixv-18773">&#9746;</ix:nonNumeric> ANNUAL REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-18774"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-18775">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-18776">2024</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="ixv-18777">&#9744;</ix:nonNumeric> TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentShellCompanyReport" id="ixv-18778">&#9744;</ix:nonNumeric> SHELL COMPANY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from ____________ to
____________</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-80"><b>001-41084</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission file number)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-88"><b>NeuroSense Therapeutics Ltd.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of Registrant as specified in its charter)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of Registrant&#8217;s name into English)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-103"><b>Israel</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Jurisdiction of incorporation or organization)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-18779">11 HaMenofim Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-18780">Building B</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-18781">Herzliya</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-18782">4672562</ix:nonNumeric> <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-18783">Israel</ix:nonNumeric><br/>
+972-9-7996183</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
<ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-18784">Or Eisenberg</ix:nonNumeric>, Chief Financial Officer<br/>
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-18785">11 HaMenofim Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2" id="ixv-18786">Building B</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-18787">Herzliya</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-18788">4672562</ix:nonNumeric> <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-18789">Israel</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-18790">+972</ix:nonNumeric>-<ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-18791">9-7996183</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, telephone, e-mail and/or facsimile number
and address of company contact person)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(b) of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td> <td style="width: 2%; text-align: center">&#160;</td> <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: center"><ix:nonNumeric contextRef="c2" name="dei:Security12bTitle" id="ixv-150"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares, no par value per share</span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c2" name="dei:TradingSymbol" id="ixv-154"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NRSN</span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c2" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-18792">Nasdaq</ix:nonNumeric> Capital Market</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><ix:nonNumeric contextRef="c3" name="dei:Security12bTitle" id="ixv-161"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants, exercisable for one ordinary share</span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c3" name="dei:TradingSymbol" id="ixv-165"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NRSNW</span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c3" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-18793">Nasdaq</ix:nonNumeric> Capital Market</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(g) of the Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-decoration:underline">None</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Title of Class)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities for which there is a reporting obligation
pursuant to Section 15(d) of the Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-decoration:underline">None</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Title of Class)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate the number of outstanding
shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report: <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-18794">23,228,941</ix:nonFraction>
ordinary shares, no par value</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark if
the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-18795">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this report is an annual
or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-18796">No</ix:nonNumeric> &#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Note &#8212; Checking the
box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
from their obligations under those Sections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-18797">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160;&#160;No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation
S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
and post such files).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-18798">Yes</ix:nonNumeric> &#9746;&#160;&#160;&#160;&#160;No &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions
of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of
the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 30%; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td style="padding-left: 0.25in"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-263"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-270"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an emerging growth company
that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the
extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a)
of the Exchange Act.&#160;<ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="ixv-18799">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that
prepared or issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="ixv-18800">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If securities are registered
pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing
reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-18801">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
any of those error corrections are restatements that required a recovery analysis of incentive based compensation received by any of the
registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check mark which
basis of accounting the registrant has used to prepare the financial statements included in this filing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 20%; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:DocumentAccountingStandard" id="ixv-18802">U.S. GAAP</ix:nonNumeric> &#9746;</span></td> <td style="width: 1%">&#160;</td> <td style="width: 63%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International Financial Reporting Standards as issued by the <br/>
International Accounting Standards Board &#9744;</span></td> <td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other &#9744;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If &#8220;Other&#8221; has
been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to
follow. N/A</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Item 17 &#9744;&#160;&#160;&#160;&#160;Item 18
&#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this is an annual report,
indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes &#9744;&#160;&#160;&#160;&#160;No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-18803">&#9746;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 90%"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1. Identity of Directors, Senior Management and Advisers</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center">1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2. Offer Statistics and Expected Timetable</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3. Key Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_033"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4. Information on the Company</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">46</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4A. Unresolved Staff Comments</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5. Operating and Financial Review and Prospects</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6. Directors, Senior Management and Employees</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">82</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7. Major Shareholders and Related Party Transactions</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8. Financial Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9. The Offer and Listing</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10. Additional Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11. Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">127</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12. Description of Securities Other than Equity Securities</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">128</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13. Defaults, Dividend Arrearages and Delinquencies</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">129</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">130</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15. Controls and Procedures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">130</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16. [Reserved]</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">131</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16A. Audit Committee Financial Expert</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">131</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16B. Code of Ethics</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">131</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16C. Principal Accountant Fees and Services</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">131</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16D. Exemptions from the Listing Standards for Audit Committees</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">132</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">132</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16F. Change in Registrant&#8217;s Certifying Accountant</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">132</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16G. Corporate Governance</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">132</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16H. Mine Safety Disclosure</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16I Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16J. Insider Trading Policies</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">133</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16K. Cybersecurity</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART III</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 17. Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">134</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 18. Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">134</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 19. Exhibits</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">134</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signatures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">136</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Index to Consolidated Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">F-1</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>References
to NeuroSense</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise indicated
or the context otherwise requires, all references in this annual report to the terms &#8220;NeuroSense,&#8221; &#8220;NeuroSense Therapeutics,&#8221;
the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to NeuroSense Therapeutics Ltd. In this annual
report, any reference to any provision of any legislation shall include any amendment, modification, re-enactment or extension thereof.
Words importing the singular shall include the plural and vice versa, and words importing the masculine gender shall include the feminine
or neutral gender.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>PRESENTATION
OF FINANCIAL INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The term &#8220;NIS&#8221;
refers to New Israeli Shekels, the lawful currency of the State of Israel, and the terms &#8220;dollar&#8221; or &#8220;$&#8221; refer
to U.S. dollars, the lawful currency of the United States. Unless derived from our financial statements or otherwise indicated, U.S. dollar
translations of NIS amounts presented in this annual report are translated using the rate of NIS 3.6470 to $1.00, based on the representative
exchange rate reported by the Bank of Israel on December 31, 2024. On June 17, 2024, we changed our accounting method from International
Financial Reporting Standards, as issued by the International Accounting Standards Board, to generally accepted accounting principles
in the United States of America, or U.S. GAAP, as of January 1, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TRADEMARKS, <span style="text-transform: uppercase">SERVICE</span>
MARKS AND TRADENAMES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The NeuroSense Therapeutics
logo and other trademarks and service marks of NeuroSense Therapeutics appearing in this annual report are the property of the Company.
Solely for convenience, some of the trademarks, service marks, logos and trade names referred to in this annual report are presented without
the <sup>&#174;</sup> and <sup>&#8482;</sup> symbols, but such references are not intended to indicate, in any way, that we will not assert,
to the fullest extent under applicable law, our rights to these trademarks, service marks and trade names. This annual report contains
additional trademarks, service marks and trade names of others. All trademarks, service marks and trade names appearing in this annual
report are, to our knowledge, the property of their respective owners. We do not intend our use or display of other companies&#8217; trademarks,
service marks, copyrights or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MARKET AND INDUSTRY DATA</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This annual report contains
industry, market and competitive position data that are based on industry publications and studies conducted by third parties as well
as our own internal estimates and research. These industry publications and third-party studies generally state that the information that
they contain has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such
information. While we believe that each of these publications and third-party studies is reliable, we have not independently verified
the market and industry data obtained from these third-party sources. Forecasts and other forward-looking information obtained from these
sources are subject to the same qualifications and uncertainties as the other forward-looking statements in this annual report. These
forecasts and forward-looking information are subject to uncertainty and risk due to a variety of factors, including those described under
&#8220;Risk Factors.&#8221; These and other factors could cause results to differ materially from those expressed in our forecasts or
estimates or those of independent third parties. While we believe our internal research is reliable and the definition of our market and
industry are appropriate, neither such research nor these definitions have been verified by any independent source.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This annual report
contains forward-looking statements concerning among other things, our ongoing and planned product development and clinical trials;
the timing of, and our ability to make, regulatory filings and obtain and maintain regulatory approvals for our product candidates;
our ability to enter into and maintain strategic collaborations, our intellectual property position; our results of operations, cash
needs; financial condition, liquidity, prospects, growth and strategies; the industry in which we operate; and the trends that may
affect the industry or us. Many of the forward-looking statements contained in this annual report can be identified by the use of
forward-looking words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221;
&#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221;
&#8220;should,&#8221; &#8220;target,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate
future events and future trends, although not all forward-looking statements contain these identifying words.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Forward-looking statements
are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. Such statements
are subject to substantial risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking
statements due to a variety of factors, including, but not limited to, those identified under the section titled &#8220;Risk Factors&#8221;
in this annual report. These risks and uncertainties include factors relating to:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
going concern reference in our financial statements and our need for substantial additional financing to achieve our goals;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
limited operating history and history of incurring significant losses and negative cash flows since our inception, which we anticipate
will continue for the foreseeable future;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
dependence on the success of our lead product candidate, PrimeC, including our obtaining of regulatory approval to market PrimeC in the
United States;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
limited experience in conducting clinical trials and reliance on clinical research organizations and others to conduct them;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to advance our preclinical product candidates into clinical development and through regulatory approval;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
results of our clinical trials, which may fail to adequately demonstrate the safety and efficacy of our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to achieve the broad degree of physician adoption and use and market acceptance necessary for commercial success;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
reliance on third parties in marketing, producing or distributing products and research materials for certain raw materials, compounds
and components necessary to produce PrimeC for clinical trials and to support commercial scale production of PrimeC, if approved;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
receipt of regulatory clarity and approvals for our therapeutic candidates and the timing of other regulatory filings and approvals;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">estimates
of our expenses, revenues, capital requirements and our needs for additional financing;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
efforts to obtain, protect or enforce our patents and other intellectual property rights related to our product candidates and technologies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
impact of the public health, political and security situation in Israel, the U.S. and other countries in which we may obtain approvals
for our products or our business;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify">our ability to maintain the listing of our ordinary shares on Nasdaq;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
impacts on our ongoing and planned trials and manufacturing as a result of the war in Israel; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">those
factors referred to in &#8220;Item 3.D. Risk Factors,&#8221; &#8220;Item 4. Information on the Company,&#8221; and &#8220;Item 5. Operating
and Financial Review and Prospects&#8221;, as well as in this annual report on Form 20-F generally.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The preceding list is not
intended to be an exhaustive list of all of our risks and uncertainties. As a result of these factors, we cannot assure you that the forward-looking
statements in this annual report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the
inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these
statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time
frame, or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, statements that
&#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon
information available to us as of the date of this annual report, and while we believe such information forms a reasonable basis for such
statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an
exhaustive inquiry into, or review of, all relevant information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The forward-looking statements
and opinions contained in this annual report are based upon information available to us as of the date of this annual report and, while
we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements
should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information.
The forward-looking statements contained in this annual report speak only as of the date of this annual report, and unless otherwise required
by law, we do not undertake any obligation to update them in light of new information or future developments or to release publicly any
revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You should read this annual
report, the documents that we reference herein and the documents that we have filed as exhibits hereto, completely and with the understanding
that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these
cautionary statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT
AND ADVISERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 3. KEY INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Selected Financial Data </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Reserved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Capitalization and Indebtedness</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C</b>. <b>Reasons for the Offer and Use of
Proceeds</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Risk Factors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Investing in our
securities, involves a high degree of risk. You should carefully consider the risks and uncertainties described below, in addition
to the other information set forth in this annual report, including the financial statements and the related notes beginning on page
F-1 of this annual report, before purchasing our securities. If any of the following risks actually occurs, our business, financial
condition, results of operations and prospects could be materially and adversely affected and, as a result, the market price of our
ordinary shares and our publicly traded warrants, or Warrants, could decline and you could lose all or part of your investment.
Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially
adversely affect our business, financial condition and results of operations.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Summary of Risk Factors </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following is a summary
of certain important factors that may make an investment in our Company speculative or risky. You should carefully consider the full risk
factor disclosure set forth below, in addition to the other information herein, including the section of this report titled &#8220;Operating
and Financial Review and Prospects&#8221; and our financial statements and related notes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements include a going concern reference. We will require substantial additional financing to achieve our goals, and a
failure to obtain this capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our
product development, commercialization efforts or other operations.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have a limited operating history and have incurred significant losses and negative cash flows since our inception, and we anticipate that we will continue to incur significant losses and negative cash flows for the foreseeable future, which makes it difficult to assess our future viability.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raising additional capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are dependent on the success of our lead product candidate, PrimeC, including obtaining regulatory approval to market PrimeC in the United States.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be unable to obtain regulatory approval for our product candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To date, we have only generated limited clinical data for our product candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have limited experience in conducting clinical trials and have never obtained approval for any product candidates, and may be unable to do so successfully.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not applied for regulatory approvals to market any of our other product candidates, and we may be delayed in obtaining or failing to obtain such regulatory approvals and to commercialize our product candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to advance our preclinical product candidates into clinical development and through regulatory approval and commercialization.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, results of earlier studies and trials may not be predictive of future trial results, and our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PrimeC or any of our other product candidates may produce undesirable side effects that we may not have detected in our previous preclinical studies and clinical trials. This could prevent us from gaining marketing approval or market acceptance for these product candidates, or from maintaining such approval and acceptance, and could substantially increase commercialization costs and even force us to cease operations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates, if approved, will face significant competition with competing technologies and our failure to compete effectively may prevent us from achieving significant market penetration.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may enter into collaborations with third parties for the development or commercialization of our product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to manage our growth effectively, our business could be disrupted.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize any of the products we develop.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our product candidates and technologies are not adequate, we may not be able to compete effectively in our market and we otherwise may be harmed.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be subject to claims that we infringe, misappropriate or otherwise violate the intellectual property rights of third parties.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may receive only limited protection, or no protection, from our issued patents and patent applications.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to protect our intellectual property rights throughout the world.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive and time consuming, delay or prevent the development and commercialization of our products and product candidates or put our patents and other proprietary rights at risk.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An active, liquid and orderly trading market for our ordinary shares or Warrants may not develop, which may inhibit the ability of our shareholders to sell ordinary shares and Warrants.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market price of our ordinary shares and Warrants may be subject to fluctuation and you could lose all or part of your investment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our ordinary shares and Warrants, the price of our ordinary shares and Warrants could decline.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future sales of our ordinary shares could reduce the market price of our ordinary shares and Warrants.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The significant share ownership position of our officers, directors and entities affiliated with certain of our directors may limit your ability to influence corporate matters.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have never paid cash dividends on our share capital, and we do not anticipate paying any cash dividends in the foreseeable future.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions of Israeli law and our amended and restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, us, even when the terms of such a transaction are favorable to us and our shareholders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your rights and responsibilities as a shareholder will be governed by Israeli law, which differs in some material respects from the rights and responsibilities of shareholders of U.S. companies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Limited Operating History,
Financial Condition and Capital Requirements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our financial statements include a going
concern reference. We will require substantial additional financing to achieve our goals, and a failure to obtain this capital when needed
and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, commercialization efforts
or other operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since our inception, almost
all of our resources have been dedicated to the preclinical and clinical development of our lead product candidate, PrimeC. As of December&#160;31,
2024, we had cash, cash equivalents of $3.4 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our financial statements
have been prepared on a going concern basis under which an entity is considered to be able to realize its assets and satisfy its liabilities
in the ordinary course of business, and our financial status creates a doubt whether we will continue as a going concern. Our future operations
are dependent upon the identification and successful completion of equity or debt financing and the achievement of profitable operations
at an indeterminate time in the future. There can be no assurances that we will be successful in completing an equity or debt financing
or in achieving or maintaining profitability. The financial statements do not give effect to any adjustments relating to the carrying
values and classification of assets and liabilities that would be necessary should we be unable to&#160;continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will require additional
capital to complete clinical trials and to obtain regulatory approval for, and commercialize, our product candidates. In addition, our
operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned,
through public or private equity, convertible debt or debt financings, third-party&#160;funding, marketing and distribution arrangements,
as well as other collaborations, strategic alliances and licensing arrangements, or a combination of these approaches. In any event, we
will require additional capital to pursue preclinical and clinical activities, and pursue regulatory approval for, and to commercialize,
our pipeline product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any additional fundraising
efforts may divert the attention of our management from day-to-day&#160;activities, which may adversely affect our ability to develop
and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts
or on terms acceptable to us, if at all. Moreover, the terms of any financing may negatively impact the holdings or the rights of our
shareholders, and the issuance of additional securities, whether equity or debt, by us or the possibility of such issuance may cause the
market price of our ordinary shares and Warrants to decline. The incurrence of indebtedness could result in increased fixed payment obligations
and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations
on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our
ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise
at an earlier stage than would be desirable and we may be required to relinquish rights to some of our technologies, intellectual property
or product candidates or otherwise agree to terms unfavorable to us, any of which may harm our business, financial condition, operating
results and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If adequate funds are not
available to us on a timely basis, we may be required or choose to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for our product candidates or any of our future product candidates or otherwise terminate our operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay, limit, reduce or terminate our other research and development activities; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay, limit, reduce or terminate our establishment or expansion of manufacturing, sales and marketing or distribution capabilities or other activities that may be necessary to commercialize PrimeC or any of our other product candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may also be unable to
expand our operations or otherwise capitalize on our business opportunities, as desired, which could harm our business, financial condition
and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have a limited operating history and
have incurred significant losses and negative cash flows since our inception, and we anticipate that we will continue to incur significant
losses and negative cash flows for the foreseeable future, which makes it difficult to assess our future viability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a clinical-stage&#160;drug
development company with a limited operating history upon which you can evaluate our business and prospects. We are not profitable and
have incurred net losses in each period since we commenced operations in February 2017, including net losses of $10.2 million and $10.1&#160;million
for the years ended December&#160;31, 2024 and 2023, respectively. We expect to continue to incur significant expenses and increasing
operating losses for the foreseeable future. Our ability to ultimately achieve recurring revenues and profitability is dependent upon
our ability to successfully complete the development of our product candidates, obtain necessary regulatory approvals for and successfully
manufacture, market and commercialize our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe that we will continue
to expend substantial resources in the foreseeable future for the clinical development of our current product candidates or any additional
product candidates and indications that we may choose to pursue in the future. These expenditures will include costs associated with research
and development, conducting preclinical studies and clinical trials, and payments for third-party&#160;manufacturing and supply, as well
as sales and marketing of any of our product candidates that are approved for sale by regulatory agencies. Because the outcome of any
clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development
and commercialization of our clinical stage and preclinical drug candidates and any other drug candidates that we may develop in the future.
Other unanticipated costs may also arise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our future capital requirements
depend on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing of, and the costs involved in, clinical development and obtaining regulatory approvals for our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in regulatory requirements during the development phase that can delay or force us to stop our activities related to any of our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of commercialization activities if our products are approved for sale, including marketing, sales and distribution costs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of third-party&#160;manufacturing of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number and characteristics of any other product candidates we develop or acquire;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish and maintain strategic collaborations, licensing or other commercialization arrangements, and the terms and timing of such arrangements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent and rate of market acceptance of any approved products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the expenses needed to attract and retain skilled personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs associated with being a public company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including potential litigation costs and the outcome of such litigation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing, receipt and amount of sales of, or royalties on, future approved products, if any;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any product liability or other lawsuits related to our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">scientific breakthroughs in the field of treatment for neurodegenerative diseases that could significantly diminish the need for our product candidates or make them obsolete; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in reimbursement policies that could have a negative impact on our future revenue stream.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, we have limited
experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered
by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Drug development is a highly speculative
undertaking and involves a substantial degree of risk. To date, we have not obtained any regulatory approvals for any of our product candidates,
commercialized any of our product candidates or generated any material revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Raising additional capital may cause dilution
to our shareholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Until such time, if ever,
as we can generate substantial product revenues, we expect to finance our cash needs through equity, convertible debt or debt financings,
as well as selectively continuing to enter into collaborations, strategic alliances and licensing arrangements. We do not currently have
any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt
securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that
adversely affect your rights as an ordinary shareholder. Debt financing, if available, may involve agreements that include covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring and distributing
dividends, and may be secured by all or a portion of our assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we raise funds by entering
into collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish additional valuable rights
to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable
to us. If we are unable to raise additional funds through equity, convertible debt or debt financings when needed, we may be required
to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market
product candidates that we would otherwise prefer to develop and market ourselves. If we are unable to raise additional funds through
collaborations, strategic alliances or licensing arrangements, we may be required to terminate product development or future commercialization
efforts or to cease operations altogether.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Business and Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are dependent on the success of our lead
product candidate, PrimeC, including obtaining regulatory approval to market PrimeC in the United States.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have invested almost all
of our efforts and financial resources in the research and development of our lead product candidate, PrimeC. Our future success depends
on our ability to develop, commercialize, market and sell PrimeC and our other product candidates. However, our product candidates are
in various stages of preclinical and clinical development and each of them has yet to receive marketing approval from the U.S. Food and
Drug Administration, or the FDA, or any other regulatory agency. Our product candidates&#8217; marketability is subject to significant
risks associated with successfully completing current and future clinical trials, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&#8217;s timely acceptance of our IND filing for our product candidates other than PrimeC for which we plan to file an IND. Without such IND acceptances, we will be unable to commence clinical trials in the United States;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&#8217;s acceptance of our parameters for regulatory approval relating to PrimeC and our other product candidates, including our proposed indications, primary and secondary endpoint assessments and measurements, safety evaluations, chemistry, manufacturing, and controls, or CMC, activities and regulatory pathways;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&#8217;s acceptance of the number, design, size, conduct and implementation of our clinical trials, our trial protocols and the interpretation of data from preclinical studies and clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to successfully complete the clinical trials of our product candidates, including timely patient enrollment and acceptable safety and efficacy data and our ability to demonstrate the safety and efficacy of the product candidates undergoing such clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to complete in a timely fashion the PrimeC pivotal trial, and that the single pivotal trial, even if successfully completed, will be sufficient to support a New Drug Application, or NDA, submission;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&#8217;s acceptance of the sufficiency of the data we collected from our preclinical studies and Phase 2a NST002 clinical trial and will collect ahead of potentially initiating a pivotal clinical trial, and our ability to commence a pivotal clinical trial in the United States for PrimeC following an IND submission, if accepted;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&#8217;s willingness to schedule an advisory committee meeting in a timely manner to evaluate and decide on the approval of our potential future NDA for PrimeC;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the recommendation of the FDA&#8217;s advisory committee to approve our applications to market PrimeC and our other product candidates in the United States, without limiting the approved labeling, specifications, distribution or use of the products, or imposing other restrictions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&#8217;s satisfaction with the safety, quality and efficacy of our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prevalence and severity of adverse events associated with our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timely and satisfactory performance by third-party&#160;contractors of their obligations in relation to our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our success in educating physicians and patients about the benefits, administration and use of our product candidates, if approved, particularly in light of the fact that there is a limited number of currently available and approved treatment options for Amyotrophic Lateral Sclerosis (ALS);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability, perceived advantages, relative cost, safety and efficacy of alternative and competing treatments for the indications addressed by our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effectiveness of our marketing, sales and distribution strategy, and operations, as well as that of any current and future licensees; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain, protect and enforce our intellectual property rights with respect to our product candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Many of these clinical, regulatory
and commercial risks are beyond our control. Accordingly, we cannot assure you that we will be able to advance any of our product candidates
through clinical development, or to obtain regulatory approval of or commercialize any of our product candidates. If we fail to achieve
these objectives or overcome the challenges presented above, we could experience significant delays or an inability to successfully commercialize
our product candidates. Accordingly, we may not be able to generate sufficient revenues through the sale of our product candidates to
enable us to continue our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to obtain regulatory approval
for our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The research, development,
testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage, recordkeeping, marketing, distribution, post-approval&#160;monitoring
and reporting, and export and import of drug products are subject to extensive regulation by the FDA, and by foreign regulatory authorities
in other countries. These regulations differ from country to country. To gain approval to market our product candidates, we must provide
clinical data that adequately demonstrate the safety and efficacy of the product for the intended indication. We have not yet obtained
regulatory approval to market any of our product candidates in the United&#160;States&#160;or any other country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our business depends upon
obtaining these regulatory approvals. There are currently a limited number of alternative drugs approved by the FDA for the treatment
of ALS. The FDA can delay, limit or deny approval of our product candidates for many reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to satisfactorily demonstrate that the product candidates are safe and effective for the target indication;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&#8217;s disagreement with our trial protocol, the interpretation of data from preclinical studies or clinical trials, or adequate conduct and control of clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the population studied in the clinical trial may not be sufficiently broad or representative to assess safety in the patient population for which we seek approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to demonstrate that clinical or other benefits of our product candidates outweigh any safety or other perceived risks;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&#8217;s determination that the 505(b)(2) regulatory pathway is not available for our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&#8217;s determination that additional preclinical studies or clinical trials are required;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&#8217;s non-approval&#160;of the formulation, labeling or the specifications of our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA&#8217;s non-acceptance of the manufacturing processes or facilities of third-party&#160;manufacturers with which we contract;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential for approval policies or regulations of the FDA to significantly change in a manner rendering our clinical data insufficient for approval; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">resistance to approval from the FDA&#8217;s advisory committee for any reason including safety or efficacy concerns.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if we eventually complete
clinical testing and receive approval of any regulatory filing for our product candidates, the FDA may grant approval contingent on the
performance of costly and potentially time-consuming&#160;additional post-approval&#160;clinical trials or subject to restrictive Risk
Evaluation and Mitigation Strategies. The FDA may also approve our product candidates for a more limited indication or a narrower patient
population than we originally requested, and the FDA may not approve the labeling that we believe is necessary or desirable for the successful
commercialization of our product candidates. To the extent we seek regulatory approval in foreign countries, we may face challenges similar
to those described above with regulatory authorities in applicable jurisdictions. Any delay in obtaining, or inability to obtain, applicable
regulatory approval for any of our product candidates would delay or prevent commercialization of our product candidates and would thus
negatively impact our business, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>To date, we have only generated limited
clinical data for our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Positive results in preclinical
testing and early clinical trials do not ensure that later clinical trials will be successful. A number of pharmaceutical companies have
suffered significant setbacks in clinical trials, including in clinical trials, after promising results in preclinical testing and early
clinical trials. These setbacks have included negative safety and efficacy observations in later clinical trials, including previously
unreported adverse effects. If our clinical trials do not ultimately indicate that our product candidates are safe or efficacious for
their intended application, the FDA may not approve any NDA that we may file to market such product candidates, and our business would
not be able to generate revenue from the sale of such product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have limited experience in conducting
clinical trials and have never obtained approval for any product candidates, and may be unable to do so successfully.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a company, we have limited
experience in conducting clinical trials and have never progressed a product candidate through to regulatory approval. In part because
of this lack of experience, our clinical trials may require more time and incur greater costs than we anticipate. We cannot be certain
that our planned clinical trials will begin or conclude on time, if at all. Large-scale&#160;trials will require significant additional
financial and management resources. Third-party&#160;clinical investigators do not operate under our control. Any performance failure
on the part of such third parties could delay the clinical development of our product candidates or delay or prevent us from obtaining
regulatory approval or commercializing our current or future product candidates, depriving us of potential product revenue and resulting
in additional losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not applied for regulatory approvals
to market any of our other product candidates, and we may be delayed in obtaining or failing to obtain such regulatory approvals and to
commercialize our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The process of
developing, obtaining regulatory approval for and commercializing our product candidates is long, complex, costly and uncertain, and
delays or failure can occur at any stage. The research, testing, manufacturing, labeling, marketing, sale and distribution of drugs
are subject to extensive and rigorous regulation by the FDA and foreign regulatory agencies, as applicable. These regulations are
agency-specific&#160;and differ by jurisdiction. We are not permitted to market any product candidate in the United States until we
receive approval of an NDA from the FDA, or in any foreign countries until we receive the requisite approval from the respective
regulatory agencies in such countries. To gain approval of an NDA or other equivalent regulatory approval, we must provide the FDA
or relevant foreign regulatory authority with preclinical and clinical data that adequately demonstrates the safety and efficacy of
the product for the intended indication. For example, we plan to file for early commercialization approval for PrimeC under Health
Canada&#8217;s Notice of Compliance with Conditions (NOC/c) policy. Although this decision follows the recommendations of Canadian
regulatory experts and recent clinical findings, there can be no assurance that Health Canada will approve our application for early
commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Before we can submit an
NDA to the FDA or similar applications to foreign regulatory authorities, generally speaking, we must conduct at least one pivotal
clinical trial for each product candidate. Based on the results of our clinical trials and our discussions with the FDA on potential
pivotal trial design, we intend to initiate a pivotal clinical trial to further evaluate PrimeC. We have completed three additional
studies to further support our future regulatory submissions. First, in September 2022 we announced positive results from our Good
Laboratory Practices (GLP)&#160;toxicity study in rats to confirm the safety of PrimeC in high doses, in accordance with the
FDA&#8217;s expectations. We also announced in September 2022 positive results of our pharmacokinetic (PK) study assessing the
exposure levels of PrimeC&#8217;s extended release, or ER, formulation, where we observed the safety and improved PK profile of
PrimeC in this formulation, in comparison to co-administration of the two marketed products that are a part of PrimeC&#8217;s
composition. We have also completed a Phase 2b trial with PrimeC&#8217;s ER formulation that increased our understanding of the
changes in the pathological pathways of ALS, demonstrated a clear safety profile of PrimeC and showed efficacy signals - all
informed the final trial design for our potential pivotal clinical trial. Following an agreement with FDA on the pivotal trial
design, the results of the PARADIGM trial and results of additional trials, we believe we could be in a position to initiate a
pivotal clinical trial of PrimeC for the treatment of ALS in the second half of 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Before commencing a clinical
trial for PrimeC in the United States, we filed an IND, which was accepted by the FDA. We cannot assure you that the FDA will not decide
to materially alter certain parameters, including among others, potentially requiring a pivotal study with several control arms, during
the trial or require us to conduct more than one pivotal trial before submitting an NDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Phase 3 clinical trials often
produce unsatisfactory results even though prior clinical trials were successful. Moreover, the results of clinical trials may be unsatisfactory
to the FDA or foreign regulatory authorities even if we believe those clinical trials to be successful. The FDA or applicable foreign
regulatory agencies may suspend one or all of our clinical trials or require that we conduct additional clinical, preclinical, manufacturing,
validation or drug product quality studies and submit that data before considering or reconsidering any NDA or comparable foreign regulatory
application that we may submit. Depending on the extent of these additional studies, approval of any applications that we submit may be
significantly delayed or may cause the termination of such programs, or may require us to expend more resources than we have available.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any of these outcomes
occur, we may not receive regulatory approval for the corresponding product candidates, and our business would not be able to generate
revenue from the sale of any such product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to advance our preclinical
product candidates into clinical development and through regulatory approval and commercialization.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain of our product candidates
are currently in preclinical development and are therefore currently subject to the risks associated with preclinical development, including
the risks associated with:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">generating adequate and sufficient preclinical safety and efficacy data in a timely fashion to support the initiation of clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining regulatory approval to commence clinical trials in any jurisdiction, including the filing and acceptance of INDs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">contracting with the necessary parties to conduct a clinical trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">enrolling sufficient numbers of patients in clinical trials; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timely manufacture of sufficient quantities of the product candidate for use in clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we are unsuccessful in
advancing our preclinical product candidates into clinical trials in a timely fashion, our business may be harmed. Even if we are successful
in advancing our preclinical product candidates into clinical development, their success will be subject to all of the clinical, regulatory
and commercial risks described elsewhere in &#8220;Risk Factors.&#8221; Accordingly, we cannot assure you that we will be able to develop,
obtain regulatory approval for, commercialize or generate significant revenue from our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical drug development involves a lengthy
and expensive process with an uncertain outcome, results of earlier studies and trials may not be predictive of future trial results,
and our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Clinical testing is expensive
and can take many years to complete, and its outcome is inherently uncertain. A&#160;failure of one or more of our clinical trials can
occur at any time during the clinical trial process. We do not know whether future clinical trials, if any, will begin on time, need to
be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. Clinical trials can be delayed, suspended
or terminated for a variety of reasons, including failure to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain regulatory approval, or feedback on trial design, in order to commence a trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify, recruit and train suitable clinical investigators;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, and have such CROs and sites effect the proper and timely conduct of our clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain and maintain institutional review board (IRB) or Ethic Committee (EC), approval at each clinical trial site;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify, recruit and enroll suitable patients to participate in a trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have a sufficient number of patients complete a trial or return for post-treatment&#160;follow-up;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensure clinical investigators and clinical trial sites observe trial protocol or continue to participate in a trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">address any patient safety concerns that arise during the course of a trial;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">address any conflicts with new or existing laws or regulations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">add a sufficient number of clinical trial sites;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture sufficient quantities at the required quality of product candidate for use in clinical trials; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">raise sufficient capital to fund a trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Patient enrollment is a significant
factor in the timing and success of clinical trials and is affected by many factors, including the size and nature of the patient population,
the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical
trials and clinicians&#8217; and patients&#8217; or caregivers&#8217; perceptions as to the potential advantages of the drug candidate
being studied in relation to other available therapies, including any new drugs or treatments that may be developed or approved for the
indications we are investigating.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may also encounter delays
if a clinical trial is suspended or terminated by us, by the IRBs or ECs of the institutions in which such trials are being conducted,
by the trial&#8217;s data safety monitoring board, by the FDA or by the applicable foreign regulatory authorities. Such authorities may
suspend or terminate one or more of our clinical trials due to a number of factors, including our failure to conduct the clinical trial
in accordance with relevant regulatory requirements or clinical protocols, inspection of the clinical trial operations or trial site by
the FDA or foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects,
failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate
funding to continue the clinical trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, disruptions
caused by a resurgence of the COVID-19&#160;pandemic may increase the likelihood that we encounter such difficulties or delays in initiating,
enrolling, conducting or completing our planned and ongoing preclinical studies and clinical trials, as applicable. For example, on March&#160;18,
2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities in
response to the COVID-19&#160;pandemic. If global health concerns continue to prevent the FDA or other regulatory authorities from conducting
their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review
and process our regulatory submissions. In addition, in 2023, after the enrollment rate of the trial was slowed down due to regulatory
approval delays, resulting from a back-log post-COVID, we changed our estimate of the expected timing of top-line&#160;results from our
Phase 2b trial from the second quarter of 2023 to the second half of 2023, which we reported in December 2023. If we experience any other
delays in the initiation, enrollment or completion of any preclinical study or clinical trial of our product candidates, or if any preclinical
studies or clinical trials of our product candidates are cancelled, the commercial prospects of our product candidates may be materially
adversely affected, and our ability to generate product revenues from any of these product candidates will be delayed or not realized
at all. In addition, any delays in completing our clinical trials may increase our costs and slow down our product candidate development
and approval process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we experience delays in
carrying out or completing any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed,
and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing
our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability
to commence product sales and generate revenues. Any of these occurrences may significantly harm our business and financial condition.
In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately
lead to the denial of regulatory approval of our product candidates.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PrimeC or any of our other product candidates
may produce undesirable side effects that we may not have detected in our previous preclinical studies and clinical trials. This could
prevent us from gaining marketing approval or market acceptance for these product candidates, or from maintaining such approval and acceptance,
and could substantially increase commercialization costs and even force us to cease operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As with most pharmaceutical
products, use of PrimeC or our other product candidates may be associated with side effects or adverse events that can vary in severity
and frequency. Side effects or adverse events associated with the use of PrimeC may be observed at any time, including in clinical trials
or once a product is commercialized, and any such side effects or adverse events may negatively affect our ability to obtain regulatory
approval or market our product candidates. We cannot assure you that we will not observe drug-related&#160;serious adverse events in the
future or that the FDA will not determine them as such. Side effects such as toxicity or other safety issues associated with the use of
our product candidates could require us to perform additional studies or halt development or sale of these product candidates or expose
us to product liability lawsuits, which will harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Furthermore, commencing the
planned pivotal clinical trial for PrimeC will involve a larger patient base than that previously studied, and the commercial marketing
of PrimeC, if approved, will further expand the clinical exposure of the drug to a wider and more diverse group of patients than those
participating in the clinical trials, which may identify undesirable side effects caused by these products that were not previously observed
or reported.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA and foreign regulatory
agency regulations require that we report certain information about adverse medical events if our products may have caused or contributed
to those adverse events. The timing of our obligation to report would be triggered by the date upon which we become aware of the adverse
event as well as the nature and severity of the event. We may fail to report adverse events of which we become aware within the prescribed
timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to
us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to
comply with our reporting obligations, the FDA or a foreign regulatory agency could take action including enforcing a hold on or cessation
of clinical trials, withdrawal of approved drugs from the market, criminal prosecution, the imposition of civil monetary penalties or
seizure of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, in the event
we discover the existence of adverse medical events or side effects caused by one of our product candidates, a number of other potentially
significant negative consequences could result, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to file an NDA or similar application for our product candidates because of insufficient risk-benefit, or the denial of such application by the FDA or foreign regulatory authorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or foreign regulatory authorities suspending or withdrawing their approval of the product;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or foreign regulatory authorities requiring the addition of labeling statements, such as warnings or contraindications or distribution and use restrictions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or foreign regulatory authorities requiring us to issue specific communications to healthcare professionals, such as letters alerting them to new safety information about our product, changes in dosage or other important information;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA or foreign regulatory authorities issuing negative publicity regarding the affected product, including safety communications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our being limited with respect to the safety-related&#160;claims that we can make in our marketing or promotional materials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our being required to change the way the product is administered, conduct additional preclinical studies or clinical trials or restrict or cease the distribution or use of the product; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our being sued and held liable for harm caused to patients.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any of these events could
prevent us from achieving approval or market acceptance of the affected product candidate and could substantially increase commercialization
costs or even force us to cease operations. We cannot assure you that we will resolve any issues related to any product-related&#160;adverse
events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and
financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if our product candidates receive marketing
approval, we may continue to face future developmental and regulatory difficulties. In addition, we are subject to government regulations
and we may experience delays in obtaining required regulatory approvals to market our proposed product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if we complete clinical
testing and receive approval of any regulatory filing for our product candidates, the FDA or applicable foreign regulatory agency may
grant approval contingent on the performance of additional costly post-approval&#160;clinical trials, risk mitigation requirements and
surveillance requirements to monitor the safety or efficacy of the product, which could negatively impact us by reducing revenues or increasing
expenses, and cause the approved product candidate not to be commercially viable. Absence of long-term&#160;safety data may further limit
the approved uses of our products, if any.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA or applicable foreign
regulatory agency also may approve our product candidates for a more limited indication or a narrower patient population than we originally
requested, or may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product
candidates. Furthermore, any such approved product will remain subject to extensive regulatory requirements, including requirements relating
to manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, distribution and recordkeeping.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we fail to comply with
the regulatory requirements of the FDA or other applicable foreign regulatory authorities, or previously unknown problems with any approved
commercial products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed
sanctions or other setbacks, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension or imposition of restrictions on operations, including costly new manufacturing requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory agency refusal to approve pending applications or supplements to applications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension of any ongoing clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension or withdrawal of marketing approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an injunction or imposition of civil or criminal penalties or monetary fines;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seizure or detention of products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">bans or restrictions on imports and exports;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance of warning letters or untitled letters;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension or imposition of restrictions on operations, including costly new manufacturing requirements; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal of regulatory authorities to approve pending applications or supplements to applications.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, various aspects
of our operations are subject to federal, state or local laws, rules and regulations, any of which may change from time to time. Costs
arising out of any regulatory developments could be time-consuming&#160;and expensive and could divert management resources and attention
and, consequently, could adversely affect our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if our product candidates receive regulatory
approval, they may fail to achieve the broad degree of physician adoption and use and market acceptance necessary for commercial success.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if we obtain FDA or
foreign regulatory approvals for our product candidates, the commercial success of such products will depend significantly on their broad
adoption and use by physicians, for approved indications. The degree and rate of physician and patient adoption of our product candidates,
if approved, will depend on a number of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the clinical indications for which the product is approved;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the prevalence and severity of adverse side effects;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">physicians&#8217; satisfaction with the results shown in clinical trials</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient satisfaction with the results and administration of our product and overall treatment experience, including relative convenience, ease of use and avoidance of, or reduction in, adverse side effects;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which physicians recommend our products to patients;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">physicians&#8217; and patients&#8217; willingness to adopt new therapies in lieu of other products or treatments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of treatment, safety and efficacy in relation to alternative treatments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which the costs of our product candidates are reimbursed by third-party&#160;payors, and patients&#8217; willingness to pay for our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the extent to which physicians adopt and prescribe PrimeC, rather than the two alternative FDA-approved&#160;drugs, ciprofloxacin and celecoxib, that we formulated to create PrimeC;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the revenues and profitability that our products will offer physicians as compared to alternative therapies; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effectiveness of our sales and marketing efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If PrimeC or any of our other
product candidates is approved for use, but fails to achieve the broad degree of physician adoption and market acceptance necessary for
commercial success, our operating results and financial condition would be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates, if approved, may
face significant competition with competing technologies and our failure to compete effectively may prevent us from achieving significant
market penetration.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The biopharmaceutical industry
is intensely competitive and subject to rapid and significant technological change. Our potential competitors include large and experienced
companies that enjoy significant competitive advantages over us, such as greater financial, research and development, manufacturing, personnel
and marketing resources, greater brand recognition and more experience and expertise in obtaining marketing approvals from the FDA and
foreign regulatory authorities. These companies may develop new drugs to treat the indications that we target, or seek to have existing
drugs approved for use for the treatment of the indications that we target.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are aware that potentially
disease modifying therapeutics for Amyotrophic Lateral Sclerosis, or ALS are being developed by several large and specialty pharmaceutical
and biotechnology companies and academic institutions, including Biogen, Amylyx Pharmaceuticals, Novartis, MT-Pharma, Sanofi, AB Science,
Prilenia Therapeutics, Brainstorm Cell Therapeutics, Clene, Corcept Therapeutics, Cytokinetics, Denali Therapeutics, Seelos, Eledon, QurAlis,
and Apellis Pharmaceuticals, among others, in various stages of clinical trials. In addition, we are aware of several large and specialty
pharmaceutical companies, such as Eli Lilly and Roche (including Genentech Inc., its wholly owned subsidiary), that are developing potentially
disease modifying therapeutics for Alzheimer&#8217;s disease, or ADS, and Parkinson&#8217;s Disease, or PD. We do not know whether these
potential competitors are already developing, or plan to develop, the same treatments or treatments for other indications that we are
pursuing, and we may be unable to ascertain whether such activities are underway in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Competition may increase
further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in
this industry. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis products that are more effective
or less costly than our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have no experience in marketing or distributing
products and no internal capability to do so, and are therefore subject to certain risks in relation to the commercialization of our product
candidates once approved.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have not yet established
a commercial organization for the marketing, sale and distribution of our product candidates. Therefore, even if we receive approval to
market our product candidates in the United States or other markets, in order to successfully commercialize our product candidates, we
will need to either build marketing, sales, distribution, managerial and other non-technical&#160;capabilities or contract with third
parties to obtain these capabilities. This involves many challenges, such as recruiting and retaining talented personnel, training employees,
setting the appropriate system of incentives, managing additional headcount and integrating new business units into an existing corporate
infrastructure. The development of our own sales infrastructure or contracting with third parties will involve substantial expense, much
of which we will incur well in advance of any marketing or sales. Moreover, we do not have experience as a company in establishing a significant
sales infrastructure, and we cannot be certain that we will successfully develop this capability or contract successfully with third parties
for the necessary services. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and
retain personnel for medical affairs, marketing and sales. If we fail to establish an effective sales and marketing infrastructure or
contract with third parties to do so, we will be unable to successfully commercialize our product candidates, which in turn would have
an adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may enter into collaborations with third
parties for the development or commercialization of our product candidates. If our collaborations are not successful, we may not be able
to capitalize on the market potential of these product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may utilize a variety
of types of collaboration, distribution and other marketing arrangements with third parties to develop our product candidates and commercialize
our approved product candidates, if any. We are not currently party to any such arrangement. Our ability to generate revenues from these
arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these
arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any future collaborations
that we enter into may pose a number of risks, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may not perform their obligations as expected;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product candidates developed by collaborators may not perform sufficiently in clinical trials to be determined to be safe and effective, thereby delaying or terminating the drug approval process and reducing or eliminating milestone payments to which we would otherwise be entitled if the product candidates had successfully met their endpoints and/or received FDA approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may not pursue development and commercialization of our product candidates that receive marketing approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would divert management attention and resources, be time-consuming&#160;and expensive;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Collaboration agreements
may not lead to the development or commercialization of product candidates in the most efficient manner, or at all. If any future collaborations
that we enter into do not result in the successful development and commercialization of products or if one of our collaborators terminates
its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we
do not receive the funding we expect under these agreements, our development of our product candidates could be delayed and we may need
additional resources to develop our product candidates. All of the risks relating to product development, regulatory approval and commercialization
described in this Annual Report on Form 20-F also apply to the activities of our collaborators.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, subject to
its contractual obligations to us, if a collaborator of ours were to be involved in a business combination, it might deemphasize or terminate
the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement
with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could
be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If in the future we acquire or in-license
technologies or product candidates, we may incur various costs, may have integration difficulties and may experience other risks that
could harm our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the future, we may acquire
or in-license&#160;additional product candidates and technologies. Any product candidate or technologies we in-license&#160;or acquire
will likely require additional development efforts prior to commercial sale, including extensive preclinical or clinical testing, or both,
and approval by the FDA and applicable foreign regulatory authorities, if any. All product candidates are prone to risks of failure inherent
in pharmaceutical product development, including the possibility that the product candidate, or product developed based on in-licensed&#160;technology,
will not be shown to be sufficiently safe and effective for approval by regulatory authorities. If intellectual property related to product
candidates or technologies we in-license&#160;is not adequate, we may not be able to commercialize the affected products even after expending
resources on their development. In addition, we may not be able to manufacture economically or successfully commercialize any product
candidate that we develop based on acquired or in-licensed&#160;technology that is granted regulatory approval, and such products may
not gain wide acceptance or be competitive in the marketplace. Moreover, integrating any newly acquired or in-licensed&#160;product candidates
could be expensive and time-consuming. If we cannot effectively manage these aspects of our business strategy, our business may be materially
harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We currently contract with third-party contractors
for certain raw materials, compounds and components necessary to produce PrimeC for clinical trials, and expect to continue to do so to
support commercial scale production of PrimeC, if approved. There are significant risks associated with contracting with third-party suppliers.
Furthermore, our existing suppliers may not be able to meet the increased need for certain raw materials, compounds and components that
may result from our potential commercialization efforts. This increases the risk that we will not have sufficient quantities of PrimeC
or be able to obtain such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization
efforts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We currently rely on third-party&#160;contract
manufacturers and suppliers for all of our required raw materials, active ingredients and finished products for our preclinical studies
and clinical trials. Because there are a limited number of suppliers for the raw materials that we use to manufacture our product candidates,
we may need to engage alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our
product candidates for our clinical trials, and if approved, ultimately for commercial sale. We do not have any control over the availability
of raw materials. If we or our manufacturers are unable to purchase these raw materials on acceptable terms, at sufficient quality levels,
or in adequate quantities, if at all, the development and commercialization of our product candidates or any future product candidates,
would be delayed or there would be a shortage in supply, which would impair our ability to meet our development objectives for our product
candidates or generate revenues from the sale of any approved products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect to continue to
rely on these or other subcontractors and suppliers to support our commercial requirements if PrimeC or any of our other product candidates
is approved for marketing by the FDA or foreign regulatory authorities. We plan to continue to rely on third parties for the raw materials,
compounds and components necessary to produce our product candidates and for preclinical studies and clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our continuing reliance on
third-party&#160;contract manufacturers and suppliers entails a number of risks, including reliance on the third party for regulatory
compliance and quality assurance, the possible breach of the manufacturing or supply agreement by the third party, and the possible termination
or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. In addition, third-party&#160;contract
manufacturers and suppliers may not be able to comply with cGMP or quality system regulation, or similar regulatory requirements outside
the United States. If any of these risks transpire, we may be unable to timely retain alternate subcontractors or suppliers on acceptable
terms and with sufficient quality standards and production capacity, which may disrupt and delay our clinical trials or the manufacture
and commercial sale of our product candidates, if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our failure or the failure
of our third-party&#160;contract manufacturers and suppliers to comply with applicable regulations could result in sanctions being imposed
on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls
of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of PrimeC
or any of our other product candidates that we may develop. Any failure or refusal to supply or any interruption in supply of the components
for PrimeC or any other product candidates or products that we may develop could delay, prevent or impair our clinical development or
commercialization efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The manufacture of pharmaceutical products
is complex and manufacturers often encounter difficulties in production. If we or any of our third-party manufacturers encounter any difficulties,
our ability to provide product candidates for clinical trials or our product candidates to patients, if approved, and the development
or commercialization of our product candidates could be delayed or stopped.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The manufacture of pharmaceutical
products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques
and process controls. We and our contract manufacturers must comply with cGMP requirements. Manufacturers of pharmaceutical products often
encounter difficulties in production, particularly in scaling up and validating initial production and contamination controls. These problems
include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing,
operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations.
Furthermore, if microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in
which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate
and remedy the contamination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We cannot assure you that
any stability or other issues relating to the manufacture of any of our product candidates will not occur in the future. Additionally,
we and our third-party&#160;manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor
disputes or unstable political environments. If we or our third-party&#160;manufacturers were to encounter any of these difficulties,
our ability to provide any product candidates to patients in clinical trials and products to patients, once approved, would be jeopardized.
Any delay or interruption in the supply of clinical trial supplies could delay the initiation or completion of clinical trials, increase
the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical
trials at additional expense or terminate clinical trials completely. Any adverse developments affecting clinical or commercial manufacturing
of our product candidates may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions
in the supply of our product candidates. We may also have to take inventory write-offs&#160;and incur other charges and expenses for products
that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures
or difficulties faced at any level of our supply chain could materially adversely affect our business and delay or impede the development
and commercialization of any of our product candidates and could have a material adverse effect on our business, prospects, financial
condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to obtain marketing approval in
international jurisdictions would prevent our product candidates from being marketed abroad.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order to market and sell
our products in the European Union and other jurisdictions, we or our third-party&#160;collaborators must obtain separate marketing approvals
and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional
testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. Regulatory approval
processes outside the United States generally include all of the risks associated with obtaining FDA approval. In addition, in many countries
outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in
that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval
by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority
outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may
not be able to file for marketing approvals and may not receive the necessary approvals to commercialize our product candidates in any
particular market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We intend to rely on third parties and consultants
to assist us in conducting our single pivotal clinical trial for PrimeC and certain preclinical and clinical trials for our other product
candidates. If these third parties or consultants do not successfully carry out their contractual duties or meet expected deadlines, we
may be unable to obtain regulatory approval for or commercialize PrimeC or any of our other product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not have the ability
to independently conduct many of our preclinical studies or our clinical trials. We rely on medical institutions, clinical investigators,
contract laboratories, and other third parties, such as CROs to conduct clinical trials on our product candidates. Third parties play
a significant role in the conduct of our clinical trials and the subsequent collection and analysis of data. These third parties are not
our employees, and except for remedies available to us under our agreements, we have limited ability to control the amount or timing of
resources that any such third party will devote to our clinical trials. If our CROs or any other third parties upon which we rely for
administration and conduct of our clinical trials do not successfully carry out their contractual duties or obligations or meet expected
deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure
to adhere to our clinical protocols, regulatory requirements, or for other reasons, or if they otherwise perform in a substandard manner,
our clinical trials may be extended, delayed, suspended or terminated, and we may not be able to complete development of, obtain regulatory
approval for, or successfully commercialize our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We and the third parties
upon whom we rely are required to comply with Good Clinical Practice, or GCP, regulations, which are regulations and guidelines enforced
by regulatory authorities around the world for products in clinical development. Regulatory authorities enforce these GCP regulations
through periodic inspections of clinical trial sponsors, principal investigators and clinical trial sites. If we or our third parties
fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and our submission
of marketing applications may be delayed or the regulatory authorities may require us to perform additional clinical trials before approving
our marketing applications. We cannot assure you that, upon inspection, a regulatory authority will determine that any of our clinical
trials comply or complied with applicable GCP regulations. In addition, our clinical trials must be conducted with material produced under
current cGMP regulations, which are enforced by regulatory authorities. Our failure to comply with these regulations may require us to
repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be impacted if our CROs, clinical
investigators or other third parties violate federal or state fraud and abuse or false claims laws and regulations or healthcare privacy
and security laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order for our clinical
trials to be carried out effectively and efficiently, it is imperative that our CROs and other third parties communicate and coordinate
with one another. Moreover, our CROs and other third parties may also have relationships with other commercial entities, some of which
may compete with us. Our CROs and other third parties may terminate their agreements with us upon as few as 30 days&#8217; notice under
certain circumstances. If our CROs or other third parties conducting our clinical trials do not perform their contractual duties or obligations,
experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality
or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for
any other reason, we may need to conduct additional clinical trials or enter into new arrangements with alternative CROs, clinical investigators
or other third parties. We may be unable to enter into arrangements with alternative CROs on commercially reasonable terms, or at all.
Switching or adding CROs, clinical investigators or other third parties can involve substantial cost and require extensive management
time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays may occur, which
can impact our ability to meet our desired clinical development timelines. Although we carefully manage our relationship with our CROs,
clinical investigators and other third parties, there can be no assurance that we will not encounter such challenges or delays in the
future or that these delays or challenges will not have a negative impact on our business, prospects, financial condition or results of
operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our product candidates are approved for
marketing, and we are found to have improperly promoted off-label uses, or if physicians misuse our products, we may become subject to
prohibitions on the sale or marketing of our products, significant sanctions, and product liability claims, and our image and reputation
within the industry and marketplace could be harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA and other regulatory
agencies strictly regulate the marketing and promotional claims that are made about drug products. In particular, a product may not be
promoted for uses or indications that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s
approved labeling. For example, if we receive marketing approval for PrimeC for treatment of ALS, the first indication we are pursuing,
we cannot promote the use of our product in a manner that is inconsistent with the approved label. If we are found to have promoted such
off-label&#160;uses, we may receive warning letters and become subject to significant liability, which would harm our business. The federal
government has levied large administrative, civil and criminal fines against companies for alleged improper promotion and has enjoined
several companies from engaging in off-label&#160;promotion. If we become the target of such an investigation or prosecution based on
our marketing and promotional practices, we could face similar sanctions, which would harm our business. In addition, management&#8217;s
attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged.
The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct
is changed or curtailed. If we are deemed by the FDA to have engaged in the promotion of our products for off-label&#160;use, we could
be subject to prohibitions on the sale or marketing of our products or significant fines and penalties, and the imposition of these sanctions
could also affect our reputation with physicians, patients and caregivers, and our position within the industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Physicians may also misuse
our products or use improper techniques, potentially leading to adverse results, side effects or injury, which may lead to product liability
claims. If our products are misused or used with improper technique, we may become subject to costly litigation. Product liability claims
could divert management&#8217;s attention from our core business, be expensive to defend, and result in sizable damage awards against
us that may not be covered by insurance. We currently carry product liability insurance covering our clinical trials with policy limits
that we believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although
we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that
is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Furthermore, the use
of our products for conditions other than those approved by the FDA may not effectively treat such conditions, which could harm our reputation
in the marketplace among physicians and patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to manage our growth effectively,
our business could be disrupted.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024,
we had seventeen full and part time&#160;employees and several part-time&#160;consultants, most of whom are based at our headquarters
in Herzliya, Israel and the rest of whom work in Switzerland and the United States. We will need to continue to expand our development,
quality, sales, managerial, operational, finance, marketing and other resources to manage our operations and clinical trials, continue
our development activities and commercialize our product candidates, if approved. Our management, personnel, systems and facilities currently
in place may not be adequate to support this future growth. Our need to effectively execute our expansion strategy requires that we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage our clinical trials effectively;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify, recruit, retain, incentivize and integrate additional employees;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage our internal development efforts effectively while carrying out our contractual obligations to third parties; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue to improve our operational, financial and management controls, reporting systems and procedures.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Due to our limited financial
resources and our limited experience in managing a larger company, we may not be able to effectively manage the expansion of our operations
or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert
our management and business development resources. Any inability to manage expansion could delay the execution of our development and
strategic objectives, or disrupt our operations; and if we are not successful in commercializing our product candidates, either on our
own or through collaborations with one or more third parties, our revenues will suffer and we would incur significant additional losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If product liability lawsuits are brought
against us, we may incur substantial liabilities and may be required to limit commercialization of any of our other products we develop.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We face an inherent risk
of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize
any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during
product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing,
defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims
could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims,
we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require
significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased demand for our product candidates or products we develop;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury to our reputation and significant negative media attention;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal of clinical trial participants or cancellation of clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs to defend the related litigation, which may be only partially recoverable even in the event of successful defenses;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a diversion of management&#8217;s time and our resources;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial monetary awards to trial participants or patients;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss of revenues;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exhaustion of any available insurance and our capital resources; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inability to commercialize any product we develop.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our inability to obtain and
maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability
claims could prevent or inhibit the commercialization of products we may develop. We currently carry general clinical trial product liability
insurance in an amount that we believe is adequate to cover the scope of our ongoing clinical programs. Although we maintain such insurance,
any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or
in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions
and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded
by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not
have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance
coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing PrimeC
or any other product candidate, we intend to expand our insurance coverage to include the commercialization of PrimeC or any other approved
product that we may have; however, we may be unable to obtain this liability insurance on commercially reasonable terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to attract and keep senior management
and key scientific personnel, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize
any of the products we develop.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our success depends in part
on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We believe that
our future success is highly dependent upon the contributions of members of our senior management, as well as our senior scientists and
other members of our management team. The loss of services of any of these individuals could delay or prevent the successful development
of our product pipeline, completion of our planned clinical trials or the commercialization of our product candidates. Although we have
employment agreements with some of our employees, these agreements do not prevent them from terminating their employment with us after
providing the appropriate notice as described in the agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although we have not historically
experienced unique difficulties in attracting and retaining qualified employees, we could experience such problems in the future. For
example, competition for qualified personnel in the pharmaceutical field is intense due to the limited number of individuals who possess
the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and
commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the
extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have
divulged proprietary or other confidential information, or that their former employers own their research output. Moreover, we are domiciled
in Israel and are predominantly based in Israel, which may make it difficult to hire necessary U.S.-based&#160;personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our internal computer systems, or those
of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a disruption of our drug
development programs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Despite the implementation
of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage
from cyber-security&#160;threats, including computer viruses, harmful code and unauthorized access, natural disasters, fire, terrorism,
war and telecommunication and electrical failures. If a disruption event were to occur and cause interruptions in our operations, it could
result in a material disruption of our drug development programs. For example, the loss of clinical trial data from completed, ongoing
or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or
reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or
inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product
candidates could be delayed. See &#8220;Item 16.K&#8212;Cybersecurity&#8221; for further information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Under applicable employment laws, we may
not be able to enforce covenants not to compete.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We generally enter into non-competition&#160;agreements
as part of our employment agreements with our employees. These agreements generally prohibit our employees, if they cease working for
us, from competing directly with us or working for our competitors for a limited period. We may be unable to enforce these agreements
under the laws of the jurisdictions in which our employees work and it may be difficult for us to restrict our competitors from benefitting
from the expertise our former employees or consultants developed while working for us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For example, Israeli labor
courts have required employers seeking to enforce non-compete&#160;undertakings of a former employee to demonstrate that the competitive
activities of the former employee will harm one of a limited number of material interests of the employer which have been recognized by
the courts as justification for the enforcement of non-compete&#160;undertakings, such as the protection of a company&#8217;s trade secrets
or other intellectual property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our employees, independent contractors,
clinical investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with
regulatory standards and requirements and insider trading.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are exposed to the risk
that our employees, independent contractors, clinical investigators, CROs, consultants and vendors may engage in fraudulent conduct or
other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct, breach of contract or
disclosure of unauthorized activities to us that violates: FDA regulations, including those laws requiring the reporting of true, complete
and accurate information to the FDA; manufacturing standards; federal, state and foreign healthcare fraud and abuse laws; or laws that
require the reporting of financial information or data accurately.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Specifically, research, sales,
marketing, education and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud,
misconduct, kickbacks, self-dealing&#160;and other abusive practices. These laws may restrict or prohibit a wide range of pricing, discounting,
education, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject
to these laws also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory
sanctions and serious harm to our reputation. We have adopted a code of business conduct and ethics, but it is not always possible to
identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may
not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions
or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, even if we are
successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business. Violations of
such laws subject us to numerous penalties, including, but not limited to, the imposition of civil, criminal and administrative penalties,
damages, monetary fines, disgorgement, individual imprisonment, additional reporting requirements and oversight if we become subject to
a corporate integrity agreement or similar agreement to resolve allegations of non-compliance&#160;with these laws, possible exclusion
from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits
and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our
results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exchange rate fluctuations between the U.S.
Dollar and the NIS may negatively affect our earnings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The U.S. dollar is our functional
and reporting currency. However, a significant portion of our operating expenses are incurred in NIS, which is the lawful currency of
the State of Israel. As a result, we are exposed to the risks that the NIS may appreciate relative to the dollar, or, if the NIS instead
devalues relative to the dollar, that the inflation rate in Israel may exceed such rate of devaluation of the NIS, or that the timing
of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations in Israel would increase
and our dollar-denominated&#160;results of operations would be adversely affected. We cannot predict any future trends in the rate of
inflation in Israel or the rate of devaluation (if any) of the NIS against the dollar. For example, the dollar strengthened against the
NIS in 2022, 2023 and 2024 by 12.5%, 3.0% and 0.55%, respectively. If the dollar cost of our operations in Israel increases, our dollar-measured&#160;results
of operations will be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business, operating results and growth
rates may be adversely affected by current or future unfavorable economic and market conditions and adverse developments with respect
to financial institutions and associated liquidity risk.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our business depends on the
economic health of the global economies. If the conditions in the global economies remain uncertain or continue to be volatile, or if
they deteriorate, including as a result of the impact of military conflict, such as the war between Russia and Ukraine, the current war
between Israel and Hamas, terrorism or other geopolitical events, our business, operating results and financial condition may be materially
adversely affected. Economic weakness, inflation and increases in interest rates, limited availability of credit, liquidity shortages
and constrained capital spending have at times in the past resulted, and may in the future result, in challenging and delayed sales cycles,
slower adoption of new technologies and increased price competition, and could negatively affect our ability to forecast future periods,
which could result in an inability to satisfy demand for our products and a loss of market share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, increases in
inflation raise our costs for commodities, labor, materials and services and other costs required to grow and operate our business, and
failure to secure these on reasonable terms may adversely impact our financial condition. Additionally, increases in inflation, along
with geopolitical developments and global supply chain disruptions, have caused, and may in the future cause, global economic uncertainty
and uncertainty about the interest rate environment, which may make it more difficult, costly or dilutive for us to secure additional
financing. A failure to adequately respond to these risks could have a material adverse impact on our financial condition, results of
operations or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There can be no assurance
that future credit and financial market instability and a deterioration in confidence in economic conditions will not occur. Our general
business strategy may be adversely affected by any such economic downturn, liquidity shortages, volatile business environment or continued
unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or if adverse developments are experienced
by financial institutions, it may cause short-term liquidity risk and also make any necessary debt or equity financing more difficult,
more costly, more onerous with respect to financial and operating covenants and more dilutive. Failure to secure any necessary financing
in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock
price and could require us to alter our operating plans. In addition, there is a risk that one or more of our service providers, financial
institutions, manufacturers, suppliers and other partners may be adversely affected by the foregoing risks, which could directly affect
our ability to attain our operating goals on schedule and on budget.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our efforts to obtain, protect or enforce
our patents and other intellectual property rights related to our product candidates and technologies are not adequate, we may not be
able to compete effectively in our market and we otherwise may be harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our commercial success depends
in significant part upon our ability to obtain, maintain, enforce and defend patent protection and utilize trade secret protection with
respect to our proprietary technologies, our products and their uses, and to operate our business without infringing, misappropriating,
or otherwise violating the intellectual property rights of others. We rely upon a combination of patents, trade secret protection, confidentiality
agreements, assignment of invention agreements and other contractual arrangements to protect the intellectual property related to PrimeC&#8217;s
fixed dose combination of ciprofloxacin and celecoxib and our other product candidates. If we are unable to obtain and maintain sufficient
intellectual property protection for our technologies and product candidates, or if the scope of the intellectual property protection
obtained is not sufficiently broad, our competitors and other third parties could develop and commercialize technologies and product candidates
similar or identical to ours, and our ability to successfully commercialize the technologies and product candidates that we may pursue
may be impaired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although we enter into confidentiality
agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees,
collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements
and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Further, we
may not be aware of all third-party&#160;intellectual property rights potentially relating to our product candidates. Publications of
discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other
jurisdictions are typically not published until 18&#160;months after filing or, in some cases, not at all. Therefore, we cannot know with
certainty whether we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the
first to file for patent protection of such inventions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">While we seek patent protection
for all of our product candidates, our patent coverage is limited, and we can provide no assurance that any of our current or future patent
applications will result in issued patents or that any issued patents will provide us with any competitive advantage. Our patent portfolio
includes U.S. Patent 10,980,780, which relates to methods for treatment of ALS using ciprofloxacin and celecoxib, and which expires in
2038. This patent also been issued in the European Patent Office, Japan, Canada, Australia and Israel. In addition, U.S. patent application
16/623,467, which relates to methods of treatment of neurodegenerative disease using combinations of ciprofloxacin and celecoxib, is currently
pending. This patent application is expected to expire on June&#160;20, 2038.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, we have developed
a pharmaceutical composition comprising, as active ingredients, ciprofloxacin and celecoxib, and have been granted US Patent 12,097,185
and have filed international PCT application PCT/IL2022/051096 relating to the compositions. These applications relate to pharmaceutical
formulations. The US patent will expire in December 2042 and the national patent applications based on the PCT application are expected
to expire on October&#160;19, 2042.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Limitations on the scope
of our intellectual property rights may limit our ability to prevent third parties from designing around such rights and competing against
us. For example, some of our patent applications and patents do not claim a new compound. Rather, the active pharmaceutical ingredients
of PrimeC are existing compounds and some of our pending patent applications are directed to, among other things, novel formulations of
these existing compounds. Accordingly, other parties may compete with us, for example, by independently developing or obtaining competing
formulations that design around our patent claims, but which may contain the same active ingredients, or by seeking to invalidate our
patents. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to
quickly duplicate or surpass our technological achievements, eroding our competitive position in the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The patent applications that
we own may fail to result in granted patents in the United States or foreign jurisdictions, or if granted may fail to prevent a potential
infringer from marketing its product or be deemed invalid and unenforceable by a court. Our ability to obtain and maintain valid and enforceable
patents depends on various factors, including interpretation of our technology and the prior art and whether the differences between them
allow our technology to be patentable. Patent applications and patents granted from them are complex, lengthy and highly technical documents
that are often prepared under very limited time constraints and may not be free from errors that make their interpretation uncertain.
The existence of errors in a patent may have an adverse effect on the patent, its scope and its enforceability. Even if our pending and
future patent applications issue as patents in relevant jurisdictions, they may not issue in a form that will provide us with any meaningful
protection for our technology or product candidates, prevent competitors from competing with us or otherwise provide us with any competitive
advantage. Additionally, our competitors may be able to circumvent our patents by developing similar or alternative technologies or product
candidates in a non-infringing&#160;manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Also, our granted patents
may be subject to challenges. We may be subject to a third-party&#160;preissuance submission of prior art to the United States Patent
and Trademark Office, or the USPTO, or become involved in opposition, derivation, revocation, ex parte reexamination, inter partes review,
post grant review, derivation, or interference proceedings challenging our patent rights or the patent rights of others, or other proceedings
in the USPTO or applicable foreign offices that challenge priority of invention or other features of patentability. For example, patents
granted by the European Patent Office may be opposed by any person within nine months from the publication of their grant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An adverse determination
in any such submission, proceeding or litigation could result in loss of exclusivity, patent claims being narrowed, invalidated or held
unenforceable, in whole or in part, or limits of the scope or duration of the patent protection of our technologies or product candidates,
all of which could limit our ability to stop others from using or commercializing similar or identical product candidates or technology
to compete directly with us, without payment to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims that we infringe,
misappropriate or otherwise violate the intellectual property rights of third parties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if our patents do successfully
issue, third parties may own rights to third party patents which relate to various aspects of the PrimeC product and any of our other
product candidates. To meet such challenges, which are part of the risks and uncertainties of developing and marketing product candidates,
we may need to evaluate third party intellectual property rights and, if appropriate, to seek licenses for such third party intellectual
property or to challenge such third party intellectual property, which may be costly and may or may not be successful, which could also
have an adverse effect on the commercial potential for PrimeC and any of our other product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may receive only limited protection,
or no protection, from our issued patents and patent applications.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we encounter delays in
our clinical trials or regulatory approval of our product candidates, the period of time during which we could market any of our product
candidates under patent protection could be reduced. Since patent applications in the United States and most other countries are confidential
for a period of time after filing, we cannot be certain that we were the first to either (i) file any patent application related to the
treatment of ALS using ciprofloxacin and celecoxib or (ii) conceive and invent any of the compositions or methods claimed in our patents
or patent applications, including patents or patent applications related to PrimeC and our other product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The patent application process,
also known as patent prosecution, is expensive and time consuming, and we or any future licensors and licensees may not be able to prepare,
file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that
we or any future licensors or licensees will fail to identify patentable aspects of inventions made in the course of development and commercialization
activities before it is too late to obtain patent protection on them. Therefore, these and any of our patents and applications may not
be prosecuted and enforced in a manner consistent with the best interests of our business. It is possible that defects of form in the
preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper
priority claims, inventorship, etc., although we are unaware of any such defects that we believe are of material import. If we or any
future licensors or licensees fail to establish, maintain or protect such patents and other intellectual property rights, such rights
may be reduced or eliminated. If any future licensors or licensees, are not fully cooperative or disagree with us as to the prosecution,
maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form or
preparation of our patents or patent applications, such patents or applications may be invalid and unenforceable. Any of these outcomes
could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The strength of patents in
the pharmaceutical field involves complex legal and scientific questions and can be uncertain. This uncertainty includes changes to the
patent laws through either legislative action to change statutory patent law or court action that may reinterpret existing law in ways
affecting the scope or validity of issued patents. The patent applications that we own or in-license&#160;may fail to result in issued
patents in the United States or foreign countries with claims that cover our product candidates. Even if patents do successfully issue
from the patent applications that we own or in-license, third parties may challenge the validity, enforceability or scope of such patents,
which may result in such patents being narrowed, invalidated or held unenforceable. For example, patents granted by the European Patent
Office may be challenged, also known as opposed, by any person within nine months from the publication of their grant. In addition, post
grant review in the USPTO begins with a third party filing a petition on or prior to the date that is 9&#160;months after the grant of
the patent or issuance of a reissue patent. Third parties can also challenge a patent in the USPTO by way of inter partes review, ex parte
reexamination, derivation, or interference proceedings. Any successful challenge to our patents could deprive us of exclusive rights necessary
for the successful commercialization of our product candidates. Furthermore, even if they are unchallenged, our patents may not adequately
protect our product candidates, provide exclusivity for our product candidates, or prevent others from designing around our claims. If
the breadth or strength of protection provided by the patents we hold or pursue with respect to our product candidates is challenged,
it could dissuade companies from collaborating with us to develop, or threaten our ability to commercialize our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Patents have a limited lifespan.
In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available;
however the life of a patent, and the protection it affords, is limited. Without patent protection for our product candidates, we may
be open to competition from generic versions of our product candidates. Further, if we encounter delays in our development efforts, including
our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to protect the confidentiality
of our trade secrets, our business and competitive position would be harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to the protection
afforded by patents, we also rely on trade secret protection to protect proprietary know-how, technology and other proprietary information
that may not be patentable or that we elect not to patent, processes for which patents may be difficult to obtain or enforce, and any
other elements of our product candidates, and our product development processes (such as manufacturing and formulation technologies) that
involve proprietary know-how, information or technology that is not covered by patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Trade secrets and know-how&#160;can
be difficult to protect. We seek to protect these trade secrets and other proprietary technology, in part, by requiring all of our employees,
consultants, advisors, and any other third parties that have access to our proprietary know-how, information or technology to execute
confidentiality agreements upon the commencement of their relationships with us.<sup>&#160;</sup>We cannot be certain that we have or
will obtain these agreements in all circumstances and we cannot guarantee that we have entered into such agreements with each party that
may have or have had access to our trade secrets or proprietary information. If the steps taken to maintain our trade secrets are deemed
inadequate, we may have insufficient recourse against third parties for misappropriating any trade secrets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Despite our efforts, any
of these parties may breach the agreements and disclose our proprietary information, including our trade secrets. Adequate remedies may
not exist in the event of unauthorized use or disclosure of our trade secrets. In addition, in some situations, these confidentiality
agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants, or advisors have previous
employment or consulting relationships. To the extent that our employees, consultants or contractors use any intellectual property owned
by third parties in their work for us, disputes may arise as to the rights in any related or resulting know-how&#160;and inventions. Any
misappropriation or unauthorized disclosure of our trade secrets could have an adverse effect on our business, impact our ability to establish
or maintain a competitive advantage in our market, or otherwise harm our business, operating results and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Furthermore, trade secret
protection does not prevent competitors from independently developing substantially equivalent information and techniques and we cannot
guarantee that our competitors will not independently develop substantially equivalent information and techniques. The FDA, as part of
its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including
information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the
FDA&#8217;s disclosure policies may change in the future, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in U.S. patent law could diminish
the value of patents in general, thereby impairing our ability to protect our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As is the case with other
pharmaceutical companies, our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents.
Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity, and therefore, is costly,
time-consuming&#160;and inherently uncertain. In addition, the Leahy-Smith&#160;America Invents Act, or the AIA, which was passed on September&#160;16,
2011, resulted in significant changes to the U.S. patent system. Further, U.S. Supreme Court rulings in recent years have either narrowed
the scope of patent protection available in certain circumstances or weakened the rights of patent owners in certain situations. In addition
to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty
with respect to the value of patents, once obtained.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The significant changes to
U.S. patent law under the AIA include provisions that affect the way patent applications will be prosecuted and may also affect patent
litigation. For our U.S. patent applications that contain or contained at any time a claim not entitled to priority before March&#160;16,
2013, there is a greater level of uncertainty in the patent law. The USPTO has developed and continues to develop regulations and procedures
to govern administration of the AIA, and many of the substantive changes to patent law associated with the AIA. The AIA and its implementation
could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our
issued patents, all of which could harm our business and financial condition. It is not clear what other, if any, impact the AIA will
have on the operation of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An important change introduced
by the AIA is that, as of March&#160;16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which
party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third
party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention
of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of
the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications
on our inventions. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between
our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States
and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (i)
file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our patents or patent applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Among some of the other changes
introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third
parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March&#160;16,
2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal court
necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO
to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court
action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated
if first challenged by the third party as a defendant in a district court action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Depending on decisions by
the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that
would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Obtaining and maintaining our patent protection
depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies,
and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The USPTO and various foreign
governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during
the patent prosecution process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Periodic maintenance fees
and various other governmental fees on any issued patent and/or pending patent applications are due to be paid to the USPTO and foreign
patent agencies in several stages over the lifetime of a patent or patent application. We have systems in place to remind us to pay these
fees, and we employ an outside firm and rely on our outside counsel to pay these fees. While an inadvertent lapse may sometimes be cured
by payment of a late fee or by other means in accordance with the applicable rules, there are many situations in which noncompliance can
result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant
jurisdiction. Non-compliance&#160;events that could result in abandonment or lapse of a patent or patent application include failure to
respond to official actions within prescribed time limits, non-payment&#160;of fees and failure to properly legalize and submit formal
documents. If we fail to maintain the patents and patent applications directed to our product candidates, our competitors might be able
to enter the market earlier than should otherwise have been the case, which could harm our business, financial condition, results of operations,
and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to protect our intellectual
property rights throughout the world.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Filing, prosecuting and defending
patents on our product candidates in all countries throughout the world would be prohibitively expensive and our intellectual property
rights in some countries outside of the United States, Europe, and Israel. The requirements for patentability may differ in certain countries,
particularly developing countries. For example, unlike other countries, China has a heightened requirement for patentability, and specifically
requires a detailed description of medical uses of a claimed drug. In addition, the laws of some foreign countries do not protect intellectual
property rights to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from practicing
our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained
patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent
protection, but enforcement on infringing activities is inadequate. These products may compete with our products, and our patents or other
intellectual property rights may not be effective or sufficient to prevent them from competing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Many companies have encountered
significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly
those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing
products in violation of our proprietary rights generally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Proceedings to enforce our
patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our
business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing,
and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other
remedies awarded, if any, may not be commercially meaningful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, some countries
have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we
may have limited remedies if our patents are infringed or if we are compelled to grant a license to our patents to a third party, which
could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to
enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual
property that we own or license. Finally, our ability to protect and enforce our intellectual property rights may be adversely affected
by unforeseen changes in foreign intellectual property laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to protect our trademarks
from infringement, our business prospects may be harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We plan to register trademarks
that identify PrimeC in the United States and Israel. Although we take steps to monitor the possible infringement or misuse of our trademarks,
it is possible that third parties may infringe, dilute or otherwise violate our trademark rights. Any unauthorized use of our trademarks
could harm our reputation or commercial interests. In addition, our enforcement against third-party&#160;infringers or violators may be
unduly expensive and time-consuming, and the outcome may be an inadequate remedy. Over the long term, if we are unable to successfully
register our trademarks and trade names and establish name recognition based on our trademarks and trade names, then we may not be able
to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to
trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial
costs and diversion of resources and could adversely impact our financial condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may become involved in lawsuits to protect
or enforce our patents or other intellectual property, which could be expensive and time consuming, delay or prevent the development and
commercialization of our products and product candidates or put our patents and other proprietary rights at risk.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Third parties may infringe
or misappropriate our intellectual property, including our existing patents, patents that may issue to us in the future. As a result,
we may be required to file infringement claims to stop third-party&#160;infringement or unauthorized use. Further, we may not be able
to prevent misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights
as fully as in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Generic drug manufacturers
may develop, seek approval for, and launch generic versions of our products. If we file an infringement action against such a generic
drug manufacturer, that company may challenge the scope, validity or enforceability of our patents, requiring us to engage in complex,
lengthy and costly litigation or other proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For example, if we initiated
legal proceedings against a third party to enforce a patent covering our product candidates, the defendant could counterclaim that the
patent covering our product candidates is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims
alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity
or unenforceability of a patent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, within and outside
of the United States, there has been a substantial amount of litigation and administrative proceedings, including inter partes review,
post grant review, interference or derivation proceedings, and ex parte reexamination proceedings before the USPTO or other comparable
proceedings in various foreign jurisdictions, regarding patent and other intellectual property rights in the pharmaceutical industry.
These proceedings bring uncertainty to the possibility of challenges to our patents in the future, including challenges by competitors
who perceive our patents as blocking entry into the market for their products, and the outcome of such challenges.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Such litigation and administrative
proceedings could result in revocation of our patents or amendment of our patents such that they do not cover our product candidates.
They may also put our pending patent applications at risk of not issuing, or issuing with limited and potentially inadequate scope to
cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect
to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner
were unaware during prosecution. Additionally, it is also possible that prior art of which we are aware, but which we do not believe affects
the validity or enforceability of a claim, may, nonetheless, ultimately be found by a court of law or an administration panel to affect
the validity or enforceability of a claim. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability,
we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could
have a negative impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Enforcing our intellectual
property rights through litigation would be very expensive, particularly for a company of our size, time-consuming, and inherently uncertain.
Some of our competitors may be able to sustain the costs of litigation more effectively than we can because of greater financial resources.
Patent litigation and other proceedings may also divert technical and management personnel from their normal responsibilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Uncertainties resulting from
the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The
occurrence of any of the foregoing could harm our business, financial condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a
risk that some of our confidential information could be compromised by disclosure. In addition, during the course of litigation or administrative
proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public
access to related documents. If investors perceive these results to be negative, the market price for our ordinary shares and Warrants
could be significantly harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may become subject to claims for remuneration
or royalties for assigned service invention rights by our employees, which could result in litigation and adversely affect our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A significant portion of
our intellectual property has been developed by our employees in the course of their employment for us. Under the Israeli Patent Law,
5727-1967, or the Patent Law, inventions conceived by an employee during the scope of his or her employment with a company are regarded
as &#8220;service inventions,&#8221; which belong to the employer, absent an agreement between the employee and employer providing otherwise.&#160;The
Patents Law also provides that if there is no agreement between an employer and an employee determining whether the employee is entitled
to receive consideration for service inventions and on what terms, this will be determined by the Israeli Compensation and Royalties Committee,
or the Committee, a body constituted under the Patents Law. Case law clarifies that the right to receive consideration for &#8220;service
inventions&#8221; can be waived by the employee and that in certain circumstances, such waiver does not necessarily have to be explicit.
The Committee will examine, on a case-by-case&#160;basis, the general contractual framework between the parties, using interpretation
rules of the general Israeli contract laws. Further, the Committee has not yet determined one specific formula for calculating this remuneration,
but rather uses the criteria specified in the Patents Law. Although we generally enter into agreements with our employees pursuant to
which such individuals assign to us all rights to any inventions created during and as a result of their employment with us, we may face
claims demanding remuneration in consideration for assigned inventions. As a consequence of such claims, we could be required to pay additional
remuneration or royalties to our current and/or former employees, or be forced to litigate such monetary claims (which will not affect
our proprietary rights), which could negatively affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third party claims alleging intellectual
property infringement may adversely affect our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our commercial success depends
in part on our avoiding infringement of the patents and proprietary rights of third parties, for example, the intellectual property rights
of competitors. Our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate
patents owned or controlled by third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned
by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries
expand and more patents are issued, the risk increases that our activities related to our product candidates may give rise to claims of
infringement of the patent rights of others. We cannot assure you that our product candidates will not infringe existing or future patents.
We may not be aware of patents that have already issued that a third party might assert are infringed by our product candidates. It is
also possible that patents of which we are aware, but which we do not believe are relevant to our product candidates, could nevertheless
be found to be infringed by our product candidates. Nevertheless, we are not aware of any issued patents that we believe would prevent
us from marketing our product candidates, if approved. There may also be patent applications that have been filed but not published that,
when issued as patents, could be asserted against us. In addition, patent holding companies that focus solely on extracting royalties
and settlements by enforcing patent rights may target us. As the biotechnology and pharmaceutical industries expand and more patents are
issued, the risk increases that we may be subject to claims of infringement of the intellectual property rights of third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Third parties making claims
against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable
relief, which could effectively block our ability to further develop and commercialize our product candidates. Further, if a patent infringement
suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product
candidate that is the subject of the suit. Defense of these claims, regardless of their merit, would cause us to incur substantial expenses
and, and would be a substantial diversion of management time and employee resources from our business. In the event of a successful claim
of infringement against us by a third party, we may have to (i) pay substantial damages, including treble damages and attorneys&#8217;
fees if we are found to have willfully infringed the third party&#8217;s patents; (ii) obtain one or more licenses from the third party;
(iii) pay royalties to the third party; and/or (iv) redesign any infringing products. Redesigning any infringing products may be impossible
or require substantial time and monetary expenditure. Further, we cannot predict whether any required license would be available at all
or whether it would be available on commercially reasonable terms. In the event that we could not obtain a license, we may be unable to
further develop and commercialize our product candidates, which could harm our business significantly. Even if we are able to obtain a
license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive,
which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing
a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims,
we are unable to enter into licenses on acceptable terms. Furthermore, even in the absence of litigation, we may need or may choose to
obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain
any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and
commercialize our product candidates, which could harm our business significantly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Defending ourselves in litigation
is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs
of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and
other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent
litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could harm
our business, financial condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims that our employees,
consultants or independent contractors have wrongfully used or disclosed confidential information or alleged trade secrets of third parties
or competitors or are in breach of non-competition or non-solicitation agreements with our competitors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We employ individuals who
were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants
or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information or trade secrets of these
third parties or our employees&#8217; former employers. Further, we may be subject to ownership disputes in the future arising, for example,
from conflicting obligations of consultants or others who are involved in developing our product candidates. We may also be subject to
claims that former employees, consultants, independent contractors, collaborators or other third parties have an ownership interest in
our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging our right
to and use of confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages,
we may lose our rights therein. Such an outcome could have a negative impact on our business. Even if we are successful in defending against
these claims, litigation could result in substantial cost and be a distraction to our management and employees. Any litigation or the
threat thereof may adversely affect our ability to hire employees. A loss of key personnel or their work product could hamper or prevent
our ability to commercialize product candidates, which could have an adverse effect on our business, results of operations and financial
condition.&#160;We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of
our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially
greater financial resources. Uncertainties resulting from the initiation and continuation of litigation proceedings could adversely affect
our ability to compete in the marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to Government Regulation </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the FDA does not conclude that PrimeC,
or our other product candidates satisfy the requirements under Section 505(b)(2) of the Federal Food Drug and Cosmetic Act, or Section
505(b)(2), or if the requirements for such product candidates are not as we expect, the approval pathway for these product candidates
will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated,
and in either case may not be successful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We intend to commence a pivotal
clinical trial for PrimeC under the FDA&#8217;s Section 505(b)(2) regulatory pathway. The Drug Price Competition and Patent Term Restoration
Act of 1984, also known as the Hatch-Waxman&#160;Act, added Section 505(b)(2) to the Federal Food, Drug and Cosmetic Act. Section 505(b)(2)
permits the filing of an NDA where at least some of the information required for approval comes from studies that were not conducted by
or for the applicant, and for which the applicant has not received a right of reference, which could expedite the development program
for PrimeC and our other product candidates by potentially decreasing the amount of preclinical and clinical data that we would need to
generate in order to obtain FDA approval. Although PrimeC is a formulation of two FDA-approved&#160;drugs, ciprofloxacin and celecoxib,
which will not be treated as new chemical entities, or NCEs, the submission of an NDA under the Section 505(b)(2) or similar regulatory
pathway does not preclude the FDA from determining that the product candidate that is the subject of such submission is an NCE and therefore
not eligible for review under such regulatory pathway.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Though we have received initial
agreement from the FDA for our development to continue under the 505(b)(2) pathway, the FDA may reverse that decision and not allow us
to pursue the Section 505(b)(2) or similar regulatory pathway as anticipated. In that case, we may need to conduct additional preclinical
experiments and clinical trials, provide additional data and information, and meet additional standards for regulatory approval. If this
were to occur, the time and financial resources required to obtain FDA approval for these product candidates, and complications and risks
associated with these product candidates, would likely increase significantly. Moreover, inability to pursue the Section 505(b)(2) or
similar regulatory pathway could result in new competitive products reaching the market more quickly than our product candidates, which
would likely harm our competitive position and prospects. Even if we are allowed to pursue the Section 505(b)(2) or similar regulatory
pathway, our product candidates may not receive the requisite approvals for commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, notwithstanding
the approval of a number of products by the FDA under Section 505(b)(2) over the last few years, certain competitors and others have objected
to the FDA&#8217;s interpretation of Section 505(b)(2). If the FDA&#8217;s interpretation of Section 505(b)(2) is successfully challenged,
the FDA may be required to change its 505(b)(2) policies and practices, which could delay or even prevent the FDA from approving any NDA
that we submit under Section 505(b)(2). In addition, the pharmaceutical industry is highly competitive, and Section 505(b)(2) NDAs are
subject to special requirements designed to protect the patent rights of sponsors of previously approved drugs that are referenced in
a Section 505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in the approval to market of our potential
future NDAs for up to 30&#160;months depending on the outcome of any litigation. It is not uncommon for a manufacturer of an approved
product to file a citizen petition with the FDA seeking to delays in the approval to market approval of, or impose additional approval
requirements for, pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval of
the new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers
and responds to the petition. In addition, even if we are able to utilize the Section 505(b)(2) regulatory pathway for our product candidates,
there is no guarantee this would ultimately lead to faster product development or earlier approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Moreover, even if these product
candidates are approved under the Section 505(b)(2) pathway, as the case may be, the approval may be subject to limitations on the indicated
uses for which the products may be marketed or to other conditions of approval, or may contain requirements for costly post-marketing&#160;testing
and surveillance to monitor the safety or efficacy of the products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We expect current and future legislation
affecting the healthcare industry, including healthcare reform, to impact our business generally and to increase limitations on reimbursement,
rebates and other payments, which could adversely affect third-party coverage of our products, our operations, and/or how much or under
what circumstances healthcare providers will prescribe or administer our products, if approved.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The United States and some
foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system
in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere,
there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving
quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been
significantly affected by major legislative initiatives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For example, in March 2010,
President Obama signed into law the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation
Act of 2010, or collectively, the ACA, a law intended, among other things, to broaden access to health insurance, improve quality of care,
and reduce or constrain the growth of healthcare spending.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Provisions of the ACA relevant
to the pharmaceutical industry include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs, not including orphan drug sales;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale&#160;discounts on negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the Federal Poverty Level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new requirements to report annually certain financial arrangements with physicians and teaching hospitals; as defined in the ACA and its implementing regulations, including reporting any payment or &#8220;transfer of value&#8221; provided to physicians and teaching hospitals and any ownership and investment interests held by physicians and their immediate family members during the preceding calendar year;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expansion of healthcare fraud and abuse laws, including the federal civil False Claims Act and the federal Anti-Kickback&#160;Statute, new government investigative powers and enhanced penalties for noncompliance; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a new Patient-Centered&#160;Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There have been judicial
and Congressional challenges to certain aspects of the ACA. As a result, there have been delays in the implementation of, and action taken
to repeal or replace, certain aspects of the ACA. In January 2017, President Trump signed an Executive Order directing federal agencies
with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision
of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers
of pharmaceuticals or medical devices. Further, in January 2017, Congress adopted a budget resolution for fiscal year 2017, or the Budget
Resolution, that authorizes the implementation of legislation that would repeal portions of the ACA. Following the passage of the Budget
Resolution, in March 2017, the U.S. House of Representatives introduced legislation known as the American Health Care Act, which, if enacted,
would amend or repeal significant portions of the ACA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, other legislative
changes have been proposed and adopted since the ACA was enacted. For example, in August 2011, President Obama signed into law the Budget
Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals
in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of an amount greater than $1.2&#160;trillion
for the years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes
aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which started in 2013 and, following
passage of the Bipartisan Budget Act of 2015, will stay in effect through 2025 unless additional Congressional action is taken. In January
2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to
several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments
to providers from three to five years. On August 16, 2022, President Biden signed into law the Inflation Reduction Act that is intended
to lower certain prescription drug costs under Medicare. The law permits the Medicare program to negotiate Medicare payments for a limited
number of drugs. Beginning in 2026, there will be 10 drugs; 2027-2029 there will be 15 drugs for each of those years; and 20 drugs for
each of the following years. In addition, the law set a cap of $2,000 in 2025 on out-of-pocket drug costs for Medicare eligible individuals.
Additionally, there have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more
transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under
Medicare, and reform government program reimbursement methodologies for drugs. Further, the U.S. House of Representatives recently formed
an Affordable Drug Pricing Task Force to advance legislation intended to control pharmaceutical drug costs and investigate pharmaceutical
drug pricing, and the U.S. Senate has requested information from certain pharmaceutical companies in connection with an investigation
into pharmaceutical drug pricing practices. If healthcare policies or reforms intended to curb healthcare costs are adopted, or if we
experience negative publicity with respect to the pricing of our products or the pricing of pharmaceutical drugs generally, the prices
that we charge for any approved products may be limited, our commercial opportunity may be limited and/or our revenues from sales of our
products may be negatively impacted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we obtain regulatory approval
and commercialization of PrimeC or any of our other product candidates, these laws may result in additional reductions in healthcare funding,
which could have an adverse effect on our customers and accordingly, our financial operations. Legislative and regulatory proposals have
been made to expand post-approval&#160;requirements and restrict sales and promotional activities for pharmaceutical products. We cannot
be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed,
or what the impact of such changes on the marketing approvals of PrimeC or our other product candidates may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although we cannot predict
the full effect on our business of the implementation of existing legislation or the enactment of additional legislation pursuant to healthcare
and other legislative reform, we believe that legislation or regulations that would reduce reimbursement for, or restrict coverage of,
our products could adversely affect how much or under what circumstances healthcare providers will prescribe or administer our products.
This could adversely affect our business by reducing our ability to generate revenues, raise capital, obtain licensees and market our
products. In addition, we believe the increasing emphasis on managed care in the United States has and will continue to put pressure on
the price and usage of pharmaceutical products, which may adversely impact product sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Orphan Drug Designation may not ensure that
we will enjoy market exclusivity in a particular market, and if we fail to obtain or maintain orphan drug exclusivity for our product
candidates, we may be subject to earlier competition and our potential revenue will be reduced.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Orphan Drug Designation entitles
a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax advantages, user-fee&#160;waivers
and market exclusivity for certain periods of time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA and the EMA have
both granted PrimeC orphan drug designation for the treatment of ALS. Even if we obtain Orphan Drug Designation for our other product
candidates, we may not be the first to obtain regulatory approval for any particular orphan indication due to the uncertainties associated
with developing biopharmaceutical products. Further, even if we obtain Orphan Drug Designation for a product candidate, that exclusivity
may not effectively protect the product from competition because different drugs with different active moieties can be approved for the
same condition. In addition, if a competitor obtains approval and marketing exclusivity for a drug product with an active moiety that
is the same as that in a product candidate we are pursuing for the same indication, approval of our product candidate would be blocked
during the period of marketing exclusivity unless we could demonstrate that our product candidate is clinically superior to the approved
product. In addition, if a competitor obtains approval and marketing exclusivity for a drug product with an active moiety that is the
same as that in a product candidate we are pursuing for a different orphan indication, this may negatively impact the market opportunity
for our product candidate. There have been legal challenges to aspects of the FDA&#8217;s regulations and policies concerning the exclusivity
provisions of the Orphan Drug Act, and future challenges could lead to changes that affect the protections afforded our product candidates
in ways that are difficult to predict.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we receive regulatory approval for
our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant
additional expenses, limit or withdraw regulatory approval and subject us to penalties if we fail to comply with applicable regulatory
requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If and when regulatory approval
has been granted, our product candidates or any approved product will be subject to continual regulatory review by the FDA and/or non-U.S.
regulatory authorities. Additionally, any product candidates, if approved, will be subject to extensive and ongoing regulatory requirements,
including labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory
requirements or experience unanticipated problems with our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any regulatory approvals
that we receive for our product candidates may also be subject to limitations on the approved indications for which the product may be
marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing&#160;testing, including Phase
4 clinical trials, and surveillance to monitor the safety and efficacy of the product. In addition, if the applicable regulatory agency
approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising,
promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include
submissions of safety and other post-marketing&#160;information and reports, registration, as well as continued compliance with cGMP and
GCP for any clinical trials that we conduct post-approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Later discovery of previously
unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or problems with our third-party&#160;manufacturers&#8217;
processes, or failure to comply with regulatory requirements, may result in, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, warnings letters or holds on clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizure or detention, or refusal to permit the import or export of products; and injunctions or the imposition of civil or criminal penalties.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ongoing regulatory requirements
may also change from time to time, potentially harming or making costlier our commercialization efforts. We cannot predict the likelihood,
nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States
or other countries. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies,
or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve
or sustain profitability, which would adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our relationships with healthcare professionals,
independent contractors, clinical investigators, CROs, consultants and vendors in connection with our current and future business activities
may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting,
and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face
penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may currently be or may
become subject to various U.S. federal and state health care laws, including those intended to prevent health care fraud and abuse.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The federal Anti-Kickback&#160;Statute
prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration
(including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either
the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which
payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid Remuneration has been broadly
defined to include anything of value, including, but not limited to, cash, improper discounts, and free or reduced price items and services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Federal false claims laws,
including the federal False Claims Act, or FCA, and civil monetary penalties law impose penalties against individuals or entities for,
among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are
false or fraudulent or making a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government.
The FCA has been used to, among other things, prosecute persons and entities submitting claims for payment that are inaccurate or fraudulent,
that are for services not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision
that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Many States have similar
fraud and abuse statutes and regulations that may be broader in scope and may apply regardless of payor, in addition to items and services
reimbursed under Medicaid and other state programs. State and federal authorities have aggressively targeted medical technology companies
for, among other things, alleged violations of these anti-fraud&#160;statutes, based on improper research or consulting contracts with
doctors, certain marketing arrangements that rely on volume-based&#160;pricing, off-label&#160;marketing schemes, and other improper promotional
practices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The federal Health Insurance
Portability and Accountability Act of 1996, or HIPAA, among other things, imposes criminal liability for knowingly and willfully executing,
or attempting to execute, a scheme to defraud any healthcare benefit program or knowingly and willfully falsifying, concealing or covering
up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items
or services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, HIPAA, as amended
by the Health Information Technology for Economic and Clinical Health Act, or HITECH Act, and their implementing regulations, also impose
certain obligations, including mandatory contractual terms, on certain types of individuals and entities with respect to safeguarding
the privacy, security and transmission of individually identifiable health information without proper written authorization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our operations will also
be subject to the federal transparency requirements under the ACA, which require certain manufacturers of drugs, devices, biologicals
and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific
exceptions, to annually report to the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health
and Human Services, or HHS, information related to payments and other transfers of value provided to physicians and teaching hospitals
and certain ownership and investment interests held by physicians and their immediate family members. We may also be subject to state
laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare
providers or marketing expenditures, and/or state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s
voluntary compliance guidelines and the relevant compliance guidelines promulgated by the federal government.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any of our business activities,
including but not limited to our relationships with healthcare providers, violate any of the aforementioned laws, we may be subject to
administrative, civil and/or criminal penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from
participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits
and future earnings and curtailment or restructuring of our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Also, the U.S. Foreign Corrupt
Practices Act and similar worldwide anti-bribery&#160;laws generally prohibit companies and their intermediaries from making improper
payments to non-U.S. officials for the purpose of obtaining or retaining business. We cannot assure you that our internal control policies
and procedures will protect us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators
or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative
impact on our business, results of operations and reputation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>It may be difficult for us to profitably
sell our product candidates if coverage and reimbursement for these products is limited by government authorities and/or third-party payor
policies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to any healthcare
reform measures which may affect reimbursement, market acceptance and sales of PrimeC and our other product candidates, if approved, will
depend on the coverage and reimbursement policies of government authorities and third-party&#160;payors. Government authorities and third-party&#160;payors,
such as private health insurers and health maintenance organizations, decide which medications they will cover and establish reimbursement
levels.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A primary trend in the U.S.
healthcare industry and elsewhere is cost containment. Third party payors decide which drugs they will pay for and establish reimbursement
and co-payment&#160;levels. Government and other third-party&#160;payors are increasingly challenging the prices charged for health care
products, examining the cost effectiveness of drugs in addition to their safety and efficacy, and limiting or attempting to limit both
coverage and the level of reimbursement for prescription drugs. We cannot be sure that coverage will be available for PrimeC or our other
product candidates, if approved, or, if coverage is available, the level of reimbursement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There is significant uncertainty
related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about reimbursement
for new medicines are typically made by CMS, an agency within the U.S. Department of HHS, as CMS decides whether and to what extent a
new medicine will be covered and reimbursed under Medicare. Private payors often follow CMS. It is difficult to predict what CMS as well
as other payors will decide with respect to reimbursement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Reimbursement may impact
the demand for, and/or the price of, any product for which we obtain marketing approval. Assuming we obtain coverage for a given product
by a third-party&#160;payor, the resulting reimbursement payment rates may not be adequate or may require co-payments&#160;that patients
find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians,
generally rely on third-party&#160;payors to reimburse all or part of the costs associated with their prescription drugs. Patients are
unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost
of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon
clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already
available or subsequently become available. There may be significant delays in obtaining coverage and reimbursement for newly approved
drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities.
Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers
our costs, including research, development, manufacture, sale and distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Reimbursement by a third-party&#160;payor
may depend upon a number of factors including the third-party&#160;payor&#8217;s determination that use of a product is:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a covered benefit under its health plan;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safe, effective and medically necessary;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appropriate for the specific patient;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effective; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">neither experimental nor investigational.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Obtaining coverage and reimbursement
approval for a product from a government or other third-party&#160;payor is a time-consuming&#160;and costly process that could require
us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. Further, no uniform
policy requirement for coverage and reimbursement for drug products exists among third-party&#160;payors in the United States. Therefore,
coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process
may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that
coverage and adequate reimbursement will be applied consistently or obtained in the first instance. We may not be able to provide data
sufficient to gain acceptance with respect to coverage and/or sufficient reimbursement levels. We cannot be sure that coverage or adequate
reimbursement will be available for PrimeC or any of our other product candidates, if approved. Also, we cannot be sure that reimbursement
amounts will not reduce the demand for, or the price of, our future products. If reimbursement is not available, or is available only
to limited levels, we may not be able to commercialize PrimeC or our other product candidates, or achieve profitably at all, even if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Legislative or regulatory healthcare reforms
in the United States or abroad may make it more difficult and costly for us to obtain regulatory clearance or approval of PrimeC or any
of our other product candidates now or in the future and to produce, market, and distribute our products after clearance or approval is
obtained.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">From time to time, legislation
is drafted and introduced in Congress or by governments in foreign jurisdictions that could significantly change the statutory provisions
governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition,
FDA or foreign regulatory agency regulations and guidance are often revised or reinterpreted by the FDA or the applicable foreign regulatory
agency in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing
regulations may impose additional costs or lengthen review times of PrimeC or any of our other product candidates now or in the future.
We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or
adopted may have on our business in the future. Such changes could, among other things, require:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes to manufacturing methods;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">change in protocol design;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional treatment arm (control);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recall, replacement, or discontinuance of one or more of our products; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional recordkeeping.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each of these would likely
entail substantial time and cost and could harm our business and our financial results. In addition, delays in receipt of or failure to
receive regulatory clearances or approvals for any future products would harm our business, financial condition, and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to an Investment in Our Ordinary
Shares and Warrants</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b><i>If we fail to maintain
compliance with Nasdaq&#8217;s continued listing requirements, our shares may be delisted from the Nasdaq Capital Market</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To continue to be listed
on the Nasdaq, we need to comply with the continued listing requirement, including a minimum closing bid price per share of $1.00 for
30 consecutive business days (the &#8220;Minimum Bid Price Rule&#8221;) and shareholders&#8217; equity of at least $2.5 million (the &#8220;Minimum
Equity Rule&#8221;). On December 21, 2023, we received a notice from the Listing Qualifications staff (the &#8220;Staff&#8221;) of The
Nasdaq Stock Market LLC indicating that we failed to comply with the continued listing requirement that we maintain either a minimum of
$2,500,000 in shareholders&#8217; equity or $35,000,000 market value of listed securities or $500,000 of net income from continuing operations
for the most recently completed fiscal year or two of the three most recently completed fiscal years, as set forth in Nasdaq Listing Rule
5550(b)(1) . On February 5, 2024, we submitted to the Staff a plan to regain compliance with the Minimum Equity Rule.&#160;After submitting
a plan to regain compliance, Nasdaq granted us an extension to regain compliance. On January 6, 2025, we announced that we had regained
compliance with the Minimum Equity Rule. Previously on September 5, 2023, we received notice from the Staff that we did not meet the Minimum
Bid Price Rule; however during February 2024, we regained compliance with the Minimum Bid Price Rule.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No assurance can be given
that we will be able to maintain compliance with the Minimum Equity Rule or the Minimum Bid Price Rule or comply with the other standards
that we are required to meet in order to maintain a listing on such exchange. Our failure to meet these requirements may result in our
securities being delisted from Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If our ordinary shares are
delisted from Nasdaq, we may seek to list them on other markets or exchanges or the ordinary shares may trade on the pink sheets. In the
event of such delisting, our shareholders&#8217; ability to trade, or obtain quotations of the market value of, our ordinary shares would
be severely limited because of lower trading volumes and transaction delays. These factors could contribute to lower prices and larger
spreads in the bid and ask prices for our securities. In addition, the substantially decreased trading in the ordinary shares and decreased
market liquidity of the ordinary shares as a result of the loss of market efficiencies associated with Nasdaq and the loss of federal
preemption of state securities laws, which could materially adversely affect our ability to obtain financing on acceptable terms, if at
all, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development
opportunities. Additionally, the market price of the ordinary shares may decline further and shareholders may lose some or all of their
investment. There can be no assurance that the ordinary shares, if delisted from the Nasdaq in the future, would be listed on another
national or international securities exchange or on a national quotation service, the Over-The-Counter Markets or the pink sheets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market price of our ordinary shares
and Warrants may be subject to fluctuation and you could lose all or part of your investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The stock market in general
has been, and the market price of our ordinary shares and Warrants in particular will likely be, subject to fluctuation, whether due to,
or irrespective of, our operating results and financial condition. The market price of our ordinary shares and Warrants on the Nasdaq
Capital Market may fluctuate as a result of a number of factors, some of which are beyond our control, including, but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to continue as a going concern;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">success, delay or failure of our research and development projects or those of our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated variations in our and our competitors&#8217; results of operations and financial condition;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">physician and market acceptance of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the mix of products that we sell;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our success or failure to obtain approval for and commercialize our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in earnings estimates or recommendations by securities analysts, if our ordinary shares and Warrants are covered by analysts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">development of technological innovations or new competitive products by others;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of technological innovations or new products by us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication of the results of preclinical or clinical trials for PrimeC or our other product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by us to achieve a publicly announced milestone;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays between our expenditures to develop and market new or enhanced product candidates and the generation of sales from those products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments concerning intellectual property rights, including our involvement in litigation brought by or against us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory developments and the decisions of regulatory authorities as to the approval or rejection of new or modified products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the amounts that we spend to develop, acquire or license new products, technologies or businesses;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in our expenditures to promote our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our sale or proposed sale, or the sale by our significant shareholders, of our ordinary shares, Warrants or other securities in the future;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in key personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the trading volume of our ordinary shares and Warrants; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general economic and market conditions and other factors, including factors unrelated to our operating performance.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These factors and any corresponding
price fluctuations may negatively impact the market price of our ordinary shares and Warrants and result in substantial losses being incurred
by our investors. In the past, following periods of market volatility, public company shareholders have often instituted securities class
action litigation. If we were involved in securities litigation, it could impose a substantial cost upon us and divert the resources and
attention of our management from our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If equity research analysts do not publish
research or reports about our business or if they issue unfavorable commentary or downgrade our ordinary shares and Warrants, the price
of our ordinary shares and Warrants could decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The trading market for our
ordinary shares and Warrants will rely in part on the research and reports that equity research analysts publish about us and our business,
if at all. We do not have control over these analysts and we do not have commitments from them to write research reports about us. The
price of our ordinary shares and Warrants could decline if no research reports are published about us or our business, or if one or more
equity research analysts downgrade our ordinary shares and Warrants or if those analysts issue other unfavorable commentary or cease publishing
reports about us or our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future sales of our ordinary shares could
reduce the market price of our ordinary shares and Warrants.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If our existing shareholders,
particularly our directors, their affiliates, or our executive officers, sell a substantial number of our ordinary shares and Warrants
in the public market, the market price of our ordinary shares and Warrants could decrease significantly. The perception in the public
market that our shareholders might sell our ordinary shares and Warrants could also depress the market price of our ordinary shares and
Warrants and could impair our future ability to obtain capital, especially through an offering of equity securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The market price of our ordinary
shares and Warrants may drop significantly at such time as we sell additional ordinary shares or similar securities in order to raise
capital. A decline in the price of our ordinary shares and Warrants might impede our ability to raise capital through the issuance of
additional ordinary shares, Warrants or other equity securities, and may cause you to lose part or all of your investment in our ordinary
shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The significant share ownership position
of our officers, directors and entities affiliated with certain of our directors may limit your ability to influence corporate matters.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of March 31, 2025, our
officers, directors and entities affiliated with certain of our directors beneficially own or control, directly or indirectly, approximately
21% of our outstanding ordinary shares. Accordingly, these persons will be able to significantly influence, though not independently determine,
the outcome of matters required to be submitted to our shareholders for approval, including decisions relating to the election of our
board of directors, and the outcome of any proposed merger or consolidation of our company. These interests may not be consistent with
those of our other shareholders. In addition, these persons&#8217; significant interest in us may discourage third parties from seeking
to acquire control of us, which may adversely affect the market price of our ordinary shares and Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have never paid cash dividends on our
share capital, and we do not anticipate paying any cash dividends in the foreseeable future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have never declared or
paid cash dividends on our share capital, nor do we anticipate paying any cash dividends on our share capital in the foreseeable future.
We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. As a result,
capital appreciation, if any, of our ordinary shares and Warrants will be investors&#8217; sole source of gain for the foreseeable future.
In addition, Israeli law limits our ability to declare and pay dividends, and may subject our dividends to Israeli withholding taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We incur significant increased costs as
a result of operating as a public company in the United States, and our management is required to devote substantial time to new compliance
initiatives.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a public company whose
ordinary shares and Warrants are listed in the United States, we are subject to an extensive regulatory regime, requiring us, among other
things, to maintain various internal controls and facilities and to prepare and file periodic and current reports and statements, including
reports on the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley&#160;Act of
2002. Complying with these requirements is costly and time consuming. We may need to retain additional employees to supplement our current
finance staff, and we may not be able to do so in a timely manner, or at all. In the event that we are unable to demonstrate compliance
with our obligations as a public company in a timely manner, or are unable to produce timely or accurate financial statements, we may
be subject to sanctions or investigations by regulatory authorities, such as the Securities and Exchange Commission, or the SEC, or the
Nasdaq Capital Market, and investors may lose confidence in our operating results and the price of our ordinary shares and Warrants could
decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our independent registered
public accounting firm has not been engaged to perform an audit of our internal control over financial reporting, and as long as we remain
an emerging growth company, as such term is defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, we are exempt
from the requirement to have an independent registered public accounting firm perform such audit. Accordingly, no such opinion was expressed
or will be expressed any during any such period. Once we cease to qualify as an emerging growth company our independent registered public
accounting firm will be required to attest to our management&#8217;s annual assessment of the effectiveness of our internal controls over
financial reporting, which will entail additional costs and expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>The Warrants may not have any
value.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Warrants are exercisable
for five years from the date of initial issuance at an initial exercise price equal to $6.00. There can be no assurance that the market
price of our ordinary shares will ever equal or exceed the exercise price of the Warrants. In the event that our ordinary share price
does not exceed the exercise price of the Warrants during the period when the Warrants are exercisable, the Warrants may not have any
value.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>A Warrant does not entitle the holder to
any rights as a holder of our ordinary shares until the holder exercises the Warrant for an ordinary shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Until you acquire an ordinary
share upon exercise of your Warrants, your Warrants will not provide you any rights as a holder of ordinary shares. Upon exercise of your
Warrants, you will be entitled to exercise the rights of a holder of ordinary shares only as to matters for which the record date occurs
after the exercise date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We expect to be classified as a &#8220;passive
foreign investment company&#8221; for U.S. federal income tax purposes, in the current taxable year as well as in future taxable years
which could cause adverse U.S. federal income tax consequences to U.S. investors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect to be classified
as a passive foreign investment company, or PFIC, for the taxable year ending December&#160;31, 2024, and we expect to be treated as a
PFIC in the current taxable year as well as in future taxable years. The determination of our PFIC status is made based on the factual
tests described below. Consequently, we cannot provide any assurances regarding our PFIC status for the current or future taxable years
or that the United States Internal Revenue Service, or IRS will agree with our conclusion regarding our PFIC status. Generally, if, for
any taxable year, at least 75&#160;percent of our gross income is &#8220;passive income&#8221; or at least 50&#160;percent of our gross
assets during the taxable year (based on the average of the fair market values of the assets determined at the end of each quarterly period)
are assets that produce or are held for the production of passive income, we would be characterized as a PFIC for U.S. federal income
tax purposes. Passive income for this purpose generally includes, among other things, dividends, interest, rents, royalties, gains from
commodities and securities transactions, and gains from assets that produce passive income. Passive income also includes amounts derived
by reason of the temporary investment of funds, including those raised in a public offering. However, rents and royalties received from
unrelated parties in connection with the active conduct of a trade or business are not considered passive income for purposes of the PFIC
test. If we are a PFIC for any taxable year in which a U.S. Holder (as defined in &#8220;Taxation&#8212;Certain Material United States
Federal Income Tax Considerations&#8221;) holds our ordinary shares or Warrants, certain adverse United States federal income tax consequences
could apply to such U.S. Holder. Such adverse consequences of PFIC status may be alleviated if a U.S. Holder makes a &#8220;mark to market&#8221;
election or an election to treat us as a &#8220;qualified electing fund&#8221;, or QEF. These elections would result in an alternative
treatment (such as mark-to-market treatment) of our ordinary shares. While we intend to provide to U.S. Holders the information required
to make a valid QEF election upon request, we cannot provide any assurances that we will have timely knowledge of our status as a PFIC,
or that the information that we provide will be adequate to allow U.S. Holders to make a QEF election.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Whether we are a PFIC for
any taxable year will depend on the composition of our income and the composition and value of our assets (which may be determined in
large part by reference to the market value of our ordinary shares, which may be volatile) from time to time, therefore there can be no
assurance regarding our PFIC status for the current or future taxable years. Each U.S. Holder is strongly urged to consult its tax advisor
regarding the possible application of the PFIC rules and any available elections to mitigate such tax consequences. For more information,
see &#8220;Taxation&#8212;Certain Material United States Federal Income Tax Considerations&#8212;Passive Foreign Investment Company Considerations.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If a United States person is treated as
owning at least 10% of our ordinary shares, such holder may be subject to adverse U.S. federal income tax consequences.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If a United States person
is treated as owning (directly, indirectly, or constructively) at least 10% of the value or voting power of our ordinary shares, such
person may be treated as a &#8220;United States shareholder&#8221; with respect to each controlled foreign corporation, or CFC, in our
group (if any). Because our group includes a U.S. subsidiary, certain of our non-U.S. subsidiaries will be treated as CFCs (regardless
of whether or not we are treated as a CFC). A United States shareholder of a CFC may be required to report annually and include in its
U.S. taxable income its pro rata share of &#8220;Subpart F income,&#8221; &#8220;global intangible low-taxed income,&#8221; and investments
in U.S. property by CFCs, regardless of whether we make any distributions. An individual that is a United States shareholder with respect
to a CFC generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder
that is a U.S. corporation. Failure to comply with these reporting obligations may subject a United States shareholder to significant
monetary penalties and may prevent the statute of limitations with respect to such shareholder&#8217;s U.S. federal income tax return
for the year for which reporting was due from starting. We cannot provide any assurances that we will assist investors in determining
whether we are treated as CFC or whether any investor is treated as a United States shareholder with respect to any such CFC or furnish
to any United States shareholders information that may be necessary to comply with the aforementioned reporting and tax paying obligations.
The IRS has provided limited guidance on situations in which investors may rely on publicly available information to comply with their
reporting and tax paying obligations with respect to foreign-controlled CFCs. Each U.S. Holder should consult its advisors regarding the
potential application of these rules to an investment in our ordinary shares or Warrants.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a foreign private issuer, we are permitted,
and intend, to follow certain home country corporate governance practices instead of otherwise applicable Nasdaq requirements, and are
not be subject to certain U.S.&#160;securities laws including, but not limited to, U.S. proxy rules and the filing of certain Exchange
Act reports.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a foreign private issuer,
we are permitted, and intend, to follow certain home country corporate governance practices instead of those otherwise required by the
Nasdaq Stock Market for domestic U.S.&#160;issuers. Following our home country governance practices as opposed to the requirements that
would otherwise apply to a U.S. company listed on the Nasdaq Capital Market may provide less protection to you than what is accorded to
investors under the Nasdaq Rules applicable to domestic U.S. issuers. See &#8220;Item 16G &#8211; Corporate Governance&#8221; for additional
information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a foreign private issuer,
we are exempt from the rules and regulations under the Exchange Act, related to the furnishing and content of proxy statements, including
disclosures with respect to executive compensation. Nevertheless, pursuant to regulations promulgated under the Israeli Companies Law,
5759-1999, or the Israeli Companies Law, we are required to disclose the annual compensation of our five most highly compensated office
holders on an individual basis. Such disclosure will not be as extensive as that required of a U.S. domestic issuer. Our officers, directors
and principal shareholders will also be exempt from the reporting and short-swing&#160;profit recovery provisions contained in Section
16 of the Exchange Act. In addition, we are required under the Exchange Act to file reports and financial statements with the SEC as frequently
or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act and are exempt from filing quarterly
reports with the SEC under the Exchange Act. Moreover, we are not required to comply with Regulation FD, which restricts the selective
disclosure of material information, although we have voluntarily adopted a corporate disclosure policy substantially similar to Regulation
FD. These exemptions and leniencies will reduce the frequency and scope of information and protections to which you may otherwise have
been eligible in relation to a U.S.&#160;domestic issuer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We would lose our foreign
private issuer status if a majority of our shares are owned by U.S. residents and a majority of our directors or executive officers are
U.S. citizens or residents or we fail to meet additional requirements necessary to avoid loss of foreign private issuer status. The regulatory
and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly higher. If we are not a foreign private
issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are
more detailed and extensive than the forms available to a foreign private issuer. We may also be required to modify certain of our policies
to comply with accepted governance practices associated with U.S. domestic issuers. Such conversion and modifications will involve additional
costs. In addition, we would lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges
that are available to foreign private issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are an emerging growth company and the
reduced disclosure requirements applicable to emerging growth companies may make our ordinary shares less attractive to investors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are an emerging growth
company, as defined in the JOBS Act, and we may take advantage of certain exemptions from various requirements that are applicable to
other public companies that are not emerging growth companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For as long as we remain
an emerging growth company we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable
to other public companies that are not &#8220;emerging growth companies.&#8221; These exemptions include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced disclosure obligations regarding executive compensation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemption from the requirement for auditors to include critical audit matters in their audit reports; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will remain an emerging
growth company until the earliest of: (i) the last day of our fiscal year during which we have total annual gross revenues of at least
$1.235&#160;billion; (ii) the last day of our fiscal year following the fifth anniversary of the closing of our initial public offering;
(iii) the date on which we have, during the previous three-year&#160;period, issued more than $1.0&#160;billion in non-convertible&#160;debt;
or (iv) the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the Exchange Act. We have opted out of the
extended transition period made available to emerging growth companies to comply with newly adopted public company accounting requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">When we are no longer deemed
to be an emerging growth company, we will not be entitled to the exemptions provided in the JOBS Act discussed above. We cannot predict
if investors will find our ordinary shares or Warrants less attractive as a result of our reliance on exemptions under the JOBS Act. If
some investors find our ordinary shares or Warrants less attractive as a result, there may be a less active trading market for our ordinary
shares or Warrants and our share price may be more volatile.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Environmental, social and corporate governance,
or ESG, issues, including those related to climate change and sustainability, may have an adverse effect on our business, financial condition
and results of operations and damage our reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There is an increasing focus
from certain investors, customers, consumers, employees and other stakeholders concerning ESG matters. Additionally, public interest and
legislative pressure related to public companies&#8217; ESG practices continue to grow. If our ESG practices fail to meet regulatory requirements
or investor, customer, consumer, employee or other shareholders&#8217; evolving expectations and standards for responsible corporate citizenship
in areas including environmental stewardship, support for local communities, board of Directors and employee diversity, human capital
management, employee health and safety practices, product quality, supply chain management, corporate governance and transparency, our
reputation, brand and employee retention may be negatively impacted, and our customers and suppliers may be unwilling to continue to do
business with us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Customers, consumers, investors
and other shareholders are increasingly focusing on environmental issues, including climate change, energy and water use, plastic waste
and other sustainability concerns. Concern over climate change may result in new or increased legal and regulatory requirements to reduce
or mitigate impacts to the environment. Changing customer and consumer preferences or increased regulatory requirements may result in
increased demands or requirements regarding plastics and packaging materials, including single-use and non-recyclable plastic products
and packaging, other components of our products and their environmental impact on sustainability, or increased customer and consumer concerns
or perceptions (whether accurate or inaccurate) regarding the effects of substances present in certain of our products. Complying with
these demands or requirements could cause us to incur additional manufacturing, operating or product development costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we do not adapt to or
comply with new regulations, including the SEC&#8217;s recently adopted new rules that require companies to provide expanded climate-related
disclosures in their periodic reporting, which may require us to incur significant additional costs to comply and impose increased oversight
obligations on our management and board of directors, or fail to meet evolving investor, industry or stakeholder expectations and concerns
regarding ESG issues, investors may reconsider their capital investment in our company, we may become subject to penalties, and customers
and consumers may choose to stop purchasing our products, if approved for commercialization, which could have a material adverse effect
on our reputation, business or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks Related to our Operations in Israel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We conduct some of our operations in Israel.
Conditions in Israel, including the recent attack by Hamas and other terrorist organizations from the Gaza Strip and Israel&#8217;s war
against them, may affect our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our corporate headquarters
is located in Herzliya, Israel. Because we are incorporated under the laws of the State of Israel, and most of our officers and fourteen
out of sixteen of our employees are residents of Israel, our business and operations are directly affected by economic, political, geopolitical
and military conditions in Israel. Since the establishment of the State of Israel in 1948, a number of armed conflicts have occurred between
Israel and its neighboring countries and terrorist organizations active in the region. These conflicts have involved missile strikes,
hostile infiltrations and terrorism against civilian targets in various parts of Israel, which have negatively affected business conditions
in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In October 2023, Hamas terrorists
infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas
also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza
Strip and in other areas within the State of Israel. These attacks resulted in thousands of deaths and injuries, and Hamas additionally
kidnapped many Israeli civilians and soldiers.&#160;Following the attack, Israel&#8217;s security cabinet declared war against Hamas and
a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. In parallel,
border clashes between Israel and the Hezbollah terrorist group on Israel&#8217;s northern border with Lebanon intensified and may escalate
into a greater regional conflict.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, since the commencement
of these events, there have been continued hostilities along Israel&#8217;s northern border with Lebanon (with the Hezbollah terror organization)&#160;and
on other fronts from various extremist groups in region, such as the Houthis in Yemen and various rebel militia groups in Syria and Iraq.
In October 2024, Israel began limited ground operations against Hezbollah in Lebanon, and in November 2024, a ceasefire was brokered between
Israel and Hezbollah. In addition, in April 2024 and October 2024, Iran (in concert with other regional actors) launched direct attacks
on Israel involving hundreds of drones and missiles and has threatened to continue to attack Israel and is widely believed to be developing
nuclear weapons. Such attacks may continue due to continuing tensions in the region. In addition, the collapse of the Assad regime in
Syria in December 2024 has led to increased instability in the region. Additionally, Yemeni rebel group, the Houthis, launched series
of attacks on global shipping routes in the Red Sea, causing disruptions of supply chain. Any or all of these conflicts may potentially
escalate in the future to more violent events which may affect Israel and us and adversely affect our ability to continue carrying out
various administrative, research, operational and commercial functions and activities both in Israel and globally.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any hostilities, armed conflicts,
terrorist activities involving Israel or the interruption or curtailment of trade between Israel and its trading partners, or any political
instability in the region could directly or indirectly adversely affect business conditions and our results of operations and could make
it more difficult for us to raise capital and could adversely affect the market price of our ordinary share. An escalation of tensions
or violence might result in a significant downturn in the economic or financial condition of Israel, which could have a material adverse
effect on our operations in Israel and our business. Parties with whom we do business have sometimes declined to travel to Israel during
periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary in order to meet our business partners
face to face. In addition, the political and security situation in Israel may result in parties with whom we have agreements involving
performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure
provisions in such agreements.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Israel Defense Force,
or IDF, the national military of Israel, is a conscripted military service, subject to certain exceptions. Since October 7, 2023, the
IDF has called up several hundred thousand of its reserve forces to serve. Sixteen out of our current 18 employees are resident in Israel.
Three of our five executive officers and the 13 other non-management employees of the Company reside in Israel. Currently none of our
executive officers nor non-management employees have been called up to perform reserve military service; however, some employees may be
called for service in the current or future wars or other armed conflicts with Hamas, Hezbollah or other regional threat actors, and such
persons may be absent for an extended period of time. As a result, our operations in Israel may be disrupted by such absences, which disruption
may materially and adversely affect our business, prospects, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since the war broke out on
October 7, 2023, our operations have not been adversely affected by this situation, and we have not experienced disruptions to our clinical
studies. As such, our clinical and business development activities remain on track. However, the intensity and duration of Israel&#8217;s
current war against Hamas and Hezbollah is difficult to predict at this stage, as are such war&#8217;s economic implications on our business
and operations and on Israel&#8217;s economy in general. If the ceasefire declared collapses or a new war commences or hostilities expand
to other fronts, our operations may be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our&#160;clinical and pre-clinical&#160;research
and development is&#160;currently&#160;being conducted in Israel,&#160;&#160;including Phase 2 trial&#160;with PrimeC&#160;for&#160;AD
which has not been affected by the war, although the quality of the study may be adversely affected if as a result of the war patients
are unable to visit the study center or the study coordinator is not able to conduct home visits and monitor the&#160;patients. We do
not believe the AD trial will be materially affected by the war and do not anticipate any delays as a result of the war would have a material
impact on us. We may also elect to set up a site in Israel for a Phase 3 pivotal ALS trial of PrimeC, but this would be in addition to
numerous other sites in United States and Europe, and as a result we do not expect the timeline or quality of this trial to be adversely
affected by the war. Our manufacturing is conducted in India. We do not currently anticipate any disruption to the supply chain relevant
to our ongoing clinical trials and believe there are alternative sources of supply from whom we could obtain the necessary finished drug
product to conduct our clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our commercial insurance
does not cover losses that may occur as a result of an event associated with the security situation in the Middle East. Although the Israeli
government is currently committed to covering the reinstatement value of direct damages that are caused by terrorist attacks or acts of
war, there can be no assurance that this government coverage will be maintained, or if maintained, will be sufficient to compensate us
fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business, financial condition
and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Finally, political conditions
within Israel may affect our operations. Israel has held five general elections between 2019 and 2022, and prior to October 2023 and more
recently, the Israeli government has pursued extensive changes to Israel&#8217;s judicial system, which has sparked extensive political
debate and unrest. Actual or perceived political instability in Israel or any negative changes in the political environment, may individually
or in the aggregate adversely affect the Israeli economy and, in turn, our business, financial condition, results of operations and growth
prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Provisions of Israeli law and our amended
and restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, us, even when the terms
of such a transaction are favorable to us and our shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Israeli corporate law regulates
mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving
directors, officers or significant shareholders and regulates other matters that may be relevant to such types of transactions. For example,
a tender offer for all of a company&#8217;s issued and outstanding shares can only be completed if shareholders not accepting the tender
offer hold less than 5% of the issued share capital. Completion of the tender offer also requires approval of a majority of the offerees
that do not have a personal interest in the tender offer, unless shareholders not accepting the tender offer hold less than 2% of the
company&#8217;s outstanding shares. Furthermore, the shareholders, including those who indicated their acceptance of the tender offer,
may, at any time within six months following the completion of the tender offer, petition an Israeli court to alter the consideration
for the acquisition, unless the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek such appraisal
rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Furthermore, Israeli tax
considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax
treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free&#160;share exchanges
to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes
the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years from the
date of the transaction during which sales and dispositions of shares of the participating companies are subject to certain restrictions.
Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes
payable even if no disposition of the shares has occurred. These provisions could delay, prevent or impede an acquisition of us or our
merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>It may be difficult to enforce a judgment
of a U.S. court against us or our officers and directors in Israel or the United States, to assert U.S. securities laws claims in Israel
or to serve process on our officers and directors and these experts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are incorporated in Israel.
A number of our directors and all of our executive officers reside outside of the United States, and most of our assets and most of the
assets of these persons are located outside of the United States. Therefore, a judgment obtained against us, or any of these persons,
including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United
States and may not be enforced by an Israeli court. It may also be difficult for you to effect service of process on these persons in
the United States or to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear
a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum in which to bring
such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable
to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses,
which can be a time consuming and costly process. Certain matters of procedure will also be governed by Israeli law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There is little binding case
law in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgment against us
in Israel, you may not be able to collect any damages awarded by either a U.S. or foreign court.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Your rights and responsibilities as a shareholder
will be governed by Israeli law, which differs in some material respects from the rights and responsibilities of shareholders of U.S.
companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The rights and responsibilities
of the holders of our ordinary shares are governed by our amended and restated articles of association and by Israeli law. These rights
and responsibilities differ in some material respects from the rights and responsibilities of shareholders in U.S. companies. In particular,
a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights and performing
its obligations towards the company and other shareholders, and to refrain from abusing its power in the company, including, among other
things, in voting at a general meeting of shareholders on matters such as amendments to a company&#8217;s articles of association, increases
in a company&#8217;s authorized share capital, mergers and acquisitions and related party transactions requiring shareholder approval,
as well as a general duty to refrain from discriminating against other shareholders. In addition, a shareholder who is aware that it possesses
the power to determine the outcome of a vote at a meeting of the shareholders or to appoint or prevent the appointment of a director or
executive officer in the company has a duty of fairness toward the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There is limited case law
available to assist us in understanding the nature of these duties or the implications of these provisions. These provisions may be interpreted
to impose additional obligations and liabilities on holders of our ordinary shares that are not typically imposed on shareholders of U.S.
companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our amended and restated articles of association
provide that, unless we consent otherwise, the District Court (Economic Division), located in Tel Aviv, Israel shall be the sole and exclusive
forum for substantially all disputes between us and our shareholders under the Companies Law and the Israeli Securities Law, which could
limit our shareholders&#8217; ability to bring claims and proceedings against, as well as obtain favorable judicial forum for disputes
with, us, our directors, officers and other employees.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The District Court (Economic
Division), located in Tel Aviv, Israel shall be the exclusive forum for (i) any derivative action or proceeding brought on behalf of us,
(ii) any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of ours to us or our shareholders,
or (iii) any action asserting a claim arising pursuant to any provision of the Companies Law or the Israeli Securities Law. This exclusive
forum provision is intended to apply to claims arising under Israeli law and would not apply to claims brought pursuant to the Securities
Act or the Exchange Act or any other claim for which U.S. federal courts would have exclusive jurisdiction. Such exclusive forum provision
in our amended and restated articles of association will not relieve us of our duties to comply with federal securities laws and the rules
and regulations thereunder, and our shareholders will not be deemed to have waived our compliance with these laws, rules and regulations.
This exclusive forum provision may limit a shareholder&#8217;s ability to bring a claim in a judicial forum of its choosing for disputes
with us or our directors, officers or other employees, which may discourage lawsuits against us, our directors, officers and other employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_033"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 4. INFORMATION ON THE COMPANY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b>A. History and Development of the
Company </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our legal and commercial
name is NeuroSense Therapeutics Ltd. Our company was incorporated on February 13, 2017 and was registered as a private company limited
by shares under the laws of the State of Israel. Our principal executive offices are located at 11 Hamenofim, Herzliya, Israel. Our telephone
number is +972-9-7996183.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our website address is&#160;https://www.neurosense-tx.com.
We use our website as a channel of distribution of Company information. The information we post on our website may be deemed material.
Accordingly, investors should monitor our website, in addition to following our press releases, SEC filings and public conference calls
and webcasts. However, the information contained on our website, or that can be accessed therefrom, does not constitute a part of this
annual report and is not incorporated by reference herein. We have included our website address in this annual report solely for informational
purposes. Our agent for service of process in the United States is Cogency Global Inc., located at 122&#160;East 42nd Street, 18th Floor,
New York, New York 10168.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In December 2021 we completed
our initial public offering on The Nasdaq Capital Market, pursuant to which we received net proceeds of approximately&#160;$9.9 million,
after deducting underwriting discounts and commissions and offering expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Ordinary Shares and Warrants
are traded on The Nasdaq Capital Market under the symbols &#8220;NRSN&#8221; and &#8220;NRSNW,&#8221; respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our capital expenditures
for the years ended December 31, 2024 and 2023 were approximately $3 thousand and $29 thousand, respectively. Our current capital expenditures
involve the purchase of equipment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify"><b>B. Business Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a clinical-stage biotechnology
company focused on discovering and developing treatments for people living with neurodegenerative diseases, including ALS AD and PD. We
believe these diseases represent some of the most significant unmet medical needs of our time, with limited effective therapeutic options
available. The burden of these diseases on both patients and society is substantial. For example, the average annual cost of ALS alone
is $180,000 per patient, and its estimated annual burden on the U.S.&#160;healthcare system is greater than $1&#160;billion. Due to the
complexity of neurodegenerative diseases, our strategy is utilizing a combined therapeutic approach to target multiple disease-related
pathways.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our lead therapeutic candidate,
PrimeC, is a novel extended-release oral formulation, fixed-dose combination of two FDA-approved drugs, ciprofloxacin and celecoxib. PrimeC
is designed to treat ALS by modulating microRNA synthesis, iron accumulation, and neuroinflammation, all of which are hallmarks of ALS
pathology. The U.S.&#160;Food and Drug Administration, or the FDA and the European Medicines Agency, or the EMA have granted PrimeC orphan
drug designation for the treatment of ALS.&#160;In addition, the EMA has granted PrimeC the Small and Medium-Sized Enterprise, or SME,
status, which offers significant potential benefits leading up to and following drug regulatory approval. We believe PrimeC&#8217;s multifunctional
mechanism of action has the potential to significantly prolong lifespan and improve ALS patients&#8217; quality of life, thereby reducing
the burden of this debilitating disease on both patients and healthcare systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">PrimeC was evaluated in PARADIGM,
a Phase&#160;2b randomized, multi-center, multinational, prospective, double-blind, placebo-controlled study, to evaluate safety, tolerability,
and efficacy of PrimeC in 68 people living with ALS.&#160;Participants were being administered PrimeC or placebo at a 2:1 ratio, respectively,
for the six-month double-blind part. Study participants were allowed to continue standard of care treatment of approved products. The
primary endpoints of the study are an evaluation of ALS-biomarkers as well as safety and tolerability assessment. Secondary and exploratory
endpoints are the evaluation of clinical efficacy (ALS Functional Rating Scale&#160;&#8212;&#160;Revised, or ALSFRS-R, and slow vital
capacity), survival, and improvement in quality of life. All subjects who completed the six-month double-blind, placebo-controlled dosing
period had the opportunity to be transferred to the PrimeC active arm for a 12-month open label extension. The study completed enrollment
in May&#160;2023, enrolling 69 participants, in which 68 are living with ALS and one participant who was misdiagnosed for ALS and was
excluded from the evaluations. Four ALS clinical centers participated in the study in three territories: Israel, Italy, and Canada. In
December 2023, we reported that we met the primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints
in the top-line results of our 6-month double-blind phase of PARADIGM. In May 2024, we announced new positive data analysis from PARADIGM
clinical trial demonstrating statistically significant slowing of disease progression in high-risk ALS patients. In July 2024, we announced
results from the 12-month analysis of the PARADIGM clinical trial which showed a significant improvement in the rate of decline of ALS
Functional Rating Scale-Revised (ALSFRS-R) scores and survival rates for subjects who received PrimeC from the start of the trial compared
to those who started on placebo. In August 2024, we announced positive 12-month biomarker data from the PARADIGM clinical trial, which
showed a significant decrease in ferritin levels and a corresponding increase in transferrin levels, both indicating alleviation of the
pathology. In October 2024, we completed the full 18-month dosing in PARADIGM, and in December 2024, we announced results from the 18-month
analysis of the PARADIGM clinical trial which showed statistically significant positive results from the 18-month data analysis of the
PARADIGM study, evaluating the efficacy of PrimeC in the treatment of ALS. In February 2025, we announced additional findings from an
18-month analysis of the PARADIGM clinical trial showing improvements in two additional endpoints, complication-free survival (analysis
which includes death from any cause or respiratory insufficiency&#160;or hospitalization due to ALS-related complications) and Slow Vital
Capacity (SVC), measuring respiratory function.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following the FDA&#8217;s
recommendation for additional non-clinical data to support long term use of Ciprofloxacin (as PrimeC is intended for long-term administration
in treating ALS) a long-term tox study was initiated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In September 2024, we announced
the successful completion of the in-life phase of the study, as we move towards the initiation of a Phase 3 study in the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In December 2024, we concluded
a productive Type C meeting with the FDA. The purpose of the meeting was to discuss the design of a proposed Phase 3 clinical study and
the plan for submission of an eventual 505(b)(2) marketing application. In light of the FDA&#8217;s feedback, we plan to submit a final
protocol to the FDA during the first half of 2025 and approach the EMA, with the aim of commencing enrollment of the pivotal Phase 3 study
in the second half of 2025, which would include approximately 300 patients divided by a ratio of 2:1, PrimeC to placebo. The Phase 3 study
is expected to be a randomized, multi-center, multinational, prospective, double-blind, placebo-controlled study, with an open label extension
(OLE), to evaluate the efficacy and safety of PrimeC in people living with ALS. Following 12 months of treatment, it is expected that
all participants will transition to PrimeC for a 12-month open label extension.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In December 2024, we <span>entered
into a binding term sheet with a leading global pharmaceutical company to advance the development and commercialization of PrimeC, in
certain key territories. We retain full rights to PrimeC in&#160;</span>other key territories. <span>The
binding term sheet outlines substantial financial terms from the pharmaceutical company, including: (i) a substantial upfront payment
upon signing a definitive agreement, (ii) funding for the Phase 3 clinical trial, (iii) regulatory and net sales milestone payments, and
(iv) a tiered royalty structure reaching double-digit percentage on annual net sales. The pharmaceutical company would have an exclusive
license to distribute, market, promote, sell and develop PrimeC for ALS in certain key markets, and non-exclusive rights for research
and manufacturing for PrimeC for ALS, subject to terms and conditions in the definitive agreement. The pharmaceutical company would have
an exclusive license to distribute, market, promote, sell and develop PrimeC for ALS in</span>&#160;certain key markets,&#160;<span>and
non-exclusive rights for research and manufacturing for PrimeC for ALS, subject to terms and conditions in the definitive agreement. The
closing of this transaction is subject to finalization of a definitive agreement. While both parties are communicating to find solutions
to the remaining open matters, there can be no assurance as to the timing of, or whether, such an agreement will ultimately be executed,
and if executed, what would be the final terms of such an agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">PrimeC was previously evaluated
in a Phase&#160;2a clinical trial, or NST002, in 15 people living with ALS, conducted at the Tel Aviv Sourasky Medical Center, Israel.
The primary endpoint of the NST002 trial, which was safety and tolerability, was met. In this trial, the safety profile observed was consistent
with known safety profiles of ciprofloxacin and celecoxib. Side effects were mild and transient in nature. There were no new or unexpected
safety signals detected during the trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, we observed
positive clinical signals in comparison to virtual controls, and a serum biomarker analysis showed significant changes following treatment,
indicating biological activity of the drug in comparison to untreated matched ALS patients. All 12 patients who completed the NST002 trial
elected to continue into an extension study with PrimeC, that was conducted as an Investigator Initiated Study. To date, we are still
supporting the drug supply for a few of the participants in this study, which is over than 40&#160;months since NST002 was initiated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We completed three additional
studies in 2022 as part of our drug development program to further support our future regulatory submissions. In April&#160;2022, we initiated
a pharmacokinetic, or PK, study, or NCT05232461, of PrimeC.&#160;The PK open-label, randomized, single-dose, three-treatment, three-period
crossover study evaluated the effect of food on the bioavailability of PrimeC as compared to the bioavailability of co-administered ciprofloxacin
tablets and celecoxib capsules in adult subjects in the U.S.&#160;under an FDA cleared IND protocol.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In August&#160;2022, we completed
enrollment and dosing of all subjects in a multi-dose PK study, or NCT05436678. On September&#160;28, 2022, we released the results of
the NCT05436678 study. Based on results, we believe the PK profile of PrimeC supports the formulation&#8217;s extended-release properties,
as the concentrations of the active components have been synchronized, aiming to potentially maximize the synergism between the two compounds.
In June&#160;2022, we reported the successful completion of the &#8220;in-life&#8221; phase of its 90-day GLP toxicology study. In this
study, the components of PrimeC, celecoxib and ciprofloxacin, were administered to rodents at doses 4x the maximal clinical dose. All
animals appeared normal, with no significant findings observed. We intend to present the data from these studies to the FDA as part of
PrimeC&#8217;s drug development plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe we have a strong
patent estate, including patents on method of use, combination, and formulation. We have secured U.S. Patent 10,980,780 relating to methods
for treatment of ALS using ciprofloxacin and celecoxib, the components of PrimeC, which expires in 2038. Equivalent patents also have
been issued in the European Patent Office, Canada, Australia, Israel and Japan. The patent estate also includes US Patent 12,097,185,
which relates to Prime C formulations. This patent will expire in December 2042. Equivalent applications are pending in many jurisdictions
worldwide. We also expect to take advantage of orphan drug exclusivity for PrimeC, if approved, for seven years in the United States and
ten years in the European Union. In addition, U.S. patent application 16/623,467, which relates to methods of treatment of neurodegenerative
disease using combinations of ciprofloxacin and celecoxib, is currently pending. This patent application, once granted, is expected to
expire on June 20, 2038.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our organization is built
around a management team with extensive experience in the pharmaceutical industry, with a particular focus on ALS research and clinical
trials. We believe that our leadership team is well-positioned to lead us through clinical development, regulatory approval and commercialization
of our product candidates. Furthermore, we maintain steadfast and extensive communication and collaboration with patient advocacy groups
and associations, underscoring the importance of patient perspectives in advancing therapeutic strategies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to PrimeC, we
extended our pipeline and conducted research and development efforts for AD and PD, with a similar strategy of combined products. The
following chart represents our current product development pipeline:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview of ALS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">ALS, which is also commonly
referred to as Lou Gehrig&#8217;s disease, is a rapidly progressing neurological disease with the onset typically occurring between 40
to 70 years of age, and patient mortality occurring in most patients within two to five years of diagnosis. ALS causes the death of motor
neurons, which are responsible for controlling muscles, resulting in weakness and paralysis of limbs, and impacts speaking, chewing, swallowing
and breathing, leading to progressive disability and eventually death, typically from respiratory failure and aspiration pneumonia. In
addition, up to 50% of patients with ALS develop cognitive impairment associated with frontotemporal dementia. The underlying cause of
damage to the motor neurons is unknown, but many pathologies can be observed, including dysregulation of miRNA, iron accumulation, neuroinflammation,
glutamate excitotoxicity, protein misfolding and oxidative stress.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">About 10% of ALS cases are
inherited, commonly referred to as &#8220;familial ALS,&#8221; and are associated with pathogenic mutations, while the remaining 90% of
cases present with sporadic onset. Over the last decade, sequencing of patients&#8217; genomes has helped pinpoint the genetic mutations
that are most commonly correlated with ALS, including TDP-43, SOD1, FUS and C9ORF72.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Despite being classified
as a rare disease, ALS is considered one of the more common neuromuscular diseases worldwide. The Centers for Disease Control and Prevention
estimates that there are approximately 20,000 cases of ALS in the United States and that approximately 5,000 new cases are diagnosed each
year. The number of total cases for the largest five markets in Europe (Germany, France, Italy, Spain and the United Kingdom) is estimated
to be slightly higher and for the broader European geography the estimate is approximately 30,000 cases. Overall, it is estimated that
our planned target market is currently over 80,000 patients, and that the patient population in the United States and Europe will grow
by 24% by 2040.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">ALS also imposes a significant
burden on the healthcare system, with an estimated $180,000 patient cost per year and an estimated annual burden greater than $1&#160;billion
on the U.S. healthcare system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Current ALS Treatment Options and Drugs in
Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are currently a limited
number of available treatments for ALS and these treatments only impart a modest effect, extending a patient&#8217;s life expectancy by
only a few months on average.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Until recently, the only
approved drug used for slowing disease progression in ALS was Rilutek (riluzole). It was the first drug to be approved by the FDA for
the treatment of ALS over 25 years ago. In May 2017, the FDA approved Radicava (edaravone), which is administered through chronic cycles
of ten days of intravenous infusions followed by a two-week&#160;treatment-free&#160;period. In recent years, the FDA has also approved
two new formulations of riluzole that address the need for an improved route of administration in patients who suffer from swallowing
complications. In September 2018, the FDA approved Tiglutik, the oral suspension of riluzole administered via syringe, and in November
2019, the FDA approved Exservan, a new soluble oral formulation of riluzole which dissolves on the tongue. In Europe, edaravone is not
approved, and therefore the only approved drug for ALS is riluzole.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In April 2023, the FDA approved
Qalsody (tofersen) to treat patients with ALS associated with a mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS). Qalsody
is an antisense oligonucleotide that targets SOD1 mRNA to reduce the synthesis of SOD1 protein. The approval was based on a correlation
between clinical outcome and reduction in plasma neurofilament light chain (NfL), a blood-based biomarker of axonal (nerve) injury and
neurodegeneration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As both currently approved
drugs, riluzole and edaravone, have been shown to have minimal effect on prolonging patient lifespans or improving their quality of life
and independence, and Qalsody is aimed for patients with SOD1 mutation, which represents approximately 2% of the overall ALS population,
we believe there is still a significant need for new treatments for patients with ALS in order to improve the disease course and to further
extend survival.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other treatments for ALS
that we are aware are under development include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Novartis</b> is developing VHB937, an anti-human TREM2 mAb, currently being tested in a Phase 2 clinical trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Brainstorm Cell Therapeutics </b>is developing NurOwn, an adult stem cell therapy, which has completed a pivotal Phase 3 trial and did not achieve the primary endpoint. NurOwn is expected to be reevaluated in a Phase 3b trial. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clene </b>is developing CNM-Au8<sup>&#174;</sup>, an investigational gold nanocrystal suspension, completed a Phase 3 clinical trial. CNM-Au8 did not meet its primary endpoint of change in ALSFRSR, However, it showed that the drug was able to reduce the risk of death in patients with ALS.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Prilenia</b>, is developing Pridopidine, which was originally developed for Huntington&#8217;s disease. The drug did not reach statistical significance in Phase 2 primary and key secondary endpoints; nevertheless, based on additional analysis, the drug is currently in preparations for a Phase 3 trial for ALS. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Eledon </b>is developing Tegoprubart, an anti-CD40L antibody, which completed a Phase 2a open-label study, and is now seeking non-equity dilutive financing to move into a Phase 3 study. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>QurAlis </b>is developing a pipeline of RNA-based therapies for ALS, now in Phase 1 clinical trials. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Solution &#8212; PrimeC for ALS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our lead product candidate,
PrimeC, is designed to treat ALS by targeting multiple pathways involved in ALS, including: regulating miRNA synthesis, influencing iron
accumulation, and reducing neuroinflammation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">miRNA are small non-coding&#160;RNAs
which play a critical role in regulating gene expression. Studies show that miRNA are dysregulated in motor neurons of autopsy tissues
from patients with ALS, and that reduction in miRNA is sufficient to cause spinal motor neuron degeneration&#160;<i>in-vivo</i>. Consequently,
dysregulation of miRNA levels due to inefficient activity of Dicer enzyme which plays a key role in their generation, is common in multiple
forms of ALS. Dysregulated miRNAs are found in multiple ALS models and patient-based&#160;microglia cells, motor neurons and skeletal
muscles controlling multiple targets, such as neuroinflammation, synaptic formation, neuronal activity and differentiation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Iron accumulation has been
shown to be present in many neurodegenerative diseases including ALS. As such, iron chelation therapies have been shown to have a positive
effect in pre-clinical models of neurodegeneration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Finally, chronic neuroinflammation
is increasingly recognized as a major factor that promotes ALS disease progression and amplifies the motor neuron death-inducing&#160;processes.
Neuroinflammation is characterized by extensive astrogliosis, microglial activation, and infiltration of peripheral immune cells at sites
of neurodegeneration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">PrimeC is a novel formulation
of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined at a specific ratio, aiming to target
multiple ALS-related&#160;pathways simultaneously.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Ciprofloxacin</i> is a
fluoroquinolone antibiotic often used to treat bacterial infections, which has been safely used for many years in large and diverse patient
populations. Ciprofloxacin is approved for use in gram-negative&#160;bacterial infections such as lower respiratory tract infections,
chronic sinusitis, genital tract infections and infections of the skin and soft tissues. Additionally, ciprofloxacin is approved for chronic
ear infections, urinary tract infections, gastro-intestinal&#160;and intra-abdominal&#160;infections, malignant external otitis, infections
of the bones and joints, prophylaxis of invasive infections due to Neisseria meningitidis, inhalation anthrax, and broncho-pulmonary&#160;infections
in cystic fibrosis caused by Pseudomonas aeruginosa. Ciprofloxacin may also be used to treat severe infections in children and adolescents
when this is considered to be necessary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Studies have shown that besides
its antibiotic mechanisms, ciprofloxacin is also able to upregulate the expression of miRNAs by inducing dicer activity and is a moderate
iron chelator.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Celecoxib</i> is a prescription
nonsteroidal anti-inflammatory&#160;drug, or NSAID, used to treat pain through the inhibition of cyclooxygenase-2, or COX-2, and the reduction
of inflammatory processes, thereby affecting glutamate excitotoxicity and oxidative stress, among others. Celecoxib is approved for use
for the management of the signs and symptoms of osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis in patients two years
and older, and ankylosing spondylitis. Additionally, celecoxib is approved for the management of acute pain in adults, and for the management
of primary dysmenorrhea. Although not shown to be beneficial in ALS when given at high doses as a single agent, low doses of celecoxib
were shown to be effective in pain management and played a synergistic role with ciprofloxacin in pre-clinical models of ALS zebrafish
(SOD1 and TDP-43).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Through analysis of blood
samples from healthy subjects and patients with ALS, we observed the relevance of PrimeC&#8217;s mechanism of action using a novel method
involving neuron-derived&#160;exosomes. In the recently competed interim analysis of NST-003 Phase 2b study conducted in ALS patients
with PrimeC, the primary endpoint of safety and tolerability was successfully met. Furthermore, the clinical parameters measured and the
quality of life questionnaires demonstrated a clinically significant benefit to ALS patients treated with PrimeC compared to placebo.
Additionally, the primary endpoint of safety and tolerability was met in our NST002 trial in ALS patients, which was completed in February
2021. Through analysis of blood samples from this study using the same exosomal method, we observed significant changes in ALS-related&#160;biomarkers,
indicating biological activity of PrimeC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Our Product Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PrimeC</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our lead product candidate,
PrimeC, is a novel ER oral formulation composed of a novel fixed dose combination of two generic FDA-approved&#160;drugs, ciprofloxacin
and celecoxib, combined in a specific ratio. PrimeC is designed to treat ALS by regulating miRNA synthesis, influencing iron accumulation
and reducing neuroinflammation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">PrimeC was evaluated in PARADIGM,
a Phase 2b randomized, multi-center, multinational, prospective, double-blind, placebo-controlled study, with an open label extension,
to evaluate safety, tolerability, and efficacy of PrimeC in 69 people living with ALS in a 2:1 ratio to receive PrimeC or placebo, respectively,
which we refer to as NST003. Study participants were allowed to continue standard of care (SOC) treatment of approved products. Primary
endpoints of the study included an evaluation of ALS-biomarkers as well as safety and tolerability assessment. Secondary and exploratory
endpoints are the evaluation of clinical efficacy (ALSFRS-R, SVC), survival, and improvement in quality of life. All subjects who complete
the six-month double-blind, placebo-controlled dosing period switched to the PrimeC active arm for a 12-month open label extension. The
study commenced recruitment of patients in Israel in May 2022 and in Italy and Canada in March 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In May 2023, we completed
enrollment for the PARADIGM trial. In November 2023, we concluded a successful Type D meeting with the FDA for PrimeC in the treatment
of ALS where we discussed PrimeC&#8217;s CMC development plans in advance of an expected Phase 3 pivotal study and potential subsequent
marketing approval. The FDA agreed with our proposed CMC development plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In December 2023, we reported
that we met the primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints in the top-line results of
our Phase 2b trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In May 2024, we announced
new positive data analysis from PARADIGM clinical trial demonstrating statistically significant slowing of disease progression in high-risk
ALS patients. In July 2024, we announced results from the 12-month analysis of the PARADIGM clinical trial which showed a significant
improvement in the rate of decline of ALS Functional Rating Scale-Revised (ALSFRS-R) scores and survival rates for subjects who received
PrimeC from the start of the trial compared to those who started on placebo. In August 2024, we announced positive 12-month biomarker
data from the PARADIGM clinical trial, which showed a significant decrease in ferritin levels and a corresponding increase in transferrin
levels, both indicating alleviation of the pathology. In February 2025, we announced additional findings from an 18-month analysis of
the PARADIGM clinical trial showing improvements in two additional endpoints, complication-free survival and Slow Vital Capacity (SVC).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In October 2024, we provided
a further update on our plans to file for early commercialization approval for PrimeC under Health Canada&#8217;s Notice of Compliance
with Conditions (NOC/c) policy. This decision follows the recommendations of Canadian regulatory experts and recent clinical findings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In December 2024, we concluded
a Type C meeting with the FDA. The purpose of the meeting was to discuss the design of a proposed Phase 3 clinical study and the plan
for submission of an eventual 505(b)(2) marketing application. We had a productive discussion with the FDA regarding the design of the
planned Phase 3 pivotal study with PrimeC, including efficacy and safety measurements. In light of the FDA&#8217;s feedback, we plan to
submit a final protocol to the FDA during the first half of 2025 with the aim of commencing enrollment of the pivotal Phase 3 study in
mid-2025, which would include approximately 300 patients divided by a ratio of 2:1, PrimeC to placebo. The Phase 3 study is expected to
be a randomized, multi-center, multinational, prospective, double-blind, placebo-controlled study, with an open label extension (OLE),
to evaluate the efficacy and safety of PrimeC in people living with ALS. Following 12 months of treatment, it is expected that all participants
will transition to PrimeC for a 12-month open label extension.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical Results </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>NST003 Phase 2b Trial in ALS</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In December 2023, we announced
topline clinical efficacy results in our Phase 2b PARADIGM (NST003) trial of PrimeC for the treatment of ALS, reporting that we met the
primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The PARADIGM study was a
randomized, multi-center, multinational, prospective, double-blind, placebo-controlled study, to evaluate safety, tolerability, and efficacy
of PrimeC in 68 people living with ALS. Participants were administered PrimeC or placebo at a 2:1 ratio, respectively. After completion
of the 6-month double-blind segment, participants had the option to enroll in a 12-month OLE, during which they all received treatment
with PrimeC. Study participants were allowed to continue standard of care treatment of approved products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The primary endpoints of
the study included an evaluation of ALS-biomarkers as well as safety and tolerability assessment. Secondary and exploratory endpoints
included the evaluation of clinical efficacy (ALSFRS-R and slow vital capacity), survival, and improvement in quality of life. The study
completed enrollment in May&#160;2023, enrolling 68 participants living with ALS in Israel, Italy, and Canada.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A primary endpoint of the
PARADIGM study pertained to the evaluation of PrimeC&#8217;s safety and tolerability profile in ALS. Noteworthy findings indicate that
the incidence of adverse events under PrimeC treatment were similar to that observed in the placebo arm, thereby underscoring the favorable
safety profile of PrimeC. Additionally, assessments of electrocardiographic parameters and laboratory indices, encompassing QTc interval,
hepatic enzymes, and renal function, revealed no significant aberrations attributable to PrimeC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Summary of Adverse Events</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Summary of All Adverse Events</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">PrimeC<br/> (N=45)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Placebo<br/> (N=23)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Adverse Events (AE)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">68.9</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">65.2</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Treatment-Emergent AEs (TEAE)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Study Drug Related Treatment-Emergent AEs (TEAE)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Serious Treatment-Emergent AEs (TEAE)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.9</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Subject death</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">TEAE leading to Study Drug Discontinuation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">TEAE leading to Study Drug Reduction</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">TEAE leading to Study Drug Interruption</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.6</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Top-line results in the PARADIGM
trial revealed a statistically significant&#160;slowing of disease progression in ALS patients, compared to the placebo. The study demonstrated
a 37.4% (p=0.03) difference in the FDA-approved ALSFRS-R compared to placebo, and a 17% difference in favor of PrimeC in slow vital capacity
(p=0.39) in the Per Protocol population, and a strong safety profile. Over the course of 6 months, patients treated with&#160;PrimeC experienced
a slowing of disease progression, including preserved daily function. The clinical efficacy results showed a 29% difference in favor of
PrimeC in ALSFRS-R (p=0.12), and a 13% difference in favor of PrimeC in slow vital capacity (p=0.5) in the Intent To Treat (ITT) population
based on data from 68 out of 69 participants, due to one misdiagnosed participant. These data include 45 patients randomized to the PrimeC
arm and 23 patients randomized to the placebo arm, from the 6-month double-blind segment. The safety and tolerability profile of PrimeC
was well comparable to the placebo. Nearly all participants, 96%, who completed the 6-month double-blind portion of the trial chose to
receive treatment with PrimeC through the 12-month open label extension.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In tandem with objective
clinical assessments, PrimeC exerted favorable influences on diverse dimensions of patients&#8217; quality of life. Comprehensive evaluations
encompassing mental health domains, as exemplified by the mental health subscale of the PROMIS-10 questionnaire, showed improvements&#160;&#160;
attributable to active treatment (PrimeC). Moreover, analyses pertaining to survival outcomes underscored the implications of PrimeC intervention
in mitigating disease progression. Across diverse analytical frameworks, including hazard ratios derived from ALS complication free survival,
MiTOS and King&#8217;s Advanced Staging system, PrimeC consistently exhibited numerical advantage over placebo, signaling tangible gains
in extending survival and delaying disease progression milestones. MiTOS and King&#8217;s Advanced Stage-free Survival in ALS are two
prognostic staging systems for ALS, assessing progression and complication free survival. ALS complication free survival is defined as
time to death from any cause or respiratory insufficiency (defined as tracheostomy or the use of non-invasive ventilation for at least
22 hours per day for at least 10 consecutive days) or hospitalization due to ALS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These data highlight a novel
approach to treating ALS, with potential implications in other neurodegenerative conditions. PrimeC&#160;is&#160;a unique fixed-dose combination
of ciprofloxacin and celecoxib, which may utilize complementary and synergistic mechanisms to preserve motor neuron health in ALS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, in a preliminary
analysis conducted following six months of double-blind, placebo-controlled treatment in the PARADIGM Phase 2b study, patients who received
PrimeC demonstrated a trend towards decreased Neurofilaments-light chain (NfL) levels compared to placebo, with this trend being more
pronounced in an earlier stage of the disease. The analysis was conducted by ALS biostatistician experts. We are now preparing for a follow-up
analysis of NfL levels after a 12-month dosing period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In May 2024, we announced
new positive data analysis from PARADIGM clinical trial demonstrating statistically significant slowing of disease progression in high-risk
ALS patients. In July 2024, we announced results from the 12-month analysis of the PARADIGM clinical trial which showed a significant
improvement in the rate of decline of ALS Functional Rating Scale-Revised (ALSFRS-R) scores and survival rates for subjects who received
PrimeC from the start of the trial compared to those who started on placebo. In August 2024, we announced positive 12-month biomarker
data from the PARADIGM clinical trial, which showed a significant decrease in ferritin levels and a corresponding increase in transferrin
levels, both indicating alleviation of the pathology. In December 2024, we announced positive 18-month clinical data from the PARADIGM
clinical trial, which showed a significant difference in ALSFRS-R when comparing participants that were treated with PrimeC for 18 months
versus those initially on placebo, indicating a disease-modifying effect. In February 2025, we announced additional findings from an 18-month
analysis of the PARADIGM clinical trial showing improvements in two additional endpoints, complication-free survival and Slow Vital Capacity
(SVC).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>NST002 Phase 2a Trial in ALS</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In February 2021, we completed
our Phase 2a NST002 trial of PrimeC for the treatment of ALS. NST002 was an open label study that was designed to assess the safety and
tolerability of an intermediate immediate-release&#160;formulation of PrimeC (PrimeC-IR), as well as routine disease progression measures.
Fifteen patients with familial or sporadic ALS received a fixed dose of PrimeC-IR&#160;three times per day for 12&#160;months. Patients
were then evaluated by phone every 1.5&#160;months and at a clinical site visit every three months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The primary endpoint of the
trial was PrimeC-IR&#8217;s safety and tolerability, which was measured by the number of patients with one or more treatment-emergent&#160;adverse
events, the number of patients who discontinued treatment prematurely, the number of patients who discontinued treatment prematurely due
to adverse events and the number of patients with significant abnormal laboratory values. The primary endpoint was met, with PrimeC-IR&#160;showing
a safety profile that was consistent with known safety profiles of ciprofloxacin and celecoxib, and was mild and transient in nature.
There were no new or unexpected safety signals detected during the trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Specifically, of the 15 patients
in the safety population, ten patients (67%) experienced at least one treatment emergent adverse event, or TEAE. While most of the TEAEs
were assessed by the investigator as unrelated to study drug, four patients (27%) experienced a TEAE that was assessed by the investigator
as related to the study drug. Of TEAEs that were assessed as related to study drug, 11 were gastrointestinal disorders (flatulence was
reported four times, nausea three times, dyspepsia twice, and abdominal pain and constipation once each), as well as dizziness and insomnia
being reported once each. None of the TEAEs related to the study drug were serious.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The TEAEs in descending order
of frequency were gastrointestinal disorders (38.4%), infections (15.4%), injury (12.8%), general disorders, psychiatric disorders, and
nervous system disorders (7.7% each), and investigative, musculoskeletal, skin, and surgical procedures (2.6% each).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Most of the TEAEs (67%) were
mild or moderate in intensity. Six patients (40%) experienced at least one severe TEAE. No clinically meaningful treatment-emergent&#160;changes
were noted for any patient in the laboratory safety parameters, vital signs, or electrocardiograms. Two male patients died at home during
the trial, and these events were considered by the investigator to be unrelated to the study drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All 12 patients who completed
the NST002 trial elected to continue into an extension study with PrimeC-IR. The primary endpoint of the extension study is safety, and
we may use this additional data in communications with the FDA when presenting on long-term&#160;safety of the combined use of ciprofloxacin
and celecoxib.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Investigators also measured
PrimeC-IR&#8217;s potential efficacy using two accepted ALS clinical endpoints: the ALSFRS-R and forced vital capacity, or FVC. The ALSFRS-R&#160;is
a validated rating scale for monitoring the progression of disability in patients with ALS. Patients are scored within the range of 0-48&#160;points
(with 48 indicating full function and zero indicating no function). ALSFRS-R&#160;scores correlate significantly with quality of life
as measured by the Sickness Impact Profile, a behaviorally-based&#160;measure of health status, indicating that the quality of function
is a strong determinant of quality of life in ALS patients. Historical data indicates that the average deterioration of ALS patients is
one point per month in the ALFRS-R. FVC is a standard measure of pulmonary function that measures the amount of air that can be exhaled
forcefully and quickly after a deep inhalation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To better understand the
ALSFRS-R&#160;and FVC data, we compared the open-label&#160;results to two prediction models and virtual patient arms. The first was a
virtual placebo generated by Origent Data Sciences, which projected an individual patient&#8217;s deterioration and survival for 12&#160;months.
This comparison indicated another aspect of safety, as it showed that the PrimeC-IR&#160;treated patients exceeded their projected survival
and did not deteriorate more than predicted. This was strengthened by the use of the ENCALS survival prediction model, which also indicated
that treated patients exceeded their projected survival.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, PrimeC-IR&#160;treated
patients were compared to a historical placebo by matching patients in the trial with similar patients in the PRO-ACT&#160;database, one
of the largest publicly available repositories of merged ALS clinical trials data. Patients were matched using a propensity score matching
method, which is a statistical method that seeks to approximate a random experiment by matching each patient in the trial with a patient
from the PRO-ACT&#160;database.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At 12&#160;months, the average
ALSFRS-R&#160;total score declined only by&#160;-0.84 points per month for patients treated with PrimeC, whereas the ALSFRS-R&#160;total
score deteriorated&#160;-1.02 for the PRO-ACT&#160;group, a difference of 18%. Additionally, when breaking down the ALSFRS-R&#160;into
the sub-domains&#160;of the four categories (bulbar, fine motor, gross motor and respiratory functions), PRO-ACT&#160;patients showed
higher deterioration in gross motor functions and respiratory functions compared to the PrimeC cohort.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Respiratory function was
further assessed by FVC. The FVC of PRO-ACT&#160;patients deteriorated by 2.99% of the predicted value, and PrimeC patients deteriorated
by 2.09% of the predicted value, or a difference of 30%, matching the results from the ALSFRS-R&#160;respiratory function section.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Despite the p-values&#160;not
showing statistical significance (i.e., p-value&#160;&lt; 0.05), we believe the study results indicate a clinical trend of slowing disease
progression, achieved with an intermediate formulation of PrimeC. Based on the trend we observed, we believe that in a study with a larger
sample size and with the optimal PrimeC dosage and formulation, there is much higher potential to achieve statistically significant clinical
benefit with PrimeC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Mechanism of Action Evaluation &#8212; Healthy
vs ALS blood sample analysis</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Neuronal derived exosomes
(NDEs) have been shown to cross the blood-brain-barrier&#160;and enter blood circulation, enabling their isolation from patients&#8217;
blood using minimally invasive procedures. NDEs carry neuronal molecular signatures echoing the content of the cells from which they originated,
providing potentially valuable information of disease pathogenesis. As a result, we believe neuron-derived&#160;exosomes can serve as
sources of potential biomarkers in neurodegenerative disorders, including ALS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In parallel to our NST002
trial, we explored the relevance of PrimeC&#8217;s mechanism of action in ALS by examination of the changes in expression or activation
of several disease biomarkers and key drug target biomarkers. The measurements were performed in neuronal extracellular vesicles, extracted
from the blood serum of patients diagnosed with ALS and then compared to corresponding healthy volunteers, in collaboration with Mass
General Hospital (MGH) in Boston.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We examined and further validated
key enzymes known the be affected in ALS in the same manner. It is well established that TDP-43&#160;levels are increased in ALS patients,
leading to a toxic accumulation. Additionally, a growing body of evidence shows decreased expression of LC3, a marker for autophagy in
a number of ALS models, suggesting reduced basal levels and a decreased overall capacity for autophagy. Lastly, Cathepsin D (CatD) is
a regularly expressed lysosomal protease that is involved in proteolytic degradation, cell invasion, and apoptosis. Growing evidence suggests
that endolysosomal and autophagic defects are key pathogenic processes in various neurodegenerative disorders such as ALS. In examining
these three biomarkers, we observed a significant difference between ALS and healthy subjects (TDP-43&#160;p-value&#160;= 0.002, LC3 p-value&#160;&lt;
0.001, CatD p-value&#160;&lt; 0.001).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Furthermore, since PrimeC
aims to target miRNA dysregulation, iron accumulation, and neuroinflammation, the target engagement markers we explored were EIF2C2 (Ago2),
a component of the Dicer complex, which is essential to the regulation of miRNA and is affected in ALS, as well as Ferroportin-1, an iron
pump serving as a marker of iron accumulation, and PGJ2, an endogenous product of inflammation, which induces neuronal death and the accumulation
of proteins into aggregates. It has been previously demonstrated that PGJ2 was accumulated in the spinal cord of sporadic ALS patients.
In this evaluation we observed clear differences between ALS and healthy subjects in these three key PrimeC targets (EIF2C2 p-value&#160;=
0.007, PGJ2 p-value&#160;&gt; 0.05, Ferroportin p-value&#160;= 0.005).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe these biomarker
evaluation results support the potential relevance of PrimeC&#8217;s mechanism of action for the treatment of ALS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>NST002 Biomarker Analysis &#8212; Assessing
the Effect of PrimeC on Key Biomarkers</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order to assess the natural
course of the observed ALS-related markers over time, longitudinal matched samples were tested over 12 months. This study was performed
to obtain an indirect placebo control. Results showed no significant changes over time in most of the tested markers. Interestingly, a
significant decrease was detected in LC3, a marker for autophagy, suggesting down regulation of the process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based on the parameters validated
in the comparison of healthy vs ALS patient samples and the indirect placebo group, generated from non-PrimeC samples, we examined the
effect of PrimeC on these biomarkers. To that end, we used our previously established NDE paradigm to examine the levels of the biomarkers
in NDEs extracted from longitudinal blood samples obtained from the participants in our NST002 clinical trial. These samples were collected
at three time points throughout the study, namely, prior to initiation of PrimeC treatment, during their interim visit between the 3-6&#160;month
point and at the 12-month&#160;end of study visit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Statistically significant
changes were observed in the levels of TDP-43, following PrimeC treatment. TDP-43&#160;is a protein highly associated with ALS pathology,
and in a recent publication neuron-derived&#160;exosomal TDP-43&#160;was shown to increase in longitudinal serum samples of patients with
ALS. TDP-43&#160;in PrimeC treated patients were observed to have a statistically significant decrease throughout the study (p-value&#160;=
0.002), indicating positive biological signs of the treatment. Analysis of additional ALS-associated&#160;pathological markers also showed
significant positive changes, including LC3, a central protein in the autophagy pathway. Among PrimeC treated patients, LC3 levels were
observed to elevate and stabilize (p-value&#160;= 0.054), suggesting that such treatment has positive effects on autophagy. Another ALS
biomarker we examined was CatD, which remained in a stable state before showing a decrease (p-value&#160;= 0.015), indicating a potential
benefit for lysosomal activity. Lastly, we assessed the change in PGJ2, downstream of COX-2, representing neuroinflammation. Levels of
PGJ2 were observed to significantly decrease during PrimeC treatment (p-value&lt;0.001), indicating a reduction in neuroinflammatory processes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe these results
indicate positive biological activity of PrimeC, in a manner that attenuates disease-related&#160;pathologies, as well as indicating target
engagement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Clinical Results &#8212; NST001 Phase 1 Trial
in ALS</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have completed our Phase
1 NST001 trial of PrimeC for the treatment of ALS. NST001 was an open label, IND-exempt&#160;study designed to assess the safety and tolerability
of an intermediate immediate-release&#160;formulation of PrimeC, at slightly different doses than NST002. The study was conducted at the
Barrow Neurological Institute (BNI) in Phoenix, Arizona. Six patients with familial or sporadic ALS received a fixed dose of PrimeC-IR&#160;twice
daily for 12&#160;months. Patients were evaluated by phone every three months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The primary endpoint of the
trial was PrimeC-IR&#8217;s safety and tolerability, measured in the same manner as in NST002: number of patients with one or more treatment-emergent&#160;adverse
events, number of patients who discontinued treatment prematurely, number of patients who discontinued treatment prematurely due to adverse
events and number of patients with significant abnormal laboratory values.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">NST001 and NST002 began simultaneously
since both these studies were designed with the goal of assessing the safety and tolerability of two different doses and regimens of PrimeC-IR
and were therefore considered independent of each other. Since no safety issues were expected due to the well-understood&#160;nature of
both generic drugs comprising PrimeC, we determined that there was not a need to wait for the completion of NST001 in order to begin NST002.
Moreover, while NST001 was an IND-exempt&#160;clinical trial, NST002 was conducted in Israel, according to Israeli regulations, and did
not require FDA input. Nonetheless, in January 2021, we participated in a pre-IND&#160;meeting with the FDA to discuss our past and future
development plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Pre-clinical Results</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In pre-clinical studies of
two models of ALS zebrafish, SOD1 and TDP-43, PrimeC was observed to improve locomotor and cellular deficits, indicating a potential neuroprotective
effect. In the SOD1 studies, treatment with PrimeC was observed to improve motor performance of the mutant larvae by 84%, and elicited
recovery of motor neuron morphology and neuromuscular junction structure (NMJ), as well as preserving ramified morphology of microglia
cells.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">mSOD1 larvae exhibited a
substantial recovery of motor neuron morphology and NMJ structure, suggesting a potential neuroprotective role for PrimeC treatment. As
shown in the graphic titled &#8220;Neuromuscular Junction Structures&#8221; below, following treatment with PrimeC, we observed a higher
number of intact organized synapses (yellow), with reduced proportion of orphaned pre-(red) and post-synaptic&#160;(green) puncta, resembling
WT zebrafish. A second study, conducted in TDP-43&#160;mutant zebrafish, substantiated these results and showed a significant improvement
in their swimming abilities with an increase of 110% in distance and 43.8% in maximum swim velocity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="text-decoration:underline">Elucidating The Synergistic
Effect of PrimeC Combination for ALS utilizing in-vivo and in-vitro models</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">PrimeC novel formulation
composed of unique doses of ciprofloxacin and celecoxib is aimed to synergistically inhibit the progression of ALS by addressing key elements
of its pathophysiology. As described below, the effectiveness of PrimeC was compared to each of the individual active substances comprising
it, celecoxib and ciprofloxacin, and PrimeC&#8217;s ability to improve drug pharmacokinetics and mode of action were assessed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pharmacokinetic (PK) studies
in rodents showed that the combination of celecoxib and ciprofloxacin had a synergistic effect, as the addition of celecoxib increased
the concentration of ciprofloxacin in the brain tissue and serum of rodents. These findings were confirmed by assessing the efficacy of
PrimeC combination in an induced pluripotent stem cell (iPSC) model. Results showed that neurons treated with PrimeC combination had higher
survival rates than those treated with individual compounds. The efficacy of PrimeC was also demonstrated in a Synaptoneurosome (SN) model,
showing a beneficial effect on PrimeC related mechanisms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In summary, data from the
PK studies suggests that PrimeC&#8217;s combination therapy can be a beneficial approach for treating ALS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The toxicology studies that
we performed with celecoxib and ciprofloxacin combination included a 90-day oral repeat-dose combination toxicity and toxicokinetic study
in rats, 21-day oral dose range-finding (DRF) repeat-dose combination toxicity and toxicokinetic study in rats, a 56 day non-GLP DRF oral
repeat-dose toxicity and toxicokinetic study of ciprofloxacin in beagle dogs and a 270 day GLP repeat-dose oral Ciprofloxacin toxicity
and toxicokinetics study in beagle dogs with a 28-day recovery period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the 90-day oral repeat-dose combination toxicity and toxicokinetic study in rats, no effects were observed at combination doses up to 50 mg/kg/day celecoxib and 600 mg/kg/day ciprofloxacin (NOAEL). These doses convert to human equivalent doses of 483 mg/day for celecoxib and 5806 mg/day for ciprofloxacin, respectively (based on body surface area conversion for a 60 kg individual), which are 3.6 times greater and 4.3 times &#160;greater, respectively, than the maximal celecoxib and ciprofloxacin proposed daily doses in the PrimeC extended-release formulation (1360 mg ciprofloxacin and 136 mg celecoxib).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the 21-day oral DRF repeat-dose combination toxicity and toxicokinetic study in rats, no adverse or combination-related effects were observed at combination doses up to 50 mg/kg/day celecoxib and 400 mg/kg/day ciprofloxacin. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the 56 day non-GLP DRF oral repeat-dose toxicity and toxicokinetic study of ciprofloxacin in beagle dogs, dogs aged 8-10 months old were dosed twice daily 8 hours apart for a period of 56 consecutive days with ciprofloxacin at 150 mg/kg/day or 300 mg/kg/day (3/sex/group) or with the vehicle (2/sex/group). No adverse effects were observed at ciprofloxacin doses up to 300 mg/kg/day, and this dose was determined as the NOAEL. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 270 day GLP repeat-dose oral Ciprofloxacin toxicity and toxicokinetics study in beagle dogs with a 28-day recovery period was completed. The NOAEL was set to 200 mg/kg/day. &#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, the Phase 2a
and Phase 2b clinical studies results, in which a total 57 ALS subjects (15 subjects from Phase 2a and 45 subjects from Phase 2b) were
treated with PrimeC, demonstrated that PrimeC is safe and well-tolerated, with the safety profile that is consistent with the known safety
profile of celecoxib and ciprofloxacin. No new or unexpected safety signals were detected. PrimeC did not result in any drug-related fatal
SAEs. See &#8220;-<b>-</b>Our Product Candidates - Clinical Results&#8221;. This safety profile has also been demonstrated in 32 healthy
volunteers in PK studies conducted by us. See &#8220;Item 3.D. Risk Factors - Risks Related to Our Business and Strategy - We have not
applied for regulatory approvals to market any of our other product candidates, and we may be delayed in obtaining or failing to obtain
such regulatory approvals and to commercialize our product candidates.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Collaboration Agreement with Biogen</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In May&#160;2023, we entered
into a Collaborative Evaluation Agreement with Biogen under which Biogen agreed to evaluate the impact of PrimeC on neurofilament levels
in the plasma of participants in PARADIGM.&#160;Biogen agreed to fund the neurofilament biomarker study and conduct the analysis. Biogen
also received a right of first refusal for a definitive licensing agreement to co-develop and/or commercialize PrimeC for the treatment
of ALS. In March 2024, Biogen and NeuroSense agreed not to continue the Collaborative Evaluation Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Collaboration Agreement with Lonza</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">In April 2024, we announced a collaboration with
Lonza to evaluate biological changes occurring in people with neurodegenerative diseases, including ALS. This agreement provides us with
access to Lonza&#8217;s unparalleled, state-of-the-art extracellular vesicles expertise and capabilities quickly and on an &#8216;on-demand&#8217;
basis, without further commitments. We will leverage Lonza&#8217;s extensive experience in biomarker utilization in neurodegenerative
diseases. Lonza will provide the development, optimization, and qualification of a method measuring biomarkers from NDEs, which will be
integrated into the development of PrimeC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Additional Studies</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In May 2023, we announced
positive preliminary results from a novel biomarker study conducted to evaluate the potential of PrimeC for the treatment of PD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In October 2023, we announced
the results of a non-sponsored <i>in vitro</i> study of PrimeC in ALS, which demonstrated that PrimeC has a positive effect ion ALS survival
in an innovative induced pluripotent stem cell model.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AD Program </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the fourth quarter of
2023, we initiated a randomized, prospective double-blind, single-center, placebo-controlled Phase 2 study to assess the safety, tolerability,
target engagement, and efficacy of PrimeC (an intermediate formulation of CogniC) in patients with mild to moderate Alzheimer&#8217;s
Disease (AD). The study is being conducted at the Rambam Medical Center site in Israel and aims to enroll 20 patients (10 participants
per study arm). The study incorporates a comprehensive panel of biomarkers utilizing both cerebrospinal fluid (CSF) and blood to evaluate
PrimeC&#8217;s biological activity and target engagement. Additionally, blood samples collected from each participant will be used to generate
induced pluripotent stem cells (iPSCs), allowing for the study of disease mechanisms and drug response at the cellular level. This approach
enables a deeper understanding of individual variability and may aid in predicting patient response to PrimeC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The current study builds
upon a proof-of-concept biomarker-driven cross-sectional study conducted in plasma samples from individuals with Alzheimer&#8217;s disease.
This study aimed to assess the relevance of PrimeC&#8217;s proposed mode of action for addressing AD pathology. To this extent, a discovery
biomarkers study was conducted utilizing neuronal-derived exosomes (NDEs) extracted from the plasma of 31 people living with AD vs. 19
neurologically healthy controls. To reinforce the study findings, the study was conducted in two cohorts to assure the robustness of the
results. The obtained results from the discovery biomarkers study, as expected, showed higher levels of known proteins implicated in AD,
i.e., A&#946;42 (p&lt;0.05) and pTau (p&lt;0.01) (Figure 4A). Moreover, we found higher levels of TDP-43 (p&lt;0.05) in AD samples (Figure
5B). Other markers related to the recycling process, such as cathepsin D (CatD), and inflammatory response, such as prostaglandin J2 (PgJ2),
is altered in AD samples in comparison to control (Figure 2C). Specifically, CatD levels were lower (p&lt;0.0001) in NDEs isolated from
AD samples compared to control, and PgJ2 levels were higher (p&lt;0.001) in AD samples. TDP-43 has been known to colocalize with senile
plaques and neurofibrillary tangles, suggesting a direct interaction between TDP-43 and amyloid-&#946; (A&#946;) or tau, which are known
to be hallmark biomarkers in AD. TDP-43 has been found in up to 57% of AD cases and aggregates of TDP-43 have been shown to be cytotoxic
both in vitro and in vivo. Neuroinflammation plays a key role in the pathophysiology of the disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In view of the shared pathophysiology
of these two neurodegenerative diseases, as well as the preliminary biomarker data, we believe that there is a reasonable basis to hypothesize
that ciprofloxacin and celecoxib combination can be an effective treatment for people living with AD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pre-clinical Pipeline </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our preclinical pipeline
includes one additional product candidate, StabiliC, for the treatment of PD. We are currently conducting pre-clinical studies related
to PD. It is likely that we will choose to consult with the FDA with regards to our findings prior to the initiation of an advanced clinical
studies, if and once relevant, and in order to obtain their advice and consent for the study design and clinical plan forward for each
of the indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Many pathological pathways
involve neuroinflammation, protein aggregation, mitophagy, excitotoxicity, oxidative stress, iron accumulation, and dysregulation of miRNAs
between neurodegenerative diseases, leading to the hypothesis that an effective drug for one neurodegenerative disease can lay the foundations
for other diseases-modifying&#160;drugs. Therefore, we aimed to evaluate the putative neuroprotective effects of celecoxib and ciprofloxacin
in a zebrafish pharmacological neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced, or &#8220;MPTP&#8221;-induced, PD model.
The objective of this study was to determine if celecoxib and ciprofloxacin were able to prevent and/or rescue MPTP-induced&#160;altered
behavior. Locomotor activity was assessed through a &#8220;tapping&#8221; assay.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Results indicated that the
symptomatic MPTP model is not relevant for StabiliC, suggesting that a different model with underlying PD pathologies may be required.
We therefore plan to further explore StabiliC&#8217;s mode of action and to assess its ability to effect or alter key PD-related&#160;hallmarks
by utilizing both the in-vitro&#160;patients&#8217; derived cells method and the in-vivo&#160;rodent adeno-associated-virus&#160;alpha
synuclein, or AAV-SYN, model. StabiliC is planned to be a combination of ciprofloxacin and celecoxib, and/or another molecule to be determined
during ongoing pre-clinical development. These assays will focus on the ability of StabiliC to reduce AAV-SYN&#160;aggregation and to
improve morphological and functional markers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Manufacturing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not own or operate
manufacturing facilities to produce our product candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable
future. We currently rely on third-party&#160;contract manufacturers for all of our required raw materials, active ingredients and finished
products for our preclinical research and clinical trials. We have commenced negotiating commercial supply agreements with our primary
third-party&#160;vendors and anticipate that these agreements will be executed in advance of the completion of a pivotal trial. We also
intend to negotiate back-up&#160;supply agreements with other third-party&#160;manufacturers for the commercial production of those products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Development and commercial
quantities of any products that we successfully develop will need to be manufactured in facilities, and by processes, that comply with
the requirements of the FDA and the regulatory agencies of other jurisdictions in which we are seeking approval. We currently employ internal
resources to manage our manufacturing contractors. The relevant manufacturers of our drug products for our current pre-clinical and clinical
trials have advised us that they are compliant with both current good laboratory practice, or cGLP, and current good manufacturing practices,
or cGMP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our product candidates, if
approved, are expected to be producible in sufficient commercial quantities, in compliance with regulatory requirements or at an acceptable
cost. We and our contract manufacturers are, and will be, subject to extensive governmental regulation in connection with the manufacture
of any pharmaceutical products. We and our contract manufacturers must ensure that all of the processes, methods and equipment are compliant
with cGMP and cGLP for drugs on an ongoing basis, as mandated by the FDA and foreign regulatory authorities, and conduct extensive audits
of vendors, contract laboratories and suppliers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We compete in an industry
characterized by rapidly advancing technologies, significant competition and a complex intellectual property landscape. We face substantial
competition from many different sources, including large pharmaceutical, specialty pharmaceutical, and biotechnology companies. Recently
we have also seen that academic research institutions and governmental agencies can and will continue to compete in this rapidly evolving
environment with support from public and private research institutions. Below is a description of competition surrounding each of our
disease targets and other technologies in development in the neurodegenerative field:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ALS. Potentially disease modifying therapeutics are being developed by several large and specialty pharmaceutical and biotechnology companies and academic institutions, including Biogen, Novartis, AB Science, Prilenia Therapeutics, Brainstorm Cell Therapeutics, Clene, QurAlis, Eledon, among others, in various stages of clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Alzheimer&#8217;s Disease</i>. Potentially disease modifying therapeutics are being developed by several large and specialty pharmaceutical and biotechnology companies, including Biogen, Eli Lilly, Eisai, Roche (including Genentech, its wholly owned subsidiary) and Alector in various stages of clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Parkinson&#8217;s Disease</i>. Potentially disease modifying therapeutics are being developed by several large and specialty pharmaceutical and biotechnology companies, including Prothena, Roche (including Genentech, its wholly owned subsidiary), Prevail/Eli Lilly, AstraZeneca, and Takeda in various stages of clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Many of our competitors,
either alone or through their collaborations, have significantly greater financial resources and expertise in research and development,
manufacturing, pre-clinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we
do. Smaller or early-stage&#160;companies may also prove to be significant competitors, particularly through collaborative arrangements
with large and established companies. These competitors also compete, or will compete, with us in recruiting and retaining qualified scientific
and management personnel and establishing clinical trial sites and patient enrollment in clinical trials, as well as in acquiring technologies
complementary to, or necessary for, our programs. As a result, our competitors may discover, develop, license, commercialize and market
products before or more successfully than we do.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our commercial success depends,
in part, on obtaining and maintaining patent, trade secret and other intellectual property and proprietary protection of our technology,
current product candidates, future product candidates and methods used to develop and manufacture them. We cannot be sure that a patent
will be granted with respect to any of our currently pending patent applications or with respect to any patent applications that we may
file in the future, nor can we be sure that our existing patent or any patents that may be granted to us in the future will be sufficient
to protect our technology or will not be challenged, invalidated or circumvented. Our success also depends on our ability to operate our
business without infringing, misappropriating or otherwise violating any patents and other intellectual property or proprietary rights
of third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patents</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our patent portfolio includes
U.S. Patent 10,980,780, which relates to methods for treatment of ALS using ciprofloxacin and celecoxib, and which expires in 2038. This
patent also been issued in the European Patent Office, Japan, Canada, Australia and Israel. In addition, U.S. patent application 16/623,467,
which relates to methods of treatment of neurodegenerative disease using combinations of ciprofloxacin and celecoxib, is currently pending.
The patent based on this application is expected to expire on June&#160;20, 2038.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, we have developed
a pharmaceutical composition comprising, as active ingredients, ciprofloxacin and celecoxib, and have been granted US Patent 12,097,185
and have filed international PCT application PCT/IL2022/051096 relating to the compositions. This patent and patent applications relate
to pharmaceutical formulations. The US patent will expire in December 2042 and the national patent applications based on the PCT application
are expected to expire in October 2042.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Product Approval Process in the United States</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Review and approval of drugs</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the United States, pharmaceutical
products are subject to extensive regulation by the FDA. The Federal Food, Drug and Cosmetic Act, or FDCA, and other federal and state
statutes and implementing regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping,
approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of
pharmaceutical products. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval
process or after approval may subject an applicant to a variety of administrative or judicial sanctions and enforcement actions brought
by the FDA, the U.S. Department of Justice, or DOJ, or other governmental entities. Possible sanctions may include the FDA&#8217;s refusal
to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters or untitled letters,
product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government
contracts, restitution, disgorgement and civil or criminal penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">FDA approval of a new drug
application is required before any new unapproved drug or dosage form, including a new use of a previously approved drug, can be marketed
in the United States. Section 505 of the FDCA describes three types of new drug applications: (1) an application that contains full reports
of investigations of safety and effectiveness (section 505(b)(1)); (2) an application that contains full reports of investigations of
safety and effectiveness but where at least some of the information required for approval comes from studies or investigations that were
not conducted by or for the applicant and by which the applicant has not obtained a right of reference or use from the person by or for
whom the investigations were conducted (section 505(b)(2)); and (3) an application that contains information to show that the proposed
product is identical in active ingredient, dosage form, strength, route of administration, labeling, quality, performance characteristics,
and intended use, among other things, to a previously approved product (section 505(j)). Section 505(b)(1) and 505(b)(2) new drug applications
are referred to as NDAs, and section 505(j) applications are referred to as ANDAs. We believe that the applications for PrimeC will be
a section 505(b)(2) NDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In general, the process required
by the FDA prior to marketing and distributing a new drug, as opposed to a generic drug subject to section 505(j), in the United States
usually involves the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practices, or GLP, requirements or other applicable regulations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of an IND, which must become effective before human clinical trials in the United States may begin;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug for its intended use;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparation and submission to the FDA of an NDA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion of an FDA advisory committee review, if applicable;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product or components thereof are produced, to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">payment of user fees and FDA review and approval of the NDA; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct post-approval studies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Preclinical studies</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Preclinical studies include
laboratory evaluation or product chemistry, formulation and toxicity, as well as animal studies to assess the potential safety and efficacy
of the product candidate. Preclinical safety tests must be conducted in compliance with the FDA regulations. The results of the preclinical
studies, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND which must become effective
before clinical trials may commence. Long-term preclinical studies, such as animal tests of reproductive toxicity and carcinogenicity,
may continue after the IND application is submitted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Clinical trials</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Clinical trials involve the
administration of an investigational product to human subjects under the supervision of qualified investigators in accordance with GCP
requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing
before their participation in any clinical trial. Clinical trials are conducted under written trial protocols detailing, among other things,
the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol
for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An IND automatically becomes
effective 30 days after receipt by the FDA unless the FDA, within the 30-day&#160;time period, raises concerns or questions related to
a proposed clinical trial and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding
concerns before the clinical trial can begin. In addition, information about certain clinical trials must be submitted within specific
timeframes to the National Institutes of Health, or NIH, for public dissemination on the NIH-maintained website,&#160;<i>www.clinicaltrials.gov.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An IRB representing each
institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution,
and the IRB must conduct continuing review at least annually. The IRB must review and approve, among other things, the trial protocol
information to be provided to trial subjects. An IRB must operate in compliance with FDA regulations. Information about certain clinical
trials must be submitted within specific timeframes to the NIH for public dissemination on the NIH-maintained website,&#160;<i>www.clinicaltrials.gov.</i>&#160;The
FDA, the IRB, or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the
subjects are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP requirements, including the
requirements for informed consent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Clinical trials are typically
conducted in three sequential phases, which may overlap or be combined:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase 1:</i> The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine optimal dosage.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase 2:</i> The drug is administered to a limited patient population to identify possible short-term adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Phase 3:</i> The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Submission of an NDA to the FDA</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The results of the preclinical
studies and clinical trials, together with other detailed information, including information on the manufacture, control and composition
of the product, are submitted to the FDA as part of an NDA requesting approval to market the product candidate for a proposed indication.
Under the Prescription Drug User Fee Act, as amended, applicants are required to pay fees to the FDA for reviewing an NDA. These user
fees, as well as the annual fees required for commercial manufacturing establishments and for approved products, can be substantial. The
NDA review fee alone can exceed $2&#160;million, subject to certain limited deferrals, waivers and reductions that may be available. The
FDA reviews an NDA to determine, among other things, whether a drug is safe and effective for its intended use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA has 60 days from
its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination
that it is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for
filing. In this event, the NDA must be resubmitted with the additional information and is subject to payment of additional user fees.
The resubmitted application is also subject to review before the FDA accepts it for filing. If found complete, the FDA will accept the
NDA for filing. Once the submission is accepted for filing, the FDA begins an in-depth&#160;substantive review.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Prescription Drug
User Fee Act, the FDA has agreed to certain performance goals in the review of NDAs through a two-tiered classification system, Standard
Review and Priority Review. Priority Review designation is given to drugs that offer major advances in treatment, or provide a treatment
where no adequate therapy exists. The FDA endeavors to review applications subject to Standard Review within approximately 10 to 12&#160;months
of receipt, whereas the FDA&#8217;s goal is to review Priority Review applications within approximately six to eight months of receipt,
depending on whether the drug is a new molecular entity. The FDA, however, may not approve a drug within these established goals, and
its review goals are subject to change from time to time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Before approving a NDA, the
FDA will inspect the facility or facilities at which the product is manufactured or facilities that are significantly involved in the
product development and distribution process, and will not approve the product unless compliance is satisfactory with cGMP. Additionally,
the FDA will typically inspect one or more clinical sites to assure compliance with GCP requirements. The FDA may also refer applications
for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee for review,
evaluation and recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the
recommendation of an advisory committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">After the FDA evaluates the
NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter to indicate that the review cycle
for an application is complete and that the application is not ready for approval. An approval letter authorizes commercial marketing
of the drug with specific prescribing information for specific indications. A complete response letter indicates that the review cycle
of the application is complete, and that the NDA will not be approved in its present form. If a complete response letter is issued, the
sponsor must resubmit the NDA and address all of the deficiencies identified in the letter, or withdraw the application. Even if such
data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A complete response letter
generally outlines the deficiencies in the NDA submission and may require substantial additional testing and/or clinical data and/or other
requirements related to clinical trials, nonclinical studies or manufacturing, in order for the FDA to reconsider the application. For
example, as a condition of NDA approval, the FDA may require a REMS to ensure that the benefits of the drug outweigh the potential risks.
For example, as a condition of NDA approval, the FDA may require a REMS to ensure that the benefits of the drug outweigh the potential
risks. If the FDA determines a REMS is necessary during review of the application, the drug sponsor must agree to the REMS plan at the
time of approval. A REMS may be required to include various elements, such as a medication guide or patient package insert, a communication
plan to educate healthcare providers of the drug&#8217;s risks, limitations on who may prescribe or dispense the drug, or other elements
to assure safe use, such as special training or certification for prescribing or dispensing, dispensing only under certain circumstances,
special monitoring and the use of patient registries. In addition, the REMS must include a timetable to periodically assess the strategy.
The requirement for a REMS can materially affect the potential market and profitability of a drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even with submission of additional
information, the approval may be for fewer or more limited indications than requested, indicated uses for which the product may be marketed,
may require that warning statements be included in the product labeling, may require that additional studies or trials be conducted following
approval as a condition of the approval, may impose restrictions and conditions on product distribution. If, or when, the deficiencies
have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Post-Approval Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any drug products for which
we may receive FDA approval will be subject to continuing regulation by the FDA. Certain requirements include, among other things, record-keeping
requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information on an
annual basis or more frequently for specific events, product sampling and distribution requirements, complying with certain electronic
records and signature requirements and complying with FDA promotion and advertising requirements. These promotion and advertising requirements
include standards for direct-to-consumer&#160;advertising, prohibitions against promoting drugs for uses or patient populations that are
not described in the drug&#8217;s approved labeling, known as &#8220;off-label use,&#8221; and other promotional activities, such as those
considered to be false or misleading. Failure to comply with FDA requirements can have negative consequences, including the immediate
discontinuation of noncomplying materials, adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications
with doctors, and civil or criminal penalties. Such enforcement may also lead to scrutiny and enforcement by other government and regulatory
bodies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The manufacturing of any
of our product candidates will be required to comply with applicable FDA manufacturing requirements contained in the FDA&#8217;s cGMP
regulations. The FDA&#8217;s cGMP regulations require, among other things, quality control and quality assurance, as well as the corresponding
maintenance of comprehensive records and documentation. Drug manufacturers and other entities involved in the manufacture and distribution
of approved drugs are also required to register their establishments and list any products they make with the FDA and to comply with related
requirements in certain states. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before
being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting
and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. These entities are
further subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly,
manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Discovery of problems with
a product after approval may result in serious and extensive restrictions on a product, manufacturer or holder of an approved NDA, as
well as lead to potential market disruptions. These restrictions may include recalls, suspension of a product until the FDA is assured
that quality standards can be met, and continuing oversight of manufacturing by the FDA under a &#8220;consent decree,&#8221; which frequently
includes the imposition of costs and continuing inspections over a period of many years, as well as possible withdrawal of the product
from the market. In addition, changes to the manufacturing process generally require prior FDA approval before being implemented. Other
types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA
review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which
such products are manufactured, as well as new application fees for supplemental applications with clinical data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The FDA also may require
post-marketing testing, or Phase 4 testing, as well as risk minimization action plans and surveillance to monitor the effects of an approved
product or place conditions on an approval that could otherwise restrict the distribution or use of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Once approval is granted,
the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after
the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated
severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions
to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks;
or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, warning letters or holds on post-approval clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizure or detention, or refusal to permit the import or export of products; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions or the imposition of civil or criminal penalties.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Hatch-Waxman Amendments</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>505(b)(2) NDAs</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section 505(b)(2) was enacted
as part of the Hatch-Waxman Amendment, and permits the filing of an NDA where at least some of the information required for approval comes
from studies or trials not conducted by or for the applicant and for which the applicant has not obtained a right of reference. As an
alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA, an applicant may
submit an NDA under Section 505(b)(2) of the FDCA. If the 505(b)(2) applicant can establish that reliance on the FDA&#8217;s previous
findings of safety and effectiveness is scientifically appropriate, it may eliminate the need to conduct certain pre-clinical studies
or clinical trials for the new product. The FDA may also require companies to perform additional studies or measurements, including clinical
trials, to support the change from the approved branded reference drug. The FDA may then approve the new product candidate for all, or
some, of the labeled indications for which the branded reference drug has been approved, as well as for any new indication sought by the
505(b)(2) applicant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Orange Book Listing</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In seeking approval for a
drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA certain patents whose claims cover the applicant&#8217;s
product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Publication
of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the &#8220;Orange Book.&#8221; Any applicant who
submits a Section 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA that (1) no patent information on
the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which
such patent expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use, or sale of the drug product
for which the application is submitted. This last certification is known as a Paragraph IV certification. The applicant may also elect
to submit a &#8220;section viii&#8221; statement certifying that its proposed label does not contain (or carves out) any language regarding
the patented method-of-use rather than certify to a listed method-of-use patent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the applicant does not
challenge one or more listed patents through a Paragraph IV certification, the FDA will not approve the Section 505(b)(2) NDA until all
the listed patents claiming the referenced product have expired. Further, the FDA will also not approve a Section 505(b)(2) NDA until
any non-patent exclusivity, as described in greater detail below, has expired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the Section 505(b)(2)
NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification
to the owner of the referenced NDA for the previously approved product and relevant patent holders within 20 days after the Section 505(b)(2)
NDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement suit against the Section
505(b)(2) applicant. Under the FDCA, the filing of a patent infringement lawsuit within 45 days of receipt of the notification regarding
a Paragraph IV certification automatically prevents the FDA from approving the Section 505(b)(2) NDA until the earliest to occur of 30&#160;months
beginning on the date the patent holder receives notice, expiration of the patent, settlement of the lawsuit, or until a court deems the
patent unenforceable, invalid or not infringed. Even if a patent infringement claim is not brought within the 45-day period, a patent
infringement claim may be brought under traditional patent law, but it does not invoke the 30-month stay.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Moreover, in cases where
a Section 505(b)(2) application containing a Paragraph IV certification is submitted after the fourth year of a previously approved drug&#8217;s
five-year NCE exclusivity period, as described more fully below, and the patent holder brings suit within 45 days of notice of the Paragraph
IV certification, the 30-month period is automatically extended to prevent approval of the Section 505(b)(2) application until the date
that is seven and one-half years after approval of the previously approved reference product that has the five-year NCE exclusivity. The
court also has the ability to shorten or lengthen either the 30-month or the seven and one-half year period if either party is found not
to be reasonably cooperating in expediting the litigation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Notwithstanding the approval
of many products by the FDA pursuant to Section 505(b)(2), over the last few years, some pharmaceutical companies and others have objected
to the FDA&#8217;s interpretation of Section 505(b)(2). If the FDA changes its interpretation of Section 505(b)(2), or if the FDA&#8217;s
interpretation is successfully challenged in court, this could delay or even prevent the FDA from approving any Section 505(b)(2) NDA
that we submit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Non-Patent Exclusivity</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to patent exclusivity,
the holder of the NDA for the listed drug may be entitled to a period of non-patent exclusivity, during which the FDA cannot approve a
505(b)(2) application that relies on the listed drug. For example, a pharmaceutical manufacturer may obtain five years of non-patent exclusivity
upon NDA approval of a new chemical entity, or NCE, which is a drug that contains an active moiety that has not been approved by FDA in
any other NDA. An &#8220;active moiety&#8221; is defined as the molecule or ion responsible for the drug substance&#8217;s physiological
or pharmacologic action. During the five year exclusivity period, the FDA cannot accept for filing any ANDA seeking approval of a generic
version of that drug or any 505(b)(2) NDA for the same active moiety and that relies on the FDA&#8217;s findings regarding that drug,
except that FDA may accept an application for filing after four years if the follow-on applicant makes a paragraph IV certification.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Another form of non-patent
exclusivity is clinical investigation exclusivity. A drug, including one approved under Section 505(b)(2), may obtain a three-year period
of exclusivity for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved
product, if one or more new clinical trials (other than bioavailability or bioequivalence studies) was essential to the approval of the
application and was conducted/ sponsored by the applicant. Should this occur, the FDA would be precluded from approving any ANDA or 505(b)(2)
application for the protected modification until after that three-year exclusivity period has run. However, unlike NCE exclusivity, the
FDA can accept an application and begin the review process during the exclusivity period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent Term Restoration and Extension</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Depending upon the timing,
duration and specifics of our product candidates, some of our U.S. patents claiming a new drug product may be eligible for limited patent
term extension under the Hatch-Waxman&#160;Amendments, which permit a patent term restoration of up to five years for the patent term
lost during product development and the FDA regulatory review process. However, a patent term restoration cannot be used to extend the
remaining term of a patent past a total of 14 years from the product&#8217;s approval date. The patent term restoration period granted
is typically one-half the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission
date of an NDA and the approval date of that NDA. Only one patent applicable to an approved drug product is eligible for the extension,
and the application for the extension must be submitted prior to the expiration of the patent. A patent that covers multiple drugs for
which approval is sought can only be extended in connection with one of the approvals. The U.S. Patent and Trademark Office reviews and
approves the PTE application in consultation with the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Review and Approval of Drug Products Outside
the United States</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition to regulations
in the United States, if we target non-U.S. markets, we will be subject to a variety of foreign regulations governing manufacturing, clinical
trials, commercial sales and distribution of our product candidates. Whether or not we obtain FDA approval for a product candidate, we
must obtain approval of the product by the comparable regulatory authorities of foreign countries before commencing clinical trials or
marketing in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required
for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly
from country to country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>European Union</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under European Union regulatory
systems, marketing authorizations may be submitted either under a centralized, national, decentralized, -or mutual recognition procedure.
The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all
European Union member states. The national procedure is only available for products intended to be authorized in a single EU member state.
The decentralized procedure includes selecting one &#8220;reference member state,&#8221; or RMS, and submitting to more than one member
state at the same time. The RSM will lead the review of an application in a mutual recognition and a decentralized procedure. The RMS
National Competent Authority conducts a detailed review and prepares a draft assessment report, a draft assessment report, a draft summary
of product characteristics and a draft of the labelling and package leaflet and shall send these documents to the concerned member states
and to the applicant, which the concerned member states provide comment. The mutual recognition procedure provides for mutual recognition
of national approval decisions. Under this procedure, , the marketing authorization holder shall request the RMS either to prepare an
assessment report on the product or, if necessary, to update any existing assessment report. In a mutual recognition or decentralized
procedure, the member states concerned shall approve the relevant document(s) within 90 days of receipt and shall inform the reference
member state accordingly. The reference member state shall record the agreement of all parties, close the procedure and inform the applicant
thereof. Each member state in which an application has been submitted under a mutual recognition or decentralized procedure shall adopt
a decision in conformity with the approved document(s), within 30 days after acknowledgement of the agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Israel</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Regulations regarding clinical trials</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The conduct of clinical studies
in Israel is subject to the study sponsor&#8217;s receipt of specific authorization from the ethics committee (the equivalent of an Institutional
Review Board) and general manager of the institution in which the sponsor intends to conduct its study, as required under the Guidelines
for Clinical Trials in Human Subjects implemented pursuant to the Israeli Public Health Regulations (Clinical Trials in Human Subjects),
as amended from time to time, and other applicable legislation, including applicable guidelines issued by the Israeli Ministry of Health,
or the MOH. These regulations also require authorization from the MOH, except in certain circumstances, and in the case of genetic trials,
special fertility trials and certain other trials, an additional authorization of the overseeing institutional ethics committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Regulations regarding new drugs approvals</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The registration of medicinal
and biological products is regulated by the Pharmacists Regulations promulgated under the Pharmacists Ordinance [New Version], 5741-1981,
or the Pharmacists Ordinance, and by guidelines issued by the MOH. According to the Pharmacists Ordinance, a person may not manufacture,
market, import or order the use of any drug, defined as any form of substance or combination of substances that complies with one of the
following, but excluding blood or blood component that have been collected from a person and it intended to fill its physiological function
and has not undergone a significant processing process: (i) has or is presented to have curing, or prevention characteristics or is designated
to treat a disease; (ii) causes or is intended to cause reproduction, replacement, correction or change of a physiological action in the
body through a pharmacological or immunological or metabolic action; (iii) is given or can be given for a medical diagnosis; or a Pharmaceutical,
and in accordance with its registration terms (subject to certain listed exceptions). The application to register a Pharmaceutical in
the Pharmaceutical Registry should be submitted in person, during a meeting at the MOH. For an imported Pharmaceutical, the application
shall also include CPP (Certificate of Pharmaceutical Product) approval, and GMP Approval from a competent authority of a Pharmaceutical
Recognized Country (as defined in the regulations) that in the site mentioned therein complies with GMP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A first Pharmaceutical registration
approval shall be granted for a period of no longer than five years. A renewal of a Pharmaceutical approval may be granted for consecutive
periods no longer than ten years each. The first batch of a Pharmaceutical marketed in Israel must be approved by the MOH as a pre-condition&#160;to
its marketing. The MOH shall approve such batch only after it has confirmed that the Pharmaceutical batch conforms to the registration
certificate, the requirements mentioned in the registration files and after the packaging, labeling and leaflets for both physicians and
consumers have been approved. In addition, the following Pharmaceuticals need to receive MOH approval before the marketing of each batch:
(i) a Pharmaceutical derived from human blood or plasma prepared by a method involving an industrial process, excluding whole blood or
blood cells; (ii) human vaccines; (iii) a registered Pharmaceutical imported pursuant to an import and marketing approval of a Compatible
Pharmaceutical (as defined in the regulations); and (iv) other Pharmaceuticals that the MOH determines should be examined to ensure public
safety.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other Healthcare Laws and Regulations and Legislative
Reform in the United States</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>U.S. Healthcare Laws and Regulations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Healthcare providers, physicians
and third-party&#160;payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain
marketing approval. Our operations, including any arrangements with healthcare providers, physicians, third-party&#160;payors and customers
may expose us to broadly applicable fraud and abuse and other healthcare laws that may affect the business or financial arrangements and
relationships through which we would market, sell and distribute our products. Our current and future operations are subject to regulation
by various federal, state, and local authorities in addition to the FDA, including but not limited to the Centers for Medicare &amp; Medicaid
Services, or CMS, the Department of Health and Human Services, or HHS, (including the Office of Inspector General, Office for Civil Rights
and the Health Resources and Services Administration), the DOJ and individual U.S. Attorney offices within the DOJ, and state and local
governments. The healthcare laws that may affect our ability to operate include, but are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal Anti-Kickback&#160;Statute, which prohibits any person or entity from, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The federal Anti-Kickback&#160;Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Additionally, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal civil and criminal false claims laws, such as the False Claims Act, which can be enforced by private citizens through civil qui tam actions, and civil monetary penalty laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment of federal funds, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Drug manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. For example, pharmaceutical companies have been prosecuted under the False Claims Act in connection with their alleged off-label&#160;promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal healthcare programs for the product. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback&#160;Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Health Insurance Portability and Accountability Act, or HIPAA, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party&#160;payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and creates federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback&#160;Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their implementing regulations, which impose privacy, security and breach reporting obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates that perform services for them that involve individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal transparency requirements under the Physician Payments Sunshine Act, created under the Patient Protection and Affordable Care Act, or ACA, which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments and other transfers of value provided to physicians, defined to include doctors, dentists, optometrists, podiatrists and chiropractors, and teaching hospitals and physician ownership and investment interests, including such ownership and investment interests held by a physician&#8217;s immediate family members. Effective January&#160;1, 2022, these reporting obligations will extend to include transfers of value made during the previous year to certain non-physician&#160;providers, including physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and anesthesiologist assistants, and certified nurse midwives;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs; such as Medicaid reimbursement requires the best price and the 340B program that requires discounts for certain providers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State and foreign laws that are analogous to each of the above federal laws, such as anti-kickback&#160;and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by non-governmental&#160;third-party&#160;payors, including private insurers, and state laws that require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other healthcare providers; state laws that require the reporting of marketing expenditures or drug pricing, including information pertaining to and justifying price increases; state and local laws that require the registration of pharmaceutical sales representatives; state laws that prohibit various marketing-related&#160;activities, such as the provision of certain kinds of gifts or meals; state laws that require the posting of information relating to clinical trials and their outcomes; and other federal, state and foreign laws that govern the privacy and security of health information or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure and protection of health-related&#160;and other personal information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus requiring additional compliance efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If our operations are found
to be in violation of any of these laws or any other current or future healthcare laws that may apply to us, we may be subject to significant
civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare
programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting
obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance&#160;with
these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. Although
effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot
be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses
and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition,
if any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance
with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government
funded healthcare programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Legislative Reform</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We operate in a highly regulated
industry, and new laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, related
to healthcare availability, the method of delivery and payment for healthcare products and services could negatively affect our business,
financial condition and prospects. There is significant interest in promoting healthcare reforms, and it is likely that federal and state
legislatures within the United States and the governments of other countries will continue to consider changes to existing healthcare
legislation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For example, the United States
and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In 2010, the U.S. Congress enacted
the ACA, which included changes to the coverage and reimbursement of drug products under government healthcare programs such as:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">established a branded prescription drug fee that pharmaceutical manufacturers of certain branded prescription drugs must pay to the federal government;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new entities to the program;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70%, effective as of 2019) point-of-sale&#160;discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">extended manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">established a new Patient-Centered&#160;Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">established the Center for Medicare &amp; Medicaid Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">created a licensure framework for follow-on&#160;biologic products.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There have been executive,
judicial and congressional challenges to certain aspects of the ACA. For example, in 2017, the U.S. Congress enacted a law informally
known as the Tax Cuts and Jobs Act, or TCIA, which eliminated the tax-based&#160;shared responsibility payment imposed by the ACA on certain
individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual
mandate.&#8221; On December&#160;14, 2018, the U.S. District Court for the Northern District of Texas held that the individual mandate
is a critical and inseverable feature of the ACA, and therefore, because it was repealed by the TCIA, the remaining provisions of the
ACA are invalid as well. On December&#160;18, 2019, the U.S. Court of Appeals for the Fifth Circuit upheld the District Court ruling that
the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions
of the ACA are invalid as well. The U.S. Supreme Court recently decided this case; oral arguments were heard on November&#160;10, 2020
and the Supreme Court&#8217;s decision was published on June&#160;17, 2021. The U.S. Supreme Court refused to hear the plaintiff&#8217;s
claims on the merits because they held the plaintiff had no standing to bring the lawsuit. Consequently, the U.S. Supreme Court reversed
the lower courts and ordered the case be dismissed. On January&#160;28, 2021, President Biden issued an executive order to initiate a
special enrollment period from February&#160;15, 2021 through May&#160;15, 2021 for purposes of obtaining health insurance coverage through
the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies
and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that
include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid
or the ACA. Further, on February&#160;10, 2021, the Biden Administration withdrew the federal government&#8217;s support for overturning
the ACA. It is unclear how the Supreme Court ruling, other such litigation and the healthcare reform measures of the Biden administration
will impact the ACA. It is difficult to predict the future legislative landscape in healthcare and the effect on our business, results
of operations, financial condition and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, there have been
and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs. In 2011,
the U.S. Congress enacted the Budget Control Act, or BCA, which included provisions intended to reduce the federal deficit. The BCA resulted
in the imposition of 2% reductions in Medicare payments to providers beginning in 2013 and, due to subsequent legislative amendments to
the statute, will remain in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020 through March&#160;31,
2021 absent additional congressional action. Legislation is currently pending to extend the suspension through December&#160;31, 2021.
In addition, in 2012, the U.S. Congress enacted the American Taxpayer Relief Act, which, among other things, further reduced Medicare
payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of
limitations period for the government to recover overpayments to providers from three to five years. If government spending is further
reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA, to continue to function at
current levels, which may impact the ability of relevant agencies to timely review and approve research and development, manufacturing
and marketing activities, which may delay our ability to develop, market and sell any product candidates we may develop. Moreover, any
significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented,
or any significant taxes or fees that may be imposed on us, as part of any broader deficit reduction effort or legislative replacement
to the BCA, could have an adverse impact on our anticipated product revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Furthermore, there has been
heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in
several congressional inquiries and proposed legislation designed to, among other things, bring more transparency to product pricing,
review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for
drug products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including
through federal budget proposals, executive orders and policy initiatives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For example, on July&#160;24,
2020 and September&#160;13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that
attempt to implement several of the administration&#8217;s proposals. The FDA also released a final rule on September&#160;24, 2020 providing
guidance for states to build and submit importation plans for drugs from Canada. Further, on November&#160;20, 2020, HHS finalized a regulation
removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either
directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been
delayed by the Biden administration from January&#160;1, 2022 to January&#160;1, 2023 in response to ongoing litigation. The rule also
creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements
between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January&#160;1, 2023. Further,
in November 2020, CMS issued an interim final rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement
rates will be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic
Cooperation and Development countries with a similar gross domestic product per capita. The MFN Model regulations mandate participation
by identified Medicare Part B providers and will apply in all U.S. states and territories for a seven-year&#160;period beginning January&#160;1,
2021, and ending December&#160;31, 2027. The Interim Final Rule has not been finalized and is subject to revision and challenge. For example,
on December&#160;28, 2020, the United States District Court for the Northern District of California issued a nationwide preliminary injunction
against the implementation of this interim final rule.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Individual states in the
United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical
product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.
In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical
products and which suppliers will be included in their prescription drug and other healthcare programs. We expect that additional U.S.
federal healthcare reform measures will be adopted in the future, particularly in light of the new presidential administration.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Facilities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our corporate headquarters
is located in Herzliya, Israel, where we lease and occupy approximately 2,300 square feet of office space. The current term of our Herzliya
lease commenced January 2022 and expires on December&#160;31, 2025 (following the exercise of the first option to extend the lease term)
and the monthly lease payments, including utilities, amount to approximately $7 thousand and are indexed to the Israeli consumer price
index. We have an option to extend the term of the lease for an additional two years. In September 2021, we entered into an agreement
which provides us access to co-working&#160;spaces, including office space in Cambridge, Massachusetts. The lease pursuant to which we
can access the co-working&#160;spaces is terminable at will by either us or the licensor for any reason upon 30 days&#8217; written notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe our existing facility
is sufficient for our needs for the foreseeable future. To meet the future needs of our business, we may lease additional or alternate
space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may be subject from time
to time to various legal proceedings lawsuits, disputes or claims in the ordinary course of our business activities. Although the results
of litigation and claims cannot be predicted with certainty, as of the date of this annual report, we do not believe we are party to any
claim or litigation, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected
to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense
and settlement costs, diversion of management resources and other factors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Scientific Advisory Board</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We maintain a Scientific
Advisory Board. The current chair of our Scientific Advisory Board is Professor Jeremy Shefner. The other members of our Scientific Advisory
Board are Professor Orla Hardiman, Professor Merit Cudkowicz, Dr. Jinsy Andrews and Dr. Jeffery Rosenfeld.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Organizational Structure</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Property, Plant and Equipment</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">See &#8220;Item 4. Information
on the Company&#8212;B. Business Overview&#8212;Facilities&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 4A. UNRESOLVED STAFF COMMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 5. OPERATING AND FINANCIAL REVIEW AND
PROSPECTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>You should read the following
discussion of our financial condition and results of operations in conjunction with the consolidated financial statements and the notes
thereto included elsewhere in this annual report. The following discussion contains forward-looking statements that reflect our plans,
estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements.&#160;Factors
that could cause or contribute to these differences include those discussed below and elsewhere in this annual report, particularly those
in &#8220;Item 3. Key Information</i>&#160;<i>&#8211;</i>&#160;<i>D. Risk Factors.&#8221; Our discussion and analysis for the year ended
December 31, 2023 can be found in our Annual Report on Form 20-F for the fiscal year ended December 31, 2023, filed with the SEC on April
4, 2024.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a clinical-stage biotechnology
company focused on discovering and developing treatments for people living with neurodegenerative diseases, including ALS AD and PD. We
believe these diseases represent some of the most significant unmet medical needs of our time, with limited effective therapeutic options
available. The burden of these diseases on both patients and society is substantial. For example, the average annual cost of ALS alone
is $180,000 per patient, and its estimated annual burden on the U.S.&#160;healthcare system is greater than $1&#160;billion. Due to the
complexity of neurodegenerative diseases, our strategy is utilizing a combined therapeutic approach to target multiple disease-related
pathways.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our lead therapeutic candidate,
PrimeC, is a novel extended-release oral formulation, fixed-dose combination of two FDA-approved drugs, ciprofloxacin and celecoxib. PrimeC
is designed to treat ALS by modulating microRNA synthesis, iron accumulation, and neuroinflammation, all of which are hallmarks of ALS
pathology. The U.S.&#160;Food and Drug Administration, or the FDA and the European Medicines Agency, or the EMA have granted PrimeC orphan
drug designation for the treatment of ALS.&#160;In addition, the EMA has granted PrimeC the Small and Medium-Sized Enterprise, or SME,
status, which offers significant potential benefits leading up to and following drug regulatory approval. We believe PrimeC&#8217;s multifunctional
mechanism of action has the potential to significantly prolong lifespan and improve ALS patients&#8217; quality of life, thereby reducing
the burden of this debilitating disease on both patients and healthcare systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have incurred operating
losses in each year since our inception. We incurred net losses of $10.21 million and $10.10&#160;million for the years ended December&#160;31,
2024 and 2023, respectively. As of December 31, 2024, we had an accumulated deficit of $36.66 million. We expect to incur significant
expenses and operating losses for the foreseeable future as we advance our product candidates from formulation development through preclinical
development and clinical trials, seek regulatory approval and pursue commercialization of any approved product candidate. In addition,
we expect that our expenses will increase substantially in connection with our ongoing activities as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue the clinical development of PrimeC ;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue the preclinical development of our other product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">file an NDA seeking regulatory approval for any product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any products for which we obtain manufacturing approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain, expand and protect our intellectual property portfolio;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">add equipment and physical infrastructure to support our research and development;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire additional clinical development, quality control and manufacturing personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur additional expenses associated with operating as a U.S. public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Operating Results</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have not recognized any
revenue to date and we do not expect to generate revenue from the sale of products in the near future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our current operating expenses
consist primarily of research and development as well as general and administrative expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Research and Development Expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Research and development
expenses consist primarily of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">salaries for research and development staff and related expenses, including employee benefits and share-based compensation expenses;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses for production of our product candidates by contract manufacturers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses paid to contract research organizations and other third parties in connection with the performance of preclinical studies, clinical trials and related expenses;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred under agreements with other third parties, including subcontractors, suppliers and consultants that conduct formulation development, regulatory activities and preclinical studies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses incurred to acquire, develop and manufacture preclinical study and clinical trial materials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Expenses on research activities
is recognized in profit or loss when incurred. Development expenditures, including patent registration costs, are capitalized only if
development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits
are probable, and we intend to and have sufficient resources to complete development and to use or sell the asset. As of December 31,
2024, no development expenditures have met the recognition criteria and thus we have expensed all of our development expenditures as incurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are currently focused
on advancing our product candidates, and our future research and development expenses will depend on their clinical success. Research
and development expenses will continue to be significant and will increase over at least the next several years as we continue to develop
our product candidates and conduct preclinical studies and clinical trials of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not believe that it
is possible at this time to accurately project total expenses required for us to reach commercialization of our product candidates. Due
to the inherently unpredictable nature of preclinical and clinical development, we are unable to estimate with certainty the costs we
will incur and the timelines that will be required in the continued development and approval of our product candidates. Clinical and preclinical
development timelines, the probability of success and development costs can differ materially from expectations. See &#8220;Risk Factors&#8212;Risks
Related to Our Business and Strategy.&#8221; In addition, we cannot forecast which product candidates may be subject to future collaborations,
if and when such arrangements will be entered into, if at all, and to what degree such arrangements would affect our development plans
and capital requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General and Administrative Expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">General and administrative
expenses consist primarily of personnel costs, including share-based compensation, related to directors, executive, finance, and human
resource functions, insurance costs, facility costs and external professional service costs, including legal, accounting, marketing and
audit services and other consulting fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We anticipate that our general
and administrative expenses will increase in the future as we increase our administrative headcount and infrastructure to support our
continued research and development programs and the potential approval and commercialization of our product candidates. We also anticipate
that we will incur increased expenses related to audit, legal, regulatory and tax-related services associated with maintaining compliance
with Nasdaq and SEC requirements, director and officer insurance premiums, director compensation, and other costs associated with being
a public company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, if any of our
product candidates receives regulatory approval and if we determine to invest in building a commercial infrastructure to support the marketing
of our products, we expect to incur greater expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financing income (Expenses), net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our net financing expenses
(income), net consist primarily of fair value revaluation of warrants, issuance costs, interest income on deposits, interest expenses
on lease liability and differences in the exchange rate between NIS and the U.S. Dollar.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Income Taxes</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have yet to generate taxable
income in Israel, as we have historically incurred operating losses resulting in carry forward tax losses totaling approximately $24.7
million as of December 31, 2024. We anticipate that we will continue to generate tax losses for the foreseeable future and that we will
be able to carry forward these tax losses indefinitely to future taxable years. Accordingly, we do not expect to pay taxes in Israel until
we have taxable income after the full utilization of our carry forward tax losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Comparison of the Year Ended December 31, 2024
to the Year Ended December 31, 2023</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our results of operations
for the years ended December 31, 2024 and 2023 were as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For&#160;the&#160;Years&#160;Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(U.S.&#160;dollars&#160;in&#160;thousands&#160;except&#160;share&#160;and per share data)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Statement of Operations:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Research and Development Expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(5,698</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(7,274</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">General and Administrative Expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,204</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,775</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Operating Loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,902</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,049</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Financing Income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(308</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,942</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net Loss and Comprehensive Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(10,210</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(10,107</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Basic and Diluted Net Loss per Share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.54</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.74</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Weighted average number of shares outstanding used in computing basic and diluted net loss per share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,602,082</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">13,640,168</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table describes
the breakdown of our research and development expenses for the indicated periods:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For&#160;the&#160;Years&#160;Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(U.S. dollars in thousands except share and per share data)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Subcontractors and consultants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,530</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,794</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">193</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">575</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salaries and social benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,905</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total research and development expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,698</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,274</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our research and development
expenses for the years ended December 31, 2024 and 2023 were $5,698 thousand and $7,274 thousand, respectively. The decrease of $1,576
thousand, or 21.6%, was mainly attributed to (i) a decrease of $1,264 thousand, or 26.3%, in subcontractor and consulting expenses relating
to clinical programs and (ii) a decrease of $382 thousand, or 66.4%, in share-based compensation expenses to our employees and service
providers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table describes
the breakdown of our general and administrative expenses for the indicated periods:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Professional services</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,998</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,486</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">364</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">962</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salaries and social benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">865</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,011</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">511</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Traveling abroad</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">534</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">641</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,204</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,775</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our general and
administrative expenses for the years ended December 31, 2024 and 2023 were $4,204 thousand and $4,775 thousand, respectively. The
decrease of $571 thousand, or 11.9%, was primarily attributable to (i) a $598 thousand, or 62.1%, decrease in share-based
compensation expenses due to fewer grants of options and restricted share units (&#8220;RSUs&#8221;) to our employees, directors and
service providers, (ii) a decrease of $202 thousand, or 39.5%, in insurance costs as a public company and (iii) a decrease of $146
thousand, or 14.4%, in salaries and social benefits, mainly due to decrease in the number of employees which were offset by a $512
thousand, or 34.4%, increase in professional services expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financing Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our financing expenses, net
for the year ended December 31, 2024 were $308 thousand compared to finance income, net of $1,942 thousand for the year ended December
31, 2023. The decrease of $2,250 thousand in finance expense was primary attributable to a $2,145 thousand decrease in revaluation
of financial instruments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Overview</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since our inception, we have
incurred losses and negative cash flows from our operations. For the year ended December 31, 2024, we incurred a net loss of approximately
$10.21 million, while net cash of approximately $10.13 million was used in our operating activities. As of December 31, 2024, we had accumulated
deficit of approximately $36.66 million. As of December 31, 2024, our cash and cash equivalents totaled approximately $3.37 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our financial statements
have been prepared on a going concern basis under which an entity is considered to be able to realize its assets and satisfy its liabilities
in the ordinary course of business, and our financial status creates a substantial doubt whether we will continue as a going concern.
Our future operations are dependent upon the identification and successful completion of equity or debt financing and the achievement
of profitable operations at an indeterminate time in the future. There can be no assurances that we will be successful in completing an
equity or debt financing or in achieving or maintaining profitability. The financial statements do not give effect to any adjustments
relating to the carrying values and classification of assets and liabilities that would be necessary should we be unable to&#160;continue
as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Through December 31,
2024, we have financed our operations primarily through our initial public offering, public and private offerings of our equity
securities, proceeds from the exercise of warrants and options, and crowd funding of equity securities. Total gross invested capital
as of December 31, 2024 was approximately $35.9 million, which included issuances of ordinary shares, SAFE agreements, options and
warrants to purchase ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In May, June and July 2021,
we received $0.80 million from SAFE agreements, in September 2021, we received an additional $1.23 million from previous investors as
a result of their exercise of outstanding warrants, in December 2021, we received gross proceeds of approximately $12.0 million from our
initial public offering, and during 2022 we received approximately $3.87 million following exercise of warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In April 2023, we
entered into a sales agreement, or A.G.P./Alliance ATM, with A.G.P./Alliance Global Partners, or AGP, pursuant to which we were able
to offer and sell, at our option, up to $5,743,677 of our ordinary shares through an at-the-market equity program under which AGP
agreed to act as sales agent. In June 2023, we and AGP reduced the maximum aggregate offering amount under the A.G.P./Alliance ATM
program to $502.30, and in October 2023, we terminated the A.G.P./Alliance ATM program with having sold 3,600 ordinary shares for
aggregate gross proceeds of $7.2 thousands.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In June 2023, we received
gross proceeds of approximately $4.5 million before deducting placement agent fee and related offering expenses million from a registered
direct offering. Total issuance expenses in connection with the offering were $0.45 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In April 2024, we received
gross proceeds of approximately $4.47 million before deducting placement agent fee and related offering expenses million from a registered
direct offering. As part of the agreement, the Company also issued 70,964 ordinary shares valued at $0.1 million as issuance expenses to
the placement agent. Total issuance expenses in cash in connection with the offering were $0.153 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In August 2024, we entered
into a Capital on Demand Sales Agreement, or the 2024 Sales Agreement, with JonesTrading Institutional Services LLC, or JonesTrading.
Pursuant to the 2024 Sales Agreement, we may offer and sell our ordinary shares having an aggregate offering price of up to $2,524,437,
from time to time through JonesTrading. As of April 4, 2025, we have sold 1,549,725 of our ordinary shares pursuant to the 2024 Sales
Agreement for aggregate gross proceeds of approximately $1.74 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In August 2024 and December
2024, we received gross proceeds of approximately $0.6 million and $5.0 million, respectively, before deducting offering expenses from
private placements. Total issuance expenses in connection with the August 2024 and December 2024 offerings were $0.01 million and $0.06
million, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In October 2024, we entered
into a Standby Equity Purchase Agreement, or the SEPA, with YA II PN, LTD., a Cayman Islands exempt limited partnership, or YA. Pursuant
to the SEPA, we have the right, but not the obligation, to sell to YA from time to time, each such occurrence, an Advance, up to $30.0
million, or the Commitment Amount, of our ordinary shares, during the 36 months following the execution of the SEPA, subject to the restrictions
and satisfaction of the conditions in the SEPA. As of the date of this annual report, we have issued 224,697 ordinary shares to YA as
consideration for YA&#8217;s irrevocable commitment to purchase our ordinary shares up to the Commitment Amount and we have not sold any
ordinary shares to YA as Advance Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 2, 2024, we entered
into a securities purchase agreement with an institutional investor and our chief executive officer pursuant to which we sold an aggregate
of (i) 2,343,729 of our ordinary shares (ii) pre-funded warrants to purchase up to an aggregate of 1,656,271 ordinary shares and (iii)
8,000,000 ordinary warrants, each representing the right to acquire one ordinary share, in a private placement at a combined offering
price of $1.25 per ordinary share and ordinary warrant and $1.2499 per pre-funded warrant and ordinary warrant. Each pre-funded warrant
represented the right to purchase one ordinary shares at an exercise price of $0.0001 per share. The pre-funded warrants were exercisable
immediately and at any time until the pre-funded warrants were exercised in full (subject to a beneficial ownership limitation set forth
therein). The ordinary warrants are exercisable immediately upon issuance at an exercise price of $1.25 per share and will expire on the
fifth anniversary of the original issuance date. Aggregate gross proceeds from the private placement were approximately $5.0 million,
before deducting offering expenses. The offering closed on December 17, 2024. </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Cash flows</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table summarizes
our statement of cash flows for the years ended December 31, 2024 and 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For&#160;the&#160;Years&#160;Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">(U.S.&#160;dollars&#160;in&#160;thousands&#160;except&#160;share&#160;and per&#160;share&#160;data)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(10,135</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(8,354</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net cash provided by (used in) investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,468</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,913</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,975</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Effects of exchange rate changes on cash and cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(41</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Increase (decrease) in cash and cash equivalents</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">738</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(903</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Net cash used in operating activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Net cash used in operating
activities was $10,135 thousand and $8,354 thousand for the years ended December 31, 2024 and 2023, respectively. The $1,781 thousand
increase was attributable primarily to higher payments to service providers and subcontractors following higher proceeds from finance
activity in 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Net cash provided by (used in) investing activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Net cash provided by (used
in) investing activities was $1 thousand and $3,468 thousand for the years ended December 31, 2024 and 2023, respectively. The $3,467
thousand decrease was attributable primarily to changes in the investment in short-term and restricted deposits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Net cash provided by financing activities</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Net cash provided by financing
activities was $10,913 thousand and $3,975 thousand for the years ended December 31, 2024 and 2023, respectively. The increase was primarily
due to the higher proceeds from issuance of shares, warrants and pre-funded warrants in 2024 compared to 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Funding Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since our inception, almost
all of our resources have been dedicated to the preclinical and clinical development of our lead product candidate, PrimeC. As of December
31, 2024, we had cash and cash equivalents of $3.37 million. We believe that our existing cash and cash equivalents will not be sufficient
to fund the Company&#8217;s operations for a period of at least 12 months from the date of approval of our consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our present and future funding
requirements will depend on many factors, including, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the progress, timing and completion of clinical trials for PrimeC;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preclinical studies and clinical trials for our other product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs related to obtaining regulatory approval for PrimeC and any of our other product candidates, and any delays we may encounter as a result of regulatory requirements or adverse clinical trial results with respect to any of these product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">selling, marketing and patent-related activities undertaken in connection with the commercialization of PrimeC and any of our other product candidates, and costs involved in the development of an effective sales and marketing organization;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs involved in filing and prosecuting patent applications and obtaining, maintaining and enforcing patents or defending against claims or infringements raised by third parties, and license royalties or other amounts we may be required to pay to obtain rights to third party intellectual property rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential new product candidates we identify and attempt to develop; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">revenues we may derive either directly or in the form of royalty payments from future sales of PrimeC and any other product candidates.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For more information as to
the risks associated with our future funding needs, see &#8220;Risk Factors &#8212; We will require substantial additional financing to
achieve our goals, and a failure to obtain this capital when needed and on acceptable terms, or at all, could force us to delay, limit,
reduce or terminate our product development, commercialization efforts or other operations.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Contractual Obligations and Commitments</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024,
we did not have any material contractual obligation and commitments, except for lease agreements with respect to offices. In December
2021, we entered into an office space lease agreement in Herzilya, Israel (which commenced on January 1, 2022). Monthly rent payments
including utilities amount to approximately $7 thousand and indexed to CPI. The lease period was for 24 months with an option to extend
the lease period for additional two periods of 24 months each. We exercised the first period option, and we expect to exercise the second
option for an additional lease period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Off-Balance Sheet Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We did not have during the
periods presented, and we do not currently have, any off-balance sheet arrangements that have or are reasonably likely to have a current
or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Offerings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On June 22, 2023, we sold
to health-care focused institutional purchaser an aggregate of (i) 1,330,000 of our ordinary shares at an offering price of $1.50 per
share and (ii) pre-funded warrants to purchase up to an aggregate of 1,670,000 ordinary shares at an offering price of $1.499 per pre-funded
warrant, in a registered direct offering. Each pre-funded warrant represented the right to purchase one ordinary shares at an exercise
price of $0.0001 per share. The pre-funded warrants were exercisable immediately and at any time until the pre-funded warrants were exercised
in full (subject to a beneficial ownership limitation set forth therein). In a concurrent private placement, we also issued an aggregate
of 3,000,000 ordinary warrants, each representing the right to acquire one ordinary share, at the same purchase price in the registered
direct offering. The ordinary warrants are exercisable immediately upon issuance at an exercise price of $1.50 per share, and will expire
on the fifth anniversary of the original issuance date. Aggregate gross proceeds from the registered direct offering and concurrent private
placement were approximately $4.5 million, before deducting the placement agent fee and related offering expenses. The offerings closed
on June 26, 2023. In June 2024, we and a certain institutional investor from the June 2023 concurrent private placement amended the ordinary
warrant to purchase up to 3,000,000 ordinary shares to make certain adjustments to the &#8220;Redemption Right&#8221; provision in the
ordinary warrant and extend the termination date of ordinary warrant to October 12, 2029. As of the date of this annual report, the pre-funded
warrants have been exercised in full.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 10, 2024, we entered
into a securities purchase agreement with an institutional investor pursuant to which we sold an aggregate of (i) 1,732,000 of our ordinary
shares at an offering price of $1.50 per share and (ii) pre-funded warrants to purchase up to an aggregate of 1,248,000 ordinary shares
at an offering price of $1.499 per pre-funded warrant, in a registered direct offering. Each pre-funded warrant represented the right
to purchase one ordinary shares at an exercise price of $0.0001 per share. The pre-funded warrants were exercisable immediately and at
any time until the pre-funded warrants were exercised in full (subject to a beneficial ownership limitation set forth therein). In a concurrent
private placement, we also issued an aggregate of 2,980,000 ordinary warrants, each representing the right to acquire one ordinary share,
at the same purchase price in the registered direct offering. The ordinary warrants are exercisable immediately upon issuance at an exercise
price of $1.50 per share, and will expire on the fifth anniversary of the original issuance date. Aggregate gross proceeds from the registered
direct offering and concurrent private placement were approximately $4.47 million, before deducting the placement agent fee and related
offering expenses. The offerings closed on April 15, 2024. In June 2024, we and a certain institutional investor from the April 2024 concurrent
private placement amended the ordinary warrant to purchase up to 2,980,000 ordinary shares to extend the termination date of the warrant
to October 12, 2029.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On August 6, 2024, we entered
into a securities purchase agreement with certain investors, including members of our senior management and existing investors, pursuant
to which we sold (i) an aggregate of 800,000 of our ordinary shares and (ii) 800,000 ordinary warrants, each representing the right to
acquire one ordinary share, in a private placement at a combined offering price of $0.75 per ordinary share and ordinary warrant. The
ordinary warrants are exercisable immediately upon issuance at an exercise price of $0.75 per share, and will expire on the fifth anniversary
of the original issuance date. Aggregate gross proceeds from private placement were approximately $0.6 million, before deducting offering
expenses. The offering closed in September 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On August 16, 2024, we entered
into the 2024 Sales Agreement with JonesTrading. Pursuant to the 2024 Sales Agreement, we may offer and sell our ordinary shares having
an aggregate offering price of up to $2,524,437, from time to time through JonesTrading. JonesTrading will receive a commission equal
to 3.0% of the gross proceeds from the sale of the ordinary shares and will be reimbursed for certain specified expenses in connection
with entering into the Sales Agreement. As of April 4, 2025, we have sold 1,549,725 of our ordinary shares pursuant to the 2024 Sales
Agreement for aggregate gross proceeds of approximately $1.74 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On October 31, 2024, we entered
into the SEPA with YA. Pursuant to the SEPA, we have the right, but not the obligation, to sell to YA from time to time up to $30.0 million
of our ordinary shares, during the 36 months following the execution of the SEPA, subject to the restrictions and satisfaction of the
conditions in the SEPA. At our option, the ordinary shares would be purchased by YA from time to time at a price equal to 97% of the lowest
of the three daily VWAPs (as hereinafter defined) during a three consecutive trading day period commencing on the date that we, subject
to certain limitations, deliver a notice to YA that we are committing YA to purchase such ordinary shares, or the Advance Shares. We may
also specify a certain minimum acceptable price per share in each Advance. &#8220;VWAP&#8221; means, for any trading day, the daily volume
weighted average price of our ordinary shares for such trading day on the Nasdaq Stock Market during regular trading hours as reported
by Bloomberg L.P. As consideration for YA irrevocable commitment to purchase our ordinary shares up to the Commitment Amount, we agreed
to issue 224,697 ordinary shares to YA and also paid a $25,000 structuring fee to an affiliate of YA. As of the date of this annual report,
we have issued 224,697 ordinary shares to YA as consideration for YA&#8217;s irrevocable commitment to purchase our ordinary shares up
to the Commitment Amount and we have not sold any ordinary shares to YA as Advance Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 2, 2024, we entered
into a securities purchase agreement with an institutional investor and our chief executive officer pursuant to which we sold an aggregate
of (i) 2,343,729 of our ordinary shares (ii) pre-funded warrants to purchase up to an aggregate of 1,656,271 ordinary shares and (iii)
8,000,000 ordinary warrants, each representing the right to acquire one ordinary share, in a private placement at a combined offering
price of $1.25 per ordinary share and ordinary warrant and $1.2499 per pre-funded warrant and ordinary warrant. Each pre-funded warrant
represented the right to purchase one ordinary shares at an exercise price of $0.0001 per share. The pre-funded warrants were exercisable
immediately and at any time until the pre-funded warrants were exercised in full (subject to a beneficial ownership limitation set forth
therein). The ordinary warrants are exercisable immediately upon issuance at an exercise price of $1.25 per share, and will expire on
the fifth anniversary of the original issuance date. Aggregate gross proceeds from the private placement were approximately $5.0 million,
before deducting offering expenses. The offering closed on December 17, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Research and Development, Patents and Licenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For a description of our
research and development programs and the amounts that we have incurred over the last three years pursuant to those programs, please see
&#8220;Item 5. Operating and Financial Review and Prospects &#8212; A. Operating Results &#8212; Research and Development Expenses.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Trend Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other than as disclosed elsewhere
in this annual report, we are not aware of any trends, uncertainties, demands, commitments or events for the period from January 1, 2024
to December 31, 2024 that are reasonably likely to have a material adverse effect on our revenue, income, profitability, liquidity or
capital resources, or that caused that disclosed financial information to be not necessarily indicative of future operating results or
financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.3pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. Critical Accounting Policies and Use of
Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We describe our material
accounting policies and estimates in Note 3 to our annual consolidated financial statements contained elsewhere in this annual report.
We believe that these accounting policies and estimates are critical in order to fully understand and evaluate our financial condition
and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We prepare our consolidated
financial statements in accordance with U.S. GAAP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In preparing these consolidated
financial statements, management has made judgments, estimates and assumptions that affect the application of our accounting policies
and the reported amounts recognized in the financial statements. On a periodic basis, we evaluate our estimates, including those related
to share-based compensation. We base our estimates on historical experience, authoritative pronouncements and various other assumptions
that we believe to be reasonable under the circumstances. Actual results may differ from these estimates. For more information, please
see Note 2 to our annual consolidated financial statements contained elsewhere in this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Emerging Growth Company Status</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We qualify as an &#8220;emerging
growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take
advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions
include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to the extent that we no longer qualify as a foreign private issuer, (i) reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (ii) exemptions from the requirement to hold a non-binding advisory vote on executive compensation, including golden parachute compensation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exemption from compliance with the requirement that the Public Company Accounting Oversight Board has adopted regarding a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may take advantage of
these exemptions for up to five years or until such earlier time that we are no longer&#160;an emerging growth company. We would cease
to be an emerging growth company upon the earliest to occur of: (i)&#160;the last day of the fiscal year in which we have total annual
gross revenues of $1.235 billion or more; (ii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the
previous three years; (iii) the date on which we are deemed to be a large accelerated filer under the rules of the SEC; or (iv) the last
day of the fiscal year following the fifth anniversary of our initial public offering. We may choose to take advantage of some but not
all of these exemptions. Section 107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the
extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards.
This means that an &#8220;emerging growth company&#8221; can delay the adoption of certain accounting standards until those standards
would otherwise apply to private companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Directors and Senior Management</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets
forth information concerning our directors and senior management, including their ages, as of the date of this annual report:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 58%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive&#160;Management</b></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alon Ben-Noon</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, Director</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Or Eisenberg</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Ferenc Tracik</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Medical Officer</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Niva Russek-Blum</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Technology Officer</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hagit Binder</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating Officer</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Executive Directors</b></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Leuchtenberger <sup>*</sup></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chair of the Board of Directors</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cary Claiborne <sup>(1) (2) *</sup></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">External Director </span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christine Pellizzari <sup>(1) (2) *</sup></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">External Director </span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roy Golan <sup>(1) *</sup></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Revital Mandil-Levin <sup>(2)</sup></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director </span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of audit committee</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member of compensation committee</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent director under Nasdaq rules</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt; text-align: justify; text-indent: 10.25pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Executive Officers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Alon Ben-Noon, Chief Executive Officer, Director.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Alon Ben-Noon&#160;is our
founder and has served as our chief executive officer and director since February 2017. Mr.&#160;Ben-Noon&#160;served as Chair of our
board of director since our founding until October&#160;1, 2021. From 2014 until 2017, Mr.&#160;Ben-Noon&#160;served as the founder and
owner of MediCan Consulting, a pharmaceutical consulting firm that advised a number of successful pharmaceutical companies, including
MediWound Ltd., Chiasma Inc., Teva Pharmaceutical Industries Limited, Sol-Gel&#160;Technologies Ltd., FutuRx Ltd., NeuroDerm Ltd. and
others. Mr.&#160;Ben-Noon&#160;holds a B.S. in Industrial Engineering and an MBA from Ben-Gurion&#160;University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Or Eisenberg, Chief Financial Officer.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Or Eisenberg has served as
our chief financial officer since June 2021. Prior to joining the Company, Mr.&#160;Eisenberg served in various finance and executive
leadership roles with Mawson Infrastructure Group Inc. (formerly Wize Pharma Inc.). From March 2015 until November 2017, Mr.&#160;Eisenberg
served as the chief financial officer and acting chief executive officer of Wize Pharma Ltd. From November 2017 until August 2021, Mr.&#160;Eisenberg
served as the chief financial officer, treasurer and secretary of Mawson. Since August 2021, Mr.&#160;Eisenberg has served as a consultant
to Mawson. Mr.&#160;Eisenberg was previously the controller at the Katzir Fund Group and has served as the external chief financial officer
for a number of companies with securities listed on the Tel Aviv Stock Exchange. Mr.&#160;Eisenberg began his career as an accountant
with Ernst &amp; Young. Mr.&#160;Eisenberg holds a B.A. in Economics and Accounting from Haifa University, and is a Certified Public Accountant
registered in the State of Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dr. Ferenc Tracik, Chief Medical Officer.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Dr. Ferenc Tracik has served
as our chief medical officer since December 1, 2021. Dr. Tracik has twenty years of experience in general management, medical affairs,
clinical development and commercialization in the biotech industry. Before joining the Company, he served as the Global Head Medical of
Orphazyme A/S. From May 2017 until November 2020, Dr. Tracik served as VP Medical Europe, Canada and Partner Markets of Biogen Inc. From
November 2013 until April 2017, Dr. Tracik served in various positions at Teva Pharmaceutical Industries Limited, including Managing Director
Specialty Medicines Germany. Dr. Tracik&#8217;s experience and expertise in therapy is extensive, and includes different disease areas
such as CNS, respiratory, oncology, ophthalmology, infectious diseases, and transplantation, with a specific focus on neurodegenerative
and neuro-autoimmune diseases. Before joining the pharmaceutical industry, Dr. Tracik worked at the university clinics of neurology at
Charit&#233; Berlin and the university clinic of Innsbruck as well as the university clinic of psychiatry of Regensburg. Dr. Tracik
holds a doctoral degree in human medicine from University of Regensburg.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dr. Niva Russek-Blum, Chief Technology Officer.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Dr. Niva Russek-Blum has
served as our chief technology officer since May 2023. Dr. Russek-Blum previously served as our Vice President of Discovery since 2021
and from 2018 to 2022 served as one of our scientific consultants. From 2012 until 2022, Dr. Russek-Blum served as a Principal Investigator
in the ADSSC Institute (under the auspices of Ben- Gurion University). Dr. Russek-Blum holds a Ph.D. in Neuroscience and a M.Sc. in Molecular
Biology from The Weizmann Institute of Science as well as a B.Med.Sc from The Hebrew University of Jerusalem.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Hagit Binder, Chief Operating Officer.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Ms. Hagit Binder has served
as our Chief Operating Officer since May 2023, overseeing all operational aspects of the company, including clinical and non-clinical
activities. Prior to this role, she served as Vice President of Operations since 2022. From 2018 to 2022, Ms. Binder held the position
of VP, Project and Marketing at Nextar Chempharma Solutions. Ms. Binder has been appointed as the general manager in Israel commencing
May 1, 2025. She holds an M.Sc.in Biotechnology, a B.Sc. in Molecular Biology, and an MBA from Bar-Ilan University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Non-Executive Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following is a brief
summary of the business experience of the members of our board of directors who are not our executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Mark Leuchtenberger, Chair of the Board of
Directors.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Mr. Leuchtenberger has served
as the chair of our Board of Directors since October 1, 2021. He is currently CEO of next generation vaccine developer Spy Biotech Ltd
and recently served as Executive Chairman for Aleta Biotherapeutics and previously as CEO of Brooklyn ImmunoTherapeutics and Chairman,
President and CEO of IRX Therapeutics. He has over 20 years of experience as a CEO in the biopharmaceutical industry and has led companies
through private financings and initial public offerings, taken products from research to IND and through to commercialization, and achieved
M&amp;A exits. Leuchtenberger was President and Chief Executive Officer and a member of the Board of Directors at Chiasma (NASDAQ: CHMA),
Acusphere, Inc., Rib-X Pharmaceuticals, Inc. (now Melinta Therapeutics, Inc.), Targanta Therapeutics Corporation and Therion Biologics
Corporation. Prior to Therion, he was a senior officer at Biogen Inc., where he led the late-stage development of the company&#8217;s
flagship product Avonex and its commercialization in North America and internationally in 65 countries. He is a past director and chairman
of the Massachusetts Biotechnology Council Board of Directors, was a cofounder of Albor Biologics, Inc. and Alvos Therapeutics, Inc. He
received his MBA from the Yale School of Management and his BA from Wake Forest University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Cary Claiborne, Director.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Mr. Claiborne became a member
of our board of directors immediately prior to the closing of our initial public offering and serves as an external director under the
Companies Law. Mr. Claiborne has served as the Chief Executive Officer since August 2022, Chief Operating Officer from December 2021 to
August 2022 and a director since November 2021 for Adial Pharmaceuticals Inc. a public biopharmaceutical company. In July 2022, Mr. Claiborne
was appointed to the board of directors of LadRx Corporation (fka CytRx Corporation), a biopharmaceutical company focused on discovering
and developing new cancer therapeutics, where he also serves as Chairman of the compensation committee and member of the audit committee.
Prior to joining Adial, Mr. Claiborne served as the CEO of Prosperity Capital Management, LLC, a US based Private Investment and Advisory
firm that he founded. From 2014 until 2017, Mr. Claiborne served as the Chief Financial Officer and board member of Indivior PLC, a public
global commercial stage pharmaceutical company. Mr. Claiborne was also on the Board of Directors of New Generation Biofuels Inc. and MedicAlert
Foundation, where he also served as the chair of the audit and finance committees. From 2011 to 2014, Mr. Claiborne was the Chief Financial
Officer of Sucampo Pharmaceuticals Inc., a public global biopharmaceutical company focused on drug discovery, development, and commercialization.
Mr. Claiborne graduated from Rutgers University with a B.A. in Business Administration. He also holds an M.B.A from Villanova University
and was previously a NACD Governance Fellow.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Christine Pellizzari, Director.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 35.9pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Ms. Pellizzari became a member
of our board of directors immediately prior to the closing of our initial public offering and serves as an external director under the
Companies Law. Ms. Pellizzari has served as the Chief Legal Officer of Science 37 since July 2021. Prior to joining Science&#160;37, Ms.
Pellizzari served as the General Counsel and Corporate Secretary of Insmed, Inc., a public biotech company focused on serious and rare
diseases, from 2013 to 2018 and as Chief Legal Officer from 2018 to 2021. She also currently serves on the board of directors of Tempest
Therapeutics, a public clinical-stage&#160;oncology company, and Celsion Corporation, a public a clinical-stage&#160;development company
focused on DNA mediated immunotherapy and next-generation&#160;nucleic vaccines. Prior to Insmed, Christine held various legal positions
of increasing responsibility at Aegerion Pharmaceuticals, Inc., most recently as Executive Senior Vice President, General Counsel and
Secretary. Prior to Aegerion, she served as Senior Vice President, General Counsel and Secretary of Dendrite International, Inc. Christine
joined Dendrite from the law firm of Wilentz, Goldman &amp; Spitzer, where she specialized in health care transactions and related regulatory
matters. She has nearly three decades of relevant experience, including having served for over 25 years as CLO and General Counsel of
publicly traded companies in biopharmaceutical and related industries. Christine earned her B.A. in Legal Studies from the University
of Massachusetts, Amherst and J.D. from the University of Colorado School of Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Roy Golan, Director.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Mr. Roy Golan&#160; has
served as a member of our board of directors since July 2024. He has acted as an independent financial advisor since July 2024 and currently
serves as a director of My Size, Inc. (NASDAQ: MYSZ), a Nasdaq listed company and omnichannel e-commerce platform and provider of AI-driven
software as service measurement solutions for fashion ecommerce companies. Mr. Golan previously served as the Chief Financial Officer
of Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company,<span>&#160;</span>from
its merger with BioSight Ltd., a private pharmaceutical company developing innovative therapeutics for hematological malignancies and
disorders, in October 2023 until June 2024. From 2019 to 2023, Mr. Golan served as Executive VP and Chief Financial Officer of BioSight
Ltd. From 2018 to 2019, Mr. Golan served as President and Chief Financial Officer of Exalenz Bioscience Ltd. (TASE: EXEN), a Tel Aviv
Stock Exchange listed global, commercial-stage diagnostics company which developed its BreathID&#174; technology platform to improve patient
care by providing breath-based tests in the fields of gastroenterology and hepatology and was later acquired by Meridian Bioscience, Inc.
(NASDAQ: VIVO). From 2015 to 2018, Mr. Golan served as the Chief Financial Officer of NeuroDerm (NASDAQ: NDRM), a Nasdaq listed clinical-stage
pharmaceutical company developing next-generation drug-device combinations for central nervous system disorders, through its initial public
offering until its acquisition by Mitsubishi Tanabe Pharma Group Company, and prior thereto he served as their VP Finance. Mr. Golan holds
an LLM from Bar Ilan University as well as a BA from The College of Management in Rishon LeZion and is also a licensed CPA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Dr. Revital Mandil-Levin, Director. </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Dr. Mandil-Levin became a
member of our board of directors in January 2022. Dr. Mandil-Levin has more than 15 years&#8217; experience in biotech startups and product
development in the pharmaceutical industry. She is currently the CEO and founder of Nanocarry Therapeutics Ltd., a private company developing
a proprietary platform technology for the delivery of biologics across the blood-brain barrier for CNS indications. From September 2019
to November 2020, she served as VP Corporate Development of Anima Biotech, a private company with a novel approach for the discovery of
small molecules involved in mRNA translation, and from April 2018 to February 2019, she served as Chief Business Development Officer of
CollPlant Ltd. (Nasdaq: CLGN), a public regenerative and aesthetic medicine company. From January 2014 to February 2018, Dr. Mandil-Levin
served as Vice President Business Development at NeuroDerm Ltd (Nasdaq: NDRM), a clinical-stage pharmaceutical company developing next-generation
treatments for CNS disorders, where she had a major role in the acquisition of NeuroDerm by Mitsubishi Tanabe Pharma Corporation for $1.1
billion. From 2004 to 2013, Dr. Mandil-Levin served as Vice President Business Development at HealOr Ltd, a clinical-stage biopharmaceutical
company that developed novel drugs for skin regeneration in hard to heal wounds and dermatological diseases. Prior to that she served
as Business Development Manager at Proteologics Ltd. Dr. Mandil-Levin holds a PhD in Biochemistry from Bar-Ilan University, Israel and
an MBA from the Israeli College of Management School of Business.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The aggregate compensation,
including share-based compensation, paid by us to our executive officers and directors for the year ended December 31, 2024 was approximately
$2,723 thousand. This amount includes accruals to provide pension, severance, retirement or similar benefits or expenses, bonuses based
on goals achieved as of December 31, 2024 but does not include business travel, relocation, professional and business association dues
and expenses reimbursed to officers, and other benefits commonly reimbursed or paid by companies in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Below is an outline of compensation
granted or paid to our executive officers during the year ended December 31, 2024. The value of equity compensation is determined based
on accounting rules that involve certain assumptions and key variables, as discussed in Note 10 of our consolidated financial statements.
Additionally, as each of our executives received an inaugural equity award in connection with our IPO, the accounting valuation of equity
compensation for 2024 is not necessarily representative of our compensation practices for the future. Social benefits provided to management
consist of payments to the National Insurance Institute, advanced education funds, managers&#8217; insurance and pension funds, vacation
pay, and recuperation pay as mandated by Israeli law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the year ended December
31, 2024, we paid a base salary or other payments including social benefits of $366 thousand to Mr. Ben-Noon and equity compensation valued
at $22 thousand, for a total of $388 thousand. Mr. Ben-Noon does not receive extra compensation for his service as a member of the board
of directors. In addition, on June 27, 2024, at our annual general meeting of shareholders, following approval by our board of directors
and compensation committee, our shareholders approved an annual bonus plan for Mr. Ben-Noon equal to an amount of twelve months&#8217;
salary, or the Target Bonus, based on a monthly salary of NIS 104,865 (approximately $28,753, based on the NIS/USD exchange rate in effect
on December 31, 2024, with the Target Bonus being calculated based on the NIS monthly salary) payable under Mr. Ben-Noon&#8217;s employment
agreement. In addition, we accrued expenses at the amount of $262 thousand to a bonus accrual, which was waived in December 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the year ended December
31, 2024, we paid a base salary including social benefits of $279 thousand to Mr. Eisenberg and equity compensation valued at $22 thousand,
for a total of $301 thousand. From the commencement of his employment until our IPO, Mr. Eisenberg agreed to the minimum monthly salary
allowed by Israeli law. In addition, we accrued expenses at the amount of $92 thousand to a bonus accrual, which was waived in December
2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the year ended December
31, 2024, we paid a base salary and other costs related to employment with the Company of $412 thousand to Dr. Tracik and an equity compensation
valued at $20 thousand for a total of $432 thousand. In addition, we accrued expenses at the amount of $117 thousand to a bonus accrual,
which was waived in December 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">From January 1, 2024 through
December 31, 2024, we paid a base salary and other costs related to employment with the Company of $188 thousand to Dr. Russek-Blum and
an equity compensation valued at $29 thousand for a total of $217 thousand. In addition, we accrued expenses at the amount of $33 thousand
to a bonus accrual, which was waived in December 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">From January 1, 2024 through
December 31, 2024, we paid a base salary and other costs related to employment with the Company of $218 thousand to Ms. Binder and an
equity compensation valued at $8 thousand for a total of $226 thousand. In addition, we accrued expenses at the amount of $37 thousand
to a bonus accrual, which was waived in December 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024,
(i) 200,000 RSUs and (ii) 681,000 options to purchase 681,000 ordinary shares at a weighted average exercise price of $2.59, granted to
our executive officers and directors were outstanding under our 2018 Share Incentive Plan, or the 2018 Plan. Each option will expire ten
years from the date of the grant thereof.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We pay each of our non-employee
directors an annual retainer of $40,000 plus applicable VAT, with an additional annual payment for service on board committees as follows:
$15,000 plus applicable VAT for the chairperson of any board committee (such additional payment for only one committee chair) and an additional
amount of $10,000 plus VAT for membership on any board committee (such additional payment for up to two committees, provided that if a
director is serving as chair of one committee and member of one or more other committees, such director would receive one payment as committee
chair and one payment as committee member). In addition, each non-employee director was granted options to acquire 72,000 ordinary shares,
one-third of which will vest one year from the grant date and the remainder to vest quarterly and become fully vested three years from
the grant date at an exercise price equal to the closing price per share on Nasdaq on the closing date of our initial public offering
(and in the case of external directors, at the closing price per share on the date of the shareholder meeting at which their appointment
as external directors was ratified), subject to such director&#8217;s continued service through such date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Equity Compensation</i>.
Since January 1, 2018, we have granted options to purchase our ordinary shares to our officers and certain of our directors. Such option
agreements may contain acceleration provisions upon certain merger, acquisition, or change of control transactions. We describe our 2018
Plan under &#8220;Management&#8212;2018 Share Incentive Plan.&#8221; If our relationship with an executive officer or a director is terminated,
except for cause (as defined in the various option plan agreements), all options that are vested will remain exercisable for 90 days after
such termination. If the relationship is terminated due to the death of the executive officer or a director, the participant may exercise
any portion of the options which have vested within 60 days of the death of the executive officer or a director, at any time but no later
than the one year anniversary of the executive officer or a director&#8217;s death or the end of the term, whichever is earlier. If our
relationship with an executive officer or a director is terminated by reason of retirement or disability the participant may exercise
any portion of the options which have vested within 90 days of the executive officer or a director&#8217;s retirement or disability, at
any time but no later than the one year anniversary of the executive officer or a director&#8217;s retirement or disability or the end
of the term, whichever is earlier.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On May 30, 2023, at our annual
general meeting of shareholders, our shareholders approved the grant of 24,000 RSUs to each of Mr. Pellizzari, Mr. Claiborne, Ms. Caren
Deardorf (former member of the board of directors in June 2024) and Ms. Mandil-Levin and the grant of 64,000 RSUs to Mr. Leuchtenberger.
The RSUs vest on the one year anniversary of the approval of our board of directors of the grant, which was May 20, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On June 27, 2024, at our
annual general meeting of shareholders, our shareholders approved the grant of 24,000 RSUs to each of Mr. Pellizzari, Mr. Claiborne, Mr.
Golan and Ms. Mandil-Levin and the grant of 64,000 RSUs to Mr. Leuchtenberger. The RSUs vest on the one year anniversary of the approval
of the date of the annual general meeting of shareholders, which will be June 27, 2025. In addition, our shareholders approved the acceleration
of 18,000 unvested options that were previously granted to Ms. Deardorf in December 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Exculpation</i>, <i>Indemnification
and Insurance</i>. Our amended and restated articles of association permit us to exculpate, indemnify and insure certain of our office
holders to the fullest extent permitted by the Companies Law. We have entered into agreements with our office holders, exculpating them
from a breach of their duty of care to us to the fullest extent permitted by law and undertaking to indemnify them to the fullest extent
permitted by law, subject to certain exceptions, to the extent that these liabilities are not covered by insurance. See &#8220;Management&#8212;Exculpation,
Insurance and Indemnification of Directors and Officers.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Compensation Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our compensation policy is
designed to promote retention and motivation of directors and executive officers, incentivize superior individual excellence, align the
interests of our directors and executive officers with our long-term&#160;performance and provide a risk management tool. To that end,
a portion of an executive officer compensation package is targeted to reflect our short and long-term&#160;goals, as well as the executive
officer&#8217;s individual performance. On the other hand, our compensation policy includes measures designed to reduce executive officers&#8217;
incentives to take excessive risks that may harm us in the long-term, such as limits on the value of cash bonuses and equity-based&#160;compensation,
limitations on the ratio between the variable and the total compensation of an executive officer and minimum vesting periods for equity-based&#160;compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The compensation policy provides
that compensation will be determined based on our executive officers&#8217; respective positions, education, scope of responsibilities
and contributions, and that we will consider the ratio between compensation of our executive officers and directors and other employees.
Pursuant to our compensation policy, the compensation that may be granted to an executive officer may include: base salary, annual bonuses
and other cash bonuses (such as a signing bonus and special bonuses with respect to any special achievements, such as outstanding personal
achievement, outstanding personal effort or outstanding company performance), equity-based&#160;compensation, benefits and retirement
and termination of service arrangements. All cash bonuses are limited to a maximum amount linked to the executive officer&#8217;s base
salary. In addition, the total variable compensation components (cash bonuses and equity-based&#160;compensation) may not exceed 90% of
each executive officer&#8217;s total compensation package with respect to any given calendar year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An annual cash bonus may
be awarded to executive officers upon the attainment of pre-set&#160;periodic objectives and individual targets. The annual cash bonus
that may be granted to our executive officers other than our chief executive officer will be based on performance objectives and a discretionary
evaluation of the executive officer&#8217;s overall performance by the chief executive officer. Performance objectives may be recommended
by our chief executive officer and will be approved by the compensation committee (and, if required by law, by our board of directors).
We may also grant annual cash bonuses to our executive officers on a discretionary basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The performance objectives
and targets of our chief executive officer will be determined by our compensation committee and board of directors. Up to 30% of the chief
executive officer&#8217;s annual cash bonus may be based on a discretionary evaluation of his overall performance by the compensation
committee and the board of directors based on quantitative and qualitative criteria.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The equity-based&#160;compensation
for our executive officers under the compensation policy is designed in a manner consistent with the underlying objectives for determining
the base salary and the annual cash bonus. Primary objectives include enhancing the alignment between the executive officers&#8217; interests
and our long-term&#160;interests and those of our shareholders and strengthening the retention and the motivation of executive officers
in the long term. Equity-based&#160;compensation may be granted in the form of options or other equity-based&#160;awards, such as restricted
shares and restricted share units, in accordance with a share incentive plan. All equity-based&#160;incentive awards granted to executive
officers will be subject to vesting periods in order to promote long-term&#160;retention of the grantee. Equity-based&#160;compensation
will be granted from time to time and be awarded according to the performance, educational background, prior business experience, qualifications,
role and the personal responsibilities of the executive officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, the compensation
policy contains compensation recovery provisions that apply in the event of an accounting restatement enables our chief executive officer
to approve immaterial changes in the terms of employment of an executive officer (provided that the changes of the terms of employment
are in accordance with our compensation policy) and allows us to exculpate, indemnify and insure our executive officers and directors
subject to certain limitations as set forth therein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The compensation policy also
provides for compensation to the members of our board of directors either (i)&#160;in accordance with the amounts provided in the Companies
Regulations (Rules Regarding the Compensation and Expenses of an External Director) of 2000, as amended by the Companies Regulations (Relief
for Public Companies Traded on Stock Exchanges Outside of Israel) of 2000, as such regulations may be amended from time to time, or (ii)&#160;in
accordance with the amounts determined in the compensation policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Employment and Consulting Agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our employees are employed
under the terms prescribed in their respective employment contracts. The employees are entitled to the social benefits prescribed by law
and as otherwise provided in their agreements. These agreements each contain provisions standard for a company in our industry regarding
non-competition, confidentiality of information and assignment of inventions. Under currently applicable labor laws, we may not be able
to enforce covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some
of our former employees. Each of the executive officers with whom we have entered into an employment or service agreement may be terminated
with immediate effect if terminated for cause as defined in their respective agreements. In cases where an executive officer is terminated
for cause they will not be entitled to receive any compensation during the notice period. See &#8220;Risk Factors&#8212;Risks Related
to Our Business and Strategy&#8221; for a further description of the enforceability of non-competition clauses. We also provide certain
of our employees with a company car, which is leased from a leasing company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our executive officers are
also employed on the terms and conditions prescribed in their employment or service agreements or terms. These agreements and terms provide
for notice periods of varying duration for termination of the agreement without cause, by us or by the relevant executive officer, during
which time the executive officer will continue to receive base salary and benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Board Practices </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Companies Law and
our amended and restated articles of association, our business and affairs will be managed under the direction of our board of directors.
Our board of directors may exercise all powers and may take all actions that are not specifically granted to our shareholders or to executive
management. Our chief executive officer (referred to as a &#8220;general manager&#8221; under the Companies Law) is responsible for our
day-to-day management. Our chief executive officer is appointed by, and serves at the discretion of, our board of directors, subject to
the agreed upon employment terms approved by our shareholders. All other executive officers are appointed by the chief executive officer,
subject to applicable corporate approvals, and are subject to the terms of any applicable employment or consulting agreements that we
may enter into with them. Under our amended and restated articles of association, other than external directors, for whom special election
requirements apply under the Companies Law, as detailed below, the number of directors on our board of directors will be no less than
five and no more than nine directors divided into three classes with staggered three-year terms. Each class of directors consists, as
nearly as possible, of one-third of the total number of directors constituting the entire board of directors (other than the external
directors). At each annual general meeting of our shareholders, the election or re-election of directors following the expiration of the
term of office of the directors of that class of directors will be for a term of office that expires on the third annual general meeting
following such election or re-election, such that from the annual general meeting of 2023 and after, each year the term of office of only
one class of directors will expire. Our directors who are not external directors will be divided among the three classes as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Class&#160;I director is Roy Golan, and her term will expire at our annual meeting of shareholders to be held in 2026; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Class&#160;II directors are Alon Ben-Noon and Mark Leuchtenberger, and their term will expire at our annual meeting of shareholders to be held in 2027; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Class&#160;III director is Dr. Revital Mandil-Levin, and her term will expire at our annual general meeting of shareholders to be held in 2025.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Cary Claiborne and Christine
Pellizzari serve as our external directors and each has a term of three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our directors, aside from
our external directors, are appointed by a simple majority vote of holders of our ordinary shares, participating and voting at an annual
general meeting of our shareholders, provided that (i)&#160;in the event of a contested election, the method of calculation of the votes
and the manner in which the resolutions will be presented to our shareholders at the general meeting shall be determined by our board
of directors in its discretion, and (ii)&#160;in the event that our board of directors does not or is unable to make a determination on
such matter, then the directors will be elected by a plurality of the voting power represented at the general meeting in person or by
proxy and voting on the election of directors. Each director, aside from our external directors, will hold office until the annual general
meeting of our shareholders for the year in which such director&#8217;s term expires, unless the tenure of such director expires earlier
pursuant to the Companies Law or unless such director is removed from office as described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under our amended and restated
articles of association, the approval of the holders of at least 66<sup>2/3</sup>% of the total voting power of our shareholders is generally
required to remove any of our directors (other than the external directors) from office and any amendment to this provision shall require
the approval of at least 66<sup>2/3</sup>% of the total voting power of our shareholders. In addition, vacancies on our board of directors
may only be filled by a vote of a simple majority of the directors then in office.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A director so appointed will
hold office until the next annual general meeting of our shareholders for the class of directors in respect of which the vacancy was created,
or in the case of a vacancy due to the number of directors being less than the maximum number of directors stated in our amended and restated
articles of association, until the next annual general meeting of our shareholders for the class of directors to which such director has
been assigned by our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Chair of the Board</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our amended and restated
articles of association provide that the chair of the board is appointed by the members of the board of directors and serves as chair
of the board throughout his or her term as a director, unless resolved otherwise by the board of directors. Under the Companies Law, in
a public company, the chief executive officer (or any relative of the chief executive officer) may not serve as the chair of the board
of directors, and the chair (or any relative of the chair) may not be vested with authorities of the chief executive officer without shareholder
approval consisting of a majority vote of the shares present and voting at a shareholders meeting, provided that either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least a majority of the shares of non-controlling shareholders or shareholders that do not have a personal interest in the approval voted at the meeting are voted in favor (disregarding abstentions); or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in such appointment voting against such appointment does not exceed 2% of the aggregate voting rights in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The shareholders&#8217; approval
can be provided for a period of five&#160;years following an initial public offering, and subsequently, for additional periods of up to
three&#160;years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, a person subordinated,
directly or indirectly, to the chief executive officer may not serve as the chair of the board of directors; the chair of the board may
not be vested with authorities that are granted to those subordinated to the chief executive officer; and the chair of the board may not
serve in any other position in the company or a controlled company, but he or she may serve as a director or chair of a subsidiary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>External Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Companies Law,
companies incorporated under the laws of the State of Israel that are &#8220;public companies,&#8221; including companies with shares
listed on Nasdaq, are generally required to appoint at least two external directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the regulations
promulgated under the Companies Law, companies whose shares are traded on specified U.S. stock exchanges, including Nasdaq, which do not
have a controlling shareholder (as such term is defined in the Companies Law) and which comply with the independent director requirements
and the audit committee and compensation committee composition requirements of U.S. law and the U.S. stock exchange applicable to domestic
issuers, may (but are not required to) elect to opt out of the requirement to maintain external directors and opt out of the composition
requirements under the Companies Law with respect to the audit and compensation committees. We currently do not qualify for such exemption.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The provisions of the Companies
Law set forth special approval requirements for the election of external directors. External directors must be elected by a majority vote
of the shares present and voting at a meeting of shareholders, provided that either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such majority includes at least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in the election of the external director (other than a personal interest not deriving from a relationship with a controlling shareholder) that are voted at the meeting, excluding abstentions, to which we refer as a disinterested majority; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the total number of shares voted by non-controlling shareholders and by shareholders who do not have a personal interest in the election of the external director against the election of the external director does not exceed 2% of the aggregate voting rights in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The term &#8220;controlling
shareholder&#8221; as used in the Companies Law for purposes of all matters related to external directors and for certain other purposes
(such as the requirements related to appointment to the audit committee or compensation committee, as described below), means a shareholder
with the ability to direct the activities of the company, other than by virtue of being an office holder. A shareholder is presumed to
be a controlling shareholder if the shareholder holds 50% or more of the voting rights in a company or has the right to appoint a majority
of the directors of the company or its general manager. With respect to certain matters (various related party transactions), a controlling
shareholder is deemed to include a shareholder that holds 25% or more of the voting rights in a public company if no other shareholder
holds more than 50% of the voting rights in the company, but excludes a shareholder whose power derives solely from his or her position
as a director of the company or from any other position with the company. For the purpose of determining the holding&#160;percentage stated
above, two or more shareholders who have a personal interest in a transaction that is brought for the company&#8217;s approval are deemed
as joint holders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The initial term of an external
director is three&#160;years. Thereafter, an external director may be re-elected, subject to certain circumstances and conditions, by
shareholders to serve in that capacity for up to two additional three-year terms, provided that either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">his or her service for each such additional term is recommended by one or more shareholders holding at least 1% of the company&#8217;s voting rights and is approved at a shareholders meeting by a disinterested majority, where the total number of shares held by non-controlling, disinterested shareholders voting for such re-election exceeds 2% of the aggregate voting rights in the company, subject to additional restrictions set forth in the Companies Law with respect to affiliations of external director nominees;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the external director proposed his or her own nomination, and such nomination was approved in accordance with the requirements described in the paragraph above; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">his or her service for each such additional term is recommended by the board of directors and is approved at a meeting of shareholders by the same majority required for the initial election of an external director (as described above).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The term of office for external
directors for Israeli companies traded on certain foreign stock exchanges, including Nasdaq, may be extended indefinitely in increments
of additional three-year terms, in each case provided that the audit committee and the board of directors of the company confirm that,
in light of the external director&#8217;s expertise and special contribution to the work of the board of directors and its committees,
the re-election for such additional period(s) is beneficial to the company, and provided that the external director is re-elected subject
to the same shareholder vote requirements (as described above regarding the re-election of external directors). Prior to the approval
of the re-election of the external director at a general meeting of shareholders, the company&#8217;s shareholders must be informed of
the term previously served by him or her and of the reasons why the board of directors and audit committee recommended the extension of
his or her term.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">External directors may be
removed from office by a special general meeting of shareholders called by the board of directors, which approves such dismissal by the
same shareholder vote&#160;percentage required for their election or by a court, in each case, only under limited circumstances, including
ceasing to meet the statutory qualifications for appointment or violating their duty of loyalty to the company. An external director may
also be removed by order of an Israeli court if, following a request made by a director or shareholder of the company, the court finds
that such external director has ceased to meet the statutory qualifications for his or her appointment as stipulated in the Companies
Law or has violated his or her duty of loyalty to the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an external directorship
becomes vacant and there are fewer than two external directors on the board of directors at the time, then the board of directors is required
under the Companies Law to call a meeting of the shareholders as soon as practicable to appoint a replacement external director. Each
committee of the board of directors that exercises the powers of the board of directors must include at least one external director, except
that the audit committee and the compensation committee must include all external directors then serving on the board of directors and
an external director must serve as chair thereof. Under the Companies Law, external directors of a company are prohibited from receiving,
directly or indirectly, any compensation from the company other than for their services as external directors pursuant to the Companies
Law and the regulations promulgated thereunder. Compensation of an external director is determined prior to his or her appointment and
may not be changed during his or her term subject to certain exceptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Companies Law provides
that a person is not qualified to be appointed as an external director if (i)&#160;the person is a relative of a controlling shareholder
of the company, or (ii)&#160;if that person or his or her relative, partner, employer, another person to whom he or she was directly or
indirectly subordinate, or any entity under the person&#8217;s control, has or had during the two&#160;years preceding the date of appointment
as an external director: (a)&#160;any affiliation or other disqualifying relationship with the company, with any person or entity controlling
the company or a relative of such person, or with any entity controlled by or under common control with the company; or (b)&#160;in the
case of a company with no controlling shareholder or any shareholder holding 25% or more of its voting rights, had at the date of appointment
as an external director any affiliation or other disqualifying relationship with a person then serving as chair of the board or chief
executive officer, a holder of 5% or more of the issued share capital or voting power in the company or the most senior financial officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The term &#8220;relative&#8221;
is defined in the Companies Law as a spouse, sibling, parent, grandparent or descendant, a spouse&#8217;s sibling, parent or descendant
and the spouse of each of the foregoing persons. Under the Companies Law, the term &#8220;affiliation&#8221; and the similar types of
disqualifying relationships include (subject to certain exceptions):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an employment relationship;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a business or professional relationship even if not maintained on a regular basis (excluding insignificant relationships);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">control; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">service as an office holder, excluding service as a director in a private company prior to the initial public offering of its shares if such director was appointed as a director of the private company in order to serve as an external director following the initial public offering.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The term &#8220;office holder&#8221;
is defined in the Companies Law as a general manager (i.e., chief executive officer), chief business manager, deputy general manager,
vice general manager, any other person assuming the responsibilities of any of these positions regardless of that person&#8217;s title,
a director and any other manager directly subordinate to the general manager.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, no person may
serve as an external director if that person&#8217;s position or professional or other activities create, or may create, a conflict of
interest with that person&#8217;s responsibilities as a director or otherwise interfere with that person&#8217;s ability to serve as an
external director or if the person is an employee of the Israel Securities Authority, or ISA, or an Israeli stock exchange. A person may
also not continue to serve as an external director if he or she received direct or indirect compensation from the company including amounts
paid pursuant to indemnification or exculpation contracts or commitments and insurance coverage for his or her service as an external
director, other than as permitted by the Companies Law and the regulations promulgated thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following the termination
of an external director&#8217;s service on a board of directors, such former external director and his or her spouse and children may
not be provided a direct or indirect benefit by the company, its controlling shareholder or any entity under its controlling shareholder&#8217;s
control. This includes engagement as an office holder of the company or a company controlled by its controlling shareholder or employment
by, or provision of services to, any such company for consideration, either directly or indirectly, including through a corporation controlled
by the former external director. This restriction extends for a period of two&#160;years with regard to the former external director and
his or her spouse or child and for one year with respect to other relatives of the former external director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If at the time at which an
external director is appointed all members of the board of directors who are not controlling shareholders or relatives of controlling
shareholders of the company are of the same gender, the external director to be appointed must be of the other gender. A director of one
company may not be appointed as an external director of another company if a director of the other company is acting as an external director
of the first company at such time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">According to the Companies
Law and regulations promulgated thereunder, a person may be appointed as an external director only if he or she has professional qualifications
or if he or she has accounting and financial expertise (each, as defined below); provided that at least one of the external directors
must be determined by our board of directors to have accounting and financial expertise. However, if at least one of our other directors
(i)&#160;meets the independence requirements under the Exchange Act, (ii)&#160;meets the independence requirements of Nasdaq rules for
membership on the audit committee and (iii)&#160;has accounting and financial expertise as defined under the Companies Law, then neither
of our external directors is required to possess accounting and financial expertise as long as each possesses the requisite professional
qualifications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A director with accounting
and financial expertise is a director who, due to his or her education, experience and skills, possesses an expertise in, and an understanding
of, financial and accounting matters and financial statements, such that he or she is able to understand the financial statements of the
company and initiate a discussion about the presentation of financial data. A director is deemed to have professional qualifications if
he or she has any of the following: (i) an academic degree in economics, business management, accounting, law or public administration,
(ii) an academic degree or has completed another form of higher education in the primary field of business of the company or in a field
which is relevant to his or her position in the company or (iii) at least five years of experience serving in one of the following capacities
or at least five years of cumulative experience serving in two or more of the following capacities: (a) a senior business management position
in a company with a significant volume of business, (b) a senior position in the company&#8217;s primary field of business or (c) a senior
position in public administration or service. The board of directors is charged with determining whether a director possesses financial
and accounting expertise or professional qualifications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors has
established the following standing committees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Companies Law Requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Companies Law,
the board of directors of a public company must appoint an audit committee. The audit committee must be comprised of at least three directors,
including all of the external directors, one of whom must serve as chair of the committee. The audit committee may not include the (i)&#160;chair
of the board; (ii)&#160;a controlling shareholder of the company; (iii)&#160;a relative of a controlling shareholder; (iv)&#160;a director
employed by or providing services on a regular basis to the company, to a controlling shareholder or to an entity controlled by a controlling
shareholder; or (v)&#160;a director who derives most of his or her income from a controlling shareholder. In addition, under the Companies
Law, the audit committee of a publicly traded company must consist of a majority of unaffiliated directors. In general, an &#8220;unaffiliated
director&#8221; under the Companies Law is defined as either an external director or as a director who meets the following criteria:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he or she meets the qualifications for being appointed as an external director, except for the requirement (i)&#160;that the director be an Israeli resident (which does not apply to companies such as ours whose securities have been offered outside of Israel or are listed for trading outside of Israel) and (ii)&#160;for accounting and financial expertise or professional qualifications; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">he or she has not served as a director of the company for a period exceeding nine consecutive&#160;years. For this purpose, a break of less than two&#160;years in his or her service as a director shall not be deemed to interrupt the continuity of the service.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each member of our audit
committee (each, as identified in the second paragraph under &#8220;&#8212;Listing Requirements&#8221; below) is an unaffiliated director
under the Companies Law, thereby fulfilling the foregoing Israeli law requirement for the composition of the audit committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Listing Requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the corporate governance
rules of Nasdaq, we are required to maintain an audit committee consisting of at least three independent directors, each of whom is financially
literate and one of whom has accounting or related financial management expertise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our audit committee consists
of Cary Claiborne, Christine Pellizzari and Roy Golan. Mr. Claiborne serves as the chair of the audit committee. All members of our audit
committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the corporate governance
rules of Nasdaq. Our board of directors has determined that Mr. Claiborne is an audit committee financial expert as defined by the SEC
rules and has the requisite financial experience as defined by the corporate governance rules of Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors has
determined that each member of our audit committee is &#8220;independent&#8221; as such term is defined in Rule&#160;10A-3(b)(1) under
the Exchange Act, which is different from the general test for independence of board and committee members.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Audit Committee Role</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors has
adopted an audit committee charter setting forth the responsibilities of the audit committee, which is consistent with the Companies Law,
the SEC rules and the corporate governance rules of Nasdaq and includes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">retaining and terminating our independent auditors, subject to ratification by the board of directors, and in the case of retention, to ratification by the shareholders;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-approving audit and non-audit services to be provided by the independent auditors and related fees and terms;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing the independence, compensation and performance of the company&#8217;s independent auditors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing with management and our independent auditor our annual and quarterly financial statements prior to publication or filing (or submission, as the case may be) to the SEC;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending to the board of directors the retention and termination of the internal auditor, and the internal auditor&#8217;s engagement fees and terms, in accordance with the Companies Law as well as approving the yearly or periodic work plan proposed by the internal auditor;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying irregularities in our business administration by, among other things, consulting with the internal auditor or with the independent auditor, and suggesting corrective measures to the board of directors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing policies and procedures with respect to transactions between the Company and officers and directors (other than transactions related to the compensation or terms of service of the officers and directors), or affiliates of officers or directors, or transactions that are not in the ordinary course of the Company&#8217;s business and deciding whether to approve such acts and transactions if so required under the Companies Law; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing procedures for the handling of employees&#8217; complaints as to the management of our business and the protection to be provided to such employees.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, under the Companies
Law, the role of the audit committee includes the identification of irregularities in our business management, among other things, by
consulting with the internal auditor or our independent auditors and suggesting an appropriate course of action to the board of directors.
In addition, the audit committee or the board of directors, as set forth in the articles of association of the company, is required to
approve the yearly or periodic work plan proposed by the internal auditor. The audit committee is required to assess the company&#8217;s
internal audit system and the performance of its internal auditor. The Companies Law also requires that the audit committee assess the
scope of the work and compensation of the company&#8217;s external auditor. In addition, the audit committee is required to determine
whether certain related party actions and transactions are &#8220;material&#8221; or &#8220;extraordinary&#8221; for the purpose of the
requisite approval procedures under the Companies Law and whether certain transactions with a controlling shareholder will be subject
to a competitive procedure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The audit committee charter
will state that in fulfilling its role the committee is empowered to conduct or authorize investigations into any matters within its scope
of responsibilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Companies Law Requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Companies Law,
the board of directors of a public company must appoint a compensation committee. The compensation committee generally (subject to certain
exceptions that do not apply to the Company) must be comprised of at least three directors, including all of the external directors, who
must constitute a majority of the members of the compensation committee. The chair of the compensation committee must be an external director.
Each compensation committee member who is not an external director must be a director whose compensation does not exceed an amount that
may be paid to an external director. The compensation committee is subject to the same Companies Law restrictions as the audit committee
as to who may not be a member of the compensation committee. Each member of our compensation committee (each, as identified in the second
paragraph under &#8220;&#8212;Listing Requirements&#8221; below) fulfils the foregoing Israeli law requirements related to the composition
of the compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Listing Requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the corporate governance
rules of Nasdaq, we are required to maintain a compensation committee consisting of at least two independent directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our compensation committee
consists of Christine Pellizzari, Cary Claiborne, and Dr. Revital Mandil Levin. Ms. Pellizzari serves as chair of the committee. Our board
of directors has determined that each member of our compensation committee is independent under the corporate governance rules of Nasdaq,
including the additional independence requirements applicable to the members of a compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation Committee Role</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with the Companies
Law, the roles of the compensation committee are, among others, as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">making recommendations to the board of directors with respect to the approval of the compensation policy for office holders and, once every three&#160;years, regarding any extensions to a compensation policy that was adopted for a period of more than three&#160;years;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing the implementation of the compensation policy and periodically making recommendations to the board of directors with respect to any amendments or updates of the compensation policy;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">resolving whether or not to approve arrangements with respect to the terms of office and employment of office holders; and</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exempting, under certain circumstances, transactions with our chief executive officer from the approval of our shareholders.</span></td></tr>
  </table><div>
</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors adopted
a compensation committee charter setting forth the responsibilities of the committee, which is consistent with the corporate governance
rules of Nasdaq and includes among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending to our board of directors for its approval a compensation policy in accordance with the requirements of the Companies Law as well as other compensation policies, incentive-based compensation plans and equity-based compensation plans, and overseeing the development and implementation of such policies and recommending to our board of directors any amendments or modifications the committee deems appropriate, including as required under the Companies Law;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving the granting of options and other incentive awards to our chief executive officer and other executive officers, including reviewing and approving corporate goals and objectives relevant to the compensation of our chief executive officer and other executive officers, including evaluating their performance in light of such goals and objectives;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving and exempting certain transactions regarding office holders&#8217; compensation pursuant to the Companies Law; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administering our equity-based compensation plans, including without limitation, approving the adoption of such plans, amending and interpreting such plans and the awards and agreements issued pursuant thereto, and making awards to eligible persons under the plans and determining the terms of such awards.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation Policy Under the Companies Law</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In general, under the Companies
Law, a public company must have a compensation policy approved by its board of directors after receiving and considering the recommendations
of the compensation committee. In addition, our compensation policy must be approved at least once every three&#160;years, first, by our
board of directors, upon recommendation of our compensation committee, and second, by a simple majority of the ordinary shares present,
in person or by proxy, and voting at a shareholders meeting, provided that either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such majority includes at least a majority of the shares held by shareholders who are not controlling shareholders and shareholders who do not have a personal interest in such compensation policy; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in the compensation policy and who vote against the policy, does not exceed 2% of the aggregate voting rights in the Company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the event that the shareholders
fail to approve the compensation policy in a duly convened meeting, the board of directors may nevertheless override that decision, provided
that the compensation committee and then the board of directors decide, on the basis of detailed reasons and after further review of the
compensation policy, that approval of the compensation policy is for the benefit of the company despite the failure of the shareholders
to approve the policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If a company that adopts
a compensation policy in advance of its initial public offering describes the policy in its prospectus for such offering, then that compensation
policy shall be deemed validly adopted in accordance with the Companies Law and will remain in effect for term of five years from the
date such company becomes a public company. Our compensation policy became effective immediately prior to the closing of our initial public
offering and will be in force for an initial period of five years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The compensation policy must
be based on certain considerations, include certain provisions and reference certain matters as set forth in the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The compensation policy must
serve as the basis for decisions concerning the financial terms of employment or engagement of office holders, including exculpation,
insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy
must relate to certain factors as set forth in the Companies Law, including advancement of the company&#8217;s objectives, business plan
and long-term strategy, and creation of appropriate incentives for office holders. It must also consider, among other things, the company&#8217;s
risk management, size and the nature of its operations. The compensation policy must furthermore consider the following additional factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the education, skills, experience, expertise and accomplishments of the relevant office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the office holder&#8217;s position, responsibilities and prior compensation agreements with him or her;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ratio between the cost of the terms of employment of an office holder and the cost of the employment of other employees of the company, including employees employed through contractors who provide services to the company, in particular the ratio between such cost, the average and median salary of the employees of the company, as well as the impact of such disparities on the work relationships in the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the terms of employment include variable components&#160;&#8212; the possibility of reducing variable components at the discretion of the board of directors and the possibility of setting a limit on the value of non-cash variable equity-based components; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the terms of employment include severance compensation&#160;&#8212; the term of employment or office of the office holder, the terms of his or her compensation during such period, the company&#8217;s performance during the such period, his or her individual contribution to the achievement of the company goals and the maximization of its profits and the circumstances under which he or she is leaving the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The compensation policy must
also include, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with regard to variable components of compensation:</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with the exception of office holders who report directly to the chief executive officer, provisions determining the variable components on the basis of long-term performance and on measurable criteria; however, the company may determine that an immaterial part of the variable components of the compensation package of an office holder shall be awarded based on non-measurable criteria, if such amount is not higher than three monthly salaries per annum, while taking into account such office holder&#8217;s contribution to the company; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ratio between variable and fixed components, as well as the limit on the values of variable components at the time of their grant.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a condition under which the office holder will return to the company, according to conditions to be set forth in the compensation policy, any amounts paid as part of his or her terms of employment, if such amounts were paid based on information later to be discovered to be wrong, and such information was restated in the company&#8217;s financial statements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">minimum holding or vesting period of variable equity-based components to be set in the terms of office or employment, as applicable, while taking into consideration long-term incentives; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a limit on retirement grants.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our compensation policy is
designed to promote retention and motivation of directors and executive officers, incentivize superior individual excellence, align the
interests of our directors and executive officers with our long-term performance and provide a risk management tool. To that end, a portion
of an executive officer compensation package is targeted to reflect our short and long-term goals, as well as the executive officer&#8217;s
individual performance. On the other hand, our compensation policy includes measures designed to reduce executive officers&#8217; incentives
to take excessive risks that may harm us in the long-term, such as limits on the value of cash bonuses and equity-based compensation,
limitations on the ratio between the variable and the total compensation of an executive officer and minimum vesting periods for equity-based
compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The compensation policy provides
that compensation will be determined based on our executive officers&#8217; respective positions, education, scope of responsibilities
and contributions, and that we will consider the ratio between compensation of our executive officers and directors and other employees.
Pursuant to our compensation policy, the compensation that may be granted to an executive officer may include: base salary, annual bonuses
and other cash bonuses (such as a signing bonus and special bonuses with respect to any special achievements, such as outstanding personal
achievement, outstanding personal effort or outstanding company performance), equity-based compensation, benefits and retirement and termination
of service arrangements. All cash bonuses are limited to a maximum amount linked to the executive officer&#8217;s base salary. In addition,
the total variable compensation components (cash bonuses and equity-based compensation) may not exceed 90% of each executive officer&#8217;s
total compensation package with respect to any given calendar year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An annual cash bonus may
be awarded to executive officers upon the attainment of pre-set periodic objectives and individual targets. The annual cash bonus that
may be granted to our executive officers other than our chief executive officer will be based on performance objectives and a discretionary
evaluation of the executive officer&#8217;s overall performance by the chief executive officer. Performance objectives may be recommended
by our chief executive officer and will be approved by the compensation committee (and, if required by law, by our board of directors).
We may also grant annual cash bonuses to our executive officers on a discretionary basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The performance objectives
and targets of our chief executive officer will be determined by our compensation committee and board of directors. Up to 30% of the chief
executive officer&#8217;s annual cash bonus may be based on a discretionary evaluation of his overall performance by the compensation
committee and the board of directors based on quantitative and qualitative criteria.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The equity-based compensation
for our executive officers under the compensation policy is designed in a manner consistent with the underlying objectives for determining
the base salary and the annual cash bonus. Primary objectives include enhancing the alignment between the executive officers&#8217; interests
and our long-term interests and those of our shareholders and strengthening the retention and the motivation of executive officers in
the long term. Equity-based compensation may be granted in the form of options or other equity-based awards, such as restricted shares
and restricted share units, in accordance with a share incentive plan. All equity-based incentive awards granted to executive officers
will be subject to vesting periods in order to promote long-term retention of the grantee. Equity-based compensation will be granted from
time to time and be awarded according to the performance, educational background, prior business experience, qualifications, role and
the personal responsibilities of the executive officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, the compensation
policy contains compensation recovery provisions that apply in the event of an accounting restatement enables our chief executive officer
to approve immaterial changes in the terms of employment of an executive officer (provided that the changes of the terms of employment
are in accordance with our compensation policy) and allows us to exculpate, indemnify and insure our executive officers and directors
subject to certain limitations as set forth therein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The compensation policy also
provides for compensation to the members of our board of directors either (i)&#160;in accordance with the amounts provided in the Companies
Regulations (Rules Regarding the Compensation and Expenses of an External Director) of 2000, as amended by the Companies Regulations (Relief
for Public Companies Traded on Stock Exchanges Outside of Israel) of 2000, as such regulations may be amended from time to time, or (ii)&#160;in
accordance with the amounts determined in the compensation policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our compensation policy,
which was approved by our board of directors on October 31, 2021 and by our shareholders on November 7, 2021, became effective immediately
prior to the closing of our initial public offering and is filed as an exhibit to this annual report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Internal Auditor</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Companies Law,
the board of directors of a public company must appoint an internal auditor based on the recommendation of the audit committee. The role
of the internal auditor is, among other things, to examine whether a company&#8217;s actions comply with applicable law and orderly business
procedure. Under the Companies Law, the internal auditor cannot be an interested party or an office holder or a relative of an interested
party or an office holder, nor may the internal auditor be the company&#8217;s independent auditor or its representative. An &#8220;interested
party&#8221; is defined in the Companies Law as: (i) a holder of 5% or more of the issued share capital or voting power in a company,
(ii) any person or entity who has the right to designate one or more directors or to designate the chief executive officer of the company,
or (iii) any person who serves as a director or as a chief executive officer of the company. On March 31, 2022, we appointed Israel Gewirts
from Fahn Kanne &amp; Co. Grant Thornton Israel, as our internal auditor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Approval of Related Party Transactions under
Israeli Law</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fiduciary Duties of Directors and Officers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Companies Law codifies
the fiduciary duties that office holders owe to a company. An office holder is defined in the Companies Law as a general manager, chief
business manager, deputy general manager, vice&#160;general manager, any other person assuming the responsibilities of any of these positions
regardless of such person&#8217;s title, a director and any other manager directly subordinate to the general manager.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An office holder&#8217;s
fiduciary duties consist of a duty of care and a duty of loyalty. The duty of care requires an office holder to act with the level of
care with which a reasonable office holder in the same position would have acted under the same circumstances. The duty of loyalty requires
that an office holder act in good faith and in the best interests of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The duty of care includes
a duty to use reasonable means to obtain:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">information on the appropriateness of a given action submitted for his or her approval or performed by virtue of his or her position; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all other important information pertaining to these actions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The duty of loyalty includes
a duty to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any conflict of interest between the performance of his or her duties in the company and his or her personal affairs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from any activity that is competitive with the business of the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain from exploiting any business opportunity of the company in order to receive a personal gain for himself or herself or others; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose to the company any information or documents relating to the company&#8217;s affairs which the office holder received as a result of his or her position as an office holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Companies Law,
a company may approve an act specified above which would otherwise constitute a breach of the office holder&#8217;s duty of loyalty, provided
that the office holder acted in good faith, neither the act nor its approval harms the company and the office holder discloses his, her
or its personal interest a sufficient time before the approval of such act. Any such approval is subject to the terms of the Companies
Law setting forth, among other things, the appropriate organs of the company required to provide such approval and the methods of obtaining
such approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Disclosure of Personal Interests of an Office
Holder and Approval of Certain Transactions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Companies Law requires
that an office holder promptly disclose to the board of directors any personal interest that he or she may have, and all related material
information known to him or her concerning any existing or proposed transaction with the company. A personal interest includes an interest
of any person in an act or transaction of a company, including a personal interest of one&#8217;s relative or of a corporate body in which
such person or a relative of such person is a 5% or greater shareholder, director or general manager or in which he or she has the right
to appoint at least one director or the general manager, but excluding a personal interest stemming solely from one&#8217;s ownership
of shares in the company. A personal interest includes the personal interest of a person for whom the office holder holds a voting proxy
or the personal interest of the office holder with respect to the officer holder&#8217;s vote on behalf of a person for whom he or she
holds a proxy even if such shareholder has no personal interest in the matter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If it is determined that
an office holder has a personal interest in a non-extraordinary transaction, approval by the board of directors is required for the transaction,
unless the company&#8217;s articles of association provide for a different method of approval. Any transaction that is adverse to the
company&#8217;s interests may not be approved by the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Approval first by the company&#8217;s
audit committee and subsequently by the board of directors is required for an extraordinary transaction, meaning any transaction that
is not in the ordinary course of business, not on market terms or that is likely to have a material impact on the company&#8217;s profitability,
assets or liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A director and any other
office holder who has a personal interest in a transaction which is considered at a meeting of the board of directors or the audit committee
may generally (unless it is with respect to a transaction which is not an extraordinary transaction) not be present at such a meeting
or vote on that matter unless a majority of the directors or members of the audit committee, as applicable, have a personal interest in
the matter. If a majority of the members of the audit committee or the board of directors has a personal interest in the approval of such
a transaction then all of the directors may participate in deliberations of the audit committee or board of directors, as applicable,
with respect to such transaction and vote on the approval thereof and, in such case, shareholder approval is also required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the Companies
Law, compensation arrangements including insurance, indemnification or exculpation arrangements with office holders generally require
compensation committee approval and subsequent approval by the board of directors. Compensation arrangements need to comply with the compensation
policy of the company. In special circumstances, the compensation committee and the board of directors may approve compensation arrangements
that do not comply with the compensation policy of the company, subject to the approval of a majority vote of the shares present and voting
at a shareholders meeting, provided that either: (a) such majority includes at least a majority of the shares held by all shareholders
who are not controlling shareholders and do not have a personal interest in such compensation arrangement; or (b) the total number of
shares of non-controlling shareholders and shareholders who do not have a personal interest in the compensation arrangement and who vote
against the arrangement does not exceed two percent of the company&#8217;s aggregate voting rights, or the Special Majority Vote for Compensation.
In the event that the Special Majority Vote for Compensation is not obtained, the compensation committee and the board of directors may,
subject to certain requirements stipulated in the Companies Law, reconsider the compensation arrangement and approve it, after a detailed
review.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain disclosure and approval
requirements apply under Israeli law to certain transactions with controlling shareholders, certain transactions in which a controlling
shareholder has a personal interest and certain arrangements regarding the terms of service or employment of a controlling shareholder.
For these purposes, a controlling shareholder is any shareholder that has the ability to direct the company&#8217;s actions, including
any shareholder holding 25% or more of the voting rights if no other shareholder owns more than 50% of the voting rights in the company.
Two or more shareholders with a personal interest in the approval of the same transaction are deemed to be one shareholder for these purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For a description of the
approvals required under Israeli law for compensation arrangements of officers and directors, see &#8220;&#8212;Compensation of Directors
and Executive Officers.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation of Directors and Executive
Officers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Directors. </i>Under the
Companies Law, the compensation of our directors requires the approval of our compensation committee, the subsequent approval of the board
of directors and, unless exempted under regulations promulgated under the Companies Law, the approval of the shareholders at a general
meeting. If the compensation of our directors is inconsistent with our compensation policy, then, the compensation committee and board
of directors may approve such compensation under special circumstances, as long as they consider those provisions that must be included
in the compensation policy according to the Companies Law, and provided that shareholder approval is obtained, which approval should satisfy
one of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in such matter, present and voting at such meeting, are voted in favor of the compensation package, excluding abstentions; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in such matter voting against the compensation package does not exceed 2% of the aggregate voting rights in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Executive Officers (other
than the Chief Executive Officer)</i>. The Companies Law requires the approval of the compensation of a public company&#8217;s executive
officers (other than the chief executive officer) in the following order: (i) the compensation committee, (ii) the company&#8217;s board
of directors and (iii) if such compensation arrangement is inconsistent with the company&#8217;s compensation policy, the company&#8217;s
shareholders (by a special majority vote as discussed above with respect to the approval of director compensation). However, if the shareholders
of the company do not approve a compensation arrangement with an executive officer that is inconsistent with the company&#8217;s compensation
policy, the compensation committee and board of directors may override the shareholders&#8217; decision if each of the compensation committee
and the board of directors provide detailed reasons for their decision.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Chief Executive Officer</i>.
The Companies Law requires the approval of the compensation of a public company&#8217;s chief executive officer in the following order:
(i) the company&#8217;s compensation committee, (ii) the company&#8217;s board of directors and (iii) the company&#8217;s shareholders
(by a special majority vote as discussed above with respect to the approval of director compensation). However, if the shareholders of
the company do not approve the compensation arrangement with the chief executive officer, the compensation committee and board of directors
may override the shareholders&#8217; decision if each of the compensation committee and the board of directors provide a detailed report
for their decision. The approval of each of the compensation committee and the board of directors should be in accordance with the company&#8217;s
compensation policy; however, in special circumstances, they may approve compensation terms of a chief executive officer that are inconsistent
with such policy provided that they have considered those provisions that must be included in the compensation policy according to the
Companies Law and that shareholder approval was obtained (by a special majority vote as discussed above with respect to the approval of
director compensation). In addition, the compensation committee may waive the shareholder approval requirement with regards to the approval
of the engagement terms of a candidate for the chief executive officer position, if they determine that the compensation arrangement is
consistent with the company&#8217;s compensation policy, and that the chief executive officer did not have a prior business relationship
with the company or a controlling shareholder of the company and that subjecting the approval of the engagement to a shareholder vote
would impede the company&#8217;s ability to employ the chief executive officer candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Shareholder Duties</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the Companies
Law, a shareholder has a duty to act in good faith and in a customary manner toward the company and other shareholders and to refrain
from abusing his or her power with respect to the company, including, among other things, in voting at a general meeting and at shareholder
class meetings with respect to the following matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an amendment to the company&#8217;s amended and restated articles of association;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an increase of the company&#8217;s authorized share capital;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a merger; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.1pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interested party transactions that require shareholder approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, a shareholder
has a general duty to refrain from discriminating against other shareholders. Certain shareholders also have a duty of fairness toward
the company. These shareholders include any controlling shareholder as such term is used under the Companies Law, any shareholder who
knows that it has the power to determine the outcome of a shareholder vote and any shareholder who has the power to appoint or to prevent
the appointment of an office holder of the company or exercise any other rights available to it under the company&#8217;s articles of
association with respect to the company. The Companies Law does not define the substance of this duty of fairness, except to state that
the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty of fairness.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exculpation, Insurance and Indemnification
of Directors and Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Companies Law,
a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office
holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty
of care but only if a provision authorizing such exculpation is included in its articles of association. Our amended and restated articles
of association include such a provision. A company may not exculpate in advance a director from liability arising from a breach of his
or her duty of care in connection with a prohibited dividend or distribution to shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As permitted under the Companies
Law, our amended and restated articles of association provide that we may indemnify an office holder in respect of the following liabilities,
payments and expenses incurred for acts performed by him or her as an office holder, either in advance of an event or following an event:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a monetary liability incurred by or imposed on the office holder in favor of another person pursuant to a court judgment, including pursuant to a settlement confirmed as judgment or arbitrator&#8217;s decision approved by a competent court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including reasonable attorneys&#8217; fees, which were incurred by the office holder as a result of an investigation or proceeding filed against the office holder by an authority authorized to conduct such investigation or proceeding, provided that such investigation or proceeding was either (i) concluded without the filing of an indictment against such office holder and without the imposition on him of any monetary obligation in lieu of a criminal proceeding, (ii) concluded without the filing of an indictment against the office holder but with the imposition of a monetary obligation on the office holder in lieu of criminal proceedings for an offense that does not require proof of criminal intent or (iii) in connection with a monetary sanction;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder or which were imposed on the office holder by a court (i) in a proceeding instituted against him or her by the company, on its behalf, or by a third party, (ii) in connection with criminal indictment of which the office holder was acquitted or (iii) in a criminal indictment for which the office holder was convicted of an offense that does not require proof of criminal intent;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses he or she incurs as a result of administrative proceedings that may be instituted against him or her under Israeli securities laws, if applicable, and payments made to injured persons under specific circumstances thereunder; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other matter in respect of which it is permitted or will be permitted under applicable law to indemnify an office holder in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As permitted under the Companies
Law, our amended and restated articles of association provide that we may insure an office holder against the following liabilities incurred
for acts performed by him or her as an office holder:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of duty of care to the company or to another person, to the extent such a breach arises out of the negligent conduct of the office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a monetary liability imposed on the office holder in favor of a third party;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses he or she incurs as a result of administrative proceedings that may be instituted against him or her under the Israeli securities laws if applicable, and payments made to injured persons under specific circumstances thereunder; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other matter in respect of which it is permitted or will be permitted under applicable law to insure the liability of an office holder in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Companies Law,
a company may not indemnify, exculpate or insure an office holder against any of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an act or omission committed with intent to derive illegal personal benefit; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a fine or forfeit levied against the office holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Companies Law,
exculpation, indemnification and insurance of office holders must be approved by the compensation committee and the board of directors
and, with respect to directors or controlling shareholders, their relatives and third parties in which controlling shareholders have a
personal interest, also by the shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our amended and restated
articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted
by law. Our office holders are currently covered by a directors&#8217; and officers&#8217; liability insurance policy. As of the date
of this annual report, no claims for directors&#8217; and officers&#8217; liability insurance have been filed under this policy and we
are not aware of any pending or threatened litigation or proceeding involving any of our office holders, including our directors, in which
indemnification is sought.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have entered into agreements
with each of our current office holders exculpating them from a breach of their duty of care to us to the fullest extent permitted by
law, subject to limited exceptions, and undertaking to indemnify them to the fullest extent permitted by law, to the extent that these
liabilities are not covered by insurance. This indemnification is limited, with respect to any monetary liability imposed in favor of
a third party, to events determined as foreseeable by the board of directors based on our activities. The maximum aggregate amount of
indemnification that we may pay to our office holders based on such indemnification agreement is the greater of (i) an amount equal to
25% of our shareholders&#8217; equity on a consolidated basis, based on our most recent financial statements made publicly available before
the date on which the indemnity payment is made, and (ii) $25 million. Such indemnification amounts are in addition to any insurance amounts.
These indemnification agreements supersede all previous letters of indemnification that we have provided to him or her in the past, if
any. However, in the opinion of the SEC, indemnification of office holders for liabilities arising under the Securities Act is against
public policy and therefore unenforceable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2024,
we had fifteen full and part time&#160;employees and several part-time&#160;consultants, most of whom work at our headquarters in Herzliya,
Israel and the rest of whom work in Zurich, Switzerland and Cambridge, Massachusetts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our human capital resources
objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors
and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through the granting
of equity-based&#160;compensation awards in order to increase shareholder value and the success of our company by motivating such individuals
to perform to the best of their abilities and achieve our objectives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have no collective bargaining
agreements with our employees. We consider our relationship with our employees to be positive and have not experienced any major labor
disputes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. Share Ownership</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For information regarding
the share ownership of our directors and executive officers, please see &#8220;Item 7.A. Major Shareholders.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2018 Share Incentive Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The 2018 Plan was
adopted by our board of directors as the 2018 Employee Share Option Plan on December 16, 2018 and was subsequently amended and
renamed the 2018 Share Incentive Plan. The 2018 Plan provides for the grant of options to our employees, offices, directors,
advisors and consultants in order to promote a close identity of interests between those individuals and the Company and/or an
affiliate of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Shares Available for Grant</i>.
As of December 31, 2024, there were 760,705 ordinary shares available for issuance under the 2018 Plan. The number of shares reserved
for issuance is subject to an annual increase to be added as of the first day of the Company&#8217;s fiscal year, equal to 4% of the total
number of shares issued and outstanding on a fully-diluted basis as of the end of the immediately preceding fiscal year (or such lesser
number of shares, including no shares, determined by the Board in its sole discretion). Ordinary shares subject to options granted under
the 2018 Plan that expire or forfeited or otherwise terminated without having been exercised in full will become available again for future
grant under the 2018 Plan. On October 31, 2021, our Board approved an amendment to the 2018 Plan to increase the number of shares reserved
under this plan to 1,151,130. On March 31, 2025, our Board approved an amendment to the 2018 Plan to increase the number of shares reserved
under this plan to 4,117,863.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Administration</i>. Our
board of directors, or a duly authorized committee of our board of directors, administers the 2018 Plan. Under the 2018 Plan, the administrator
has the authority, subject to applicable law, to interpret the terms of the 2018 Plan, determine eligible participants, the number of
awards for each participant and the exercise price, time or times at which awards will be granted, whether, to what extent, and under
what circumstances an award may be settled, cancelled, forfeited, exchanged, or surrendered, any terms and conditions in addition to those
specified in the 2018 Plan under which an award may be granted, accelerate the date of exercise of granted awards, waive or amend 2018
Plan provisions relating to exercise of awards, including exercise of Awards after termination of employment, for any reason and the terms
and conditions under which a participant may elect to receive ordinary shares upon the exercise of the award or in exchange for the underlying
shares and take any actions, as deemed necessary or advisable for the administration and implementation of the Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Eligibility</i>. The 2018
Plan provides for granting options, shares, restricted shares and RSUs in compliance with Section 102 of the Israeli Income Tax Ordinance
(New Version), 5721-1961, or the Ordinance, or, for awards granted to consultants, advisors, service providers or controlling shareholders
of the company, under Section 3(i) of the Ordinance. Section 102 of the Ordinance allows employees, directors and officers who are not
controlling shareholders and are considered Israeli residents to receive favorable tax treatment for compensation in the form of awards.
Our non-employee service providers and controlling shareholders may only be granted awards under section 3(i) of the Ordinance, which
does not provide for similar tax benefits. Section 102 includes two alternatives for tax treatment involving the issuance of awards to
a trustee for the benefit of the grantees and also includes an additional alternative for the issuance of awards directly to the grantee.
Section 102(b)(2) of the Ordinance, the most favorable tax treatment for the grantee, permits the issuance to a trustee under the &#8220;capital
gain track.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Grant</i>. All awards
granted pursuant to the 2018 Plan will be evidenced by a grant letter. The grant letter will set forth the terms and conditions of the
option grant, including the tax provision under which the award is granted, the tax track that the Company has elected according to the
2018 Plan (if applicable), the exercise price, the number of awards granted to the participant, the date of grant and the vesting schedule.
Each option will expire ten years from the date of the grant thereof, unless such shorter term of expiration is otherwise designated by
the administrator.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Exercise</i>. An option
under the 2018 Plan may be exercised by providing the company with an exercise notice in a form prescribed by the administrator, including
the identity of the participant, the number of options to be exercised and the exercise price to be paid and full payment of the exercise
price for such shares underlying the option, in such manner as determined by the administrator. An option may not be exercised for fractional
shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Transferability</i>. Awards
may not be sold, assigned, transferred, pledged, hypothecated or otherwise disposed of, except by will or the laws of descent</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Termination of Employment</i>.
In the event of termination of a participant&#8217;s employment or service with the company or any of its affiliates and except as described
below:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(i) all vested and exercisable
options held by such as of the date of termination may be exercised within ninety days after such date of termination, unless otherwise
provided by the administrator. All other options held by such participant will expire upon the date of termination of employment;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(ii) all RSUs not vested
on the date of termination shall terminate immediately and have no legal effect, unless determined otherwise by the administrator; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iii) all ordinary shares
remaining subject to a vesting schedule or performance conditions on the date of termination shall terminate immediately and have no legal
effect, unless determined otherwise by the administrator.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the event of termination
of a participant&#8217;s employment or service with the company or any of its affiliates for cause, all unexercised options held by such
participant, whether vested or not on the date of termination will expire on the date of such termination and any unvested options Shares
shall terminate and expire on the day the Participant has been notified of his/her dismissal, or on such earlier date as the Administrator
may determine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the event of termination
of a participant&#8217;s employment or service with the company or any of its affiliates due to such participant&#8217;s death, all options
held by such participant as of the date of termination to the extent they are vested with sixty days of the participant&#8217;s death,
may be exercised by the participant&#8217;s estate, personal representative or beneficiaries at any time but not later than the earlier
of: (i) the one-year anniversary of the participant&#8217;s death or (ii) the end of the term of the options.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the event of termination
of an participant&#8217;s employment or service with the company or any of its affiliates by reason of retirement or disability of the
participant, the participant may exercise any portion of the options which have vested within the ninety days period following the date
of retirement or disability, at any time but not later than the earlier of: (i) the one-year anniversary of the participant&#8217;s retirement
or disability, as the case may be; or (ii) the end of the term of the options. All other options for the benefit of a participant and
which have not vested within such 90 days period shall expire upon the date of retirement or disability, as applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Transactions</i>. In the
event of a stock split, reverse stock split, combination, reclassification, the payment of a stock dividend, or any other increase or
decrease in the number of issued shares effected without receipt of consideration by the company (but not including the conversion of
any convertible securities of the company), the administrator in its sole discretion shall make an appropriate adjustment in the number
of shares related to each outstanding award, the number of shares reserved for issuance under the 2018 Plan, and the exercise price per
share of each outstanding award. Except as expressly provided therein, no issuance by the company of shares of any class, or securities
convertible into shares of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price
of shares subject to an award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the event a sale of all
or substantially all of the assets of the Company and its subsidiaries taken as a whole, or the sale or disposition (whether by merger
or otherwise) of one or more subsidiaries of the Company if substantially all of the assets of the Company and its subsidiaries taken
as a whole are held by such subsidiary or subsidiaries; or a sale of all or substantially all of the shares of the share capital of the
Company whether by a single transaction or a series of related transactions which occur either over a period of 12 months or within the
scope of the same acquisition agreement; or a merger, consolidation or like transaction of the Company with or into another corporation
in which the Company is not the surviving entity, including a reverse triangular merger but excluding a re-organization as defined under
the 2018 Plan (any of the foregoing, a &#8220;Transaction&#8221;), any and all outstanding and unexercised unvested awards will be cancelled
for no consideration, unless determined otherwise by the Administrator, and the Administrator at its sole and absolute discretion may
decide: (i) if and how the unvested awards, as the case may be, shall be canceled, exchanged, assumed, replaced, repurchased or accelerated,
(ii) if and how vested awards (including awards with respect to which the vesting period has been accelerated) shall be exercised, exchanged,
assumed, replaced and/or sold by the Trustee or the Company (as the case may be) on behalf of the participants, including determining
that all unexercised vested awards shall be cancelled for no consideration upon a Transaction; (iii) how underlying shares issued upon
exercise of the options (or, if applicable, the vesting of other Awards) granted under of the trust tracks and held by the trustee under
Section 102 of the Ordinance on behalf of participants shall be replaced and/or sold by the trustee on behalf of these participant; and
(iv) how any treatment of awards and underlying shares may be made subject to any payment or escrow arrangement, or any other arrangement
determined within the scope of the Transaction in relation to awards and underlying shares of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the case of assumption
and/or substitution of awards, appropriate adjustments shall be made so as to reflect such action and all other terms and conditions of
the grant letter shall remain unchanged, including but not limited to the vesting schedule, all subject to the determination of the Board,
which its determination shall be at its sole discretion and final. The grant of any substitutes for the awards to participants further
to a Transaction will be considered to be in full compliance with the terms of this Plan. The value of the exchanged awards pursuant to
this provision will be determined in good faith solely by the Board, based on the fair market value as defined in the 2018 Plan, and its
decision shall be final and binding on all the participants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Without derogating from the
above, in the event of a Transaction the Board may, at its sole discretion, require the participants to exercise all vested awards within
a set time period and sell all of their shares on the same terms and conditions as applicable to the other shareholders selling their
Company shares as part of the Transaction. Each participant acknowledges and agrees that the Board shall be entitled, subject to any applicable
law, to authorize any one of its members to sign any agreement and any share transfer deeds in customary form with respect to the shares
held by such participant and that such agreement and share transfer deed, as applicable, shall bind the participant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>F. Disclosure of a registrant&#8217;s action
to recover erroneously awarded compensation.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There was no erroneously awarded compensation
that was required to be recovered pursuant to the NeuroSense Therapeutics Ltd. Compensation Clawback Policy during the fiscal year ended
December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY
TRANSACTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Major Shareholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table presents
information relating to the beneficial ownership of our ordinary shares as of April 7, 2025, for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding ordinary shares;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our executive officers and directors; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all of our executive officers and directors as a group.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The beneficial ownership
of our ordinary shares is determined in accordance with the rules of the SEC. Under these rules, a person is deemed to be a beneficial
owner of a security if that person has or shares voting power, which includes the power to vote or to direct the voting of the security,
or investment power, which includes the power to dispose of or to direct the disposition of the security. For purposes of the table below,
we deem ordinary shares issuable pursuant to options that are currently exercisable or exercisable within 60 days of the date of this
annual report to be outstanding and to be beneficially owned by the person holding the options or warrants for the purposes of computing
the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership
of any other person. The percentage of ordinary shares beneficially owned is based on 23,988,669 ordinary shares outstanding as of April
7, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except where otherwise indicated,
we believe, based on information furnished to us by such owners, that the beneficial owners of the ordinary shares listed below have sole
investment and voting power with respect to such shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">None of our shareholders
has different voting rights from other shareholders. We are not aware of any arrangement that may, at a subsequent date, result in a change
of control of our company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except where otherwise indicated,
each shareholder&#8217;s address is c/o NeuroSense Therapeutics Ltd., 11 HaMenofim Street, Building B, Herzliya 4672562 Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Shareholder</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">5% Shareholders</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alon Ben-Noon<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,281,932</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13.62</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rimon Gold Assets Ltd. <sup>(2)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,407,229</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.99</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Executive Officers and Directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alon Ben-Noon<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,281,932</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13.62</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Or Eisenberg<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">568,590</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.36</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Ferenc Tracik<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">364,285</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.51</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Niva Russek-Blum<sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">111,428</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hagit Binder<sup>(6)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Leuchtenberger<sup>(7)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">232,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cary Claiborne<sup>(8)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roy Golan<sup>(9)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christine Pellizzari<sup>(10)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revital Mandil-Levin<sup>(11)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,526</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">All executive officers and directors, as&#160;a group (10 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,915,761</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.81</td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates beneficial ownership of less than 1% of the total outstanding ordinary shares.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 3,175,266
    ordinary shares and warrants to purchase 106,666 ordinary shares that are exercisable within 60 days of April 7, 2025. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="padding-bottom: 0pt; text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based in part
                                                         upon information contained in a Schedule 13G filed by the shareholder on December 9, 2024. </span>Consists of (i) 2,303,729 ordinary
                                                         shares, and (ii) 103,500 ordinary shares issuable upon exercise of pre-funded warrants. Does not include (i) 1,552,771 ordinary
                                                         shares issuable upon exercise of pre-funded warrants, and (iii) 7,920,000 ordinary shares issuable upon exercise of warrants. The
                                                         pre-funded warrants and warrants are subject to a beneficial ownership limitation of 9.99%, which such limitation restricts holder
                                                         from exercising that portion of the pre-funded warrants and warrants that would result in the holder and its affiliates owning,
                                                         after exercise, a number of ordinary shares in excess of the beneficial ownership limitation. <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rimon
                                                         Gold Assets Ltd. (&#8220;Rimon Gold&#8221;), an Israeli private company, is wholly owned by the Goldfinger Trust (the
                                                         &#8220;Trust&#8221;), a trust organized under the laws of Jersey. Mr. Abir Raveh serves as Trustee of the Trust and as the sole
                                                         director and executive officer of Rimon Gold. Yair Goldfinger is the sole beneficiary of the Trust. The principal business office of
                                                         each of Rimon Gold and the Goldfinger Trust is 32A Habarzel, Tel Aviv, Israel. The address of Mr. Raveh is 32 Brenner St. Herzelia,
                                                         Israel.</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 480,924 ordinary shares and options to purchase 21,000 ordinary shares and warrants to purchase 66,666 ordinary shares that are exercisable within 60 days of April 7, 2025. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 189,618
    ordinary shares and options to purchase 108,000 ordinary shares and warrants to purchase 66,667 ordinary shares that are exercisable
    within 60 days of April 7, 2025. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 75,428 ordinary shares and options to purchase 36,000 ordinary shares that are exercisable within 60 days of April 7, 2025. Does not include 10,000 ordinary shares issuable upon vesting of outstanding RSUs that are not do not vest within 60 days of April 7, 2025.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.3in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 32,000
    ordinary shares and options to purchase 33,000 ordinary shares that are exercisable within 60 days of April 7, 2025. Does not
    include 10,000 ordinary shares issuable upon vesting of outstanding RSUs do not vest within 60 days of April 7, 2025 and 3,000
    ordinary shares issuable upon exercise of outstanding options that are not exercisable within 60 days of April 7, 2025.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.3in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 64,000 ordinary shares and options to purchase 168,000 ordinary shares that are exercisable within 60 days of April 7, 2025. Does not include 24,000 ordinary shares issuable upon exercise of outstanding options that are not exercisable within 60 days of April 7, 2025 and 64,000 ordinary shares issuable upon vesting of outstanding RSUs that do not vest within 60 days of April 7, 2025.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.3in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 24,000 ordinary shares and options to purchase 72,000 ordinary shares that are exercisable within 60 days of April 7, 2025. Does not include 24,000 ordinary shares issuable upon vesting of outstanding RSUs that do not vest within 60 days of April 7, 2025.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.3in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does not include 24,000 ordinary shares issuable upon vesting of outstanding RSUs that do not vest within 60 days of April 7, 2025.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.3in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 24,000 ordinary shares and options to purchase 72,000 ordinary shares that are exercisable within 60 days of April 7, 2025. Does not include 24,000 ordinary shares issuable upon vesting of outstanding RSUs that do not vest within 60 days of April 7, 2025.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.3in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 28,526 ordinary shares and options to purchase 72,000 ordinary shares that are exercisable within 60 days of April 7, 2025. Does not include 24,000 ordinary shares issuable upon vesting of outstanding RSUs that do not vest within 60 days of April 7, 2025.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Significant Changes in the Ownership of Major
Shareholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To our knowledge, other than
as disclosed in the table above, our other filings with the SEC and this annual report, there has been no significant change in the percentage
ownership held by any major shareholder since January 1, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Holdings by U.S. Shareholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As &#160;of April 7, 2025, there were 1,361 holders of record of our
ordinary shares, out of which 15 holders of record had a registered address in the United States. The number of record holders is not
representative of the number of beneficial holders of our ordinary shares, as 78.4% of our outstanding ordinary shares are recorded in
the name of Cede &amp; Co. as nominee for the Depository Trust Company, in whose name all shares held in &#8220;street name&#8221; are
held in the United States. Except where otherwise indicated, we believe, based on information furnished to us by such owners, that the
beneficial owners of the ordinary shares listed below have sole investment and voting power with respect to such shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Related Party Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Agreements with Directors and Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have entered into employment
agreements with each of our executive officers. See &#8220;Item 6B. Directors, Senior Management and Employees &#8212; Compensation.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>December 2024 Offering</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 2, 2024, we entered
into a securities purchase agreement with an institutional investor and our chief executive officer pursuant to which we sold an aggregate
of (i) 2,343,729 of our ordinary shares (ii) pre-funded warrants to purchase up to an aggregate of 1,656,271 ordinary shares and (iii)
8,000,000 ordinary warrants, each representing the right to acquire one ordinary share, in a private placement at a combined offering
price of $1.25 per ordinary share and ordinary warrant and $1.2499 per pre-funded warrant and ordinary warrant. Each pre-funded warrant
represented the right to purchase one ordinary shares at an exercise price of $0.0001 per share. The pre-funded warrants were exercisable
immediately and at any time until the pre-funded warrants were exercised in full (subject to a beneficial ownership limitation set forth
therein). The ordinary warrants are exercisable immediately upon issuance at an exercise price of $1.25 per share, and will expire on
the fifth anniversary of the original issuance date. Aggregate gross proceeds from the private placement were approximately $5.0 million,
before deducting offering expenses. The offering closed on December 17, 2024. All consideration in this issuance was classified to equity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Interests of Experts and Counsel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 8. FINANCIAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Financial Statements and Other Financial
Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The financial statements
required by this item are found at the end of this annual report, beginning on page F-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are not currently a party
to any material legal proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividend Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have never declared or
paid any cash dividends on our ordinary shares and we anticipate that, for the foreseeable future, we will retain any future earnings
to support operations and to finance the growth and development of our business. Therefore, we do not expect to pay cash dividends for
at least the next several years. See &#8220;Risk Factors&#8212;Risks Related to an Investment in Our Ordinary Shares and Warrants.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The distribution of dividends
may also be limited by the Companies Law, which permits the distribution of dividends only out of retained earnings or earnings derived
over the two most recent fiscal years, whichever is higher, provided that there is no reasonable concern that payment of a dividend will
prevent a company from satisfying its existing and foreseeable obligations as they become due. As of December 31, 2024, we did not have
distributable earnings pursuant to the Companies Law. Dividend distributions may be determined by our board of directors, as our amended
and restated articles of association do not provide that such distributions require shareholder approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Significant Changes</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except as otherwise disclosed
in this annual report, no significant change has occurred since December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 9. THE OFFER AND LISTING</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Offer and Listing Details</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Ordinary Shares and Warrants
have been trading on The Nasdaq Capital Market under the symbol &#8220;NRSN&#8221; and &#8220;WNRSN&#8221;, respectively, since December
9, 2021. Prior to that date, there was no public trading market for our Ordinary Shares or Warrants. Our initial public offering of units
comprised of one Ordinary Share and one Warrant was priced at $6.00 per unit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 4, 2025, the last
reported closing price of our Ordinary Shares on The Nasdaq Capital Market was $0.99 per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April 4, 2025, the last
reported closing price of our Warrants on The Nasdaq Capital Market was $0.20 per warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Plan of Distribution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Markets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Ordinary Shares and Warrants
are listed and traded on The Nasdaq Capital Market under the symbols &#8220;NRSN&#8221; and &#8220;NRSNW,&#8221; respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Selling Shareholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. Dilution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>F. Expenses of the Issue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 10. ADDITIONAL INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Share Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Memorandum and Articles of Association</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our authorized share capital
consists of 90,000,000 ordinary shares, no par value per share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All of our outstanding ordinary
shares are validly issued, fully paid and non-assessable. Our ordinary shares are not redeemable and do not have any preemptive rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Registration Number and Purpose</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our registration number with
the Israeli Registrar of Companies, or IRC, is 51-5610822. Our purpose as set forth in our amended and restated articles of association
is to engage in any lawful activity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Voting Rights and Conversion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All ordinary shares will
have identical voting and other rights in all respects. None of our major shareholders have different voting rights than our other shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transfer of Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our fully paid ordinary shares
are issued in registered form and may be freely transferred under our amended and restated articles of association, unless the transfer
is restricted or prohibited by another instrument, applicable law or the rules of a stock exchange on which the shares are listed for
trade. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our amended and restated
articles of association or the laws of the State of Israel, except for ownership by nationals of some countries that are, or have been,
in a state of war with Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liability to Further Capital Calls</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors may
make, from time to time, such calls as it may deem fit upon shareholders with respect to any sum unpaid with respect to shares held by
such shareholders, which is not payable at a fixed time. Such shareholder shall pay the amount of every call so made upon him. Unless
otherwise stipulated by the board of directors, each payment in response to a call shall be deemed to constitute a pro rata payment on
account of all shares with respect to which such call was made. A shareholder shall not be entitled to his rights as shareholder, including
the right to dividends, unless such shareholder has fully paid all the notices of call delivered to him, or which according to our amended
and restated articles of association are deemed to have been delivered to him, together with interest, linkage and expenses, if any, unless
otherwise determined by the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Business Combinations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under our amended and restated
articles of association, we may not engage in any &#8220;business combinations&#8221; with any &#8220;interested shareholder&#8221; for
a three-year period following the time that such shareholder became an interested shareholder, unless:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior to the time that such shareholder became an interested shareholder, our board of directors approved either the business combination or the transaction which resulted in the shareholder becoming an interested shareholder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon consummation of the transaction which resulted in the shareholder becoming an interested shareholder, the interested shareholder owned at least 85% of our voting shares outstanding at the time the transaction commenced, excluding for purposes of determining our voting shares outstanding (but not the outstanding voting shares owned by the interested shareholder) those shares owned by persons who are directors and also officers; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the time that such shareholder became an interested shareholder, or subsequent to such time, the business combination is approved by our board of directors and authorized at a general meeting of shareholders by the affirmative vote of at least 66<sup>2/3</sup>% of our voting shares outstanding that are not owned by the interested shareholder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Generally, a &#8220;business
combination&#8221; includes any merger, consolidation, sale or other transaction resulting in a financial benefit to the interested shareholder.
Subject to certain exceptions, an &#8220;interested shareholder&#8221; is any person (other than us and any of our direct or indirect
majority-owned subsidiaries) who, together with such person&#8217;s affiliates and associates, owns, or within the previous three years
owned, 15% or more of our voting shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under certain circumstances,
this provision will make it more difficult for a person who would be an &#8220;interested shareholder&#8221; to effect various business
combinations with a corporation for a three-year period. This provision may encourage companies interested in acquiring us to negotiate
in advance with our board of directors because the shareholder approval requirement would be avoided if our board of directors approves
either the business combination or the transaction which results in the shareholder becoming an interested shareholder. These provisions
also may have the effect of preventing changes in our board of directors and may make it more difficult to accomplish transactions which
shareholders may otherwise deem to be in their best interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Election of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ordinary shares do not
have cumulative voting rights for the election of directors. As a result, the holders of a majority of the voting power represented at
a shareholders meeting have the power to elect our directors, subject to the special approval requirements for external directors under
the Companies Law described under &#8220;Management&#8212;External Directors.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under our amended and restated
articles of association, the number of directors on our board of directors must be no less than three and no more than nine, including
any external directors required to be appointed under the Companies Law. The minimum and maximum number of directors may be changed, at
any time and from time to time, by a special vote of the holders of at least 66<sup>2/3</sup> of our outstanding shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Other than external directors,
for whom special election requirements apply under the Companies Law, the vote required to appoint a director is a simple majority vote.
In addition, under our amended and restated articles of association, our board of directors may elect new directors to fill vacancies
(whether such vacancy is due to a director no longer serving or due to the number of directors serving being less than the maximum required
in our amended and restated articles of association), provided that the total number of directors shall not, at any time, exceed nine
directors and provided that our board of directors may not elect external directors. Our amended and restated articles of association
provide that the term of a director appointed by our board of directors to fill any vacancy will be for the remaining term of office of
the director(s) whose office(s) have been vacated. Furthermore, under our amended and restated articles of association, our directors,
other than external directors, are divided into three classes with staggered three-year terms. Each class of directors consists, as nearly
as possible, of 1/3 of the total number of directors constituting the entire board of directors (other than the external directors). For
a more detailed description on the composition of our board of election procedures of our directors, other than our external directors,
see &#8220;Management&#8212;Board of Directors.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">External directors are elected
for an initial term of three years, may be elected for additional three-year terms, and may be removed from office pursuant to the terms
of the Companies Law. For further information on the election and removal of external directors, see &#8220;Management&#8212;External
Directors.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividend and Liquidation Rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may declare a dividend
to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Companies Law, dividend distributions
are determined by the board of directors and do not require the approval of the shareholders of a company unless the company&#8217;s articles
of association provide otherwise. Our amended and restated articles of association do not require shareholder approval of a dividend distribution
and provide that dividend distributions may be determined by our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the Companies
Law, subject to certain exceptions with respect to the buyback by the Company of its ordinary shares, the distribution amount is limited
to the greater of retained earnings or earnings generated over the previous two years, according to our then last reviewed or audited
financial statements (less the amount of previously distributed dividends, if not reduced from the earnings), provided that the end of
the period to which the financial statements relate is not more than six months prior to the date of the distribution. If we do not meet
such criteria, then we may distribute dividends only with court approval. In each case, we are only permitted to distribute a dividend
if our board of directors and, if applicable, the court determines that there is no reasonable concern that payment of the dividend will
prevent us from satisfying our existing and foreseeable obligations as they become due. In the event of our liquidation, after satisfaction
of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to their shareholdings.
This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to
the holders of a class of shares with preferential rights that may be authorized in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Shareholder Meetings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under Israeli law, we are
required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months after
the date of the previous annual general meeting. All general meetings other than the annual meeting of shareholders are referred to in
our amended and restated articles of association as special meetings. Our board of directors may call special meetings whenever it sees
fit, at such time and place, within or outside of Israel, as it may determine. In addition, as a company whose shares are listed for trade
on an exchange outside of Israel, Israeli law provides that our board of directors is required to convene a special general meeting upon
the written request of (i) any two of our directors or one-quarter of the members of our board of directors or (ii) one or more shareholders
holding, in the aggregate, either (a) 10% or more of our outstanding issued shares and 1% or more of our outstanding voting power or (b)
10% or more of our outstanding voting power.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under Israeli law, one or
more shareholders holding at least 1% of the voting rights at the general meeting may request that the board of directors include a matter
in the agenda of a general meeting to be convened in the future (or, with respect to a company whose shares are listed for trade on an
exchange outside of Israel, 5% if the matter is the appointment or removal of a director, provided that it is appropriate to discuss such
a matter at the general meeting. Our amended and restated articles of association contain procedural guidelines and disclosure items with
respect to the submission of shareholder proposals for shareholders meetings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the provisions
of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are
the shareholders of record on a date to be decided by the board of directors, which may be between four and 60 days prior to the date
of the meeting. Furthermore, the Companies Law requires that resolutions regarding, among other things, the following matters must be
passed at a general meeting of our shareholders:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendments to our amended and restated articles of association;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment or termination of our auditors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">election of directors, including external directors (unless otherwise determined in our amended and restated articles of association);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval of certain related party transactions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases or reductions of our authorized share capital;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a merger; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exercise of our board of directors&#8217; powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under our amended and restated
articles of association, we are not required to give notice to our registered shareholders pursuant to the Companies Law, unless otherwise
required by law. The Companies Law requires that a notice of any annual general meeting or special general meeting be provided to shareholders
at least 21 days prior to the meeting and if the agenda of the meeting includes the appointment or removal of directors, the approval
of transactions with office holders or interested or related parties, or an approval of a merger, or as otherwise required under applicable
law, notice must be provided at least 35 days prior to the meeting. Under the Companies Law, shareholders of a public company are not
permitted to take action by written consent in lieu of a meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Voting Rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Quorum Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to our amended and
restated articles of association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to
a vote before the shareholders at a general meeting. Under our amended and restated articles of association, the quorum required for general
meetings of shareholders must consist of at least two shareholders present in person or by proxy (including by voting deed) holding 25%
or more of our voting rights. A meeting adjourned for lack of a quorum will generally be adjourned to the same day of the following week
at the same time and place, or to such other day, time or place as indicated by our board of directors if so specified in the notice of
the meeting. At the reconvened meeting, any number of shareholders present in person or by proxy shall constitute a lawful quorum.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Vote Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our amended and restated
articles of association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by
the Companies Law or by our amended and restated articles of association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our amended and restated
articles of association provide that all resolutions of our board of directors require a simple majority vote of the directors present
and voting at such meeting, unless otherwise required by the Companies Law or by our amended and restated articles of association. Pursuant
to our amended and restated articles of association, in the event the vote is tied, the chair of the board of directors will have a casting
vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to our amended and
restated articles of association, an amendment to our articles of association regarding any change of the composition or election procedures
of our directors will require a special majority vote (66&#8532;%). In addition, any change to the rights and privileges of the holders
of any class of our shares requires a simple majority of the class so affected (or otherwise in accordance with the terms of such class),
in addition to the simple majority vote of all classes of shares voting together as a single class at a shareholder meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Companies Law,
each of (i) the approval of an extraordinary transaction with a controlling shareholder and (ii) the terms of employment or other engagement
of the controlling shareholder of the company or such controlling shareholder&#8217;s relative (even if not extraordinary) requires the
approval described above under &#8220;Management&#8212;Approval of Related Party Transactions under Israeli Law&#8212;Fiduciary Duties
of Directors and Officers.&#8221; Certain transactions with respect to remuneration of our office holders and directors require further
approvals described above under &#8220;Management&#8212;Approval of Related Party Transactions under Israeli Law&#8212;Fiduciary Duties
of Directors and Officers.&#8221; Another exception to the simple majority vote requirement is a resolution for the voluntary winding
up, or an approval of a scheme of arrangement or reorganization, of the company pursuant to Section 350 of the Companies Law, which requires
the approval of holders of 75% of the voting rights represented at the meeting, in person or by proxy and voting on the resolution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Access to Corporate Records</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Companies Law,
shareholders are provided access to: minutes of our general meetings; our shareholders register and material shareholders register, our
amended and restated articles of association, our financial statements and any document that we are required by law to file publicly with
the Israeli Companies Registrar or the ISA. In addition, shareholders may request to be provided with any document related to an action
or transaction requiring shareholder approval under the related party transaction provisions of the Companies Law. We may deny this request
if we believe it has not been made in good faith or if such denial is necessary to protect our interest or protect a trade secret or patent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Modification of Class Rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Companies Law and
our amended and restated articles of association, the rights attached to any class of share, such as voting, liquidation and dividend
rights, may be amended by adoption of a resolution by the holders of a majority of the shares of that class present at a separate class
meeting, or otherwise in accordance with the terms of such class of shares, in addition to the simple majority vote of all classes of
shares voting together as a single class at a shareholder meeting, as set forth in our amended and restated articles of association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Acquisitions Under Israeli Law</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Full Tender Offer. </i>A
person wishing to acquire shares of an Israeli public company and who would as a result hold over 90% of the target company&#8217;s issued
and outstanding share capital is required by the Companies Law to make a tender offer to all of the company&#8217;s shareholders for the
purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of an Israeli public company and
who would as a result hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender
offer to all of the shareholders who hold shares of the relevant class for the purchase of all of the issued and outstanding shares of
that class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company
or of the applicable class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer,
all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer
will also be accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of
the company or of the applicable class of shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon a successful completion
of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer
or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender
offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions,
the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli
court as described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If (a) the shareholders who
did not respond or accept the tender offer hold at least 5% of the issued and outstanding share capital of the company or of the applicable
class or the shareholders who accept the offer constitute less than a majority of the offerees that do not have a personal interest in
the acceptance of the tender offer or (b) the shareholders who did not accept the tender offer hold 2% or more of the issued and outstanding
share capital of the company (or of the applicable class), the acquirer may not acquire shares of the company that will increase its holdings
to more than 90% of the company&#8217;s issued and outstanding share capital or of the applicable class from shareholders who accepted
the tender offer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Special Tender Offer</i>.
The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer
if as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. Similarly, the
Companies Law provides that an acquisition of shares in a public company must be made by means of a special tender offer if as a result
of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company. These requirements do not
apply if, in general, the acquisition (1) was made in a private placement that received shareholder approval, (2)&#160;was from a 25%
or greater shareholder of the company which resulted in the acquirer becoming a 25% or greater shareholder of the company, or (3) was
from a 45% or greater shareholder of the company which resulted in the acquirer becoming a 45% or greater shareholder of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A special tender offer must
be extended to all shareholders of a company but the offeror is not required to purchase shares representing more than 5% of the voting
power attached to the company&#8217;s outstanding shares, regardless of how many shares are tendered by shareholders. A special tender
offer may be consummated only if (i) at least 5% of the voting power attached to the company&#8217;s outstanding shares will be acquired
by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding
the purchaser and its controlling shareholders, holders of 25% or more of the voting rights in the company or any person having a personal
interest in the acceptance of the tender offer or any other person acting on their behalf, including the relatives and entities under
such person&#8217;s control). If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under
common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares
of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless
the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Merger</i>. The Companies
Law permits merger transactions if approved by each party&#8217;s board of directors and, unless certain requirements described under
the Companies Law are met, by a majority vote of each party&#8217;s shares, and, in the case of the target company, a majority vote of
each class of its shares, voted on the proposed merger at a shareholders meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For purposes of the shareholder
vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of shares represented at the shareholders
meeting that are held by parties other than the other party to the merger, or by any person (or group of persons acting in concert) who
holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25% or more of the directors of the other
party, vote against the merger. If, however, the merger involves a merger with a company&#8217;s own controlling shareholder or if the
controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority approval
that governs all extraordinary transactions with controlling shareholders. See &#8220;Management&#8212;Approval of Related Party Transactions
under Israeli Law&#8212;Fiduciary Duties of Directors and Officers&#8212;Disclosure of Personal Interests of an Office Holder and Approval
of Certain Transactions.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the transaction would
have been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes
of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting
rights of a company, if the court holds that the merger is fair and reasonable, taking into account the value to the parties to the merger
and the consideration offered to the shareholders of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon the request of a creditor
of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern
that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further
give instructions to secure the rights of creditors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, a merger may
not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each
party with the IRC and at least 30 days have passed from the date on which the merger was approved by the shareholders of each party.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Israeli tax law treats some
acquisitions, such as share-for-share exchanges between an Israeli company and a foreign company, less favorably than U.S. tax laws. For
example, Israeli tax law may, under certain circumstances, subject a shareholder who exchanges his ordinary shares for shares in another
corporation to taxation prior to the sale of the shares received in such share-for-share swap.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Anti-Takeover Measures Under Israeli Law</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Companies Law allows
us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred
rights with respect to voting, distributions or other matters and shares having preemptive rights. No preferred shares are authorized
under our amended and restated articles of association. In the future, if we do authorize, create and issue a specific class of preferred
shares, such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent
a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The
authorization and designation of a class of preferred shares will require an amendment to our amended and restated articles of association,
which requires the prior approval of the holders of a majority of the voting power attaching to our issued and outstanding shares at a
general meeting. The convening of the meeting, the shareholders entitled to participate and the majority vote required to be obtained
at such a meeting will be subject to the requirements set forth in the Companies Law as described above in &#8220;&#8212;Voting Rights.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Borrowing Powers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the Companies
Law and our amended and restated articles of association, our board of directors may exercise all powers and take all actions that are
not required under law or under our amended and restated articles of association to be exercised or taken by our shareholders, including
the power to borrow money for company purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Changes in Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our amended and restated
articles of association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Companies
Law and must be approved by a resolution duly adopted by our shareholders at a general meeting. In addition, transactions that have the
effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits,
require the approval of both our board of directors and an Israeli court.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Establishment</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We were incorporated under
the laws of the State of Israel on February 13, 2017. We are registered with the IRC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exclusive Forum</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our amended and restated
articles of association provide that unless we consent in writing to the selection of an alternative forum, the federal district courts
of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities
Act. This choice of forum provision may limit a shareholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable
for disputes with us or our directors, officers or other employees and may increase the costs associated with such lawsuits, which may
discourage such lawsuits against us and our directors, officers and employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This exclusive forum provision
would not apply to claims brought pursuant to the Securities Act or the Exchange Act or any other claim for which U.S. federal courts
would have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange
Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the
rules and regulations thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Alternatively, if a court
were to find these provisions of our amended and restated articles of association inapplicable to, or unenforceable in respect of, one
or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other
jurisdictions, which could adversely affect our business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our amended and restated
articles of association also provide that unless we consent in writing to the selection of an alternative forum, the competent courts
in Tel Aviv, Israel shall be the exclusive forum for any derivative action or proceeding brought on behalf of the Company, any action
asserting a breach of a fiduciary duty owed by any of our directors, officers or other employees to the Company or our shareholders or
any action asserting a claim arising pursuant to any provision of the Companies Law or the Israeli Securities Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any person or entity purchasing
or otherwise acquiring any interest in our share capital shall be deemed to have notice of and to have consented to these choice of forum
provisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Transfer Agent and Registrar</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The transfer agent and registrar
for our ordinary shares and Warrants is Equiniti Trust Company, LLC. Its address is 6201 15<sup>th</sup>&#160;Avenue, Brooklyn, New York
11219, and its telephone number is (800) 937-5449.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Material Contracts</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For a description of other
material agreements, please see &#8220;Item 4. Information on the Company &#8211; B. Business Overview.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. Exchange Controls</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are currently no Israeli
currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the shares or interest or
other payments to non-residents&#160;of Israel, except for shareholders who are subjects of certain countries that are, or have been,
in a state of war with Israel at such time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>E. Taxation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Israeli Tax Considerations and Government Programs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following description
is not intended to constitute a complete analysis of all tax consequences relating to the acquisition, ownership and disposition of our
securities offered hereby. You should consult your own tax advisor concerning the tax consequences of your particular situation, as well
as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Israeli Tax Considerations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following is a brief
summary of certain material Israeli tax laws applicable to us, and certain Israeli government programs that benefit us. This section also
contains a discussion of certain material Israeli tax consequences concerning the ownership and disposition of our securities offered
hereby. This summary does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his
or her personal investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of such
investors include residents of Israel or traders in securities who are subject to special tax regimes not covered in this discussion.
To the extent that the discussion is based on tax legislation that has not yet been subject to judicial or administrative interpretation,
we cannot assure you that the appropriate tax authorities or the courts will accept the views expressed in this discussion. The discussion
below is not intended, and should not be construed, as legal or professional tax advice and is not exhaustive of all possible tax considerations.
The discussion is subject to change, including due to amendments under Israeli law or changes to the applicable judicial or administrative
interpretations of Israeli law, which change could affect the tax consequences described below, possibly with a retroactive effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">THEREFORE, YOU ARE URGED
TO CONSULT YOUR OWN TAX ADVISORS AS TO THE ISRAELI OR OTHER TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR SECURITIES
OFFERED HEREBY, INCLUDING, IN PARTICULAR, THE EFFECT OF ANY FOREIGN, STATE OR LOCAL TAXES.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General Corporate Tax Structure in Israel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Israeli companies are generally
subject to corporate tax at a flat rate. In December 2016, the Israeli Parliament approved the Economic Efficiency Law (Legislative Amendments
for Applying the Economic Policy for the 2017 and 2018 Budget Years) (or &#8220;EEL&#8221;), which reduced the corporate income tax rate
from 25% to 24% effective from January&#160;1, 2017, and to 23% effective from January&#160;1, 2018 and thereafter. However, the effective
tax rate payable by a company that derives income from an Approved Enterprise, a Preferred Enterprise, a Benefited Enterprise or a Preferred
Technological Enterprise (as discussed below) may be considerably lower. Capital gains derived by an Israeli company are generally subject
to corporate tax rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Law for the Encouragement of Industry (Taxes),
5729-1969</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Law for the Encouragement
of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, (or &#8220;IEL&#8221;), provides several tax
benefits for &#8220;Industrial Companies.&#8221; We may qualify as an Industrial Company within the meaning of the IEL.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The IEL defines an &#8220;Industrial
Company&#8221; as an Israeli resident-company, of which 90% or more of its income in any tax year, other than income from certain government
loans, capital gains, interest and dividends, is derived from an &#8220;Industrial Enterprise&#8221; owned by it and located in Israel
or in the &#8220;Area,&#8221; in accordance with the definition under Section 3A of the Israeli Income Tax Ordinance (New Version) 1961
(or the &#8220;Ordinance&#8221;). An &#8220;Industrial Enterprise&#8221; is defined as an enterprise whose principal activity in a given
tax year is industrial production.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following are the main
tax benefits available to Industrial Companies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization of the cost of purchased patent, rights to use a patent, and know-how, which were purchased in good faith and are used for the development or advancement of the Industrial Enterprise, over an eight-year&#160;period, commencing on the year in which such rights were first exercised;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under limited conditions, an election to file consolidated tax returns with controlled Israeli Industrial&#160;Companies; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses related to a public offering are deductible in equal amounts over three years commencing on the year of the offering.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Eligibility for benefits
under the Industry Encouragement Law is not contingent upon approval of any governmental authority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Tax Benefits and Grants for Research and Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Israeli tax law allows, under
certain conditions, a tax deduction for expenditures related to scientific research and development projects, including capital expenditures,
for the year in which they are incurred. Expenditures are deemed related to scientific research and development projects, if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The research and expenditures are approved by the relevant Israeli government ministry, determined by the field of research;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The research and development must be for the promotion of the company; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The research and development is carried out by or on behalf of the company seeking such tax deduction.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The amount of such deductible
expenses is reduced by the sum of any funds received through government grants for the finance of such scientific research and development
projects. No deduction under these research and development deduction rules is allowed if such deduction is related to an expense invested
in an asset depreciable under the general depreciation rules of the Ordinance. Expenditures that are unqualified under the conditions
above are deductible, under certain conditions in equal amounts over three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">From time to time we may
apply to the Israel Innovation Authority, (or &#8220;IIA&#8221;) for approval to allow a tax deduction for all or most of research and
development expenses during the year incurred. There can be no assurance that such application will be accepted. If we will not be able
to deduct research and development expenses during the year of the payment, we may be able to deduct research and development expenses
in equal amounts over a period of three years commencing in the year of the payment of such expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Law for the Encouragement of Capital Investments,
5719-1959</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Law for the Encouragement
of Capital Investments, 5719-1959 (or &#8220;the Investment Law&#8221;), provides certain incentives for capital investments in production
facilities (or other eligible assets). Generally, an investment program that is implemented in accordance with the provisions of the Investment
Law, referred to as an Approved Enterprise, a Beneficiary Enterprise, a Preferred Enterprise, a Preferred Technological Enterprise, or
a Special Preferred Technological Enterprise, is entitled to benefits as discussed below. These benefits may include cash grants from
the Israeli government and tax benefits, based upon, among other things, the geographic location in Israel of the facility in which the
investment is made. In order to qualify for these incentives, the Company is required to comply with the requirements of the Investment
Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Investment Law was significantly
amended effective as of April&#160;1, 2005, (or the &#8220;2005 Amendment&#8221;), as of January&#160;1, 2011, (or the &#8220;2011 Amendment&#8221;),
and as of January&#160;1, 2017 (or the &#8220;2017 Amendment&#8221;). Pursuant to the 2005 Amendment, tax benefits granted in accordance
with the provisions of the Investment Law prior to its revision by the 2005 Amendment remain in force but any benefits granted subsequently
are subject to the provisions of the amended Investment Law. Similarly, the 2011 Amendment introduced new benefits to replace those granted
in accordance with the provisions of the Investment Law in effect prior to the 2011 Amendment. However, companies entitled to benefits
under the Investment Law as in effect prior to January&#160;1, 2011 were entitled to choose to continue to enjoy such benefits, provided
that certain conditions are met, or elect instead, irrevocably, to forego such benefits and have the benefits of the 2011 Amendment apply.
The 2017 Amendment introduces new benefits for Technological Enterprises, alongside the existing tax benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Benefits Under the 2011 Amendment</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The 2011 Amendment canceled
the availability of the benefits granted to Industrial Companies under the Investment Law prior to 2011 and, instead, introduced new benefits
for income generated by a &#8220;Preferred Company&#8221; through its &#8220;Preferred Enterprise&#8221; (as such terms are defined in
the Investment Law) as of January&#160;1, 2011. The definition of a Preferred Company includes a company incorporated in Israel that is
not fully owned by a governmental entity, and that has, among other things, Preferred Enterprise status and is controlled and managed
from Israel. Pursuant to the 2011 Amendment, a Preferred Company is entitled to a reduced corporate tax rate of 16% with respect to its
income derived by its Preferred Enterprise in 2011 and 2012, unless the Preferred Enterprise is located in a specified development zone,
in which case the rate will be 10%. Under the 2011 Amendment, such corporate tax rate was reduced from 15% and 10%, respectively, to 12.5%
and 7%, respectively, in 2013, 16% and 9% respectively, in 2014, 2015 and 2016, and 16% and 7.5%, respectively, in 2017 and thereafter.
Income derived by a Preferred Company from a &#8220;Special Preferred Enterprise&#8221; (as such term is defined in the Investment Law)
would be entitled, subject to certain conditions and during a benefits period of 10 years, to further reduced tax rates of 8%, or 5% if
the Special Preferred Enterprise is located in a certain development zone.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Dividends distributed from
income which is attributed to a &#8220;Preferred Enterprise&#8221; will be subject to tax at the following rates: (i) Israeli resident
corporations&#8211;0% (although, if such dividends are subsequently distributed to individuals or a non-Israeli&#160;company the below
rates detailed in sub sections (ii) and (iii) shall apply) (ii) Israeli resident individuals&#8211;20% (iii) non-Israeli&#160;residents
(individuals and corporations)&#8211;20%, subject to a reduced tax rate under the provisions of any applicable tax treaty. The withholding
tax rate applicable to distribution of dividend from such income to non-Israeli&#160;residents is 25% (or 30% if distributed to a &#8220;substantial
shareholder&#8221; at the time of the sale or at any time during the preceding twelve months period, as defined below), which may be reduced
under an applicable tax treaty by applying in advance for a withholding certificate from the Israel Tax Authority (or &#8220;ITA&#8221;).
A &#8220;substantial shareholder&#8221; is generally a person who alone or together with such person&#8217;s relative or another person
who collaborates with such person on a permanent basis, holds, directly or indirectly, at least 10% of any of the &#8220;Means of Control&#8221;
of the corporation. &#8220;Means of control&#8221; generally include the right to vote, receive profits, nominate a director or an executive
officer, receive assets upon liquidation, or order someone who holds any of the aforesaid rights how to act, regardless of the source
of such right.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The 2011 Amendment also provided
transitional provisions to address companies already enjoying existing tax benefits under the Investment Law. These transitional provisions
provide, among other things, that unless an irrevocable request is made to apply the provisions of the Investment Law as amended in 2011
with respect to income to be derived as of January&#160;1, 2011, a Beneficiary Enterprise can elect to continue to benefit from the benefits
provided to it before the 2011 Amendment came into effect, provided that certain conditions are met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>New Tax Benefits Under the 2017 Amendment
That Became Effective on January 1, 2017</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The 2017 Amendment was enacted
as part of the EEL that was published on December&#160;29, 2016 and is effective as of January&#160;1, 2017. The 2017 Amendment provides
new tax benefits for two types of &#8220;Technological Enterprises,&#8221; as described below, and is in addition to the other existing
tax beneficial programs under the Investment Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The 2017 Amendment provides
that a Preferred Company satisfying certain conditions will qualify as having a &#8220;Preferred Technological Enterprise&#8221; and will
thereby enjoy a reduced corporate tax rate of 12% on income that qualifies as &#8220;Preferred Technological Income,&#8221; as defined
in the Investment Law. The corporate tax rate is further reduced to 7.5% with respect to a Preferred Technological Enterprise located
in development zone &#8220;A.&#8221; In addition, a Preferred Company qualify as having a &#8220;Preferred Technological Enterprise&#8221;
will enjoy a reduced corporate tax rate of 12% on capital gain derived from the sale of certain &#8220;Benefitted Intangible Assets&#8221;
(as defined in the Investment Law) to a related foreign company if the Benefitted Intangible Assets were acquired from a foreign company
on or after January&#160;1, 2017 for at least NIS 200&#160;million, and the sale receives prior approval from the IIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The 2017 Amendment further
provides that a Preferred Company satisfying certain conditions (including group consolidated revenues of at least NIS 10&#160;billion)
will qualify as having a &#8220;Special Preferred Technological Enterprise&#8221; and will thereby enjoy a reduced corporate tax rate
of 6% on &#8220;Preferred Technological Income&#8221; regardless of the company&#8217;s geographic location within Israel. In addition,
a Special Preferred Technological Enterprise will enjoy a reduced corporate tax rate of 6% on capital gain derived from the sale of certain
&#8220;Benefitted Intangible Assets&#8221; to a related foreign company if the Benefitted Intangible Assets were either developed by the
Special Preferred Enterprise or acquired from a foreign company on or after January&#160;1, 2017, and the sale received prior approval
from the IIA. A Special Preferred Technological Enterprise that acquires Benefitted Intangible Assets from a foreign company for more
than NIS 500&#160;million will be eligible for these benefits for at least ten years, subject to certain approvals as specified in the
Investment Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Dividends distributed by
a Preferred Technological Enterprise or a Special Preferred Technological Enterprise, paid out of Preferred Technological Income, are
generally subject to tax at the rate of 20% or such lower rate as may be provided in an applicable tax treaty. The withholding tax rate
applicable to distribution of dividend from such income to non-Israeli&#160;residents is 25% (or 30% if distributed to a &#8220;substantial
shareholder&#8221; at the time of the sale or at any time during the preceding twelve months period), which may be reduced under an applicable
tax treaty by applying in advance for a withholding certificate from the ITA. In addition, if such dividends are distributed to a foreign
company that holds solely or together with other foreign companies 90% or more in the Israeli company and other conditions are met, the
withholding tax rate will be 4% (subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate).
However, if such dividends are paid to an Israeli company, no tax is required to be withheld.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Taxation of Our Securityholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Capital gains&#160;Tax on Sales of our Ordinary
Shares and Warrants</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Israeli law generally imposes
a capital gains tax on the sale of any capital assets by Israeli residents, as defined for Israeli tax purposes, and on the sale of capital
assets located in Israel, including shares of Israeli companies, by both Israeli residents and non-Israeli&#160;residents, unless a specific
exemption is available or unless a tax treaty between Israel and the shareholder&#8217;s country of residence provides otherwise. The
Ordinance distinguishes between real gain and inflationary surplus. The inflationary surplus is a portion of the total capital gain equivalent
to the increase of the relevant asset&#8217;s purchase price attributable to an increase in the Israeli consumer price index, or in certain
circumstances a foreign currency exchange rate, between the date of purchase and the date of sale. Inflationary surplus is currently not
subject to tax in Israel. The real gain is the excess of the total capital gain over the inflationary surplus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Capital Gains Taxes Applicable to Non-Israeli
Resident Securityholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A non-Israeli&#160;resident
who derives capital gains from the sale of shares or warrants in an Israeli resident company that were purchased after the company was
listed for trading on a stock exchange outside of Israel, will be exempt from Israeli tax as long as (among other conditions) the securities
were not held through a permanent establishment that the non-resident&#160;maintains in Israel. However, non-Israeli&#160;corporations
will not be entitled to the foregoing exemption if Israeli residents: (i) have a controlling interest of more than 25% in such non-Israeli&#160;corporation
whether directly or indirectly, or (ii) are the beneficiaries of, or are entitled to, 25% or more of the revenues or profits of such non-Israeli&#160;corporation,
whether directly or indirectly. In addition, such exemption is not applicable to a person whose gains from selling or otherwise disposing
of the securities are deemed to be business income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, a sale of securities
by a non-Israeli&#160;resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty. For example,
under the Convention Between the Government of the United States of America and the Government of the State of Israel with respect to
Taxes on Income, as amended, or the U.S. Israel Tax Treaty, the sale, exchange or other disposition of shares by a shareholder who is
a United States resident (for purposes of the treaty) holding the shares as a capital asset and is entitled to claim the benefits afforded
to such a resident by the U.S. Israel Tax Treaty (or a &#8220;U.S. Resident&#8221;), is generally exempt from Israeli capital gains tax
unless: (i) the capital gain arising from such sale, exchange or disposition is attributed to real estate located in Israel; (ii) the
capital gain arising from such sale, exchange or disposition is attributed to royalties; (iii) the capital gain arising from the such
sale, exchange or disposition is attributed to a permanent establishment in Israel, under certain terms; (iv) such U.S. Resident holds,
directly or indirectly, shares representing 10% or more of the voting capital during any part of the 12&#160;month period preceding the
disposition, subject to certain conditions; or (v) such U.S. Resident is an individual and was present in Israel for 183 days or more
during the relevant taxable year. In any such case, the sale, exchange or disposition of such shares by the U.S. Resident would be subject
to Israeli tax (unless exempt under the Israeli domestic law as described above). Under the U.S. Israel Tax Treaty, the gain may be treated
as foreign source income for United States foreign tax credit purposes, upon an election by the U.S. Resident, and such U.S. Resident
may be permitted to claim a credit for such taxes against the United States federal income tax imposed on such sale, subject to the limitations
under the United States federal income tax laws applicable to foreign tax credits. The U.S. Israel Tax Treaty does not provide such credit
against any United States state or local taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Regardless of whether securityholders
may be liable for Israeli tax on the sale of our securities, the payment of the consideration may be subject to the withholding of Israeli
tax at source. Securityholders may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding
at source at the time of sale (i.e., provide a non-Israeli&#160;resident certificate and other documentation).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Capital Gains Taxes Applicable to Israeli
Resident Securityholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An Israeli resident corporation
who derives capital gains from the sale of shares or warrants in an Israeli resident company will generally be subject to tax on the real
capital gains generated on such sale at the corporate tax rate (currently of 23%). An Israeli resident individual will generally be subject
to capital gain tax at the rate of 25%. However, if the individual securityholder is claiming deduction of interest expenditures or he
is a &#8220;substantial shareholder&#8221; at the time of the sale or at any time during the preceding twelve months period, such gain
will be taxed at the rate of 30%. Individual holders dealing in securities in Israel for whom the income from the sale of securities is
considered &#8220;business income&#8221; as defined in section 2(1) of the Ordinance are taxed at the marginal tax rates applicable to
business income (at a rate of up to 47% in 2025 (not including Surtax as discussed below)). Certain Israeli institutions who are exempt
from tax under section 9(2) or section 129(C)(a)(1) of the Ordinance (such as exempt trust funds and pension funds) may be exempt from
capital gains tax from the sale of the securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exercise of Warrants and Certain Adjustments
to the Warrants</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Purchasers will generally
not recognize gain or loss for Israeli tax purposes on the exercise of a Warrant and related receipt of an ordinary share (unless, for
instance, cash is received in lieu of the issuance of a fractional ordinary share). Nevertheless, the Israeli income tax treatment and
the tax consequences of a cashless exercise of Warrants into ordinary shares is unclear. Furthermore, the exercise terms of the Warrants
may be adjusted in certain circumstances. An adjustment to the number of ordinary shares that will be issued on the exercise of the Warrants
or an adjustment to the exercise price of a Warrant may be treated as a taxable event under Israeli tax law even if such holder does not
receive any cash or other property in connection with the adjustment. Purchasers should consult their tax advisors regarding the proper
treatment of any exercise of and/or adjustments to the Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of Israeli Shareholders on Receipt
of Dividends</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An Israeli resident individual
is generally subject to Israeli income tax on the receipt of dividends paid on our ordinary shares at the rate of 25%. With respect to
a person who is a &#8220;substantial shareholder&#8221; at the time of receiving the dividend or on any time during the preceding twelve
months, the applicable tax rate is 30%. Such dividends are generally subject to Israeli withholding tax at a rate of 25% if the shares
are registered with a nominee company (whether the recipient is a substantial shareholder or not). If the recipient of the dividend is
an Israeli resident corporation such dividend income will be exempt from tax provided the income from which such dividend is distributed
was derived or accrued within Israel and was received directly or indirectly from another corporation that is liable to Israeli corporate
tax. An exempt trust fund, pension fund or other entity that is exempt from tax under section 9(2) or section 129C(a)(1) of the Ordinance
is exempt from tax on a dividend.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Dividend distribution by
a Preferred Technology Enterprise or a Special Preferred Technology Enterprise is subject to beneficial withholding tax rates. For a further
discussion, see &#8220;Taxation and Government Programs&#8212;Israeli Tax Considerations&#8212;Law for the Encouragement of Capital Investments,
5719-1959&#8212;New Tax Benefits Under the 2017 Amendment that Became Effective on January&#160;1, 2017.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of Non-Israeli Shareholders on
Receipt of Dividends</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Non-Israeli&#160;residents
(either individuals or corporations) are generally subject to Israeli income tax on the receipt of dividends paid on our ordinary shares
at the rate of 25%, which tax will be withheld at source, unless relief is provided in a treaty between Israel and the shareholder&#8217;s
country of residence. With respect to a person who is a &#8220;substantial shareholder&#8221; at the time of receiving the dividend or
on any time during the preceding twelve months, the applicable tax rate is 30%. Such dividends are generally subject to Israeli withholding
tax at a rate of 25% if the shares are registered with a nominee company (whether the recipient is a substantial shareholder or not),
unless a reduced rate is provided under an applicable tax treaty (subject to the receipt in advance of a valid certificate from the ITA
allowing for a reduced tax rate). For example, under the U.S. Israel Tax Treaty, the maximum rate of tax withheld at source in Israel
on dividends paid to a holder of our ordinary shares who is a U.S. Resident is 25%. However, generally, the maximum rate of withholding
tax on dividends, not generated by a Preferred Technological Enterprise, Preferred Enterprise, Approved Enterprise or Beneficial Enterprise,
that are paid to a United States corporation holding 10% or more of the outstanding voting capital throughout the tax year in which the
dividend is distributed as well as during the previous tax year, is 12.5%, provided that not more than 25% of the gross income for such
preceding year consists of certain types of dividends and interest. Notwithstanding the foregoing, dividends distributed from income attributed
to an Approved Enterprise, Preferred Technological Enterprise, Benefited Enterprise or Preferred Enterprise are not entitled to such reduction
under the tax treaty but are subject to a withholding tax rate of 15% for a shareholder that is a U.S. corporation, provided that the
conditions related to the outstanding voting rights and the gross income for the previous year (as set forth in the previous sentences)
are met. If the dividend is attributable partly to income derived from an Approved Enterprise, Preferred Technological Enterprise, Benefited
Enterprise or Preferred Enterprise, and partly to other sources of income, the withholding rate may be a blended rate reflecting the relative
portions of the two types of income. We cannot assure you that we will designate the profits that we may distribute in a way that will
reduce shareholders&#8217; tax liability. Application for the reduced tax rate requires appropriate documentation presented and specific
instruction received from the ITA. To the extent tax is withheld at source at the maximum rates (see above), a qualified tax treaty recipient
will have to comply with some administrative procedures with the ITA in order to receive a refund of any excess tax withheld.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A foreign resident who had
income from a dividend that was accrued from Israeli source, from which (among other conditions) the full tax was deducted, will be exempt
from filing a tax return in Israel, unless (i)&#160;such income was generated from a business conducted in Israel by such foreign resident,
(ii)&#160;such foreign resident has other taxable sources of income in Israel with respect to which a tax return is required to be filed,
or (iii) such foreign resident is liable to Surtax (see below) in accordance with section 121B of the Ordinance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Dividend distribution by
a Preferred Technology Enterprise or a Special Preferred Technology Enterprise is subject to beneficial withholding tax rates. For a further
discussion, see &#8220;Taxation and Government Programs&#8212;Israeli Tax Considerations&#8212;Law for the Encouragement of Capital Investments,
5719-1959&#8212;New Tax benefits Under the 2017 Amendment that Became Effective on January&#160;1, 2017.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Surtax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Individual holders who are
subject to tax in Israel (whether any such individual is an Israeli resident or non-Israeli resident) are also subject to an additional
tax at a rate of 3% on annual income, including, but not limited to, income derived from dividends, interest and capital gains, exceeding
a certain threshold (currently NIS 721,560 for years 2024 through 2027, which amount will be updated annually starting January 1, 2028,
based on the change in the Israeli consumer price index) (the &#8220;Threshold Amount&#8221;). An additional 2% tax applies to &#8220;capital
income&#8221; earned as of January 1, 2025 (including capital gains, dividends, and interest) exceeding the Threshold Amount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Estate and Gift Tax</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Israeli law presently does
not impose estate or gift taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Certain Material United States Federal Income
Tax Considerations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following discussion
describes certain material United States federal income tax considerations relating to the acquisition, ownership, and disposition of
ordinary shares and Warrants by a U.S. Holder (as defined below) and holds them as a capital asset. This discussion is based on the tax
laws of the United States, including the Code, the United States Department of the Treasury, or Treasury, regulations promulgated or proposed
thereunder, administrative and judicial interpretations thereof, and the United States-Israel income tax treaty all as in effect on the
date hereof. These tax laws are subject to change, possibly with retroactive effect, and subject to differing interpretations that could
affect the tax consequences described herein. This discussion does not address the tax consequences to a U.S. Holder under the laws of
any state, local or foreign taxing jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For purposes of this discussion,
a &#8220;U.S. Holder&#8221; is a beneficial owner of our ordinary shares or Warrants that, for United States federal income tax purposes,
is:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual who is a citizen or resident of the United States;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a corporation or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States, any state thereof, or the District of Columbia corporation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate the income of which is subject to United States federal income taxation regardless of its source; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust if (1) a court within the United States is able to exercise primary supervision over the trust&#8217;s administration and one or more United States persons have the authority to control all substantial decisions of the trust or (2) a valid election under the Treasury regulations is in effect for the trust to be treated as a United States person.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This discussion does not
address all aspects of United States federal income taxation that may be applicable to U.S. Holders in light of their particular circumstances
or status (including, for example, banks and other financial institutions, insurance companies, broker and dealers in securities or currencies,
traders in securities that have elected to mark securities to market, regulated investment companies, real estate investment trusts, grantor
trusts, partnerships or other pass-through&#160;entities and arrangements, corporations that accumulate earnings to avoid U.S. federal
income tax, tax-exempt&#160;organizations, pension plans, persons that own or who are treated as constructively owning 10&#160;percent
or more of our stock by vote or by value, persons who expatriates out of the United States or former long-term residents of the United
States, persons who acquired our ordinary shares or Warrants in connection with employment or other performance of services, persons that
hold our ordinary shares or Warrants as part of a straddle, hedge or other integrated investment, and persons subject to alternative minimum
tax or whose &#8220;functional currency&#8221; is not the U.S. dollar).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If a partnership (including
any entity or arrangement treated as a partnership for United States federal income tax purposes) holds our ordinary shares or Warrants
the tax treatment of a person treated as a partner in the partnership for United States federal income tax purposes generally will depend
on the status of the partner and the activities of the partnership. Partnerships (and other entities or arrangements so treated for United
States federal income tax purposes) and their partners should consult their own tax advisors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>This discussion addresses
only U.S. Holders and does not discuss any tax considerations other than United States federal income tax considerations. Investors are
urged to consult their own tax advisors regarding the United States federal, state, and local, and non-United&#160;States tax consequences
of the purchase, ownership, and disposition of our ordinary shares and Warrants.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exercise or Expiration of Warrants</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In general, a U.S. Holder
will not recognize gain or loss for U.S. federal income tax purposes upon exercise of a Warrant. A U.S. Holder will take a tax basis in
the ordinary shares acquired on the exercise of a Warrant equal to the exercise price of the Warrant, increased by such U.S. Holder&#8217;s
adjusted tax basis in the Warrant exercised. Subject to the PFIC, rules discussed below, such U.S. Holder&#8217;s holding period in the
ordinary shares acquired on exercise of the Warrant will begin on the date of exercise of the Warrant and will not include any period
for which such U.S. Holder held the Warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The lapse or expiration of
a Warrant generally will be treated as if the U.S. Holder sold or exchanged the Warrant and recognized a capital loss equal to the U.S.
Holder&#8217;s adjusted tax basis in the Warrant. The deductibility of capital losses is subject to limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The tax consequences of a
cashless exercise of Warrants are unclear and could differ from the consequences described above. It is possible that a cashless exercise
could be a taxable event. U.S. Holders should consult their own tax advisors regarding the U.S. federal income tax consequences of the
cashless exercise of Warrants, including with respect to whether the exercise is a taxable event, and their holding period and tax basis
in the ordinary shares received.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not expect to make
any distribution with respect to our ordinary shares. However, if we make any such distribution, under the United States federal income
tax laws, and subject to the PFIC rules discussed below, the gross amount of any dividend we pay out of our current or accumulated earnings
and profits (as determined for United States federal income tax purposes) will be includible in income for a U.S.&#160;Holder and subject
to United States federal income taxation. Dividends paid to a noncorporate U.S. Holder that constitute qualified dividend income will
be taxable at a preferential tax rate applicable to long-term&#160;capital gains of, currently, 20 percent, provided that the U.S. Holder
holds the ordinary shares for more than 60 days during the 121-day&#160;period beginning 60 days before the ex-dividend&#160;date and
meets other holding period requirements. If we are treated as a PFIC, dividends paid to a U.S. Holder will not be treated as qualified
dividend income. If we are not treated as a PFIC, dividends we pay with respect to the ordinary shares generally will be qualified dividend
income, provided that the holding period requirements are satisfied by the U.S. Holder and in the year that the U.S. Holder receives the
dividend, our ordinary shares are readily tradable on an established securities market in the United States or we are eligible for benefits
under the United States-Israel income tax treaty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A U.S. Holder must include
any Israeli tax withheld from the dividend payment in the gross amount of the dividend even though the U. S. Holder does not in fact receive
it. The dividend is taxable to the U.S. Holder when the U.S. Holder of ordinary shares receives the dividend, actually or constructively.
Because we are not a United States corporation, the dividend will not be eligible for the dividends-received&#160;deduction generally
allowed to United States corporations in respect of dividends received from other United States corporations. The amount of the dividend
distribution includible in a U.S. Holder&#8217;s income will be the U.S. dollar value of the NIS payments made, determined at the spot
NIS/U.S. dollar rate on the date the dividend distribution is includible in income, regardless of whether the payment is in fact converted
into U.S. dollars. Generally, any gain or loss resulting from currency exchange fluctuations during the period from the date the dividend
payment is included in income to the date the payment is converted into U.S. dollars will be treated as ordinary income or loss and will
not be eligible for the special tax rate applicable to qualified dividend income. The gain or loss generally will be income or loss from
sources within the United States for foreign tax credit limitation purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to certain significant
conditions and limitations, including potential limitations under the United States-Israel income tax treaty, the non-refundable Israeli
tax withheld in accordance with the United States - Israel income tax treaty and paid over to Israel may be creditable or deductible against
a U.S. Holder&#8217;s United States federal income tax liability, if the U.S. Holder satisfies certain minimum holding period requirements.
The election to credit or deduct foreign taxes is made on a year-by-year basis and applies to all foreign taxes paid by a U.S. Holder
or withheld from a U.S. Holder that year. Dividends that we distribute generally should constitute &#8220;passive category income,&#8221;
or, in the case of certain U.S. Holders, &#8220;general category income&#8221; for foreign tax credit limitation purposes. As a result
of recent changes to the U.S. foreign tax credit rules, a withholding tax may need to satisfy certain additional requirements in order
to be considered a creditable tax for a U.S. Holder. We have not determined whether these requirements have been met and, accordingly,
no assurance can be given that any withholding tax on dividends paid by us will be creditable. The rules relating to the determination
of the foreign tax credit limitation are complex, and U.S. Holders should consult their tax advisor to determine whether and to what extent
they will be entitled to a credit for Israeli withholding taxes imposed in respect of any dividend we distribute.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To the extent a distribution
with respect to our ordinary shares exceeds our current or accumulated earnings and profits, as determined under United States federal
income tax principles, the distribution will be treated, first, as a tax-free&#160;return of the U.S. Holder&#8217;s investment, up to
the U.S. Holder&#8217;s adjusted tax basis in its ordinary shares, and, thereafter, as capital gain, which is subject to the tax treatment
described below in&#8221;&#8212;Gain on Sale, Exchange or Other Taxable Disposition of our Ordinary Shares or Warrants.&#8221; We may
not calculate our earnings and profits under United States federal income tax principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Gain on Sale, Exchange or Other Taxable Disposition
of our Ordinary Shares or Warrants</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the PFIC rules
described below under &#8220;<b><i>&#8212;&#160;</i></b>Passive Foreign Investment<b><i>&#160;</i></b>Company Considerations,&#8221; a
U.S. Holder that sells, exchanges or otherwise disposes of ordinary shares or Warrants in a taxable disposition generally will recognize
capital gain or loss for United States federal income tax purposes equal to the difference between the U.S.&#160;Dollar value of the amount
realized and the U.S. Holder&#8217;s tax basis, determined in U.S. Dollars, in the ordinary shares or Warrants. Gain or loss recognized
on such a sale, exchange or other disposition of ordinary shares or Warrants generally will be long-term&#160;capital gain if the U.S.
Holder&#8217;s holding period in the ordinary shares or Warrants exceeds one year. Long-term&#160;capital gains of non-corporate&#160;U.S.
Holders are generally taxed at preferential rates. The gain or loss generally will be income or loss from sources within the United States
for foreign tax credit limitation purposes. A U.S. Holder&#8217;s ability to deduct capital losses is subject to limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Passive Foreign Investment Company Considerations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based on our income and assets,
we expect to be a PFIC for the preceding taxable year and expect to be a PFIC for the current taxable year. Because the determination
of our PFIC status is made based on the factual tests described below, however, we cannot provide any assurances regarding our PFIC status
for the current or future taxable years or that the IRS will agree with our conclusion regarding our PFIC status. If we were classified
as a PFIC in any taxable year, a U.S. Holder would be subject to special rules with respect to distributions on and sales, exchanges and
other dispositions of the ordinary shares or Warrants. We will be treated as a PFIC for any taxable year in which at least 75 percent
of our gross income is &#8220;passive income&#8221; or at least 50 percent of our gross assets during the taxable year (based on the average
of the fair market values of the assets determined at the end of each quarterly period) are assets that produce or are held for the production
of passive income. Passive income for this purpose generally includes, among other things, dividends, interest, rents, royalties, gains
from commodities and securities transactions, and gains from assets that produce passive income. Passive income also includes amounts
derived by reason of the temporary investment of funds, including those raised in a public offering. However, rents and royalties received
from unrelated parties in connection with the active conduct of a trade or business are not considered passive income for purposes of
the PFIC test. In determining whether we are a PFIC, a pro rata portion of the income and assets of each corporation in which we own,
directly or indirectly, at least a 25% interest (by value) is taken into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Excess Distribution Rules</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we were a PFIC with respect
to a U.S. Holder, then unless the holder makes one of the elections described below, a special tax regime would apply to the U.S. Holder
with respect to (a) any &#8220;excess distribution&#8221; (generally, aggregate distributions in any year that are greater than 125% of
the average annual distribution received by the U.S. Holder in the shorter of the three preceding years or the U. S. Holder&#8217;s holding
period for the ordinary shares) and (b) any gain realized on the sale or other disposition of the ordinary shares or Warrants. Under this
regime, any excess distribution and realized gain will be treated as ordinary income and will be subject to tax as if (a) the excess distribution
or gain had been realized ratably over the U.S. Holder&#8217;s holding period, (b) the amount deemed realized in each year had been subject
to tax in each year of that holding period at the highest marginal rate for such year (other than income allocated to the current period
or any taxable period before we became a PFIC, which would be subject to tax at the U.S. Holder&#8217;s regular ordinary income rate for
the current year and would not be subject to the interest charge discussed below), and (c) the interest charge generally applicable to
underpayments of tax had been imposed on the taxes deemed to have been payable in those years. In addition, dividend distributions would
not qualify for the lower rates of taxation applicable to long-term&#160;capital gains discussed above under &#8220;Dividends.&#8221;
For ordinary shares acquired pursuant to the exercise of Warrants, a U.S. Holder&#8217;s holding period will for this purpose include
the holding period of such Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we are treated as a PFIC
for any taxable year during the holding period of a non-electing U.S. Holder (i.e., a U.S. Holder that does not elect to be taxed under
one of the alternative regimes discussed below), we will continue to be treated as a PFIC for all succeeding years during which such non-electing
U.S. Holder is treated as a direct or indirect non-electing U.S. Holder even if we are not a PFIC for such years. A U.S. Holder is encouraged
to consult its tax advisor with respect to any available elections that may be applicable in such a situation, including the &#8220;deemed
sale&#8221; election of Code Section 1298(b)(1) (which will be taxed under the adverse tax rules described above).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain elections by a U.S.
Holder would alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment of the ordinary shares,
as described below. However, these elections are not available with respect to the Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>QEF Election</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we were a PFIC, the rules
above would not apply to a U.S. Holder that makes an election to treat our ordinary shares as stock of a QEF. A U.S. Holder that makes
a QEF election is required to include in income its pro rata share of our ordinary earnings and net capital gain as ordinary income and
long-term&#160;capital gain, respectively, subject to a separate election to defer payment of taxes, which deferral is subject to an interest
charge. A U.S. Holder makes a QEF election generally by attaching a completed IRS Form 8621 (Information Return by a Shareholder of a
Passive Foreign Investment Company or Qualified Electing Fund), or IRS Form 8621, to a timely filed United States federal income tax return
for the year beginning with which the QEF election is to be effective (taking into account any extensions). A QEF election can be revoked
only with the consent of the IRS. In order for a U.S. Holder to make a valid QEF election, we must annually provide or make available
to the U.S. Holder certain information. While we intend to provide to U.S. Holders the information required to make a valid QEF election,
upon request, we cannot provide any assurances that we will have timely knowledge of our status as a PFIC, or that the information that
we provide will be adequate to allow U.S. Holders to make a QEF election. A QEF election is not available for Warrants regardless of whether
we provide such information</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Mark-to-Market Election</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we were a PFIC, the rules
above also would not apply to a U.S. Holder that makes a &#8220;mark-to-market&#8221; election with respect to the ordinary shares, but
this election will be available with respect to the ordinary shares only if they meet certain minimum trading requirements to be considered
&#8220;marketable stock&#8221; for purposes of the PFIC rules. A mark-to-market&#160;election is not available for Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Ordinary shares will be marketable
stock if they are regularly traded on a national securities exchange that is registered with the Securities and Exchange Commission or
on a non-U.S. exchange or market that meets certain requirements under the Treasury regulations. Ordinary shares generally will be considered
regularly traded during any calendar year during which they are traded, other than in&#160;<i>de minimis</i>&#160;quantities, on at least
15 days during each calendar quarter. Any trades that have as their principal purpose meeting this requirement will be disregarded.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A U.S. Holder that makes
a valid mark-to-market&#160;election for the first tax year in which the U.S. Holder holds (or is deemed to hold) our ordinary shares
and for which we are a PFIC will be required to include each year an amount equal to the excess, if any, of the fair market value of such
shares the holder owns as of the close of the taxable year over the U.S. Holder&#8217;s adjusted tax basis in such shares. The U.S. Holder
will be entitled to a deduction for the excess, if any, of the U.S. Holder&#8217;s adjusted tax basis in the ordinary shares over the
fair market value of such shares as of the close of the taxable year, but only to the extent of any net mark-to-market&#160;gains with
respect to such shares included by the U.S. Holder under the election for prior taxable years. The U.S. Holder&#8217;s basis in such ordinary
shares will be adjusted to reflect the amounts included or deducted pursuant to the election. Amounts included in income pursuant to a
mark-to-market&#160;election, as well as gain on the sale, exchange or other taxable disposition of such ordinary shares, will be treated
as ordinary income. The deductible portion of any mark-to-market&#160;loss, as well as loss on a sale, exchange or other disposition of
our ordinary shares to the extent that the amount of such loss does not exceed net mark-to-market&#160;gains previously included in income,
will be treated as ordinary loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The mark-to-market&#160;election
applies to the taxable year for which the election is made and all subsequent taxable years, unless the ordinary shares cease to be treated
as marketable stock for purposes of the PFIC rules or the IRS consents to its revocation. The excess distribution rules described above
generally will not apply to a U.S. Holder for tax years for which a mark-to-market&#160;election is in effect. However, if we were a PFIC
for any year in which the U.S. Holder owns the ordinary shares but before a mark-to-market&#160;election is made, the interest charge
rules described above would apply to any mark-to-market&#160;gain recognized in the year the election is made.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PFIC Reporting Obligations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A U.S. Holder of PFIC shares
or Warrants must generally file an annual information return on IRS Form 8621 containing such information as the Treasury may require.
The failure to file IRS Form 8621 could result in the imposition of penalties and the extension of the statute of limitations with respect
to U.S. federal income tax.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>U.S. Holders are urged
to consult their tax advisors as to our status as a PFIC, and the tax consequences to them if we were a PFIC, including the reporting
requirements and the desirability of making, and the availability of, a QEF election or a mark-to-market&#160;election with respect to
the ordinary shares or Warrants<i>.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Medicare Tax</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Non-corporate&#160;U.S. Holders
that are individuals, estates or trusts and whose income exceeds certain thresholds generally are subject to a 3.8% tax on all or a portion
of their net investment income, which may include their gross dividend income and net gains from the disposition of ordinary shares or
Warrants. A United States person that is an individual, estate or trust is encouraged to consult its tax advisors regarding the applicability
of this Medicare tax to its income and gains in respect of any investment in our ordinary shares and Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Certain Information Reporting with Respect
to Foreign Financial Assets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain U.S. Holders may
be required to file IRS Form 926, Return by U.S. Transferor of Property to a Foreign Corporation, and IRS Form 5471, Information Return
of U.S. Persons With Respect to Certain Foreign Corporations, reporting transfers of cash or other property to us and information relating
to the U.S. Holder and us. Substantial penalties may be imposed upon a U.S. Holder that fails to comply. See also the discussion regarding
Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund, above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Individual U.S. Holders may
be subject to certain reporting obligations on IRS Form 8938 (Statement of Specified Foreign Financial Asset) with respect to the ordinary
shares or Warrants for any taxable year during which the U.S.&#160;Holder&#8217;s aggregate value of these and certain other &#8220;specified
foreign financial assets&#8221; exceed a threshold amount that varies with the filing status of the individual. This reporting obligation
also applies to domestic entities formed or availed of to hold, directly or indirectly, specified foreign financial assets, including
the ordinary shares and Warrants. Significant penalties can apply if U.S. Holders are required to make this disclosure and fail to do
so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Information Reporting and Backup Withholding</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In general, information reporting,
on IRS Form 1099, will apply to dividends in respect of ordinary shares and the proceeds from the sale, exchange or redemption of ordinary
shares or Warrants that are paid to a U.S. Holder of ordinary shares or Warrants within the United States (and in certain cases, outside
the United States), unless such U.S. Holder is an exempt recipient such as a corporation. Backup withholding (currently at a 24% rate)
may apply to such payments if a U.S. Holder of ordinary shares or Warrants fails to provide a taxpayer identification number (generally
on an IRS Form W-9) or certification of other exempt status or fails to report in full dividend and interest income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Backup withholding is not
an additional tax. A U.S. Holder generally may obtain a refund of any amounts withheld under the backup withholding rules that exceed
the U.S. Holder&#8217;s income tax liability by filing a refund claim with the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b>The discussion above is
a general summary and is not intended to constitute a complete analysis of all tax consequences relating to the purchase, ownership and
disposition of our ordinary shares or Warrants. It does not cover all tax matters that may be of importance to a U.S. Holder. U.S. Holders
should consult their own tax advisors concerning the tax consequences relating to the purchase, ownership and disposition of our ordinary
shares or Warrants.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>F. Dividends and Paying Agents</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>G. Statement by Experts</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>H. Documents on Display</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are subject to the information
reporting requirements of the Exchange Act, applicable to foreign private issuers, and under those requirements, we file reports with
the SEC. Our filings with the SEC are available to the public through the SEC&#8217;s website at http://website at http://www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a foreign private issuer,
we are exempt from the rules under the Exchange Act, related to the furnishing and content of proxy statements, and our officers, directors
and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange
Act. In addition, we are not required under the Exchange Act, to file annual, quarterly and current reports and financial statements with
the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we are required
to comply with the informational requirements of the Exchange Act, and, accordingly, file current reports on Form 6-K, annual reports
on Form 20-F and other information with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>I. Subsidiary Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>J. Annual Report to Security Holders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES
ABOUT MARKET RISK</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Market risk is the risk of
loss related to changes in market prices, including interest rates and foreign exchange rates, of financial instruments that may adversely
impact our financial position, results of operations or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Foreign Currency Exchange Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The U.S. dollar is our functional
and reporting currency. However, a significant portion of our operating expenses are incurred in NIS. As a result, we are exposed to the
risk that the NIS may appreciate relative to the dollar, or, if the NIS instead devalues relative to the dollar, that the inflation rate
in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In
any such event, the dollar cost of our operations in Israel would increase and our dollar-denominated&#160;results of operations would
be adversely affected. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation, if any, of the
NIS against the dollar. For example, the dollar strengthened against the NIS in 2022, 2023 and 2024 by 12.5%, 3.0% and 0.55%, respectively.
If the dollar cost of our operations in Israel increases, our dollar-measured&#160;results of operations will be adversely affected. Our
operations also could be adversely affected if we are unable to effectively hedge against currency fluctuations in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Moreover, for the first few
years after we are able to successfully commercialize one of our product candidates, we expect that the substantial majority of our revenues
from the sale of our products in the United States, if any, will be denominated in U.S. dollars. Since a portion of our expenses is denominated
in NIS and other non-U.S. currencies, we are exposed to risk associated with exchange rate fluctuations vis-&#224;-vis&#160;the non-U.S.
currencies. See &#8220;Risk Factors&#8212;Exchange rate fluctuations between the U.S. Dollar and the New Israeli Shekel may negatively
affect our earnings.&#8221; If the NIS fluctuates significantly against the U.S. dollar it may have a negative impact on our results of
operations. As of the date of this annual report and for the periods under review, fluctuations in the currencies exchange rates have
not materially affected our results of operations or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not hedge our foreign
currency exchange risk. In the future, we may enter into formal currency hedging transactions to decrease the risk of financial exposure
from fluctuations in the exchange rates of our principal operating currencies. These measures, however, may not adequately protect us
from the material adverse effects of such fluctuations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Liquidity Risk</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We monitor forecasts of our
liquidity reserve (comprising cash and cash equivalents and deposits). We generally carry this out based on our expected cash flows in
accordance with practice and limits set by our management. We are in the research and development stage and we are therefore exposed to
liquidity risk. We believe that our existing cash, cash equivalents and short-term deposits will not be sufficient to fund our operations
for a period of at least 12 months from the date of approval of our consolidated financial statements. We expect that we will require
additional capital to complete clinical trials, obtain regulatory approval for, and commercialize, our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN
EQUITY SECURITIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A. Debt Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>B. Warrants and Rights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Warrants entitle the
registered holders to purchase ordinary shares at a price equal to $6.00 per share, subject to adjustment as discussed below, immediately
following the issuance of such Warrants and terminating at 5:00 p.m., New York City time, five years after the closing of our initial
public offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The exercise price and number
of ordinary shares issuable upon exercise of the Warrants may be adjusted in certain circumstances, including in the event of a stock
dividend or recapitalization, reorganization, merger or consolidation. However, the Warrants will not be adjusted for issuances of ordinary
shares at prices below its exercise price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Exercisability</i>. The
Warrants are exercisable immediately upon issuance and at any time up to the date that is five years from the date of issuance. The Warrants
are exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and payment in
full for the number of ordinary shares purchased upon such exercise. Each Warrant entitles the holder thereof to purchase one ordinary
share. Warrants are not exercisable for a fraction of a share and may only be exercised into whole numbers of shares. In lieu of fractional
shares, we will, pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price and round down to the
nearest whole share. Unless otherwise specified in the Warrant, the holder will not have the right to exercise the Warrants, in whole
or in part, if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or 9.99% at the holder&#8217;s election)
of the number of our ordinary shares outstanding immediately after giving effect to the exercise, as such percentage is determined in
accordance with the terms of the Warrant. However, any holder may increase or decrease such percentage to any other percentage not in
excess of 9.99% upon at least 61 days&#8217; prior notice from the holder to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Exercise Price</i>. The
exercise price per ordinary share purchasable upon exercise of the Warrants is $6.00, and is subject to adjustments for stock splits,
reclassifications, subdivisions, and other similar transactions. In addition to the exercise price per ordinary share, and other applicable
charges and taxes are due and payable upon exercise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Warrant Agent; Global
Certificate</i>. The Warrants were issued in registered form under a warrant agency agreement between a warrant agent and us. The Warrants
will initially be represented only by one or more global warrants deposited with the warrant agent, as custodian on behalf of The Depository
Trust Company, or DTC, and registered in the name of Cede &amp; Co., a nominee of DTC, or as otherwise directed by DTC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Transferability</i>. Subject
to applicable laws, the Warrants may be transferred at the option of the holders upon surrender of the Warrants to the warrant agent,
together with the appropriate instruments of transfer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Adjustments; Fundamental
Transaction</i>. The exercise price and the number of shares underlying the Warrants are subject to appropriate adjustment in the event
of stock splits, stock dividends on our ordinary shares, stock combinations or similar events affecting our ordinary shares. In addition,
in the event we consummate a merger or consolidation with or into another person or other reorganization event in which our ordinary shares
are converted or exchanged for securities, cash or other property, or we sell, lease, license, assign, transfer, convey or otherwise dispose
of all or substantially all of our assets or we or another person acquire 50% or more of our outstanding ordinary shares (each, a Fundamental
Transaction), then following such Fundamental Transaction the holders of the Warrants will be entitled to receive upon exercise of the
Warrants the same kind and amount of securities, cash or property which the holders would have received had they exercised the Warrants
immediately prior to such Fundamental Transaction. Any successor to us or surviving entity will assume the obligations under the Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Rights as a Shareholder</i>.
Except by virtue of such holder&#8217;s ownership of our ordinary shares, the holder of a Warrant does not have rights or privileges of
a shareholder, including any voting rights, until the holder exercises such Warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>Redemption. </i>The Warrants
are callable by us in certain circumstances. Subject to certain exceptions, if, after 13 months from the initial exercise date of the
Warrants, (i) the volume weighted average price of our ordinary shares for 10 consecutive trading days, or the Measurement Period, which
Measurement Period shall not have commenced until 13 months after the initial exercise date of the Warrants, exceeds 300% of the then
exercise price, (ii) the average daily trading volume of our ordinary shares for such Measurement Period exceeds $1,000,000 per trading
day, and (iii) the holders of the Warrants are not in possession of any information that constitutes or might constitute, material non-public
information which was provided by us, then we may, within one trading day of the end of such Measurement Period, upon notice to the holders
of the Warrants, a Call Notice, call for cancellation of all of the Warrants for which a notice of exercise has not yet been delivered,
or a Call, for consideration equal to $0.001 per warrant share. Any portion of a Warrant subject to such Call Notice for which a notice
of exercise shall not have been received by us on the Call Date will be cancelled at 6:30 p.m. (New York City time) on the thirtieth day
after the date the Call Notice is received by the holder. Our right to call the Warrants will be exercised with respect to all of the
then issued and outstanding Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>C. Other Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>D. American Depositary Shares</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND
DELINQUENCIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS
OF SECURITY HOLDERS AND USE OF PROCEEDS </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In December 2021, we completed
our initial public offering and issued 2,000,000 units, each consisting of one ordinary share and a warrant representing the right to
purchase one ordinary share with an exercise price of&#160;$6.00 per share, at an initial public offering price of&#160;$6.00&#160;per
unit. In addition, the underwriter partially exercised its overallotment option and purchased an additional 300,000 warrants, each representing
the right to purchase one ordinary share.&#160;We received net proceeds of approximately&#160;$9.9 million (&#8220;IPO proceeds&#8221;),
after deducting underwriting discounts and commissions and estimated offering expenses. In March 2022, we received proceeds of $3.87 million
from exercise of 645,000 Warrants at a price per share of $6.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We used a portion of our
IPO proceeds through December 31, 2023 proceeds to advance the clinical development of our lead product candidate, for preclinical research
and development and for working capital and general corporate purposes. Other than director fees to directors and compensation to Alon-Ben
Noon for his services as the Company&#8217;s chief executive officer, none of the net proceeds of our offering have been paid directly
or indirectly to any of our directors or executive officers, to their associates, persons owning ten percent or more of any class of our
equity securities, or to any of our affiliates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 15. CONTROLS AND PROCEDURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) <span style="text-decoration:underline">Disclosure Controls and Procedures</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We performed an evaluation
of the effectiveness of our disclosure controls and procedures that are designed to ensure that information required to be disclosed and
filed with the SEC is recorded, processed, summarized and reported timely within the time period specified in the SEC&#8217;s rules and
forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required
to be disclosed by us in the reports that we file or submit under the Exchange Act, is accumulated and communicated to our management,
including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely
decisions regarding required disclosure. There can be no assurance that our disclosure controls and procedures will detect or uncover
all failures of persons within the company to disclose information otherwise required to be set forth in our reports. Nevertheless, our
disclosure controls and procedures are designed to provide reasonable assurance of achieving the desired control objectives. Based on
our evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, have concluded that our disclosure
controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this
report are effective at such reasonable assurance level.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) <span style="text-decoration:underline">Management&#8217;s Annual Report on
Internal Control over Financial Reporting</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our management, under the
supervision of our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal
control over our financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act of 1934, as amended. The Company&#8217;s
internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
Internal control over financial reporting includes policies and procedures that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.35pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and asset dispositions</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide reasonable assurance that transactions are recorded as necessary to permit the preparation of our financial statements in accordance with generally accepted accounting principles</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide reasonable assurance that receipts and expenditures are made only in accordance with authorizations of our management and board of directors (as appropriate); and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Due to its inherent limitations,
internal control over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the supervision and
with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we assessed the effectiveness
of our internal control over financial reporting as of December 31, 2024 based on the framework for Internal Control-Integrated Framework
set forth by The Committee of Sponsoring Organizations of the Treadway Commission (COSO) (2013).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based on our assessment and
this framework, our management concluded that the Company&#8217;s internal control over financial reporting was effective as of December
31, 2024.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(c) <span style="text-decoration:underline">Attestation Report of Registered Public
Accounting Firm</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This Annual Report does not
include an attestation report of our registered public accounting firm due to our status as an emerging growth company and, accordingly,
are exempt from the requirement to provide such a report</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(d) <span style="text-decoration:underline">Changes in Internal Controls Over Financial
Reporting</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There were no changes in
our internal control over financial reporting that occurred during the year ended December 31, 2024 that have materially affected or are
reasonably likely to materially affect our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16. [RESERVED]</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our board of directors has
determined that Mr.&#160;Claiborne is an audit committee financial expert as defined by the SEC rules and has the requisite financial
experience as defined by the corporate governance rules of Nasdaq.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16B. CODE OF ETHICS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have adopted a code of
ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons
performing similar functions.&#160;This code of ethics is posted on our website at https://neurosense.investorroom.com/governance-documents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Fees Paid to Independent Registered Public
Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets
forth, for each of the years indicated, the aggregate fees billed by our independent registered public accounting firm Somekh Chaikin,
Tel Aviv, Israel, ID 1057 for professional services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Services Rendered</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(U.S. dollars in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Audit Fees (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">238</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">170</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Audit Related Fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Tax Fees (2)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">All Other Fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">249</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">177</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.1pt; text-align: justify; text-indent: -27pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Includes professional services rendered in connection with the audit of our annual financial statements, review of our interim financial statements, and fees relating to regulatory filings including review of registration statements. (2) Tax fees are the aggregate fees for professional services rendered during the period for tax compliance and tax advice other than in connection with the audit.</i></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.1pt; text-align: justify; text-indent: -27pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.1pt; text-align: justify; text-indent: -27pt"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.1pt; text-align: justify; text-indent: -27pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Audit Committee Pre-Approval Policies and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our audit committee&#8217;s
specific responsibilities in carrying out its oversight of the quality and integrity of the accounting, auditing and reporting practices
of the Company include the approval of audit and non-audit services to be provided by the external auditor. The audit committee approves
in advance the particular services or categories of services to be provided to the Company during the following yearly period and also
sets forth a specific budget for such audit and non-audit services. Additional non-audit services may be pre-approved by the audit committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS
FOR AUDIT COMMITTEES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16E. PURCHASES OF EQUITY SECURITIES BY
THE ISSUER AND AFFILIATED PURCHASERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING
ACCOUNTANT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16G. CORPORATE GOVERNANCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As an Israeli company, we
are subject to various corporate governance requirements under the Companies Law, relating to matters such as external directors, the
audit committee, the compensation committee and an internal auditor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a foreign private issuer,
we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors
and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the
Exchange Act. Also, we are not required to comply with Regulation FD, which restricts the selective disclosure of material information,
although we have voluntarily adopted a corporate disclosure policy substantially similar to Regulation FD</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a foreign private issuer
whose shares are listed on The Nasdaq Capital Market, we are permitted to follow certain home country corporate governance practices instead
of certain requirements of the rules of The Nasdaq Capital Market. We are permitted to comply with Israeli corporate governance practices
instead of the Nasdaq corporate governance rules, provided that we disclose which requirements we are not following and the equivalent
Israeli requirement. Pursuant to this &#8220;home country practice exemption&#8221; with respect to the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we follow the quorum requirement for shareholder meetings. As permitted under the Companies Law, pursuant to our amended and restated articles of association, the quorum required for an ordinary meeting of shareholders will consist of at least two shareholders present in person, by proxy or by other voting instrument in accordance with the Companies Law, who hold at least 25% of the voting power of its shares (and in an adjourned meeting, with some exceptions, any number of shareholders), instead of 33<sup>1/3</sup>% of the issued share capital required under the Nasdaq corporate governance rules;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we intend to adopt and approve material changes to equity incentive plans in accordance with the Companies Law which does not impose a requirement of shareholder approval for such actions. In addition, we intend to follow Israeli corporate governance practice instead of the Nasdaq corporate governance rule which requires shareholder approval prior to an issuance of securities in connection with equity-based&#160;compensation of officers, directors, employees, or consultants;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we also intend to follow Israeli corporate governance practice instead of the Nasdaq corporate governance rule requiring shareholder approval for certain dilutive events (such as issuances that will result in a change of control, certain transactions other than a public offering involving issuances of a 20% or greater interest in us and certain acquisitions of the stock or assets of another company); and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as permitted by the Companies Law, our board of directors selects director nominees, and we do not have a written charter or board resolution addressing the nominations process. Directors are not selected, or recommended for board of director selection, by independent directors constituting a majority of the board&#8217;s independent directors or by a nominations committee comprised solely of independent directors as required by the Nasdaq corporate governance rule.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We otherwise intend to comply
with the rules generally applicable to U.S. domestic companies listed on Nasdaq. We may in the future decide to use the foreign private
issuer exemption with respect to some or all of the other corporate governance rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16H. MINE SAFETY DISCLOSURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS
THAT PREVENT INSPECTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16J. INSIDER TRADING POLICIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="ixv-18804">adopted</ix:nonNumeric> a statement of trading policies that governs the trading in our securities by our directors, officers and certain other covered
persons, and which is reasonably designed to promote compliance with applicable insider trading laws, rules and regulations, and any listing
standards applicable to the Company. A copy of the Insider Trading Policy is included as Exhibit 11.1 to this annual report. In addition,
with regard to any trading in our own securities, it is our policy to comply with the federal securities laws and the applicable exchange
listing requirements.</span><span>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16K. CYBERSECURITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="ixv-12103"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our current cybersecurity
risk assessment and protection program consists of various cybersecurity software features designed to protect our systems and data and
alert us of any cybersecurity incidents, such as software to strengthen protection against forms of malware, including ransomware, spyware,
keyloggers and adware and various measures which limit the ability of different sectors within our organization to access certain types
of information. We also maintain backups to our systems and data which would help us in recovery and mitigation in the event of a cybersecurity
incident. Additionally, we work with external service providers that provide us with information technology services, including the assessment
and identification of risks from cybersecurity threats and to help manage our risk assessment program.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="ixv-18805">The oversight of cybersecurity
threats is undertaken by our CFO, who has experience in various leadership and consultancy roles. In the event of a material incident
or threat, our CEO is <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="ixv-18806">notified</ix:nonNumeric> as well. <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="ixv-18807">The CEO would then be expected to report the threat to the audit committee of the Board of Directors</ix:nonNumeric>,
which is <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="ixv-18808">responsible</ix:nonNumeric> for oversight of strategic, financial and other major risks to the Company, which could include those posed by cybersecurity
threats.</ix:nonNumeric> The level of each risk would be determined by considering the impact of the risk itself and the likelihood of the risk materializing
and high scoring risks are actioned upon. The Company&#8217;s risk assessment occurs annually, or as business needs change, and covers identification
of risks that could act against the company&#8217;s objectives as well as specific risks related to a compromise to the security of data.&#160;See
&#8220;Item 3.D Risk Factors&#8212;Risks Related to Our Business and Strategy&#8212;Our internal computer systems, or those of our CROs
or other contractors or consultants, may fail or suffer security breaches, which could result in a disruption of our drug development
programs.&#8221;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of the date of this report,
<ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" id="ixv-18809">we are <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="ixv-18810">not</ix:nonNumeric> aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially
affect us, including our business strategy, results of operations or financial condition.</ix:nonNumeric></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 17. FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="a_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 18. FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The financial statements
required by this item are found at the end of this annual report, beginning on page F-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_030"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 19. EXHIBITS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;no.</b></span></td>
    <td style="white-space: nowrap; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1*</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea023729501ex1-1_neuro.htm">Amended and Restated Articles of Association</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1*</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea023729501ex2-1_neuro.htm">Description of the Registrant&#8217;s Securities Registered Pursuant to Section&#160;12 of the Securities Exchange Act of 1934.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390021058163/ff12021a2ex10-1_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form F-1/A, filed with the SEC on December 6, 2021)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2*</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea023729501ex4-2_neuro.htm">2018 Share Incentive Plan</a></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390021058163/ff12021a2ex10-3_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation Policy (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form F-1/A, filed with the SEC on December 6, 2021)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390021053322/ff12021ex4-1_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Share Purchase Agreement (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form F-1/A, filed with the SEC on December 6, 2021)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390021058163/ff12021a2ex4-4_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s Specimen Certificate for Ordinary Shares (incorporated by reference to Exhibit 4.4 to the Registration Statement on Form F-1/A, filed with the SEC on December 6, 2021)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390021060769/ff12021a3ex4-5_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriter&#8217;s Warrant (incorporated by reference to Exhibit 4.5 to the Registration Statement on Form F-1/A, filed with the SEC on December 6, 2021)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390021063522/ff12021a4ex4-6_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Ordinary Share Purchase Warrant (incorporated by reference to Exhibit 4.6 to the Registration Statement on Form F-1/A, filed with the SEC on December 6, 2021)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390021060769/ff12021a3ex4-7_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant Agency Agreement between American Stock Transfer &amp; Trust Company. LLC and NeuroSense Therapeutics Ltd. (incorporated by reference to Exhibit 4.7 to the Registration Statement on Form F-1/A, filed with the SEC on December 6, 2021)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1875091/000121390023029915/ea176908ex10-1_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales Agreement, dated April 14, 2023, by and between NeuroSense Therapeutics Ltd. and A.G.P./Alliance Global Partners (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Report on Form 6-K filed with the SEC on April 14, 2023)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1875091/000121390023051355/ea180854ex1-1_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement Agent Agreement, dated as of June 22, 2023, by and between NeuroSense Therapeutics Ltd. and A.G.P./Alliance Global Partners (incorporated by reference to Exhibit 1.1 to the Registrant&#8217;s Report on Form 6-K filed with the SEC on June 23, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1875091/000121390023051355/ea180854ex10-1_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement, dated as of June 22, 2023, by and between NeuroSense Therapeutics Ltd. and the purchaser identified on the signature page thereto (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Report on Form 6-K filed with the SEC on June 23, 2023)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1875091/000121390023051355/ea180854ex4-1_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Ordinary Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Report on Form 6-K filed with the SEC on June 23, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1875091/000121390023051355/ea180854ex4-2_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 to the Registrants Report on Form 6-K filed with the SEC on June 23, 2023)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390024032576/ea020366201ex4-1_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Report on Form 6-K filed with the SEC on April 12, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390024032576/ea020366201ex10-1_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement Agent Agreement, dated as of April 10, 2024, by and between NeuroSense Therapeutics Ltd. and A.G.P./Alliance Global Partners (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Report on Form 6-K filed with the SEC on April 12, 2024)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390024032576/ea020366201ex10-2_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement, dated as of April 10, 2024, by and between NeuroSense Therapeutics Ltd. and the purchaser identified on the signature page thereto (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Report on Form 6-K filed with the SEC on April 12, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390024032576/ea020366201ex10-3_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Ordinary Warrant (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Report on Form 6-K filed with the SEC on April 12, 2024)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390024065940/ea021078301ex10-1_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement, dated as of August 6, 2024, by and between NeuroSense Therapeutics Ltd. and the purchaser identified on the signature page thereto (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Report on Form 6-K filed with the SEC on August 7, 2024)</span></a></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</span></td>
    <td style="white-space: nowrap; text-align: justify; width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390024065940/ea021078301ex10-2_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Report on Form 6-K filed with the SEC on August 7, 2024)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390024070239/ea021153001ex10-1_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital on Demand&#8482; Sales Agreement, dated August 16, 2024, by and between NeuroSense Therapeutics Ltd. and JonesTrading Institutional Services LLC (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Report on Form 6-K filed with the SEC on August 16, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390024092946/ea021948301ex10-1_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Standby Equity Purchase Agreement dated October 31, 2024, by and between NeuroSense Therapeutics Ltd. and YA II PN, LTD. (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Report on Form 6-K filed with the SEC on October 31, 2024)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390024104568/ea022334001ex10-1_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement, dated as of December 2, 2024, by and between NeuroSense Therapeutics Ltd. and the purchasers identified on the signature pages thereto (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Report on Form 6-K filed with the SEC on December 2, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.23</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390024104568/ea022334001ex10-2_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Report on Form 6-K filed with the SEC on December 2, 2024)</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.24</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390024104568/ea022334001ex10-3_neurosense.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Ordinary Warrant (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Report on Form 6-K filed with the SEC on December 2, 2024)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390024030439/ea020296401ex8-1_neuro.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries of NeuroSense Therapeutics Ltd. <span style="text-decoration:underline;text-decoration: none">(incorporated by reference to Exhibit 8.1 to the Annual Report on Form 20-F, filed with the SEC on April 4, 2024)</span></span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">11.1*</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea023729501ex11-1_neuro.htm">Insider Trading Policy</a></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1*</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea023729501ex12-1_neuro.htm">Certification of the Chief Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2*</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea023729501ex12-2_neuro.htm">Certification of the Chief Financial Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934</a></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1*</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea023729501ex13-1_neuro.htm">Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2*</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea023729501ex13-2_neuro.htm">Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350</a></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1*</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea023729501ex15-1_neuro.htm">Consent of Somekh Chaikin (Member firm of KPMG International), Independent Registered Public Accounting Firm</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1+</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1875091/000121390024030439/ea020296401ex97-1_neuro.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clawback Policy <span style="text-decoration:underline;text-decoration: none">(incorporated by reference to Exhibit 97.1 to the Annual Report on Form 20-F, filed with the SEC on April 4, 2024)</span></span></a></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: #CCECFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management contract or compensatory plan or arrangement.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><div><a id="a_031"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Registrant hereby certifies
that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this
annual report on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">NeuroSense Therapeutics LTD.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Alon Ben-Noon</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 5%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</span></td>
    <td style="width: 32%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alon Ben-Noon</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Or Eisenberg</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Or Eisenberg</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: April 7, 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_032"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 90%; padding-left: 10pt; text-indent: -10pt">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="padding-left: 10pt; text-indent: -10pt"><a href="#fin_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm</span> (PCAOB ID: ID <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-18811">1057</ix:nonNumeric>)</a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr> <tr style="vertical-align: top; "> <td style="padding-left: 10pt; text-indent: -10pt"><a href="#fin_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Financial Position as of December 31, 2024 and 2023</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="padding-left: 10pt; text-indent: -10pt"><a href="#fin_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2024, 2023 and 2022</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr> <tr style="vertical-align: top; "> <td style="padding-left: 10pt; text-indent: -10pt"><a href="#fin_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Equity (Deficit) for the Years Ended December 31, 2024, 2023 and 2022</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="padding-left: 10pt; text-indent: -10pt"><a href="#fin_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the Years Ended December 31, 2024, 2023 and 2022</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr> <tr style="vertical-align: top; "> <td style="padding-left: 10pt; text-indent: -10pt"><a href="#fin_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Consolidated Financial Statements</span></a></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7 - F-28</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="fin_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Shareholders and Board of Directors of<br/>
NeuroSense Therapeutics Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AuditorOpinionTextBlock-c0_cont_1" escape="true" name="dei:AuditorOpinionTextBlock" id="ixv-12667"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Opinion on the Consolidated Financial Statements</i></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_AuditorOpinionTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying
consolidated statements of financial position of NeuroSense Therapeutics Ltd. and its subsidiaries (the &#8220;Company&#8221;) as of December
31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, changes in equity (deficit), and cash flows
for each of the years in the three-year period ended December&#160;31, 2024, and the related notes (collectively, the &#8220;consolidated
financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in
the three-year period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Going Concern</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1B to the consolidated
financial statements, the Company&#8217;s recurring losses and its expectation to incur significant additional losses raise substantial
doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note
1B. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Basis for Opinion</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These consolidated financial
statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted our audits in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we
are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audits included performing
procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates
made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits
provide a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-18812">Somekh Chaikin</ix:nonNumeric></span></td> <td style="width: 60%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Somekh Chaikin</span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Member&#160;Firm&#160;of&#160;KPMG&#160;International</span></td> <td>&#160;</td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2020.<br/>
<ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-18813">Tel-Aviv, Israel</ix:nonNumeric><br/>
April 7, 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 2; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="fin_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Consolidated Statements of Financial Position<br/>
(U.S. dollars in thousands, except share and per share data) </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Current assets:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: 0in; padding-left: 0.125in">Cash and cash equivalent</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">3</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-18814">3,378</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-18815">2,640</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.25in">Other receivables</td><td>&#160;</td>
    <td style="text-align: center">4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" unitRef="usd" id="ixv-18816">989</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" unitRef="usd" id="ixv-18817">236</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Restricted deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">2G</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndInvestmentsCurrent" scale="3" unitRef="usd" id="ixv-18818">35</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndInvestmentsCurrent" scale="3" unitRef="usd" id="ixv-18819">40</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-18820">4,402</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-18821">2,916</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Non-current assets:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.25in">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: center">5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-18822">66</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-18823">85</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.25in">Right of use assets</td><td>&#160;</td>
    <td style="text-align: center">6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-18824">84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-18825">162</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Restricted deposit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">2G</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" scale="3" unitRef="usd" id="ixv-18826">23</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" scale="3" unitRef="usd" id="ixv-18827">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd" id="ixv-18828">173</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd" id="ixv-18829">269</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-18830">4,575</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-18831">3,185</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Liabilities shareholders&#8217; and equity</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.25in">Trade payables</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd" id="ixv-18832">1,160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd" id="ixv-18833">1,459</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-18834">832</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-18835">2,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-18836">1,992</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-18837">3,459</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Non-current liabilities:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Lease liability less current maturity</td><td>&#160;</td>
    <td style="text-align: center">6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-18838">73</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Liability in respect of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">8</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" unitRef="usd" id="ixv-18839">1,412</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-18840">1,485</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-18841">1,992</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-18842">4,944</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">Shareholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: center">9,10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in">Ordinary shares, <span style="-sec-ix-hidden: hidden-fact-5"><span style="-sec-ix-hidden: hidden-fact-6">no</span></span> par value:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.25in">Authorized: <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-18843">90,000,000</ix:nonFraction> shares at December 31, 2024 and <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-18844">60,000,000</ix:nonFraction> shares at December 31, 2023; Issued and outstanding: <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-18845"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-18846">23,228,941</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-18847"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-18848">15,379,042</ix:nonFraction></ix:nonFraction> shares at December 31, 2024 and 2023, respectively</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; text-align: left; padding-left: 0.25in">Share Premium and Capital Reserve</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-18849">39,243</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-18850">24,362</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-18851">36,660</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-18852">26,121</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total shareholders&#8217; equity (deficit)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-18853">2,583</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-18854">1,759</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and shareholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-18855">4,575</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-18856">3,185</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 3; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="fin_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Consolidated Statements of Income and Comprehensive Loss<br/>
(U.S. dollars in thousands, except share and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended <br/> December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">11</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-18857">5,698</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-18858">7,274</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-18859">5,587</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">12</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-18860">4,204</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-18861">4,775</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-18862">4,967</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Operating loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18863">9,902</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18864">12,049</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18865">10,554</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Financing income (expenses), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">13</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-18866">308</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-18867">1,942</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-18868">62</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss and comprehensive loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18869">10,210</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18870">10,107</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18871">10,492</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Basic and diluted net loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-18872"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-18873">0.54</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-18874"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-18875">0.74</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-18876"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-18877">0.91</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Weighted average number of ordinary shares used in computing basic net loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-18878"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-18879">18,602,082</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-18880"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-18881">13,640,168</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-18882"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-18883">11,504,521</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="fin_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Consolidated Statements of Changes in Equity (deficit)<br/>
(U.S. dollars in thousands, except share and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Share<br/> Premium&#160;and<br/> Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total<br/> Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Reserve</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Deficit)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 40%; font-weight: bold">Balance as of January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-18884">10,943,534</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-18885">16,356</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-18886">5,522</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-18887">10,834</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Repurchase of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" unitRef="usd" id="ixv-18888">96</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" unitRef="usd" id="ixv-18889">96</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Exercise of warrants and vested RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-18890">838,429</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-18891">3,870</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-18892">3,870</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share based payment compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd" id="ixv-18893">1,728</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd" id="ixv-18894">1,728</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss and comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18895">10,492</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18896">10,492</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Balance as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-18897">11,781,963</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-18898">21,858</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-18899">16,014</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-18900">5,844</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of shares and pre-funded warrants, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="nrsn:StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet" scale="0" unitRef="shares" id="ixv-18901">1,333,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet" scale="3" unitRef="usd" id="ixv-18902">806</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet" scale="3" unitRef="usd" id="ixv-18903">806</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Exercise of pre-funded warrants, options and vested RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="nrsn:StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants" scale="0" unitRef="shares" id="ixv-18904">2,263,479</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share based payment compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd" id="ixv-18905">1,698</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd" id="ixv-18906">1,698</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss and comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18907">10,107</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18908">10,107</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold">Balance as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-18909">15,379,042</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-18910">24,362</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-18911">26,121</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-18912">1,759</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of shares and pre-funded warrants, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="nrsn:StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet" scale="0" unitRef="shares" id="ixv-18913">5,981,238</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet" scale="3" unitRef="usd" id="ixv-18914">10,806</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet" scale="3" unitRef="usd" id="ixv-18915">10,806</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Exercise of pre-funded warrants, options and vested RSUs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="nrsn:StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants" scale="0" unitRef="shares" id="ixv-18916">1,573,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*</span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of shares due to SEPA agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="nrsn:StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement" scale="0" unitRef="shares" id="ixv-18917">224,697</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement" scale="3" unitRef="usd" id="ixv-18918">281</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement" scale="3" unitRef="usd" id="ixv-18919">281</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Reclassification of warrants into equity (see Note 8)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" unitRef="usd" id="ixv-18920">1,695</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" sign="-" unitRef="usd" id="ixv-18921">329</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" unitRef="usd" id="ixv-18922">1,366</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Bonus accrual reclassification to equity (see Note 14)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity" scale="3" unitRef="usd" id="ixv-18923">1,434</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity" scale="3" unitRef="usd" id="ixv-18924">1,434</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" unitRef="shares" id="ixv-18925">70,964</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd" id="ixv-18926">665</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd" id="ixv-18927">665</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss and comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18928">10,210</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18929">10,210</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-18930">23,228,941</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-18931">39,243</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-18932">36,660</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-18933">2,583</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">less than $1.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="fin_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Consolidated Statements of Cash Flows<br/>
(U.S. dollars in thousands, except share and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash flows from operating activities</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 9pt">Net loss for the year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18934">10,210</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18935">10,107</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-18936">10,492</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-18937">22</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-18938">21</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-18939">12</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-18940">557</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-18941">1,537</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-18942">1,728</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Revaluation of liability in respect to warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:RevaluationOfLiabilityInRespectToWarrants" scale="3" unitRef="usd" id="ixv-18943">46</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:RevaluationOfLiabilityInRespectToWarrants" scale="3" unitRef="usd" id="ixv-18944">2,191</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Financing expenses, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="3" unitRef="usd" id="ixv-18945">323</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="3" unitRef="usd" id="ixv-18946">473</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="3" unitRef="usd" id="ixv-18947">41</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -7.1pt; padding-left: 0.25in">Changes in assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Decrease in operating right of use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:DecreaseInOperatingRightOfUseAsset" scale="3" unitRef="usd" id="ixv-18948">78</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:DecreaseInOperatingRightOfUseAsset" scale="3" unitRef="usd" id="ixv-18949">74</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:DecreaseInOperatingRightOfUseAsset" scale="3" unitRef="usd" id="ixv-18950">70</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Decrease in operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:DecreaseInOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-18951">69</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:DecreaseInOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-18952">69</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:DecreaseInOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-18953">95</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Decrease (increase) in other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" unitRef="usd" id="ixv-18954">753</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-18955">19</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-18956">55</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Increase (decrease) in trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" sign="-" unitRef="usd" id="ixv-18957">299</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd" id="ixv-18958">961</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd" id="ixv-18959">459</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Increase &#160;in other payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" unitRef="usd" id="ixv-18960">262</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" unitRef="usd" id="ixv-18961">928</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" unitRef="usd" id="ixv-18962">606</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-18963">10,135</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-18964">8,354</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-18965">7,616</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Purchase of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-18966">3</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-18967">29</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-18968">70</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Redemption of (investment in) short-term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:RedemptionofinvestmentInShorttermDeposits" scale="3" unitRef="usd" id="ixv-18969">3,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:RedemptionofinvestmentInShorttermDeposits" scale="3" sign="-" unitRef="usd" id="ixv-18970">3,500</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Redemption of (investment in) restricted deposit, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:RedemptionOfinvestmentInRestrictedDepositNet" scale="3" sign="-" unitRef="usd" id="ixv-18971">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:RedemptionOfinvestmentInRestrictedDepositNet" scale="3" unitRef="usd" id="ixv-18972">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:RedemptionOfinvestmentInRestrictedDepositNet" scale="3" unitRef="usd" id="ixv-18973">20</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-18974">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-18975">3,468</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-18976">3,590</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Payment in respect of cancellation of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfOtherEquity" scale="3" unitRef="usd" id="ixv-18977">96</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">Exercise of warrants and options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd" id="ixv-18978">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd" id="ixv-18979">3,870</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Issuance of shares, warrants and pre-funded warrants, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" unitRef="usd" id="ixv-18980">11,304</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" unitRef="usd" id="ixv-18981">4,334</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0.25in">Issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" unitRef="usd" id="ixv-18982">391</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" unitRef="usd" id="ixv-18983">364</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-18984">10,913</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-18985">3,975</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-18986">3,774</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Effects of exchange rate changes on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-18987">41</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-18988">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-18989">88</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Increase (decrease) in cash and cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" scale="3" unitRef="usd" id="ixv-18990">738</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" scale="3" sign="-" unitRef="usd" id="ixv-18991">903</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" scale="3" sign="-" unitRef="usd" id="ixv-18992">7,520</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents as at the beginning of the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-18993">2,640</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-18994">3,543</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-18995">11,063</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents as of the end of the year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-18996">3,378</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-18997">2,640</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-18998">3,543</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Non-cash investing and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Reclassification of warrants into equity</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:ReclassificationOfWarrantsIntoEquity" scale="3" unitRef="usd" id="ixv-18999">1,366</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bonus accrual reclassification to equity (See Note 14)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:BonusAccrualReclassificationToEquity" scale="3" unitRef="usd" id="ixv-19000">1,434</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Recognition of right of use assets</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-19001">306</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest received</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:NoncashOrPartNoncashAcquisitionInterestReceived" scale="3" unitRef="usd" id="ixv-19002">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:NoncashOrPartNoncashAcquisitionInterestReceived" scale="3" unitRef="usd" id="ixv-19003">179</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:NoncashOrPartNoncashAcquisitionInterestReceived" scale="3" unitRef="usd" id="ixv-19004">49</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="fin_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(U.S. dollars in thousands, except share and
per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ixv-14807"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1 - General</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroSense Therapeutics Ltd. (&#8220;NeuroSense&#8221; or the &#8220;Company&#8221;) was incorporated in Israel on <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:EntityIncorporationDateOfIncorporation" id="ixv-19005">February 13, 2017</ix:nonNumeric>. NeuroSense is a clinical-stage pharmaceutical company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. The Company&#8217;s lead product candidate, PrimeC, is a novel oral formulation of a fixed dose combination composed of a specific ratio and doses of two FDA-approved drugs.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In addition to PrimeC, the Company
has initiated research and development efforts in Alzheimer&#8217;s disease and Parkinson&#8217;s disease, with a similar strategy of
combined products.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s ordinary shares
and warrants began trading on the Nasdaq Capital Market on&#160;December 9, 2021&#160;under the ticker symbols &#8220;NRSN&#8221; and
&#8220;NRSNW,&#8221; respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently has no products approved for sale and the Company&#8217;s operations have been funded primarily by its shareholders. To date, the Company has generated no sales or revenues, has incurred losses and expects to incur significant additional losses due to the continuing focus on the research, development, clinical activities of its product candidates, preclinical programs, business development, organizational structure and to advance the programs within the Company&#8217;s pipeline. Consequently, its operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in the research and development of pharmaceutical compounds. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Based on current expected level of
operating expenditures, the Company&#8217;s cash resources as at December 31, 2024 shall not be sufficient to fund the Company&#8217;s
operations for a period of at least 12 months from the approval of these consolidated financial statements, assuming that the Company
will continue its development plan in accordance with the original pipeline and without delaying or slowing down the progress of its plans.
The Company will require additional cash to fund the execution of its mid and long-term development program. The Company anticipates raising
additional funds through public or private sales of debt or equity securities, collaborative arrangements, or some combination thereof.
Whilst management is progressing with its plans to secure external financing, these still require approval by third parties, and accordingly,
there is no assurance that any such arrangement will be entered into or that financing will be available when needed in order to allow
it to continue its operations, or if available, on terms favorable or acceptable to it.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
the event financing is not obtained, the Company may pursue cost cutting measures or may be required to delay, reduce the scope of,
or eliminate any of its development programs or clinical trials, these events could have a material adverse effect on its business.
These factors&#160;raise substantial doubt&#160;about the Company ability to continue as a going concern. The consolidated financial
statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and
classification of liabilities that might be necessary should the Company be unable to continue as a going concern. </span>The
going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of
business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 3, 2022, the Company established a US based subsidiary, NeuroSense US Inc. (&#8220;US Subsidiary&#8221;). From establishment through December 31, 2024, the US Subsidiary had no activity. The U.S. subsidiary was formed to perform research and development activity and engage in possible collaboration agreements. On July, 2023, the Company established a German based subsidiary, NeuroSense GmbH (&#8220;NeuroSense GmbH &#8220;). NeuroSense GmbH was formed to perform research and development activity and engage in possible collaboration agreements. From establishment through December 31, 2024, NeuroSense GmbH had no material activity.</span></td></tr>
  </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1 - General (cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Following the attack, Israel&#8217;s security cabinet declared war against Hamas and commenced a military campaign against Hamas. In addition, since the commencement of these events, there have been continued hostilities along Israel&#8217;s northern border with Lebanon (with the Hezbollah terror organization), Israel&#8217;s southern border with the Gaza Strip (with the Hamas terrorist organization) and on other fronts from various extremist groups in region, such as the Houthis in Yemen and various rebel militia groups in Syria and Iraq. Further, on April 13, 2024, and on October 1, 2024, Iran launched a series of drone and missile strikes against Israel. As of December 31, 2024 a ceasefire agreement has been reached between Israel the Hezbollah terror organization in Lebanon. To date the Company&#8217;s operations and financial results have not been materially affected. Since the war broke out in October 2023, the Company&#8217;s operations have not been adversely affected by this situation, and it has not experienced disruptions to its clinical studies. As such, its clinical and business development activities remain on track. However, the intensity and duration of Israel&#8217;s current war against Hamas and Hezbollah is difficult to predict at this stage, as are such war&#8217;s economic implications on its business and operations and on Israel&#8217;s economy in general. If the ceasefire declared collapses or a new war commences or hostilities expand to other fronts, its operations may be adversely affected.</span></td></tr>
  </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-14880"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 2 - Significant Accounting Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-14884"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of presentation</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
consolidated financial statements have been prepared in accordance accounting principles generally accepted in the United States of America
(&#8220;US GAAP&#8221;)</span> assuming the Company will continue as a going concern.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-14898"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates in preparation of consolidated financial statements</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts
reported in the consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including
those related to fair value of financial instruments and share based compensation. The Company&#8217;s management believes that the estimates,
judgment, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and
assumptions can affect the reported amounts of assets and liabilities and disclosure of liabilities at the dates of the consolidated financial
statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ixv-14911"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Functional currency</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The functional currency of the Company and its subsidiaries, all of which are primarily direct and integral component of the Company&#8217;s
operation, is the U.S. dollar (&#8220;$&#8221; or &#8220;dollar&#8221;), as the dollar is primary currency of the economic environment
in which the Company and its subsidiaries have operated and expects to continue to operate in foreseeable future.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In accordance with ASC 830, &#8220;Foreign
Currency Matters&#8221;, balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing
at the applicable balance sheet date. For foreign currency transactions included in the consolidated statement of operations and comprehensive
loss, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates
used in the translation of such transactions are presented within financing income or expenses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock" id="ixv-14927"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principles of Consolidation</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The consolidated financial statements
include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated upon
consolidation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-14940"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash and cash equivalents</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Cash and cash equivalents include highly
liquid investments, including short-term bank deposits (with original maturity dates of up to three months from date of deposit) that
are not restricted as to withdrawal or use.</p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 2 - Significant Accounting Policy (cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="nrsn_ShortTermDepositsPolicyTextBlock-c0_cont_1" escape="true" name="nrsn:ShortTermDepositsPolicyTextBlock" id="ixv-14980"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Short-term deposits</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="nrsn_ShortTermDepositsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Short-term deposits in banking institutions
for periods in excess of three months following the date of deposit. The deposits are presented in accordance with the terms of their
deposit.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="nrsn_RestrictedDepositsPolicyTextBlock-c0_cont_1" escape="true" name="nrsn:RestrictedDepositsPolicyTextBlock" id="ixv-14993"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restricted deposits</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="nrsn_RestrictedDepositsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Restricted deposits consist of deposits
held in restricted deposit bank accounts including deposits held as collateral for guarantees to third parties, classified as current
or non-current based on expected timing of the disbursement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-15006"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property and equipment</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets. When an asset is disposed of, the related cost and accumulated depreciation are removed from the respective accounts and the net
difference less any amount realized from disposition is reflected in the consolidated statements of operations and comprehensive loss.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s long-lived assets are
reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment&#8221;, whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.
To date, the Company has not incurred any impairment losses.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="nrsn:ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock" id="ixv-15022"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_4" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The lives used in computing straight-line
depreciation for financial reporting purposes are as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="width: 80%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and peripherals and equipment</span></td> <td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c32" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-15039"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office furniture and equipment</span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c33" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-19006">7</ix:nonNumeric> - <ix:nonNumeric contextRef="c34" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-19007">15</ix:nonNumeric></span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-55">The shorter of the lease term and the useful life</span></span></td></tr> </table></ix:continuation></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-15055"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research and Development</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Research and development costs are
expensed as incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-15068"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurements</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company measures and discloses
fair value in accordance with the ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; which defines fair value, establishes
a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements.
Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined
based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions
there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 1 - unadjusted quoted prices
are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 2 - pricing inputs are other
than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 3 - pricing inputs are unobservable
for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability
at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Level
3 inputs are considered as the lowest priority within the fair value hierarchy. The valuation of certain financial instruments classified
under fair value through profit or loss category falls under this category.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b><br/>
&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 2 - Significant Accounting Policy (cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurements (cont.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">This hierarchy requires the Company
to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of the reported periods, the fair
values of the Company&#8217;s cash, cash equivalents, short-term bank deposits, current and non-current restricted deposits, other current
assets, trade payables and other current liabilities approximated the carrying values of these instruments presented in the Company&#8217;s
consolidated balance sheets because of their nature.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-15132"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>K.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations of credit risk</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Financial instruments that potentially
subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents as well as certain other current assets
that do not amount to a significant amount. Cash and cash equivalents, which are primarily held in dollar and New Israeli Shekels (NIS),
are deposited with major bank in Israel. Management believes that such financial institutions are financially sound and, accordingly,
minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration
of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-15145"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>L.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company entered into non-cancelable
lease agreements for offices for use in its operations, which are classified as operating leases (see below).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_3" id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company applies ASC 842, &#8220;Leases&#8221;
under which the Company determines if an arrangement is a lease at inception. The Company&#8217;s assessment is based on: (i) whether
the contract involves the use of an identified asset, (ii) whether the Company obtains the right to substantially all of the economic
benefits from the use of the asset throughout the period of use, and (iii) whether the Company has the right to direct the use of the
asset.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_4" id="_LesseeLeasesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Leases are classified as either finance
leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers
ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain
to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset, (iv) the present value of the lease
payments equals or exceeds substantially all of the fair value of the asset, or (v) the underlying asset is of such a specialized nature
that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if
it does not meet any one of these criteria. Since all the Company&#8217;s lease contracts for premises do not meet any of the criteria
above, the Company concluded that all its lease contracts should be classified as operating leases.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Right of Use (&#8220;ROU&#8221;) assets
and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For
this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company&#8217;s
leases do not provide an implicit rate, the Company uses its Incremental Borrowing Rate (&#8220;IBR&#8221;) based on the information available
on the commencement date in determining the present value of lease payments. The Company&#8217;s IBR is estimated to approximate the interest
rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The
ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover,
the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease
had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, &#8220;Property, Plant, and Equipment
- Overall&#8221;, to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases
include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset
and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless
it is reasonably certain that the Company will not exercise the option.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b><br/>
&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 2 - Significant Accounting Policy (cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="ixv-15192"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>M.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commitment and contingencies</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies under which a provision is recorded when it is both probable that liability has
been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted
to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events
pertaining to a particular matter.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_EmployeeStockOwnershipPlanESOPPolicy-c0_cont_1" escape="true" name="us-gaap:EmployeeStockOwnershipPlanESOPPolicy" id="ixv-15205"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N.</b></span></td> <td style="padding-bottom: 6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employee benefit plans </b></span></td></tr> </table></ix:nonNumeric>
<ix:continuation id="_EmployeeStockOwnershipPlanESOPPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s liability for severance
pay to its Israeli employees is subject to Section 14 of the Israeli Severance Compensation Act, 1963 (&#8220;Section 14&#8221;), pursuant
to which all of the Company&#8217;s employees are entitled to monthly deposits by the Company, at a rate of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" unitRef="pure" id="ixv-19008">8.33</ix:nonFraction>% of their monthly salary,
made in the employee&#8217;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release
the Company from any future severance payments in respect of those employees. The fund is made available to the employee at the time the
employer-employee relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section
14 are not reflected in the balance sheets as the severance pay risks have been irrevocably transferred to the severance funds. All deposits
required through December 31, 2024 have been made.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-15217"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>O.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income taxes</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company accounts for income taxes
in accordance with ASC 740, &#8220;Income Taxes&#8221;. Accordingly, deferred income taxes are determined utilizing the asset and liability
method based on the estimated future tax effects of differences between the financial statement carrying amount and the tax bases of assets
and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax rates expected to be in effect
when these differences reverse. A valuation allowance in respect of deferred tax assets is provided for, if necessary, to reduce deferred
tax assets to the amounts more likely than not to be realized.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company implements a&#160;two-step&#160;approach
to recognize and measure tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by
determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits,
the tax position will be sustained on examination, including resolution of any related appeals or litigation processes. The second step
is to measure the tax benefit as the largest amount that is greater than&#160;<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" unitRef="pure" id="ixv-19009">50</ix:nonFraction>% likely to be realized upon settlement. The Company&#8217;s
accounting policy is to classify interest and penalties relating to income taxes under income taxes, however the Company did not recognize
such items in its consolidated financial statements during the reported periods and did not recognize any liability with respect to an
unrecognized tax benefits in its balance sheets.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.9pt; ">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-15233"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>P.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based compensation</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s employees&#8217;
and directors&#8217; share-based payment awards are classified as equity awards. The Company accounts for these awards using the grant-date
fair value method. For employees, the fair value of share-based payment transactions is recognized as an expense over the requisite service
period for each separately vesting tranche of the award as if the award is, in-substance, multiple awards. Forfeitures are recognized
as they occur.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">For nonemployees, compensation costs
are recognized in the same period and in the same manner the Company would if it had paid cash for those goods or services.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-15249"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basic and diluted net loss per share</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Basic net loss per share is computed
using the weighted average number of ordinary shares, pre-funded warrants to purchase ordinary shares for an exercise price of $<ix:nonFraction contextRef="c31" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-19010">0.0001</ix:nonFraction>&#160;which
are exercisable immediately and fully vested restricted share units (RSUs) outstanding during the period.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b><br/>
&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 2 - Significant Accounting Policy (cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basic and diluted net loss per share (cont.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Diluted loss per share gives effect
to all potentially dilutive common shares outstanding during the year using the treasury stock method with respect to options and non-vested
RSUs granted under employee stock compensation plan and certain warrants granted through its Initial Public Offering (IPO) and using the
if-converted method with respect to certain warrants granted through registered direct offering and accounted for as derivative liability.
In computing diluted loss per share, the average share price for the period is used in determining the number of shares assumed to be
purchased from the exercise of share options or warrants.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the reported periods, all outstanding
share options, warrants and non-vested RSUs have been excluded from the calculation of the diluted net loss per share as all such securities
are anti-dilutive for all years presented.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-15305"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>R.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segment</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s chief operating
decision maker (&#8220;CODM&#8221;) is its Chief Executive Officer. The CODM reviews financial information on an aggregate basis for the
purposes of evaluating financial performance and allocating the Company&#8217;s resources. Accordingly, the Company has determined that
it operates in <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure" id="ixv-19011">one</ix:nonFraction> segment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityPolicyTextBlock" id="ixv-15320"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>S.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share capital</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p>

<ix:continuation id="_StockholdersEquityPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Ordinary shares are classified as equity.
Incremental costs directly attributable to the issuance of the shares are recognized as a deduction from equity.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="nrsn_ContractsOverOwnEquityPolicyTextBlock-c0_cont_1" escape="true" name="nrsn:ContractsOverOwnEquityPolicyTextBlock" id="ixv-15333"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><b>T.</b></td><td style="text-align: justify"><b>Contracts over own equity</b></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:continuation continuedAt="nrsn_ContractsOverOwnEquityPolicyTextBlock-c0_cont_2" id="nrsn_ContractsOverOwnEquityPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">When the Company becomes party to freestanding
financial instruments, the Company first analyzes the provisions of ASC&#160;480 in order to determine whether the instrument should be
classified as a liability, with subsequent changes in fair value recognized in the statements of operations in each period. Warrants to
purchase ordinary shares are not within the scope of ASC&#160;480, and as such the Company further analyzes the provisions of ASC&#160;815-40&#160;in
order to determine whether the contract should be classified within equity or classified as a liability, with subsequent changes in fair
value recognized in the statements of operations in each period.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="nrsn_ContractsOverOwnEquityPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company reassesses the classification
of a contract over its own equity under the guidance above at each balance sheet date. If classification changes as a result of events
during the reporting period, the Company reclassifies the contract as of the date of the event that caused the reclassification. When
a contract over own equity is reclassified from a liability to equity, gains or losses recorded to account for the contract at fair value
during the period that the contract was classified as a liability are not reversed, and the contract is marked to fair value immediately
before the reclassification.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-15348"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
adopted accounting pronouncements</b></span></td>
</tr></table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>1.</b></td><td style="text-align: justify">In&#160;August 2020,&#160;the FASB issued ASU&#160;2020-06&#160;&#8220;Debt-
Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging- Contracts in Entity&#8217;s Own Equity (Subtopic&#160;815-40)
(&#8220;ASU&#160;2020-06&#8221;): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221;. This guidance
simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments
and contracts on an entity&#8217;s own equity. Furthermore, ASU&#160;2020-06&#160;requires the application of the if-converted method
for calculating diluted earnings per share. ASU 2020-06 is effective for the Company for annual periods beginning after December 15,
2023,&#160;and interim periods within those fiscal years. The Company adopted this guidance on January 1, 2024, and there was no material
impact on the Company&#8217;s consolidated balance sheet and the consolidated statements of operations and comprehensive loss upon adoption.</td>
</tr></table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>NeuroSense
Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements<br/>
</b></span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 2 - Significant Accounting Policy (cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently adopted accounting pronouncements (cont.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><b>2.</b></td><td style="text-align: justify">In November 2023, the FASB issued ASU 2023-07 &#8220;Segment
Reporting: Improvements to Reportable Segment Disclosures&#8221; which expands public entities&#8217; segment disclosures primarily by
requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within
each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures
of a reportable segment&#8217;s profit or loss and assets. Public entities with a single reportable segment are required to provide the
new disclosures and all the disclosures required under ASC 280.</td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The guidance is effective for the Company&#8217;s
annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company
has adopted this standard for the fiscal year 2024 annual financial statements and interim financial statements thereafter and has applied
this standard retrospectively for all prior periods presented in the financial statements. See&#160;Note 15 &#8211; Segment Reporting&#160;for
further information.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_1" escape="true" name="nrsn:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" id="ixv-15416"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>V.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently issued accounting pronouncements, not yet adopted</b></span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_2" id="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As an emerging growth company, the
Jumpstart Our Business Startup Act (&#8220;JOBS Act&#8221;) allows the Company to delay adoption of new or revised accounting pronouncements
applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this
extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_3" id="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">1.</td><td style="text-align: justify">In December 2023, the FASB issued ASU 2023-09 &#8220;Improvements to Income Tax Disclosures&#8221; which
improves the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in
the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain amendments to improve income
tax disclosures effectiveness. The guidance is effective for the Company&#8217;s annual periods beginning January 1, 2026, with early
adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on the consolidated financial
statement disclosures.</td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<ix:continuation id="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">2.</td><td style="text-align: justify">In November 2024, the FASB issued ASU No. 2024-03 Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense
Disaggregation Disclosures (Subtopic 220-40). The ASU improves the disclosures about a public business entity&#8217;s expenses and provides
more detailed information about the types of expenses in commonly presented expense captions. The amendments require that at each interim
and annual reporting period an entity will, inter alia, disclose amounts of purchases of inventory, employee compensation, depreciation
and amortization included in each relevant expense caption (such as cost of sales, SG&amp;A and research and development). The ASU is
effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027.
Early adoption is permitted. The Company is currently evaluating this ASU to determine its impact on the Company&#8217;s disclosures.</td></tr></table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="ixv-15445"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 3 - Cash and cash equivalent </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="ixv-15449"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars<br/> in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Denominated in NIS</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-19012">3,057</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-19013">107</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Denominated in USD</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-19014">321</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">*2,533</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-19015">3,378</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-19016">2,640</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US">Including short term bank deposit for a period of 1-2 months
at an interest rate of <ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRate" scale="-2" unitRef="pure" id="ixv-19018">5</ix:nonFraction>%.</ix:footnote></td>
</tr></table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="ixv-15524"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4 - Other receivables</b></p>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="ixv-15529"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars<br/> in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Advance to suppliers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Supplies" scale="3" unitRef="usd" id="ixv-19019">738</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Government agencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GovernmentContractReceivable" scale="3" unitRef="usd" id="ixv-19020">60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GovernmentContractReceivable" scale="3" unitRef="usd" id="ixv-19021">29</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-19022">87</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-19023">70</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesGrossCurrent" scale="3" unitRef="usd" id="ixv-19024">104</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesGrossCurrent" scale="3" unitRef="usd" id="ixv-19025">137</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" unitRef="usd" id="ixv-19026">989</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" unitRef="usd" id="ixv-19027">236</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-15601"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 5 - Property and equipment, net</b></p>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Balance as of December 31, 2024:</p>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-15607"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers<br/> and<br/> peripherals<br/> and <br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Office<br/> furniture <br/> and<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cost:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance at January 1, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-19028">92</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-19029">28</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-19030">3</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-19031">123</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Purchases during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-19032">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-19033">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-19034">95</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-19035">28</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-19036">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-19037">126</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-19038">34</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-19039">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif; font-size: 10pt">(*</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-19040">38</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" scale="3" unitRef="usd" id="ixv-19041">20</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" scale="3" unitRef="usd" id="ixv-19042">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif; font-size: 10pt">(*</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" scale="3" unitRef="usd" id="ixv-19043">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-19044">54</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-19045">6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif; font-size: 10pt">(*</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-19046">60</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">Depreciated cost at December&#160;31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-19047">41</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-19048">22</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-19049">3</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-19050">66</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Balance as of December 31, 2023:</p>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers<br/> and<br/> peripherals<br/> and <br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Office<br/> furniture <br/> and<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cost:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-19051">66</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-19052">25</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-19053">3</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-19054">94</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Purchases during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-19055">26</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-19056">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-19057">29</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-19058">92</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-19059">28</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-19060">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-19061">123</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-19062">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-19063">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-19064">17</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" scale="3" unitRef="usd" id="ixv-19065">20</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" scale="3" unitRef="usd" id="ixv-19066">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif; font-size: 10pt">(*</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" scale="3" unitRef="usd" id="ixv-19067">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-19068">34</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-19069">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif; font-size: 10pt">(*</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-19070">38</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">Depreciated cost at December&#160;31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-19071">58</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-19072">24</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-19073">3</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-19074">85</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
than $1 thousand.</span></ix:footnote></td>
</tr></table></ix:continuation></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-16168"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 6 - Operating lease</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The Company has lease agreements with respect
to offices. In December 2021, the Company entered into an office space lease agreement (which commenced on January 1, 2022). Monthly rent
payments including utilities amount to approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="3" unitRef="usd" id="ixv-19075">7</ix:nonFraction> thousand and indexed to Israeli consumer price index. The lease period is for
<ix:nonNumeric contextRef="c4" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-19076">24</ix:nonNumeric> months with an <ix:nonNumeric contextRef="c0" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="ixv-19077">option to extend the lease period for additional two periods of 24 months</ix:nonNumeric> each (the first one was exercised by the Company).
Accordingly, the Company recognized in the consolidated balance sheet a right-of-use asset in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:InitialRecognitionRightofuseAssets" scale="3" unitRef="usd" id="ixv-19078">306</ix:nonFraction> thousand concurrently
with the recognition of a lease liability in the same amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><span style="text-decoration:underline">Operating lease</span>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="nrsn:LesseeOperatingLeaseDisclosureTableTextBlock" id="ixv-16178"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars<br/> in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Operating right of use asset</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-19079">84</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-sec-ix-hidden: hidden-fact-67">Current operating lease liability</span></td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-19080">73</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-Current operating lease liability</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-68">-</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total operating lease liability</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-19081">73</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-16219"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><span style="text-decoration:underline">Maturity analysis of the Company&#8217;s lease liability</span>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S. dollars<br/>
in thousands</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less than one year</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-19082">75</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two years</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating lease payments</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-19083">75</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: imputed interest</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-19084">2</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)<b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of lease liability</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-19085">73</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><span style="text-decoration:underline">Additional information on lease</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-16308"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The following is a summary of weighted average
remaining lease terms and discount rate for Company&#8217;s leases:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Lease term (years)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-19086">1</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>Weighted average discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-19087">6</ix:nonFraction></td><td style="text-align: left">%</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Presented hereunder are the lease payments the
Company paid in the year ended December 31, 2024, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Lease payments</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePaymentsUse" scale="3" unitRef="usd" id="ixv-19088">75</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePaymentsUse" scale="3" unitRef="usd" id="ixv-19089">75</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePaymentsUse" scale="3" unitRef="usd" id="ixv-19090">79</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-19091">75</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-19092">75</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-19093">79</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="ixv-16405"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 7 - Other Current Liabilities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="ixv-16409"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars<br/> in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Employees and payroll accruals (*)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd">498</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd">1,481</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Short term lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-19096">73</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-19097">69</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-19098">261</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-19099">450</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-19100">832</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-19101">2,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US">see Note 14 regarding waiver signed of bonus accrual.</ix:footnote></td>
</tr></table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="nrsn_LiabilityInRespectOfWarrantsTextBlock-c0_cont_1" escape="true" name="nrsn:LiabilityInRespectOfWarrantsTextBlock" id="ixv-16479"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 8 - Liability in respect of warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">On June 22, 2023, the Company entered
into a registered direct offering under which, the Company issued to an institutional investor <ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-19103">3,000,000</ix:nonFraction> warrants, each representing the
right to acquire <ix:nonFraction contextRef="c54" decimals="0" format="ixt-sec:numwordsen" name="nrsn:NumberOfOrdinaryShares" scale="0" unitRef="pure" id="ixv-19104">one</ix:nonFraction> ordinary share at an exercise price of $<ix:nonFraction contextRef="c55" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-19105">1.50</ix:nonFraction> and expiring on the fifth anniversary of the original issuance date.
Due to the warrants&#8217; terms, with respect to the fundamental transaction provisions, the warrants were accounted as a financial liability
measured at fair-value through profit and losses until their expiration or exercise.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">On June 26, 2024, the Company and the
institutional investor entered into an amendment to the warrant which included revisions to the fundamental transactions provision and
the extension of the termination date from June 26, 2028 to October 12, 2029. The Company concluded that the amended warrants meet equity
classification criteria and thus the warrants should be accounted as equity from the date of amendment. As a result, on June 26, 2024
the Company reclassified the warrant liability into equity according to its fair value for the same date in the amount of $<ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="6" unitRef="usd" id="ixv-19106">1.366</ix:nonFraction> million.
Revaluation income in the amount of $<ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities" scale="3" unitRef="usd" id="ixv-19107">46</ix:nonFraction> thousands until June 26, 2024 was recorded within the Company&#8217;s finance expanse and the effect
of the amendment was recorded in the Company&#8217;s equity in the amount of <ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="3" sign="-" unitRef="usd" id="ixv-19108">329</ix:nonFraction> thousands.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="ixv-16487"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The Company&#8217;s financial measured
at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars<br/> in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Liability in respect of warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" unitRef="usd" id="ixv-19109">1,412</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" unitRef="usd" id="ixv-19110">1,412</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">As of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="ixv-16550"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The fair value of the warrants, as
of it&#8217;s the date of reclassification to equity, was determined by the management using the assistance of external appraiser and
by using the Black-Scholes option pricing model and the following inputs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June&#160;26,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Financial liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c62" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-19111">86.56</ix:nonFraction>-<ix:nonFraction contextRef="c63" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-19112">92.52</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%">Share price (in $)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c64" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-19113">0.85</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c62" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-19114">4.44</ix:nonFraction>-<ix:nonFraction contextRef="c63" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-19115">4.40</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected life (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c62" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-19116">3.98</ix:nonNumeric>-<ix:nonNumeric contextRef="c63" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-19117">5.30</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 8 - Liability in respect of warrants (cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:continuation id="nrsn_LiabilityInRespectOfWarrantsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">As of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The fair value of the warrants was determined by the management using the assistance of external appraiser and by using Black-Scholes option pricing model and the following inputs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Financial liabilities:</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Expected volatility (%)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c66" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-19118">93.91</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>Share price (in $)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c67" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-19119">0.785</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c66" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-19120">3.90</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected life (years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c66" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-19121">4.47</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="text-align: left">&#160;</td></tr> </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="ixv-16676"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The following table summarizes the movement in warrant liability during
the year ended December 31, 2023 and December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars<br/> in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Balance as at January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left">Recognition of liability in respect to warrants at the initial date</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate" scale="3" unitRef="usd" id="ixv-19122">3,603</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Revaluation of liability in respect to warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:ReclassificationOfWarrantsIntoEquity" scale="3" sign="-" unitRef="usd" id="ixv-19123">2,191</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Balance as at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" unitRef="usd" id="ixv-19124">1,412</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Revaluation of liability in respect to warrants through finance expanse</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse" scale="3" sign="-" unitRef="usd" id="ixv-19125">46</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Revaluation of liability in respect to warrants through equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:RevaluationOfLiabilityInRespectToWarrantsThroughEquity" scale="3" unitRef="usd" id="ixv-19126">329</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Reclassification of warrants into equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:RevaluationOfLiabilityInRespectToWarrants" scale="3" unitRef="usd" id="ixv-19127">1,695</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 2.5pt">Balance as at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-16744"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 9 - Shareholders&#8217; Equity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfCapitalUnitsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfCapitalUnitsTextBlock" id="ixv-16754"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share capital</b></span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<ix:continuation id="_ScheduleOfCapitalUnitsTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares<br/> December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/> outstanding 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/> outstanding 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 2.5pt"><div style="-sec-ix-hidden: hidden-fact-78"><div style="-sec-ix-hidden: hidden-fact-79">Ordinary shares of <span style="-sec-ix-hidden: hidden-fact-76"><span style="-sec-ix-hidden: hidden-fact-77">no</span></span> par value</div></div></td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-19128">90,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-19129">23,228,941</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-19130">60,000,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-19131">15,379,042</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022, the Company received an amount of $<ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-19132">3,870</ix:nonFraction> thousand as a result of the exercise of <ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-19133">645,000</ix:nonFraction> warrants at a price per share of
$<ix:nonFraction contextRef="c74" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-19134">6.00</ix:nonFraction>.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April&#160;14, 2023, the Company entered into a sales agreement with Alliance Global Partners, pursuant to which the Company may offer
and sell, from time to time, to or through the Alliance Global Partners as agent or principal, ordinary shares an at-the-market&#160;offering,
having an aggregate offering price of up to $<ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="3" unitRef="usd" id="ixv-19135">5,744</ix:nonFraction> thousands. On June&#160;22, 2023, the Company filed a prospectus supplement reflecting
a reduction in the size of the at-the-market&#160;offering to $<ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:MarketOfferingCost" scale="3" unitRef="usd" id="ixv-19136">502</ix:nonFraction> thousand. During the reporting period, the Company sold <ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-19137">3,600</ix:nonFraction> ordinary
shares for gross proceeds of $<ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-19138">7</ix:nonFraction> thousand through the at-the-market&#160;offering. Issuance expenses were equal to the proceeds received.</span></td>
</tr></table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 9 - Shareholders&#8217; Equity (cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share capital (cont.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 22, 2023, the Company&#160;entered
into a securities purchase agreement pursuant to which the Company agreed to issue and sell, in a registered direct offering: (i) an
aggregate of <ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-19139">1,330,000</ix:nonFraction> ordinary shares, no par value, and (ii) an aggregate of <ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-19140">1,670,000</ix:nonFraction> pre-funded warrants, each representing the right
to acquire <ix:nonFraction contextRef="c79" decimals="0" format="ixt-sec:numwordsen" name="nrsn:NumberOfOrdinaryShares" scale="0" unitRef="pure" id="ixv-19141">one</ix:nonFraction> ordinary share with exercise price of $<ix:nonFraction contextRef="c80" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-19142">0.0001</ix:nonFraction>, exercisable at any time until exercised in full and (iii) an aggregate
of <ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-19143">3,000,000</ix:nonFraction> warrants. The warrants are exercisable immediately upon issuance at an exercise price of $<ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-19144">1.50</ix:nonFraction> per ordinary share and will
expire on the fifth anniversary of the original issuance date. The gross proceeds were approximately $<ix:nonFraction contextRef="c82" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" unitRef="usd" id="ixv-19145">4.5</ix:nonFraction> million before deducting the
placement agent fee and related offering expenses of $<ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoninterestExpenseOfferingCost" scale="3" unitRef="usd" id="ixv-19146">455</ix:nonFraction> thousand. The warrant instrument is classified as a liability with an original
fair value in the amount of $<ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" unitRef="usd" id="ixv-19147">3,603</ix:nonFraction> thousand and the remaining amount of $<ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:RemainingFairValueAmount" scale="3" unitRef="usd" id="ixv-19148">897</ix:nonFraction> thousand was attributed to the ordinary shares and pre-funded
warrants and recognized in equity. The direct incremental issuance costs, amounting to $<ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="3" unitRef="usd" id="ixv-19149">454</ix:nonFraction> thousand, have been allocated in the same
proportion as the gross proceeds. An amount of $<ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:AllocatedAmountToOrdinaryWarrants" scale="3" unitRef="usd" id="ixv-19150">365</ix:nonFraction> thousands was allocated to the ordinary warrants and carried directly to profit or
loss as finance expense and an amount of $<ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd" id="ixv-19151">91</ix:nonFraction> thousands was allocated to the ordinary shares and the pre-funded warrants and recognized
as a reduction of equity. See also Note 8 regarding the agreement amendment signed on June 26, 2024 and the resulting reclassification
of the warrant liability into equity.</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 23, 2023, one of the Company&#8217;s employees exercised <ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-19152">126,000</ix:nonFraction> options into <ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-19153">126,000</ix:nonFraction> ordinary shares for a total consideration of $<ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" unitRef="usd" id="ixv-19154">5</ix:nonFraction> thousands.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
October 2023, <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares" id="ixv-19155">1,670,000</ix:nonFraction> pre-funded warrants were exercised into <ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares" id="ixv-19156">1,670,000</ix:nonFraction> ordinary shares of the Company. See also Note 9(a)(c) above.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 10, 2024, the Company&#160;entered into a securities purchase agreement (the &#8220;April 2024 Purchase Agreement&#8221;) with an institutional investor (the &#8220;April 2024 Purchaser&#8221;), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the April 2024 Purchaser (i) an aggregate of <ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-19157">1,732,000</ix:nonFraction> ordinary shares,; (ii) an aggregate of <ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-19158">1,248,000</ix:nonFraction> pre-funded warrants, each representing the right to acquire <ix:nonFraction contextRef="c89" decimals="0" format="ixt-sec:numwordsen" name="nrsn:NumberOfOrdinaryShares" scale="0" unitRef="Number" id="ixv-19159">one</ix:nonFraction> ordinary share at an exercise price of $<ix:nonFraction contextRef="c88" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-19160">0.0001</ix:nonFraction> (either physically or on a net-cash basis at the April 2024 Purchaser&#8217;s discretion), exercisable at any time upon their issuance until exercised in full and (iii) an aggregate of <ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-19161">2,980,000</ix:nonFraction> warrants, each representing the right to acquire <ix:nonFraction contextRef="c91" decimals="0" format="ixt-sec:numwordsen" name="nrsn:NumberOfOrdinaryShares" scale="0" unitRef="Number" id="ixv-19162">one</ix:nonFraction> ordinary share at an exercise price of $<ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-19163">1.50</ix:nonFraction> (either physically or on a net-cash basis at the April 2024 Purchaser&#8217;s discretion) and will expire on the fifth anniversary of the original issuance date. The gross proceeds were approximately $<ix:nonFraction contextRef="c92" decimals="-4" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" unitRef="usd" id="ixv-19164">4.47</ix:nonFraction> million. As part of the April 2024 Purchase Agreement, the Company also issued <ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-19165">70,964</ix:nonFraction> ordinary shares valued at <ix:nonFraction contextRef="c92" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherNoninterestExpense" scale="6" unitRef="usd" id="ixv-19166">0.1</ix:nonFraction> million as issuance expenses to the placement agent in the registered direct offering. Total issuance expenses in cash amounted to $<ix:nonFraction contextRef="c92" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" unitRef="usd" id="ixv-19167">0.153</ix:nonFraction> million. All consideration in this issuance was classified to equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 26, 2024, the Company and the April 2024 Purchaser reached an agreement to amend the terms of the warrants to extend the termination date from April 15, 2029, to October 12, 2029. The impact on the financial statements is immaterial.</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 27, 2024, the Company&#8217;s shareholders approved an amendment to the Company&#8217;s articles of association to increase the
registered share capital of the Company by an additional <ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" unitRef="shares" id="ixv-19168">30,000,000</ix:nonFraction> ordinary shares, such that the total registered share capital of
the Company would consist of <ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" scale="0" unitRef="shares" id="ixv-19169">90,000,000</ix:nonFraction> ordinary shares, no par value per share.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 6, 2024, the Company entered into a securities purchase agreement with certain investors, which include members of the Company&#8217;s senior management and existing investors. The Company agreed to sell an aggregate of <ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-19170">800,000</ix:nonFraction> ordinary shares and warrants to purchase an aggregate of <ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" unitRef="shares" id="ixv-19171">800,000</ix:nonFraction> ordinary shares, at a combined purchase price of $<ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="nrsn:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-19172">0.75</ix:nonFraction> per share and accompanying warrant. All consideration in this issuance was classified to equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each warrant was immediately exercisable upon issuance and has a five-year term from the issuance date. The exercise price of each warrant is $<ix:nonFraction contextRef="c98" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-19173">0.75</ix:nonFraction> per share, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if at the time of exercise thereof there is no effective registration statement registering the ordinary shares underlying the warrants. The gross proceeds were approximately $<ix:nonFraction contextRef="c99" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" unitRef="usd" id="ixv-19174">0.6</ix:nonFraction> million. Total issuance expenses in cash amounted to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" unitRef="usd" id="ixv-19175">0.015</ix:nonFraction> million.</p></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 9 - Shareholders&#8217; Equity (cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share capital (cont.)</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 16, 2024, the Company entered into
a Capital on Demand Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as sales agent
(the &#8220;Sales Agent&#8221;), pursuant to which the Company may offer and sell, from time to time, to or through the Sales Agent,
ordinary shares, having an aggregate offering price of up to gross sale proceeds of up to $<ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="3" unitRef="usd" id="ixv-19176">2,524</ix:nonFraction> thousand. The Company agreed to pay
the Sales Agent a commission equal to <ix:nonFraction contextRef="c100" decimals="3" format="ixt:num-dot-decimal" name="nrsn:SaleOfOrdinaryShareGrossProceedsPercentage" scale="-2" unitRef="pure" id="ixv-19177">3.0</ix:nonFraction>% of the gross proceeds from the sale of the ordinary shares pursuant to the Sales Agreement.
The Company has also agreed to reimburse the Sales Agent for certain specified expenses in connection with entering into the Sales Agreement
in the amount of up to $<ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" unitRef="shares" id="ixv-19178">50</ix:nonFraction> thousand. As of December 31, 2024, the Company sold <ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-19179">1,105,509</ix:nonFraction> ordinary shares for aggregate gross proceeds
of $<ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-19180">1,234</ix:nonFraction> thousand (net proceeds of $<ix:nonFraction contextRef="c101" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:NetProceedsFromTheOrdinaryShares" scale="3" unitRef="usd" id="ixv-19181">1,067</ix:nonFraction> thousand) under the Sales Agreement.</p></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company issued <ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares" id="ixv-19182">1,248,000</ix:nonFraction> and <ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares" id="ixv-19183">325,000</ix:nonFraction> ordinary shares following exercise of pre-funded warrants
from the Purchase Agreement (see Note 9f) and vested RSU&#8217;s, respectively.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 31, 2024,&#160;the &#8220;Company entered into a standby equity purchase agreement (the &#8220;SEPA&#8221;) with&#160;YA II PN, LTD., a Cayman Islands exempt limited partnership (&#8220;Yorkville&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the SEPA, the Company has the
right, but not the obligation, to sell to Yorkville from time to time (each such occurrence, an &#8220;Advance&#8221;) up to $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted" scale="6" unitRef="usd" id="ixv-19184">30.0</ix:nonFraction> million
(the &#8220;Commitment Amount&#8221;) of the Company&#8217;s ordinary shares,&#160;during the 36 months following the execution of the&#160;SEPA,
subject to the restrictions and satisfaction of the conditions in the SEPA. At the Company&#8217;s option, the ordinary shares would
be purchased by Yorkville from time to time at a price equal to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" unitRef="pure" id="ixv-19185">97</ix:nonFraction>% of the lowest of the three daily VWAPs (as hereinafter defined) during
a three consecutive trading day period commencing on the date that the Company, subject to certain limitations, delivers a notice to
Yorkville that the Company is committing Yorkville to purchase such ordinary shares (the &#8220;Advance Shares&#8221;).&#160;The Company
may also specify a certain minimum acceptable price per share in each Advance.&#160;&#8220;VWAP&#8221; means, for any trading day, the
daily volume weighted average price of the Company&#8217;s ordinary shares for such trading day on the Nasdaq Stock Market during regular
trading hours as reported by Bloomberg L.P. As consideration for Yorkville&#8217;s irrevocable commitment to purchase the Company&#8217;s
ordinary shares up to the Commitment Amount, the Company agreed to issue <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-19186">224,697</ix:nonFraction> ordinary shares valued at $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-19187">281</ix:nonFraction> thousand to Yorkville
and also paid a $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRestructuring" scale="3" unitRef="usd" id="ixv-19188">25,000</ix:nonFraction> structuring fee to Yorkville. The fee and shares fair value were recognized as finance expenses.</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 2, 2024, the Company&#160;entered
into a securities purchase agreement with a single investor the Company&#8217;s chief executive officer (together, the &#8220;December
2024 Purchasers&#8221;) in a private placement. The Company issued to the December 2024 Purchasers (i) an aggregate of <ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-19189">2,343,729</ix:nonFraction> ordinary
shares, (ii) an aggregate of <ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-19190">1,656,271</ix:nonFraction> pre-funded warrants, each representing the right to acquire <ix:nonFraction contextRef="c106" decimals="0" format="ixt-sec:numwordsen" name="nrsn:NumberOfOrdinaryShares" scale="0" unitRef="pure" id="ixv-19191">one</ix:nonFraction> ordinary share, and (iii) an aggregate
of <ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-19192">8,000,000</ix:nonFraction> ordinary warrants, each representing the right to acquire <ix:nonFraction contextRef="c108" decimals="0" format="ixt-sec:numwordsen" name="nrsn:NumberOfOrdinaryShares" scale="0" unitRef="pure" id="ixv-19193">one</ix:nonFraction> ordinary share for total gross proceeds to the Company of
$<ix:nonFraction contextRef="c109" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" unitRef="usd" id="ixv-19194">5</ix:nonFraction> million (net proceeds of $<ix:nonFraction contextRef="c109" decimals="-4" format="ixt:num-dot-decimal" name="nrsn:NetProceedsFromIssuanceOfWarrants" scale="6" unitRef="usd" id="ixv-19195">4.94</ix:nonFraction> million). The ordinary warrants are exercisable immediately upon issuance at an exercise price of $<ix:nonFraction contextRef="c110" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-19196">1.25</ix:nonFraction>
per share and expire <ix:nonNumeric contextRef="c110" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-19197">five years</ix:nonNumeric> from the date of issuance. The pre-funded warrants are exercisable immediately upon issuance at an exercise
price of $<ix:nonFraction contextRef="c105" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-19198">0.0001</ix:nonFraction> per share and may be exercised at any time until the pre-funded warrants are exercised in full. All consideration in
this issuance was classified to equity.</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary Shares Right</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Each ordinary share is entitled to <ix:nonNumeric contextRef="c25" name="us-gaap:CommonStockVotingRights" id="ixv-19199">one</ix:nonNumeric> vote. The
holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the board
of directors, subject to the prior rights of holders of all classes of shares outstanding.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-17021"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 10 - Share Based Payment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">On December 16, 2018, the Company&#8217;s board
of directors approved an employee share option plan (&#8220;ESOP&#8221;). According to the provisions of the ESOP, the exercise period,
exercise price and vesting conditions for each option grant will be determined by the board of directors. The number of shares reserved
for issuance is subject to an annual increase to be added as of the first day of the Company&#8217;s fiscal year, equal to <ix:nonFraction contextRef="c111" decimals="2" format="ixt:num-dot-decimal" name="nrsn:NumberOfSharesPercentage" scale="-2" unitRef="pure" id="ixv-19200">4</ix:nonFraction>% of the total
number of shares issued and outstanding on a fully-diluted basis as of the end of the immediately preceding fiscal year (or such lesser
number of shares, including no shares, determined by the Board in its sole discretion). Ordinary shares subject to options granted under
the 2018 Plan that expire or forfeited or otherwise terminated without having been exercised in full will become available again for future
grant under the 2018 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The expiration date of the options granted to
employees and directors is after <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="nrsn:ExpirationDateGrantTerm" id="ixv-19201">10</ix:nonNumeric> years from the grant date. Relating to options granted to services providers, the expiration date
of the options is between <ix:nonNumeric contextRef="c112" format="ixt-sec:duryear" name="nrsn:ExpirationDateGrantTerm" id="ixv-19202">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c113" format="ixt-sec:duryear" name="nrsn:ExpirationDateGrantTerm" id="ixv-19203">10</ix:nonNumeric> years from the grant date. In addition, pursuant to the grant letters, the options granted to employees,
directors and service providers shall become vested and exercisable upon any merger or consolidation in which the Company is a constituent
party as described in the grant letters (&#8220;Exit Event&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">On October&#160;31, 2021, the Company&#8217;s
board of directors approved an amendment to the Company&#8217;s 2018 Employee Share Option Plan. The amendment determines that the total
number of underlying shares reserved for future issuance under the plan and any modification thereof, shall be:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-19204">900,000</ix:nonFraction>
shares, plus</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
annual increase to be added as of the first&#160;day of the Company&#8217;s fiscal year, beginning in 2022 and occurring each year thereafter
through 2032, equal to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="nrsn:NumberOfSharesPercentage" scale="-2" unitRef="pure" id="ixv-19205">4</ix:nonFraction>% of the total number of ordinary shares issued and outstanding on a fully-diluted basis as of the end of the
Company&#8217;s immediately preceding fiscal year (or such lesser number of shares, including no shares, determined by the board of directors
in its sole discretion).</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Following this amendment, the number of shares
reserved under this plan was <ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-19206">1,151,130</ix:nonFraction>. As of December 31, 2024, <ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-19207">688,705</ix:nonFraction> ordinary shares are available for future grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10 and January 11, 2022, the Company&#8217;s entered into option settlement agreement (&#8220;Agreements&#8221;) with certain
consultants of the Company. According to the Agreements, the Company exchanged <ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-19208">27,000</ix:nonFraction> options granted to certain consultants with cash
payments in the aggregate of $<ix:nonFraction contextRef="c118" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" unitRef="usd" id="ixv-19209">96</ix:nonFraction> thousand. The cash payment is deemed as the sole and complete settlement of the promised options. The
Company recorded an additional expense of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd" id="ixv-19210">23</ix:nonFraction> thousand for such settlement which was recorded in profit and loss. The Company recorded
the settlement agreement as a reduction in share premium and capital reserve.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 25, 2022 and March 10, 2022, the Company&#8217;s board of directors and shareholders, respectively, approved the compensation
of each of the Company&#8217;s external directors and a newly appointed director. Such compensation included the grant of <ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-19211">72,000</ix:nonFraction> options
to each such director at an exercise price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19212">1.43</ix:nonFraction> per share (total <ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-19213">216,000</ix:nonFraction> options to three directors), pursuant to the Company&#8217;s
2018 Employee Share Option Plan. One-third of each option award vests one year from the grant date and the remainder vests quarterly
and becomes fully vested <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-19214">three years</ix:nonNumeric> from the grant date. The options expire <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-19215">10</ix:nonNumeric> years after grant date.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 25, 2022, the Company&#8217;s board of directors approved the grant of aggregate amount of <ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-19216">192,000</ix:nonFraction> options to several employees.
The options have an exercise price of $<ix:nonFraction contextRef="c121" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19217">2.18</ix:nonFraction> per share. The options vest quarterly over three years starting January 25, 2022. The options
expire <ix:nonNumeric contextRef="c122" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-19218">10</ix:nonNumeric> years after grant date.</span></td>
</tr></table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -21.25pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 10 - Share Based Payment (cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022, the Company&#8217;s board of directors approved the grant of aggregate amount of <ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-19219">36,000</ix:nonFraction> options to an employee and amount
of <ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-19220">5,000</ix:nonFraction> options consultant of the Company. The options have an exercise price of $<ix:nonFraction contextRef="c125" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19221">3.97</ix:nonFraction> and $<ix:nonFraction contextRef="c126" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19222">2.18</ix:nonFraction>, respectively, per share. The options
vest quarterly over <ix:nonNumeric contextRef="c125" continuedAt="_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-c125_cont_1" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-19223">three</ix:nonNumeric> and <ix:nonNumeric contextRef="c126" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-19224">one<ix:continuation id="_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-c125_cont_1"> years</ix:continuation></ix:nonNumeric>, respectively, from grant date. The options expire <ix:nonNumeric contextRef="c127" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-19226">10</ix:nonNumeric> years after grant date.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July and August 2022, the Company&#8217;s board of directors approved the grant of aggregate amount of <ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-19227">20,000</ix:nonFraction> options to a consultant
and an amount of <ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-19228">120,000</ix:nonFraction> options to several employees of the Company. The options have an exercise price of $<ix:nonFraction contextRef="c128" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19229">2.18</ix:nonFraction> and $<ix:nonFraction contextRef="c129" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19230">1.99</ix:nonFraction>, respectively,
per share. The options vest quarterly over <ix:nonNumeric contextRef="c130" continuedAt="_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-c130_cont_1" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-19231">three</ix:nonNumeric> and <ix:nonNumeric contextRef="c131" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-19232">one<ix:continuation id="_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-c130_cont_1"> years</ix:continuation></ix:nonNumeric>, respectively, from grant date. The options expire <ix:nonNumeric contextRef="c131" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-19234"><ix:nonNumeric contextRef="c130" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-19235">10</ix:nonNumeric></ix:nonNumeric> years after grant
date.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2022 the Company issued <ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-19236">85,449</ix:nonFraction> of its ordinary shares to certain consultants in exchange for their services, with fair value of $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" unitRef="usd" id="ixv-19237">119</ix:nonFraction>
thousand. One of the consultants received <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" unitRef="shares" id="ixv-19238">44,000</ix:nonFraction> shares of restricted stock which were issued in <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="nrsn:NumberOfInstallments" scale="0" unitRef="pure" id="ixv-19239">4</ix:nonFraction> equal installments and subject to
<ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="nrsn:InstallmentsLockUpPeriod" id="ixv-19240">2</ix:nonNumeric> year lock-up period. Other consultant&#8217;s shares are subject to 6 months restriction period (which ended by December 31, 2022).</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">7.</td><td style="text-align: justify">On&#160;March 20, 2023, the Company&#8217;s board of directors,
approved the following awards:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
of <ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-19241">320,479</ix:nonFraction> RSUs to certain officers, in lieu of cash with respect to the 2022 bonus plan grants in the amount of $<ix:nonFraction contextRef="c133" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" unitRef="usd" id="ixv-19242">161</ix:nonFraction>&#160;thousand.
The RSUs vest quarterly over <ix:nonNumeric contextRef="c133" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-19243">two years</ix:nonNumeric> with acceleration condition upon meeting certain milestones. The Company met the milestones in
2023 and therefore the vesting was accelerated accordingly.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
bonus for certain employees in the form of <ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" scale="0" unitRef="shares" id="ixv-19244">100,000</ix:nonFraction> and <ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" scale="0" unitRef="shares" id="ixv-19245">60,000</ix:nonFraction> RSUs. The RSUs vest on a quarterly basis over <ix:nonNumeric contextRef="c136" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-19246">one year</ix:nonNumeric> following the grant
and on an annual basis over <ix:nonNumeric contextRef="c137" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-19247">three years</ix:nonNumeric> following the grant, respectively.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the grants in accordance with the 2022 bonus plan mentioned above, a raise of additional <ix:nonFraction contextRef="c138" decimals="2" format="ixt:num-dot-decimal" name="nrsn:RaiseOfAdditionalBonusPercentage" scale="-2" unitRef="pure" id="ixv-19248">30</ix:nonFraction>% of the annual 2022 bonus will
be granted to the Company&#8217;s CEO.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
grant of <ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-19249">13,628</ix:nonFraction> options to a consultant of the Company with a total fair value of $<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" unitRef="usd" id="ixv-19250">22,500</ix:nonFraction>. The options have an exercise price of $<ix:nonFraction contextRef="c140" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19251">1.82</ix:nonFraction>
per share. The options will vest monthly, over <ix:nonNumeric contextRef="c141" format="ixt-sec:durmonth" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-19252">9</ix:nonNumeric> months commencing January 1, 2023. The options expire <ix:nonNumeric contextRef="c141" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-19253">10</ix:nonNumeric> years after their grant date.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">8.</td><td style="text-align: justify">On May 30, 2023, the Company granted <ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-19254">160,000</ix:nonFraction> RSUs to directors
of the Company. The RSUs have an exercise price of $<ix:nonFraction contextRef="c143" decimals="2" format="ixt:num-dot-decimal" name="nrsn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19255">1.53</ix:nonFraction> per share. The RSUs shall vest entirely on the first anniversary of the vesting
commencement date, provided that no termination of employment of the grantee occurs prior to such anniversary.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">9.</td><td style="text-align: justify">On August 15, 2023, the Company&#8217;s board of directors
approved the grant of aggregate amount of <ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-19256">60,000</ix:nonFraction> options to several employees. The options have an exercise price of $<ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19257">0.96</ix:nonFraction> per share
and vest quarterly over <ix:nonNumeric contextRef="c144" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-19258">3</ix:nonNumeric> years starting August 15, 2023, and (ii) the grant of <ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-19259">9,000</ix:nonFraction> options to an employee. The options have an exercise
price of $<ix:nonFraction contextRef="c147" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19260">0.96</ix:nonFraction> per share and vest annually over <ix:nonNumeric contextRef="c146" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-19261">3</ix:nonNumeric> years starting August 15, 2023.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">10.</td><td style="text-align: justify">In May 2024, the Company&#8217;s board of directors, approved
the grant of <ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-19262">24,000</ix:nonFraction> RSUs to a consultant of the Company. <ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-19263">12,000</ix:nonFraction> RSUs vested on grant date, and the remaining <ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-19264">12,000</ix:nonFraction> RSUs will vest monthly
(<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-19265">2,000</ix:nonFraction> RSUs each month), over six months and until November 1, 2024. The fair value of RSUs is estimated by multiplying the number of
RSUs granted by the share price at grant date.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">11.</td><td style="text-align: justify">In May 2024, the Company&#8217;s board of directors, approved
the grant of <ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-19266">24,000</ix:nonFraction> RSUs to a consultant of the Company. <ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-19267">4,000</ix:nonFraction> RSUs vested on grant date, and the remaining <ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-19268">20,000</ix:nonFraction> RSUs will vest monthly
(<ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-19269">4,000</ix:nonFraction> RSUs each month), over six months and until October 1, 2024. The fair value of RSUs is estimated by multiplying the number of
RSUs granted by share price at grant date.</td>
</tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 10 - Share Based Payment (cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">12.</td><td style="text-align: justify">In May 2024, the Company&#8217;s board of directors, approved
the grant of <ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-19270">9,000</ix:nonFraction> options to an employee of the Company. The options will vest in equal amount annually over a <ix:nonNumeric contextRef="c153" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-19271">3</ix:nonNumeric> year period commencing
April 8, 2024. The options have an exercise price of $<ix:nonFraction contextRef="c154" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19272">1.27</ix:nonFraction> per share</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 27, 2024, the Company&#8217;s annual general meeting
of shareholders approved the following proposed resolutions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">A grant of <ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" unitRef="shares" id="ixv-19273">160,000</ix:nonFraction> RSUs to the non-management directors of
the Company. Such RSUs would vest on the <ix:nonNumeric contextRef="c155" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-19274">one year</ix:nonNumeric> anniversary of the date of the meeting.</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">To approve an amendment to the Company&#8217;s Articles of
Association to increase the authorized share capital of the Company.</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">3.</td><td style="text-align: justify">An acceleration of the vesting of the <ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-19275">18,000</ix:nonFraction> unvested options
of a former director, and extending the term of the unexercised options, such that they will expire <ix:nonNumeric contextRef="c94" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-19276">10</ix:nonNumeric> years from the date of grant</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The weighted average grant date fair value of
options granted during the years ended December&#160;31, 2024, 2023 and 2022 was $<ix:nonFraction contextRef="c157" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-19277">0.88</ix:nonFraction>, $<ix:nonFraction contextRef="c158" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-19278">0.80</ix:nonFraction> and $<ix:nonFraction contextRef="c159" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-19279">1.40</ix:nonFraction> per option, respectively. The
weighted average grant date fair value of RSUs granted during the years ended December&#160;31, 2024 and 2023 was $<ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-19280">1.08</ix:nonFraction> and $<ix:nonFraction contextRef="c161" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-19281">1.75</ix:nonFraction> per
RSU, respectively.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Regarding issuance of <ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" unitRef="shares" id="ixv-19282">70,964</ix:nonFraction> ordinary shares as
issuance costs in April 2024, see also Note 9A(f).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Stock-based compensation expenses recognized in
profit and loss as an operating expense based on fair value of the option at the grant date by using Binominal option pricing model for
employees and directors and Black and Scholes pricing
model for non-employees. The inputs for the valuation analysis of the share options include several assumptions of which the most significant
are the fair market value of the underlying ordinary share, the expected share price volatility and the expected option term. Expected
volatility was calculated based upon historical volatility of the Company and peer companies in the same industry on weekly basis. Expected
option term represents the period that the Company&#8217;s share options are expected to be outstanding. Risk-free interest rate is based
on the yield from U.S. treasury bonds with an equivalent term. Expected dividend yield assumption is based on the Company&#8217;s historical
experience and expectation of no future dividend payouts. The Company has historically not paid cash dividends and has no foreseeable
plans to pay cash dividends in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-17241"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The following table lists the inputs used for calculation
of fair value of the options granted to employees and directors for the years ended December 31, 2024, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Expected volatility</td><td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: center"><ix:nonFraction contextRef="c165" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-19283">93.72</ix:nonFraction>%</td><td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: center"><ix:nonFraction contextRef="c166" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-19284">91.80</ix:nonFraction>% - <ix:nonFraction contextRef="c167" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-19285">93.51</ix:nonFraction>%</td><td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: center"><ix:nonFraction contextRef="c168" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-19286">93.63</ix:nonFraction>% - <ix:nonFraction contextRef="c169" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-19287">93.79</ix:nonFraction>%</td></tr> <tr style="vertical-align: bottom; "> <td>Exercise price</td><td>&#160;</td> <td style="text-align: center"><ix:nonFraction contextRef="c170" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19288">1.27</ix:nonFraction></td><td>&#160;</td> <td style="text-align: center"><ix:nonFraction contextRef="c171" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19289">0.96</ix:nonFraction> - <ix:nonFraction contextRef="c172" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19290">1.99</ix:nonFraction></td><td>&#160;</td> <td style="text-align: center"><ix:nonFraction contextRef="c173" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19291">1.43</ix:nonFraction> - <ix:nonFraction contextRef="c174" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19292">3.97</ix:nonFraction></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Share price</td><td>&#160;</td> <td style="text-align: center"><ix:nonFraction contextRef="c170" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-19293">1.27</ix:nonFraction></td><td>&#160;</td> <td style="text-align: center"><ix:nonFraction contextRef="c171" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-19294">0.96</ix:nonFraction> - <ix:nonFraction contextRef="c172" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-19295">1.99</ix:nonFraction></td><td>&#160;</td> <td style="text-align: center"><ix:nonFraction contextRef="c173" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-19296">1.43</ix:nonFraction> - <ix:nonFraction contextRef="c174" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-19297">3.97</ix:nonFraction></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td> <td style="text-align: center"><ix:nonFraction contextRef="c165" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-19298">4.61</ix:nonFraction>%</td><td>&#160;</td> <td style="text-align: center"><ix:nonFraction contextRef="c166" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-19299">3.24</ix:nonFraction>% - <ix:nonFraction contextRef="c167" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-19300">4.35</ix:nonFraction>%</td><td>&#160;</td> <td style="text-align: center"><ix:nonFraction contextRef="c168" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-19301">2.12</ix:nonFraction>% - <ix:nonFraction contextRef="c169" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-19302">2.46</ix:nonFraction>%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td>&#160;</td> <td style="text-align: center"><ix:nonFraction contextRef="c165" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-19303">0</ix:nonFraction></td><td>&#160;</td> <td style="text-align: center"><ix:nonFraction contextRef="c175" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-19304">0</ix:nonFraction></td><td>&#160;</td> <td style="text-align: center"><ix:nonFraction contextRef="c176" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-19305">0</ix:nonFraction></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected life (years)</td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c165" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-19306">10</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c175" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-19307">10</ix:nonNumeric></td><td>&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c176" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-19308">10</ix:nonNumeric></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The following table lists the inputs used for
calculation of fair value of the options granted to consultants for the years ended December 31, 2024, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-19309">100.540</ix:nonFraction>%</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-19310">93.64</ix:nonFraction>%</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise price</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19311">1.82</ix:nonFraction></span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c18" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19312">2.18</ix:nonFraction></span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share price </span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-19313">1.82</ix:nonFraction></span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-19314">1.41</ix:nonFraction> - <ix:nonFraction contextRef="c178" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-19315">1.96</ix:nonFraction></span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-19316">3.64</ix:nonFraction>%</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c179" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-19317">1.91</ix:nonFraction>% - <ix:nonFraction contextRef="c180" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-19318">2.91</ix:nonFraction>%</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td> <td style="width: 1%">&#160;</td> <td style="white-space: nowrap; width: 13%; text-align: center"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="width: 1%">&#160;</td> <td style="white-space: nowrap; width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-19319">0</ix:nonFraction></span></td> <td style="width: 1%">&#160;</td> <td style="white-space: nowrap; width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-19320">0</ix:nonFraction></span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (years)</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-17387"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></ix:nonNumeric></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-19321">10</ix:nonNumeric></span></td></tr> </table></ix:nonNumeric></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 10 - Share Based Payment (cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-17419"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The following table summarizes the share option activity for employees,
directors, and non-employees for the annual periods ended on December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Number of</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted<br/> Average </b></span></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Weighted<br/> average<br/> remaining</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Intrinsic<br/>
value</b></span></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Share<br/>
Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Exercise<br/> Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">contractual<br/> life (years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">U.S. dollars<br/> in thousands</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Options outstanding at January 1, 2024</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c181" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-19322">1,069,128</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c181" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19323">2.26</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c182" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-19324">8.00</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c181" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd" id="ixv-19325">62</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c183" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-19326">9,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c183" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19327">1.27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c183" format="ixt-sec:duryear" name="nrsn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted" id="ixv-19328">10</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c183" decimals="INF" format="ixt:num-dot-decimal" name="nrsn:ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod" scale="0" sign="-" unitRef="shares" id="ixv-19329">9,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c183" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19330">0.96</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif">(*</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 2.5pt">Options outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c184" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-19331">1,069,128</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c184" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19332">2.30</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="c183" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-19333">6.68</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c184" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-19334">936,968</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c184" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19335">2.34</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="c183" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-19336">6.52</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">less than $1 thousands</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The income tax benefit for the share options exercised
expense after the valuation allowance is <ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="0" unitRef="usd" id="ixv-19337">0</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="ixv-17566"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The following table summarizes the RSUs activity for the annual periods
ended on December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted<br/>
 average<br/>
 grant date<br/>
 fair value</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Number of<br/>
    RSUs</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">U.S. dollars<br/>
 in&#160;thousands</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding at January 1, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c185" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-19338">317,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c185" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd" id="ixv-19339">249</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c160" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-19340">208,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c160" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" scale="3" unitRef="usd" id="ixv-19341">224</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c160" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-19342">325,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c163" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-19343">200,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><ix:nonFraction contextRef="c163" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd" id="ixv-19344">236</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The income tax benefit for the stock-based compensation
expense after the valuation allowance is <ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="0" unitRef="usd" id="ixv-19345">0</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="srt:CondensedStatementOfComprehensiveIncomeTableTextBlock" id="ixv-17635"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The share-based expense recognized in the statements of operations
were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Share-based compensation expense - Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c186" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-19346">193</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c187" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-19347">575</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c188" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-19348">570</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Share-based compensation expense - General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c189" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-19349">364</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c190" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-19350">962</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c191" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-19351">1,158</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-19352">557</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-19353">1,537</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-19354">1,728</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">As of December 31, 2024, there was $<ix:nonFraction contextRef="c163" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" unitRef="usd" id="ixv-19355"><ix:nonFraction contextRef="c164" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" unitRef="usd" id="ixv-19356">43</ix:nonFraction></ix:nonFraction> thousand
of unrecognized compensation expense related to unvested options and RSUs. Such unrecognized expenses will be recognized over a weighted
average period of approximately <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-19357">1.25</ix:nonNumeric> years.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="ixv-17725"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 11 - <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" id="ixv-19358">Research and development expenses</ix:nonNumeric></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Subcontractors and consultants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:SubcontractorsAndConsultants" scale="3" unitRef="usd" id="ixv-19359">3,530</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:SubcontractorsAndConsultants" scale="3" unitRef="usd" id="ixv-19360">4,794</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:SubcontractorsAndConsultants" scale="3" unitRef="usd" id="ixv-19361">3,612</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:SharebasedCompensation" scale="3" unitRef="usd" id="ixv-19362">193</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:SharebasedCompensation" scale="3" unitRef="usd" id="ixv-19363">575</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:SharebasedCompensation" scale="3" unitRef="usd" id="ixv-19364">570</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salaries and social benefits (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:SalariesAndSocialBenefits" scale="3" unitRef="usd" id="ixv-19365">1,975</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:SalariesAndSocialBenefits" scale="3" unitRef="usd" id="ixv-19366">1,905</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:SalariesAndSocialBenefits" scale="3" unitRef="usd" id="ixv-19367">1,405</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-19368">5,698</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-19369">7,274</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-19370">5,587</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="nrsn:GeneralAndAdministrativeExpensesDisclosureTextBlock" id="ixv-17825"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 12 - General and Administrative Expenses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="nrsn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" id="ixv-17829"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professional services</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" unitRef="usd" id="ixv-19371">1,998</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" unitRef="usd" id="ixv-19372">1,486</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" unitRef="usd" id="ixv-19373">1,085</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd" id="ixv-19374">364</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd" id="ixv-19375">962</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd" id="ixv-19376">1,158</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salaries and social benefits (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="3" unitRef="usd">865</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="3" unitRef="usd">1,011</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="3" unitRef="usd">1,014</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="3" unitRef="usd" id="ixv-19380">309</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="3" unitRef="usd" id="ixv-19381">511</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="3" unitRef="usd" id="ixv-19382">1,174</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Traveling abroad</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TravelAndEntertainmentExpense" scale="3" unitRef="usd" id="ixv-19383">134</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TravelAndEntertainmentExpense" scale="3" unitRef="usd" id="ixv-19384">164</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TravelAndEntertainmentExpense" scale="3" unitRef="usd" id="ixv-19385">165</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-19386">534</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-19387">641</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-19388">371</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-19389">4,204</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-19390">4,775</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-19391">4,967</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US">During 2024, 2023 and 2022, the Company paid to pension funds
and to insurance companies an amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionContributions" scale="3" unitRef="usd" id="ixv-19393">115</ix:nonFraction> thousand, $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionContributions" scale="3" unitRef="usd" id="ixv-19394">104</ix:nonFraction> thousand and $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionContributions" scale="3" unitRef="usd" id="ixv-19395">85</ix:nonFraction> thousand which are included in Company&#8217;s salary expenses
under research and development and general and administrative expenses, respectively.</ix:footnote></td>
</tr></table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock" id="ixv-17959"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 13 - Financing Income (expenses), net</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="ixv-17963"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Finance Income:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Revaluation of warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" sign="-" unitRef="usd" id="ixv-19396">46</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" sign="-" unitRef="usd" id="ixv-19397">2,191</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deposit interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd" id="ixv-19398">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd" id="ixv-19399">178</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd" id="ixv-19400">91</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rates</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:ExchangeRates" scale="3" unitRef="usd" id="ixv-19401">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" unitRef="usd" id="ixv-19402">48</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" unitRef="usd" id="ixv-19403">2,390</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" unitRef="usd" id="ixv-19404">91</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="3" unitRef="usd" id="ixv-19405">306</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="3" unitRef="usd" id="ixv-19406">439</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exchange rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ExchangeFees" scale="3" unitRef="usd" id="ixv-19407">45</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ExchangeFees" scale="3" unitRef="usd" id="ixv-19408">22</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Bank fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseLoansFromOtherFederalHomeLoanBanks" scale="3" unitRef="usd" id="ixv-19409">5</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseLoansFromOtherFederalHomeLoanBanks" scale="3" unitRef="usd" id="ixv-19410">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseLoansFromOtherFederalHomeLoanBanks" scale="3" unitRef="usd" id="ixv-19411">7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" unitRef="usd" id="ixv-19412">356</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" unitRef="usd" id="ixv-19413">448</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" unitRef="usd" id="ixv-19414">29</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total financing income (expanse), net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-19415">308</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-19416">1,942</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-19417">62</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-18179"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 14 - Related Parties Balances and Transactions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 10 and June 21, 2022, the Company&#8217;s board of directors and shareholders, respectively, approved a bonus plan for 2022 for the
Company&#8217;s officers. The bonus plan defined specified millstones (in fields of clinic trial progress, business developments and
raise of money) which their achievements entitled the officers with different percentages out of fix amount of bonus.&#160;As detailed
in the plan, such bonuses (if entitled) will be paid in cash or, if the Company has less than $<ix:nonFraction contextRef="c177" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" unitRef="usd" id="ixv-19418">6</ix:nonFraction> million of cash and cash equivalents
and deposits on December 31, 2022, a number of ordinary shares of the Company with a value equal to the cash bonus amount to which the
officer would otherwise have been entitled, valuing each ordinary share at the closing price of the Company&#8217;s shares on Nasdaq
on December 31, 2022. Since the cash and cash equivalents and deposits on December 31,2022 was more than $<ix:nonFraction contextRef="c178" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" unitRef="usd" id="ixv-19419">6</ix:nonFraction> million, the 2022 bonus should
have been paid in cash. Based on the goals achieved&#160;as of December 31, 2022, the Company recorded a payment liability in the amount
of $<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-19420">370</ix:nonFraction> thousand which has been recorded as salary fee in the year ending December 31, 2022. In March 2023, certain officer&#8217;s 2022
bonus was replaced by issuance of RSUs and an update to 2022 annual bonus of the CEO was approved (see also Note 10).</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
March and May 2023, certain officers and directors were granted with options and RSUs, see also Note 10.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March and May, 2023, the Company&#8217;s board of directors and shareholders, respectively, approved a bonus plan for 2023 for the Company&#8217;s
officers. The bonus plan defined specified millstones (in fields of clinic trail progress, regulatory efforts, business developments
and raise of money) which their achievements entitled the officers with different percentages out of fix amount of bonus.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2024, the Company&#8217;s board of directors approved a change to the 2023 bonuses plan to the Company&#8217;s officers for which
included a change to the bonus calculations previously approved. Following the change, such bonuses will become effective and paid only
after a capital raise, that will allow the initiation of the Company&#8217;s planned phase 3 clinical study, of at least $<ix:nonFraction contextRef="c192" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:AccruedBonusesCurrentAndNoncurrent" scale="6" unitRef="usd" id="ixv-19421">18</ix:nonFraction> million.
The aggregate amount of the potential bonus payable to the officers after such capital raise will be approximately $<ix:nonFraction contextRef="c193" decimals="-5" format="ixt:num-dot-decimal" name="nrsn:PotentialBonusPayable" scale="6" unitRef="usd" id="ixv-19422">0.8</ix:nonFraction> million.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2024, the Company&#8217;s board of directors approved a bonus plan for 2024 for certain Company&#8217;s officers. The bonus plan
defined specified millstones (in fields of clinic trail progress, regulatory affairs, business developments and capital raising).</span></td>
</tr></table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 14 - Related Parties Balances and Transactions (cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">5.</td><td style="text-align: justify">On June 27, 2024, the Company&#8217;s annual general meeting
of shareholders approved the following proposed resolutions, among others:</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in">1.</td> <td style="text-align: justify">An acceleration of the vesting of the <ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-19423">18,000</ix:nonFraction> unvested options of a former director, and extending the term of the unexercised options, such that they will expire <ix:nonNumeric contextRef="c94" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-19424">10</ix:nonNumeric> years from the date of grant</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>2.</td> <td style="text-align: justify">To approve a 2024 bonus plan for the Company&#8217;s CEO Officer of the Company, based on the achievement of certain Company milestones.</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>3.</td> <td style="text-align: justify">To approve the renewal of Mr. Alon Ben-Noon&#8217;s the Company&#8217;s CEO&#8217;s employment agreement with the Company and in addition, an update to his salary in the event that the Company raises an aggregate of US <ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-19425">25,000,000</ix:nonFraction>.</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>4.</td> <td style="text-align: justify">To approve the grant of <ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-19426">160,000</ix:nonFraction> RSUs to the Company&#8217;s directors, see Note 10.</td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 17, 2024, the Company&#8217;s CEO, together with CFO, CMO, CTO, COO, signed a waiver letter with respect to bonuses, that they
were entitled for the years 2022-2024 in their capacity as shareholders. As part of this waiver, the Company recorded an amount of $<ix:nonFraction contextRef="c196" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="3" unitRef="usd" id="ixv-19427">1,434</ix:nonFraction>
thousands within additional paid in capital.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
August and December 2024, the Company entered into a share purchase agreement with certain senior management, see also Note 9A(h) and
9A(l).</span></td>
</tr></table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock" id="ixv-18307"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 15 &#8211; Segment Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Segment information is prepared on the same basis
that the chief executive officer, who is the Company&#8217;s chief operating decision maker, manages the business, makes business decisions
and assesses performance. The Company has one reportable segment specializing in the development of treatments for patients suffering
from debilitating neurodegenerative diseases, as described in Note 1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The CODM assesses performance for this segment
and decides how to allocate resources based on net loss. This net loss comprised of research and development expenses related to its product,
general and administrative costs and net financing income or expanses. The CODM performs the assessment of segment performance by using
the reported measure of segment profit or loss to monitor budget versus actual results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net profit or loss report regularly reviewed
by the CODM is identical to the Consolidated Statements of Income and Comprehensive Loss and the related notes in the financial statements
of the company for years ending December 31, 2024, 2023 and 2022.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-18338"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 16 - Income Taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Israeli taxation: </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The tax rate relevant to the Company
in the years 2024, 2023 and 2022 was <ix:nonFraction contextRef="c197" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" scale="-2" unitRef="pure" id="ixv-19428"><ix:nonFraction contextRef="c198" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" scale="-2" unitRef="pure" id="ixv-19429"><ix:nonFraction contextRef="c199" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" scale="-2" unitRef="pure" id="ixv-19430">23</ix:nonFraction></ix:nonFraction></ix:nonFraction>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.45pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of December 31, 2024, the Company
has net operating loss carryforwards for Israeli income tax purposes of approximately $<ix:nonFraction contextRef="c200" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-19431">24,730</ix:nonFraction>, which can be offset against future taxable
income for an indefinite period of time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.45pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company has
final (considered final) tax assessments in Israel through the 2019 tax year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred taxes reflect the net tax effects of carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-19432">Significant components of the Company&#8217;s net deferred tax assets are as follows:</ix:nonNumeric></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-size: 1pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>U.S. dollars<br/>
 in thousands</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net operating loss carryforward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-19433">5,688</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-19434">3,315</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Other temporary differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsStateTaxes" scale="3" unitRef="usd" id="ixv-19435">95</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsStateTaxes" scale="3" unitRef="usd" id="ixv-19436">71</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Capitalized research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-19437">1,282</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-19438">1,395</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:DeferredTaxAssetsOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-19439">17</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:DeferredTaxAssetsOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-19440">33</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Vacation and convalescence accrual</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:DeferredTaxAssetsVacationAndConvalescenceAccrual" scale="3" unitRef="usd" id="ixv-19441">67</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="nrsn:DeferredTaxAssetsVacationAndConvalescenceAccrual" scale="3" unitRef="usd" id="ixv-19442">50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Total deferred tax assets:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-19443">7,149</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-19444">4,864</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Deferred tax liability: Operating lease right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" unitRef="usd" id="ixv-19445">19</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" unitRef="usd" id="ixv-19446">35</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total deferred tax liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" unitRef="usd" id="ixv-19447">19</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" unitRef="usd" id="ixv-19448">35</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Net deferred tax assets:</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-19449">7,130</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-19450">4,829</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Less: Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-19451">7,130</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-19452">4,829</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In assessing the realization of deferred
tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.
The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which
temporary differences are deductible and net operating loss carryforward are available. Based on consideration of these factors, the Company
recorded a valuation allowance as of December 31, 2024 and 2023 for all deferred tax assets not supported by reversing taxable temporary
differences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.45pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The portion of the valuation allowance
for deferred tax assets for which subsequently recognized tax benefits would be applied directly to contributed capital was $<ix:nonFraction contextRef="c197" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-19453">782</ix:nonFraction> thousand
and $<ix:nonFraction contextRef="c198" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" unitRef="usd" id="ixv-19454">693</ix:nonFraction> thousand in 2024 and 2023, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.45pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.45pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NeuroSense Therapeutics Ltd.<br/>
Notes to the Consolidated Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 16 - Income Taxes (cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify">During the years ended December 31, 2024 and 2023, the main reconciling item between the statutory income tax rate in Israel, the country of domicile of the Company (as noted in Note 16A) and the effective tax rate is mainly the recognition of valuation allowance in respect of deferred taxes relating to net operating loss carryforwards and other temporary differences due to the uncertainty of the realization of such deferred taxes.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.25in"> The net change during the year ended December 31, 2024, 2023 and 2022 in the total valuation allowance amounted was $<ix:nonFraction contextRef="c197" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" unitRef="usd" id="ixv-19455">2,301</ix:nonFraction> thousands, $<ix:nonFraction contextRef="c198" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" unitRef="usd" id="ixv-19456">1,813</ix:nonFraction> thousands and $$<ix:nonFraction contextRef="c199" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" unitRef="usd" id="ixv-19457">1,419</ix:nonFraction> thousands, respectively. &#160; </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="ixv-18598"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The movement of the valuation allowance (through income statement) is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt"><b>U.S. dollars in thousands</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">Balance at the beginning of the year</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-19458">4,829</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-19459">3,016</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-19460">1,607</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Addition of valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" unitRef="usd" id="ixv-19461">2,301</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" unitRef="usd" id="ixv-19462">1,813</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" unitRef="usd" id="ixv-19463">1,409</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Net change in the valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" unitRef="usd" id="ixv-19464">2,301</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" unitRef="usd" id="ixv-19465">1,813</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" unitRef="usd" id="ixv-19466">1,409</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Balance at the end of the year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-19467">7,130</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-19468">4,829</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-19469">3,016</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-18722"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 17 - Subsequent Events </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the date hereof, the Company sold <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-19470">444,216</ix:nonFraction> of it&#8217;s ordinary shares pursuant to the Sales Agreement for aggregate gross proceeds of approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" unitRef="usd" id="ixv-19471">509</ix:nonFraction>.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 31, 2025, the Company&#8217;s board of directors approved the grant of aggregate amount of <ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" unitRef="shares" id="ixv-19472">108,000</ix:nonFraction> options to several employees. The options have an exercise price of $<ix:nonFraction contextRef="c202" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19473">0.93</ix:nonFraction> per share. The options vest quarterly over <ix:nonNumeric contextRef="c201" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-19474">three years</ix:nonNumeric> and expire <ix:nonNumeric contextRef="c201" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-19475">10</ix:nonNumeric> years after grant date.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 31, 2025, the Company&#8217;s board of directors approved the grant of an aggregate amount of <ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-19476">355,512</ix:nonFraction> RSUs to several consultants and service providers. </span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 31, 2025, the Company&#8217;s board of directors approved the grant of an aggregate amount of <ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-19477">20,000</ix:nonFraction> options to several consultants. The options have an exercise price of $<ix:nonFraction contextRef="c205" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-19478">0.93</ix:nonFraction> per share. The options vest over <ix:nonNumeric contextRef="c204" continuedAt="_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-c204_cont_1" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-19479">one</ix:nonNumeric><ix:continuation id="_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-c204_cont_1"> year</ix:continuation> and expire <ix:nonNumeric contextRef="c204" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-19481">10</ix:nonNumeric> years after grant date.</span></td></tr> </table></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-28</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

















</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c4" id="hidden-fact-0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-1" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-2" name="us-gaap:LiabilitiesNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-3" name="us-gaap:CommonStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-4" name="us-gaap:CommonStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-5" name="us-gaap:CommonStockNoParValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-6" name="us-gaap:CommonStockNoParValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c8" id="hidden-fact-7" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-8" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-9" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-10" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-11" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-12" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-13" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-14" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-15" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-16" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-17" name="nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-18" name="nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-19" name="nrsn:StockIssuedDuringPeriodValuePre-fundedWarrantsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-20" name="nrsn:StockIssuedDuringPeriodValuePre-fundedWarrantsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-21" name="nrsn:StockIssuedDuringPeriodValuePre-fundedWarrantsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-22" name="nrsn:StockIssuedDuringPeriodValuePre-fundedWarrantsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-23" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-24" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-25" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-26" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-27" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-28" name="nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-29" name="nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-30" name="nrsn:StockIssuedDuringPeriodValuePre-fundedWarrantsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-31" name="nrsn:StockIssuedDuringPeriodValuePre-fundedWarrantsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-32" name="nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-33" name="nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-34" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-35" name="nrsn:StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-36" name="nrsn:StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-37" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-38" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-39" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-40" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-41" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-42" name="nrsn:RevaluationOfLiabilityInRespectToWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-43" name="nrsn:RedemptionofinvestmentInShorttermDeposits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-44" name="us-gaap:PaymentsForRepurchaseOfOtherEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-45" name="us-gaap:PaymentsForRepurchaseOfOtherEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-46" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-47" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-48" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-49" name="nrsn:ReclassificationOfWarrantsIntoEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-50" name="nrsn:ReclassificationOfWarrantsIntoEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-51" name="nrsn:BonusAccrualReclassificationToEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-52" name="nrsn:BonusAccrualReclassificationToEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-53" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-54" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c35" id="hidden-fact-55" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric>
<ix:nonFraction contextRef="c39" id="hidden-fact-56" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-57" name="us-gaap:Supplies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-58" name="us-gaap:PropertyPlantAndEquipmentAdditions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-59" name="us-gaap:PropertyPlantAndEquipmentAdditions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c42" id="hidden-fact-60" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c45" id="hidden-fact-61" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-62" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-63" name="us-gaap:PropertyPlantAndEquipmentAdditions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-64" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-65" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c42" id="hidden-fact-66" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c4" id="hidden-fact-67" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">http://fasb.org/us-gaap/2024#LiabilitiesCurrent</ix:nonNumeric>
<ix:nonFraction contextRef="c4" id="hidden-fact-68" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-69" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-70" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-71" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-72" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-73" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c68" id="hidden-fact-74" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-75" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-76" name="us-gaap:CommonStockNoParValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-77" name="us-gaap:CommonStockNoParValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="INF" id="hidden-fact-78" name="us-gaap:CommonStockSharesOutstanding" unitRef="shares">15379042</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="INF" id="hidden-fact-79" name="us-gaap:CommonStockSharesOutstanding" unitRef="shares">23228941</ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-80" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-81" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-82" name="us-gaap:SharePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-83" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-85" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xsi:nil="true"></ix:nonNumeric>
<ix:nonNumeric contextRef="c183" id="hidden-fact-86" name="nrsn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c184" id="hidden-fact-87" name="nrsn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c184" id="hidden-fact-88" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c184" id="hidden-fact-89" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-90" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-91" name="nrsn:ExchangeRates" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-92" name="nrsn:ExchangeRates" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-93" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-94" name="us-gaap:ExchangeFees" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-95" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-96" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-19581">0001875091</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-19582">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-19583">FY</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="nrsn-20241231.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="hidden-fact-56" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-60 hidden-fact-61 hidden-fact-62 hidden-fact-65 hidden-fact-66" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_0_fact ix_1_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_2_fact ix_3_fact ix_4_fact" toRefs="ix_3_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrsn:OrdinarySharesNoParValuePerShareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrsn:WarrantsExercisableForOneOrdinaryShareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:PrefundedWarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-22</xbrli:startDate>
    <xbrli:endDate>2023-06-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-26</xbrli:startDate>
    <xbrli:endDate>2024-06-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-26</xbrli:startDate>
    <xbrli:endDate>2024-06-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:LiabilityInRespectOfWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:LiabilityInRespectOfWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-06-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:WarrantLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:WarrantLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:WarrantLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:WarrantLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:WarrantLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-31</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrsn:AllianceGlobalPartnersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-04-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-22</xbrli:startDate>
    <xbrli:endDate>2023-06-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-22</xbrli:startDate>
    <xbrli:endDate>2023-06-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-22</xbrli:startDate>
    <xbrli:endDate>2023-06-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-22</xbrli:startDate>
    <xbrli:endDate>2023-06-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-22</xbrli:startDate>
    <xbrli:endDate>2023-06-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-23</xbrli:startDate>
    <xbrli:endDate>2023-06-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-23</xbrli:startDate>
    <xbrli:endDate>2023-06-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:AprilTwoThousandTwentyFourPurchaseAgrementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-10</xbrli:startDate>
    <xbrli:endDate>2024-04-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:PrefundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:AprilTwoThousandTwentyFourPurchaseAgrementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:PrefundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:AprilTwoThousandTwentyFourPurchaseAgrementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-10</xbrli:startDate>
    <xbrli:endDate>2024-04-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:AprilTwoThousandTwentyFourPurchaseAgrementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:AprilTwoThousandTwentyFourPurchaseAgrementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-10</xbrli:startDate>
    <xbrli:endDate>2024-04-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:AprilTwoThousandTwentyFourPurchaseAgrementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-10</xbrli:startDate>
    <xbrli:endDate>2024-04-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:AprilTwoThousandTwentyFourPurchaseAgrementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-10</xbrli:startDate>
    <xbrli:endDate>2024-04-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-27</xbrli:startDate>
    <xbrli:endDate>2024-06-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-06</xbrli:startDate>
    <xbrli:endDate>2024-08-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-06</xbrli:startDate>
    <xbrli:endDate>2024-08-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYr+wciqhzO/TfNA0j8XAlDAX7Zs47GSe9YMpKX3MDHhrSmRPgkEK2u4ljrzwvIHfipcuE8XnwJBLDmhtLtl0Wkd3Ky+cGV3Eyy38kF0sLLqLlSwS0k9bURwWYWBfc634LCqUrXFOnmt5cVMGx9HtlaGkOgF0h8jEXpNuhYUKaCY+uhBk8nA3wEfnqV0gileaPM8GZVpEOik5keRqcHfnwDb/IfAuMyEk8nfZrG0zmWpe6TZP15grSxGNo3vhrysuRGGgJqrBI6Ow==] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:SalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-16</xbrli:startDate>
    <xbrli:endDate>2024-08-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-16</xbrli:startDate>
    <xbrli:endDate>2024-08-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:PrefundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:PurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:PurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-02</xbrli:startDate>
    <xbrli:endDate>2024-12-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-02</xbrli:startDate>
    <xbrli:endDate>2024-12-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-02</xbrli:startDate>
    <xbrli:endDate>2024-12-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-02</xbrli:startDate>
    <xbrli:endDate>2024-12-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-12-16</xbrli:startDate>
    <xbrli:endDate>2018-12-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrsn:TwoThousandEighteenEmployeeShareOptionPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-31</xbrli:startDate>
    <xbrli:endDate>2021-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrsn:TwoThousandEighteenEmployeeShareOptionPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrsn:TwoThousandEighteenEmployeeShareOptionPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-10</xbrli:startDate>
    <xbrli:endDate>2022-01-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-11</xbrli:startDate>
    <xbrli:endDate>2022-01-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrsn:TwoThousandEighteenEmployeeShareOptionPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-01-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-25</xbrli:startDate>
    <xbrli:endDate>2022-01-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrsn:TwoThousandEighteenEmployeeShareOptionPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-31</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-31</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrsn:TwoThousandEighteenEmployeeShareOptionPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-31</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrsn:TwoThousandEighteenEmployeeShareOptionPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-31</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-31</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-31</xbrli:startDate>
    <xbrli:endDate>2022-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-31</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-07-31</xbrli:startDate>
    <xbrli:endDate>2022-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-08-31</xbrli:startDate>
    <xbrli:endDate>2022-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrsn:TwoThousandTwentyTwoBonusPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-20</xbrli:startDate>
    <xbrli:endDate>2023-03-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-20</xbrli:startDate>
    <xbrli:endDate>2023-03-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-20</xbrli:startDate>
    <xbrli:endDate>2023-03-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrsn:TwoThousandTwentyTwoBonusPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-20</xbrli:startDate>
    <xbrli:endDate>2023-03-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-20</xbrli:startDate>
    <xbrli:endDate>2023-03-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-20</xbrli:startDate>
    <xbrli:endDate>2023-03-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-30</xbrli:startDate>
    <xbrli:endDate>2023-05-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-30</xbrli:startDate>
    <xbrli:endDate>2023-05-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-15</xbrli:startDate>
    <xbrli:endDate>2023-08-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-08-15</xbrli:startDate>
    <xbrli:endDate>2023-08-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-08-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-01</xbrli:startDate>
    <xbrli:endDate>2024-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-01</xbrli:startDate>
    <xbrli:endDate>2024-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">nrsn:November12024Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-01</xbrli:startDate>
    <xbrli:endDate>2024-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-01</xbrli:startDate>
    <xbrli:endDate>2024-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">nrsn:October12024Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-01</xbrli:startDate>
    <xbrli:endDate>2024-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-01</xbrli:startDate>
    <xbrli:endDate>2024-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-27</xbrli:startDate>
    <xbrli:endDate>2024-06-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-30</xbrli:startDate>
    <xbrli:endDate>2024-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-31</xbrli:startDate>
    <xbrli:endDate>2024-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrsn:MrAlonBenNoonsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrsn:MrAlonBenNoonsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-27</xbrli:startDate>
    <xbrli:endDate>2024-06-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-17</xbrli:startDate>
    <xbrli:endDate>2024-12-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-31</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-31</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:ConsultantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-31</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001875091</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:ConsultantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="Number">
  <xbrli:measure>nrsn:Number</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ea023729501ex1-1_neuro.htm
<DESCRIPTION>AMENDED AND RESTATED ARTICLES OF ASSOCIATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED ARTICLES OF ASSOCIATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>of</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>NeuroSense
Therapeutics LTD.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INTERPRETATION</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In these Articles the following terms shall bear the meanings set opposite to them, unless the context otherwise requires:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Terms</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 70%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Meanings</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Articles</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These Amended and Restated Articles of Association as may be amended from time to time.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Auditor </B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined under the Companies Law.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board </B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board of Directors of the Company.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business Day</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any day other than Saturday, Sunday or public holiday under the laws of Israel or the State of New York or other day on which banking institutions are authorized or obligated to close in Israel or the State of New York.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chairperson</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board, or the Chairperson of the General Meeting, as the context implies.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CEO</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer of the Company, also referred to under the Companies Law as the General Manager.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Class Meeting</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A meeting of the holders of a class of shares. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroSense Therapeutics Ltd. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Companies Law</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli Companies Law, 5759-1999 and any other law which may come in its stead, in each case, as amended from time to time.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Derivative Transaction</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined below.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividend</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined under the Companies Law.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EC Law</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli Economic Competition Law, 5748-1988.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>External Director</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 70%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined under the Companies Law.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General Meeting</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An annual meeting or special meeting of the shareholders of the Company (as such terms are defined in Article 19 of these Articles), as the case may be.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Internal Auditor</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An internal auditor appointed by the Company in accordance with Section 146(a) of the Companies Law.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Office </B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registered office of the Company from time to time.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Office Holder</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As defined under the Companies Law.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary Share(s)</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&rsquo;s Ordinary Shares, of no par value per share.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Person</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A company, corporate body, partnership, corporation, limited liability company, association, trust, unincorporated organization, or a government or agency or political subdivision thereof, or an individual.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Register</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&rsquo;s shareholders register, maintained in accordance with the Companies Law.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities Law</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli Securities Law, 5728-1968.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Simple Majority</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A majority of more than fifty percent (50%) of the votes cast by those shareholders voting in person or by proxy (including by voting deed), not taking into consideration abstaining votes.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Special Majority</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A majority of sixty-six and two thirds percent (66 2/3%) or more of the votes cast by those shareholders voting in person or by proxy (including by voting deed), not taking into consideration abstaining votes.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statutes</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Companies Law and, to the extent applicable to the Company, the Israeli Companies Ordinance (New Version) 1983, the Securities Law and all applicable laws and regulations applicable in any relevant jurisdiction (including without limitation U.S. federal laws and regulations), and rules of any stock market in which the Company&rsquo;s shares are registered for trading as shall be in force from time to time.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 38px; text-align: justify">Subject to the provisions of this
Article 1 and unless the context necessitates another meaning, terms and expressions in these Articles which have been defined in the
Statutes shall have the meanings ascribed to them therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Words importing the singular shall include the plural, and <I>vice versa</I>. Any pronoun shall include the corresponding masculine, feminine and neuter forms; and words importing persons shall include corporate bodies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Any provision or part thereof of these
Articles, prohibited by applicable law, shall be ineffective, without invalidating any other part of these Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NAME OF THE COMPANY</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The name of the Company is NeuroSense
Therapeutics Ltd. (and in Hebrew <B>&#1504;&#1493;&#1497;&#1512;&#1493;&#1505;&#1504;&#1505; &#1514;&#1512;&#1508;&#1497;&#1493;&#1496;&#1497;&#1511;&#1505;
&#1489;&#1506;&rdquo;&#1502;</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OBJECTIVES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The objectives of the Company shall
be to engage in any activity permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PUBLIC COMPANY</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company is a public company as
such term is defined in, and for so long as it qualifies under, the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIMITED LIABILITY</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The liability of each shareholder
for the Company&rsquo;s obligations is limited to the <FONT STYLE="background-color: white">payment of the nominal value</FONT> of the
shares held by such shareholder, subject to the provisions of the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CAPITAL, SHARES AND RIGHTS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registered share capital of the Company consists of 90 million Ordinary Shares without par value.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to Article 13, all issued and outstanding shares of the Company of the same class are of equal rights between them for all intents and purposes concerning the rights set forth in these Articles.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to Article 13, each issued Ordinary Share entitles its holder to the rights as described below:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The equal right to participate in and vote at the Company&rsquo;s General Meetings, and each of the shares in the Company shall entitle the holder thereof, who is present at the meeting and participating in the vote, whether in person, or by proxy, to one vote.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The equal right to participate in any Dividend or distribution of bonus shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The equal right to participate in the distribution of assets available for distribution in the event of liquidation of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If two or more persons are registered as joint holders of any shares, any one of such persons may give effectual receipts for any dividend or other monies in respect of such share and his or her confirmation will bind all holders of such share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHARE CERTIFICATES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the extent that the Board determines that all shares shall be certificated or, if the Board does not so determine, to the extent that any Shareholder requests a share certificate or the Company&rsquo;s transfer agent so requires, share certificates shall be issued under the corporate seal of the Company or its written, typed or stamped name and shall bear the signature of one Director, the CEO, or any person or persons authorized therefor by the Board. Signatures may be affixed in any mechanical or electronic form, as the Board may prescribe.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may issue a new certificate <I>in lieu of </I>a certificate that was issued and was lost, defaced, or destroyed, on the basis of such proof and guarantees as the Company may require, and after payment of an amount that shall be prescribed by the Company, and the Company may also replace existing certificates with new certificates, free of charge, subject to such conditions as the Company shall stipulate.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTERED HOLDER</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as otherwise provided in these Articles, the Company shall be entitled to treat the registered holder of any share as the absolute owner thereof, and, accordingly, shall not, except as ordered by a court of competent jurisdiction, or as required by statute, be bound to recognize any equitable or other claim to, or interest in, such share on the part of any other person.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to and in accordance with the provisions of Sections&nbsp;138 and 139 of the Companies Law, the Company may cause supplementary registers to be kept in any place outside Israel as the Board may think fit, and, subject to all applicable requirements of law, the Board may from time to time adopt such rules and procedures as it may think fit in connection with the keeping of such branch registers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ISSUANCE AND REPURCHASE OF SHARES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unissued shares from time to time shall be under the control of the Board (and, to the full extent permitted by law, any Committee thereof), which shall have the power to issue or otherwise dispose of shares and of securities convertible or exercisable into or other rights to acquire from the Company to such persons, on such terms and conditions, or subject to the provisions of the Companies Law, at a discount and/or with payment of commission, and at such times, as the Board (or the Committee, as the case may be) deems fit, and the power to give to any person the option to acquire from the Company any shares or securities convertible or exercisable into or other rights to acquire from the Company, or, subject as aforesaid, at a discount and/or with payment of commission, during such time and for such consideration as the Board (or the Committee, as the case may be) deems fit.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may at any time and from time to time, subject to the Companies Law, repurchase or finance the purchase of any shares or other securities issued by the Company, in such manner and under such terms as the Board shall determine, whether from any one or more Shareholders. Such purchase shall not be deemed as payment of dividends and as such, no Shareholder will have the right to require the Company to purchase his shares or offer to purchase shares from any other Shareholders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRANSFER OF SHARES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration of Transfer &ndash; No transfer of shares shall be registered unless a proper writing or instrument of transfer (in any customary form or any other form satisfactory to the Board or an executive officer of the Company) has been submitted to the Company (or its transfer agent), together with any share certificate(s) and such other evidence of title as the Board or an officer of the Company to be designated by the CEO may require. Until the transferee has been registered in the Register of Shareholders in respect of the shares so transferred, the Company may continue to regard the transferor as the owner thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board, may, from time to time, prescribe a fee of the registration of a transfer, and may approve other methods of recognizing the transfer of shares in order to facilitate the trading of the Company&rsquo;s shares on the Nasdaq Stock Market or on any other applicable stock exchange on which the Company&rsquo;s shares are then listed for trading.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding anything to the contrary herein, shares registered in the name of The Depository Trust Company or its nominee shall be transferrable in accordance with the policies and procedures of The Depository Trust Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suspension of Registration &ndash; The Board may, in its discretion to the extent it deems necessary, close the Register and suspend the registration of transfers for a period of time as the Board shall deem fit, and no registration of transfer of shares shall be made by the Company during any such period during which the Register is so closed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRANSMISSION OF SHARES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the case of the death, liquidation, bankruptcy, dissolution, winding-up or a similar occurrence of a shareholder, the legal successors, receivers, or liquidators (as the case may be) of such shareholder shall be the only persons recognized by the Company (after receipt of evidence to the entitlement thereto) as having any title to such shares, but nothing herein contained shall release the estate of the predecessor from any liability in respect of such shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The legal successors may, upon producing such evidence of title as the Board shall require, be registered themselves as holders of the shares, or subject to the provisions as to transfers herein contained, transfer the same to some other person.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CALLS ON SHARES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board may, from time to time, make such calls as it may, in its sole discretion, deem appropriate upon shareholders with respect to the payment of any sum unpaid in respect of shares held by such shareholders which is not, by the terms of allotment thereof or otherwise, payable at a fixed time, and each shareholder shall pay the amount of every call so made upon him (and of each installment thereof if the same is payable in installments), to the person(s) and at the time(s) and place(s) designated by the Board, as any such time(s) may be thereafter extended and/or such person(s) or place(s) changed. Unless otherwise stipulated by the Board (and in the notice hereafter referred to), each payment in response to a call shall be deemed to constitute a pro rata payment on account of all shares in respect of which such call was made.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of any call shall be given in writing to the applicable shareholder(s) not less than fourteen (14) days prior to the time of payment, specifying the time and place of payment, and designating the person to whom and the place where such payment shall be made; <U>provided</U>, <U>however</U>, that before the time for any such payment, the Board may, by notice in writing to such shareholder(s), revoke such call in whole or in part, extend such time, or alter such designated person and/or place. In the event of a call payable in installments, only one notice thereof need be given.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If, by the terms of allotment of any share or otherwise, any amount is made payable at any fixed time, every such amount shall be payable at such time as if it were a call duly made by the Board and of which due notice had been given, and all the provisions herein contained with respect to calls shall apply to each such amount.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The joint holders of a share shall be jointly and severally liable to pay all calls in respect thereof and all interest payable thereon.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any amount unpaid in respect of a call shall bear interest from the date on which it is payable until actual payment thereof, at such rate (not exceeding the then prevailing debtor rate charged by leading commercial banks in Israel), and at such time(s) as the Board may prescribe.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>



<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.6.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A shareholder shall not be entitled to his rights as shareholder, including the right to dividends, unless such shareholder has fully paid all the notices of call delivered to him, or which according to these Articles are deemed to have been delivered to him, together with interest, linkage and expenses, if any, unless otherwise determined by the Board.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.7.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the allotment of shares, the Board may provide for differences among the allottees of such shares as to the amount of calls and/or the times of payment thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ALTERATIONS OF THE REGISTERED SHARE CAPITAL</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the Statutes, a General Meeting of shareholders may from time to time resolve to:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">alter or add classes of shares that shall constitute the Company&rsquo;s registered capital, including shares with preference rights, deferred rights, conversion rights or any other special rights or limitations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase the Company&rsquo;s registered share capital by creating new shares either of an existing class or of a new class;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidate and/or split all or any of its share capital;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancel any registered shares not yet allocated, provided that the Company has made no commitment to allocate such shares; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce the Company&rsquo;s share capital and any reserved fund for redemption of capital.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In executing any resolution adopted according to Article 13.1 above, the Board may, at its discretion, resolve any related issues.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If as a result of a consolidation or split of shares authorized under these Articles, fractions of a share will stand to the credit of any shareholder, the Board is authorized at its discretion, to act as follows:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine that fractions of shares that do not entitle their owners to a whole share, will be sold by the Company and that the consideration for the sale be paid to the beneficiaries, on terms the Board may determine;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allot to every shareholder, who holds a fraction of a share resulting from a consolidation and/or split, shares of the class that existed prior to the consolidation and/or split, in a quantity that, when consolidated with the fraction, will constitute a whole share, and such allotment will be considered valid immediately prior to the consolidation or split;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine the manner for paying the amounts to be paid for shares allotted in accordance with Article 13.3(b) above, including on account of bonus shares; and/or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine that the owners of fractions of shares will not be entitled to receive a whole Share in respect of a share fraction or that they may receive a whole share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as otherwise provided by or pursuant to these Articles or by the conditions of issue, any new share capital shall be considered as part of the original share capital and shall be subject to the same provisions of these Articles with reference to payment of calls, lien, transfer, transmission, forfeiture and otherwise, which applies to the original share capital.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORFEITURE AND SURRENDER</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If any Shareholder fails to pay an amount payable by virtue of a call, installment or interest thereon as provided for in accordance herewith, on or before the day fixed for payment of the same, the Board may at any time after the day fixed for such payment, so long as such amount (or any portion thereof) or interest thereon (or any portion thereof) remains unpaid, forfeit all or any of the shares in respect of which such payment was called for. All expenses incurred by the Company in attempting to collect any such amount or interest thereon, including, without limitation, attorneys&rsquo; fees and costs of legal proceedings, shall be added to, and shall, for all purposes (including the accrual of interest thereon) constitute a part of, the amount payable to the Company in respect of such call.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the adoption of a resolution as to the forfeiture of a Shareholder&rsquo;s share, the Board shall cause notice thereof to be given to such Shareholder, which notice shall state that, in the event of the failure to pay the entire amount so payable by a date specified in the notice (which date shall be not less than fourteen (14) days after the date such notice is given and which may be extended by the Board), such shares shall be ipso facto forfeited, provided, however, that, prior to such date, the Board may cancel such resolution of forfeiture, but no such cancellation shall stop the Board from adopting a further resolution of forfeiture in respect of the non-payment&nbsp;of the same amount.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without derogating from Articles 31.2 and 31.8 hereof, whenever shares are forfeited as herein provided, all dividends, if any, theretofore declared in respect thereof and not actually paid shall be deemed to have been forfeited at the same time.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company, by resolution of the Board, may accept the voluntary surrender of any share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any share forfeited or surrendered as provided herein, shall become the property of the Company as a dormant share, and the same, subject to the provisions of these Articles, may be sold, re-issued&nbsp;or otherwise disposed of as the Board deems fit.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.6.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any person whose shares have been forfeited or surrendered shall cease to be a shareholder in respect of the forfeited or surrendered shares, but shall, notwithstanding, be liable to pay, and shall forthwith pay, to the Company, all calls, interest and expenses owing upon or in respect of such shares at the time of forfeiture or surrender, together with interest thereon from the time of forfeiture or surrender until actual payment, at the rate prescribed in Article 12.5 above, and the Board, in its discretion, may, but shall not be obligated to, enforce or collect the payment of such amounts, or any part thereof, as it shall deem fit. In the event of such forfeiture or surrender, the Company, by resolution of the Board, may accelerate the date(s) of payment of any or all amounts then owing to the Company by the person in question (but not yet due) in respect of all shares owned by such Shareholder, solely or jointly with another.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.7.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board may at any time, before any share so forfeited or surrendered shall have been sold, re-issued&nbsp;or otherwise disposed of, nullify the forfeiture or surrender on such conditions as it deems fit, but no such nullification shall stop the Board from re-exercising&nbsp;its powers of forfeiture pursuant to this Article 14.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIEN</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except to the extent the same may be waived or subordinated in writing, the Company shall have a first and paramount lien upon all the shares registered in the name of each Shareholder (without regard to any equitable or other claim or interest in such shares on the part of any other person), and upon the proceeds of the sale thereof, for his or her debts, liabilities and engagements to the Company arising from any amount payable by such Shareholder in respect of any unpaid or partly paid share, whether or not such debt, liability or engagement has matured. Such lien shall extend to all dividends from time to time declared or paid in respect of such share. Unless otherwise provided, the registration by the Company of a transfer of shares shall be deemed to be a waiver on the part of the Company of the lien (if any) existing on such shares immediately prior to such transfer.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board may cause the Company to sell a share subject to such a lien when the debt, liability or engagement giving rise to such lien has matured, in such manner as the Board deems fit, but no such sale shall be made unless such debt, liability or engagement has not been satisfied within fourteen (14) days after written notice of the intention to sell shall have been served on such Shareholder, his or her executors or administrators.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The net proceeds of any such sale, after payment of the costs and expenses thereof or ancillary thereto, shall be applied in or toward satisfaction of the debts, liabilities or engagements of such shareholder in respect of such share (whether or not the same have matured), and the remaining proceeds (if any) shall be paid to the Shareholder, his or her executors, administrators or assigns.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SALE AFTER FORFEITURE OR SURRENDER OR FOR ENFORCEMENT OF LIEN </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon any sale of a share after forfeiture or surrender
or for enforcing a lien, the Board may appoint any person to execute an instrument of transfer of the share so sold and cause the purchaser&rsquo;s
name to be entered in the Register in respect of such share. The purchaser shall be registered as the shareholder and shall not be bound
to see to the regularity of the sale proceedings, or to the application of the proceeds of such sale, and after his or her name has been
entered in the Register in respect of such share, the validity of the sale shall not be impeached by any person, and the remedy of any
person aggrieved by the sale shall be in damages only and against the Company exclusively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MODIFICATION OF CLASS RIGHTS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If at any time the share capital is divided into different classes of shares, any change to the rights and privileges of the holders of any such class of shares shall require the approval of a Class Meeting of such class of shares by a Simple Majority (unless otherwise provided by the Statutes or by the terms of issue of the shares of that class), in addition to the Simple Majority of all classes of shares voting together as a single class at a shareholder meeting. The provisions of this Article 17 relating to General Meetings shall apply,&nbsp;<I>mutatis mutandis</I>, to any separate General Meeting of the holders of the shares of a particular class, it being clarified that the requisite quorum at any such separate General Meeting shall be at least two shareholders in person or by proxy (including by voting deed) holding 25% of the voting rights in the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The rights and privileges of the holders of any class of shares shall not be deemed to have been altered by creating or issuing shares of any class, including a new class (unless otherwise provided by the terms of issue of the shares of that class).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BORROWING POWERS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company may, by resolution of
the Board, from time to time, raise or borrow or secure the payment of any sum or sums of money for the purposes of the Company. The Company,
by resolution of the Board, may also raise or secure the payment or repayment of such sum or sums in such manner and upon such terms and
conditions in all respects as it deems fit, and in particular by the issue of debentures or debenture stock of the Company charged upon
all or any part of the property of the Company (both present and future) including its unissued and/or its uncalled capital for the time
being. Issuance of any series of debentures shall require Board approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENERAL MEETINGS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual general meetings shall be held at least once a calendar year, but not later than fifteen (15) months after the last annual general meeting. The meeting shall be held at such time and at such place, either within or outside Israel, as may be determined by the Board. Such general meetings shall be called &ldquo;Annual Meetings&rdquo; and all other general meetings of the Company shall be called &ldquo;Special Meetings&rdquo;.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Annual Meeting shall review the Company&rsquo;s financial statements and shall transact any other business required pursuant to these Articles or the Companies Law, and any other matter as shall be determined by the Board. The Board may convene a Special Meeting by its resolution, and is required to convene a Special Meeting should it receive a request, in writing, from a person or persons entitled, under the Companies Law, to demand such meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any request for convening a meeting must specify the purposes for which the meeting is to be called, shall be signed by the persons requesting the meeting, and shall be delivered to the Company&rsquo;s Corporate Secretary.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to any applicable law and stock exchange rules and regulations, any shareholder or shareholders of the Company holding at least the required percentage under the Companies Law of the voting rights of the Company which confers the right to request to include a matter on the agenda of a General Meeting (the &ldquo;<B>Proposing Shareholder(s)</B>&rdquo;) may request, subject to the Companies Law, that the Board include a matter on the agenda of a General Meeting to be held in the future, provided that the Board determines that the matter is appropriate to be considered at a General Meeting (a &ldquo;<B>Proposal Request</B>&rdquo;). In order for the Board to consider a Proposal Request and whether to include the matter stated therein in the agenda of a General Meeting, notice of the Proposal Request must be timely delivered in accordance with applicable law, and the Proposal Request must comply with the requirements of these Articles (including this Article 19.4) and any applicable law and stock exchange rules and regulations. The Proposal Request must be in writing, signed by all of the Proposing Shareholder(s) making such request, delivered, either in person or by certified mail, postage prepaid, and received by the Corporate Secretary (or, in the absence thereof by the CEO). The announcement of an adjournment or postponement of a General Meeting shall not commence a new time period (or extend any time period) for the delivery of a Proposal Request as described above. In addition to any information required to be included in accordance with applicable law, a Proposal Request must include the following: (i) the name, address, telephone number, fax number and email address of the Proposing Shareholder (or each Proposing Shareholder, as the case may be) and, if an entity, the name(s) of the person(s) that controls or manages such entity; (ii) the number of Shares held by the Proposing Shareholder(s), directly or indirectly (and, if any of such Shares are held indirectly, an explanation of how they are held and by whom), which shall be in such number no less than as is required to qualify as a Proposing Shareholder, accompanied by evidence satisfactory to the Company of the record holding of such Shares by the Proposing Shareholder(s) as of the date of the Proposal Request, and a representation that the Proposing Shareholder(s) intends to appear in person or by proxy at the meeting; (iii) the matter requested to be included on the agenda of a General Meeting, all information related to such matter, the reason that such matter is proposed to be brought before the General Meeting, the complete text of the resolution that the Proposing Shareholder proposes to be voted upon at the General Meeting and, if the Proposing Shareholder wishes to have a position statement in support of the Proposal Request, a copy of such position statement that complies with the requirement of any applicable law (if any), (iv) a description of all arrangements or understandings between the Proposing Shareholders and any other Person(s) (naming such Person or Persons) in connection with the matter that is requested to be included on the agenda and a declaration signed by all Proposing Shareholder(s) of whether any of them has a personal interest in the matter and, if so, a description in reasonable detail of such personal interest; (v) a description of all Derivative Transactions (as defined below) by each Proposing Shareholder(s) during the previous twelve (12) month period, including the date of the transactions and the class, series and number of securities involved in, and the material economic terms of, such Derivative Transactions; and (vi) a declaration that all of the information that is required under the Companies Law and any other applicable law and stock exchange rules and regulations to be provided to the Company in connection with such matter, if any, has been provided to the Company. The Board, may, in its discretion, to the extent it deems necessary, request
that the Proposing Shareholder(s) provide additional information necessary so as to include a matter in the agenda of a General Meeting, as the Board may reasonably require.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">A &ldquo;<B>Derivative Transaction</B>&rdquo;
means any agreement, arrangement, interest or understanding entered into by, or on behalf or for the benefit of, any Proposing Shareholder
or any of its affiliates or associates, whether of record or beneficial: (1) the value of which is derived in whole or in part from the
value of any class or series of shares or other securities of the Company, (2) which otherwise provides any direct or indirect opportunity
to gain or share in any gain derived from a change in the value of securities of the Company, (3) the effect or intent of which is to
mitigate loss, manage risk or benefit of security value or price changes, or (4) which provides the right to vote or increase or decrease
the voting power of, such Proposing Shareholder, or any of its affiliates or associates, with respect to any shares or other securities
of the Company, which agreement, arrangement, interest or understanding may include, without limitation, any option, warrant, debt position,
note, bond, convertible security, swap, share appreciation right, short position, profit interest, hedge, right to dividends, voting agreement,
performance-related fee or arrangement to borrow or lend shares (whether or not subject to payment, settlement, exercise or conversion
in any such class or series), and any proportionate interest of such Proposing Shareholder in the securities of the Company held by any
general or limited partnership, or any limited liability company, of which such Proposing Shareholder is, directly or indirectly, a general
partner or managing member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The information required pursuant
to this Article shall be updated as of (i) the record date of the General Meeting, (ii) five days before the General Meeting, and (iii)
as of the General Meeting, and any adjournment or postponement thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The provisions of Articles 16.2&nbsp;and
16.3&nbsp;shall apply,&nbsp;<I>mutatis mutandis</I>,&nbsp;on any matter to be included on the agenda of a Special Meeting which is convened
pursuant to a request of a Shareholder duly delivered to the Company in accordance with the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to applicable law, the Board shall determine the agenda of any General Meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.6.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An amendment to Articles 19.4 or 19.5 or this Article 19.6 shall require a Special Majority.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.7.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice of General Meetings</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is not required to give notice of a General Meeting, subject to any mandatory provision of the Companies Law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accidental omission to give notice of a General Meeting to any Shareholder, or the non-receipt&nbsp;of notice sent to such Shareholder, shall not invalidate the proceedings at such meeting or any resolution adopted thereat.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROCEEDINGS AT GENERAL MEETINGS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quorum</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No business shall be transacted at any General Meeting of the Company unless a quorum of shareholders is present at the opening of the General Meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as provided in the following Article with regard to an adjourned General Meeting, the quorum for any General Meeting shall be the presence of at least two shareholders in person or by proxy (including by voting deed) holding 25% of the voting rights in the Company. For this purpose, abstaining shareholders shall be deemed present at the General Meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If within half an hour from the time appointed for the holding of a General Meeting a quorum is not present, the General Meeting shall stand adjourned to the same day in the following week at the same time and place or to such other day, time and place as the Board may indicate in a notice to the shareholders. At such adjourned General Meeting any number of shareholders shall constitute a quorum for the business for which the original General Meeting was called.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chairperson of the General Meeting</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Chairperson of the Board shall preside as the Chairperson at every General Meeting, but if there shall be no such Chairperson or if at any meeting the Chairperson shall not be present within fifteen (15) minutes after the time appointed for holding the same, or shall be unwilling to act as chairperson of the meeting, then any of the following may preside as Chairperson of the meeting (and in the following order): a Director designated by the Board, the CEO, the Chief Financial Officer, the General Counsel/Secretary, or any person designated by any of the foregoing. If at any such meeting none of the foregoing persons is present or all are unwilling or unable to act as Chairperson, the shareholders (or shareholder as the case may be) present at the meeting shall choose a shareholder as chairman of the meeting .</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Chairperson of the General Meeting may, with the consent of a General Meeting at which a quorum is present, and shall if so directed by the General Meeting, adjourn any meeting, discussion or the resolution with respect to a matter that is on the agenda, from time to time and from place to place as the meeting shall determine. Except as may be required by the Companies Law, no shareholder shall be entitled to any notice of an adjournment or of the business to be transacted at an adjourned meeting. No business shall be transacted at any adjourned meeting other than the business which might have been transacted at the meeting from which the adjournment took place.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to Article 20.2(a) above, a vote in respect of the election of the Chairperson of the meeting or regarding a resolution to adjourn the meeting shall be carried out immediately. All other matters shall be voted upon during the meeting at such time and order as decided by the Chairperson of the General Meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>VOTE OF SHAREHOLDERS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All resolutions proposed at any General Meeting will require a Simple Majority, unless otherwise expressly required by the Statutes or these Articles.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A declaration by the Chairperson of the meeting that a resolution has been adopted or rejected, whether unanimously or with a specific majority and an entry to that effect in the minutes of the meeting shall be regarded as <I>prima facie</I> evidence thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.3.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A General Meeting, the consideration of any matter on its agenda or the resolution on any matter on its agenda may be postponed or adjourned, from time to time and from place to place: (i) by the Chairperson of a General Meeting at which a quorum is present (and he shall do so if directed by the General Meeting, with the consent of the holders of a majority of the voting power represented in person or by proxy and voting on the question of adjournment); or (ii) by the Board (whether prior to or at a General Meeting), but no business shall be transacted at any such adjourned meeting except business which might lawfully have been transacted at the meeting as originally called, or a matter on its agenda with respect to which no resolution was adopted at the meeting originally called.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Chairperson of the meeting will not have a second and/or a casting vote. If the vote is tied with regard to a certain proposed resolution such proposal shall be deemed rejected.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.5.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If two or more persons are jointly entitled to a share, the vote of the senior one who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other registered holders of the share, and for this purpose seniority shall be determined by the order in which the names stand in the Register.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.6.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A proxy may be appointed in respect of only some of the shares held by a shareholder, and a shareholder may appoint more than one proxy, each empowered to vote by virtue of a portion of the shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.7.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A proxyholder need not be a shareholder of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.8.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The instrument appointing a proxy shall be in writing signed by the grantor of the proxy or his attorney-in-fact duly authorized in writing. A corporate entity shall vote by a representative duly appointed in writing by such entity. Any instrument appointing a representative of a corporate entity or a proxy (whether for a specified meeting or otherwise) shall be in a form satisfactory to the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Such instrument shall be duly signed
by the appointer or his duly authorized attorney or, if such appointer is a company or other corporate body, under its common seal, stamp
or printed name or the hand of its duly authorized agent(s) or attorney(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.9.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a Shareholder is a minor, under protection, bankrupt or legally incompetent, or in the case of a corporation, is in receivership or liquidation, such shareholder may vote through a trustee, receiver, liquidator, natural guardian or another legal guardian, who may themselves vote in person or by proxy.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.10.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise determined by the Board, the instrument of appointment must be submitted to the Office no later than 48 hours prior to the time fixed for such General Meeting to be attended by such proxy or representative. Notwithstanding the above, the Chairperson of the meeting shall have the right to waive the time requirement provided above with respect to all instruments of appointment and to accept any and all instruments of appointment until the beginning of a General Meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.11.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the Companies Law, an instrument appointing a proxy shall be deemed revoked (i) upon receipt by the Company or the Chairperson, subsequent to receipt by the Company of such instrument, of written notice signed by the person signing such instrument or by the Shareholder appointing such proxy canceling the appointment thereunder (or the authority pursuant to which such instrument was signed) or of an instrument appointing a different proxy (and such other documents, if any, required under these Articles for such new appointment), provided such notice of cancellation or instrument appointing a different proxy were so received at the place and within the time for delivery of the instrument revoked thereby as referred to in these Articles, or (ii) if the appointing Shareholder is present in person at the meeting for which such instrument of proxy was delivered, upon receipt by the Chairperson of such meeting of written notice from such Shareholder of the revocation of such appointment, or if and when such Shareholder votes at such meeting. A vote cast in accordance with an instrument appointing a proxy shall be valid notwithstanding the revocation or purported cancellation of the appointment, or the presence in person or vote of the appointing Shareholder at a meeting for which it was rendered, unless such instrument of appointment was deemed revoked in accordance with the foregoing provisions of this Article 21.11 at or prior to the time such vote was cast.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.12.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A shareholder being of unsound mind or pronounced to be unfit to vote by a competent court of law may vote through a legally appointed guardian or any other representative appointed by a court of law to vote on behalf of such shareholder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.13.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A vote cast in accordance with an instrument appointing a proxy shall be valid notwithstanding the prior death or bankruptcy of the appointing Shareholder (or of his or her attorney-in-fact, if any, who signed such instrument), or the transfer of the share in respect of which the vote is cast, unless written notice of such matters shall have been received by the Company or by the Chairperson of such meeting prior to such vote being cast<B>.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.14.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A shareholder entitled to vote may signify in writing his approval of, or dissent from, or may abstain from any resolution included in a proxy instrument furnished by the Company. A proxy instrument may include resolutions pertaining to such issues which are permitted to be included in a proxy instrument according to the Statutes, and such other issues which the Board may decide, in a certain instance or in general, to allow voting through a proxy. A shareholder voting or abstaining through a proxy instrument shall be taken into account in determining the presence of a quorum as if such shareholder is present at the meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.15.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Chairperson of the General Meeting shall be responsible for recording the minutes of the General Meeting and any resolution adopted.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.16.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A defect in convening or conducting a General Meeting, including a defect resulting from the&nbsp;non-fulfillment&nbsp;of any provision or condition set forth in the Companies Law or these Articles, including with regard to the manner of convening or conducting the General Meeting, shall not disqualify any resolution passed at the General Meeting and shall not affect the discussions or decisions which took place thereat.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.17.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provisions of this Article 21 relating to General Meetings shall, <I>mutatis mutandis</I>, apply to Class Meetings.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECTORS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Powers, Number of Directors, Composition &amp; Election</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board shall have and execute all powers and/or responsibilities allocated to the Board by the Statutes and these Articles, including, without limitation, (i) the powers granted to the Board pursuant to Section 92 of the Companies Law, and (ii) setting the Company&rsquo;s policies and supervision over the execution of the powers and responsibilities of the CEO. The Board may execute any power of the Company that is not specifically allocated by the Statutes or by these Articles to another organ of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without limiting the generality of the foregoing, the Board may, from time to time, set aside any amount(s) out of the profits of the Company as a reserve or reserves for any purpose(s) which the Board, in its absolute discretion, shall deem fit, including without limitation, capitalization and distribution of bonus shares, and may invest any sum so set aside in any manner and from time to time deal with and vary such investments and dispose of all or any part thereof, and employ any such reserve or any part thereof in the business of the Company without being bound to keep the same separate from other assets of the Company, and may subdivide or re-designate&nbsp;any reserve or cancel the same or apply the funds therein for another purpose, all as the Board may from time to time think fit.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of directors on the Board shall be no less than three (3) but no more than nine (9), including any External Directors required to be appointed by the Companies Law (if required). A reduction of the maximum number of directors on the Board under this Article 22.1(c), shall not affect the term in office of serving directors determined prior to such reduction.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding anything to the contrary herein, this Article 22.1 may only be amended or replaced by a resolution adopted by the Special Majority.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The directors, excluding the External Directors, shall be classified, with respect to the term for which they each severally hold office, into three classes, as nearly equal in number as practicable, hereby designated as Class I, Class II and Class III. The Board may assign members of the Board already in office to such classes at the time such classification becomes effective.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 76px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The term of office of the initial Class I directors shall expire at the first Annual Meeting to be held in 2022 and when their successors are elected and qualified;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 76px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The term of office of the initial Class II directors shall expire at the first Annual Meeting following the Annual Meeting referred to in Article 22.1(e) above and when their successors are elected and qualified, and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 76px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The term of office of the initial Class III directors shall expire at the first Annual Meeting following the Annual Meeting referred to in Article 22.1(e)(2) above and when their successors are elected and qualified.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At each Annual Meeting, commencing with the Annual Meeting to be held in 2022 , each of the successors elected to replace the directors of a Class whose term shall have expired at such Annual Meeting shall be elected to hold office until the third Annual Meeting next succeeding his or her election and until his or her respective successor shall have been elected and qualified. Notwithstanding anything to the contrary, each director shall serve until his or her successor is elected and qualified or until such earlier time as such director&rsquo;s office is vacated.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board may at any time and from time to time appoint any person as a director to fill a vacancy (whether such vacancy is due to a director no longer serving or due to the number of directors serving being less than the maximum number stated in Article 22.1(c) above). In the event of one or more such vacancies in the Board, the continuing directors may continue to act in every matter; provided, however, that if their number is less than the minimum number provided for pursuant to Article 22.1(c) above, they may only act in an urgent matter or to fill the office of a director which has become vacant up to a number equal to the minimum number provided for pursuant to Article 22.1(c) above. The office of a director that was appointed by the Board to fill any vacancy shall only be for the remaining period of time during which the director whose service has ended was filled would have held office, or in case of a vacancy due to the number of directors serving being less than the maximum number stated in Article 22.1(c) above, the Board shall determine at the time of appointment the class pursuant to Article 22.1(e) above, to which the additional director shall be assigned. Other than as provided in this Article 22.1(g) directors may be elected only at Annual Meetings.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to every General Meeting of the Company at which directors are to be elected, and subject to clauses (a) and (h) of this Article, the Board (or a Committee thereof) shall select, by a resolution adopted by a majority of the Board (or such Committee), a number of persons to be proposed to the shareholders of the Company for election as directors at such General Meeting (the &ldquo;<B>Nominees</B>&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any Proposing Shareholder requesting to include on the agenda of a General Meeting a nomination of a Person to be proposed to the Shareholders for election as director (such person, an &ldquo;<B>Alternate Nominee</B>&rdquo;), may so request provided that it complies with this Article and Article 19.4 and applicable law. Unless otherwise determined by the Board, a Proposal Request relating to an Alternate Nominee is deemed to be a matter that is appropriate to be considered only at an Annual Meeting. In addition to any information required to be included in accordance with applicable law, such a Proposal Request shall include information required pursuant to Article 19.4, and shall also set forth: (i) the name, address, telephone number and email address of the Alternate Nominee and all citizenships and residencies of the Alternate Nominee; (ii) a description of all arrangements, relations or understandings during the past three (3) years, and any other material relationships, between the Proposing Shareholder(s) or any of its affiliates and each Alternate Nominee; (iii) a declaration signed by the Alternate Nominee that he consents to be named in the Company&rsquo;s notices and proxy materials relating to the General Meeting, if provided or published, and, if elected, to serve on the Board and to be named in the Company&rsquo;s disclosures and filings, (iv) a declaration signed by each Alternate Nominee as required under the Companies Law and any other applicable law and stock exchange rules and regulations for the appointment of such an Alternate Nominee and an undertaking that all of the information that is required under law and stock exchange rules and regulations to be provided to the Company in connection with such an appointment has been provided (including, information in respect of the Alternate Nominee as would be provided in response to the applicable disclosure requirements under the applicable form prescribed by the SEC; (v) a declaration made by the Alternate Nominee of whether he meets the criteria for an independent director and, if applicable, External Director of the Company under the Companies Law and/or under any applicable law, regulation or stock exchange rules, and if not, then an explanation of why not; and (vi) any other information required at the time of submission of the Proposal Request by applicable law, regulations or stock exchange rules. In addition, the Proposing Shareholder shall promptly provide any other information reasonably requested by the Company. The Board may refuse to acknowledge the nomination of any person not made in compliance with the foregoing. The Company shall be entitled to publish any information provided by a Proposing Shareholder pursuant to this Article and Article 19, and the Proposing Shareholder shall be responsible for the accuracy and completeness thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">The Nominees or Alternate Nominees
shall be elected by a resolution adopted at the General Meeting at which they are subject for election. Notwithstanding Article <B>&lrm;</B>19.4(e),
in the event of a Contested Election (as defined below), the method of calculation of the votes and the manner in which the resolutions
will be presented to the General Meeting shall be determined by the Board in its discretion. In the event that the Board does not or is
unable to make a determination on such matter, then the method described in clause (ii) below shall apply. The Board may consider, among
other things, the following methods: (i) election of competing slates of director nominees (determined in a manner approved by the Board)
by a majority of the voting power represented at the General Meeting in person or by proxy and voting on such competing slates, (ii) election
of individual directors by a plurality of the voting power represented at the General Meeting in person or by proxy and voting on the
election of directors (which shall mean that the nominees receiving the largest number of &ldquo;for&rdquo; votes will be elected in such
Contested Election), (iii) election of each nominee by a majority of the voting power represented at the General Meeting in person or
by proxy and voting on the election of directors, provided that if the number of such nominees exceeds the number of directors to be elected,
then as among such nominees the election shall be by plurality of the voting power as described above, and (iv) such other method of voting
as the Board deems appropriate, including use of a &ldquo;universal proxy card&rdquo; listing all Nominees and Alternate Nominees by the
Company. For the purposes of these Articles, election of directors at a General Meeting shall be considered a &ldquo;<B>Contested Election</B>&rdquo;
if the aggregate number of Nominees and Alternate Nominees at such meeting exceeds the total number of Directors to be elected at such
meeting, with the determination thereof being made by the Secretary (or, in the absence thereof, by the CEO of the Company) as of the
close of the applicable notice of nomination period under Article <B>&lrm;</B>19.4 or under applicable law, based on whether one or more
notice(s) of nomination were timely filed in accordance with Article <B>&lrm;</B>22.1(j), this Article and applicable law; provided, however,
that the determination that an election is a Contested Election shall not be determinative as to the validity of any such notice of nomination;
and provided further, that, if, prior to the time of such meeting, one or more notices of nomination of an Alternate Nominee are withdrawn
such that the number of candidates for election as director no longer exceeds the number of directors to be elected, the election shall
not be considered a Contested Election. At any General Meeting at which Directors are to be elected, each shareholder shall be entitled
to cast a number of votes with respect to nominees for election to the Board up to the total number of Directors to be elected at such
meeting. Shareholders shall not be entitled to cumulative voting in the election of Directors, except to the extent specifically set forth
in this Article.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The term of office of a director shall commence on the date of such director&rsquo;s election by the Annual Meeting or by the Board or on a later date, should such date be determined in the resolution of appointment of the Annual Meeting or of the Board. <FONT STYLE="background-color: white">A General Meeting may dismiss a director during the term, with or without cause, only by a Special Majority vote</FONT>.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding anything to the contrary in these Articles, the election, qualification, removal, or dismissal of External Directors shall be in accordance with the applicable provisions set forth in the Companies Law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Remuneration</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company shall determine the remuneration
of the directors, if any, in accordance with the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.3.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chairperson of the Board</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Board shall appoint one of its
members to serve as the Chairperson and may replace the Chairperson from time to time. The Chairperson shall preside at meetings of the
Board, but if at any meeting the Chairperson is not present within fifteen (15) minutes after the time appointed for holding the meeting,
the present directors shall choose a present director to be chairman of such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vacation of Office </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The office of a Director shall be
vacated and he shall be dismissed or removed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>ipso facto</I>, upon his death;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if he is prevented by applicable law from serving as a Director;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the Board determines that due to his mental or physical state he is unable to serve as a director;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if his directorship expires pursuant to these Articles and/or applicable law;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by a resolution adopted at a General Meeting by a Special Majority. Such removal shall become effective on the date fixed in such resolution;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">by his written resignation, such resignation becoming effective on the date fixed therein, or upon the delivery thereof to the Company, whichever is later; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with respect to an External Director, if so elected, and notwithstanding anything to the contrary herein, only pursuant to applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROCEEDINGS OF THE DIRECTORS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The directors shall meet together for the conduct of business, adjourn, and otherwise regulate their meetings as they deem fit, subject to these Articles.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise determined by the Board, written notice of any meeting of the Board and the agenda setting out the matters to be discussed at such meeting, shall be given to all directors at least forty-eight (48) hours (or such shorter notice (i) if all the directors so agree or (ii) in the case of emergency, if a majority of the directors so agree) before the meeting. A majority of the members of the Board may decide to hold a meeting without such notice, provided the Chairperson participates in such meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quorum</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">No business shall be transacted at
any meeting of the Board unless a quorum of directors is present when a meeting is called to order. A quorum shall be deemed to exist
when there are present at least a majority of those members of the Board then in office who are not legally prevented from participating
and voting in the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">If a quorum is not present at the
meeting of the Board within half an hour after the time scheduled for the meeting, the meeting may be adjourned to another time as shall
be decided by the Chairperson, or in his absence, the directors present at the meeting, provided that notice of no less than two (2) days
in advance shall be given to all the directors of the time of the adjourned meeting. A directors may waive the necessity of such notice
either beforehand or retrospectively. The quorum for the commencement of the adjourned meeting shall be at least one member of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Methods of Attending Meetings</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Some or all of the directors may attend
meetings of the Board through computer network, telephone or any other media of communication, enabling all the directors participating
to hear and communicate with each other simultaneously, provided that due prior notice detailing the time and manner of holding a given
meeting is served upon all the directors. The Board may waive the necessity of such notice either beforehand or retrospectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Any resolution adopted by the Board
in such a meeting, pursuant to the provisions of these Articles, will be recorded in writing and signed by the Chairperson (or in his
absence by the chairman of the meeting), and shall be valid as if adopted at a meeting of the Board duly convened and held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.5.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A resolution in writing signed by all of the directors eligible to participate in the discussion and vote on such resolution, or in respect of which all such directors have agreed (in writing by mail, fax, or electronic mail) not to convene, shall be as valid and effective for all purposes as if passed at a meeting of the Board duly convened and held.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Any such resolution may consist of
several counterparts, each signed by one or more directors. Unless otherwise provided therein, such resolution in writing shall be effective
as of the last date appearing on the resolution, or if the resolution is signed in two or more counterparts, as of the last date appearing
on the counterparts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.6.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While exercising his/her voting right, each director shall have one vote. Resolutions of the Board will be decided by a simple majority of the directors present and voting, not taking into consideration abstaining votes, except as otherwise provided in these Articles or by the Statutes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.7.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Reserved]</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.8.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delegation of Powers</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board may, subject to the provisions of the Companies Law, delegate any or all of its powers to committees (in these Articles referred to as a &ldquo;<B>Committee</B>&rdquo;), each consisting of one or more persons, and it may from time to time revoke such delegation or alter the composition of any such Committee. Any Committee so formed shall, in the exercise of the powers so delegated, conform to any regulations imposed on it by the Board, subject to applicable law. No regulation imposed by the Board on any Committee and no resolution of the Board shall invalidate any prior act done pursuant to a resolution by the Committee which would have been valid if such regulation or resolution of the Board had not been adopted. The meetings and proceedings of any such Committee shall,&nbsp;<I>mutatis mutandis</I>, be governed by the provisions herein contained for regulating the meetings of the Board, to the extent not superseded by any regulations adopted by the Board. Unless otherwise expressly prohibited by the Board or the applicable law, in delegating powers to a Committee, such Committee shall be empowered to further delegate such powers. If the Board delegates powers to a board committee, at least one external director shall serve on such committee.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Without derogating from the provisions of Article&nbsp;24, the Board may from time to time </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appoint <FONT STYLE="background-color: white">a Secretary to the Company, as well as Officers, agents, employees and independent contractors, as the Board deems fit, and may terminate the service of any such person. The Board may, subject to the provisions of the Companies Law, determine the powers and duties, as well as the salaries and compensation, of all such persons.</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Board may from time to time, by power of attorney or otherwise, appoint any person, </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">company<FONT STYLE="background-color: white">, firm or body of persons to be the attorney or attorneys of the Company at law or in fact for such purpose(s)&nbsp;and with such powers, authorities and discretions, and for such period and </FONT>subject <FONT STYLE="background-color: white">to such conditions, as it deems fit, and any such power of attorney or other appointment may contain such provisions for the protection and convenience of persons dealing with any such attorney as the Board deems fit, and may also authorize any such attorney to delegate all or any of the powers, authorities and discretions vested in the Board.</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.9.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Meetings of committees and proceedings thereat (including the convening of the meetings, the election of the chairman and the votes) shall be governed by the provisions herein contained for regulating the meetings and proceedings of the Board so far as the same are applicable thereto and unless otherwise determined by the Board, including by an adoption of a charter governing the committee proceedings.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONFLICT OF INTEREST; APPROVAL OF CERTAIN TRANSACTIONS WITH RELATED PARTIES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the Companies Law and these Articles, a transaction between the Company and an Office Holder, and a transaction between the Company and another entity in which an Office Holder of the Company has a personal interest, in each case, which is not an Extraordinary Transaction (as defined by the Companies Law), shall require only approval by the Board or a Committee of the Board subject to the Companies Law. Such authorization, as well as the actual approval, may be for a particular transaction or more generally for specific type of transactions. Subject to the provisions of the Companies Law and these Articles, no Director shall be disqualified by virtue of his office from holding any office or place of profit in the Company or in any company in which the Company shall be a shareholder or otherwise interested, or from contracting with the Company as vendor, purchaser or otherwise, nor shall any such contract, or any contract or arrangement entered into by or on behalf of the Company in which any Director shall be in any way interested, be avoided, nor, other than as required under the Companies Law, shall any Director be liable to account to the Company for any profit arising from any such office or place of profit or realized by any such contract or arrangement by reason only of such Director&rsquo;s holding that office or of the fiduciary relations thereby established, but the nature of his interest, as well as any material fact or document, must be disclosed by him at the meeting of the Board at which the contract or arrangement is first considered, if his interest then exists, or, in any other case, at no later than the first meeting of the Board after the acquisition of his interest.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RECORDS AND VALIDITY OF ACTS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The resolutions of the Board shall be recorded in the Company&rsquo;s minutes book, as required under the Statutes, signed by the Chairperson or the chairman of a certain meeting. Such signed minutes shall be deemed <I>prima facie</I> evidence of the meeting and the resolutions resolved therein.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All acts done <I>bona fide</I> by any meeting of the Board or of a Committee or by any person acting as a director, shall, notwithstanding it be afterwards discovered that there was some defect in the appointment of any such director or person acting as aforesaid, or that they or any of them were disqualified, be as valid as if every such person had been duly appointed and was qualified to be a director.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHIEF EXECUTIVE OFFICER</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board shall from time to time appoint one or more persons, whether or not directors, as CEO of the Company and may confer upon such person(s), and from time to time modify or revoke, such titles and such duties and authorities of the Board as the Board may deem fit, subject to such limitations and restrictions as the Board may from time to time prescribe. Such appointment(s) may be either for a fixed term or without any limitation of time, and the Board may from time to time (subject to any additional approvals required under, and the provisions of, the Companies Law and of any contract between any such person and the Company) fix their salaries and compensation, remove, or dismiss them from office and appoint another or others in his or their place or places.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise determined by the Board, the CEO shall have authority with respect to the management and operations of the Company in the ordinary course of business.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MINUTES </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Any minutes of the General Meeting
or the Board or any committee thereof, if purporting to be signed by the Chairperson of the General Meeting, the Board or a committee
thereof, as the case may be, or by the Chairperson of the next succeeding General Meeting, meeting of the Board or meeting of a Committee,
as the case may be, shall constitute prima facie evidence of the matters recorded therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INSURANCE, EXCULPATION, AND INDEMNITY</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Insurance of Office Holders</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may insure against liability of an Office Holder, to the fullest extent permitted under the Statutes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without derogating from the aforesaid, the Company may enter into a contract to insure the liability of an officer therein for an obligation imposed on him in consequence of an act done in his capacity as an Office Holder, in any of the following cases:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 76px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A breach of the duty of care vis-a-vis the Company or vis-a-vis another person.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 76px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A breach of the duty of loyalty vis-a-vis the Company, provided that the Office Holder acted in good faith and had a reasonable basis to believe that the act would not harm the Company;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 76px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A monetary obligation imposed on him in favor of another person;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 76px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A monetary liability imposed on such Office Holder in favor of a payment to a injured party at an Administrative Procedure as set forth in Section 52(54)(a)(1)(a) to the Securities Law and expenses regarding Administrative Procedures conducted in connection with such Office Holder and/or in connection with a monetary sanction, including reasonable litigation expenses and reasonable attorney&rsquo;s fees;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 76px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any other matter in respect of which it is permitted or will be permitted under applicable law to insure the liability of an Office Holder in the Company, and to the extent such law requires the inclusion of a provision permitting such insurance in these Articles, then such provision is deemed to be included and incorporated herein by reference (including, without limitation, in accordance with Section&nbsp;50P of the Israeli Economic Competition Law, 5758-1988, and the regulations promulgated thereunder), if and to the extent applicable).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnity of Office Holders</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company may indemnify an Office
Holder, to the fullest extent permitted under the Statutes. Without derogating from the aforesaid, the Company may indemnify an Office
Holder for a liability or expense imposed on him in consequence of an act done in his capacity as an Office Holder in the Company, as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a monetary liability incurred by or imposed on the Office Holder in favor of another person pursuant to a court judgment, including pursuant to a settlement confirmed as judgment or arbitrator&rsquo;s decision approved by a competent court;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including reasonable attorneys&rsquo; fees, which were incurred by the Office Holder as a result of an investigation or proceeding filed against the Office Holder by an authority authorized to conduct such investigation or proceeding, provided that such investigation or proceeding was either (i) concluded without the filing of an indictment against such Office Holder and without the imposition on him of any monetary obligation in lieu of a criminal proceeding; (ii) concluded without the filing of an indictment against the Office Holder but with the imposition of a monetary obligation on the Office Holder in lieu of criminal proceedings for an offense that does not require proof of criminal intent; or (iii) in connection with a monetary sanction;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable litigation expenses, including attorneys&rsquo; fees, incurred by the Office Holder or which were imposed on the Office Holder by a court (i) in a proceeding instituted against the Office Holder by the Company, on its behalf, or by a third party, or (ii) in connection with criminal indictment of which the Office Holder was acquitted, or (iii) in a criminal indictment which the Office Holder was convicted of an offense that does not require proof of criminal intent;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a monetary liability imposed on the Office Holder in favor of all the injured parties by the breach in an Administrative Procedure as set forth in Section 52(54)(a)(1)(a) to the Securities Law;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses expended by the Office Holder with respect to an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys&rsquo; fees; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other obligation or expense in respect of which it is permitted or will be permitted under applicable law to indemnify an Office Holder, and to the extent such law requires the inclusion of a provision permitting such indemnity in these Articles, then such provision is deemed to be included and incorporated herein by reference (including, without limitation, in accordance with Section&nbsp;50P(b)(2)&nbsp;of the EC Law, if and to the extent applicable.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.3.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advance Indemnity</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company may give an advance undertaking
to indemnify an Office Holder therein in respect of the following matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">matters as detailed in Article 28.2, provided however, that the undertaking is restricted to events, which in the opinion of the Board, are anticipated in light of the Company&rsquo;s activities at the time of granting the obligation to indemnify and is limited to a sum or measurement determined by the Board as reasonable under the circumstances; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">matters as detailed in Articles 28.2(2) through 28.2(6).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Retroactive Indemnity</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company may indemnify an Office
Holder retroactively with respect of the matters as detailed in Article 28.2, subject to any applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.5.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exculpation</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company may exempt an Office Holder
in advance for all or any of his liability for damage in consequence of a breach of the duty of care vis-a-vis the Company, to the fullest
extent permitted under the Statutes. However, the Company may not exempt a director in advance from his liability toward the Company due
to the breach of his/her duty of care in a Dividend distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.6.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Insurance, Exculpation, and Indemnity &ndash; General</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The above provisions with regard to insurance, exemption and indemnity are not and shall not limit the Company in any way with regard to its entering into an insurance contract and/or with regard to the grant of indemnity and/or exemption in connection with a person who is not an Office Holder of the Company, including employees, contractors or consultants of the Company, all subject to any applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may enter into a contract in relation to exemption, indemnification and insurance of Office Holders in companies under its control, related companies and other companies in which it has any interest, to the maximum extent permitted under the Statutes, and in this context the foregoing provisions in relation to exemption, indemnification and insurance of Office Holders in the Company shall apply, <I>mutatis mutandis</I>.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any amendment to the Companies Law and/or the Statute or any other applicable law adversely affecting the right of any Office Holder to be indemnified, insured or exempt pursuant to Articles 28.1 to 28.5 and any amendments to Articles 28.1 to 28.5 shall be prospective in effect, and shall not affect the Company&rsquo;s obligation or ability to indemnify, insure or exempt an Office Holder for any act or omission occurring prior to such amendment, unless otherwise provided by applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An undertaking in relation to exemption, indemnification and insurance of an Office Holder as aforesaid may also be valid after the office of such Office Holder in the Company has terminated.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>APPOINTMENT OF AN AUDITOR</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the Statutes, shareholders at an Annual Meeting shall appoint an Auditor for a period ending at the next Annual Meeting, or for a longer period, but no longer than until the third Annual Meeting after the meeting at which the Auditor has been appointed. The same Auditor may be re-appointed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the Statutes, the terms of service (including fees) of the Auditor for the audit services shall be determined by the Board, at its discretion, or a committee of the Board if such determination was delegated to a committee, including undertakings or payments to the Auditor. The Board shall report the fees of the Auditor to the Annual Meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATORIES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Signatory rights on behalf of the
Company shall be determined from time to time by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIVIDENDS </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board may from time declare, and cause the Company to pay, such dividend as may appear to the Board to be justified by the profits of the Company and as permitted by the Companies Law. The Board shall determine the time for payment of such dividends and the record date for determining the shareholders entitled thereto.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the provisions of these Articles and subject to the rights or conditions attached at that time to any share in the capital of the Company granting preferential, special or deferred rights or not granting any rights with respect to dividends, any dividend paid by the Company shall be allocated among the shareholders entitled thereto in proportion to their respective holdings of the shares in respect of which such dividends are being paid.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.3.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No dividend of the Company shall accrue interest.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board may determine that the Company (i) may cause any moneys, investments, or other assets forming part of the undivided profits of the Company, standing to the credit of a reserve fund, or to the credit of a reserve fund for the redemption of capital, or in the hands of the Company and available for dividends, or representing premiums received on the issuance of shares and standing to the credit of the share premium account, to be capitalized and distributed among such of the Shareholders as would be entitled to receive the same if distributed by way of dividend and in the same proportion, on the footing that they become entitled thereto as capital; and (ii) may cause such distribution or payment to be accepted by such Shareholders in full satisfaction of their interest in the said capitalized sum.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.5.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All unclaimed dividends or other moneys payable in respect of a share may be invested or otherwise made use of by the Board for the benefit of the Company until claimed. The payment by the Directors of any unclaimed dividend or such other moneys into a separate account shall not constitute the Company a trustee in respect thereof, and any dividend unclaimed after a period of seven (7) years from the date of declaration of such dividend, and any such other moneys unclaimed after a like period from the date the same were payable, shall be forfeited and shall revert to the Company, provided, however, that the Board may, at its discretion, cause the Company to pay any such dividend or such other moneys, or any part thereof, to a person who would have been entitled thereto had the same not reverted to the Company. The principal (and only the principal) of any unclaimed dividend of such other moneys shall be, if claimed, paid to a person entitled thereto.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.6.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any dividend or other moneys payable in cash in respect of a share may be paid by check or payment order sent through the post to, or left at, the registered address of the person entitled thereto or by transfer to a bank account specified by such person (or, if two or more persons are registered as joint holders of such share or are entitled jointly thereto in consequence of the death or bankruptcy of the holder or otherwise, to the joint holder whose name is registered first in the Register or his bank account or the person who the Company may then recognize as the owner thereof or entitled thereto under these Articles, as applicable, or such person&rsquo;s bank account), or to such person and at such other address as the person entitled thereto may by writing direct, or in any other manner the Board deems appropriate. Every such check or warrant or other method of payment shall be made payable to the order of the person to whom it is sent, or to such person as the person entitled thereto as aforesaid may direct, and payment of the check or warrant by the banker upon whom it is drawn shall be a good discharge to the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.7.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board may settle, as it deems fit, any difficulty arising with regard to the distribution of dividends, bonus shares or otherwise, and in particular, to issue certificates for fractions of shares and sell such fractions of shares in order to pay their consideration to those entitled thereto, or to set the value for the distribution of certain assets and to determine that cash payments shall be paid to the Shareholders on the basis of such value, or that fractions whose value is less than NIS 0.01 shall not be taken into account. The Board may instruct to pay cash or convey these certain assets to a trustee in favor of those people who are entitled to a dividend, as the Board shall deem appropriate.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.8.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board may deduct from any dividend or other moneys payable to any Shareholder in respect of a share any and all sums of money then payable by him or her to the Company on account of calls or otherwise in respect of shares of the Company and/or on account of any other matter of transaction whatsoever.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board may retain any dividend or other moneys payable or property distributable in respect of a share on which the Company has a lien, and may apply the same in or toward satisfaction of the debts, liabilities, or engagements in respect of which the lien exists.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Board may retain any dividend or other moneys payable or property distributable in respect of a share in respect of which any person is, under Article 11, entitled to become a Shareholder, or which any person is, under said Article, entitled to transfer, until such person shall become a Shareholder in respect of such share or shall transfer the same.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.9.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If two or more persons are registered as joint holders of any share, or are entitled jointly thereto in consequence of the death or bankruptcy of the holder or otherwise, any one of them may give effectual receipts for any dividend or other moneys payable or property distributable in respect of such share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REDEEMABLE SECURITIES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company may, subject to applicable
law, issue redeemable securities and redeem the same upon terms and conditions to be set forth in a written agreement between the Company
and the holder of such securities or in their terms of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACCOUNTS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company&rsquo;s books of account
shall be kept at the office of the Company, or at such other place or places as the Board may think fit, and they shall always be open
to inspection by all directors. No shareholder, not being a director, shall have any right to inspect any account or book or other similar
document of the Company, except as conferred by law or authorized by the Board. The Company shall make copies of its annual financial
statements available for inspection by the shareholders at the Office of the Company. The Company shall not be required to send copies
of its annual financial statements to its shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DONATIONS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company may make donations of
reasonable amounts, as the Board may determine in its discretion, to worthy causes, even if such donations are not within the framework
of business considerations for maximizing the Company&rsquo;s profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35.1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the Statutes, notice or any other document which the Company shall deliver and which it is entitled or required to give pursuant to the provisions of these Articles and/or the Statutes shall be delivered by the Company to any person, in any one of the following manners as the Company may choose: in person, by mail, transmission by email or by other electronic form.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Any notice or other document which
shall be sent shall be deemed to have reached its destination:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">(i) in the case of mailing, forty-eight
(48) hours after it has been posted, or when actually received by the addressee if sooner than forty-eight hours after it has been posted;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">(ii) in the case of overnight air
courier, on the next business day following the day sent, with receipt confirmed by the courier, or when actually received by the addressee
if sooner than three business days after it has been sent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">(iii) in the case of personal delivery,
when actually tendered in person, to such addressee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">(iv) in the case of facsimile, email
or other electronic transmission, on the first business day (during normal business hours in place of addressee) on which the sender receives
automatic electronic confirmation by the addressee&rsquo;s facsimile machine that such notice was received by the addressee or delivery
confirmation from the addressee&rsquo;s email or other communication server.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">If a notice is, in fact, received
by the addressee, it shall be deemed to have been duly served, when received, notwithstanding that it was defectively addressed or failed,
in some other respect, to comply with the provisions of this Article 35.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Should it be required to prove delivery,
it shall be sufficient to prove that the notice or document sent contains the correct mailing or e-mail details as registered in the Register
or any other address which the shareholder submitted in writing to the Company as the address and fax or e-mail details for the submission
of notices or other documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Notwithstanding anything to the contrary
hereunder, subject to the provisions of the Statutes, a notice to a shareholder (including a notice by the Company of a General Meeting)
may be served, as a general notice to all shareholders, published by the Company on the website of (i) the SEC and/or (ii) the Company,
in accordance with applicable rules and regulations of any stock market upon which the Company&rsquo;s shares are listed and, if so published,
shall be deemed to have been duly given on the date of such publication to any shareholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">In cases where it is necessary to
give advance notice of a particular number of days or notice which shall remain in effect for a particular period, the day the notice
was sent shall be excluded and the scheduled day of the meeting or the last date of the period shall be included in the count.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company shall not be required
to give notice to its registered shareholders pursuant to the Companies Law, unless otherwise required by the Statutes. Subject to the
Statutes, the Company shall not be required to send notices to any shareholder who is not registered in the Register or has not provided
the Company with accurate and sufficient mailing details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35.2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any notice to be given to the shareholders shall be given, with respect to joint shareholders, to the person whose name appears first in the Register as the holder of the said share, and any notice so given shall be sufficient notice for all holders of the said share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35.3.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any notice or other document served upon or sent to any shareholder in accordance with these Articles shall, notwithstanding that he be then deceased or bankrupt, and whether the Company received notice of his death or bankruptcy or not, be deemed to be duly served or sent in respect of any shares held by him (either alone or jointly with others) until some other person is registered in his stead as the holder or joint holder of such shares, and such service or sending shall be a sufficient service or sending on or to his heirs, executors, administrators or assigns and all other persons (if any) interested in such share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35.4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accidental omission to give notice to any shareholder or the non-receipt of any such notice shall not cancel or annul any action made in reliance on the notice.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WINDING-UP</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">If the Company is wound up, then,
subject to applicable law and to the rights of the holders of shares with special rights upon winding up, the assets of the Company available
for distribution among the shareholders shall be distributed to them in proportion to the nominal value of their respective holdings of
the shares in respect of which such distribution is being made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BUSINESS COMBINATIONS WITH INTERESTED SHAREHOLDERS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37.1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding any other provision of these Articles and subject to the provisions of applicable law, the Company shall not engage in any Business Combination (as defined below) with any Interested Shareholder (as defined below) for a period of three (3) years following the time that such shareholder became an Interested Shareholder, unless:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the time that such shareholder become an Interested Shareholder, the Board approved either the Business Combination or the transaction which resulted in the shareholder becoming an Interested Shareholder, or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon consummation of the transaction which resulted in the shareholder becoming an Interested Shareholder, the Interested Shareholder owned at least 85% of the Voting Shares (as defined below) of the Company outstanding at the time the transaction commenced excluding for purposes of determining the Voting Shares outstanding (but not the outstanding Voting Shares owned by the Interested Shareholder) those shares owned by persons who are directors and also officers, or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the time that such shareholder became an Interested Shareholder, or subsequent to such time, the Business Combination is approved by the Board and authorized at a General Meeting of shareholders by the affirmative vote of at least 66 2/3% of the Voting Shares outstanding that are not owned by the Interested Shareholder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37.2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The restrictions set forth in this Article shall not apply if shareholder becomes an Interested Shareholder inadvertently and (i) as soon as practicable divests itself of ownership of sufficient shares so that the shareholders cease to be an interested shareholder; and (ii) would not, at anytime within the 3-year period immediately prior to a Business Combination between the Company and such shareholder, have been an Interested Shareholder but for the inadvertent acquisition of ownership;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37.3.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As used in this Article only, the term:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Affiliate&rdquo; means a Person (as defined below) that directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with another Person.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Associate&rdquo; when used to indicate a relationship with any Person, means (A) any corporation, partnership, unincorporated association or other entity of which such Person is a director, officer or partner or is, directly or indirectly, the owner of twenty percent (20%) or more of any class of Voting Shares, (B) any trust or other estate in which such Person has at least a twenty percent (20%) beneficial interest or as to which such Person serves as trustee or in a similar fiduciary capacity, and (C) any relative or spouse of such Person, or any relative of such spouse, who has the same residence as such Person.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Business Combination&rdquo; when used in reference to the Company and any Interested Shareholder of the Company, means:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 76px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any merger or consolidation of the Company or any direct or indirect majority owned subsidiary of the Company with (1) the Interested Shareholder, or (2) with any other corporation, partnership, unincorporated association, or other entity if the merger or consolidation is caused by the Interested Shareholder and as a result of such merger or consolidation subsection (a) of this Article is not applicable to the surviving entity;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 76px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions), except proportionately as a shareholder of such Company, to or with the Interested Shareholder, whether as part of a dissolution or otherwise, of assets of the Company or of any direct or indirect majority owned subsidiary of the Company, which assets have an aggregate market value equal to ten percent (10%) or more of either the aggregate market value of all of the assets of the Company determined on a consolidated basis or the aggregate market value of all of the outstanding shares of the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 76px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any transaction which results in the issuance or transfer by the Company or by any direct or indirect majority-owned subsidiary of the Company of any shares of the Company or of such subsidiary to the Interested Shareholder, except (1) pursuant to the exercise, exchange or conversion of securities exercisable for or convertible into shares of the Company or any such subsidiary, which securities were outstanding prior to the time that the Interested Shareholder became such; (2) pursuant to Section 337(a) or Section 337(a1) of the Companies Law, (3) pursuant to a dividend or distribution paid or made, or the exercise, exchange or conversion of securities exercisable for, exchangeable for or convertible into shares of the Company or any such subsidiary, which security is distributed pro-rata to all holders of shares of the Company subsequent to the time the Interested Shareholder became such; (4) pursuant to an exchange offer by the Company to purchase shares made on the same terms to all holders of said shares; or (5) any issuance or transfer of shares by the Company; provided, that in no case under (2) through (5) above shall there be an increase in the Interested Shareholder&rsquo;s proportionate share of the shares or of the voting shares of the Company;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 76px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any transaction involving the Company or any direct or indirect majority-owned subsidiary of the Company which has the effect directly or indirectly of increasing the proportionate share of the shares of any class or series or securities convertible into the shares of any class or series of the Company or of any such subsidiary which is owned by the Interested Shareholder except as a result of immaterial changes due to fractional share adjustments or as a result of any purchase or redemption of any shares not caused, directly or indirectly, by the Interested Shareholder; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 76px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any receipt by the Interested Shareholder of the benefit, directly or indirectly (except proportionately as a shareholder of such company), of any loans, advances, guarantees, pledges, or any other financial benefits (other than those expressly permitted in subparagraphs (1) through (4) above) provided by or through the Company or any direct or indirect majority owned subsidiary.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Control&rdquo; including the term &ldquo;Controlling&rdquo;, &ldquo;Controlled by&rdquo; and &ldquo;under common control with&rdquo; means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a person, whether through the ownership of Voting Shares, by contract or otherwise. A Person who is the owner of twenty percent (20%) or more of the outstanding Voting Shares of any corporation, partnership, unincorporated association or other entity shall be presumed to have control of such entity. Notwithstanding the foregoing, a presumption of control shall not apply where such Person holds Voting Shares in good faith and not for the purpose of circumventing this Article as an agent, bank, broker, nominee, custodian, or trustee for one or more owners who do not individually or as a group have control of such entity.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Interested Shareholder&rdquo; means any person (other than the Company and any direct or indirect majority-owned subsidiary of the Company) that (A) is the Owner of fifteen percent (15%) or more of the outstanding Voting Shares of the Company, or (B) is an Affiliate or Associate of the Company and was the Owner of fifteen percent (15%) or more of the outstanding Voting Shares of the Company at any time within the 3-year period immediately prior to the date on which it is sought to be determined whether such person is an Interested Shareholder, and the Affiliates and Associates of such person. Notwithstanding the foregoing, the term Interested Shareholder shall not include any Person whose ownership of outstanding Voting Shares in excess of the fifteen percent (15%) limitation set forth herein is the result of action taken solely by the Company; provided that such Person shall be an Interested Shareholder if thereafter such person acquires, without prior approval of the Board, additional Voting Shares of the Company, except as a result of further corporate action not caused, directly or indirectly, by such Person. For the purpose of determining whether a person is an Interested Shareholder, the Voting Shares of the Company deemed to be outstanding shall include shares deemed to be owned by the person through application of paragraph (ix) of this subsection but shall not include any other unissued shares of the Company which may be issuable pursuant to any agreement, arrangement or understanding, or upon exercise of conversion rights, warrants or options, or otherwise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Person&rdquo; means any individual, corporation, partnership, unincorporated association or other entity.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Share&rdquo; means with respect to any corporation shares of its capital and with respect to any other entity or equity interest.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Voting Shares&rdquo; mean with respect to any corporation Shares of any class or series entitled to vote generally in the election of directors and, with respect to any entity that is not a corporation, any equity interest entitled to vote generally in the election of the governing body of such entity.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Owner&rdquo; including the terms &ldquo;own&rdquo; and &ldquo;owned&rdquo;, when used with respect to any Share, means a Person that individually or with or through any of its Affiliates or Associates:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 76px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">beneficially owns such share, directly or indirectly: or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 76px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">has (1) the right to acquire such share (whether such right is exercisable immediately or only after the passage of time) pursuant to any agreement, arrangement or understanding or upon the exercise of conversion rights, warrants or options, or otherwise; provided however, that a Person shall not be deemed the owner of share tendered pursuant to a tender or exchange; or (2) the right to vote such share pursuant to any agreement, arrangement or understanding; provided however, that a person shall not be deemed the owner of any share because of such person&rsquo;s right to vote such share if the agreement, arrangement, or understanding to vote such share arises solely from a recoverable proxy or consent given in response to a proxy or consent solicitation made to ten (10) or more Persons: or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 64.35pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 76px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">has any agreement, arrangement or understanding for the purpose of acquiring, holding, voting (except voting pursuant to a revocable proxy or consent as described in item (2) of clause B of this paragraph) or disposing of such Share with any other Person that beneficially owns or whose Affiliates or Associates beneficially own, directly or indirectly, such share.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37.4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any change to this Article 37 shall only be adopted by a resolution of the shareholders of the Company, adopted by the holders of securities representing at least 85% of the Voting Shares of the Company then outstanding.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDMENT</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any amendment of these Articles shall require,
in addition to the approval of the General Meeting of shareholders in accordance with these Articles, also the approval of the Board with
the affirmative vote of a majority of the then serving Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORUM SELECTION</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40.1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless the Company consents in writing to the selection of an alternative forum:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933 as amended, including against any person or entity, including such claims brought against the Company, its directors, officers, employees, advisors, attorneys, accountants or underwriters;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 38px">&nbsp;</TD>
    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Tel Aviv District Court (Economic Division) shall be the exclusive forum for (A) any derivative action or proceeding brought on behalf of the Company, (B) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company&rsquo;s shareholders, or (C) any action asserting a claim arising pursuant to any provision of the Companies Law or the Securities Law and providing that any person or entity purchasing or otherwise acquiring&nbsp;or holding&nbsp;any interest in&nbsp;shares of the Company shall be deemed to have notice of and consented to these provisions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">

    <TD STYLE="width: 38px; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40.2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any person or entity purchasing or otherwise acquiring any interest in any shares of the Company shall be deemed to have notice of and consented to the provisions of this Article.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">* * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 28; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>3
<FILENAME>ea023729501ex2-1_neuro.htm
<DESCRIPTION>DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 2.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>DESCRIPTION OF SHARE
CAPITAL AND ARTICLES OF ASSOCIATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The following descriptions of our share capital
and provisions of our amended and restated articles of association are summaries and are qualified by reference to the amended and restated
articles of association, which are filed as an exhibit to this Annual Report on Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our authorized share capital consists of 90,000,000
ordinary shares, no par value per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">All of our outstanding ordinary shares will
be validly issued, fully paid and non-assessable. Our ordinary shares are not redeemable and do not have any preemptive rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Registration Number and Purpose</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our registration number with the Israeli Registrar
of Companies, or IRC, is 51-5610822. Our purpose as set forth in our amended and restated articles of association is to engage in any
lawful activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Voting Rights and Conversion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">All ordinary shares will have identical voting
and other rights in all respects. None of our major shareholders have different voting rights than our other shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Transfer of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our fully paid ordinary shares are issued
in registered form and may be freely transferred under our amended and restated articles of association, unless the transfer is restricted
or prohibited by another instrument, applicable law or the rules of a stock exchange on which the shares are listed for trade. The ownership
or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our amended and restated articles of association
or the laws of the State of Israel, except for ownership by nationals of some countries that are, or have been, in a state of war with
Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Liability to Further Capital Calls</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our board of directors may make, from time
to time, such calls as it may deem fit upon shareholders with respect to any sum unpaid with respect to shares held by such shareholders,
which is not payable at a fixed time. Such shareholder shall pay the amount of every call so made upon him. Unless otherwise stipulated
by the board of directors, each payment in response to a call shall be deemed to constitute a pro rata payment on account of all shares
with respect to which such call was made. A shareholder shall not be entitled to his rights as shareholder, including the right to dividends,
unless such shareholder has fully paid all the notices of call delivered to him, or which according to our amended and restated articles
of association are deemed to have been delivered to him, together with interest, linkage and expenses, if any, unless otherwise determined
by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Business Combinations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Under our amended and restated articles of
association, we may not engage in any &ldquo;business combinations&rdquo; with any &ldquo;interested shareholder&rdquo; for a three-year
period following the time that such shareholder became an interested shareholder, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior to the time that such shareholder became an interested shareholder, our board of directors approved either the business combination or the transaction which resulted in the shareholder becoming an interested shareholder;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon consummation of the transaction which resulted in the shareholder becoming an interested shareholder, the interested shareholder owned at least 85% of our voting shares outstanding at the time the transaction commenced, excluding for purposes of determining our voting shares outstanding (but not the outstanding voting shares owned by the interested shareholder) those shares owned by persons who are directors and also officers; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the time that such shareholder became an interested shareholder, or subsequent to such time, the business combination is approved by our board of directors and authorized at a general meeting of shareholders by the affirmative vote of at least 66 2/3% of our voting shares outstanding that are not owned by the interested shareholder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">Generally, a &ldquo;business combination&rdquo;
includes any merger, consolidation, sale or other transaction resulting in a financial benefit to the interested shareholder. Subject
to certain exceptions, an &ldquo;interested shareholder&rdquo; is any person (other than us and any of our direct or indirect majority-owned
subsidiaries) who, together with such person&rsquo;s affiliates and associates, owns, or within the previous three years owned, 15% or
more of our voting shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">Under certain circumstances, this provision
will make it more difficult for a person who would be an &ldquo;interested shareholder&rdquo; to effect various business combinations
with a corporation for a three-year period. This provision may encourage companies interested in acquiring us to negotiate in advance
with our board of directors because the shareholder approval requirement would be avoided if our board of directors approves either the
business combination or the transaction which results in the shareholder becoming an interested shareholder. These provisions also may
have the effect of preventing changes in our board of directors and may make it more difficult to accomplish transactions which shareholders
may otherwise deem to be in their best interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Election of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">Our ordinary shares do not have cumulative
voting rights for the election of directors. As a result, the holders of a majority of the voting power represented at a shareholders
meeting have the power to elect our directors, subject to the special approval requirements for external directors under the Companies
Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">Under our amended and restated articles of
association, the number of directors on our board of directors must be no less than three and no more than nine, including any external
directors required to be appointed under the Companies Law. The minimum and maximum number of directors may be changed, at any time and
from time to time, by a special vote of the holders of at least 66 2/3 of our outstanding shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Other than external directors, for whom special
election requirements apply under the Companies Law, the vote required to appoint a director is a simple majority vote. In addition, under
our amended and restated articles of association, our board of directors may elect new directors to fill vacancies (whether such vacancy
is due to a director no longer serving or due to the number of directors serving being less than the maximum required in our amended and
restated articles of association), provided that the total number of directors shall not, at any time, exceed nine directors and provided
that our board of directors may not elect external directors. Our amended and restated articles of association provide that the term of
a director appointed by our board of directors to fill any vacancy will be for the remaining term of office of the director(s) whose office(s)
have been vacated. Furthermore, under our amended and restated articles of association, our directors, other than external directors,
are divided into three classes with staggered three-year terms. Each class of directors consists, as nearly as possible, of 1/3 of the
total number of directors constituting the entire board of directors (other than the external directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">External directors are elected for an initial
term of three years, may be elected for additional three-year terms, and may be removed from office pursuant to the terms of the Companies
Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Dividend and Liquidation Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We may declare a dividend to be paid to the
holders of our ordinary shares in proportion to their respective shareholdings. Under the Companies Law, dividend distributions are determined
by the board of directors and do not require the approval of the shareholders of a company unless the company&rsquo;s articles of association
provide otherwise. Our amended and restated articles of association do not require shareholder approval of a dividend distribution and
provide that dividend distributions may be determined by our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Pursuant to the Companies Law, subject to
certain exceptions with respect to the buyback by the Company of its ordinary shares, the distribution amount is limited to the greater
of retained earnings or earnings generated over the previous two years, according to our then last reviewed or audited financial statements
(less the amount of previously distributed dividends, if not reduced from the earnings), provided that the end of the period to which
the financial statements relate is not more than six months prior to the date of the distribution. If we do not meet such criteria, then
we may distribute dividends only with court approval. In each case, we are only permitted to distribute a dividend if our board of directors
and, if applicable, the court determines that there is no reasonable concern that payment of the dividend will prevent us from satisfying
our existing and foreseeable obligations as they become due. In the event of our liquidation, after satisfaction of liabilities to creditors,
our assets will be distributed to the holders of our ordinary shares in proportion to their shareholdings. This right, as well as the
right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of
shares with preferential rights that may be authorized in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Exchange Controls</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">There are currently no Israeli currency control
restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the shares or interest or other payments to
non-residents of Israel, except for shareholders who are subjects of certain countries that are, or have been, in a state of war with
Israel at such time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Shareholder Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Under Israeli law, we are required to hold
an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months after the date of the
previous annual general meeting. All general meetings other than the annual meeting of shareholders are referred to in our amended and
restated articles of association as special meetings. Our board of directors may call special meetings whenever it sees fit, at such time
and place, within or outside of Israel, as it may determine. In addition, as a company whose shares are listed for trade on an exchange
outside of Israel, Israeli law provides that our board of directors is required to convene a special general meeting upon the written
request of (i) any two of our directors or one-quarter of the members of our board of directors or (ii) one or more shareholders holding,
in the aggregate, either (a) 10% or more of our outstanding issued shares and 1% or more of our outstanding voting power or (b) 10% or
more of our outstanding voting power.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Under Israeli law, one or more shareholders
holding at least 1% of the voting rights at the general meeting may request that the board of directors include a matter in the agenda
of a general meeting to be convened in the future (or, with respect to a company whose shares are listed for trade on an exchange outside
of Israel, 5% if the matter is the appointment or removal of a director, provided that it is appropriate to discuss sucha matter at the
general meeting. Our amended and restated articles of association contain procedural guidelines and disclosure items with respect to the
submission of shareholder proposals for shareholders meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Subject to the provisions of the Companies
Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are the shareholders
of record on a date to be decided by the board of directors, which may be between four and 60 days prior to the date of the meeting. Furthermore,
the Companies Law requires that resolutions regarding, among other things, the following matters must be passed at a general meeting of
our shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendments to our amended and restated articles of association;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment or termination of our auditors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">election of directors, including external directors (unless otherwise determined in our amended and restated articles of association);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval of certain related party transactions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases or reductions of our authorized share capital;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a merger; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exercise of our board of directors&rsquo; powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Under our amended and restated articles of
association, we are not required to give notice to our registered shareholders pursuant to the Companies Law, unless otherwise required
by law. The Companies Law requires that a notice of any annual general meeting or special general meeting be provided to shareholders
at least 21 days prior to the meeting and if the agenda of the meeting includes the appointment or removal of directors, the approval
of transactions with office holders or interested or related parties, or an approval of a merger, or as otherwise required under applicable
law, notice must be provided at least 35 days prior to the meeting. Under the Companies Law, shareholders of a public company are not
permitted to take action by written consent in lieu of a meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Voting Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Quorum Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Pursuant to our amended and restated articles
of association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote before the
shareholders at a general meeting. Under our amended and restated articles of association, the quorum required for general meetings of
shareholders must consist of at least two shareholders present in person or by proxy (including by voting deed) holding 25% or more of
our voting rights. A meeting adjourned for lack of a quorum will generally be adjourned to the same day of the following week at the same
time and place, or to such other day, time or place as indicated by our board of directors if so specified in the notice of the meeting.
At the reconvened meeting, any number of shareholders present in person or by proxy shall constitute a lawful quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Vote Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our amended and restated articles of association
provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law or by
our amended and restated articles of association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our amended and restated articles of association
provide that all resolutions of our board of directors require a simple majority vote of the directors present and voting at such meeting,
unless otherwise required by the Companies Law or by our amended and restated articles of association. Pursuant to our amended and restated
articles of association, in the event the vote is tied, the chair of the board of directors will have a casting vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Pursuant to our amended and restated articles
of association, an amendment to our articles of association regarding any change of the composition or election procedures of our directors
will require a special majority vote (66&frac23;%). In addition, any change to the rights and privileges of the holders of any class of
our shares requires a simple majority of the class so affected (or otherwise in accordance with the terms of such class), in addition
to the simple majority vote of all classes of shares voting together as a single class at a shareholder meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Under the Companies Law, each of (i) the approval
of an extraordinary transaction with a controlling shareholder and (ii) the terms of employment or other engagement of the controlling
shareholder of the company or such controlling shareholder&rsquo;s relative (even if not extraordinary) requires special approval. Certain
transactions with respect to remuneration of our office holders and directors require further approvals. Another exception to the simple
majority vote requirement is a resolution for the voluntary winding up, or an approval of a scheme of arrangement or reorganization, of
the company pursuant to Section 350 of the Companies Law, which requires the approval of holders of 75% of the voting rights represented
at the meeting, in person or by proxy and voting on the resolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Access to Corporate Records</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Under the Companies Law, shareholders are
provided access to: minutes of our general meetings; our shareholders register and material shareholders register, our amended and restated
articles of association, our financial statements and any document that we are required by law to file publicly with the Israeli Companies
Registrar or the ISA. In addition, shareholders may request to be provided with any document related to an action or transaction requiring
shareholder approval under the related party transaction provisions of the Companies Law. We may deny this request if we believe it has
not been made in good faith or if such denial is necessary to protect our interest or protect a trade secret or patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Modification of Class Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Under the Companies Law and our amended and
restated articles of association, the rights attached to any class of share, such as voting, liquidation and dividend rights, may be amended
by adoption of a resolution by the holders of a majority of the shares of that class present at a separate class meeting, or otherwise
in accordance with the terms of such class of shares, in addition to the simple majority vote of all classes of shares voting together
as a single class at a shareholder meeting, as set forth in our amended and restated articles of association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Acquisitions Under Israeli Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Full Tender Offer. A person wishing to acquire
shares of an Israeli public company and who would as a result hold over 90% of the target company&rsquo;s issued and outstanding share
capital is required by the Companies Law to make a tender offer to all of the company&rsquo;s shareholders for the purchase of all of
the issued and outstanding shares of the company. A person wishing to acquire shares of an Israeli public company and who would as a result
hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the
shareholders who hold shares of the relevant class for the purchase of all of the issued and outstanding shares of that class. If the
shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable
class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of the shares that
the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will also be accepted
if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the
applicable class of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Upon a successful completion of such a full
tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not, may,
within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender offer was
for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions, the offeror
may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli court
as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">If (a) the shareholders who did not respond
or accept the tender offer hold at least 5% of the issued and outstanding share capital of the company or of the applicable class or the
shareholders who accept the offer constitute less than a majority of the offerees that do not have a personal interest in the acceptance
of the tender offer or (b) the shareholders who did not accept the tender offer hold 2% or more of the issued and outstanding share capital
of the company (or of the applicable class), the acquirer may not acquire shares of the company that will increase its holdings to more
than 90% of the company&rsquo;s issued and outstanding share capital or of the applicable class from shareholders who accepted the tender
offer.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Special Tender Offer. The Companies Law provides
that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition
the purchaser would become a holder of 25% or more of the voting rights in the company. Similarly, the Companies Law provides that an
acquisition of shares in a public company must be made by means of a special tender offer if as a result of the acquisition the purchaser
would become a holder of more than 45% of the voting rights in the company. These requirements do not apply if, in general, the acquisition
(1) was made in a private placement that received shareholder approval, (2)&nbsp;was from a 25% or greater shareholder of the company
which resulted in the acquirer becoming a 25% or greater shareholder of the company, or (3) was from a 45% or greater shareholder of the
company which resulted in the acquirer becoming a 45% or greater shareholder of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">A special tender offer must be extended to
all shareholders of a company but the offeror is not required to purchase shares representing more than 5% of the voting power attached
to the company&rsquo;s outstanding shares, regardless of how many shares are tendered by shareholders. A special tender offer may be consummated
only if (i) at least 5% of the voting power attached to the company&rsquo;s outstanding shares will be acquired by the offeror and (ii)
the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding the purchaser and
its controlling shareholders, holders of 25% or more of the voting rights in the company or any person having a personal interest in the
acceptance of the tender offer or any other person acting on their behalf, including the relatives and entities under such person&rsquo;s
control). If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with
the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the target company
and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such
person or entity undertook to effect such an offer or merger in the initial special tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Merger. The Companies Law permits merger transactions
if approved by each party&rsquo;s board of directors and, unless certain requirements described under the Companies Law are met, by a
majority vote of each party&rsquo;s shares, and, in the case of the target company, a majority vote of each class of its shares, voted
on the proposed merger at a shareholders meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">For purposes of the shareholder vote, unless
a court rules otherwise, the merger will not be deemed approved if a majority of the votes of shares represented at the shareholders meeting
that are held by parties other than the other party to the merger, or by any person (or group of persons acting in concert) who holds
(or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25% or more of the directors of the other party,
vote against the merger. If, however, the merger involves a merger with a company&rsquo;s own controlling shareholder or if the controlling
shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority approval that governs
all extraordinary transactions with controlling shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">If the transaction would have been approved
by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes of certain shareholders
as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company,
if the court holds that the merger is fair and reasonable, taking into account the value to the parties to the merger and the consideration
offered to the shareholders of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Upon the request of a creditor of either party
to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result
of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further give instructions
to secure the rights of creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In addition, a merger may not be consummated
unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each party with the IRC
and at least 30 days have passed from the date on which the merger was approved by the shareholders of each party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Israeli tax law treats some acquisitions,
such as share-for-share exchanges between an Israeli company and a foreign company, less favorably than U.S. tax laws. For example, Israeli
tax law may, under certain circumstances, subject a shareholder who exchanges his ordinary shares for shares in another corporation to
taxation prior to the sale of the shares received in such share-for-share swap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Anti-Takeover Measures Under Israeli Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Companies Law allows us to create and
issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred rights with
respect to voting, distributions or other matters and shares having preemptive rights. No preferred shares are authorized under our amended
and restated articles of association. In the future, if we do authorize, create and issue a specific class of preferred shares, such class
of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover or otherwise
prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization and designation
of a class of preferred shares will require an amendment to our amended and restated articles of association, which requires the prior
approval of the holders of a majority of the voting power attaching to our issued and outstanding shares at a general meeting. The convening
of the meeting, the shareholders entitled to participate and the majority vote required to be obtained at such a meeting will be subject
to the requirements set forth in the Companies Law as described above in &ldquo;&mdash;Voting Rights.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Borrowing Powers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Pursuant to the Companies Law and our amended
and restated articles of association, our board of directors may exercise all powers and take all actions that are not required under
law or under our amended and restated articles of association to be exercised or taken by our shareholders, including the power to borrow
money for company purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Changes in Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our amended and restated articles of association
enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Companies Law and must be approved
by a resolution duly adopted by our shareholders at a general meeting. In addition, transactions that have the effect of reducing capital,
such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the approval of both
our board of directors and an Israeli court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Establishment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We were incorporated under the laws of the
State of Israel on February 13, 2017. We are registered with the IRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Exclusive Forum</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our amended and restated articles of association
provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall
be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. This choice of
forum provision may limit a shareholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable for disputes with
us or our directors, officers or other employees and may increase the costs associated with such lawsuits, which may discourage such lawsuits
against us and our directors, officers and employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This exclusive forum provision would not apply
to claims brought pursuant to the Securities Act or the Exchange Act or any other claim for which U.S. federal courts would have exclusive
jurisdiction. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive
federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Alternatively, if a court were to find these
provisions of our amended and restated articles of association inapplicable to, or unenforceable in respect of, one or more of the specified
types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could
adversely affect our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our amended and restated articles of association
also provide that unless we consent in writing to the selection of an alternative forum, the competent courts in Tel Aviv, Israel shall
be the exclusive forum for any derivative action or proceeding brought on behalf of the Company, any action asserting a breach of a fiduciary
duty owed by any of our directors, officers or other employees to the Company or our shareholders or any action asserting a claim arising
pursuant to any provision of the Companies Law or the Israeli Securities Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Any person or entity purchasing or otherwise
acquiring any interest in our share capital shall be deemed to have notice of and to have consented to these choice of forum provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>ea023729501ex4-2_neuro.htm
<DESCRIPTION>2018 SHARE INCENTIVE PLAN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NEUROSENSE THERAPEUTICS LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2018 SHARE INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED BY THE BOARD OF DIRECTORS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ON AUGUST 30, 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NEUROSENSE THERAPEUTICS LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2018 SHARE INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1. <FONT STYLE="font-variant: small-caps">Purpose</FONT></B>.
The purpose of this 2018 Share Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;) is to advance the interests of the Company and its shareholders
by attracting and retaining the best available personnel for positions of substantial responsibility, providing additional incentives
to employees, officers, directors, Consultants and promoting a close identity of interests between those persons and the Company and/or
an Affiliate (as defined below). The provisions specified hereunder apply only to persons who are subject to taxation by the State of
Israel with respect to their Awards (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>2. Definitions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.35pt; text-align: justify; text-indent: -44.25pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0.5in; text-align: justify"><B>2.1
<FONT STYLE="font-variant: small-caps">Defined Terms</FONT></B><FONT STYLE="font-variant: small-caps">.</FONT> Initially capitalized
terms, as used in this Plan, shall have the meaning ascribed thereto as set forth below:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; width: 28%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>102 Participant</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; width: 2%; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; width: 70%; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, an Israeli tax resident who is an employee or a director of the Company or an Israeli Affiliate, on behalf of whom an Award is granted under Section 102.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&ldquo;<B>Administrator</B>&rdquo; </FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means the Board, or a committee to which the Board shall have delegated power to act on its behalf with respect to the Plan.&nbsp;&nbsp;The Administrator, if it is a committee, shall consist of such number of members (but not less than two (2)) as may be determined by the Board.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Affiliate(s)</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means a present or future company that either (i) Controls the Company, (ii) is Controlled by the Company; or (iii) is Controlled by the same person or entity that Controls the Company.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Applicable Law</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means all laws applicable to the grant of Awards pursuant to this Plan, including but not limited to the requirements under tax laws, social security laws, security laws, companies laws, any stock exchange or quotation system on which the Shares are listed or quoted, the applicable law in the country or jurisdiction of any such system, and the applicable law of any other country or jurisdiction where Awards are granted under the Plan.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Articles</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means the Articles of Association of the Company, as may be amended from time to time.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Award</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, individually or collectively, Options, Shares, Restricted Shares, or Restricted Share Units.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Board</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means the board of directors of the Company.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Capital
Gains Track Through a Trustee</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means the Company&rsquo;s choice of the capital gains track of taxation for share allocation to employees under Section 102 through a trustee. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&ldquo;<B>Cause</B>&rdquo;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"> means, when used in connection with the termination of a Participant&rsquo;s employment with, or services to the Company or an Affiliate, and forming the basis of such termination: (a) the definition ascribed to Cause in the individual employment agreement or services agreement between the Company and/or its Affiliate and the Participant; or (b) if no such definition exists, then any of the following, including but not limited to: dishonesty toward the Company or Affiliate, insubordination, substantial malfeasance or nonfeasance of duty, unauthorized disclosure of confidential information and conduct substantially prejudicial to the business of the Company or Affiliate; or any substantial breach by the Participant of: (A) his or her employment or service agreement with the Company or an Affiliate; or (B) any other obligations towards the Company or an Affiliate. For the sake of clarity, it is hereby clarified that the Administrator may adopt another definition(s) for the term &ldquo;Cause&rdquo; in the applicable Grant Letter. </TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Commencement&nbsp;&nbsp;Date</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt; width: 2%">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt; width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means the date of commencement of the vesting schedule with respect to a Grant of Awards which, unless otherwise determined by the Administrator, shall be the date on which such Awards shall be granted. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Company</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means <B>NeuroSense Therapeutics Ltd.</B>, a company incorporated under the laws of the State of Israel.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Consultant</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means an Israeli resident, who serves as a consultant or adviser of the Company or of an Israeli resident Affiliate and is not entitled to receive Awards under Section 102, on behalf of whom an Award is granted under Section 3(i). For the sake of clarity, non-Israeli consultants or advisers to the Company or any of its Affiliates may only be granted Awards under Section 3(i).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Control</B>&rdquo; <B>or</B> &ldquo;<B>Controlled</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall have the meaning ascribed thereto in Section 102.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Date of Grant</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall have the meaning set forth in <U>Section 6.2</U> of this Plan.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Director</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means a member of the Board.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Disability</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means total and permanent physical or mental impairment or sickness of a Participant, making it impossible for the Participant to continue such Participant&rsquo;s employment with or service to the Company or Affiliate. For the sake of clarity, it is hereby clarified that the Administrator may adopt another definition(s) for the term &ldquo;Disability&rdquo; in the applicable Grant Letter.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Earned Income Track</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means the Company&rsquo;s choice of the work income course of taxation for share allocation to employees under Section 102 through a trustee.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Election</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall have the meaning set forth in <U>Section 11.1</U> of this Plan.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Employee</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall have the meaning set forth in Section 102.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Exercise Conditions&rdquo;</B></FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means a vesting schedule and/or Performance Conditions.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Exercise Notice</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shall have the meaning set forth in <U>Section 7.4(a)</U> of this Plan.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Exercise Price</B>&rdquo; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means the price determined by the Administrator in accordance with <U>Section 7.1</U> below which is to be paid to the Company in order to exercise a Granted Award and convert such Award into an Underlying Share.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Exercised Share</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means a Share issued upon exercise of an Award or vesting of an Award, as applicable, or, if applicable, a freely transferable Share issued to a Participant not resulting from another type of Award.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Fair Market Value</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt; width: 2%">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt; width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, as of any date, the value of a Share determined as follows: (i) if the Company&rsquo;s shares are listed on any established stock exchange or a national market system, including without limitation the Nasdaq Global Select Market, Nasdaq Global Market or the Nasdaq Capital Market of the Nasdaq Stock Market, the Fair Market Value shall be the closing sales price of such shares (or the closing bid, if no sales were reported) as quoted on such exchange or system for the last market trading day prior to the time of determination, as reported in <I>The Wall Street Journal</I> or such other source as the Administrator deems reliable; without derogating from the above and solely for the purpose of determining the tax liability pursuant to Section 102 (and in particular Section 102(b)(3)), if on the date of grant the Company&rsquo;s shares are listed on any established stock exchange or a national market system or if the Company&rsquo;s shares will be registered for trading within ninety days following the date of grant under the Section 102 Capital Gains Track Through a Trustee, the Fair Market Value of a Share on its date of grant shall be determined in accordance with the average value of the Company&rsquo;s shares during the thirty trading days immediately preceding the date of grantor during the thirty (30) trading days immediately following the date of registration for trading (if the Company&rsquo;s shares will be listed within ninety days following the date of grant), as the case may be; or (ii) if the Company&rsquo;s shares are regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value shall be the mean between the high bid and low asked prices for the Company&rsquo;s shares on the last market trading day prior to the day of determination; or (iii) in the absence of an established market for the Company&rsquo;s shares, the Fair Market Value shall be determined in good faith by the Administrator (including in accordance with an independent third party valuation of the Company which may be obtained by the Administrator).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Grant Letter</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means a written agreement between the Company to a Participant evidencing the terms and conditions of an individual grant of Awards. The Grant Letter shall specify among others: (i) the Tax Provision under which the Award is granted; (ii) the Tax Track that the Company has elected according to <U>Section 11</U> of the Plan (if applicable); (iii) the Exercise Price, if applicable; (iv) the number of Awards granted to the Participant; (v) the Date of Grant; and (vi) the vesting schedule (including acceleration events, if any).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Grant of Awards</B>&rdquo; or &ldquo;<B>Granted Awards</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means the grant of Awards by the Company to a Participant pursuant to a Grant Letter.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Holding Period</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means with respect to Awards granted under Section 102, the minimum period in which the Awards granted to a Participant or, upon exercise thereof, the Underlying Shares, are to be held by the Trustee on behalf of the Participant, in accordance with Section 102, and pursuant to the Tax Track which the Company elected. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>IPO</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means the initial public offering of shares of the Company and the listing of such shares for trading on any recognized stock exchange or over-the-counter or computerized securities trading system.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>ITA</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means the Israeli Tax Authority.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Merger Transaction</B>&rdquo; or &ldquo;<B>Merger</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means any of the following but excluding any Re-organization or Spin-off Transaction: (a) a sale of all or substantially all of the assets of the Company and its subsidiaries taken as a whole, or the sale or disposition (whether by merger or otherwise) of one or more subsidiaries of the Company if substantially all of the assets of the Company and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries; or (b) a sale of all or substantially all of the shares of the share capital of the Company whether by a single transaction or a series of related transactions which occur either over a period of 12 months or within the scope of the same acquisition agreement; or (c) a merger, consolidation or like transaction of the Company with or into another corporation in which the Company is not the surviving entity, including a reverse triangular merger but excluding a merger which falls within the definition of Re-organization. For the sake of clarity, whether a transaction is a &ldquo;Merger Transaction&rdquo; or &ldquo;Merger&rdquo; shall be finally and conclusively determined by the Board in its absolute discretion.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Option</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt; width: 2%">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt; width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means an option to purchase one Share of the Company.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Non-Qualified Participant</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means a person who is not qualified to receive Awards under the provisions of Section 102, on behalf of whom an Award is granted under Section 3(i). </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Participant</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means 102 Participant, or a Non-Qualified Participant, or a Consultant.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Performance Based Award</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means a performance based Award as defined in Section 8B.1 below.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Performance Conditions</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mean Performance Conditions as defined in Section 8B.1 below</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Plan</B>&rdquo; or &ldquo;<B>Incentive Plan</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means this 2018 Share Incentive Plan, as may be amended from time to time.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Re-organization</B>&rdquo; &nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, any re-domestication of the Company, share flip, creation of a holding company for the Company which will hold substantially all of the shares of the Company or any other transaction involving the Company in which the ordinary shares of the Company outstanding immediately prior to such transaction continue to represent, or are converted into or exchanged for shares that represent, immediately following such transaction, at least a majority, by voting power, of the share capital of the surviving, acquiring or resulting corporation and in which there is no material change to the interests held by the Shareholders prior to such transaction and thereafter.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Restricted Share</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means a Share issued under this Plan to a Participant for such consideration, if any, and subject to such restrictions as established by the Company, as detailed in Section 8A below</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>RSU</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means Restricted Share Unit, as defined in Section 8 below.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Retirement</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means the termination of a Participant&rsquo;s employment as a result of his or her reaching the earlier of (i) the age of retirement as defined by the Applicable Law; or (ii) the age of retirement specified in the Participant&rsquo;s employment agreement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Section 102</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means Section 102 of the Tax Ordinance. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Section 102 Rules</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means the Income Tax Rules (Tax Relief for Issuance of Shares to Employees), 2003.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Section 3(i)</B>&rdquo; </FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means section 3(i) of the Tax Ordinance and the applicable rules thereto or under applicable regulations.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Service Provider</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means an Employee, Director or Consultant.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Share</B>&rdquo; &ldquo;<B>Shareholders</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, ordinary share(s) of the Company, having a no par value. means, the shareholders of the Company.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Spin-off Transaction</B>&rdquo; &nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, any transaction in which assets of the Company are transferred or sold to a company or corporate entity in which the Shareholders hold equal stakes, pro-rata to their ownership of the Company. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Tax Ordinance</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means the Israeli Income Tax Ordinance [New Version], 1961, as amended, and any regulations, rules, orders or procedures promulgated thereunder.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Tax Provision</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt; width: 2%">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt; width: 70%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, with respect to the Grant of Awards, the provisions of one of the three Tax Tracks in Section 102, or the provisions of Section 3(i). </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Tax Track</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means one of the three tax tracks described under Section 102, specifically: (1) the Capital Gains Track Through a Trustee; (2) Earned Income Track; or (3) the Income Tax Track Without a Trustee.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Term of the Awards</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, with respect to granted but unexercised Awards, the time period set forth in <U>Section 9</U> below.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Trust Agreement</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means the agreement/s between the Company and the Trustee regarding the Awards granted under this Plan to Section 102 Partipants and the underlying Shares to be held in trust, as in effect from time to time.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Trustee</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means a trustee appointed by the Company and approved by the ITA, all in accordance with the provisions of Section 102(a) of the Tax Ordinance, to hold in trust, the Granted Awards and the Underlying Shares issued upon exercise of such Awards, on behalf of Participants. The Trustee may be replaced from time to time subject to the provisions of Section 102.&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt 5.4pt 0pt 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Underlying Shares</B>&rdquo;</FONT></TD>
    <TD STYLE="padding: 0pt 5.4pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt 0pt 0pt 5.4pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means Shares issued or to be issued upon exercise of the Awards granted in accordance with the Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.2</B> <FONT STYLE="font-variant: small-caps"><B>General</B>.</FONT>
Without derogating from the meanings ascribed to the capitalized terms above, all singular references in this Plan shall include the plural
and vice versa, and reference to one gender shall include the other, unless otherwise required by the context.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>3. Shares
Available for Awards.</B></FONT> The total number of Underlying Shares reserved for issuance under the Plan and any modification thereof,
shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) 1,400,000&nbsp;Shares,
plus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.6pt; text-indent: 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) an annual
increase to be added as of the first day of the Company&rsquo;s fiscal year, beginning in 2022 and occurring each year thereafter through
2032, equal to the 4% of the total number of Shares issued and outstanding on a fully-diluted basis as of the end of the Company&rsquo;s
immediately preceding fiscal year (or such lesser number of shares, including no shares, determined by the Board in its sole discretion).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Such number of Shares shall be subject to adjustment
as required for the implementation of the provisions of the Plan, in accordance with Section 4 below. In the event that Awards are expired
or forfeited or otherwise terminated in accordance with the provisions of the Plan, such expired or terminated Awards shall become available
for future grants under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>4. Adjustments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.1</B> <FONT STYLE="font-variant: small-caps"><B>Changes
in Capitalization</B></FONT>. Subject to any required action by the Shareholders, the number of Underlying Shares covered by each outstanding
Award, and the number of Shares which have been authorized for issuance under the Plan but as to which no Awards have yet been granted
or which have been returned to the Plan, and the per share exercise price of each such Award, shall be proportionately and equitably adjusted
for any increase or decrease in the number of issued Shares resulting from a stock split, reverse stock split, combination, reclassification,
the payment of a stock dividend on the Shares or any other increase or decrease in the number of such Shares effected without receipt
of consideration by the Company without changing the aggregate exercise price, <I><U>provided, however</U>,</I> that conversion of any
convertible securities of the Company shall not be deemed to have been effected without receipt of consideration. Such adjustment shall
be made by the Administrator, whose determination in that respect shall be final, binding and conclusive. Except as expressly provided
herein, no issue by the Company of shares of any class, or securities convertible into shares of any class, shall affect, and no adjustment
by reason thereof shall be made with respect to, the number or price of Shares subject to an Award. The Administrator may, if it so determines
in the exercise of its sole discretion, also make provision for proportionately adjusting the number or class of securities covered by
any Award, as well as the price to be paid therefor, in the event that the Company effects one or more reorganizations, recapitalizations,
rights offerings, or other increases or reductions of its outstanding Shares, and in the event of the Company being consolidated with
or merged into any other corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.2 <FONT STYLE="font-variant: small-caps">Merger
Transaction</FONT></B>. In the event of a Merger Transaction, any and all outstanding and unexercised unvested Awards will be cancelled
for no consideration, unless determined otherwise by the Administrator. The Administrator at its sole and absolute discretion may decide:
(i) if and how the unvested Awards, as the case may be, shall be canceled, exchanged, assumed, replaced, repurchased or accelerated; (ii)
if and how vested Awards (including Awards with respect to which the vesting period has been accelerated) shall be exercised, exchanged,
assumed, replaced and/or sold by the Trustee or the Company (as the case may be) on behalf of the Participants, including determining
that all unexercised vested Awards shall be cancelled for no consideration upon a Merger Transaction; (iii) how Underlying Shares issued
upon exercise of the Options (or, if applicable, the vesting of other Awards) granted under of the trust tracks and held by the Trustee
on behalf of 102 Participants shall be replaced and/or sold by the Trustee on behalf of these Participant; and (iv) how any treatment
of Awards and underlying Shares may be made subject to any payment or escrow arrangement, or any other arrangement determined within the
scope of the Merger Transaction in relation to Awards and underlying Shares of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the case of assumption
and/or substitution of Awards, appropriate adjustments shall be made so as to reflect such action and all other terms and conditions of
the Grant Letter shall remain unchanged, including but not limited to the vesting schedule, all subject to the determination of the Board,
which its determination shall be at its sole discretion and final. The grant of any substitutes for the Awards to Participants further
to a Merger Transaction, as provided in this section, shall be considered to be in full compliance with the terms of this Plan. The value
of the exchanged Awards pursuant to this section shall be determined in good faith solely by the Board, based on the Fair Market Value,
and its decision shall be final and binding on all the Participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the purposes of this
section, the mechanism for determining the assumption or exchange as aforementioned shall be agreed upon between the Board and the successor
company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Without derogating from the
above, in the event of a Merger Transaction, the Board shall be entitled, at its sole discretion, to require the Participants to exercise
all vested Awards within a set time period and sell all of their Shares on the same terms and conditions as applicable to the other shareholders
selling their Company&rsquo;s Shares as part of the Merger Transaction. Each Participant acknowledges and agrees that the Board shall
be entitled, subject to any applicable law, to authorize any one of its members to sign any agreement and any share transfer deeds in
customary form with respect to the Shares held by such Participant and that such agreement and share transfer deed, as applicable, shall
bind the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite the aforementioned
and for the avoidance of any doubt, if and when the method of treatment of Awards within the scope of a Merger Transaction, as provided
above, will in the sole opinion of the Board prevent the consummation of the Merger Transaction, or materially risk the consummation of
the Merger Transaction, the Board may determine different treatment for different Awards held by Participants such that not all Awards
will be treated equally within the scope of the Merger Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.3 <FONT STYLE="font-variant: small-caps">Fraction
of Shares</FONT></B>. In the event that the Company will be required to issue to a Participant a fraction of a Share pursuant to this
<U>Section 4</U>, the Company will not issue fraction of a Share and the number of Shares shall be rounded down to the closest whole number
of Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.4</B> <FONT STYLE="font-variant: small-caps"><B>Calculation</B>.</FONT>
For the purposes of this section, the Company&rsquo;s calculation will be final, and the Participant shall have no claims or demands against
the Company or anyone on its behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.5</B> <FONT STYLE="font-variant: small-caps"><B>Re-Organization</B></FONT>.
In the event of a Re-Organization the Shares underlying the Awards subject to the Plan shall be exchanged or converted into Shares of
the Company or successor company in accordance with the exchange effectuated in relation to the Shares of the Company, and the Exercise
Price and quantity of shares shall be adjusted in accordance with the terms of the Re-organization. The adjustments required thereby shall
be determined in good faith solely by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>4.6</B></FONT><B>
<FONT STYLE="font-variant: small-caps">Spin-Off Transaction</FONT></B><FONT STYLE="font-size: 10pt">. In the event of a Spin-Off Transaction,
the Board may determine that the holders of Awards shall be entitled to receive equity in the new company formed as a result of the Spin-Off
Transaction, in accordance with equity granted to the ordinary Shareholders within the Spin-Off Transaction, taking into account the
terms of the Awards, including the vesting schedule and Exercise Price. The determination regarding the Participant&rsquo;s entitlement
within the scope of a Spin-Off Transaction shall be in the sole and absolute discretion of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>5. <FONT STYLE="font-variant: small-caps">Administration
of the Plan</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.1</B> <FONT STYLE="font-variant: small-caps"><B>Power</B>.</FONT>
Subject to the Applicable Law, the Articles and any resolution to the contrary by the Board, the Administrator is authorized, at its sole
and absolute discretion, to exercise all powers and authorities either specifically granted to it under the Plan or necessary or advisable
in the administration of the Plan (subject to the approval of the Board, if such approval is required by the Applicable Law) including,
without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(A) to determine: (i) the
Participants in the Plan, the number of Awards for each Participant&rsquo;s benefit and the Exercise Price; (ii) the time or times at
which Awards shall be granted; (iii) whether, to what extent, and under what circumstances an Award may be settled, canceled, forfeited,
exchanged, or surrendered; (iv) any terms and conditions in addition to those specified in the Plan under which an Award may be granted;
(v) any measures, and to take any actions, as deemed necessary or advisable for the administration and implementation of the Plan; (vi)
the terms and conditions under which a Participant may elect to receive Ordinary Shares upon the exercise of the Award or in exchange
for the Underlying Shares; (vii) subject to Applicable Law, to make an Election and (viii) to appoint a Trustee; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(B)
to interpret the provisions of the Plan and to take all actions resulting therefrom including without limitation: (i) subject to <U>Section
7</U> below, to accelerate the date on which Granted Award under the Plan becomes exercisable; (ii) to waive or amend Plan provisions
relating to exercise of Awards, including exercise of Awards after termination of employment, for any reason; and (iii) to amend any of
the terms of the Plan, or any prior determinations of the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>5.2</B> <B>Limitations</B>.
</FONT>Notwithstanding the provisions of <U>Section 5.1</U> above, no interpretations, determinations or actions of the Administrator
shall contradict the provisions of Applicable Law, and no waiver or amendment with respect to the Plan shall have a material adverse affect
on any Participant&rsquo;s rights in connection with any Granted Award under the Plan without receiving the consent of such Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>6. Grant
of Options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.1</B> <FONT STYLE="font-variant: small-caps"><B>Conditions
for Granting Options</B>.</FONT> Options may be granted at any time after the fulfillment of all of the following conditions: (i) the
Plan has been approved by the necessary corporate bodies of the Company; (ii) thirty (30) days after a request for approval of the Plan
has been filed for approval with the ITA or any longer period, as pursuant to the requirements of the Tax Ordinance; (iii) the Grant has
been approved by the necessary corporate bodies of the Company; and (iv) all other approvals, consents or requirements necessary by Applicable
Law have been received or met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>6.2 Date
of grant</B>.</FONT> The date on which Options shall be deemed granted under the Plan shall be the date on which the Company&rsquo;s Board
approved the grant or the date specified as the date of grant in the Grant Letter, if specified (the &ldquo;<B>Date of Grant</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.3</B> <FONT STYLE="font-variant: small-caps"><B>Eligibility
for Options</B>. </FONT>The Administrator may grant Options to any Employee, officer, Director, or Consultant of the Company and its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>6.4
 Grant Letter</B>.</FONT> Any grant of Options to a Participant shall be made in a form of a
Grant Letter and shall include a copy of the Plan. The receipt by a Participant of such Grant Letter shall be deemed as consent by such
Participant that the Option is subject to all the terms and conditions of the Grant Letter and the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.5</B> <FONT STYLE="font-variant: small-caps"><B>Material
Breach</B>.</FONT> In an event of a material breach by a Participant of the terms of this Plan or the Grant Letter provided to the Participant,
or the applicable engagement agreement with such Participant, and without derogating from any of the remedies available to the Company
under any Applicable Law, the Company may, at its sole discretion, after sending a written notice to such Participant, forfeit the right
of the Participant to some or all the Options granted to such Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>7. <FONT STYLE="font-variant: small-caps">Exercise
of Options and Sale of Shares </FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.1</B> <FONT STYLE="font-variant: small-caps"><B>Exercise
Price</B></FONT><B>; <FONT STYLE="font-variant: small-caps">Purchase Price</FONT></B><FONT STYLE="font-variant: small-caps">.</FONT> The
Exercise Price per Underlying Share deliverable upon the exercise of an Option shall be determined by the Administrator. The Exercise
Price shall be set forth in the respective Grant Letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>7.2 Vesting
Schedule</B>.</FONT> All Options granted on a certain date may be subjected to continued employment with or service to the Company or
Affiliate by the Participant, become vested and exercisable in accordance with the vesting schedule as shall be determined by the Administrator
for each Participant and detailed in the respective Grant Letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>7.3</B> </FONT><FONT STYLE="font-variant: small-caps"><B>minimum
<FONT STYLE="font-size: 10pt">Exercise</FONT></B></FONT><FONT STYLE="font-size: 10pt">. Unless otherwise determined by the Administrator,
no exercise of Options by any Participant shall be for a quantity of less than 10% of the Granted Options. An Option may not be exercised
for fractional shares. The exercise of a portion of the Granted Options shall not cause the expiration, termination or cancellation of
the remaining unexercised Options. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.4</B> <FONT STYLE="font-variant: small-caps"><B>Manner
of Exercise</B></FONT>. An Option may be exercised by and upon the fulfillment of the following prerequisite terms and conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 56.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><I>(A) <U>Exercise
Notice</U>-</I> The signing by the Participant, and delivery to both the Company (at its principal office) and the Trustee (if the Options
are held by a Trustee), of an exercise notice form as prescribed by the Administrator, with such details including but not limited to:
(i) the identity of the Participant; (ii) the number of Options to be exercised; and (iii) the Exercise Price to be paid (the &ldquo;<B>Exercise
Notice</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><I>(B) <U>Exercise
Price</U>-</I> The payment by the Participant to the Company, in such manner as shall be determined by the Administrator, of the Exercise
Price with respect to all the Options exercised, as set forth in the Exercise Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><I>(C) <U>Issuance
of Underlying Shares</U>-</I> Upon the delivery of a duly signed Exercise Notice and the payment to the Company of the Exercise Price
with respect to all the Options specified therein, the Company shall issue the Underlying Shares to the Trustee (according to the applicable
Holding Period) or to the Participant, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><I>(D) <U>Expenses</U>-</I>
All costs and expenses including broker fees and bank commissions, derived from the exercise of Options or Underlying Shares, shall be
borne solely by the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.5</B>
<FONT STYLE="font-variant: small-caps"><B>Net Exercise.</B></FONT> Notwithstanding the provisions of Section 7.4 above, the Board may
determine (and, if so, only if indicated the same in the Grant Letter or amendment thereto) that Options may be exercised (either as an
alternative for the cash exercise method in Section 7.4 or as the only exercise method) using the following method (the &ldquo;Net Exercise&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">(a) Upon
exercise of the Options, the Company shall issue to the Participant (or for his benefit) the Net Exercise Shares (as defined below), and
the following formula shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">X=Y(A-B) / A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.85pt; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whereas:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">X = The number of Shares resulting from
the exercise of the Options (the &ldquo;Net Exercise Shares&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Y = The number Options in respect of
which an Exercise Notice has been delivered to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">A= The Fair Market Value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">B= The Exercise Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">(b)  The
Participant shall not be required to pay to the Company any sum with respect to the exercise of such Options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">(c) In
any event, no fractional Shares will be issued to the Participant and the number of Shares granted to the Participant under the Plan shall
be rounded off (upward or downward, as the Administrator shall determine) to the nearest whole number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.6</B> <FONT STYLE="font-variant: small-caps"><B>Exercise
Restrictions</B></FONT>. Notwithstanding anything to the contrary herein, in the event the Participant initiates any legal proceedings
to be maintained or instituted against the Company or its Representatives or participates in any manner in any legal proceedings against
the Company or its respective Representatives at any time, the Participant&rsquo;s right to exercise any unexercised Options granted to
such Participant, whether vested or not on such date, shall cease as of such date and the Options shall thereupon expire. For purposes
of this Section only, the term &ldquo;<B>Representatives</B>&rdquo; shall mean the respective past, present and future officers, directors,
employees, consultants, holders of equity securities, Affiliates, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>8. Restricted
Share Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1 Subject
to the sole and absolute discretion and determination of the Administrator, the Administrator may decide to grant under the Plan, Restricted
Share Unit(s) (&ldquo;<B>RSU(s)</B>&rdquo;). A RSU is a right to receive a Share of the Company, under certain terms and conditions, for
no consideration. Upon the lapse of the Exercise Conditions of a RSU, such RSU shall automatically vest into an Exercised Share of the
Company (subject to adjustments under Section 4 herein).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2 Unless
determined otherwise by the Administrator, in the event of a Termination of Employment (as defined under section 11.1 below) of a Participant,
for any reason, whether voluntary or involuntary (including the Participant&rsquo;s death or disability), then all RSUs theretofore granted
to such Participant when such Participant was a Service Provider of the Company that are not vested on the date of Termination of Employment,
shall terminate immediately and have no legal effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">8.3 All
other terms and conditions of the Plan applicable to Options (section 6 and 7 above), shall apply to RSUs, <I>mutatis mutandis</I>. It
is clarified, that without deviating from the foregoing in Sub-Section 8.2, the provisions of Section 11 herein, shall, <I>mutatis mutandis</I>,
apply to RSUs in the event of Termination of Employment (as defined under section 11.1 below)</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>8A.
Restricted Share</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8A.1 Restricted
Share Awards may be granted upon such terms and conditions, as the Administrator shall determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8A.2 <U>Purchase
Price</U>. No monetary payment (other than payments made for applicable Taxes) shall be required as a condition of receiving Shares pursuant
to a grant of Restricted Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8A.3 <U>Vesting
and Restrictions on Transfer</U>. Shares issued pursuant to any Restricted Shares may (but need not) be made subject to Exercise Conditions
as described herein, as shall be established by the Administrator and set forth in the applicable Grant Letter evidencing such Award.
During any restriction period in which Shares acquired pursuant to an award of Restricted Shares remain subject to Exercise Conditions,
such Shares may not be sold, exchanged, transferred, pledged, assigned or otherwise disposed of unless otherwise provided in the Plan.
Upon request by the Company, each Participant shall execute any agreement evidencing such transfer restrictions prior to the receipt of
Shares hereunder, and the Company may place appropriate legends evidencing any such transfer restrictions on the relevant share certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8A.4 <U>Voting
Rights; Dividends and Distributions</U>. Except as provided in this section and in any Grant Letter, during any restriction period applicable
to Shares subject to an award of Restricted Shares, the Participant shall have all of the rights of a shareholder of the Company holding
Shares, including the right to receive all dividends and other distributions paid with respect to such Shares. However, in the event of
a dividend or distribution paid in Shares or other property or any other adjustment made upon a change in the capital structure of the
Company as described in Section&nbsp;4, any and all new, substituted or additional securities or other property (other than normal cash
dividends) to which the Participant is entitled by reason of the Participant&rsquo;s award of Restricted Shares shall be immediately subject
to the same Exercise Conditions as the Shares subject to the award of Restricted Shares with respect to which such dividends or distributions
were paid or adjustments were made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">8A.5 <U>Termination of Employment</U>.
Unless otherwise provided by the Administrator, in the event of Termination of Employment (as defined under section 11.1 below) of a Participant,
for any reason, whether voluntary or involuntary (including the Participant&rsquo;s death or disability), then the Participant shall forfeit
to the Company any Shares acquired by the Participant pursuant to an award of Restricted Shares which remain subject to Exercise Conditions
as of the date of Termination of Employment. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8A.6 All
other terms and conditions of the Plan applicable to Options (sections 6 and 7 above), shall apply to Restricted Shares, <I>mutatis mutandis</I>.
It is clarified, that without deviating from the foregoing in Sub-Section 8A.5., the provisions of Section 11 herein, shall, <I>mutatis
mutandis</I>, apply to Restricted Shares in the event of Termination of Employment (as defined under section 11.1 below)<FONT STYLE="font-variant: small-caps"><B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>8B.
Performance Based Awards:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">8B.1</FONT> Subject
to the sole and absolute discretion and determination of the Administrator, the Administrator may decide to grant Awards under the Plan,
the exercise or vesting of which, as applicable, shall be conditional upon the performance of the Company and/or an Affiliate and/or a
division or other business unit of the Company or of an Affiliate and/or upon the performance of the Participant, over such period and
measured against such criteria as shall be determined by the Administrator and notified to the Participant as part of the Grant Letter
(&ldquo;<B>Performance Based Award(s)</B>&rdquo;). In granting each Performance Based Award, the Administrator shall establish in writing
the applicable performance period (&ldquo;<B>Performance Period</B>&rdquo;), performance formula (&ldquo;<B>Performance Formula</B>&rdquo;)
and one or more performance goals (&ldquo;<B>Performance Goal(s)</B>&rdquo;) which, when measured at the end of the Performance Period,
shall determine on the basis of said Performance Formula the extent to which the Performance Based Award has vested and/or become exercisable
(collectively, the &ldquo;<B>Performance Conditions</B>&rdquo;). For the avoidance of doubt, Performance Conditions may be determined
for an Award either in addition to, or in substitution for, a Vesting Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8B.2 After
a Performance Based Award has been granted, the Administrator may, in appropriate circumstances, amend any Performance Condition, at its
sole and absolute discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8B.3 If,
in consequence of the applicable Performance Conditions being met a Performance Based Award becomes vested and/or exercisable in respect
of some, but not all of the number of Shares underlying such Award, the portion of the Performance Based Award which did not become vested
and exercisable by the end of the Performance Period, shall thereupon lapse and cease to be exercisable in respect of the balance of the
Shares over which it was held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">8B.4 Performance Conditions shall not be
automatically waived merely due to an event of (i) a Termination of Employment, (ii) a Merger Transaction, (iii) any other
adjustment under Section 4 above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">8B.5 <U>Measurement of Performance
Goals</U><B>.</B> Performance Goals shall be established by the Administrator on the basis of targets to be attained with respect to
one or more measures of business or financial performance or individual key performance indicators (&ldquo;<B>KPIs</B>&rdquo;) that may
have the same meanings as used in the Company&rsquo;s financial statements, or, if such terms are not used in the Company&rsquo;s financial
statements, they may have the meaning applied pursuant to generally accepted accounting principles, or as used generally in the Company&rsquo;s
industry or, if based on individual or other KPIs, in all cases, as determined by the Administrator (&ldquo;<B>Performance Measures</B>&rdquo;).
For purposes of the Plan, the Performance Measures applicable to a Performance Based Award shall be calculated as instructed by the Administrator,
which may include being calculated in accordance with generally accepted accounting principles, excluding the effect (whether positive
or negative) of any change in accounting standards or any extraordinary, unusual or nonrecurring item, as determined by the Administrator,
occurring after the establishment of the Performance Goals applicable to the Performance Based Award. Each such adjustment, if any, shall
be made solely for the purpose of providing a consistent basis from period to period for the calculation of Performance Measures in order
to prevent the dilution or enlargement of the Participant&rsquo;s rights with respect to a Performance Based Award. Performance Measures
may be, among others, one or more of the following, as determined by the Administrator: revenue; sales; expenses; operating income; gross
margin; operating margin; earnings before any one or more of: share-based compensation expense, interest, taxes, depreciation and amortization;
pre-tax profit; net operating income; net income; economic value added; free cash flow; operating cash flow; share price; earnings per
share; return on shareholder equity; return on capital; return on assets; return on investment; employee satisfaction and/or individual
KPIs; employee retention; balance of cash, cash equivalents and marketable securities; market share; customer satisfaction; product development;
research and development expenses; R&amp;D development milestones, including with respect to clinical trials; completion of an identified
special project; and completion of a joint venture or other Corporate Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8B.6 All
other terms and conditions of the Plan applicable to Awards, shall apply to Performance Based Awards, <I>mutatis mutandis.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>9. Waiver
of Award Rights</B></FONT>. At any time prior to the expiration of any unexercised Granted Award, a Participant may waive his rights to
such Award by a written notice to the Company&rsquo;s principal office. Such notice shall specify the number of Granted Awards, which
the Participant waives, and shall be signed by the Participant. Upon receipt by the Company of a notice of waiver of such rights, such
Awards shall expire and shall become available for future Grants under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>10. Term
of the Awards</B></FONT>. Unless earlier terminated pursuant to the provisions of this Plan, all granted but unexercised Awards shall
expire and cease to be exercisable at 5:00 p.m. Israel time on the 10<SUP>th</SUP> anniversary of the Commencement Date of such Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>11. Termination
of Employment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.<FONT STYLE="font-variant: small-caps">1
Termination of Employment</FONT></B><FONT STYLE="font-variant: small-caps">.</FONT> If a Participant ceases to be an employee,
director, officer or Consultant of the Company or Affiliate for any reason (&ldquo;<B>Termination of Employment</B>&rdquo;) other
than by reason of death, Retirement, Disability or Cause, then any vested but unexercised Awards on the date of Termination of
Employment (as shall be determined by the Company or Affiliate, at its sole discretion) granted on the Participant&rsquo;s behalf
(&ldquo;<B>Exercisable Awards</B>&rdquo;) may be exercised, if not previously expired, on or prior to the earlier of: (a) 90 days
after the date of Termination of Employment; or (b) the end of the Term of the Awards. All other Granted Awards for the benefit of
Participant shall expire upon the date of Termination of Employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>11.2 Termination
for Cause</B>. </FONT>In the event of Termination of Employment of a Participant for Cause, then: (A) the Participant&rsquo;s right to
exercise any unexercised Granted Awards, whether vested or not on the date of Termination of Employment, shall cease as of such date of
Termination of Employment, and the Awards shall thereupon expire, and (B) any unvested Shares shall terminate and expire on the day the
Participant has been notified of his/her dismissal.&nbsp;Pending a determination of whether a Participant&rsquo;s conduct, activities
or circumstances give rise to Cause, the Administrator shall have the authority to suspend the exercise, payment, delivery or settlement
of all or any portion of such Participant&rsquo;s outstanding Awards pending any investigation of the matter. If subsequent to the Participant&rsquo;s
Termination of Employment, but prior to the exercise of Awards granted to such Participant, the Administrator determines that either prior
or subsequent to the Participant&rsquo;s Termination of Employment, the Participant engaged in conduct which would constitute Cause, then
the Participant&rsquo;s right to exercise the Awards granted to such Participant shall immediately cease upon such determination and the
Awards shall thereupon expire. The determination by the Administrator as to the occurrence of Cause shall be final and conclusive for
all purposes of this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>11.3 Termination
by Reason of Death, Retirement, or Disability</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><I>(A) <U>Death</U>-</I>
If Termination of Employment is by reason of death of the Participant, than his/her estate, personal representative or beneficiaries may
exercise the Participant&rsquo;s Awards, to the extent it was vested within the sixty (60) days period following the Participant&rsquo;s
death, at any time but not later than the earlier of: (i) the one (1) year anniversary of Participant&rsquo;s death; or (ii) the end of
the Term of the Awards. All other Awards granted for the benefit of a Participant and which have not vested within such 60-days period
shall expire upon the date of death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><I>(B) <U>Disability and
Retirement</U></I>- If Termination of Employment is by reason of Retirement or Disability of the Participant, the Participant may exercise
any portion of the Awards which have vested within the ninety (90) days period following the date of Retirement or Disability, at any
time but not later than the earlier of: (i) the one (1) year anniversary of the date of Retirement or Disability, as the case may be;
or (ii) the end of the Term of the Awards. All other Awards for the benefit of a Participant and which have not vested within such 90
days period shall expire upon the date of Retirement or Disability, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>11.4</B> <B>Exceptions</B>.
</FONT>In special circumstances pertaining to the Termination of Employment of a certain Participant, the Administrator may at its sole
discretion decide to extend any of the periods stated above in <U>Sections 10.1-10.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>11.5</B> <B>Transfer
of Employment or Service</B>. </FONT>Subject to the receipt of appropriate approvals from the ITA, if applicable, a Participant&rsquo;s
right to Awards granted to him/her under this Plan shall not be terminated, expire or forfeited solely as a result of the fact that the
Participant&rsquo;s employment or service as an employee, officer or director changes from the Company to an Affiliate or vice versa.
Any and all tax consequence of such a transfer, if any, shall be solely borne by the Participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, and notwithstanding the foregoing
provisions of this Section 11, unless determined otherwise by the Administrator, the transfer of a Participant from a status of an Employee
to a status of a Consultant or from a status of a Consultant to a status of an Employee, shall not be deemed a Termination of Employment
for purposes hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>12. Awards
and Tax Provisions</B>. </FONT>All Awards shall be granted under the Plan in accordance with one of the following Tax Provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(A)
The Company may grant Awards to 102 Participant in accordance with the provisions of Section 102 and the Section 102 Rules; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(B) The Company may Grant
Awards to Non-Qualified Participant in accordance with the provisions of Section 3(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>12.1</B> <B>Tax
Provision Selection</B>. </FONT>The Company shall elect under which Tax Provision each Award is granted at its sole discretion and in
accordance with any Applicable Law (the &ldquo;<B>Election</B>&rdquo;). The Company shall notify each Participant in the Grant Letter,
under which Tax Provision the Awards and/or Shares are granted and, if applicable, under which Tax Track, each Award is granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>12.2 Section
102 Trustee Tax Tracks</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a) If the Company elects
to grant Awards to 102 Participants through: (i) the Capital Gains Track Through a Trustee; or (ii) the Earned Income Track, then, in
accordance with the requirements of Section 102, the Company shall appoint a Trustee who will hold in trust at least for the Holding period
on behalf of each 102 Participant the granted Awards and the Underlying Shares issued upon exercise of such Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b) The Holding Period for
the Awards and/or Shares will be as follows: (i) <I>The Capital Gains Tax Track Through a Trustee</I> - if the Company elects to grant
the Awards according to the provisions of this track, then the Holding Period will be 24 months from the Date of Grant, or such period
as may be determined in any amendment of Section 102; and (ii) <I>Earned Income Track </I>- if the Company elects to grant Awards according
to the provisions of this track, then the Holding Period will be 12 months from the Date of Grant, or such period as may be determined
in any amendment of Section 102.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c) Subject to Section 102
and the Section 102 Rules, Participants shall not be able to receive from the Trustee, nor shall they be able to sell or dispose of the
Awards or Underlying Shares before the end of the applicable Holding Period. If a Participant sells or removes the Awards or the Underlying
Shares form the Trustee before the end of the applicable Holding Period (&ldquo;<B>Breach</B>&rdquo;), the Participant shall pay all applicable
taxes imposed on such Breach by Section 7 of the Section 102 Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d) In the event of a distribution
of rights, including an issuance of bonus shares, in connection with Awards and/or Underlying Shares (the &ldquo;<B>Additional Rights</B>&rdquo;),
all such Additional Rights shall be granted and/or issued to the Trustee for the benefit of Participants, and shall be held by the Trustee
at least for the remainder of the Holding Period applicable to the Awards and/or Underlying Shares, as applicable. Such Additional Rights
shall be treated in accordance with the provisions of the applicable Tax Track.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-variant: small-caps"><B>12.3</B> <B>Income
Tax Track Without a Trustee</B>. </FONT>If the Company elects to grant Awards to 102 Participants according to the provisions of the Income
Tax Track Without a Trustee, then the Awards will not be subject to a Holding Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-variant: small-caps"><B>12.4</B> <B>Concurrent
Conditions</B>.</FONT> The Holding Period, if any, is in addition to the vesting period with respect to Awards, as specified in <U>Section
7.2</U> of the Plan or in the Grant Letter. The Holding Period and vesting period may run concurrently, but neither is a substitute for
the other, and each are independent terms and conditions for granted Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-variant: small-caps"><B>12.5</B> <B>Trust
Agreement</B>.</FONT> The terms and conditions applicable to the trust relating to the Tax Track elected by the Company, as appropriate,
shall be set forth in Trust Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>13. Term
of Shares Held In Trust</B></FONT>. Unless otherwise extended by the Administrator, in its sole discretion, no Underlying Shares issued
upon exercise of Awards shall be held by the Trustee on behalf of the Participant for a period longer than ten (10) years after the end
of the Term of the applicable Awards. The Administrator shall instruct the Trustee as to the transfer of any Underlying Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>14. Rights
as a Shareholder</B></FONT>. Unless otherwise specified in the Plan, a Participant shall not have any rights as a Shareholder with respect
to Underlying Shares issued under this Plan, until such time as the Shares shall be registered in the name of the Participant in the Company&rsquo;s
register of Shareholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>14.1</B> <FONT STYLE="font-variant: small-caps"><B>Dividend</B></FONT>.
The Participants shall be entitled to receive any cash dividend paid to the Shareholders with respect to Underlying Shares issued to
them under this Plan. Payments of such dividend to the Participants shall be subject to any required tax being withheld or otherwise
deducted by the Trustee or the Company, as agreed between the Company and the Trustee, in accordance with Applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>15. No
Special Employment Rights</B></FONT>. Nothing contained in this Plan shall confer upon any Participant any right with respect to the continuation
of employment by or service to the Company or Affiliate or to interfere in any way with the right of the Company or Affiliate, to terminate
such employment or service or to increase or decrease the compensation of the Participant. The Awards are extraordinary, one-time benefits
granted to the Participants and are not and shall not be deemed a salary component for any purpose whatsoever, including, in connection
with calculating severance compensation under any Applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>16. Restrictions
on Sale of Awards and Shares </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>16.1</B> <B>Awards</B>.</FONT>
Awards may not be sold, assigned, transferred, pledged, hypothecated or otherwise disposed of, except by will or the laws of descent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>16.2 Acceleration
Provision</B>. </FONT>The Administrator, at its sole discretion, may decide to add a provision in certain Grant Letters, according to
which in case of a Merger or other events, all or some of the unvested Awards or/and Shares, shall automatically accelerate, and become
fully vested and exercisable upon such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>16.3</B> <FONT STYLE="font-variant: small-caps"><B>Acknowledgement
To Restrictions</B>.</FONT> As a condition for the grant of Awards and issuance of Underlying Shares thereunder, each Participant shall
acknowledge the terms and provisions of the corporate documents of the Company, including organizational documents, as amended from time
to time, and all other agreements among the Shareholders which are applicable to the holders of the Company&rsquo;s Shares and shall agree
to be bound by their terms with respect to any restriction applicable to the Shares of the Company (including without limitation, any
right of first refusal, co-sale and bring along provisions, as applicable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>17. Tax
Matters</B></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(a) This Plan shall be governed
by, and shall conform with and be interpreted so as to comply with, the requirements of Section 102 and any written approval or ruling
from the ITA. All tax consequences under any Applicable Law (other than stamp duty) which may arise from the Grant of the Awards, from
the exercise of Awards or from the holding or sale of the Underlying Shares (or other securities issued under the Plan) by or on behalf
of the Participant or from any other event or act hereunder (whether any act of the Participant or of the Company or its Affiliates or
of the Trustee), shall be borne solely on the Participant. The Participant shall indemnify the Company and/or Affiliate and /or the Trustee,
as the case may be, and hold them harmless, against and from any liability for any such tax or any penalty, interest or indexing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(b) Except as otherwise required
by Applicable Law, the Company shall not be obligated to honor the exercise of any Award by or on behalf of a Participant or the sale,
exchange or other transfer of any Underlying Shares issued upon exercise of Awards until all tax consequences (if any) arising from the
exercise of such Awards or sale, exchange or other transfer of Shares are resolved to the full satisfaction of the Company. Without derogating
from the above, the Company and/or, when applicable, the Trustee shall not be required to release any share certificate to a Participant
until all required payments have been fully made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(c) If the Company elects
to grant Awards according to the provisions of the Income Tax Track Without a Trustee, and if prior to the Exercise of any and/or all
of these Awards, such Participant ceases to be an Employee, director, or officer of the Company or Affiliate, the Participant shall deposit
with the Company a guarantee or other security as required by law, in order to ensure the payment of applicable taxes upon the Exercise
of such Awards, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(d) It is clarified that
if any grants made under either of the tax tracks under Section 102 do not comply with the requirement of such tax route, the grant shall
be considered subject to the Income Tax Track Without a Trustee, or Section 3(i) or Section 2 of the Tax Ordinance, as applicable, and
the Participant irrevocably waives any claim and/or demand it has or may have with respect to the tax treatment of the Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>18. <FONT STYLE="font-variant: small-caps">Withholding
Taxes</FONT></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(a) Whenever an amount with
respect to withholding tax relating to Awards granted to a Participant and/or Underlying Shares issued upon the exercise or vesting thereof
is due from the Participant and/or the Company and/or an Affiliate, the Company and/or an Affiliate and/or the Trustee shall have the
right to demand from a Participant such amount that would be sufficient to satisfy any applicable withholding tax requirements related
thereto, and whenever Shares or any other non-cash assets are to be delivered pursuant to the exercise or vesting of an Award and the
sale of Underlying Shares, or transferred thereafter, the Company and/or an Affiliate and/or the Trustee shall have the right to require
the Participant to remit to the Company and/or to the Affiliate, or to the Trustee an amount in cash sufficient to satisfy any applicable
withholding tax requirements related thereto, and if such amount is not timely remitted, the Company and/or the Affiliate and/or the Trustee
shall have the right to withhold or set-off (subject to Applicable Law) such Shares or any other non-cash assets pending payment by the
Participant of such amounts. In particular, the Company shall have the right, but not the obligation, to deduct from (i) the Shares issuable
to a Grantee upon the exercise or vesting of an Award, or to accept from the Grantee the tender of, and/or to make resales (in the Stock
Market, if applicable) of, in each case, a number of whole Shares having a fair market value, as determined by the Company, and/or (ii)
Grantee&rsquo;s compensation (including salary) a cash amount, in each case, that will enable the Company to satisfy any tax withholding
obligations of the Company or its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(b) In any case where a tax
is required to be withheld in connection with the delivery of Shares of the Company or of an Affiliate under the Plan, the Administrator
may at its sole discretion (subject to Applicable Law) grant (either at the time of the grant or thereafter) to a Participant the right
to elect, pursuant to such rules and subject to such conditions as the Administrator may establish, that: (i) the Company reduce the number
of Shares to be delivered by (or otherwise reacquire from the Participant) the appropriate number of Shares, valued in a consistent manner
at their Fair Market Value or at the sales price in accordance with authorized procedures for cashless exercises, necessary to satisfy
the minimum applicable withholding obligation on exercise, vesting or payment; or (ii) have the Company withhold from proceeds of the
sale of such Shares (either through a voluntary sale or through a mandatory sale arranged by the Company on the Participant&rsquo;s behalf)
the minimum amount required to be withheld.(c) Until all taxes have been paid in accordance with Rule 7 of the Section 102 Rules or any
other Applicable Law, Awards and/or Underlying Shares may not be sold, transferred, assigned, pledged, encumbered, or otherwise willfully
hypothecated or disposed of, and no power of attorney or deed of transfer, whether for immediate or future use may be validly given. Notwithstanding
the foregoing, the Awards and the Underlying Shares may be validly transferred upon the death of a Participant in accordance with <U>Section
19</U> of this Plan, provided that the transferee thereof shall be subject to the provisions of Section 102 and the Section 102 Rules
as would have been applicable to the deceased Participant in the event he/she would have survived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>19. <FONT STYLE="font-variant: small-caps">No
Transfer of Awards</FONT></B>. The Trustee shall not transfer Awards to any third party, including a 102 Participant, except in accordance
with instructions received from the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>20. Transfer
of Rights Upon Death</B></FONT>. No transfer of any Award or Underlying Share issued upon the exercise thereof by will or by the laws
of descent shall be effective to bind the Company unless the Company shall have been furnished with all of the following signed and notarized
documents: (i) a written request for such transfer and a copy of the legal documents creating and confirming the right of the person acting
with respect to the Participant&rsquo;s estate and of the transferee; (ii) written consent by the transferee to pay any payment due according
to the provisions of the Plan and otherwise comply by all the terms of the Plan; and (iii) any such other evidence as the Administrator
may deem necessary to establish the right to the transfer of the Granted Awards or Underlying Shares issued upon the exercise thereof
and the validity of the transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>21. No
Right of Others to Awards</B></FONT>. Subject to the provisions of the Plan, no person other than the Participant shall have any right
with respect to Awards granted to the Participants under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>22. Expenses
and Receipts</B></FONT>. The expenses incurred in connection with the administration and implementation of the Plan (including any applicable
stamp duty) shall be borne by the Company. Any proceeds received by the Company in connection with the exercise of any Award may be used
for general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>23. Required
Approvals</B></FONT>. The Plan is subject to the receipt of all approvals required under the Applicable Law including under the Tax Ordinance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>24. Treatment
of Participants</B></FONT>. There is no obligation for uniformity of treatment of Participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>25.
No Conflicts</B>.</FONT> In the event of any conflict between the terms of the Plan and the Grant Letter, the Plan shall prevail, unless
the Grant Letter stated specifically that the conflicting provision in the Grant Letter shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>26. Participant
Undertakings</B></FONT>. By execution of any Grant Letter, the Participant shall be deemed to have agreed to the following: (i) agree
and acknowledge that he or she have received and read the Plan, the Grant Letter and the Trust Agreement; (ii) undertake all the provisions
set forth in Section 3(i) or Section 102 as applicable (including provisions regarding the applicable Tax Track that the Company has elected),
the Plan, the Grant Letter and the Trust Agreement (if applicable); (iii) sign any required documentation, including but not limited,
an irrevocable power of attorney and proxy; and (iv) to the extent the Awards are granted under Section 102, the 102 Participant shall
undertake that subject to the provisions of Section 102 and the Section 102 Rules, he/she shall not sell or release the Awards or Underlying
Shares from trust before the end of the Holding Period (if any).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>27. <FONT STYLE="font-variant: small-caps">Governing
Law and Jurisdiction</FONT></B>. This Plan shall be governed by and construed and enforced in accordance with the laws of the State of
Israel, without giving effect to its principles of conflict of laws. The competent courts of Tel-Aviv, Israel shall have sole jurisdiction
in any matters pertaining to this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>28. <FONT STYLE="font-variant: small-caps">Non-Exclusivity
of the Plan</FONT></B>. The adoption of this Plan by the Board shall not be construed as amending, modifying or rescinding any
previously approved incentive arrangements or imposing any limitations on the power of the Board to adopt other incentive
arrangements as it may deem desirable, including, without limitation, the granting of shares or Awards otherwise than under this
Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">* * * * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-11.1
<SEQUENCE>5
<FILENAME>ea023729501ex11-1_neuro.htm
<DESCRIPTION>INSIDER TRADING POLICY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 11.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">NeuroSense
TherapEutics Ltd.<BR>
<BR>
Insider Trading Compliance Policy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Effective Date: November 9, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. federal securities laws
prohibit trading in the securities of a company while in possession of material nonpublic information and providing material nonpublic
information to others so that they can trade. Violating such laws can undermine investor trust, harm the Company&rsquo;s reputation, and
result in your dismissal from NeuroSense Therapeutics Ltd. (together with its subsidiaries, the &ldquo;<U>Company</U>&rdquo;) or even
serious criminal and civil charges against you and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Insider Trading Compliance
Policy (this &ldquo;<U>Policy</U>&rdquo;) outlines your responsibilities to avoid insider trading and implements certain procedures to
help you avoid even the appearance of insider trading.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">I.</TD><TD STYLE="text-align: justify"><U>Summary</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preventing insider trading
is necessary to comply with U.S. federal securities laws and to preserve the reputation and integrity of the Company. &ldquo;<U>Insider
trading</U>&rdquo; occurs when any person purchases or sells a security while in possession of material nonpublic information relating
to the security. Insider trading is a crime. The criminal penalties for violating insider trading laws include imprisonment and fines
of up to $5 million for individuals and $25 million for corporations. Insider trading may also result in civil penalties, including disgorgement
of profits and civil fines of up to the greater of $1,275,000 or three times the profit made or loss avoided. Insider trading is also
prohibited by this Policy, and violation of this Policy may result in Company-imposed sanctions, including removal or dismissal for cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy applies to all
officers, directors, and employees of the Company. As someone subject to this Policy, you are responsible for ensuring that members of
your household (and individuals not residing in your household but whose transactions are subject to your influence or control), your
spouse, domestic partner and minor children (even if financially independent), and anyone to whom you provide significant financial support
also comply with this Policy. This Policy also applies to any entities you control (control is generally applicable when you have greater
than 50% ownership of an entity), including any corporations, partnerships, or trusts, and transactions by such entities should be treated
for the purposes of this Policy and applicable securities laws as if they were for your own account. The Company may determine that this
Policy applies to additional persons with access to material nonpublic information, such as contractors or consultants. This Policy extends
to all activities within and outside your Company duties. Every officer, director, and employee must review this Policy. Questions regarding
the Policy should be directed to the Company&rsquo;s Compliance Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this Policy,
the &ldquo;<U>Compliance Officer</U>&rdquo; shall be the Company&rsquo;s Chief Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In all cases, as someone subject
to this Policy, you bear full responsibility for ensuring your compliance with this Policy, and also for ensuring that members of your
household (and individuals not residing in your household but whose transactions are subject to your influence or control), your spouse,
domestic partner and minor children (even if financially independent), anyone to whom you provide significant financial support and entities
under your influence or control are in compliance with this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Actions taken by the Company,
the Compliance Officer, or any other Company personnel do not constitute legal advice, nor do they insulate you from the consequences
of noncompliance with this Policy.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">II.</TD><TD STYLE="text-align: justify"><U>Statement of Policies Prohibiting Insider Trading</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No officer, director, or employee
(or any other person designated as subject to this Policy) shall purchase or sell any type of security while in possession of material
nonpublic information relating to the security or the issuer of such security, whether the issuer of such security is the Company or any
other company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These prohibitions do not
apply to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">purchases of the Company&rsquo;s securities from
the Company or sales of the Company&rsquo;s securities to the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">exercises of stock options or other equity awards
or the surrender of shares to the Company in payment of the exercise price or in satisfaction of any tax withholding obligations in a
manner permitted by the applicable equity award agreement, or vesting of equity-based awards that, in each case, do not involve a market
sale of the Company&rsquo;s securities (the &ldquo;<U>cashless exercise</U>&rdquo; of a Company stock option through a broker <I>does</I>
involve a market sale of the Company&rsquo;s securities, and therefore would not qualify under this exception);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>bona fide</I> gifts of the Company&rsquo;s
securities; or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">purchases or sales of the Company&rsquo;s securities
made pursuant to any binding contract, specific instruction or written plan entered into while the purchaser or seller, as applicable,
was unaware of any material nonpublic information and which contract, instruction, or plan (i) meets all requirements of the affirmative
defense provided by Rule 10b5-1 (&ldquo;<U>Rule 10b5-1</U>&rdquo;) promulgated under the Securities Exchange Act of 1934, as amended (the
&ldquo;<U>1934 Act</U>&rdquo;), (ii) was precleared in advance pursuant to this Policy and (iii) has not been amended or modified in any
respect after such initial preclearance without such amendment or modification being precleared in advance pursuant to this Policy. For
more information about Rule 10b5-1 trading plans, see Section VI below.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No officer, director, or employee
shall directly or indirectly communicate (or &ldquo;<U>tip</U>&rdquo;) material nonpublic information to anyone outside the Company (except
in accordance with the Company&rsquo;s policies regarding the protection or authorized external disclosure of Company information) or
to anyone within the Company other than on a &ldquo;need-to-know&rdquo; basis.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">III.</TD><TD STYLE="text-align: justify"><U>Explanation of Insider Trading</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Insider trading</U>&rdquo;
refers to the purchase or sale of a security while in possession of material nonpublic information relating to the security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase</U>&rdquo;
and &ldquo;<U>Sale</U>&rdquo; are defined broadly under the federal securities law. &ldquo;Purchase&rdquo; includes not only the actual
purchase of a security, but any contract to purchase or otherwise acquire a security. &ldquo;Sale&rdquo; includes not only the actual
sale of a security, but any contract to sell or otherwise dispose of a security. These definitions extend to a broad range of transactions,
including conventional cash-for-stock transactions, conversions, the exercise of stock options, and acquisitions and exercises of warrants
or puts, calls, or other derivative securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is generally understood
that insider trading includes the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">trading by insiders while in possession of material,
non-public information;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">trading by persons other than insiders while
in possession of material, non-public information, if the information either was given in breach of an insider&rsquo;s fiduciary duty
to keep it confidential or was misappropriated; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">communicating or tipping material, non-public
information to others, including recommending the purchase or sale of a security while in possession of such information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
includes stocks, bonds, notes, debentures, options, warrants, and other convertible securities, as well as derivative instruments.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify">What Facts Are Material?</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The materiality of a fact
depends upon the circumstances. A fact is considered &ldquo;<U>material</U>&rdquo; if there is a substantial likelihood that a reasonable
investor would consider it important in making a decision to buy, sell, or hold a security, or if the fact is likely to have a significant
effect on the market price of the security. Material information can be positive or negative and can relate to virtually any aspect of
a company&rsquo;s business or to any type of security, debt, or equity. Also, information that something is likely to happen in the future&mdash;or
even just that it may happen&mdash;could be deemed material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Examples of material information
include (but are not limited to) information about corporate earnings or earnings forecasts; significant changes in key performance indicators
of the Company; possible mergers, acquisitions, tender offers, joint ventures or dispositions; changes in control of the Company or changes
in senior management; new products or developments regarding customers (e.g., the acquisition or loss of a contract); changes in auditors
or auditor notification that the Company may no longer rely on an audit report; significant events concerning the Company&rsquo;s physical
assets; events regarding the Company&rsquo;s securities (e.g., defaults on senior securities, calls of securities for redemption, repurchase
plans, stock splits, dividends, changes to the rights of security holders or public or private sales of additional securities); new equity
or debt offerings or significant borrowing; changes in debt ratings, or analyst upgrades or downgrades of the issuer or one of its securities;
bankruptcies or receiverships; cybersecurity or data security incidents; the initiation, suspension and results of the Company&rsquo;s
clinical trials and any other material information relating thereto; significant actions by regulatory bodies; significant changes in
accounting treatment, write-offs or effective tax rate; receipt, cancellation or deferral of significant purchase orders; and significant
litigation or regulatory actions. Moreover, material information does not have to be related to a company&rsquo;s business. For example,
the contents of a forthcoming newspaper column that is expected to affect the market price of a security can be material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Questions regarding material
information should be directed to the Compliance Officer. A good rule of thumb: when in doubt, do not trade.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: justify">What Is Nonpublic?</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information is &ldquo;<U>nonpublic</U>&rdquo;
if it is not available to the general public. In order for information to be considered public, it must be widely disseminated in a manner
making it generally available to investors, through newswire services such as Dow Jones, Reuters, Bloomberg, Business Wire, The Wall Street
Journal, Associated Press, or United Press International; broadcasts on widely available radio or television programs; publication in
a widely available newspaper, magazine, or news website; a Regulation FD-compliant conference call; or public disclosure documents filed
with the U.S. Securities and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo;) that are available on the SEC&rsquo;s website. Note that
simply posting information to the Company&rsquo;s website may not be sufficient disclosure to make the information public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The circulation of rumors,
even if accurate and reported in the media, does not constitute effective public dissemination. In addition, even after a public announcement,
a reasonable period of time must lapse in order for the market to react to the information. Generally, one should allow two full trading
days following publication as a reasonable waiting period before such information is deemed to be public.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: justify">Who Is an Insider?</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Insiders</U>&rdquo;
include officers, directors, and any employees of a company, or anyone else who has material nonpublic information about a company. Insiders
have independent fiduciary duties to their company and its stockholders not to trade on material nonpublic information relating to the
company&rsquo;s securities. Insiders may not trade in the Company&rsquo;s securities while in possession of material nonpublic information
relating to the Company, nor may they tip such information to anyone outside the Company (except in accordance with the Company&rsquo;s
policies regarding the protection or authorized external disclosure of Company information) or to anyone within the Company other than
on a &ldquo;need-to-know&rdquo; basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Individuals subject to this
Policy are responsible for ensuring that members of their households, their spouses, domestic partners and minor children (even if financially
independent), and anyone to whom such individuals subject to this Policy provide significant financial support also comply with this Policy.
This Policy also applies to any entities controlled by individuals subject to the Policy, including any corporations, partnerships or
trusts, and transactions by these entities should be treated for the purposes of this Policy and applicable securities laws as if they
were for the individual&rsquo;s own account. Further, this Policy applies to (i) any account over which the individuals subject to this
Policy have or share the power, directly or indirectly, to make investment decisions (whether or not such persons have a financial interest
in the account) and (ii) those accounts established or maintained by such persons with their consent or knowledge and in which such persons
have a direct or indirect financial interest.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: justify">Trading by Persons Other Than Insiders</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insiders may be liable for
communicating or tipping material nonpublic information to a third party (&ldquo;<U>tippee</U>&rdquo;), and insider trading violations
are not limited to trading or tipping by insiders. Persons other than insiders can also be liable for insider trading, including tippees
who trade on material nonpublic information tipped to them or individuals who trade on material nonpublic information that has been misappropriated.
Insiders may be held liable for tipping even if they receive no personal benefit from tipping and even if no close personal relationship
exists between them and the tippee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tippees inherit an insider&rsquo;s
duties and are liable for trading on material, non-public information illegally tipped to them by an insider. Similarly, just as insiders
are liable for the insider trading of their tippees, so are tippees who pass the information along to others who trade. In other words,
a tippee&rsquo;s liability for insider trading is no different from that of an insider. Tippees can obtain material, non-public information
by receiving overt tips from others or through, among other things, conversations at social, business, or other gatherings.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">E.</TD><TD STYLE="text-align: justify">Penalties for Engaging in Insider Trading</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Penalties for trading on or
tipping material nonpublic information can extend significantly beyond any profits made or losses avoided, both for individuals engaging
in such unlawful conduct and their employers. The SEC and Department of Justice have made the civil and criminal prosecution of insider
trading violations a top priority. Enforcement remedies available to the government or private plaintiffs under the federal securities
laws include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SEC administrative sanctions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">securities industry self-regulatory organization
sanctions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">civil injunctions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">damage awards to private plaintiffs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">disgorgement of all profits;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">civil fines for the violator of up to three times
the amount of profit gained or loss avoided;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">civil fines for the employer or other controlling
person of a violator (i.e., where the violator is an employee or other controlled person) of up to the greater of $1.425 million or three
times the amount of profit gained or loss avoided by the violator;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">criminal fines for individual violators of up
to $5 million ($25 million for an entity); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">jail sentences of up to 20 years.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, insider trading
could result in serious sanctions by the Company, including dismissal. Insider trading violations are not limited to violations of the
federal securities laws. Other federal and state civil or criminal laws, such as the laws prohibiting mail and wire fraud and the Racketeer
Influenced and Corrupt Organizations Act (RICO), may also be violated in connection with insider trading.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">F.</TD><TD STYLE="text-align: justify">Size of Transaction and Reason for Transaction Do Not Matter</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The size of the transaction
or the amount of profit received does not have to be significant to result in prosecution. The SEC has the ability to monitor even the
smallest trades, and the SEC performs routine market surveillance. Brokers or dealers are required by law to inform the SEC of any possible
violations by people who may have material nonpublic information. The SEC aggressively investigates even small insider trading violations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">G.</TD><TD STYLE="text-align: justify">Other Companies&rsquo; Stock</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Employees and directors who
learn material information about suppliers, customers, or competitors through their work at the Company must keep it confidential and
not buy or sell stock in such companies until the information becomes public. Employees and directors should not give tips about such
stock.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">IV.</TD><TD STYLE="text-align: justify"><U>Statement of Procedures to Prevent Insider Trading</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following procedures have
been established, and will be maintained and enforced, by the Company to prevent insider trading.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify">Blackout Periods</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The period during which the
Company prepares quarterly financials is a sensitive time for insider trading purposes, as Company personnel may be more likely to possess,
or be presumed to possess, material nonpublic information. To avoid the appearance of impropriety and assist Company personnel in planning
transactions in the Company&rsquo;s securities for appropriate times, no officer, director, or employee shall purchase or sell any security
of the Company during the period beginning on the 14th calendar day before the end of any fiscal quarter of the Company and ending upon
completion of the second full trading day after the public release of earnings data for such fiscal quarter or during any other trading
suspension period declared by the Company, except for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">purchases of the Company&rsquo;s securities from
the Company or sales of the Company&rsquo;s securities to the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">exercises of stock options or other equity awards,
the surrender of shares to the Company in payment of the exercise price or in satisfaction of any tax withholding obligations in a manner
permitted by the applicable equity award agreement, or the vesting of equity-based awards that do not involve a market sale of the Company&rsquo;s
securities (the cashless exercise of a Company stock option through a broker <U>does</U> involve a market sale of the Company&rsquo;s
securities, and therefore would not qualify under this exception);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>bona fide</I> gifts of the Company&rsquo;s
securities; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">purchases or sales of the Company&rsquo;s securities
made pursuant to any binding contract, specific instruction, or written plan entered into while the purchaser or seller, as applicable,
was unaware of any material nonpublic information and which contract, instruction, or plan (i) meets all requirements of the affirmative
defense provided by Rule 10b5-1, (ii) was precleared in advance pursuant to this Policy, and (iii) has not been amended or modified in
any respect after such initial preclearance without such amendment or modification being precleared in advance pursuant to this Policy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Exceptions to the blackout
period policy may be approved only by the Company&rsquo;s Chief Financial Officer or, in the case of exceptions for directors, the Board
of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, the Company,
through the Board of Directors or Chief Financial Officer, may recommend that officers, directors, employees, or others suspend trading
in the Company&rsquo;s securities because of developments that have not yet been disclosed to the public. Subject to the exceptions noted
above, all those affected should not trade in the Company&rsquo;s securities while the suspension is in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When such event-specific blackout
periods occur, those subject to it will be notified by the Company. The event-specific blackout period will not be announced to those
not subject to it, and those subject to it or otherwise aware of it should not disclose it to others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if the Company has not
notified you that you are subject to an event-specific blackout period, if you are aware of material nonpublic information about the Company,
you should not trade in Company securities. Even if the Company does not designate you as subject to an event-specific blackout period,
or does not notify you of such designation, this does not relieve you of your obligation not to trade in the Company&rsquo;s securities
while possessing material nonpublic information. None of the Company, the Compliance Officer, or the Company&rsquo;s other employees will
have any liability for any decisions regarding event-specific blackout periods or delays or failures to notify individuals of event-specific
blackout periods.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: justify">Preclearance of All Trades by All Officers, Directors and Certain Key Employees</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To provide assistance in preventing
inadvertent violations of applicable securities laws and to avoid the appearance of impropriety in connection with the purchase and sale
of the Company&rsquo;s securities, all transactions in the Company&rsquo;s securities (including, without limitation, acquisitions and
dispositions of Company stock; the exercise of stock options; elective transactions under any 401(k), ESPP or deferred compensation plans;
and the sale of Company stock issued upon exercise of stock options) by officers, directors, and certain key employees listed on <U>Schedule
I</U> (as amended from time to time) (each, a &ldquo;<U>Preclearance Person</U>&rdquo;) must be precleared by the Company&rsquo;s Compliance
Officer, except for certain exempt transactions as explained in Section VI of this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A request for preclearance
should be in writing (including by e-mail), should be made at least two business days in advance of the proposed transaction, and should
include the identity of the Preclearance Person, a description of the proposed transaction, the proposed date of the transaction, and
the number of shares or other securities to be involved. In addition, the Preclearance Person must execute a certification (in the form
approved by the Compliance Officer) that he or she is not aware of material nonpublic information about the Company. The Compliance Officer
shall have sole discretion to decide whether to clear any contemplated transaction. All trades that are precleared must be effected within
five business days of receipt of the preclearance, unless a specific exception has been granted by the Compliance Officer. A precleared
trade (or any portion of a precleared trade) that has not been effected during the five business day period must be precleared again prior
to execution. Notwithstanding receipt of preclearance, if the Preclearance Person becomes aware of material nonpublic information or becomes
subject to a blackout period before the transaction is effected, the transaction may not be completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of the Company, the Compliance
Officer, or the Company&rsquo;s other employees will have any liability for any delay in reviewing, or refusal of, a request for preclearance
submitted pursuant to this Section IV.B. Notwithstanding any preclearance of a transaction pursuant to this Section IV.B, none of the
Company, the Compliance Officer, or the Company&rsquo;s other employees assumes any liability for the legality or consequences of such
transaction to the person engaging in such transaction.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: justify">Post-Termination Transactions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With the exception of the
preclearance requirement, this Policy continues to apply to transactions in the Company&rsquo;s securities even after termination of service
to the Company. If you are in possession of material nonpublic information when your service terminates, you may not trade in the Company&rsquo;s
securities until that information has become public or is no longer material.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: justify">Information Relating to the Company</TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-style: normal">1. </FONT>Access
to Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Access to material nonpublic
information about the Company, including the Company&rsquo;s business, earnings, or prospects, should be limited to officers, directors,
and employees of the Company on a &ldquo;need-to-know&rdquo; basis. In addition, such information should not be communicated to anyone
outside the Company under any circumstances (except in accordance with the Company&rsquo;s policies regarding the protection or authorized
external disclosure of Company information) or to anyone within the Company on an other than &ldquo;need-to-know&rdquo; basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In communicating material
nonpublic information to employees of the Company, all officers, directors, and employees must take care to emphasize the need for confidential
treatment of such information and adherence to the Company&rsquo;s policies with regard to confidential information.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-style: normal"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-style: normal">2. </FONT>Inquiries
From Third Parties</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inquiries from third parties,
such as industry analysts or members of the media, about the Company should be directed to the Chief Financial Officer at or@neurosense-tx.com</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">V.</TD><TD STYLE="text-align: justify"><U>Additional Prohibited Transactions</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has determined
that there is a heightened legal risk and/or the appearance of improper or inappropriate conduct if the persons subject to this Policy
engage in certain types of transactions. Therefore, officers, directors, and employees shall comply with the following policies with respect
to certain transactions in the Company securities:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify">Short Sales</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Short sales of the Company&rsquo;s
securities evidence an expectation on the part of the seller that the securities will decline in value, and therefore signal to the market
that the seller has no confidence in the Company or its short-term prospects. In addition, short sales may reduce the seller&rsquo;s incentive
to improve the Company&rsquo;s performance. This type of activity is inherently speculative in nature and is contrary to the best interests
of the Company and its stockholders. For these reasons, short sales of the Company&rsquo;s securities are prohibited by this Policy.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: justify">Publicly Traded Options</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A transaction in options is,
in effect, a bet on the short-term movement of the Company&rsquo;s stock and therefore creates the appearance that an officer, director,
or employee is trading based on material nonpublic information. Transactions in options may also focus an officer&rsquo;s, director&rsquo;s,
or employee&rsquo;s attention on short-term performance at the expense of the Company&rsquo;s long-term objectives. Accordingly, transactions
in puts, calls, or other derivative securities involving the Company&rsquo;s equity securities, on an exchange or in any other organized
market, are prohibited by this Policy.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: justify">Hedging Transactions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain forms of hedging or
monetization transactions, such as zero-cost collars and forward sale contracts, allow an officer, director, or employee to lock in much
of the value of his or her stock holdings, often in exchange for all or part of the potential for upside appreciation in the stock. Such
transactions allow the officer, director, or employee to continue to own the covered securities, but without the full risks and rewards
of ownership. When that occurs, the officer, director, or employee may no longer have the same objectives as the Company&rsquo;s other
stockholders. Therefore, such transactions involving the Company&rsquo;s equity securities are prohibited by this Policy.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: justify">Purchases of the Company&rsquo;s Securities on Margin; Pledging the Company&rsquo;s Securities to Secure
Margin or Other Loans</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Purchasing on margin means
borrowing from a brokerage firm, bank, or other entity in order to purchase the Company&rsquo;s securities (other than in connection with
a cashless exercise of stock options under the Company&rsquo;s equity plans). Margin purchases of the Company&rsquo;s securities are prohibited
by this Policy. Pledging the Company&rsquo;s securities as collateral to secure loans is also prohibited. This prohibition means, among
other things, that you cannot hold the Company&rsquo;s securities in a &ldquo;margin account&rdquo; (which would allow you to borrow against
your holdings to buy securities).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">VI.</TD><TD STYLE="text-align: justify"><U>Rule 10b5-1 Trading Plans</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading restrictions set
forth do not apply to transactions under a previously established contract, plan, or instruction to trade in the Company&rsquo;s stock
in accordance with the terms of Rule 10b5-1 and all applicable state laws (a &ldquo;<U>Trading Plan</U>&rdquo;) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">has been submitted to and preapproved by the
Company&rsquo;s Compliance Officer, or such other person as the Board of Directors may designate from time to time (the &ldquo;<U>Authorizing
Officer</U>&rdquo;), at least 30 days before the commencement of any transactions under the Trading Plan; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">you entered into in good faith at a time when
you were not in possession of material nonpublic information about the Company; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">either (i) specifies the amounts, prices, and
dates of all security transactions under the Trading Plan, (ii) provides a written formula, algorithm, or computer program for determining
the amount, price, and date of the transactions, or (iii) prohibits you from exercising any subsequent influence over the transactions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You may adopt more than one
Trading Plan at a time. You may only amend or revoke a Trading Plan outside of quarterly trading blackout periods when you do not possess
material nonpublic information. Any amendment or revocation of a Trading Plan must be preapproved by the Authorizing Officer at least
30 days before you trade under an amended Trading Plan or outside of a revoked Trading Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company reserves the right
to publicly announce, or respond to inquiries from the media regarding, the implementation of Trading Plans or the execution of transactions
made under a Trading Plan. The Company also reserves the right, from time to time, to suspend, discontinue, or otherwise prohibit transactions
under a Trading Plan if the Authorizing Officer or the Board of Directors, in its discretion, determines that such suspension, discontinuation,
or other prohibition is in the best interests of the Company. Transactions prohibited under Section V of this Policy, including short
sales and hedging transactions, may not be carried out through a Trading Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Compliance of a Trading Plan
with the terms of Rule 10b5-1 and the execution of transactions pursuant to the Trading Plan are the sole responsibility of the person
initiating the Trading Plan, and none of the Company, the Authorizing Officer, or the Company&rsquo;s other employees assume any liability
for any delay in reviewing and/or refusing a Trading Plan submitted for approval nor the legality or consequences relating to a person
entering into or trading under a Trading Plan.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">VII.</TD><TD STYLE="text-align: justify"><U>Execution and Return of Certification of Compliance</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After reading this Policy,
all officers, directors, and employees should execute and return to the Company&rsquo;s Compliance Officer the Certification of Compliance
form attached hereto as &ldquo;Attachment A.&rdquo;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Schedule I</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Individuals Subject to Preclearance Requirement</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-style: normal">1.</FONT></TD><TD><FONT STYLE="font-style: normal">Alon Ben-Noon</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-style: normal">2.</FONT></TD><TD><FONT STYLE="font-style: normal">Or Eisenberg</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-style: normal">3.</FONT></TD><TD><FONT STYLE="font-style: normal">Ferenc Tracik</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD>Mark Leuchtenberger</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD>Cary Claiborne</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">6.</TD><TD>Christine Pellizzari</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">7.</TD><TD>Caren Deardorf</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">8.</TD><TD STYLE="text-align: justify">Yael German</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Attachment A</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Certification of Compliance</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Return by [_________] [<I>insert return deadline</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">To:</TD><TD STYLE="text-align: justify">__________________, [____]</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">From:</TD><TD STYLE="text-align: justify">__________________________</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">Re:</TD><TD STYLE="text-align: justify">Insider Trading Compliance Policy of NeuroSense Therapeutics Ltd.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I have received, reviewed,
and understand the above-referenced Insider Trading Compliance Policy and undertake, as a condition to my present and continued employment
(or, if I am not an employee, affiliation with) NeuroSense Therapeutics Ltd., to comply fully with the policies and procedures contained
therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I hereby certify, to the best
of my knowledge, that during the calendar year ending December 31, 20[__], I have complied fully with all policies and procedures set
forth in the above-referenced Insider Trading Compliance Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Signature</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">12</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>6
<FILENAME>ea023729501ex12-1_neuro.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION BY CHIEF EXECUTIVE OFFICER <BR>
PURSUANT
TO SECTION 302 OF THE&nbsp;SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">I, Alon Ben-Noon, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 20-F of NeuroSense
Therapeutics Ltd.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 183pt; text-align: justify; text-indent: -154.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the company as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -14.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -14.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the company&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -14.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the company&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 183pt; text-align: justify; text-indent: -154.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the
audit committee of the company&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 183pt; text-align: justify; text-indent: -154.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 183pt; text-align: justify; text-indent: -119.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 183pt; text-align: justify; text-indent: -154.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: left">Date: April 7, 2025</TD>
    <TD STYLE="width: 60%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">/s/ Alon Ben-Noon</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Alon Ben-Noon</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Chief Executive Officer</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>7
<FILENAME>ea023729501ex12-2_neuro.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 283.5pt"><B>Exhibit 12.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION BY CHIEF FINANCIAL OFFICER <BR>
PURSUANT
TO SECTION 302 OF THE&nbsp;SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">I,&nbsp;Or Eisenberg, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 20-F of NeuroSense
Therapeutics Ltd.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 183pt; text-align: justify; text-indent: -154.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the company as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">e)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -14.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">f)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -14.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">g)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the company&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -14.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">h)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the company&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 183pt; text-align: justify; text-indent: -154.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The company&rsquo;s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the
audit committee of the company&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 183pt; text-align: justify; text-indent: -154.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 183pt; text-align: justify; text-indent: -119.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 183pt; text-align: justify; text-indent: -154.65pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: left">Date: April 7, 2025</TD>
    <TD STYLE="width: 60%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">/s/ Or Eisenberg</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Or Eisenberg</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Chief Financial Officer</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 557.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>8
<FILENAME>ea023729501ex13-1_neuro.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 7.05pt"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 7.05pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION BY CHIEF EXECUTIVE OFFICER<BR>
 PURSUAN&nbsp;TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report of NeuroSense
Therapeutics Ltd. (the &ldquo;Company&rdquo;) on Form 20-F for the period ended December&nbsp;31, 2024 as filed with the Securities and
Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned officer of the Company certifies, pursuant to 18 U.S.C.
&sect;1350, as adopted pursuant to &sect;906 of the Sarbanes-Oxley Act of 2002, that to such officer&rsquo;s knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of section
13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: left">Dated: April 7, 2025</TD>
    <TD STYLE="width: 60%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">/s/ Alon Ben-Noon</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Alon Ben-Noon</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Chief Executive Officer</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>9
<FILENAME>ea023729501ex13-2_neuro.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 7.05pt"><B>Exhibit 13.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 7.05pt"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION BY CHIEF FINANCIAL OFFICER <BR>
PURSUAN&nbsp;TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report of NeuroSense
Therapeutics Ltd. (the &ldquo;Company&rdquo;) on Form 20-F for the period ended December&nbsp;31, 2024 as filed with the Securities and
Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned officer of the Company certifies, pursuant to 18 U.S.C.
&sect;1350, as adopted pursuant to &sect;906 of the Sarbanes-Oxley Act of 2002, that to such officer&rsquo;s knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of section
13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: left">Dated: April 7, 2025</TD>
    <TD STYLE="width: 60%; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">/s/ Or Eisenberg</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Or Eisenberg</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">Chief Financial Officer</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>10
<FILENAME>ea023729501ex15-1_neuro.htm
<DESCRIPTION>CONSENT OF SOMEKH CHAIKIN (MEMBER FIRM OF KPMG INTERNATIONAL), INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent of Independent Registered Public Accounting
Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the incorporation by reference in
the registration statements (No. 333-262480) on Form S-8 and (No. 333-269306, No. 333-284051, 333-283656 and 333-260338) on Form F-3 of
our report dated April 7, 2025, with respect to the consolidated financial statements of Neurosense Therapeutics Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-size: 10pt">/s/ Somekh Chaikin</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Member Firm of KPMG International</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Tel Aviv, Israel</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">April 7, 2025</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Y G # 2(  A$! Q$!_\0
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M6/S(2$4@<D/P2.QJ:YT+0K8DK<32HEO))Q,@$I4 C:><9)(QBE[/!_\ /O\
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M2>W&!Q[UFU1_E->;&_S_ (K_ "#_ (3?4/\ GWM?R;_&E_X374/^?>V_)O\
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MLO#=OQ9PG_"!W>/^/RW_ .^#0? =X?\ E\M_^^#7=T4>UD+^RL+V?WLX/_A
M[S_G]@_[X-6M.\#^3>)+?7$<T*\^6BD;C[^U=E12=23''+,-%I\OXE2_BNY+
M)HK"2.&4C:'<9"CV [UQK> [YF+-?P%B<DE6R37>T5*DUL;5\'2Q#3J7T\S@
M?^$ O?\ G^M_^^#2?\(!>_\ /];_ /?!KOZ*?.SG_LG"]G][//\ _A7UX?\
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M3%N(7;:LJ$^@- $E%%% !1110 4444 %%%!( R3@4 %%1"XA9MHE0GTW5+0
M4444 %%%% !1110 44$@#)X%1"XA+;1*A/INH EHHHH **** "BBB@ HHHH
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M -:N(]DU/M,'_/:/_OH4?:8/^>T?_?0K+_LJX]8_S_\ K4?V5<>L?Y__ %J
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MK'^?_P!:@#4^TP?\]H_^^A1]I@_Y[1_]]"LO^RKCUC_/_P"M1_95QZQ_G_\
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M_P#K4?V5<>L?Y_\ UJ -3[3!_P ]H_\ OH4?:8/^>T?_ 'T*R_[*N/6/\_\
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M<RR/<*RY>-@VU""<XY48/ VT_2[&YM=0ME>,H%%PS' ^XS*5!Q\H.<G XP*
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MR& )(^F>E=%15*<HJR9$J<)-.23:\B."!+>/8@X[D]34E%%26%%%% !1110
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M5I6OI_6AUE%8W]JW'I'^1H_M6X](_P C6!Z1LT5C?VK<>D?Y&C^U;CTC_(T
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M5/10!0N=%TV\N%N+BSBDE50H8CG 8,!^# &HK?PYI%J<PV*+^]$V,D@."2&
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MR+[+!_SQC_[Y%'V6#_GC'_WR*EHH B^RP?\ /&/_ +Y%(;6W((\E/^^14U%
M'$Z[HMP+D7%L=LZ_=;.-V.A![&L"71]8U6^,EX=I8_-*[ G'L!7JC*KC#*"/
M0BF);PQG*1(#Z@5U4L5.DK12//K9=1JSYI7UW2>C,[2-*BM+)(VC&U5"HK#.
M!Z_4UH?98/\ GC'_ -\BI:*YFVW=G>DDK(B^RP?\\8_^^11]E@_YXQ_]\BI:
M*0R+[+!_SQC_ .^11]E@_P">,?\ WR*EHH B^RP?\\8_^^17(ZYHUS%>+=V;
M;)T/RMG&<=.?6NSI&4,,, 1Z&JC)Q=T95J,:L>21Y2^BZOJ5ZTEW\A=LO*[
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M?PI9=#L90VY'RVXY#G@D*"?_ !U?RITVEQ7%XL\CL0$12OJ4?<IS['/US0!
MFN)*86B@9X9;AK=9 X(W D=.X^4G/85>L;M;ZQAN54J)%R5/\)[C\#5<:/;I
M=+<Q-*DBEV WDKEVW-Q[G].*L6-HMC8PVRL6$:X+'^(]S^= %BBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI;+?_9MO)/-917D"1.QPKOM((/)('.!UZ5U0TG3ED61;&V#J%"L(AD;05'Y
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M?*C_ .>:_E1Y4?\ SS7\J .<)+$DG)/)I*MWED\$A9%+1GD$=JJJI8X4$GT
MH DAN)+=BT; $C!R*F_M.Y_OK_WS5VPLO*4O,HW-T4\X%7/*C_YYK^5 &-_:
M=S_?7_OFC^T[G^^O_?-;/E1_\\U_*CRH_P#GFOY4 8W]IW/]]?\ OFC^T[G^
M^O\ WS6SY4?_ #S7\J/*C_YYK^5 &-_:=S_?7_OFJK,7<NQR6.2:Z/RH_P#G
MFOY5DWUD\<C21J3&>>/X: *-20SR6[[XS@XQS3 "3@ D^@%:NGV)3,LRC)&
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A<]_]E?RJ[10 @& !SQZFEHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>nrsn-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 07 20:27:37 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:nrsn="http://www.neurosensetx.com/20241231" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://www.neurosensetx.com/20241231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="nrsn-20241231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nrsn-20241231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nrsn-20241231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="nrsn-20241231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ConsolidatedBalanceSheet" id="nrsn_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ConsolidatedBalanceSheet_Parentheticals" id="nrsn_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Consolidated Statements of Financial Position (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ConsolidatedIncomeStatement" id="nrsn_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Consolidated Statements of Income and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ShareholdersEquityType2or3" id="nrsn_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - Consolidated Statements of Changes in Equity (deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ConsolidatedCashFlow" id="nrsn_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/General" id="nrsn_r_General">
        <link:definition>995306 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/SignificantAccountingPolicy" id="nrsn_r_SignificantAccountingPolicy">
        <link:definition>995307 - Disclosure - Significant Accounting Policy</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/CashandCashEquivalent" id="nrsn_r_CashandCashEquivalent">
        <link:definition>995308 - Disclosure - Cash and Cash Equivalent</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/OtherReceivables" id="nrsn_r_OtherReceivables">
        <link:definition>995309 - Disclosure - Other Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/PropertyandEquipmentNet" id="nrsn_r_PropertyandEquipmentNet">
        <link:definition>995310 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/OperatingLease" id="nrsn_r_OperatingLease">
        <link:definition>995311 - Disclosure - Operating Lease</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/OtherCurrentLiabilities" id="nrsn_r_OtherCurrentLiabilities">
        <link:definition>995312 - Disclosure - Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/LiabilityinRespectofWarrants" id="nrsn_r_LiabilityinRespectofWarrants">
        <link:definition>995313 - Disclosure - Liability in Respect of Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ShareholdersEquity" id="nrsn_r_ShareholdersEquity">
        <link:definition>995314 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ShareBasedPayment" id="nrsn_r_ShareBasedPayment">
        <link:definition>995315 - Disclosure - Share Based Payment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ResearchandDevelopmentExpenses" id="nrsn_r_ResearchandDevelopmentExpenses">
        <link:definition>995316 - Disclosure - Research and Development Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/GeneralandAdministrativeExpenses" id="nrsn_r_GeneralandAdministrativeExpenses">
        <link:definition>995317 - Disclosure - General and Administrative Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/FinancingIncomeExpensesNet" id="nrsn_r_FinancingIncomeExpensesNet">
        <link:definition>995318 - Disclosure - Financing Income (Expenses), Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactions" id="nrsn_r_RelatedPartiesBalancesandTransactions">
        <link:definition>995319 - Disclosure - Related Parties Balances and Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/SegmentReporting" id="nrsn_r_SegmentReporting">
        <link:definition>995320 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/IncomeTaxes" id="nrsn_r_IncomeTaxes">
        <link:definition>995321 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/SubsequentEvents" id="nrsn_r_SubsequentEvents">
        <link:definition>995322 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/AccountingPoliciesByPolicy" id="nrsn_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/SignificantAccountingPolicyTables" id="nrsn_r_SignificantAccountingPolicyTables">
        <link:definition>996001 - Disclosure - Significant Accounting Policy (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/CashandCashEquivalentTables" id="nrsn_r_CashandCashEquivalentTables">
        <link:definition>996002 - Disclosure - Cash and Cash Equivalent (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/OtherReceivablesTables" id="nrsn_r_OtherReceivablesTables">
        <link:definition>996003 - Disclosure - Other Receivables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/PropertyandEquipmentNetTables" id="nrsn_r_PropertyandEquipmentNetTables">
        <link:definition>996004 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/OperatingLeaseTables" id="nrsn_r_OperatingLeaseTables">
        <link:definition>996005 - Disclosure - Operating Lease (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/OtherCurrentLiabilitiesTables" id="nrsn_r_OtherCurrentLiabilitiesTables">
        <link:definition>996006 - Disclosure - Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsTables" id="nrsn_r_LiabilityinRespectofWarrantsTables">
        <link:definition>996007 - Disclosure - Liability in Respect of Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ShareholdersEquityTables" id="nrsn_r_ShareholdersEquityTables">
        <link:definition>996008 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ShareBasedPaymentTables" id="nrsn_r_ShareBasedPaymentTables">
        <link:definition>996009 - Disclosure - Share Based Payment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ResearchandDevelopmentExpensesTables" id="nrsn_r_ResearchandDevelopmentExpensesTables">
        <link:definition>996010 - Disclosure - Research and Development Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/GeneralandAdministrativeExpensesTables" id="nrsn_r_GeneralandAdministrativeExpensesTables">
        <link:definition>996011 - Disclosure - General and Administrative Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/FinancingIncomeExpensesNetTables" id="nrsn_r_FinancingIncomeExpensesNetTables">
        <link:definition>996012 - Disclosure - Financing Income (Expenses), Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/IncomeTaxesTables" id="nrsn_r_IncomeTaxesTables">
        <link:definition>996013 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/GeneralDetails" id="nrsn_r_GeneralDetails">
        <link:definition>996014 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/SignificantAccountingPolicyDetails" id="nrsn_r_SignificantAccountingPolicyDetails">
        <link:definition>996015 - Disclosure - Significant Accounting Policy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation" id="nrsn_r_SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation">
        <link:definition>996016 - Disclosure - Significant Accounting Policy - Schedule of the Lives Used in Computing Straight-Line Depreciation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/CashandCashEquivalentDetails" id="nrsn_r_CashandCashEquivalentDetails">
        <link:definition>996017 - Disclosure - Cash and Cash Equivalent (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleofCashAndCashEquivalentTable" id="nrsn_r_ScheduleofCashAndCashEquivalentTable">
        <link:definition>996018 - Disclosure - Cash and Cash Equivalent - Schedule of Cash And Cash Equivalent (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable" id="nrsn_r_ScheduleofOtherReceivablesTable">
        <link:definition>996019 - Disclosure - Other Receivables - Schedule of Other Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable" id="nrsn_r_ScheduleofPropertyandEquipmentNetTable">
        <link:definition>996020 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/OperatingLeaseDetails" id="nrsn_r_OperatingLeaseDetails">
        <link:definition>996021 - Disclosure - Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYr+wciqhzO/TfNA0j8XAlDAX7Zs47GSe9YMpKX3MDHhrSmRPgkEK2u4ljrzwvIHfipcuE8XnwJBLDmhtLtl0Wkd3Ky+cGV3Eyy38kF0sLLqLlSwS0k9bURwWYWBfc634LCqUrXFOnmt5cVMGx9HtlaGkOgF0h8jEXpNuhYUKaCY+uhBk8nA3wEfnqV0gileaPM8GZVpEOik5keRqcHfnwDb/IfAuMyEk8nfZrG0zmWpe6TZP15grSxGCBxwqMtHqK77I9JaKADIIBu0UMflTh7] CSR-->
      <link:roleType roleURI="http://www.neurosensetx.com/role/OperatingLeaseDetailsScheduleofOperatingLease" id="nrsn_r_OperatingLeaseDetailsScheduleofOperatingLease">
        <link:definition>996022 - Disclosure - Operating Lease - Schedule of Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable" id="nrsn_r_ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable">
        <link:definition>996023 - Disclosure - Operating Lease - Schedule of Maturity Analysis of Company&#8217;s Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable" id="nrsn_r_ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable">
        <link:definition>996024 - Disclosure - Operating Lease - Schedule of Weighted Average Remaining Lease Terms and Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleofOtherCurrentLiabilitiesTable" id="nrsn_r_ScheduleofOtherCurrentLiabilitiesTable">
        <link:definition>996025 - Disclosure - Other Current Liabilities - Schedule of Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails" id="nrsn_r_LiabilityinRespectofWarrantsDetails">
        <link:definition>996026 - Disclosure - Liability in Respect of Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleofFinancialMeasuredatFairValueonaRecurringBasisTable" id="nrsn_r_ScheduleofFinancialMeasuredatFairValueonaRecurringBasisTable">
        <link:definition>996027 - Disclosure - Liability in Respect of Warrants - Schedule of Financial Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable" id="nrsn_r_ScheduleofFairValueoftheWarrantsTable">
        <link:definition>996028 - Disclosure - Liability in Respect of Warrants - Schedule of Fair Value of the Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleoftheMovementinWarrantLiabilityTable" id="nrsn_r_ScheduleoftheMovementinWarrantLiabilityTable">
        <link:definition>996029 - Disclosure - Liability in Respect of Warrants - Schedule of the Movement in Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ShareholdersEquityDetails" id="nrsn_r_ShareholdersEquityDetails">
        <link:definition>996030 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleofShareCapitalTable" id="nrsn_r_ScheduleofShareCapitalTable">
        <link:definition>996031 - Disclosure - Shareholders' Equity - Schedule of Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleofShareCapitalTable_Parentheticals" id="nrsn_r_ScheduleofShareCapitalTable_Parentheticals">
        <link:definition>996032 - Disclosure - Shareholders' Equity - Schedule of Share Capital (Parentheticals) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ShareBasedPaymentDetails" id="nrsn_r_ShareBasedPaymentDetails">
        <link:definition>996033 - Disclosure - Share Based Payment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable" id="nrsn_r_ScheduleofFairValueoftheOptionsGrantedTable">
        <link:definition>996034 - Disclosure - Share Based Payment - Schedule of Fair Value of the Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable" id="nrsn_r_ScheduleofShareOptionActivityTable">
        <link:definition>996035 - Disclosure - Share Based Payment - Schedule of Share Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleofRestrictedStockUnitRSUsActivityTable" id="nrsn_r_ScheduleofRestrictedStockUnitRSUsActivityTable">
        <link:definition>996036 - Disclosure - Share Based Payment - Schedule of Restricted Stock Unit (RSU&#8217;s) Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleofShareBasedExpenseRecognizedintheStatementsofOperationTable" id="nrsn_r_ScheduleofShareBasedExpenseRecognizedintheStatementsofOperationTable">
        <link:definition>996037 - Disclosure - Share Based Payment - Schedule of Share-Based Expense Recognized in the Statements of Operation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleofResearchandDevelopmentExpensesTable" id="nrsn_r_ScheduleofResearchandDevelopmentExpensesTable">
        <link:definition>996038 - Disclosure - Research and Development Expenses - Schedule of Research and Development Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/GeneralandAdministrativeExpensesDetails" id="nrsn_r_GeneralandAdministrativeExpensesDetails">
        <link:definition>996039 - Disclosure - General and Administrative Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable" id="nrsn_r_ScheduleofGeneralandAdministrativeExpensesTable">
        <link:definition>996040 - Disclosure - General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable" id="nrsn_r_ScheduleofFinancingIncomeExpensesNetTable">
        <link:definition>996041 - Disclosure - Financing Income (Expenses), Net - Schedule of Financing Income (Expenses), Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails" id="nrsn_r_RelatedPartiesBalancesandTransactionsDetails">
        <link:definition>996042 - Disclosure - Related Parties Balances and Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/IncomeTaxesDetails" id="nrsn_r_IncomeTaxesDetails">
        <link:definition>996043 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable" id="nrsn_r_ScheduleoftheCompanysNetdeferredTaxAssetsTable">
        <link:definition>996044 - Disclosure - Income Taxes - Schedule of the Company&#8217;s Net deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/ScheduleoftheMovementoftheValuationAllowanceTable" id="nrsn_r_ScheduleoftheMovementoftheValuationAllowanceTable">
        <link:definition>996045 - Disclosure - Income Taxes - Schedule of the Movement of the Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/SubsequentEventsDetails" id="nrsn_r_SubsequentEventsDetails">
        <link:definition>996046 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.neurosensetx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <xs:element name="ScheduleOfCashAndCashEquivalentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ScheduleOfCashAndCashEquivalentAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfFinancialMeasuredAtFairValueOnARecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ScheduleOfFinancialMeasuredAtFairValueOnARecurringBasisAbstract"/>
  <xs:element name="ScheduleOfFairValueOfTheWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ScheduleOfFairValueOfTheWarrantsAbstract"/>
  <xs:element name="ScheduleOfFairValueOfTheOptionsGrantedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ScheduleOfFairValueOfTheOptionsGrantedAbstract"/>
  <xs:element name="ScheduleOfShareOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ScheduleOfShareOptionActivityAbstract"/>
  <xs:element name="ScheduleOfRestrictedStockUnitRsuSActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ScheduleOfRestrictedStockUnitRsuSActivityAbstract"/>
  <xs:element name="ScheduleOfShareBasedExpenseRecognizedInTheStatementsOfOperationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ScheduleOfShareBasedExpenseRecognizedInTheStatementsOfOperationAbstract"/>
  <xs:element name="ScheduleOfFinancingIncomeExpensesNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract"/>
  <xs:element name="ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract"/>
  <xs:element name="OrdinarySharesNoParValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_OrdinarySharesNoParValueAbstract"/>
  <xs:element name="CostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_CostAbstract"/>
  <xs:element name="AccumulatedDepreciationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_AccumulatedDepreciationAbstract"/>
  <xs:element name="CostAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_CostAbstract0"/>
  <xs:element name="AccumulatedDepreciationAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_AccumulatedDepreciationAbstract0"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_UnlabeledAbstract"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet"/>
  <xs:element name="StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet"/>
  <xs:element name="StockIssuedDuringPeriodValuePre-fundedWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised"/>
  <xs:element name="StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement"/>
  <xs:element name="StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement"/>
  <xs:element name="StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity"/>
  <xs:element name="RevaluationOfLiabilityInRespectToWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_RevaluationOfLiabilityInRespectToWarrants"/>
  <xs:element name="DecreaseInOperatingRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_DecreaseInOperatingRightOfUseAsset"/>
  <xs:element name="DecreaseInOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_DecreaseInOperatingLeaseLiability"/>
  <xs:element name="RedemptionofinvestmentInShorttermDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_RedemptionofinvestmentInShorttermDeposits"/>
  <xs:element name="RedemptionOfinvestmentInRestrictedDepositNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_RedemptionOfinvestmentInRestrictedDepositNet"/>
  <xs:element name="ReclassificationOfWarrantsIntoEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ReclassificationOfWarrantsIntoEquity"/>
  <xs:element name="BonusAccrualReclassificationToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_BonusAccrualReclassificationToEquity"/>
  <xs:element name="NoncashOrPartNoncashAcquisitionInterestReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_NoncashOrPartNoncashAcquisitionInterestReceived"/>
  <xs:element name="LiabilityInRespectOfWarrantsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_LiabilityInRespectOfWarrantsTextBlock"/>
  <xs:element name="GeneralAndAdministrativeExpensesDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock"/>
  <xs:element name="ShortTermDepositsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ShortTermDepositsPolicyTextBlock"/>
  <xs:element name="RestrictedDepositsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_RestrictedDepositsPolicyTextBlock"/>
  <xs:element name="ContractsOverOwnEquityPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ContractsOverOwnEquityPolicyTextBlock"/>
  <xs:element name="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
  <xs:element name="ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock"/>
  <xs:element name="LesseeOperatingLeaseDisclosureTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_LesseeOperatingLeaseDisclosureTableTextBlock"/>
  <xs:element name="ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
  <xs:element name="LiabilityinRespectofWarrantsScheduleoftheMovementinWarrantLiabilityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nrsn_LiabilityinRespectofWarrantsScheduleoftheMovementinWarrantLiabilityDetailsTable"/>
  <xs:element name="RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate"/>
  <xs:element name="RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse"/>
  <xs:element name="RevaluationOfLiabilityInRespectToWarrantsThroughEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity"/>
  <xs:element name="ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nrsn_ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable"/>
  <xs:element name="ShareBasedPaymentScheduleofShareOptionActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nrsn_ShareBasedPaymentScheduleofShareOptionActivityDetailsTable"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited"/>
  <xs:element name="ShareBasedPaymentScheduleofRestrictedStockUnitRSUsActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nrsn_ShareBasedPaymentScheduleofRestrictedStockUnitRSUsActivityDetailsTable"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted"/>
  <xs:element name="SubcontractorsAndConsultants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_SubcontractorsAndConsultants"/>
  <xs:element name="SharebasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_SharebasedCompensation"/>
  <xs:element name="SalariesAndSocialBenefits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_SalariesAndSocialBenefits"/>
  <xs:element name="ExchangeRates" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ExchangeRates"/>
  <xs:element name="DeferredTaxAssetsOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_DeferredTaxAssetsOperatingLeaseLiability"/>
  <xs:element name="DeferredTaxAssetsVacationAndConvalescenceAccrual" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual"/>
  <xs:element name="SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable"/>
  <xs:element name="SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems"/>
  <xs:element name="SignificantAccountingPolicyDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nrsn_SignificantAccountingPolicyDetailsTable"/>
  <xs:element name="OperatingLeaseDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nrsn_OperatingLeaseDetailsTable"/>
  <xs:element name="InitialRecognitionRightofuseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_InitialRecognitionRightofuseAssets"/>
  <xs:element name="LiabilityinRespectofWarrantsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nrsn_LiabilityinRespectofWarrantsDetailsTable"/>
  <xs:element name="NumberOfOrdinaryShares" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_NumberOfOrdinaryShares"/>
  <xs:element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nrsn_ShareholdersEquityDetailsTable"/>
  <xs:element name="MarketOfferingCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_MarketOfferingCost"/>
  <xs:element name="RemainingFairValueAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_RemainingFairValueAmount"/>
  <xs:element name="AllocatedAmountToOrdinaryWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_AllocatedAmountToOrdinaryWarrants"/>
  <xs:element name="PurchasePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="nrsn_PurchasePricePerShare"/>
  <xs:element name="SaleOfOrdinaryShareGrossProceedsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_SaleOfOrdinaryShareGrossProceedsPercentage"/>
  <xs:element name="NetProceedsFromTheOrdinaryShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_NetProceedsFromTheOrdinaryShares"/>
  <xs:element name="NetProceedsFromIssuanceOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_NetProceedsFromIssuanceOfWarrants"/>
  <xs:element name="ShareBasedPaymentDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nrsn_ShareBasedPaymentDetailsTable"/>
  <xs:element name="NumberOfSharesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_NumberOfSharesPercentage"/>
  <xs:element name="ExpirationDateGrantTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ExpirationDateGrantTerm"/>
  <xs:element name="NumberOfInstallments" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_NumberOfInstallments"/>
  <xs:element name="InstallmentsLockUpPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_InstallmentsLockUpPeriod"/>
  <xs:element name="RaiseOfAdditionalBonusPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_RaiseOfAdditionalBonusPercentage"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice"/>
  <xs:element name="RelatedPartiesBalancesandTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nrsn_RelatedPartiesBalancesandTransactionsDetailsTable"/>
  <xs:element name="PotentialBonusPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="nrsn_PotentialBonusPayable"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nrsn_IncomeTaxesDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="nrsn_SubsequentEventsDetailsTable"/>
  <xs:element name="AllianceGlobalPartnersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_AllianceGlobalPartnersMember"/>
  <xs:element name="AprilTwoThousandTwentyFourPurchaseAgrementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember"/>
  <xs:element name="ConsultantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ConsultantsMember"/>
  <xs:element name="EmployeesAndDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_EmployeesAndDirectorsMember"/>
  <xs:element name="LiabilityInRespectOfWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_LiabilityInRespectOfWarrantsMember"/>
  <xs:element name="MrAlonBenNoonsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_MrAlonBenNoonsMember"/>
  <xs:element name="November12024Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_November12024Member"/>
  <xs:element name="October12024Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_October12024Member"/>
  <xs:element name="OrdinarySharesNoParValuePerShareMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_OrdinarySharesNoParValuePerShareMember"/>
  <xs:element name="PrefundedWarrantMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_PrefundedWarrantMember"/>
  <xs:element name="PrefundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_PrefundedWarrantsMember"/>
  <xs:element name="PurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_PurchaseAgreementMember"/>
  <xs:element name="SalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_SalesAgreementMember"/>
  <xs:element name="SecuritiesPurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_SecuritiesPurchaseAgreementMember"/>
  <xs:element name="TwoThousandEighteenEmployeeShareOptionPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember"/>
  <xs:element name="TwoThousandTwentyTwoBonusPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_TwoThousandTwentyTwoBonusPlanMember"/>
  <xs:element name="WarrantLiabilityMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_WarrantLiabilityMember"/>
  <xs:element name="WarrantsExercisableForOneOrdinaryShareMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_WarrantsExercisableForOneOrdinaryShareMember"/>
  <xs:element name="ScheduleOfTheMovementInWarrantLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_ScheduleOfTheMovementInWarrantLiabilityAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="nrsn_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>nrsn-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 07 20:27:37 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ConsolidatedBalanceSheet" roleURI="http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ConsolidatedIncomeStatement" roleURI="http://www.neurosensetx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ConsolidatedCashFlow" roleURI="http://www.neurosensetx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofOtherReceivablesTable" roleURI="http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable" roleURI="http://www.neurosensetx.com/role/ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable" roleURI="http://www.neurosensetx.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofOtherCurrentLiabilitiesTable" roleURI="http://www.neurosensetx.com/role/ScheduleofOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofResearchandDevelopmentExpensesTable" roleURI="http://www.neurosensetx.com/role/ScheduleofResearchandDevelopmentExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofFinancingIncomeExpensesNetTable" roleURI="http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleoftheCompanysNetdeferredTaxAssetsTable" roleURI="http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable"/>
  <calculationLink xlink:role="http://www.neurosensetx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndInvestmentsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_RestrictedCashAndInvestmentsNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.neurosensetx.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.neurosensetx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="nrsn_DecreaseInOperatingRightOfUseAsset" xlink:href="nrsn-20241231.xsd#nrsn_DecreaseInOperatingRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nrsn_DecreaseInOperatingRightOfUseAsset" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="nrsn_RevaluationOfLiabilityInRespectToWarrants" xlink:href="nrsn-20241231.xsd#nrsn_RevaluationOfLiabilityInRespectToWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nrsn_RevaluationOfLiabilityInRespectToWarrants" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="nrsn_DecreaseInOperatingLeaseLiability" xlink:href="nrsn-20241231.xsd#nrsn_DecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="nrsn_DecreaseInOperatingLeaseLiability" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="nrsn_RedemptionofinvestmentInShorttermDeposits" xlink:href="nrsn-20241231.xsd#nrsn_RedemptionofinvestmentInShorttermDeposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="nrsn_RedemptionofinvestmentInShorttermDeposits" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="nrsn_RedemptionOfinvestmentInRestrictedDepositNet" xlink:href="nrsn-20241231.xsd#nrsn_RedemptionOfinvestmentInRestrictedDepositNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="nrsn_RedemptionOfinvestmentInRestrictedDepositNet" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfOtherEquity" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYr+wciqhzO/TfNA0j8XAlDAX7Zs47GSe9YMpKX3MDHhrSmRPgkEK2u4ljrzwvIHfipcuE8XnwJBLDmhtLtl0Wkd3Ky+cGV3Eyy38kF0sLLqLlSwS0k9bURwWYWBfc634LCqUrXFOnmt5cVMGx9HtlaGkOgF0h8jEXpNuhYUKaCY+uhBk8nA3wEfnqV0gileaPM8GZVpEOik5keRqcHfnwDb/IfAuMyEk8nfZrG0zmWpe6TZP15grSxGN3J8x1qs4C+7SxxcOhM5w==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Supplies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_Supplies" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentContractReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentContractReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_GovernmentContractReceivable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesGrossCurrent" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePaymentsUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePaymentsUse"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePaymentsUse" order="1" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofResearchandDevelopmentExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:label="nrsn_SubcontractorsAndConsultants" xlink:href="nrsn-20241231.xsd#nrsn_SubcontractorsAndConsultants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="nrsn_SubcontractorsAndConsultants" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="nrsn_SharebasedCompensation" xlink:href="nrsn-20241231.xsd#nrsn_SharebasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="nrsn_SharebasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="nrsn_SalariesAndSocialBenefits" xlink:href="nrsn-20241231.xsd#nrsn_SalariesAndSocialBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="nrsn_SalariesAndSocialBenefits" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralInsuranceExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralInsuranceExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TravelAndEntertainmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="nrsn_ExchangeRates" xlink:href="nrsn-20241231.xsd#nrsn_ExchangeRates"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="nrsn_ExchangeRates" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExchangeFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExchangeFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_ExchangeFees" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsStateTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsStateTaxes" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="nrsn_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="nrsn-20241231.xsd#nrsn_DeferredTaxAssetsOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="nrsn_DeferredTaxAssetsOperatingLeaseLiability" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual" xlink:href="nrsn-20241231.xsd#nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>nrsn-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 07 20:27:37 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ConsolidatedBalanceSheet" roleURI="http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.neurosensetx.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ConsolidatedIncomeStatement" roleURI="http://www.neurosensetx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ShareholdersEquityType2or3" roleURI="http://www.neurosensetx.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ConsolidatedCashFlow" roleURI="http://www.neurosensetx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_General" roleURI="http://www.neurosensetx.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_SignificantAccountingPolicy" roleURI="http://www.neurosensetx.com/role/SignificantAccountingPolicy"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_CashandCashEquivalent" roleURI="http://www.neurosensetx.com/role/CashandCashEquivalent"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_OtherReceivables" roleURI="http://www.neurosensetx.com/role/OtherReceivables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_PropertyandEquipmentNet" roleURI="http://www.neurosensetx.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_OperatingLease" roleURI="http://www.neurosensetx.com/role/OperatingLease"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_OtherCurrentLiabilities" roleURI="http://www.neurosensetx.com/role/OtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_LiabilityinRespectofWarrants" roleURI="http://www.neurosensetx.com/role/LiabilityinRespectofWarrants"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ShareholdersEquity" roleURI="http://www.neurosensetx.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ShareBasedPayment" roleURI="http://www.neurosensetx.com/role/ShareBasedPayment"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ResearchandDevelopmentExpenses" roleURI="http://www.neurosensetx.com/role/ResearchandDevelopmentExpenses"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_GeneralandAdministrativeExpenses" roleURI="http://www.neurosensetx.com/role/GeneralandAdministrativeExpenses"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_FinancingIncomeExpensesNet" roleURI="http://www.neurosensetx.com/role/FinancingIncomeExpensesNet"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_RelatedPartiesBalancesandTransactions" roleURI="http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactions"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_SegmentReporting" roleURI="http://www.neurosensetx.com/role/SegmentReporting"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_IncomeTaxes" roleURI="http://www.neurosensetx.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_SubsequentEvents" roleURI="http://www.neurosensetx.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_AccountingPoliciesByPolicy" roleURI="http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_SignificantAccountingPolicyTables" roleURI="http://www.neurosensetx.com/role/SignificantAccountingPolicyTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_CashandCashEquivalentTables" roleURI="http://www.neurosensetx.com/role/CashandCashEquivalentTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_OtherReceivablesTables" roleURI="http://www.neurosensetx.com/role/OtherReceivablesTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_PropertyandEquipmentNetTables" roleURI="http://www.neurosensetx.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_OperatingLeaseTables" roleURI="http://www.neurosensetx.com/role/OperatingLeaseTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_OtherCurrentLiabilitiesTables" roleURI="http://www.neurosensetx.com/role/OtherCurrentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_LiabilityinRespectofWarrantsTables" roleURI="http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ShareholdersEquityTables" roleURI="http://www.neurosensetx.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ShareBasedPaymentTables" roleURI="http://www.neurosensetx.com/role/ShareBasedPaymentTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ResearchandDevelopmentExpensesTables" roleURI="http://www.neurosensetx.com/role/ResearchandDevelopmentExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_GeneralandAdministrativeExpensesTables" roleURI="http://www.neurosensetx.com/role/GeneralandAdministrativeExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_FinancingIncomeExpensesNetTables" roleURI="http://www.neurosensetx.com/role/FinancingIncomeExpensesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_IncomeTaxesTables" roleURI="http://www.neurosensetx.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofCashAndCashEquivalentTable" roleURI="http://www.neurosensetx.com/role/ScheduleofCashAndCashEquivalentTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofOtherReceivablesTable" roleURI="http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable" roleURI="http://www.neurosensetx.com/role/ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable" roleURI="http://www.neurosensetx.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofOtherCurrentLiabilitiesTable" roleURI="http://www.neurosensetx.com/role/ScheduleofOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofFinancialMeasuredatFairValueonaRecurringBasisTable" roleURI="http://www.neurosensetx.com/role/ScheduleofFinancialMeasuredatFairValueonaRecurringBasisTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofFairValueoftheWarrantsTable" roleURI="http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleoftheMovementinWarrantLiabilityTable" roleURI="http://www.neurosensetx.com/role/ScheduleoftheMovementinWarrantLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofShareCapitalTable" roleURI="http://www.neurosensetx.com/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofShareCapitalTable_Parentheticals" roleURI="http://www.neurosensetx.com/role/ScheduleofShareCapitalTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofFairValueoftheOptionsGrantedTable" roleURI="http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofShareOptionActivityTable" roleURI="http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofRestrictedStockUnitRSUsActivityTable" roleURI="http://www.neurosensetx.com/role/ScheduleofRestrictedStockUnitRSUsActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofShareBasedExpenseRecognizedintheStatementsofOperationTable" roleURI="http://www.neurosensetx.com/role/ScheduleofShareBasedExpenseRecognizedintheStatementsofOperationTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofResearchandDevelopmentExpensesTable" roleURI="http://www.neurosensetx.com/role/ScheduleofResearchandDevelopmentExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofFinancingIncomeExpensesNetTable" roleURI="http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleoftheCompanysNetdeferredTaxAssetsTable" roleURI="http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleoftheMovementoftheValuationAllowanceTable" roleURI="http://www.neurosensetx.com/role/ScheduleoftheMovementoftheValuationAllowanceTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation" roleURI="http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_OperatingLeaseDetailsScheduleofOperatingLease" roleURI="http://www.neurosensetx.com/role/OperatingLeaseDetailsScheduleofOperatingLease"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_GeneralDetails" roleURI="http://www.neurosensetx.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_SignificantAccountingPolicyDetails" roleURI="http://www.neurosensetx.com/role/SignificantAccountingPolicyDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_CashandCashEquivalentDetails" roleURI="http://www.neurosensetx.com/role/CashandCashEquivalentDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_OperatingLeaseDetails" roleURI="http://www.neurosensetx.com/role/OperatingLeaseDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_LiabilityinRespectofWarrantsDetails" roleURI="http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ShareholdersEquityDetails" roleURI="http://www.neurosensetx.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ShareBasedPaymentDetails" roleURI="http://www.neurosensetx.com/role/ShareBasedPaymentDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_GeneralandAdministrativeExpensesDetails" roleURI="http://www.neurosensetx.com/role/GeneralandAdministrativeExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_RelatedPartiesBalancesandTransactionsDetails" roleURI="http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_IncomeTaxesDetails" roleURI="http://www.neurosensetx.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_SubsequentEventsDetails" roleURI="http://www.neurosensetx.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#DocumentAndEntityInformation" roleURI="http://www.neurosensetx.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RestrictedCashAndInvestmentsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RestrictedCashAndInvestmentsNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockNoParValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_RevaluationOfLiabilityInRespectToWarrants" xlink:href="nrsn-20241231.xsd#nrsn_RevaluationOfLiabilityInRespectToWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="nrsn_RevaluationOfLiabilityInRespectToWarrants" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_DecreaseInOperatingRightOfUseAsset" xlink:href="nrsn-20241231.xsd#nrsn_DecreaseInOperatingRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="nrsn_DecreaseInOperatingRightOfUseAsset" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_DecreaseInOperatingLeaseLiability" xlink:href="nrsn-20241231.xsd#nrsn_DecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="nrsn_DecreaseInOperatingLeaseLiability" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_RedemptionofinvestmentInShorttermDeposits" xlink:href="nrsn-20241231.xsd#nrsn_RedemptionofinvestmentInShorttermDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="nrsn_RedemptionofinvestmentInShorttermDeposits" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_RedemptionOfinvestmentInRestrictedDepositNet" xlink:href="nrsn-20241231.xsd#nrsn_RedemptionOfinvestmentInRestrictedDepositNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="nrsn_RedemptionOfinvestmentInRestrictedDepositNet" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfOtherEquity" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_ReclassificationOfWarrantsIntoEquity" xlink:href="nrsn-20241231.xsd#nrsn_ReclassificationOfWarrantsIntoEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="nrsn_ReclassificationOfWarrantsIntoEquity" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_BonusAccrualReclassificationToEquity" xlink:href="nrsn-20241231.xsd#nrsn_BonusAccrualReclassificationToEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="nrsn_BonusAccrualReclassificationToEquity" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_NoncashOrPartNoncashAcquisitionInterestReceived" xlink:href="nrsn-20241231.xsd#nrsn_NoncashOrPartNoncashAcquisitionInterestReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="nrsn_NoncashOrPartNoncashAcquisitionInterestReceived" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/General" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/SignificantAccountingPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/CashandCashEquivalent" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/OtherReceivables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/OperatingLease" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/OtherCurrentLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/LiabilityinRespectofWarrants" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="nrsn_LiabilityInRespectOfWarrantsTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_LiabilityInRespectOfWarrantsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="nrsn_LiabilityInRespectOfWarrantsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ShareholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ShareBasedPayment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ResearchandDevelopmentExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/GeneralandAdministrativeExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/FinancingIncomeExpensesNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/SegmentReporting" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_ShortTermDepositsPolicyTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_ShortTermDepositsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nrsn_ShortTermDepositsPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_RestrictedDepositsPolicyTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_RestrictedDepositsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nrsn_RestrictedDepositsPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_ContractsOverOwnEquityPolicyTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_ContractsOverOwnEquityPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nrsn_ContractsOverOwnEquityPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/SignificantAccountingPolicyTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/CashandCashEquivalentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/OtherReceivablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/OperatingLeaseTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="nrsn_LesseeOperatingLeaseDisclosureTableTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_LesseeOperatingLeaseDisclosureTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="nrsn_LesseeOperatingLeaseDisclosureTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/OtherCurrentLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ShareholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalUnitsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCapitalUnitsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfCapitalUnitsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ShareBasedPaymentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ResearchandDevelopmentExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/GeneralandAdministrativeExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/FinancingIncomeExpensesNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleofCashAndCashEquivalentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="srt_CurrencyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain_0" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_ILS" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Supplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_Supplies" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentContractReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentContractReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_GovernmentContractReceivable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherReceivablesGrossCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePaymentsUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePaymentsUse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeasePaymentsUse" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleofOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleofFinancialMeasuredatFairValueonaRecurringBasisTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_LiabilityInRespectOfWarrantsMember" xlink:href="nrsn-20241231.xsd#nrsn_LiabilityInRespectOfWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrsn_LiabilityInRespectOfWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleoftheMovementinWarrantLiabilityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="nrsn_LiabilityinRespectofWarrantsScheduleoftheMovementinWarrantLiabilityDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_LiabilityinRespectofWarrantsScheduleoftheMovementinWarrantLiabilityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nrsn_LiabilityinRespectofWarrantsScheduleoftheMovementinWarrantLiabilityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_LiabilityinRespectofWarrantsScheduleoftheMovementinWarrantLiabilityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_WarrantLiabilityMember" xlink:href="nrsn-20241231.xsd#nrsn_WarrantLiabilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrsn_WarrantLiabilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate" xlink:href="nrsn-20241231.xsd#nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_ReclassificationOfWarrantsIntoEquity" xlink:href="nrsn-20241231.xsd#nrsn_ReclassificationOfWarrantsIntoEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nrsn_ReclassificationOfWarrantsIntoEquity" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse" xlink:href="nrsn-20241231.xsd#nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity" xlink:href="nrsn-20241231.xsd#nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_RevaluationOfLiabilityInRespectToWarrants" xlink:href="nrsn-20241231.xsd#nrsn_RevaluationOfLiabilityInRespectToWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nrsn_RevaluationOfLiabilityInRespectToWarrants" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleofShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleofShareCapitalTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_CommonStockNoParValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="nrsn_ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nrsn_ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_EmployeesAndDirectorsMember" xlink:href="nrsn-20241231.xsd#nrsn_EmployeesAndDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nrsn_EmployeesAndDirectorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="nrsn_ShareBasedPaymentScheduleofShareOptionActivityDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_ShareBasedPaymentScheduleofShareOptionActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nrsn_ShareBasedPaymentScheduleofShareOptionActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_ShareBasedPaymentScheduleofShareOptionActivityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted" xlink:href="nrsn-20241231.xsd#nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod" xlink:href="nrsn-20241231.xsd#nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited" xlink:href="nrsn-20241231.xsd#nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited" xlink:href="nrsn-20241231.xsd#nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleofRestrictedStockUnitRSUsActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="nrsn_ShareBasedPaymentScheduleofRestrictedStockUnitRSUsActivityDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_ShareBasedPaymentScheduleofRestrictedStockUnitRSUsActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nrsn_ShareBasedPaymentScheduleofRestrictedStockUnitRSUsActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYr+wciqhzO/TfNA0j8XAlDAX7Zs47GSe9YMpKX3MDHhrSmRPgkEK2u4ljrzwvIHfipcuE8XnwJBLDmhtLtl0Wkd3Ky+cGV3Eyy38kF0sLLqLlSwS0k9bURwWYWBfc634LCqUrXFOnmt5cVMGx9HtlaGkOgF0h8jEXpNuhYUKaCY+uhBk8nA3wEfnqV0gileaPM8GZVpEOik5keRqcHfnwDb/IfAuMyEk8nfZrG0zmWpe6TZP15grSxZb4bK7OTFTpVzlzu10cQzS0sLuQwfdim] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_ShareBasedPaymentScheduleofRestrictedStockUnitRSUsActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:href="nrsn-20241231.xsd#nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleofShareBasedExpenseRecognizedintheStatementsofOperationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleofResearchandDevelopmentExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="nrsn_SubcontractorsAndConsultants" xlink:href="nrsn-20241231.xsd#nrsn_SubcontractorsAndConsultants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="nrsn_SubcontractorsAndConsultants" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_SharebasedCompensation" xlink:href="nrsn-20241231.xsd#nrsn_SharebasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="nrsn_SharebasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_SalariesAndSocialBenefits" xlink:href="nrsn-20241231.xsd#nrsn_SalariesAndSocialBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="nrsn_SalariesAndSocialBenefits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralInsuranceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralInsuranceExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TravelAndEntertainmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_TravelAndEntertainmentExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_ExchangeRates" xlink:href="nrsn-20241231.xsd#nrsn_ExchangeRates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract" xlink:to="nrsn_ExchangeRates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExchangeFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExchangeFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract" xlink:to="us-gaap_ExchangeFees" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract" xlink:to="us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsStateTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsStateTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="nrsn-20241231.xsd#nrsn_DeferredTaxAssetsOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="nrsn_DeferredTaxAssetsOperatingLeaseLiability" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual" xlink:href="nrsn-20241231.xsd#nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ScheduleoftheMovementoftheValuationAllowanceTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems" xlink:href="nrsn-20241231.xsd#nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems" xlink:to="nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/OperatingLeaseDetailsScheduleofOperatingLease" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/GeneralDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/SignificantAccountingPolicyDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="nrsn_SignificantAccountingPolicyDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_SignificantAccountingPolicyDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="nrsn_SignificantAccountingPolicyDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_SignificantAccountingPolicyDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_PrefundedWarrantMember" xlink:href="nrsn-20241231.xsd#nrsn_PrefundedWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrsn_PrefundedWarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/CashandCashEquivalentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_InvestmentInterestRate" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/OperatingLeaseDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <loc xlink:type="locator" xlink:label="nrsn_OperatingLeaseDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_OperatingLeaseDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nrsn_OperatingLeaseDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForRent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_InitialRecognitionRightofuseAssets" xlink:href="nrsn-20241231.xsd#nrsn_InitialRecognitionRightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="nrsn_InitialRecognitionRightofuseAssets" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="nrsn_LiabilityinRespectofWarrantsDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_LiabilityinRespectofWarrantsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nrsn_LiabilityinRespectofWarrantsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_LiabilityinRespectofWarrantsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_LiabilityinRespectofWarrantsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_LiabilityinRespectofWarrantsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_NumberOfOrdinaryShares" xlink:href="nrsn-20241231.xsd#nrsn_NumberOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nrsn_NumberOfOrdinaryShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="nrsn_ShareholdersEquityDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_ShareholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nrsn_ShareholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_ShareholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_ShareholdersEquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_ShareholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_ShareholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember" xlink:href="nrsn-20241231.xsd#nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_SalesAgreementMember" xlink:href="nrsn-20241231.xsd#nrsn_SalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrsn_SalesAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_SecuritiesPurchaseAgreementMember" xlink:href="nrsn-20241231.xsd#nrsn_SecuritiesPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrsn_SecuritiesPurchaseAgreementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_PurchaseAgreementMember" xlink:href="nrsn-20241231.xsd#nrsn_PurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="nrsn_PurchaseAgreementMember" order="3" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_PrefundedWarrantsMember" xlink:href="nrsn-20241231.xsd#nrsn_PrefundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="nrsn_PrefundedWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_AllianceGlobalPartnersMember" xlink:href="nrsn-20241231.xsd#nrsn_AllianceGlobalPartnersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nrsn_AllianceGlobalPartnersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_MarketOfferingCost" xlink:href="nrsn-20241231.xsd#nrsn_MarketOfferingCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nrsn_MarketOfferingCost" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_NumberOfOrdinaryShares" xlink:href="nrsn-20241231.xsd#nrsn_NumberOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nrsn_NumberOfOrdinaryShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseOfferingCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoninterestExpenseOfferingCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_NoninterestExpenseOfferingCost" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_RemainingFairValueAmount" xlink:href="nrsn-20241231.xsd#nrsn_RemainingFairValueAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nrsn_RemainingFairValueAmount" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_AllocatedAmountToOrdinaryWarrants" xlink:href="nrsn-20241231.xsd#nrsn_AllocatedAmountToOrdinaryWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nrsn_AllocatedAmountToOrdinaryWarrants" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_OtherExpenses" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoninterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoninterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_OtherNoninterestExpense" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_PurchasePricePerShare" xlink:href="nrsn-20241231.xsd#nrsn_PurchasePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nrsn_PurchasePricePerShare" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_SaleOfOrdinaryShareGrossProceedsPercentage" xlink:href="nrsn-20241231.xsd#nrsn_SaleOfOrdinaryShareGrossProceedsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nrsn_SaleOfOrdinaryShareGrossProceedsPercentage" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_NetProceedsFromTheOrdinaryShares" xlink:href="nrsn-20241231.xsd#nrsn_NetProceedsFromTheOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nrsn_NetProceedsFromTheOrdinaryShares" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_PaymentsForRestructuring" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_NetProceedsFromIssuanceOfWarrants" xlink:href="nrsn-20241231.xsd#nrsn_NetProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="nrsn_NetProceedsFromIssuanceOfWarrants" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="35" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/ShareBasedPaymentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="nrsn_ShareBasedPaymentDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_ShareBasedPaymentDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="nrsn_ShareBasedPaymentDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_ShareBasedPaymentDetailsTable" xlink:to="us-gaap_GranteeStatusAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_ShareBasedPaymentDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_ShareBasedPaymentDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_ShareBasedPaymentDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_ShareBasedPaymentDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_ShareBasedPaymentDetailsTable" xlink:to="srt_RangeAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_ShareBasedPaymentDetailsTable" xlink:to="us-gaap_AwardDateAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember" xlink:href="nrsn-20241231.xsd#nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_TwoThousandTwentyTwoBonusPlanMember" xlink:href="nrsn-20241231.xsd#nrsn_TwoThousandTwentyTwoBonusPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="nrsn_TwoThousandTwentyTwoBonusPlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_November12024Member" xlink:href="nrsn-20241231.xsd#nrsn_November12024Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="nrsn_November12024Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_October12024Member" xlink:href="nrsn-20241231.xsd#nrsn_October12024Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="nrsn_October12024Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_NumberOfSharesPercentage" xlink:href="nrsn-20241231.xsd#nrsn_NumberOfSharesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="nrsn_NumberOfSharesPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_ExpirationDateGrantTerm" xlink:href="nrsn-20241231.xsd#nrsn_ExpirationDateGrantTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="nrsn_ExpirationDateGrantTerm" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_OtherExpenses" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_NumberOfInstallments" xlink:href="nrsn-20241231.xsd#nrsn_NumberOfInstallments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="nrsn_NumberOfInstallments" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_InstallmentsLockUpPeriod" xlink:href="nrsn-20241231.xsd#nrsn_InstallmentsLockUpPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="nrsn_InstallmentsLockUpPeriod" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_RaiseOfAdditionalBonusPercentage" xlink:href="nrsn-20241231.xsd#nrsn_RaiseOfAdditionalBonusPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="nrsn_RaiseOfAdditionalBonusPercentage" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" xlink:href="nrsn-20241231.xsd#nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="30" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/GeneralandAdministrativeExpensesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionContributions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionContributions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_PensionContributions" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="nrsn_RelatedPartiesBalancesandTransactionsDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_RelatedPartiesBalancesandTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrsn_RelatedPartiesBalancesandTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_RelatedPartiesBalancesandTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_RelatedPartiesBalancesandTransactionsDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_RelatedPartiesBalancesandTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_RelatedPartiesBalancesandTransactionsDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_MrAlonBenNoonsMember" xlink:href="nrsn-20241231.xsd#nrsn_MrAlonBenNoonsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="nrsn_MrAlonBenNoonsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedSalariesCurrentAndNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_PotentialBonusPayable" xlink:href="nrsn-20241231.xsd#nrsn_PotentialBonusPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="nrsn_PotentialBonusPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:label="nrsn_IncomeTaxesDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="nrsn_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IsraelTaxAuthorityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IsraelTaxAuthorityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IsraelTaxAuthorityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="nrsn_SubsequentEventsDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nrsn_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_SubsequentEventsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_SubsequentEventsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="nrsn_SubsequentEventsDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_ConsultantsMember" xlink:href="nrsn-20241231.xsd#nrsn_ConsultantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="nrsn_ConsultantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:to="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.neurosensetx.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_OrdinarySharesNoParValuePerShareMember" xlink:href="nrsn-20241231.xsd#nrsn_OrdinarySharesNoParValuePerShareMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nrsn_OrdinarySharesNoParValuePerShareMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="nrsn_WarrantsExercisableForOneOrdinaryShareMember" xlink:href="nrsn-20241231.xsd#nrsn_WarrantsExercisableForOneOrdinaryShareMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="nrsn_WarrantsExercisableForOneOrdinaryShareMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorOpinionTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="37" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>nrsn-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 07 20:27:37 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders&#8217; equity (deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss and comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Ordinary shares, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Ordinary shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents as at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents as of the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">General [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Significant Accounting Policy [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and Cash Equivalent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrentAbstract_lbl" xml:lang="en-US">Other Receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Schedule of Other Receivables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Cost, Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Cost, Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated depreciation Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Operating Lease [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Maturity Analysis of Company&#8217;s Lease Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total operating lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Terms and Discount Rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Total lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Other Current Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Schedule of Other Current Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US">Liability In Respect of Warrants [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_ScheduleOfFinancialMeasuredAtFairValueOnARecurringBasisAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfFinancialMeasuredAtFairValueOnARecurringBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ScheduleOfFinancialMeasuredAtFairValueOnARecurringBasisAbstract_lbl" xml:lang="en-US">Schedule of Financial Measured at Fair Value on a Recurring Basis [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ScheduleOfFinancialMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="nrsn_ScheduleOfFinancialMeasuredAtFairValueOnARecurringBasisAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_ScheduleOfTheMovementInWarrantLiabilityAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfTheMovementInWarrantLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ScheduleOfTheMovementInWarrantLiabilityAbstract_lbl" xml:lang="en-US">Schedule of the Movement in Warrant Liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ScheduleOfTheMovementInWarrantLiabilityAbstract" xlink:to="nrsn_ScheduleOfTheMovementInWarrantLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl1" xml:lang="en-US">Liability in respect of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Shareholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xml:lang="en-US">Schedule of Share Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share Based Payment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Shares, Outstanding beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Shares, Outstanding ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Number of Share Options, Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Weighted average grant date fair value, Outstanding beginning (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0" xml:lang="en-US">Weighted average grant date fair value, ending (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xml:lang="en-US">Research and Development Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Schedule of Research and Development Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General and Administrative Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">Schedule of General and Administrative Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Financing Income Expenses Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract_lbl" xml:lang="en-US">Schedule Of Financing Income Expenses Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract" xlink:to="nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Total income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Total expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total financing income (expanse), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Financing income (expenses), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Parties Balances and Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceAbstract_lbl" xml:lang="en-US">Schedule of the Movement of the Valuation Allowance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_ValuationAllowanceAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Balance at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Balance at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US">Less: Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndInvestmentsCurrent_lbl" xml:lang="en-US">Restricted deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:to="us-gaap_RestrictedCashAndInvestmentsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Depreciated cost at December 31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent_lbl" xml:lang="en-US">Restricted deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndInvestmentsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities shareholders&#8217; and equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability less current maturity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_OrdinarySharesNoParValueAbstract" xlink:href="nrsn-20241231.xsd#nrsn_OrdinarySharesNoParValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_OrdinarySharesNoParValueAbstract_lbl" xml:lang="en-US">Ordinary shares, no par value:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_OrdinarySharesNoParValueAbstract" xlink:to="nrsn_OrdinarySharesNoParValueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares, no par value: Authorized: 90,000,000 shares at December 31, 2024 and 60,000,000 shares at December 31, 2023; Issued and outstanding: 23,228,941 and 15,379,042 shares at December 31, 2024 and 2023, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockNoParValue_lbl" xml:lang="en-US">Ordinary shares, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockNoParValue_lbl0" xml:lang="en-US">Ordinary shares, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Ordinary shares, Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Ordinary shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Share Premium and Capital Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of ordinary shares used in computing basic net loss per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of ordinary shares used in computing diluted net loss per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of warrants and vested RSUs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Exercise warrant received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of warrants and vested RSUs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Shares, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Exercise shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet_lbl" xml:lang="en-US">Issuance of shares and pre-funded warrants, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet" xlink:to="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet_lbl" xml:lang="en-US">Issuance of shares and pre-funded warrants, net (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet" xlink:to="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised_lbl" xml:lang="en-US">Exercise of pre-funded warrants, options and vested RSUs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised" xlink:to="nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants_lbl" xml:lang="en-US">Exercise of pre-funded warrants, options and vested RSUs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants" xlink:to="nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement_lbl" xml:lang="en-US">Issuance of shares due to SEPA agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement" xlink:to="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement_lbl" xml:lang="en-US">Issuance of shares due to SEPA agreement (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement" xlink:to="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl" xml:lang="en-US">Reclassification of warrants into equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity_lbl" xml:lang="en-US">Bonus accrual reclassification to equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity" xlink:to="nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0" xml:lang="en-US">Reimburse for certain specific expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1" xml:lang="en-US">Issuance of ordinary shares as issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Financing expenses, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_DecreaseInOperatingRightOfUseAsset" xlink:href="nrsn-20241231.xsd#nrsn_DecreaseInOperatingRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_DecreaseInOperatingRightOfUseAsset_lbl" xml:lang="en-US">Decrease in operating right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_DecreaseInOperatingRightOfUseAsset" xlink:to="nrsn_DecreaseInOperatingRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Increase (decrease) in trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Increase in other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_RedemptionofinvestmentInShorttermDeposits" xlink:href="nrsn-20241231.xsd#nrsn_RedemptionofinvestmentInShorttermDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_RedemptionofinvestmentInShorttermDeposits_lbl" xml:lang="en-US">Redemption of (investment in) short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RedemptionofinvestmentInShorttermDeposits" xlink:to="nrsn_RedemptionofinvestmentInShorttermDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Exercise of warrants and options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Issuance of shares, warrants and pre-funded warrants, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0" xml:lang="en-US">Gross proceeds from warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effects of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_ReclassificationOfWarrantsIntoEquity" xlink:href="nrsn-20241231.xsd#nrsn_ReclassificationOfWarrantsIntoEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_ReclassificationOfWarrantsIntoEquity_lbl" xml:lang="en-US">Reclassification of warrants into equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ReclassificationOfWarrantsIntoEquity" xlink:to="nrsn_ReclassificationOfWarrantsIntoEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nrsn_ReclassificationOfWarrantsIntoEquity_lbl0" xml:lang="en-US">Revaluation of liability in respect to warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ReclassificationOfWarrantsIntoEquity" xlink:to="nrsn_ReclassificationOfWarrantsIntoEquity_lbl0"/>
    <loc xlink:type="locator" xlink:label="nrsn_BonusAccrualReclassificationToEquity" xlink:href="nrsn-20241231.xsd#nrsn_BonusAccrualReclassificationToEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_BonusAccrualReclassificationToEquity_lbl" xml:lang="en-US">Bonus accrual reclassification to equity (See Note 14)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_BonusAccrualReclassificationToEquity" xlink:to="nrsn_BonusAccrualReclassificationToEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Recognition of right of use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_NoncashOrPartNoncashAcquisitionInterestReceived" xlink:href="nrsn-20241231.xsd#nrsn_NoncashOrPartNoncashAcquisitionInterestReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_NoncashOrPartNoncashAcquisitionInterestReceived_lbl" xml:lang="en-US">Interest received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NoncashOrPartNoncashAcquisitionInterestReceived" xlink:to="nrsn_NoncashOrPartNoncashAcquisitionInterestReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Repurchase of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl0" xml:lang="en-US">Cash payment for options granted (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="nrsn_RevaluationOfLiabilityInRespectToWarrants" xlink:href="nrsn-20241231.xsd#nrsn_RevaluationOfLiabilityInRespectToWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nrsn_RevaluationOfLiabilityInRespectToWarrants_lbl" xml:lang="en-US">Revaluation of liability in respect to warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RevaluationOfLiabilityInRespectToWarrants" xlink:to="nrsn_RevaluationOfLiabilityInRespectToWarrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="nrsn_RevaluationOfLiabilityInRespectToWarrants_lbl0" xml:lang="en-US">Reclassification of warrants into equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RevaluationOfLiabilityInRespectToWarrants" xlink:to="nrsn_RevaluationOfLiabilityInRespectToWarrants_lbl0"/>
    <loc xlink:type="locator" xlink:label="nrsn_DecreaseInOperatingLeaseLiability" xlink:href="nrsn-20241231.xsd#nrsn_DecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nrsn_DecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Decrease in operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_DecreaseInOperatingLeaseLiability" xlink:to="nrsn_DecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Decrease (increase) in other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_RedemptionOfinvestmentInRestrictedDepositNet" xlink:href="nrsn-20241231.xsd#nrsn_RedemptionOfinvestmentInRestrictedDepositNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nrsn_RedemptionOfinvestmentInRestrictedDepositNet_lbl" xml:lang="en-US">Redemption of (investment in) restricted deposit, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RedemptionOfinvestmentInRestrictedDepositNet" xlink:to="nrsn_RedemptionOfinvestmentInRestrictedDepositNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfOtherEquity_lbl" xml:lang="en-US">Payment in respect of cancellation of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:to="us-gaap_PaymentsForRepurchaseOfOtherEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_OrdinarySharesNoParValuePerShareMember" xlink:href="nrsn-20241231.xsd#nrsn_OrdinarySharesNoParValuePerShareMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_OrdinarySharesNoParValuePerShareMember_lbl" xml:lang="en-US">Ordinary Shares, no par value per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_OrdinarySharesNoParValuePerShareMember" xlink:to="nrsn_OrdinarySharesNoParValuePerShareMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_WarrantsExercisableForOneOrdinaryShareMember" xlink:href="nrsn-20241231.xsd#nrsn_WarrantsExercisableForOneOrdinaryShareMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_WarrantsExercisableForOneOrdinaryShareMember_lbl" xml:lang="en-US">Warrants, exercisable for one ordinary share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_WarrantsExercisableForOneOrdinaryShareMember" xlink:to="nrsn_WarrantsExercisableForOneOrdinaryShareMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Share premium and capital reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">General</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock_lbl" xml:lang="en-US">Schedule of the Lives Used in Computing Straight-Line Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock" xlink:to="nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xml:lang="en-US">Cash and cash equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash And Cash Equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Supplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Supplies_lbl" xml:lang="en-US">Advance to suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Supplies" xlink:to="us-gaap_Supplies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentContractReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentContractReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GovernmentContractReceivable_lbl" xml:lang="en-US">Government agencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentContractReceivable" xlink:to="us-gaap_GovernmentContractReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesGrossCurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesGrossCurrent" xlink:to="us-gaap_OtherReceivablesGrossCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_CostAbstract" xlink:href="nrsn-20241231.xsd#nrsn_CostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_CostAbstract_lbl" xml:lang="en-US">Cost:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_CostAbstract" xlink:to="nrsn_CostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl" xml:lang="en-US">Cost, Purchases during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_AccumulatedDepreciationAbstract" xlink:href="nrsn-20241231.xsd#nrsn_AccumulatedDepreciationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_AccumulatedDepreciationAbstract_lbl" xml:lang="en-US">Accumulated depreciation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_AccumulatedDepreciationAbstract" xlink:to="nrsn_AccumulatedDepreciationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_lbl" xml:lang="en-US">Accumulated Depreciation during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_CostAbstract0" xlink:href="nrsn-20241231.xsd#nrsn_CostAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_CostAbstract0_lbl" xml:lang="en-US">Cost:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_CostAbstract0" xlink:to="nrsn_CostAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_AccumulatedDepreciationAbstract0" xlink:href="nrsn-20241231.xsd#nrsn_AccumulatedDepreciationAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_AccumulatedDepreciationAbstract0_lbl" xml:lang="en-US">Accumulated depreciation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_AccumulatedDepreciationAbstract0" xlink:to="nrsn_AccumulatedDepreciationAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_LesseeOperatingLeaseDisclosureTableTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_LesseeOperatingLeaseDisclosureTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_LesseeOperatingLeaseDisclosureTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_LesseeOperatingLeaseDisclosureTableTextBlock" xlink:to="nrsn_LesseeOperatingLeaseDisclosureTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturity Analysis of Company&#8217;s Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Less than one year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Two years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Short term lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Terms and Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Lease term (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePaymentsUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePaymentsUse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl" xml:lang="en-US">Lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employees and payroll accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_LiabilityInRespectOfWarrantsTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_LiabilityInRespectOfWarrantsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_LiabilityInRespectOfWarrantsTextBlock_lbl" xml:lang="en-US">Liability in respect of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_LiabilityInRespectOfWarrantsTextBlock" xlink:to="nrsn_LiabilityInRespectOfWarrantsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Financial Measured at Fair Value on a Recurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_UnlabeledAbstract" xlink:href="nrsn-20241231.xsd#nrsn_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_UnlabeledAbstract" xlink:to="nrsn_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of the Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_lbl" xml:lang="en-US">Financial liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price (in $) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield (%)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of the Movement in Warrant Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate" xlink:href="nrsn-20241231.xsd#nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate_lbl" xml:lang="en-US">Recognition of liability in respect to warrants at the initial date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate" xlink:to="nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse" xlink:href="nrsn-20241231.xsd#nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse_lbl" xml:lang="en-US">Revaluation of liability in respect to warrants through finance expanse</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse" xlink:to="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity" xlink:href="nrsn-20241231.xsd#nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity_lbl" xml:lang="en-US">Revaluation of liability in respect to warrants through equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity" xlink:to="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Shareholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalUnitsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCapitalUnitsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCapitalUnitsTextBlock_lbl" xml:lang="en-US">Schedule of Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCapitalUnitsTextBlock" xlink:to="us-gaap_ScheduleOfCapitalUnitsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share Based Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of the Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Options exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life (years) , Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value, Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Share Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share option granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted" xlink:href="nrsn-20241231.xsd#nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted_lbl" xml:lang="en-US">Weighted average remaining contractual life (years), Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted" xlink:to="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod" xlink:href="nrsn-20241231.xsd#nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Share Options, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod" xlink:to="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited" xlink:href="nrsn-20241231.xsd#nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited_lbl" xml:lang="en-US">Weighted average remaining contractual life (years), Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited" xlink:to="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited" xlink:href="nrsn-20241231.xsd#nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited_lbl" xml:lang="en-US">Intrinsic value, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited" xlink:to="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Share Options, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Options exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual life (years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Options expiry term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Intrinsic value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Unit (RSU&#8217;s) Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:href="nrsn-20241231.xsd#nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_lbl" xml:lang="en-US">Granted Weighted average grant date fair value, Granted (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:to="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-Based Expense Recognized in the Statements of Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_lbl" xml:lang="en-US">Schedule of Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:to="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_SubcontractorsAndConsultants" xlink:href="nrsn-20241231.xsd#nrsn_SubcontractorsAndConsultants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_SubcontractorsAndConsultants_lbl" xml:lang="en-US">Subcontractors and consultants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SubcontractorsAndConsultants" xlink:to="nrsn_SubcontractorsAndConsultants_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_SharebasedCompensation" xlink:href="nrsn-20241231.xsd#nrsn_SharebasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_SharebasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SharebasedCompensation" xlink:to="nrsn_SharebasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_SalariesAndSocialBenefits" xlink:href="nrsn-20241231.xsd#nrsn_SalariesAndSocialBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_SalariesAndSocialBenefits_lbl" xml:lang="en-US">Salaries and social benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SalariesAndSocialBenefits" xlink:to="nrsn_SalariesAndSocialBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock_lbl" xml:lang="en-US">General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock" xlink:to="nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Professional services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xml:lang="en-US">Salaries and social benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralInsuranceExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralInsuranceExpense_lbl" xml:lang="en-US">Insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TravelAndEntertainmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TravelAndEntertainmentExpense_lbl" xml:lang="en-US">Traveling abroad</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TravelAndEntertainmentExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xml:lang="en-US">Financing Income (Expenses), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Financing Income (Expenses), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeDisclosureNonoperatingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeDisclosureNonoperatingAbstract_lbl" xml:lang="en-US">Finance Income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_OtherIncomeDisclosureNonoperatingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl" xml:lang="en-US">Deposit interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_ExchangeRates" xlink:href="nrsn-20241231.xsd#nrsn_ExchangeRates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_ExchangeRates_lbl" xml:lang="en-US">Exchange rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ExchangeRates" xlink:to="nrsn_ExchangeRates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenseDisclosureNonoperatingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenseDisclosureNonoperatingAbstract_lbl" xml:lang="en-US">Finance Expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:to="us-gaap_OtherExpenseDisclosureNonoperatingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Parties Balances and Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of the Company&#8217;s Net deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsStateTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes_lbl" xml:lang="en-US">Other temporary differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsStateTaxes" xlink:to="us-gaap_DeferredTaxAssetsStateTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized research and development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="nrsn-20241231.xsd#nrsn_DeferredTaxAssetsOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_DeferredTaxAssetsOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="nrsn_DeferredTaxAssetsOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual" xlink:href="nrsn-20241231.xsd#nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual_lbl" xml:lang="en-US">Vacation and convalescence accrual</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual" xlink:to="nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US">Schedule of the Movement of the Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Addition of valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0" xml:lang="en-US">Net change in the valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl1" xml:lang="en-US">Net change in total valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Revaluation of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl0" xml:lang="en-US">Fair value of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl1" xml:lang="en-US">Fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExchangeFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExchangeFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ExchangeFees_lbl" xml:lang="en-US">Exchange rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExchangeFees" xlink:to="us-gaap_ExchangeFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks_lbl" xml:lang="en-US">Bank fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks" xlink:to="us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US">Deferred tax liability: Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_ILS_lbl" xml:lang="en-US">Denominated in NIS [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_ILS" xlink:to="currency_ILS_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="currency_USD_lbl" xml:lang="en-US">Denominated in USD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers and peripherals and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office furniture and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_LiabilityInRespectOfWarrantsMember" xlink:href="nrsn-20241231.xsd#nrsn_LiabilityInRespectOfWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_LiabilityInRespectOfWarrantsMember_lbl" xml:lang="en-US">Liability in Respect of Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_LiabilityInRespectOfWarrantsMember" xlink:to="nrsn_LiabilityInRespectOfWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_WarrantLiabilityMember" xlink:href="nrsn-20241231.xsd#nrsn_WarrantLiabilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_WarrantLiabilityMember_lbl" xml:lang="en-US">Warrant Liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_WarrantLiabilityMember" xlink:to="nrsn_WarrantLiabilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_EmployeesAndDirectorsMember" xlink:href="nrsn-20241231.xsd#nrsn_EmployeesAndDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_EmployeesAndDirectorsMember_lbl" xml:lang="en-US">Employees and Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_EmployeesAndDirectorsMember" xlink:to="nrsn_EmployeesAndDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US">RSU [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Share-based compensation expense - Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">Share-based compensation expense - General and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US">Incorporation date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Monthly deposits by company, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl" xml:lang="en-US">Tax benefit rate realized upon settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Warrants price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Operating segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentInterestRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Monthly rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Description of operating lease, option to extend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_InitialRecognitionRightofuseAssets" xlink:href="nrsn-20241231.xsd#nrsn_InitialRecognitionRightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_InitialRecognitionRightofuseAssets_lbl" xml:lang="en-US">Initial recognition of right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_InitialRecognitionRightofuseAssets" xlink:to="nrsn_InitialRecognitionRightofuseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Issued warrant (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Aggregate warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <loc xlink:type="locator" xlink:label="nrsn_NumberOfOrdinaryShares" xlink:href="nrsn-20241231.xsd#nrsn_NumberOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_NumberOfOrdinaryShares_lbl" xml:lang="en-US">Number of ordinary share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NumberOfOrdinaryShares" xlink:to="nrsn_NumberOfOrdinaryShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nrsn_NumberOfOrdinaryShares_lbl0" xml:lang="en-US">Number of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NumberOfOrdinaryShares" xlink:to="nrsn_NumberOfOrdinaryShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities_lbl" xml:lang="en-US">Revaluation Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities" xlink:to="us-gaap_DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Aggregate offering price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_MarketOfferingCost" xlink:href="nrsn-20241231.xsd#nrsn_MarketOfferingCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_MarketOfferingCost_lbl" xml:lang="en-US">Market offering cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_MarketOfferingCost" xlink:to="nrsn_MarketOfferingCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Shares issued under sale agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Aggregate of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Shares reserved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseOfferingCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoninterestExpenseOfferingCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoninterestExpenseOfferingCost_lbl" xml:lang="en-US">Offering expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseOfferingCost" xlink:to="us-gaap_NoninterestExpenseOfferingCost_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_RemainingFairValueAmount" xlink:href="nrsn-20241231.xsd#nrsn_RemainingFairValueAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_RemainingFairValueAmount_lbl" xml:lang="en-US">Remaining fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RemainingFairValueAmount" xlink:to="nrsn_RemainingFairValueAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US">Incremental issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_AllocatedAmountToOrdinaryWarrants" xlink:href="nrsn-20241231.xsd#nrsn_AllocatedAmountToOrdinaryWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_AllocatedAmountToOrdinaryWarrants_lbl" xml:lang="en-US">Allocated amount to ordinary warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_AllocatedAmountToOrdinaryWarrants" xlink:to="nrsn_AllocatedAmountToOrdinaryWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Financial expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Additional expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Total consideration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoninterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoninterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoninterestExpense_lbl" xml:lang="en-US">Issuance expenses to placement agent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoninterestExpense" xlink:to="us-gaap_OtherNoninterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Total issuance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">additional ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl" xml:lang="en-US">Registered capital shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US">Purchase an aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_PurchasePricePerShare" xlink:href="nrsn-20241231.xsd#nrsn_PurchasePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_PurchasePricePerShare_lbl" xml:lang="en-US">Purchase price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_PurchasePricePerShare" xlink:to="nrsn_PurchasePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_SaleOfOrdinaryShareGrossProceedsPercentage" xlink:href="nrsn-20241231.xsd#nrsn_SaleOfOrdinaryShareGrossProceedsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_SaleOfOrdinaryShareGrossProceedsPercentage_lbl" xml:lang="en-US">Sale of ordinary shares percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SaleOfOrdinaryShareGrossProceedsPercentage" xlink:to="nrsn_SaleOfOrdinaryShareGrossProceedsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_NetProceedsFromTheOrdinaryShares" xlink:href="nrsn-20241231.xsd#nrsn_NetProceedsFromTheOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_NetProceedsFromTheOrdinaryShares_lbl" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NetProceedsFromTheOrdinaryShares" xlink:to="nrsn_NetProceedsFromTheOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_lbl" xml:lang="en-US">Commitment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:to="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Percentage of purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Ordinary shares value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US">Structuring fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_NetProceedsFromIssuanceOfWarrants" xlink:href="nrsn-20241231.xsd#nrsn_NetProceedsFromIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_NetProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NetProceedsFromIssuanceOfWarrants" xlink:to="nrsn_NetProceedsFromIssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Expire term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US">Voting rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_NumberOfSharesPercentage" xlink:href="nrsn-20241231.xsd#nrsn_NumberOfSharesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_NumberOfSharesPercentage_lbl" xml:lang="en-US">Total number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NumberOfSharesPercentage" xlink:to="nrsn_NumberOfSharesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_ExpirationDateGrantTerm" xlink:href="nrsn-20241231.xsd#nrsn_ExpirationDateGrantTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_ExpirationDateGrantTerm_lbl" xml:lang="en-US">Expiration date grant term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ExpirationDateGrantTerm" xlink:to="nrsn_ExpirationDateGrantTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Ordinary shares available for future grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Option vested quarterly term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Options expire grant date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Options expiry term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US">Total fair value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US">Shares of restricted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_NumberOfInstallments" xlink:href="nrsn-20241231.xsd#nrsn_NumberOfInstallments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_NumberOfInstallments_lbl" xml:lang="en-US">Number of installments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NumberOfInstallments" xlink:to="nrsn_NumberOfInstallments_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_InstallmentsLockUpPeriod" xlink:href="nrsn-20241231.xsd#nrsn_InstallmentsLockUpPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_InstallmentsLockUpPeriod_lbl" xml:lang="en-US">Installments lock-up period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_InstallmentsLockUpPeriod" xlink:to="nrsn_InstallmentsLockUpPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">RSUs granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Shares approved the grant (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl" xml:lang="en-US">RSUs grants amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Options to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_lbl" xml:lang="en-US">Bonus allocated in the form of RSUs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_RaiseOfAdditionalBonusPercentage" xlink:href="nrsn-20241231.xsd#nrsn_RaiseOfAdditionalBonusPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_RaiseOfAdditionalBonusPercentage_lbl" xml:lang="en-US">Raise of additional bonus percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RaiseOfAdditionalBonusPercentage" xlink:to="nrsn_RaiseOfAdditionalBonusPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" xlink:href="nrsn-20241231.xsd#nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_lbl" xml:lang="en-US">RSU&apos;s exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" xlink:to="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of shares vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Grant shares to non-management directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of unvested options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value of RSUs (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl" xml:lang="en-US">Income tax benefit for compensation expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized compensation expense related to unvested RSUs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense related to unvested options (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period of unrecognized expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYr+wciqhzO/TfNA0j8XAlDAX7Zs47GSe9YMpKX3MDHhrSmRPgkEK2u4ljrzwvIHfipcuE8XnwJBLDmhtLtl0Wkd3Ky+cGV3Eyy38kF0sLLqLlSwS0k9bURwWYWBfc634LCqUrXFOnmt5cVMGx9HtlaGkOgF0h8jEXpNuhYUKaCY+uhBk8nA3wEfnqV0gileaPM8GZVpEOik5keRqcHfnwDb/IfAuMyEk8nfZrG0zmWpe6TZP15grSx4o09yTkz6XKdmcAvgh1o/A==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_PensionContributions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionContributions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionContributions_lbl" xml:lang="en-US">Pension funds paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionContributions" xlink:to="us-gaap_PensionContributions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Cash and cash equivalents and deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedSalariesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued bonus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_PotentialBonusPayable" xlink:href="nrsn-20241231.xsd#nrsn_PotentialBonusPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_PotentialBonusPayable_lbl" xml:lang="en-US">Potential bonus payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_PotentialBonusPayable" xlink:to="nrsn_PotentialBonusPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Vesting of unvested options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Additional paid in capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl" xml:lang="en-US">Corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred tax assets recognized tax benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Options granted to employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Options issued for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates in preparation of consolidated financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_ShortTermDepositsPolicyTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_ShortTermDepositsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_ShortTermDepositsPolicyTextBlock_lbl" xml:lang="en-US">Short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ShortTermDepositsPolicyTextBlock" xlink:to="nrsn_ShortTermDepositsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_RestrictedDepositsPolicyTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_RestrictedDepositsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_RestrictedDepositsPolicyTextBlock_lbl" xml:lang="en-US">Restricted deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RestrictedDepositsPolicyTextBlock" xlink:to="nrsn_RestrictedDepositsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of credit risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Commitment and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPolicy_lbl" xml:lang="en-US">Employee benefit plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xml:lang="en-US">Share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_ContractsOverOwnEquityPolicyTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_ContractsOverOwnEquityPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_ContractsOverOwnEquityPolicyTextBlock_lbl" xml:lang="en-US">Contracts over own equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ContractsOverOwnEquityPolicyTextBlock" xlink:to="nrsn_ContractsOverOwnEquityPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently adopted accounting pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US">Recently issued accounting pronouncements, not yet adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_PrefundedWarrantMember" xlink:href="nrsn-20241231.xsd#nrsn_PrefundedWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_PrefundedWarrantMember_lbl" xml:lang="en-US">Pre-funded warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_PrefundedWarrantMember" xlink:to="nrsn_PrefundedWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_AllianceGlobalPartnersMember" xlink:href="nrsn-20241231.xsd#nrsn_AllianceGlobalPartnersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_AllianceGlobalPartnersMember_lbl" xml:lang="en-US">Alliance Global Partners [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_AllianceGlobalPartnersMember" xlink:to="nrsn_AllianceGlobalPartnersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_PrefundedWarrantsMember" xlink:href="nrsn-20241231.xsd#nrsn_PrefundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_PrefundedWarrantsMember_lbl" xml:lang="en-US">Pre-funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_PrefundedWarrantsMember" xlink:to="nrsn_PrefundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember" xlink:href="nrsn-20241231.xsd#nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember_lbl" xml:lang="en-US">April 2024 Purchase Agrement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember" xlink:to="nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_SalesAgreementMember" xlink:href="nrsn-20241231.xsd#nrsn_SalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SalesAgreementMember" xlink:to="nrsn_SalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_SecuritiesPurchaseAgreementMember" xlink:href="nrsn-20241231.xsd#nrsn_SecuritiesPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SecuritiesPurchaseAgreementMember" xlink:to="nrsn_SecuritiesPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_PurchaseAgreementMember" xlink:href="nrsn-20241231.xsd#nrsn_PurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_PurchaseAgreementMember" xlink:to="nrsn_PurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember" xlink:href="nrsn-20241231.xsd#nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember_lbl" xml:lang="en-US">2018 Employee Share Option Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember" xlink:to="nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember_lbl0" xml:lang="en-US">Two Thousand Eighteen Employee Share Option Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember" xlink:to="nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_TwoThousandTwentyTwoBonusPlanMember" xlink:href="nrsn-20241231.xsd#nrsn_TwoThousandTwentyTwoBonusPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_TwoThousandTwentyTwoBonusPlanMember_lbl" xml:lang="en-US">2022 Bonus Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_TwoThousandTwentyTwoBonusPlanMember" xlink:to="nrsn_TwoThousandTwentyTwoBonusPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Employee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_November12024Member" xlink:href="nrsn-20241231.xsd#nrsn_November12024Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_November12024Member_lbl" xml:lang="en-US">November 1, 2024 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_November12024Member" xlink:to="nrsn_November12024Member_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_October12024Member" xlink:href="nrsn-20241231.xsd#nrsn_October12024Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_October12024Member_lbl" xml:lang="en-US">October 1, 2024 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_October12024Member" xlink:to="nrsn_October12024Member_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_MrAlonBenNoonsMember" xlink:href="nrsn-20241231.xsd#nrsn_MrAlonBenNoonsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_MrAlonBenNoonsMember_lbl" xml:lang="en-US">Mr. Alon Ben-Noon&#8217;s [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_MrAlonBenNoonsMember" xlink:to="nrsn_MrAlonBenNoonsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IsraelTaxAuthorityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IsraelTaxAuthorityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl" xml:lang="en-US">Israel Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_ConsultantsMember" xlink:href="nrsn-20241231.xsd#nrsn_ConsultantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nrsn_ConsultantsMember_lbl" xml:lang="en-US">Consultants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ConsultantsMember" xlink:to="nrsn_ConsultantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US">All Currencies [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xml:lang="en-US">Cash and Cash Equivalent [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US">Schedule of Cash And Cash Equivalent [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property and Equipment Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_LiabilityinRespectofWarrantsScheduleoftheMovementinWarrantLiabilityDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_LiabilityinRespectofWarrantsScheduleoftheMovementinWarrantLiabilityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_LiabilityinRespectofWarrantsScheduleoftheMovementinWarrantLiabilityDetailsTable_lbl" xml:lang="en-US">Liability in Respect of Warrants - Schedule of the Movement in Warrant Liability (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_LiabilityinRespectofWarrantsScheduleoftheMovementinWarrantLiabilityDetailsTable" xlink:to="nrsn_LiabilityinRespectofWarrantsScheduleoftheMovementinWarrantLiabilityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Schedule of the Movement in Warrant Liability [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable_lbl" xml:lang="en-US">Share Based Payment - Schedule of Fair Value of the Options Granted (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable" xlink:to="nrsn_ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Schedule of Fair Value of the Options Granted [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_ShareBasedPaymentScheduleofShareOptionActivityDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_ShareBasedPaymentScheduleofShareOptionActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ShareBasedPaymentScheduleofShareOptionActivityDetailsTable_lbl" xml:lang="en-US">Share Based Payment - Schedule of Share Option Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ShareBasedPaymentScheduleofShareOptionActivityDetailsTable" xlink:to="nrsn_ShareBasedPaymentScheduleofShareOptionActivityDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl0" xml:lang="en-US">Schedule of Share Option Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_ShareBasedPaymentScheduleofRestrictedStockUnitRSUsActivityDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_ShareBasedPaymentScheduleofRestrictedStockUnitRSUsActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ShareBasedPaymentScheduleofRestrictedStockUnitRSUsActivityDetailsTable_lbl" xml:lang="en-US">Share Based Payment - Schedule of Restricted Stock Unit (RSU&#8217;s) Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ShareBasedPaymentScheduleofRestrictedStockUnitRSUsActivityDetailsTable" xlink:to="nrsn_ShareBasedPaymentScheduleofRestrictedStockUnitRSUsActivityDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" xml:lang="en-US">Schedule of Restricted Stock Unit (RSU&apos;s) Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable_lbl" xml:lang="en-US">Condensed Statement of Comprehensive Income [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Schedule of Share-Based Expense Recognized in the Statements of Operation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable_lbl" xml:lang="en-US">Significant Accounting Policy - Schedule of the Lives Used in Computing Straight-Line Depreciation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable" xlink:to="nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems" xlink:href="nrsn-20241231.xsd#nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems_lbl" xml:lang="en-US">Significant Accounting Policy - Schedule of the Lives Used in Computing Straight-Line Depreciation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems" xlink:to="nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_SignificantAccountingPolicyDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_SignificantAccountingPolicyDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_SignificantAccountingPolicyDetailsTable_lbl" xml:lang="en-US">Significant Accounting Policy (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SignificantAccountingPolicyDetailsTable" xlink:to="nrsn_SignificantAccountingPolicyDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Significant Accounting Policy [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_OperatingLeaseDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_OperatingLeaseDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_OperatingLeaseDetailsTable_lbl" xml:lang="en-US">Operating Lease (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_OperatingLeaseDetailsTable" xlink:to="nrsn_OperatingLeaseDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Operating Lease [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_LiabilityinRespectofWarrantsDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_LiabilityinRespectofWarrantsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_LiabilityinRespectofWarrantsDetailsTable_lbl" xml:lang="en-US">Liability in Respect of Warrants (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_LiabilityinRespectofWarrantsDetailsTable" xlink:to="nrsn_LiabilityinRespectofWarrantsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl0" xml:lang="en-US">Liability in Respect of Warrants [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_ShareholdersEquityDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_ShareholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ShareholdersEquityDetailsTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ShareholdersEquityDetailsTable" xlink:to="nrsn_ShareholdersEquityDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl1" xml:lang="en-US">Shareholders&apos; Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US">Grantee Status [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US">Award Date [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_ShareBasedPaymentDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_ShareBasedPaymentDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ShareBasedPaymentDetailsTable_lbl" xml:lang="en-US">Share Based Payment (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ShareBasedPaymentDetailsTable" xlink:to="nrsn_ShareBasedPaymentDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl0" xml:lang="en-US">Share Based Payment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="nrsn_RelatedPartiesBalancesandTransactionsDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_RelatedPartiesBalancesandTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_RelatedPartiesBalancesandTransactionsDetailsTable_lbl" xml:lang="en-US">Related Parties Balances and Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RelatedPartiesBalancesandTransactionsDetailsTable" xlink:to="nrsn_RelatedPartiesBalancesandTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Parties Balances and Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Jurisdiction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_IncomeTaxesDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_IncomeTaxesDetailsTable" xlink:to="nrsn_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="nrsn_SubsequentEventsDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SubsequentEventsDetailsTable" xlink:to="nrsn_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_AllocatedAmountToOrdinaryWarrants_lbl0" xml:lang="en-US">Represent the allocated amount to ordinary warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_AllocatedAmountToOrdinaryWarrants" xlink:to="nrsn_AllocatedAmountToOrdinaryWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_BonusAccrualReclassificationToEquity_lbl0" xml:lang="en-US">The amount of bonus accrual reclassification to equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_BonusAccrualReclassificationToEquity" xlink:to="nrsn_BonusAccrualReclassificationToEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_ContractsOverOwnEquityPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for contracts over own equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ContractsOverOwnEquityPolicyTextBlock" xlink:to="nrsn_ContractsOverOwnEquityPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_DecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Represent the amount of decrease in operating lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_DecreaseInOperatingLeaseLiability" xlink:to="nrsn_DecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_DecreaseInOperatingRightOfUseAsset_lbl0" xml:lang="en-US">Decrease in operating right of use asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_DecreaseInOperatingRightOfUseAsset" xlink:to="nrsn_DecreaseInOperatingRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_DeferredTaxAssetsOperatingLeaseLiability_lbl0" xml:lang="en-US">Represent the amount of deferred tax assets operating lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="nrsn_DeferredTaxAssetsOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual_lbl0" xml:lang="en-US">Amount represents deferred tax assets vacation and convalescence accrual.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual" xlink:to="nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_ExchangeRates_lbl0" xml:lang="en-US">Exchange rates.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ExchangeRates" xlink:to="nrsn_ExchangeRates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_ExpirationDateGrantTerm_lbl0" xml:lang="en-US">Represent the expiration date grant term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ExpirationDateGrantTerm" xlink:to="nrsn_ExpirationDateGrantTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock_lbl0" xml:lang="en-US">The entire disclosure for general and administrative expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock" xlink:to="nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_InitialRecognitionRightofuseAssets_lbl0" xml:lang="en-US">The amount of initial recognition.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_InitialRecognitionRightofuseAssets" xlink:to="nrsn_InitialRecognitionRightofuseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_InstallmentsLockUpPeriod_lbl0" xml:lang="en-US">Installments lock-up period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_InstallmentsLockUpPeriod" xlink:to="nrsn_InstallmentsLockUpPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_LesseeOperatingLeaseDisclosureTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure for lessee&apos;s operating leases. Includes, but is not limited to, description of lessee&apos;s operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_LesseeOperatingLeaseDisclosureTableTextBlock" xlink:to="nrsn_LesseeOperatingLeaseDisclosureTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_LiabilityInRespectOfWarrantsTextBlock_lbl0" xml:lang="en-US">The entire disclosure for liability in respect of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_LiabilityInRespectOfWarrantsTextBlock" xlink:to="nrsn_LiabilityInRespectOfWarrantsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_MarketOfferingCost_lbl0" xml:lang="en-US">Represent  the at the market offering cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_MarketOfferingCost" xlink:to="nrsn_MarketOfferingCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_NetProceedsFromIssuanceOfWarrants_lbl0" xml:lang="en-US">Represents the amount of net proceeds from issuance of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NetProceedsFromIssuanceOfWarrants" xlink:to="nrsn_NetProceedsFromIssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_NetProceedsFromTheOrdinaryShares_lbl0" xml:lang="en-US">Represent the net proceeds from the ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NetProceedsFromTheOrdinaryShares" xlink:to="nrsn_NetProceedsFromTheOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_NoncashOrPartNoncashAcquisitionInterestReceived_lbl0" xml:lang="en-US">Represent then interest received &quot;Part noncash&quot; refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NoncashOrPartNoncashAcquisitionInterestReceived" xlink:to="nrsn_NoncashOrPartNoncashAcquisitionInterestReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_NumberOfInstallments_lbl0" xml:lang="en-US">Number of installments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NumberOfInstallments" xlink:to="nrsn_NumberOfInstallments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_NumberOfOrdinaryShares_lbl1" xml:lang="en-US">Number of ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NumberOfOrdinaryShares" xlink:to="nrsn_NumberOfOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_NumberOfSharesPercentage_lbl0" xml:lang="en-US">Number of shares percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NumberOfSharesPercentage" xlink:to="nrsn_NumberOfSharesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_PotentialBonusPayable_lbl0" xml:lang="en-US">Amount of potential bonus payable to the officers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_PotentialBonusPayable" xlink:to="nrsn_PotentialBonusPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_PurchasePricePerShare_lbl0" xml:lang="en-US">Represent the combined purchase price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_PurchasePricePerShare" xlink:to="nrsn_PurchasePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_RaiseOfAdditionalBonusPercentage_lbl0" xml:lang="en-US">The percentage of raise of additional bonus.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RaiseOfAdditionalBonusPercentage" xlink:to="nrsn_RaiseOfAdditionalBonusPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for recently issued accounting pronouncements, not yet adopted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_ReclassificationOfWarrantsIntoEquity_lbl1" xml:lang="en-US">Represents the amount of reclassification of warrants into equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ReclassificationOfWarrantsIntoEquity" xlink:to="nrsn_ReclassificationOfWarrantsIntoEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate_lbl0" xml:lang="en-US">Recognition of liability in respect to warrants at the initial date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate" xlink:to="nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_RedemptionOfinvestmentInRestrictedDepositNet_lbl0" xml:lang="en-US">Represent the redemption of investment in restricted deposit, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RedemptionOfinvestmentInRestrictedDepositNet" xlink:to="nrsn_RedemptionOfinvestmentInRestrictedDepositNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_RedemptionofinvestmentInShorttermDeposits_lbl0" xml:lang="en-US">Represent the amount of redemption of (investment in) short-term deposits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RedemptionofinvestmentInShorttermDeposits" xlink:to="nrsn_RedemptionofinvestmentInShorttermDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_RemainingFairValueAmount_lbl0" xml:lang="en-US">Represent the remaining fair value warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RemainingFairValueAmount" xlink:to="nrsn_RemainingFairValueAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_RestrictedDepositsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for restricted deposits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RestrictedDepositsPolicyTextBlock" xlink:to="nrsn_RestrictedDepositsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_RevaluationOfLiabilityInRespectToWarrants_lbl1" xml:lang="en-US">Revaluation of liability in respect to warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RevaluationOfLiabilityInRespectToWarrants" xlink:to="nrsn_RevaluationOfLiabilityInRespectToWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity_lbl0" xml:lang="en-US">Represented the amount of revaluation of liability in respect to warrants through equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity" xlink:to="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse_lbl0" xml:lang="en-US">Represented the amount of revaluation of liability in respect to warrants through finance expanse.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse" xlink:to="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_SalariesAndSocialBenefits_lbl0" xml:lang="en-US">Salaries and social benefits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SalariesAndSocialBenefits" xlink:to="nrsn_SalariesAndSocialBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_SaleOfOrdinaryShareGrossProceedsPercentage_lbl0" xml:lang="en-US">Percentage of  sale of ordinary share gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SaleOfOrdinaryShareGrossProceedsPercentage" xlink:to="nrsn_SaleOfOrdinaryShareGrossProceedsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of general and administrative expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of lives used in computing straight-line depreciation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock" xlink:to="nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_lbl0" xml:lang="en-US">Per share or unit weighted-average of exercise price award granted under share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" xlink:to="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Number of Share Options, Forfeited.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod" xlink:to="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_SharebasedCompensation_lbl0" xml:lang="en-US">Share-based compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SharebasedCompensation" xlink:to="nrsn_SharebasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_lbl0" xml:lang="en-US">Intrinsic value of granted award under share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:to="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited_lbl0" xml:lang="en-US">Represent the amount of intrinsic value forfeited.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited" xlink:to="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited_lbl0" xml:lang="en-US">The weighted average remaining contractual life forfeited.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited" xlink:to="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted_lbl0" xml:lang="en-US">The weighted average remaining contractual life granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted" xlink:to="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_ShortTermDepositsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for short-term deposits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ShortTermDepositsPolicyTextBlock" xlink:to="nrsn_ShortTermDepositsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet_lbl0" xml:lang="en-US">Represent the shares of issuance of shares and pre-funded warrants, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet" xlink:to="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement_lbl0" xml:lang="en-US">Represent the shares issuance of shares due to SEPA agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement" xlink:to="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants_lbl0" xml:lang="en-US">Represent the number of shares exercise of pre-funded warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants" xlink:to="nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity_lbl0" xml:lang="en-US">Represent the amount of bonus accrual reclassification to equity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity" xlink:to="nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet_lbl0" xml:lang="en-US">Represent the amount of issuance of shares and prefunded warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet" xlink:to="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement_lbl0" xml:lang="en-US">Represent the amount of issuance of shares due to SEPA agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement" xlink:to="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised_lbl0" xml:lang="en-US">Represent the amount of exercise of pre-funded warrants, options and vested RSUs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised" xlink:to="nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nrsn_SubcontractorsAndConsultants_lbl0" xml:lang="en-US">Subcontractors and consultants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SubcontractorsAndConsultants" xlink:to="nrsn_SubcontractorsAndConsultants_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember_lbl" xml:lang="en-US">The shorter of the lease term and the useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:to="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Current operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl1" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExchangeFees_lbl0" xml:lang="en-US">Exchange Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExchangeFees" xlink:to="us-gaap_ExchangeFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate_lbl1" xml:lang="en-US">Recognition Of Liability In Respect To Warrants At The Initial Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate" xlink:to="nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_RevaluationOfLiabilityInRespectToWarrants_lbl2" xml:lang="en-US">Revaluation Of Liability In Respect To Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RevaluationOfLiabilityInRespectToWarrants" xlink:to="nrsn_RevaluationOfLiabilityInRespectToWarrants_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPolicy_lbl0" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl1" xml:lang="en-US">Recently Issued Accounting Pronouncements Not Yet Adopted Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_SharebasedCompensation_lbl1" xml:lang="en-US">Sharebased Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SharebasedCompensation" xlink:to="nrsn_SharebasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl0" xml:lang="en-US">Condensed Statement of Comprehensive Income [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl0" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl0" xml:lang="en-US">Interest Income, Deposits with Financial Institutions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Salaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedSalariesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl0" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_lbl0" xml:lang="en-US">Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentContractReceivable_lbl0" xml:lang="en-US">Government Contract Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentContractReceivable" xlink:to="us-gaap_GovernmentContractReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_PotentialBonusPayable_lbl1" xml:lang="en-US">Potential Bonus Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_PotentialBonusPayable" xlink:to="nrsn_PotentialBonusPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl2" xml:lang="en-US">Warrants and Rights Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_InitialRecognitionRightofuseAssets_lbl1" xml:lang="en-US">Initial Recognition Rightofuse Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_InitialRecognitionRightofuseAssets" xlink:to="nrsn_InitialRecognitionRightofuseAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl0" xml:lang="en-US">Other Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_AllianceGlobalPartnersMember_lbl0" xml:lang="en-US">Alliance Global Partners Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_AllianceGlobalPartnersMember" xlink:to="nrsn_AllianceGlobalPartnersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Sale or Disposal of Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl0" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="nrsn_ScheduleOfShareOptionActivityAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfShareOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ScheduleOfShareOptionActivityAbstract_lbl" xml:lang="en-US">Schedule Of Share Option Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ScheduleOfShareOptionActivityAbstract" xlink:to="nrsn_ScheduleOfShareOptionActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl0" xml:lang="en-US">Operating Lease, Payments, Use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ExpirationDateGrantTerm_lbl1" xml:lang="en-US">Expiration Date Grant Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ExpirationDateGrantTerm" xlink:to="nrsn_ExpirationDateGrantTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfOtherEquity_lbl0" xml:lang="en-US">Payments for Repurchase of Other Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:to="us-gaap_PaymentsForRepurchaseOfOtherEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity_lbl1" xml:lang="en-US">Stock Issued During Period Value Bonus Accrual Reclassification To Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity" xlink:to="nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl3" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities_lbl0" xml:lang="en-US">Debtor Reorganization Items, Revaluation of Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities" xlink:to="us-gaap_DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_RestrictedDepositsPolicyTextBlock_lbl1" xml:lang="en-US">Restricted Deposits Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RestrictedDepositsPolicyTextBlock" xlink:to="nrsn_RestrictedDepositsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_MarketOfferingCost_lbl1" xml:lang="en-US">Market Offering Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_MarketOfferingCost" xlink:to="nrsn_MarketOfferingCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_CostAbstract0_lbl0" xml:lang="en-US">Cost Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_CostAbstract0" xlink:to="nrsn_CostAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl2" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, State and Local, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_November12024Member_lbl0" xml:lang="en-US">November12024 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_November12024Member" xlink:to="nrsn_November12024Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_lbl0" xml:lang="en-US">Schedule of Other Operating Cost and Expense, by Component [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:to="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_SalariesAndSocialBenefits_lbl1" xml:lang="en-US">Salaries And Social Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SalariesAndSocialBenefits" xlink:to="nrsn_SalariesAndSocialBenefits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_NetProceedsFromTheOrdinaryShares_lbl1" xml:lang="en-US">Net Proceeds From The Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NetProceedsFromTheOrdinaryShares" xlink:to="nrsn_NetProceedsFromTheOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_ILS_lbl0" xml:lang="en-US">Israel, New Shekels</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_ILS" xlink:to="currency_ILS_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet_lbl1" xml:lang="en-US">Stock Issued During Period Shares Issuance Of Shares And Prefunded Warrants Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet" xlink:to="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_PurchaseAgreementMember_lbl0" xml:lang="en-US">Purchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_PurchaseAgreementMember" xlink:to="nrsn_PurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_lbl0" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Number of Allocated Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_LiabilityInRespectOfWarrantsTextBlock_lbl1" xml:lang="en-US">Liability In Respect Of Warrants Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_LiabilityInRespectOfWarrantsTextBlock" xlink:to="nrsn_LiabilityInRespectOfWarrantsTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_EmployeesAndDirectorsMember_lbl0" xml:lang="en-US">Employees And Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_EmployeesAndDirectorsMember" xlink:to="nrsn_EmployeesAndDirectorsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="nrsn_ScheduleOfCashAndCashEquivalentAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfCashAndCashEquivalentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ScheduleOfCashAndCashEquivalentAbstract_lbl" xml:lang="en-US">Schedule Of Cash And Cash Equivalent Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ScheduleOfCashAndCashEquivalentAbstract" xlink:to="nrsn_ScheduleOfCashAndCashEquivalentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRestructuring_lbl0" xml:lang="en-US">Payments for Restructuring</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember_lbl1" xml:lang="en-US">Two Thousand Eighteen Employee Share Option Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember" xlink:to="nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl0" xml:lang="en-US">Salary and Wage, Excluding Cost of Good and Service Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl0" xml:lang="en-US">Other Nonoperating Income and Expense [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" xlink:to="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_AllocatedAmountToOrdinaryWarrants_lbl1" xml:lang="en-US">Allocated Amount To Ordinary Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_AllocatedAmountToOrdinaryWarrants" xlink:to="nrsn_AllocatedAmountToOrdinaryWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_RaiseOfAdditionalBonusPercentage_lbl1" xml:lang="en-US">Raise Of Additional Bonus Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RaiseOfAdditionalBonusPercentage" xlink:to="nrsn_RaiseOfAdditionalBonusPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionContributions_lbl0" xml:lang="en-US">Payment for Pension Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionContributions" xlink:to="us-gaap_PensionContributions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl0" xml:lang="en-US">Investor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_October12024Member_lbl0" xml:lang="en-US">October12024 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_October12024Member" xlink:to="nrsn_October12024Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl1" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_SubcontractorsAndConsultants_lbl1" xml:lang="en-US">Subcontractors And Consultants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SubcontractorsAndConsultants" xlink:to="nrsn_SubcontractorsAndConsultants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_OrdinarySharesNoParValuePerShareMember_lbl0" xml:lang="en-US">Ordinary Shares No Par Value Per Share Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_OrdinarySharesNoParValuePerShareMember" xlink:to="nrsn_OrdinarySharesNoParValuePerShareMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember_lbl0" xml:lang="en-US">April Two Thousand Twenty Four Purchase Agrement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember" xlink:to="nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_DecreaseInOperatingLeaseLiability_lbl1" xml:lang="en-US">Decrease In Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_DecreaseInOperatingLeaseLiability" xlink:to="nrsn_DecreaseInOperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised_lbl1" xml:lang="en-US">Stock Issued During Period Value Pre-funded Warrants Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised" xlink:to="nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_NetProceedsFromIssuanceOfWarrants_lbl1" xml:lang="en-US">Net Proceeds From Issuance Of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NetProceedsFromIssuanceOfWarrants" xlink:to="nrsn_NetProceedsFromIssuanceOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl2" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl0" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_UnlabeledAbstract" xlink:to="nrsn_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse_lbl1" xml:lang="en-US">Revaluation Of Liability In Respect To Warrants Through Finance Expanse</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse" xlink:to="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl2" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity_lbl1" xml:lang="en-US">Revaluation Of Liability In Respect To Warrants Through Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity" xlink:to="nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_AccumulatedDepreciationAbstract0_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_AccumulatedDepreciationAbstract0" xlink:to="nrsn_AccumulatedDepreciationAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentInterestRate_lbl0" xml:lang="en-US">Investment Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl0" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl2" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNoParValue_lbl1" xml:lang="en-US">Common Stock, No Par Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ReclassificationOfWarrantsIntoEquity_lbl2" xml:lang="en-US">Reclassification Of Warrants Into Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ReclassificationOfWarrantsIntoEquity" xlink:to="nrsn_ReclassificationOfWarrantsIntoEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_OrdinarySharesNoParValueAbstract_lbl0" xml:lang="en-US">Ordinary Shares No Par Value Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_OrdinarySharesNoParValueAbstract" xlink:to="nrsn_OrdinarySharesNoParValueAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_LesseeOperatingLeaseDisclosureTableTextBlock_lbl1" xml:lang="en-US">Lessee Operating Lease Disclosure Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_LesseeOperatingLeaseDisclosureTableTextBlock" xlink:to="nrsn_LesseeOperatingLeaseDisclosureTableTextBlock_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_SecuritiesPurchaseAgreementMember_lbl0" xml:lang="en-US">Securities Purchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SecuritiesPurchaseAgreementMember" xlink:to="nrsn_SecuritiesPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock_lbl1" xml:lang="en-US">Schedule Of The Lives Used In Computing Straight Line Depreciation Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock" xlink:to="nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl0" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="nrsn_ScheduleOfRestrictedStockUnitRsuSActivityAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfRestrictedStockUnitRsuSActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ScheduleOfRestrictedStockUnitRsuSActivityAbstract_lbl" xml:lang="en-US">Schedule Of Restricted Stock Unit Rsu SActivity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ScheduleOfRestrictedStockUnitRsuSActivityAbstract" xlink:to="nrsn_ScheduleOfRestrictedStockUnitRsuSActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes_lbl0" xml:lang="en-US">Deferred Tax Assets, State Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsStateTaxes" xlink:to="us-gaap_DeferredTaxAssetsStateTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl0" xml:lang="en-US">Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ShortTermDepositsPolicyTextBlock_lbl1" xml:lang="en-US">Short Term Deposits Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ShortTermDepositsPolicyTextBlock" xlink:to="nrsn_ShortTermDepositsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl0" xml:lang="en-US">Other Nonoperating Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCapitalUnitsTextBlock_lbl0" xml:lang="en-US">Schedule of Capital Units [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCapitalUnitsTextBlock" xlink:to="us-gaap_ScheduleOfCapitalUnitsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Supplies_lbl0" xml:lang="en-US">Prepaid Supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Supplies" xlink:to="us-gaap_Supplies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl0" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees&apos; Gross Pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Contractual Life Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted" xlink:to="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ContractsOverOwnEquityPolicyTextBlock_lbl1" xml:lang="en-US">Contracts Over Own Equity Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ContractsOverOwnEquityPolicyTextBlock" xlink:to="nrsn_ContractsOverOwnEquityPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Contractual Life Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited" xlink:to="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl1" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_BonusAccrualReclassificationToEquity_lbl1" xml:lang="en-US">Bonus Accrual Reclassification To Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_BonusAccrualReclassificationToEquity" xlink:to="nrsn_BonusAccrualReclassificationToEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <loc xlink:type="locator" xlink:label="nrsn_ScheduleOfFairValueOfTheOptionsGrantedAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfFairValueOfTheOptionsGrantedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ScheduleOfFairValueOfTheOptionsGrantedAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Of The Options Granted Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ScheduleOfFairValueOfTheOptionsGrantedAbstract" xlink:to="nrsn_ScheduleOfFairValueOfTheOptionsGrantedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payments Award Options Forfeitures In Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod" xlink:to="nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl0" xml:lang="en-US">Other Nonoperating Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_PrefundedWarrantMember_lbl0" xml:lang="en-US">Prefunded Warrant Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_PrefundedWarrantMember" xlink:to="nrsn_PrefundedWarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks_lbl0" xml:lang="en-US">Interest Expense, Loans from Other Federal Home Loan Banks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks" xlink:to="us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_RedemptionOfinvestmentInRestrictedDepositNet_lbl1" xml:lang="en-US">Redemption Ofinvestment In Restricted Deposit Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RedemptionOfinvestmentInRestrictedDepositNet" xlink:to="nrsn_RedemptionOfinvestmentInRestrictedDepositNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_RedemptionofinvestmentInShorttermDeposits_lbl1" xml:lang="en-US">Redemptionofinvestment In Shortterm Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RedemptionofinvestmentInShorttermDeposits" xlink:to="nrsn_RedemptionofinvestmentInShorttermDeposits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl0" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_MrAlonBenNoonsMember_lbl0" xml:lang="en-US">Mr Alon Ben Noons Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_MrAlonBenNoonsMember" xlink:to="nrsn_MrAlonBenNoonsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl0" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent_lbl0" xml:lang="en-US">Restricted Cash and Investments, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndInvestmentsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockVotingRights_lbl0" xml:lang="en-US">Common Stock, Voting Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Other Current Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralInsuranceExpense_lbl0" xml:lang="en-US">General Insurance Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl0" xml:lang="en-US">Property, Plant and Equipment, Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ExchangeRates_lbl1" xml:lang="en-US">Exchange Rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ExchangeRates" xlink:to="nrsn_ExchangeRates_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_SaleOfOrdinaryShareGrossProceedsPercentage_lbl1" xml:lang="en-US">Sale Of Ordinary Share Gross Proceeds Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SaleOfOrdinaryShareGrossProceedsPercentage" xlink:to="nrsn_SaleOfOrdinaryShareGrossProceedsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <loc xlink:type="locator" xlink:label="nrsn_ScheduleOfFairValueOfTheWarrantsAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfFairValueOfTheWarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ScheduleOfFairValueOfTheWarrantsAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Of The Warrants Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ScheduleOfFairValueOfTheWarrantsAbstract" xlink:to="nrsn_ScheduleOfFairValueOfTheWarrantsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement_lbl1" xml:lang="en-US">Stock Issued During Period Value Issuance Of Shares Due To SEPAAagreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement" xlink:to="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenseDisclosureNonoperatingAbstract_lbl0" xml:lang="en-US">Other Expense, Nonoperating [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:to="us-gaap_OtherExpenseDisclosureNonoperatingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndInvestmentsCurrent_lbl0" xml:lang="en-US">Restricted Cash and Investments, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:to="us-gaap_RestrictedCashAndInvestmentsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_NumberOfInstallments_lbl1" xml:lang="en-US">Number Of Installments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NumberOfInstallments" xlink:to="nrsn_NumberOfInstallments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl0" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_CostAbstract_lbl0" xml:lang="en-US">Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_CostAbstract" xlink:to="nrsn_CostAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="nrsn_ScheduleOfShareBasedExpenseRecognizedInTheStatementsOfOperationAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfShareBasedExpenseRecognizedInTheStatementsOfOperationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ScheduleOfShareBasedExpenseRecognizedInTheStatementsOfOperationAbstract_lbl" xml:lang="en-US">Schedule Of Share Based Expense Recognized In The Statements Of Operation Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ScheduleOfShareBasedExpenseRecognizedInTheStatementsOfOperationAbstract" xlink:to="nrsn_ScheduleOfShareBasedExpenseRecognizedInTheStatementsOfOperationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual_lbl1" xml:lang="en-US">Deferred Tax Assets Vacation And Convalescence Accrual</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual" xlink:to="nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual_lbl1"/>
    <loc xlink:type="locator" xlink:label="nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Schedule Of The Company SNet Deferred Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl0" xml:lang="en-US">Reclassifications of Temporary to Permanent Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl0" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_LiabilityInRespectOfWarrantsMember_lbl0" xml:lang="en-US">Liability In Respect Of Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_LiabilityInRespectOfWarrantsMember" xlink:to="nrsn_LiabilityInRespectOfWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseOfferingCost_lbl0" xml:lang="en-US">Noninterest Expense Offering Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseOfferingCost" xlink:to="us-gaap_NoninterestExpenseOfferingCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl1" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl1"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_WarrantLiabilityMember_lbl0" xml:lang="en-US">Warrant Liability Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_WarrantLiabilityMember" xlink:to="nrsn_WarrantLiabilityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:to="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl2" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_DeferredTaxAssetsOperatingLeaseLiability_lbl1" xml:lang="en-US">Deferred Tax Assets Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="nrsn_DeferredTaxAssetsOperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_USD_lbl0" xml:lang="en-US">United States of America, Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_NumberOfOrdinaryShares_lbl2" xml:lang="en-US">Number Of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NumberOfOrdinaryShares" xlink:to="nrsn_NumberOfOrdinaryShares_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeDisclosureNonoperatingAbstract_lbl0" xml:lang="en-US">Other Income, Nonoperating [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_OtherIncomeDisclosureNonoperatingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl2" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants_lbl1" xml:lang="en-US">Stock Issued During Period Shares Stock Options Exercisedof Pre-funded Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants" xlink:to="nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_InstallmentsLockUpPeriod_lbl1" xml:lang="en-US">Installments Lock Up Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_InstallmentsLockUpPeriod" xlink:to="nrsn_InstallmentsLockUpPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_lbl0" xml:lang="en-US">Supply Commitment, Remaining Minimum Amount Committed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:to="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesGrossCurrent_lbl0" xml:lang="en-US">Other Receivables, Gross, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesGrossCurrent" xlink:to="us-gaap_OtherReceivablesGrossCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_TwoThousandTwentyTwoBonusPlanMember_lbl0" xml:lang="en-US">Two Thousand Twenty Two Bonus Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_TwoThousandTwentyTwoBonusPlanMember" xlink:to="nrsn_TwoThousandTwentyTwoBonusPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_AccumulatedDepreciationAbstract_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_AccumulatedDepreciationAbstract" xlink:to="nrsn_AccumulatedDepreciationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_NumberOfSharesPercentage_lbl1" xml:lang="en-US">Number Of Shares Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NumberOfSharesPercentage" xlink:to="nrsn_NumberOfSharesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl1" xml:lang="en-US">Stock Repurchased During Period, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl0" xml:lang="en-US">Israel Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl1" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl1" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl2" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl1" xml:lang="en-US">Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_PrefundedWarrantsMember_lbl0" xml:lang="en-US">Prefunded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_PrefundedWarrantsMember" xlink:to="nrsn_PrefundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of General And Administrative Expenses Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_WarrantsExercisableForOneOrdinaryShareMember_lbl0" xml:lang="en-US">Warrants Exercisable For One Ordinary Share Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_WarrantsExercisableForOneOrdinaryShareMember" xlink:to="nrsn_WarrantsExercisableForOneOrdinaryShareMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl1" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet_lbl1" xml:lang="en-US">Stock Issued During Period Value Issuance Of Shares And Prefunded Warrants Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet" xlink:to="nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock_lbl1" xml:lang="en-US">General And Administrative Expenses Disclosure Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock" xlink:to="nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Intrinsic Value Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited" xlink:to="nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl0" xml:lang="en-US">Professional and Contract Services Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_RemainingFairValueAmount_lbl1" xml:lang="en-US">Remaining Fair Value Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_RemainingFairValueAmount" xlink:to="nrsn_RemainingFairValueAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement_lbl1" xml:lang="en-US">Stock Issued During Period Shares Issuance Of Shares Due To SEPAAagreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement" xlink:to="nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_DecreaseInOperatingRightOfUseAsset_lbl1" xml:lang="en-US">Decrease In Operating Right Of Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_DecreaseInOperatingRightOfUseAsset" xlink:to="nrsn_DecreaseInOperatingRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl0" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_SalesAgreementMember_lbl0" xml:lang="en-US">Sales Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_SalesAgreementMember" xlink:to="nrsn_SalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_NoncashOrPartNoncashAcquisitionInterestReceived_lbl1" xml:lang="en-US">Noncash Or Part Noncash Acquisition Interest Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_NoncashOrPartNoncashAcquisitionInterestReceived" xlink:to="nrsn_NoncashOrPartNoncashAcquisitionInterestReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ConsultantsMember_lbl0" xml:lang="en-US">Consultants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ConsultantsMember" xlink:to="nrsn_ConsultantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoninterestExpense_lbl0" xml:lang="en-US">Other Noninterest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoninterestExpense" xlink:to="us-gaap_OtherNoninterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <loc xlink:type="locator" xlink:label="nrsn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_ScheduleOfPropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="nrsn_ScheduleOfPropertyAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl1" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TravelAndEntertainmentExpense_lbl0" xml:lang="en-US">Travel and Entertainment Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TravelAndEntertainmentExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nrsn_PurchasePricePerShare_lbl1" xml:lang="en-US">Purchase Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nrsn_PurchasePricePerShare" xlink:to="nrsn_PurchasePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>nrsn-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Apr 07 20:27:37 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ConsolidatedBalanceSheet" roleURI="http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.neurosensetx.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ConsolidatedIncomeStatement" roleURI="http://www.neurosensetx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ShareholdersEquityType2or3" roleURI="http://www.neurosensetx.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ConsolidatedCashFlow" roleURI="http://www.neurosensetx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_General" roleURI="http://www.neurosensetx.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_SignificantAccountingPolicy" roleURI="http://www.neurosensetx.com/role/SignificantAccountingPolicy"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_CashandCashEquivalent" roleURI="http://www.neurosensetx.com/role/CashandCashEquivalent"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_OtherReceivables" roleURI="http://www.neurosensetx.com/role/OtherReceivables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_PropertyandEquipmentNet" roleURI="http://www.neurosensetx.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_OperatingLease" roleURI="http://www.neurosensetx.com/role/OperatingLease"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_OtherCurrentLiabilities" roleURI="http://www.neurosensetx.com/role/OtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_LiabilityinRespectofWarrants" roleURI="http://www.neurosensetx.com/role/LiabilityinRespectofWarrants"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ShareholdersEquity" roleURI="http://www.neurosensetx.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ShareBasedPayment" roleURI="http://www.neurosensetx.com/role/ShareBasedPayment"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ResearchandDevelopmentExpenses" roleURI="http://www.neurosensetx.com/role/ResearchandDevelopmentExpenses"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_GeneralandAdministrativeExpenses" roleURI="http://www.neurosensetx.com/role/GeneralandAdministrativeExpenses"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_FinancingIncomeExpensesNet" roleURI="http://www.neurosensetx.com/role/FinancingIncomeExpensesNet"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_RelatedPartiesBalancesandTransactions" roleURI="http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactions"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_SegmentReporting" roleURI="http://www.neurosensetx.com/role/SegmentReporting"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_IncomeTaxes" roleURI="http://www.neurosensetx.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_SubsequentEvents" roleURI="http://www.neurosensetx.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_AccountingPoliciesByPolicy" roleURI="http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_SignificantAccountingPolicyTables" roleURI="http://www.neurosensetx.com/role/SignificantAccountingPolicyTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_CashandCashEquivalentTables" roleURI="http://www.neurosensetx.com/role/CashandCashEquivalentTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_OtherReceivablesTables" roleURI="http://www.neurosensetx.com/role/OtherReceivablesTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_PropertyandEquipmentNetTables" roleURI="http://www.neurosensetx.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_OperatingLeaseTables" roleURI="http://www.neurosensetx.com/role/OperatingLeaseTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_OtherCurrentLiabilitiesTables" roleURI="http://www.neurosensetx.com/role/OtherCurrentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_LiabilityinRespectofWarrantsTables" roleURI="http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ShareholdersEquityTables" roleURI="http://www.neurosensetx.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ShareBasedPaymentTables" roleURI="http://www.neurosensetx.com/role/ShareBasedPaymentTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ResearchandDevelopmentExpensesTables" roleURI="http://www.neurosensetx.com/role/ResearchandDevelopmentExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_GeneralandAdministrativeExpensesTables" roleURI="http://www.neurosensetx.com/role/GeneralandAdministrativeExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_FinancingIncomeExpensesNetTables" roleURI="http://www.neurosensetx.com/role/FinancingIncomeExpensesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_IncomeTaxesTables" roleURI="http://www.neurosensetx.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofCashAndCashEquivalentTable" roleURI="http://www.neurosensetx.com/role/ScheduleofCashAndCashEquivalentTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofOtherReceivablesTable" roleURI="http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable" roleURI="http://www.neurosensetx.com/role/ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable" roleURI="http://www.neurosensetx.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofOtherCurrentLiabilitiesTable" roleURI="http://www.neurosensetx.com/role/ScheduleofOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofFinancialMeasuredatFairValueonaRecurringBasisTable" roleURI="http://www.neurosensetx.com/role/ScheduleofFinancialMeasuredatFairValueonaRecurringBasisTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofFairValueoftheWarrantsTable" roleURI="http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleoftheMovementinWarrantLiabilityTable" roleURI="http://www.neurosensetx.com/role/ScheduleoftheMovementinWarrantLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofShareCapitalTable" roleURI="http://www.neurosensetx.com/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofShareCapitalTable_Parentheticals" roleURI="http://www.neurosensetx.com/role/ScheduleofShareCapitalTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofFairValueoftheOptionsGrantedTable" roleURI="http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofShareOptionActivityTable" roleURI="http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofRestrictedStockUnitRSUsActivityTable" roleURI="http://www.neurosensetx.com/role/ScheduleofRestrictedStockUnitRSUsActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofShareBasedExpenseRecognizedintheStatementsofOperationTable" roleURI="http://www.neurosensetx.com/role/ScheduleofShareBasedExpenseRecognizedintheStatementsofOperationTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofResearchandDevelopmentExpensesTable" roleURI="http://www.neurosensetx.com/role/ScheduleofResearchandDevelopmentExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleofFinancingIncomeExpensesNetTable" roleURI="http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleoftheCompanysNetdeferredTaxAssetsTable" roleURI="http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ScheduleoftheMovementoftheValuationAllowanceTable" roleURI="http://www.neurosensetx.com/role/ScheduleoftheMovementoftheValuationAllowanceTable"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation" roleURI="http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_OperatingLeaseDetailsScheduleofOperatingLease" roleURI="http://www.neurosensetx.com/role/OperatingLeaseDetailsScheduleofOperatingLease"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_GeneralDetails" roleURI="http://www.neurosensetx.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_SignificantAccountingPolicyDetails" roleURI="http://www.neurosensetx.com/role/SignificantAccountingPolicyDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_CashandCashEquivalentDetails" roleURI="http://www.neurosensetx.com/role/CashandCashEquivalentDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_OperatingLeaseDetails" roleURI="http://www.neurosensetx.com/role/OperatingLeaseDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_LiabilityinRespectofWarrantsDetails" roleURI="http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ShareholdersEquityDetails" roleURI="http://www.neurosensetx.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_ShareBasedPaymentDetails" roleURI="http://www.neurosensetx.com/role/ShareBasedPaymentDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_GeneralandAdministrativeExpensesDetails" roleURI="http://www.neurosensetx.com/role/GeneralandAdministrativeExpensesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_RelatedPartiesBalancesandTransactionsDetails" roleURI="http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_IncomeTaxesDetails" roleURI="http://www.neurosensetx.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="nrsn-20241231.xsd#nrsn_r_SubsequentEventsDetails" roleURI="http://www.neurosensetx.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndInvestmentsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCashAndInvestmentsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockNoParValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValuePre-fundedWarrantsExercised" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValuePre-fundedWarrantsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity" xlink:href="nrsn-20241231.xsd#nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_0" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfLiabilityInRespectToWarrants" xlink:href="nrsn-20241231.xsd#nrsn_RevaluationOfLiabilityInRespectToWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="RevaluationOfLiabilityInRespectToWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecreaseInOperatingRightOfUseAsset" xlink:href="nrsn-20241231.xsd#nrsn_DecreaseInOperatingRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="DecreaseInOperatingRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecreaseInOperatingLeaseLiability" xlink:href="nrsn-20241231.xsd#nrsn_DecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="DecreaseInOperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="RedemptionofinvestmentInShorttermDeposits" xlink:href="nrsn-20241231.xsd#nrsn_RedemptionofinvestmentInShorttermDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="RedemptionofinvestmentInShorttermDeposits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RedemptionOfinvestmentInRestrictedDepositNet" xlink:href="nrsn-20241231.xsd#nrsn_RedemptionOfinvestmentInRestrictedDepositNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="RedemptionOfinvestmentInRestrictedDepositNet" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfOtherEquity" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassificationOfWarrantsIntoEquity" xlink:href="nrsn-20241231.xsd#nrsn_ReclassificationOfWarrantsIntoEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ReclassificationOfWarrantsIntoEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BonusAccrualReclassificationToEquity" xlink:href="nrsn-20241231.xsd#nrsn_BonusAccrualReclassificationToEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="BonusAccrualReclassificationToEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoncashOrPartNoncashAcquisitionInterestReceived" xlink:href="nrsn-20241231.xsd#nrsn_NoncashOrPartNoncashAcquisitionInterestReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="NoncashOrPartNoncashAcquisitionInterestReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/General" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/SignificantAccountingPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/CashandCashEquivalent" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/OtherReceivables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/OperatingLease" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/OtherCurrentLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/LiabilityinRespectofWarrants" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="LiabilityInRespectOfWarrantsTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_LiabilityInRespectOfWarrantsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="LiabilityInRespectOfWarrantsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ShareholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ShareBasedPayment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ResearchandDevelopmentExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/GeneralandAdministrativeExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralAndAdministrativeExpensesDisclosureTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="GeneralAndAdministrativeExpensesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/FinancingIncomeExpensesNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/SegmentReporting" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShortTermDepositsPolicyTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_ShortTermDepositsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ShortTermDepositsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedDepositsPolicyTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_RestrictedDepositsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RestrictedDepositsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContractsOverOwnEquityPolicyTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_ContractsOverOwnEquityPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ContractsOverOwnEquityPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/SignificantAccountingPolicyTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/CashandCashEquivalentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/OtherReceivablesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherReceivablesNetCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/OperatingLeaseTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseDisclosureTableTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_LesseeOperatingLeaseDisclosureTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LesseeOperatingLeaseDisclosureTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/OtherCurrentLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ShareholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalUnitsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCapitalUnitsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfCapitalUnitsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ShareBasedPaymentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ResearchandDevelopmentExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/GeneralandAdministrativeExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/FinancingIncomeExpensesNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofCashAndCashEquivalentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashAndCashEquivalentAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfCashAndCashEquivalentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAndCashEquivalentAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="srt_CurrencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="currency_ILS" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_ILS"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_ILS" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_USD" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Supplies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Supplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_Supplies" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentContractReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentContractReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_GovernmentContractReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesGrossCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesGrossCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherReceivablesGrossCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePaymentsUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePaymentsUse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeasePaymentsUse" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofFinancialMeasuredatFairValueonaRecurringBasisTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialMeasuredAtFairValueOnARecurringBasisAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfFinancialMeasuredAtFairValueOnARecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LiabilityInRespectOfWarrantsMember" xlink:href="nrsn-20241231.xsd#nrsn_LiabilityInRespectOfWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="LiabilityInRespectOfWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheWarrantsAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfFairValueOfTheWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheWarrantsAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="us-gaap_SharePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleoftheMovementinWarrantLiabilityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheMovementInWarrantLiabilityAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfTheMovementInWarrantLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="LiabilityinRespectofWarrantsScheduleoftheMovementinWarrantLiabilityDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_LiabilityinRespectofWarrantsScheduleoftheMovementinWarrantLiabilityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheMovementInWarrantLiabilityAbstract" xlink:to="LiabilityinRespectofWarrantsScheduleoftheMovementinWarrantLiabilityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilityinRespectofWarrantsScheduleoftheMovementinWarrantLiabilityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="WarrantLiabilityMember" xlink:href="nrsn-20241231.xsd#nrsn_WarrantLiabilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="WarrantLiabilityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilityinRespectofWarrantsScheduleoftheMovementinWarrantLiabilityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse" xlink:href="nrsn-20241231.xsd#nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfLiabilityInRespectToWarrantsThroughEquity" xlink:href="nrsn-20241231.xsd#nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse" xlink:to="RevaluationOfLiabilityInRespectToWarrantsThroughEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfLiabilityInRespectToWarrants" xlink:href="nrsn-20241231.xsd#nrsn_RevaluationOfLiabilityInRespectToWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse" xlink:to="RevaluationOfLiabilityInRespectToWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <loc xlink:type="locator" xlink:label="RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate" xlink:href="nrsn-20241231.xsd#nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassificationOfWarrantsIntoEquity" xlink:href="nrsn-20241231.xsd#nrsn_ReclassificationOfWarrantsIntoEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ReclassificationOfWarrantsIntoEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofShareCapitalTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_CommonStockNoParValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheOptionsGrantedAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfFairValueOfTheOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheOptionsGrantedAbstract" xlink:to="ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeesAndDirectorsMember" xlink:href="nrsn-20241231.xsd#nrsn_EmployeesAndDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="EmployeesAndDirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYr+wciqhzO/TfNA0j8XAlDAX7Zs47GSe9YMpKX3MDHhrSmRPgkEK2u4ljrzwvIHfipcuE8XnwJBLDmhtLtl0Wkd3Ky+cGV3Eyy38kF0sLLqLlSwS0k9bURwWYWBfc634LCqUrXFOnmt5cVMGx9HtlaGkOgF0h8jEXpNuhYUKaCY+uhBk8nA3wEfnqV0gileaPM8GZVpEOik5keRqcHfnwDb/IfAuMyEk8nfZrG0zmWpe6TZP15grSxfDGACuJ1Ai3G0v5ANK+88w==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareOptionActivityAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfShareOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentScheduleofShareOptionActivityDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_ShareBasedPaymentScheduleofShareOptionActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareOptionActivityAbstract" xlink:to="ShareBasedPaymentScheduleofShareOptionActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentScheduleofShareOptionActivityDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentScheduleofShareOptionActivityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted" xlink:href="nrsn-20241231.xsd#nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod" xlink:href="nrsn-20241231.xsd#nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited" xlink:href="nrsn-20241231.xsd#nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited" xlink:href="nrsn-20241231.xsd#nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofRestrictedStockUnitRSUsActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRestrictedStockUnitRsuSActivityAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfRestrictedStockUnitRsuSActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentScheduleofRestrictedStockUnitRSUsActivityDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_ShareBasedPaymentScheduleofRestrictedStockUnitRSUsActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedStockUnitRsuSActivityAbstract" xlink:to="ShareBasedPaymentScheduleofRestrictedStockUnitRSUsActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentScheduleofRestrictedStockUnitRSUsActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentScheduleofRestrictedStockUnitRSUsActivityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:href="nrsn-20241231.xsd#nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofShareBasedExpenseRecognizedintheStatementsofOperationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareBasedExpenseRecognizedInTheStatementsOfOperationAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfShareBasedExpenseRecognizedInTheStatementsOfOperationAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedExpenseRecognizedInTheStatementsOfOperationAbstract" xlink:to="srt_CondensedStatementOfComprehensiveIncomeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofResearchandDevelopmentExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="SubcontractorsAndConsultants" xlink:href="nrsn-20241231.xsd#nrsn_SubcontractorsAndConsultants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="SubcontractorsAndConsultants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensation" xlink:href="nrsn-20241231.xsd#nrsn_SharebasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="SharebasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalariesAndSocialBenefits" xlink:href="nrsn-20241231.xsd#nrsn_SalariesAndSocialBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="SalariesAndSocialBenefits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralInsuranceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralInsuranceExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TravelAndEntertainmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_TravelAndEntertainmentExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancingIncomeExpensesNetAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeDisclosureNonoperatingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancingIncomeExpensesNetAbstract" xlink:to="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRates" xlink:href="nrsn-20241231.xsd#nrsn_ExchangeRates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="ExchangeRates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenseDisclosureNonoperatingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancingIncomeExpensesNetAbstract" xlink:to="us-gaap_OtherExpenseDisclosureNonoperatingAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExchangeFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExchangeFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:to="us-gaap_ExchangeFees" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:to="us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpenseDisclosureNonoperatingAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancingIncomeExpensesNetAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:href="nrsn-20241231.xsd#nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsStateTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsStateTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsStateTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsOperatingLeaseLiability" xlink:href="nrsn-20241231.xsd#nrsn_DeferredTaxAssetsOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="DeferredTaxAssetsOperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsVacationAndConvalescenceAccrual" xlink:href="nrsn-20241231.xsd#nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="DeferredTaxAssetsVacationAndConvalescenceAccrual" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ScheduleoftheMovementoftheValuationAllowanceTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems" xlink:href="nrsn-20241231.xsd#nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable" xlink:to="SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/OperatingLeaseDetailsScheduleofOperatingLease" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/GeneralDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/SignificantAccountingPolicyDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPolicyDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_SignificantAccountingPolicyDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SignificantAccountingPolicyDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPolicyDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantMember" xlink:href="nrsn-20241231.xsd#nrsn_PrefundedWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PrefundedWarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPolicyDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/CashandCashEquivalentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_InvestmentInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/OperatingLeaseDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_OperatingLeaseDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="OperatingLeaseDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseDetailsTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForRent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitialRecognitionRightofuseAssets" xlink:href="nrsn-20241231.xsd#nrsn_InitialRecognitionRightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="InitialRecognitionRightofuseAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="LiabilityinRespectofWarrantsDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_LiabilityinRespectofWarrantsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="LiabilityinRespectofWarrantsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilityinRespectofWarrantsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilityinRespectofWarrantsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilityinRespectofWarrantsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_InvestorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilityinRespectofWarrantsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOrdinaryShares" xlink:href="nrsn-20241231.xsd#nrsn_NumberOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfOrdinaryShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ReclassificationsOfTemporaryToPermanentEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_ShareholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AprilTwoThousandTwentyFourPurchaseAgrementMember" xlink:href="nrsn-20241231.xsd#nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="AprilTwoThousandTwentyFourPurchaseAgrementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SalesAgreementMember" xlink:href="nrsn-20241231.xsd#nrsn_SalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SalesAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecuritiesPurchaseAgreementMember" xlink:href="nrsn-20241231.xsd#nrsn_SecuritiesPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SecuritiesPurchaseAgreementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseAgreementMember" xlink:href="nrsn-20241231.xsd#nrsn_PurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="PurchaseAgreementMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AllianceGlobalPartnersMember" xlink:href="nrsn-20241231.xsd#nrsn_AllianceGlobalPartnersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AllianceGlobalPartnersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsMember" xlink:href="nrsn-20241231.xsd#nrsn_PrefundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PrefundedWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketOfferingCost" xlink:href="nrsn-20241231.xsd#nrsn_MarketOfferingCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="MarketOfferingCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOrdinaryShares" xlink:href="nrsn-20241231.xsd#nrsn_NumberOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfOrdinaryShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseOfferingCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoninterestExpenseOfferingCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_NoninterestExpenseOfferingCost" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RemainingFairValueAmount" xlink:href="nrsn-20241231.xsd#nrsn_RemainingFairValueAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="RemainingFairValueAmount" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllocatedAmountToOrdinaryWarrants" xlink:href="nrsn-20241231.xsd#nrsn_AllocatedAmountToOrdinaryWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="AllocatedAmountToOrdinaryWarrants" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_OtherExpenses" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoninterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoninterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_OtherNoninterestExpense" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePricePerShare" xlink:href="nrsn-20241231.xsd#nrsn_PurchasePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="PurchasePricePerShare" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfOrdinaryShareGrossProceedsPercentage" xlink:href="nrsn-20241231.xsd#nrsn_SaleOfOrdinaryShareGrossProceedsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="SaleOfOrdinaryShareGrossProceedsPercentage" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceedsFromTheOrdinaryShares" xlink:href="nrsn-20241231.xsd#nrsn_NetProceedsFromTheOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NetProceedsFromTheOrdinaryShares" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRestructuring"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_PaymentsForRestructuring" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceedsFromIssuanceOfWarrants" xlink:href="nrsn-20241231.xsd#nrsn_NetProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NetProceedsFromIssuanceOfWarrants" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/ShareBasedPaymentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_ShareBasedPaymentDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedPaymentDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="us-gaap_GranteeStatusAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandEighteenEmployeeShareOptionPlanMember" xlink:href="nrsn-20241231.xsd#nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandEighteenEmployeeShareOptionPlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyTwoBonusPlanMember" xlink:href="nrsn-20241231.xsd#nrsn_TwoThousandTwentyTwoBonusPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwentyTwoBonusPlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="srt_RangeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="us-gaap_AwardDateAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="November12024Member" xlink:href="nrsn-20241231.xsd#nrsn_November12024Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="November12024Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="October12024Member" xlink:href="nrsn-20241231.xsd#nrsn_October12024Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="October12024Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesPercentage" xlink:href="nrsn-20241231.xsd#nrsn_NumberOfSharesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="NumberOfSharesPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpirationDateGrantTerm" xlink:href="nrsn-20241231.xsd#nrsn_ExpirationDateGrantTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ExpirationDateGrantTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_OtherExpenses" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfInstallments" xlink:href="nrsn-20241231.xsd#nrsn_NumberOfInstallments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="NumberOfInstallments" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InstallmentsLockUpPeriod" xlink:href="nrsn-20241231.xsd#nrsn_InstallmentsLockUpPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="InstallmentsLockUpPeriod" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RaiseOfAdditionalBonusPercentage" xlink:href="nrsn-20241231.xsd#nrsn_RaiseOfAdditionalBonusPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="RaiseOfAdditionalBonusPercentage" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" xlink:href="nrsn-20241231.xsd#nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="26.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/GeneralandAdministrativeExpensesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionContributions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionContributions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_PensionContributions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesBalancesandTransactionsDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_RelatedPartiesBalancesandTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartiesBalancesandTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesBalancesandTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesBalancesandTransactionsDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesBalancesandTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MrAlonBenNoonsMember" xlink:href="nrsn-20241231.xsd#nrsn_MrAlonBenNoonsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="MrAlonBenNoonsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesBalancesandTransactionsDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesBalancesandTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedSalariesCurrentAndNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PotentialBonusPayable" xlink:href="nrsn-20241231.xsd#nrsn_PotentialBonusPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="PotentialBonusPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IsraelTaxAuthorityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IsraelTaxAuthorityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IsraelTaxAuthorityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.neurosensetx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="nrsn-20241231.xsd#nrsn_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ConsultantsMember" xlink:href="nrsn-20241231.xsd#nrsn_ConsultantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="ConsultantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="12.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityListingsTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="13.0"/>
    <loc xlink:type="locator" xlink:label="dei_NameChangeEventTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NameChangeEventTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_NameChangeEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="14.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesNoParValuePerShareMember" xlink:href="nrsn-20241231.xsd#nrsn_OrdinarySharesNoParValuePerShareMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="OrdinarySharesNoParValuePerShareMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercisableForOneOrdinaryShareMember" xlink:href="nrsn-20241231.xsd#nrsn_WarrantsExercisableForOneOrdinaryShareMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="WarrantsExercisableForOneOrdinaryShareMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesNoParValuePerShareMember" xlink:href="nrsn-20241231.xsd#nrsn_OrdinarySharesNoParValuePerShareMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="OrdinarySharesNoParValuePerShareMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercisableForOneOrdinaryShareMember" xlink:href="nrsn-20241231.xsd#nrsn_WarrantsExercisableForOneOrdinaryShareMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="WarrantsExercisableForOneOrdinaryShareMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorTable_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorTable_0" xlink:to="dei_EntityAddressesAddressTypeAxis" order="11.0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NeuroSense Therapeutics Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001875091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity Incorporation, Date of Incorporation</a></td>
<td class="text">Feb. 13,  2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11 HaMenofim Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building B<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Herzliya<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4672562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">23,228,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nrsn_OrdinarySharesNoParValuePerShareMember', window );">Ordinary Shares, no par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, no par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NRSN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nrsn_WarrantsExercisableForOneOrdinaryShareMember', window );">Warrants, exercisable for one ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants, exercisable for one ordinary share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NRSNW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Or Eisenberg<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11 HaMenofim Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building B<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Herzliya<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4672562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">9-7996183<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nrsn_OrdinarySharesNoParValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nrsn_OrdinarySharesNoParValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nrsn_WarrantsExercisableForOneOrdinaryShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nrsn_WarrantsExercisableForOneOrdinaryShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Somekh Chaikin<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel-Aviv, Israel<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Opinion on the Consolidated Financial Statements</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying
consolidated statements of financial position of NeuroSense Therapeutics Ltd. and its subsidiaries (the &#8220;Company&#8221;) as of December
31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, changes in equity (deficit), and cash flows
for each of the years in the three-year period ended December&#160;31, 2024, and the related notes (collectively, the &#8220;consolidated
financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in
the three-year period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalent</a></td>
<td class="nump">$ 3,378<span></span>
</td>
<td class="nump">$ 2,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">989<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Restricted deposits</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">4,402<span></span>
</td>
<td class="nump">2,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Restricted deposit</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,575<span></span>
</td>
<td class="nump">3,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">1,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">832<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,992<span></span>
</td>
<td class="nump">3,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability less current maturity</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Liability in respect of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,412<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,485<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,992<span></span>
</td>
<td class="nump">4,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, no par value: Authorized: 90,000,000 shares at December 31, 2024 and 60,000,000 shares at December 31, 2023; Issued and outstanding: 23,228,941 and 15,379,042 shares at December 31, 2024 and 2023, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Share Premium and Capital Reserve</a></td>
<td class="nump">39,243<span></span>
</td>
<td class="nump">24,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(36,660)<span></span>
</td>
<td class="num">(26,121)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity (deficit)</a></td>
<td class="nump">2,583<span></span>
</td>
<td class="num">(1,759)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 4,575<span></span>
</td>
<td class="nump">$ 3,185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">90,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">23,228,941<span></span>
</td>
<td class="nump">15,379,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">23,228,941<span></span>
</td>
<td class="nump">15,379,042<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">$ (5,698)<span></span>
</td>
<td class="num">$ (7,274)<span></span>
</td>
<td class="num">$ (5,587)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(4,204)<span></span>
</td>
<td class="num">(4,775)<span></span>
</td>
<td class="num">(4,967)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(9,902)<span></span>
</td>
<td class="num">(12,049)<span></span>
</td>
<td class="num">(10,554)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financing income (expenses), net</a></td>
<td class="num">(308)<span></span>
</td>
<td class="nump">1,942<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (10,210)<span></span>
</td>
<td class="num">$ (10,107)<span></span>
</td>
<td class="num">$ (10,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="num">$ (0.91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (0.74)<span></span>
</td>
<td class="num">$ (0.91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares used in computing basic net loss per share (in Shares)</a></td>
<td class="nump">18,602,082<span></span>
</td>
<td class="nump">13,640,168<span></span>
</td>
<td class="nump">11,504,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares used in computing diluted net loss per share (in Shares)</a></td>
<td class="nump">18,602,082<span></span>
</td>
<td class="nump">13,640,168<span></span>
</td>
<td class="nump">11,504,521<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity (deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Ordinary shares</div></th>
<th class="th"><div>Share premium and capital reserve</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 16,356<span></span>
</td>
<td class="num">$ (5,522)<span></span>
</td>
<td class="nump">$ 10,834<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">10,943,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of options</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(96)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of warrants and vested RSUs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,870<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of warrants and vested RSUs (in Shares)</a></td>
<td class="nump">838,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,728<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,492)<span></span>
</td>
<td class="num">(10,492)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21,858<span></span>
</td>
<td class="num">(16,014)<span></span>
</td>
<td class="nump">5,844<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">11,781,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet', window );">Issuance of shares and pre-funded warrants, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">806<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet', window );">Issuance of shares and pre-funded warrants, net (in Shares)</a></td>
<td class="nump">1,333,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised', window );">Exercise of pre-funded warrants, options and vested RSUs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants', window );">Exercise of pre-funded warrants, options and vested RSUs (in Shares)</a></td>
<td class="nump">2,263,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,698<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,107)<span></span>
</td>
<td class="num">(10,107)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">24,362<span></span>
</td>
<td class="num">(26,121)<span></span>
</td>
<td class="num">$ (1,759)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">15,379,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,379,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet', window );">Issuance of shares and pre-funded warrants, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,806<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet', window );">Issuance of shares and pre-funded warrants, net (in Shares)</a></td>
<td class="nump">5,981,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised', window );">Exercise of pre-funded warrants, options and vested RSUs</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants', window );">Exercise of pre-funded warrants, options and vested RSUs (in Shares)</a></td>
<td class="nump">1,573,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement', window );">Issuance of shares due to SEPA agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement', window );">Issuance of shares due to SEPA agreement (in Shares)</a></td>
<td class="nump">224,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Reclassification of warrants into equity</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,695<span></span>
</td>
<td class="num">(329)<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity', window );">Bonus accrual reclassification to equity</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,434<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">665<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in Shares)</a></td>
<td class="nump">70,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,210)<span></span>
</td>
<td class="num">(10,210)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 39,243<span></span>
</td>
<td class="num">$ (36,660)<span></span>
</td>
<td class="nump">$ 2,583<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="nump">23,228,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,228,941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the shares of issuance of shares and pre-funded warrants, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the shares issuance of shares due to SEPA agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the number of shares exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of bonus accrual reclassification to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of issuance of shares and prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of issuance of shares due to SEPA agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of exercise of pre-funded warrants, options and vested RSUs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the year</a></td>
<td class="num">$ (10,210)<span></span>
</td>
<td class="num">$ (10,107)<span></span>
</td>
<td class="num">$ (10,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">1,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_RevaluationOfLiabilityInRespectToWarrants', window );">Revaluation of liability in respect to warrants</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(2,191)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Financing expenses, net</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">473<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_DecreaseInOperatingRightOfUseAsset', window );">Decrease in operating right of use asset</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_DecreaseInOperatingLeaseLiability', window );">Decrease in operating lease liability</a></td>
<td class="num">(69)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Decrease (increase) in other current assets</a></td>
<td class="num">(753)<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Increase (decrease) in trade payables</a></td>
<td class="num">(299)<span></span>
</td>
<td class="nump">961<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Increase in other payables</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">928<span></span>
</td>
<td class="nump">606<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(10,135)<span></span>
</td>
<td class="num">(8,354)<span></span>
</td>
<td class="num">(7,616)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_RedemptionofinvestmentInShorttermDeposits', window );">Redemption of (investment in) short-term deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="num">(3,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_RedemptionOfinvestmentInRestrictedDepositNet', window );">Redemption of (investment in) restricted deposit, net</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3,468<span></span>
</td>
<td class="num">(3,590)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfOtherEquity', window );">Payment in respect of cancellation of options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(96)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of warrants and options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">3,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Issuance of shares, warrants and pre-funded warrants, net</a></td>
<td class="nump">11,304<span></span>
</td>
<td class="nump">4,334<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs</a></td>
<td class="num">(391)<span></span>
</td>
<td class="num">(364)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">10,913<span></span>
</td>
<td class="nump">3,975<span></span>
</td>
<td class="nump">3,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effects of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(41)<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">738<span></span>
</td>
<td class="num">(903)<span></span>
</td>
<td class="num">(7,520)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents as at the beginning of the year</a></td>
<td class="nump">2,640<span></span>
</td>
<td class="nump">3,543<span></span>
</td>
<td class="nump">11,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents as of the end of the year</a></td>
<td class="nump">3,378<span></span>
</td>
<td class="nump">2,640<span></span>
</td>
<td class="nump">3,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_ReclassificationOfWarrantsIntoEquity', window );">Reclassification of warrants into equity</a></td>
<td class="nump">1,366<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_BonusAccrualReclassificationToEquity', window );">Bonus accrual reclassification to equity (See Note 14)</a></td>
<td class="nump">1,434<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Recognition of right of use assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_NoncashOrPartNoncashAcquisitionInterestReceived', window );">Interest received</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_BonusAccrualReclassificationToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of bonus accrual reclassification to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_BonusAccrualReclassificationToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_DecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of decrease in operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_DecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_DecreaseInOperatingRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in operating right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_DecreaseInOperatingRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_NoncashOrPartNoncashAcquisitionInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent then interest received "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_NoncashOrPartNoncashAcquisitionInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_ReclassificationOfWarrantsIntoEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of reclassification of warrants into equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_ReclassificationOfWarrantsIntoEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_RedemptionOfinvestmentInRestrictedDepositNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the redemption of investment in restricted deposit, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_RedemptionOfinvestmentInRestrictedDepositNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_RedemptionofinvestmentInShorttermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of redemption of (investment in) short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_RedemptionofinvestmentInShorttermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_RevaluationOfLiabilityInRespectToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revaluation of liability in respect to warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_RevaluationOfLiabilityInRespectToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from change in exchange rate. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalents include, but are not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to reacquire equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">General</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1 - General</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroSense Therapeutics Ltd. (&#8220;NeuroSense&#8221; or the &#8220;Company&#8221;) was incorporated in Israel on February 13, 2017. NeuroSense is a clinical-stage pharmaceutical company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. The Company&#8217;s lead product candidate, PrimeC, is a novel oral formulation of a fixed dose combination composed of a specific ratio and doses of two FDA-approved drugs.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In addition to PrimeC, the Company
has initiated research and development efforts in Alzheimer&#8217;s disease and Parkinson&#8217;s disease, with a similar strategy of
combined products.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s ordinary shares
and warrants began trading on the Nasdaq Capital Market on&#160;December 9, 2021&#160;under the ticker symbols &#8220;NRSN&#8221; and
&#8220;NRSNW,&#8221; respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently has no products approved for sale and the Company&#8217;s operations have been funded primarily by its shareholders. To date, the Company has generated no sales or revenues, has incurred losses and expects to incur significant additional losses due to the continuing focus on the research, development, clinical activities of its product candidates, preclinical programs, business development, organizational structure and to advance the programs within the Company&#8217;s pipeline. Consequently, its operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in the research and development of pharmaceutical compounds. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Based on current expected level of
operating expenditures, the Company&#8217;s cash resources as at December 31, 2024 shall not be sufficient to fund the Company&#8217;s
operations for a period of at least 12 months from the approval of these consolidated financial statements, assuming that the Company
will continue its development plan in accordance with the original pipeline and without delaying or slowing down the progress of its plans.
The Company will require additional cash to fund the execution of its mid and long-term development program. The Company anticipates raising
additional funds through public or private sales of debt or equity securities, collaborative arrangements, or some combination thereof.
Whilst management is progressing with its plans to secure external financing, these still require approval by third parties, and accordingly,
there is no assurance that any such arrangement will be entered into or that financing will be available when needed in order to allow
it to continue its operations, or if available, on terms favorable or acceptable to it.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
the event financing is not obtained, the Company may pursue cost cutting measures or may be required to delay, reduce the scope of,
or eliminate any of its development programs or clinical trials, these events could have a material adverse effect on its business.
These factors&#160;raise substantial doubt&#160;about the Company ability to continue as a going concern. The consolidated financial
statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and
classification of liabilities that might be necessary should the Company be unable to continue as a going concern. </span>The
going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of
business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 3, 2022, the Company established a US based subsidiary, NeuroSense US Inc. (&#8220;US Subsidiary&#8221;). From establishment through December 31, 2024, the US Subsidiary had no activity. The U.S. subsidiary was formed to perform research and development activity and engage in possible collaboration agreements. On July, 2023, the Company established a German based subsidiary, NeuroSense GmbH (&#8220;NeuroSense GmbH &#8220;). NeuroSense GmbH was formed to perform research and development activity and engage in possible collaboration agreements. From establishment through December 31, 2024, NeuroSense GmbH had no material activity.</span></td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Following the attack, Israel&#8217;s security cabinet declared war against Hamas and commenced a military campaign against Hamas. In addition, since the commencement of these events, there have been continued hostilities along Israel&#8217;s northern border with Lebanon (with the Hezbollah terror organization), Israel&#8217;s southern border with the Gaza Strip (with the Hamas terrorist organization) and on other fronts from various extremist groups in region, such as the Houthis in Yemen and various rebel militia groups in Syria and Iraq. Further, on April 13, 2024, and on October 1, 2024, Iran launched a series of drone and missile strikes against Israel. As of December 31, 2024 a ceasefire agreement has been reached between Israel the Hezbollah terror organization in Lebanon. To date the Company&#8217;s operations and financial results have not been materially affected. Since the war broke out in October 2023, the Company&#8217;s operations have not been adversely affected by this situation, and it has not experienced disruptions to its clinical studies. As such, its clinical and business development activities remain on track. However, the intensity and duration of Israel&#8217;s current war against Hamas and Hezbollah is difficult to predict at this stage, as are such war&#8217;s economic implications on its business and operations and on Israel&#8217;s economy in general. If the ceasefire declared collapses or a new war commences or hostilities expand to other fronts, its operations may be adversely affected.</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policy<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policy [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policy</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 2 - Significant Accounting Policy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of presentation</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
consolidated financial statements have been prepared in accordance accounting principles generally accepted in the United States of America
(&#8220;US GAAP&#8221;)</span> assuming the Company will continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates in preparation of consolidated financial statements</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts
reported in the consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including
those related to fair value of financial instruments and share based compensation. The Company&#8217;s management believes that the estimates,
judgment, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and
assumptions can affect the reported amounts of assets and liabilities and disclosure of liabilities at the dates of the consolidated financial
statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Functional currency</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The functional currency of the Company and its subsidiaries, all of which are primarily direct and integral component of the Company&#8217;s
operation, is the U.S. dollar (&#8220;$&#8221; or &#8220;dollar&#8221;), as the dollar is primary currency of the economic environment
in which the Company and its subsidiaries have operated and expects to continue to operate in foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In accordance with ASC 830, &#8220;Foreign
Currency Matters&#8221;, balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing
at the applicable balance sheet date. For foreign currency transactions included in the consolidated statement of operations and comprehensive
loss, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates
used in the translation of such transactions are presented within financing income or expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principles of Consolidation</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The consolidated financial statements
include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated upon
consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash and cash equivalents</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Cash and cash equivalents include highly
liquid investments, including short-term bank deposits (with original maturity dates of up to three months from date of deposit) that
are not restricted as to withdrawal or use.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Short-term deposits</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Short-term deposits in banking institutions
for periods in excess of three months following the date of deposit. The deposits are presented in accordance with the terms of their
deposit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restricted deposits</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Restricted deposits consist of deposits
held in restricted deposit bank accounts including deposits held as collateral for guarantees to third parties, classified as current
or non-current based on expected timing of the disbursement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property and equipment</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets. When an asset is disposed of, the related cost and accumulated depreciation are removed from the respective accounts and the net
difference less any amount realized from disposition is reflected in the consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s long-lived assets are
reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment&#8221;, whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.
To date, the Company has not incurred any impairment losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The lives used in computing straight-line
depreciation for financial reporting purposes are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="width: 80%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and peripherals and equipment</span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office furniture and equipment</span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7 - 15</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-55">The shorter of the lease term and the useful life</span></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research and Development</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Research and development costs are
expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurements</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company measures and discloses
fair value in accordance with the ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; which defines fair value, establishes
a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements.
Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined
based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions
there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 1 - unadjusted quoted prices
are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 2 - pricing inputs are other
than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 3 - pricing inputs are unobservable
for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability
at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Level
3 inputs are considered as the lowest priority within the fair value hierarchy. The valuation of certain financial instruments classified
under fair value through profit or loss category falls under this category.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">This hierarchy requires the Company
to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of the reported periods, the fair
values of the Company&#8217;s cash, cash equivalents, short-term bank deposits, current and non-current restricted deposits, other current
assets, trade payables and other current liabilities approximated the carrying values of these instruments presented in the Company&#8217;s
consolidated balance sheets because of their nature.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>K.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations of credit risk</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Financial instruments that potentially
subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents as well as certain other current assets
that do not amount to a significant amount. Cash and cash equivalents, which are primarily held in dollar and New Israeli Shekels (NIS),
are deposited with major bank in Israel. Management believes that such financial institutions are financially sound and, accordingly,
minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration
of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>L.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company entered into non-cancelable
lease agreements for offices for use in its operations, which are classified as operating leases (see below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company applies ASC 842, &#8220;Leases&#8221;
under which the Company determines if an arrangement is a lease at inception. The Company&#8217;s assessment is based on: (i) whether
the contract involves the use of an identified asset, (ii) whether the Company obtains the right to substantially all of the economic
benefits from the use of the asset throughout the period of use, and (iii) whether the Company has the right to direct the use of the
asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Leases are classified as either finance
leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers
ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain
to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset, (iv) the present value of the lease
payments equals or exceeds substantially all of the fair value of the asset, or (v) the underlying asset is of such a specialized nature
that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if
it does not meet any one of these criteria. Since all the Company&#8217;s lease contracts for premises do not meet any of the criteria
above, the Company concluded that all its lease contracts should be classified as operating leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Right of Use (&#8220;ROU&#8221;) assets
and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For
this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company&#8217;s
leases do not provide an implicit rate, the Company uses its Incremental Borrowing Rate (&#8220;IBR&#8221;) based on the information available
on the commencement date in determining the present value of lease payments. The Company&#8217;s IBR is estimated to approximate the interest
rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The
ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover,
the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease
had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, &#8220;Property, Plant, and Equipment
- Overall&#8221;, to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases
include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset
and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless
it is reasonably certain that the Company will not exercise the option.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>M.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commitment and contingencies</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies under which a provision is recorded when it is both probable that liability has
been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted
to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events
pertaining to a particular matter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N.</b></span></td> <td style="padding-bottom: 6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employee benefit plans </b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s liability for severance
pay to its Israeli employees is subject to Section 14 of the Israeli Severance Compensation Act, 1963 (&#8220;Section 14&#8221;), pursuant
to which all of the Company&#8217;s employees are entitled to monthly deposits by the Company, at a rate of 8.33% of their monthly salary,
made in the employee&#8217;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release
the Company from any future severance payments in respect of those employees. The fund is made available to the employee at the time the
employer-employee relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section
14 are not reflected in the balance sheets as the severance pay risks have been irrevocably transferred to the severance funds. All deposits
required through December 31, 2024 have been made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>O.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income taxes</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company accounts for income taxes
in accordance with ASC 740, &#8220;Income Taxes&#8221;. Accordingly, deferred income taxes are determined utilizing the asset and liability
method based on the estimated future tax effects of differences between the financial statement carrying amount and the tax bases of assets
and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax rates expected to be in effect
when these differences reverse. A valuation allowance in respect of deferred tax assets is provided for, if necessary, to reduce deferred
tax assets to the amounts more likely than not to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company implements a&#160;two-step&#160;approach
to recognize and measure tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by
determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits,
the tax position will be sustained on examination, including resolution of any related appeals or litigation processes. The second step
is to measure the tax benefit as the largest amount that is greater than&#160;50% likely to be realized upon settlement. The Company&#8217;s
accounting policy is to classify interest and penalties relating to income taxes under income taxes, however the Company did not recognize
such items in its consolidated financial statements during the reported periods and did not recognize any liability with respect to an
unrecognized tax benefits in its balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.9pt; ">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>P.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based compensation</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s employees&#8217;
and directors&#8217; share-based payment awards are classified as equity awards. The Company accounts for these awards using the grant-date
fair value method. For employees, the fair value of share-based payment transactions is recognized as an expense over the requisite service
period for each separately vesting tranche of the award as if the award is, in-substance, multiple awards. Forfeitures are recognized
as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">For nonemployees, compensation costs
are recognized in the same period and in the same manner the Company would if it had paid cash for those goods or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basic and diluted net loss per share</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Basic net loss per share is computed
using the weighted average number of ordinary shares, pre-funded warrants to purchase ordinary shares for an exercise price of $0.0001&#160;which
are exercisable immediately and fully vested restricted share units (RSUs) outstanding during the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Diluted loss per share gives effect
to all potentially dilutive common shares outstanding during the year using the treasury stock method with respect to options and non-vested
RSUs granted under employee stock compensation plan and certain warrants granted through its Initial Public Offering (IPO) and using the
if-converted method with respect to certain warrants granted through registered direct offering and accounted for as derivative liability.
In computing diluted loss per share, the average share price for the period is used in determining the number of shares assumed to be
purchased from the exercise of share options or warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the reported periods, all outstanding
share options, warrants and non-vested RSUs have been excluded from the calculation of the diluted net loss per share as all such securities
are anti-dilutive for all years presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>R.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segment</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s chief operating
decision maker (&#8220;CODM&#8221;) is its Chief Executive Officer. The CODM reviews financial information on an aggregate basis for the
purposes of evaluating financial performance and allocating the Company&#8217;s resources. Accordingly, the Company has determined that
it operates in one segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>S.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share capital</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Ordinary shares are classified as equity.
Incremental costs directly attributable to the issuance of the shares are recognized as a deduction from equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><b>T.</b></td><td style="text-align: justify"><b>Contracts over own equity</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">When the Company becomes party to freestanding
financial instruments, the Company first analyzes the provisions of ASC&#160;480 in order to determine whether the instrument should be
classified as a liability, with subsequent changes in fair value recognized in the statements of operations in each period. Warrants to
purchase ordinary shares are not within the scope of ASC&#160;480, and as such the Company further analyzes the provisions of ASC&#160;815-40&#160;in
order to determine whether the contract should be classified within equity or classified as a liability, with subsequent changes in fair
value recognized in the statements of operations in each period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company reassesses the classification
of a contract over its own equity under the guidance above at each balance sheet date. If classification changes as a result of events
during the reporting period, the Company reclassifies the contract as of the date of the event that caused the reclassification. When
a contract over own equity is reclassified from a liability to equity, gains or losses recorded to account for the contract at fair value
during the period that the contract was classified as a liability are not reversed, and the contract is marked to fair value immediately
before the reclassification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
adopted accounting pronouncements</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>1.</b></td><td style="text-align: justify">In&#160;August 2020,&#160;the FASB issued ASU&#160;2020-06&#160;&#8220;Debt-
Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging- Contracts in Entity&#8217;s Own Equity (Subtopic&#160;815-40)
(&#8220;ASU&#160;2020-06&#8221;): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221;. This guidance
simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments
and contracts on an entity&#8217;s own equity. Furthermore, ASU&#160;2020-06&#160;requires the application of the if-converted method
for calculating diluted earnings per share. ASU 2020-06 is effective for the Company for annual periods beginning after December 15,
2023,&#160;and interim periods within those fiscal years. The Company adopted this guidance on January 1, 2024, and there was no material
impact on the Company&#8217;s consolidated balance sheet and the consolidated statements of operations and comprehensive loss upon adoption.</td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>2.</b></td><td style="text-align: justify">In November 2023, the FASB issued ASU 2023-07 &#8220;Segment
Reporting: Improvements to Reportable Segment Disclosures&#8221; which expands public entities&#8217; segment disclosures primarily by
requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within
each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures
of a reportable segment&#8217;s profit or loss and assets. Public entities with a single reportable segment are required to provide the
new disclosures and all the disclosures required under ASC 280.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The guidance is effective for the Company&#8217;s
annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company
has adopted this standard for the fiscal year 2024 annual financial statements and interim financial statements thereafter and has applied
this standard retrospectively for all prior periods presented in the financial statements. See&#160;Note 15 &#8211; Segment Reporting&#160;for
further information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>V.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently issued accounting pronouncements, not yet adopted</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As an emerging growth company, the
Jumpstart Our Business Startup Act (&#8220;JOBS Act&#8221;) allows the Company to delay adoption of new or revised accounting pronouncements
applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this
extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">1.</td><td style="text-align: justify">In December 2023, the FASB issued ASU 2023-09 &#8220;Improvements to Income Tax Disclosures&#8221; which
improves the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in
the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain amendments to improve income
tax disclosures effectiveness. The guidance is effective for the Company&#8217;s annual periods beginning January 1, 2026, with early
adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on the consolidated financial
statement disclosures.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">2.</td><td style="text-align: justify">In November 2024, the FASB issued ASU No. 2024-03 Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense
Disaggregation Disclosures (Subtopic 220-40). The ASU improves the disclosures about a public business entity&#8217;s expenses and provides
more detailed information about the types of expenses in commonly presented expense captions. The amendments require that at each interim
and annual reporting period an entity will, inter alia, disclose amounts of purchases of inventory, employee compensation, depreciation
and amortization included in each relevant expense caption (such as cost of sales, SG&amp;A and research and development). The ASU is
effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027.
Early adoption is permitted. The Company is currently evaluating this ASU to determine its impact on the Company&#8217;s disclosures.</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalent<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and cash equivalent</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 3 - Cash and cash equivalent </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars<br/> in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Denominated in NIS</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,057</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">107</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Denominated in USD</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">321</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">*2,533</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,378</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,640</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Including short term bank deposit for a period of 1-2 months
at an interest rate of 5%.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrentAbstract', window );"><strong>Other Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Other receivables</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4 - Other receivables</b></p>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars<br/> in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Advance to suppliers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;738</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Government agencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">104</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">137</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">989</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">236</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310-10/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 5 - Property and equipment, net</b></p>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Balance as of December 31, 2024:</p>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers<br/> and<br/> peripherals<br/> and <br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Office<br/> furniture <br/> and<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cost:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance at January 1, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;28</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">123</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Purchases during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">95</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">126</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif; font-size: 10pt">(*</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif; font-size: 10pt">(*</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif; font-size: 10pt">(*</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">Depreciated cost at December&#160;31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">41</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">22</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">66</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Balance as of December 31, 2023:</p>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers<br/> and<br/> peripherals<br/> and <br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Office<br/> furniture <br/> and<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cost:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;66</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">94</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Purchases during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">92</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">123</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif; font-size: 10pt">(*</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif; font-size: 10pt">(*</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">Depreciated cost at December&#160;31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">58</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">24</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">85</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
than $1 thousand.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating lease</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 6 - Operating lease</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The Company has lease agreements with respect
to offices. In December 2021, the Company entered into an office space lease agreement (which commenced on January 1, 2022). Monthly rent
payments including utilities amount to approximately $7 thousand and indexed to Israeli consumer price index. The lease period is for
24 months with an option to extend the lease period for additional two periods of 24 months each (the first one was exercised by the Company).
Accordingly, the Company recognized in the consolidated balance sheet a right-of-use asset in the amount of $306 thousand concurrently
with the recognition of a lease liability in the same amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><span style="text-decoration:underline">Operating lease</span>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars<br/> in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Operating right of use asset</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;84</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-sec-ix-hidden: hidden-fact-67">Current operating lease liability</span></td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-Current operating lease liability</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-68">-</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total operating lease liability</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><span style="text-decoration:underline">Maturity analysis of the Company&#8217;s lease liability</span>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S. dollars<br/>
in thousands</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less than one year</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two years</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating lease payments</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: imputed interest</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)<b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of lease liability</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><span style="text-decoration:underline">Additional information on lease</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The following is a summary of weighted average
remaining lease terms and discount rate for Company&#8217;s leases:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Lease term (years)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>Weighted average discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Presented hereunder are the lease payments the
Company paid in the year ended December 31, 2024, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Lease payments</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;75</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;75</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;79</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">75</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">75</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">79</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Current Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 7 - Other Current Liabilities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars<br/> in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Employees and payroll accruals (*)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">498</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,481</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Short term lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">261</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">450</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">832</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">see Note 14 regarding waiver signed of bonus accrual.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability in Respect of Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Liability In Respect of Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_LiabilityInRespectOfWarrantsTextBlock', window );">Liability in respect of warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 8 - Liability in respect of warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">On June 22, 2023, the Company entered
into a registered direct offering under which, the Company issued to an institutional investor 3,000,000 warrants, each representing the
right to acquire one ordinary share at an exercise price of $1.50 and expiring on the fifth anniversary of the original issuance date.
Due to the warrants&#8217; terms, with respect to the fundamental transaction provisions, the warrants were accounted as a financial liability
measured at fair-value through profit and losses until their expiration or exercise.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">On June 26, 2024, the Company and the
institutional investor entered into an amendment to the warrant which included revisions to the fundamental transactions provision and
the extension of the termination date from June 26, 2028 to October 12, 2029. The Company concluded that the amended warrants meet equity
classification criteria and thus the warrants should be accounted as equity from the date of amendment. As a result, on June 26, 2024
the Company reclassified the warrant liability into equity according to its fair value for the same date in the amount of $1.366 million.
Revaluation income in the amount of $46 thousands until June 26, 2024 was recorded within the Company&#8217;s finance expanse and the effect
of the amendment was recorded in the Company&#8217;s equity in the amount of 329 thousands.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The Company&#8217;s financial measured
at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars<br/> in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Liability in respect of warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,412</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,412</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">As of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The fair value of the warrants, as
of it&#8217;s the date of reclassification to equity, was determined by the management using the assistance of external appraiser and
by using the Black-Scholes option pricing model and the following inputs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June&#160;26,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Financial liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86.56-92.52</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%">Share price (in $)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.85</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.44-4.40</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected life (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.98-5.30</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">As of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The fair value of the warrants was determined by the management using the assistance of external appraiser and by using Black-Scholes option pricing model and the following inputs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Financial liabilities:</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Expected volatility (%)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">93.91</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>Share price (in $)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.785</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.90</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected life (years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4.47</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="text-align: left">&#160;</td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The following table summarizes the movement in warrant liability during
the year ended December 31, 2023 and December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars<br/> in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Balance as at January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left">Recognition of liability in respect to warrants at the initial date</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,603</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Revaluation of liability in respect to warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,191</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Balance as at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,412</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Revaluation of liability in respect to warrants through finance expanse</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(46</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Revaluation of liability in respect to warrants through equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">329</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Reclassification of warrants into equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,695</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 2.5pt">Balance as at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_LiabilityInRespectOfWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liability in respect of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_LiabilityInRespectOfWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Shareholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders&#8217; Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 9 - Shareholders&#8217; Equity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share capital</b></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares<br/> December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/> outstanding 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/> outstanding 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 2.5pt"><div style="-sec-ix-hidden: hidden-fact-78"><div style="-sec-ix-hidden: hidden-fact-79">Ordinary shares of <span style="-sec-ix-hidden: hidden-fact-76"><span style="-sec-ix-hidden: hidden-fact-77">no</span></span> par value</div></div></td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">90,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">23,228,941</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">60,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">15,379,042</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022, the Company received an amount of $3,870 thousand as a result of the exercise of 645,000 warrants at a price per share of
$6.00.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April&#160;14, 2023, the Company entered into a sales agreement with Alliance Global Partners, pursuant to which the Company may offer
and sell, from time to time, to or through the Alliance Global Partners as agent or principal, ordinary shares an at-the-market&#160;offering,
having an aggregate offering price of up to $5,744 thousands. On June&#160;22, 2023, the Company filed a prospectus supplement reflecting
a reduction in the size of the at-the-market&#160;offering to $502 thousand. During the reporting period, the Company sold 3,600 ordinary
shares for gross proceeds of $7 thousand through the at-the-market&#160;offering. Issuance expenses were equal to the proceeds received.</span></td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 22, 2023, the Company&#160;entered
into a securities purchase agreement pursuant to which the Company agreed to issue and sell, in a registered direct offering: (i) an
aggregate of 1,330,000 ordinary shares, no par value, and (ii) an aggregate of 1,670,000 pre-funded warrants, each representing the right
to acquire one ordinary share with exercise price of $0.0001, exercisable at any time until exercised in full and (iii) an aggregate
of 3,000,000 warrants. The warrants are exercisable immediately upon issuance at an exercise price of $1.50 per ordinary share and will
expire on the fifth anniversary of the original issuance date. The gross proceeds were approximately $4.5 million before deducting the
placement agent fee and related offering expenses of $455 thousand. The warrant instrument is classified as a liability with an original
fair value in the amount of $3,603 thousand and the remaining amount of $897 thousand was attributed to the ordinary shares and pre-funded
warrants and recognized in equity. The direct incremental issuance costs, amounting to $454 thousand, have been allocated in the same
proportion as the gross proceeds. An amount of $365 thousands was allocated to the ordinary warrants and carried directly to profit or
loss as finance expense and an amount of $91 thousands was allocated to the ordinary shares and the pre-funded warrants and recognized
as a reduction of equity. See also Note 8 regarding the agreement amendment signed on June 26, 2024 and the resulting reclassification
of the warrant liability into equity.</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 23, 2023, one of the Company&#8217;s employees exercised 126,000 options into 126,000 ordinary shares for a total consideration of $5 thousands.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
October 2023, 1,670,000 pre-funded warrants were exercised into 1,670,000 ordinary shares of the Company. See also Note 9(a)(c) above.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 10, 2024, the Company&#160;entered into a securities purchase agreement (the &#8220;April 2024 Purchase Agreement&#8221;) with an institutional investor (the &#8220;April 2024 Purchaser&#8221;), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the April 2024 Purchaser (i) an aggregate of 1,732,000 ordinary shares,; (ii) an aggregate of 1,248,000 pre-funded warrants, each representing the right to acquire one ordinary share at an exercise price of $0.0001 (either physically or on a net-cash basis at the April 2024 Purchaser&#8217;s discretion), exercisable at any time upon their issuance until exercised in full and (iii) an aggregate of 2,980,000 warrants, each representing the right to acquire one ordinary share at an exercise price of $1.50 (either physically or on a net-cash basis at the April 2024 Purchaser&#8217;s discretion) and will expire on the fifth anniversary of the original issuance date. The gross proceeds were approximately $4.47 million. As part of the April 2024 Purchase Agreement, the Company also issued 70,964 ordinary shares valued at 0.1 million as issuance expenses to the placement agent in the registered direct offering. Total issuance expenses in cash amounted to $0.153 million. All consideration in this issuance was classified to equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 26, 2024, the Company and the April 2024 Purchaser reached an agreement to amend the terms of the warrants to extend the termination date from April 15, 2029, to October 12, 2029. The impact on the financial statements is immaterial.</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 27, 2024, the Company&#8217;s shareholders approved an amendment to the Company&#8217;s articles of association to increase the
registered share capital of the Company by an additional 30,000,000 ordinary shares, such that the total registered share capital of
the Company would consist of 90,000,000 ordinary shares, no par value per share.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 6, 2024, the Company entered into a securities purchase agreement with certain investors, which include members of the Company&#8217;s senior management and existing investors. The Company agreed to sell an aggregate of 800,000 ordinary shares and warrants to purchase an aggregate of 800,000 ordinary shares, at a combined purchase price of $0.75 per share and accompanying warrant. All consideration in this issuance was classified to equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each warrant was immediately exercisable upon issuance and has a five-year term from the issuance date. The exercise price of each warrant is $0.75 per share, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if at the time of exercise thereof there is no effective registration statement registering the ordinary shares underlying the warrants. The gross proceeds were approximately $0.6 million. Total issuance expenses in cash amounted to $0.015 million.</p></td></tr> </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 16, 2024, the Company entered into
a Capital on Demand Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as sales agent
(the &#8220;Sales Agent&#8221;), pursuant to which the Company may offer and sell, from time to time, to or through the Sales Agent,
ordinary shares, having an aggregate offering price of up to gross sale proceeds of up to $2,524 thousand. The Company agreed to pay
the Sales Agent a commission equal to 3.0% of the gross proceeds from the sale of the ordinary shares pursuant to the Sales Agreement.
The Company has also agreed to reimburse the Sales Agent for certain specified expenses in connection with entering into the Sales Agreement
in the amount of up to $50 thousand. As of December 31, 2024, the Company sold 1,105,509 ordinary shares for aggregate gross proceeds
of $1,234 thousand (net proceeds of $1,067 thousand) under the Sales Agreement.</p></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2024, the Company issued 1,248,000 and 325,000 ordinary shares following exercise of pre-funded warrants
from the Purchase Agreement (see Note 9f) and vested RSU&#8217;s, respectively.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 31, 2024,&#160;the &#8220;Company entered into a standby equity purchase agreement (the &#8220;SEPA&#8221;) with&#160;YA II PN, LTD., a Cayman Islands exempt limited partnership (&#8220;Yorkville&#8221;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the SEPA, the Company has the
right, but not the obligation, to sell to Yorkville from time to time (each such occurrence, an &#8220;Advance&#8221;) up to $30.0 million
(the &#8220;Commitment Amount&#8221;) of the Company&#8217;s ordinary shares,&#160;during the 36 months following the execution of the&#160;SEPA,
subject to the restrictions and satisfaction of the conditions in the SEPA. At the Company&#8217;s option, the ordinary shares would
be purchased by Yorkville from time to time at a price equal to 97% of the lowest of the three daily VWAPs (as hereinafter defined) during
a three consecutive trading day period commencing on the date that the Company, subject to certain limitations, delivers a notice to
Yorkville that the Company is committing Yorkville to purchase such ordinary shares (the &#8220;Advance Shares&#8221;).&#160;The Company
may also specify a certain minimum acceptable price per share in each Advance.&#160;&#8220;VWAP&#8221; means, for any trading day, the
daily volume weighted average price of the Company&#8217;s ordinary shares for such trading day on the Nasdaq Stock Market during regular
trading hours as reported by Bloomberg L.P. As consideration for Yorkville&#8217;s irrevocable commitment to purchase the Company&#8217;s
ordinary shares up to the Commitment Amount, the Company agreed to issue 224,697 ordinary shares valued at $281 thousand to Yorkville
and also paid a $25,000 structuring fee to Yorkville. The fee and shares fair value were recognized as finance expenses.</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 2, 2024, the Company&#160;entered
into a securities purchase agreement with a single investor the Company&#8217;s chief executive officer (together, the &#8220;December
2024 Purchasers&#8221;) in a private placement. The Company issued to the December 2024 Purchasers (i) an aggregate of 2,343,729 ordinary
shares, (ii) an aggregate of 1,656,271 pre-funded warrants, each representing the right to acquire one ordinary share, and (iii) an aggregate
of 8,000,000 ordinary warrants, each representing the right to acquire one ordinary share for total gross proceeds to the Company of
$5 million (net proceeds of $4.94 million). The ordinary warrants are exercisable immediately upon issuance at an exercise price of $1.25
per share and expire five years from the date of issuance. The pre-funded warrants are exercisable immediately upon issuance at an exercise
price of $0.0001 per share and may be exercised at any time until the pre-funded warrants are exercised in full. All consideration in
this issuance was classified to equity.</p></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary Shares Right</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Each ordinary share is entitled to one vote. The
holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the board
of directors, subject to the prior rights of holders of all classes of shares outstanding.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share Based Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share Based Payment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 10 - Share Based Payment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">On December 16, 2018, the Company&#8217;s board
of directors approved an employee share option plan (&#8220;ESOP&#8221;). According to the provisions of the ESOP, the exercise period,
exercise price and vesting conditions for each option grant will be determined by the board of directors. The number of shares reserved
for issuance is subject to an annual increase to be added as of the first day of the Company&#8217;s fiscal year, equal to 4% of the total
number of shares issued and outstanding on a fully-diluted basis as of the end of the immediately preceding fiscal year (or such lesser
number of shares, including no shares, determined by the Board in its sole discretion). Ordinary shares subject to options granted under
the 2018 Plan that expire or forfeited or otherwise terminated without having been exercised in full will become available again for future
grant under the 2018 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The expiration date of the options granted to
employees and directors is after 10 years from the grant date. Relating to options granted to services providers, the expiration date
of the options is between 3-10 years from the grant date. In addition, pursuant to the grant letters, the options granted to employees,
directors and service providers shall become vested and exercisable upon any merger or consolidation in which the Company is a constituent
party as described in the grant letters (&#8220;Exit Event&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">On October&#160;31, 2021, the Company&#8217;s
board of directors approved an amendment to the Company&#8217;s 2018 Employee Share Option Plan. The amendment determines that the total
number of underlying shares reserved for future issuance under the plan and any modification thereof, shall be:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">900,000
shares, plus</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
annual increase to be added as of the first&#160;day of the Company&#8217;s fiscal year, beginning in 2022 and occurring each year thereafter
through 2032, equal to 4% of the total number of ordinary shares issued and outstanding on a fully-diluted basis as of the end of the
Company&#8217;s immediately preceding fiscal year (or such lesser number of shares, including no shares, determined by the board of directors
in its sole discretion).</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Following this amendment, the number of shares
reserved under this plan was 1,151,130. As of December 31, 2024, 688,705 ordinary shares are available for future grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10 and January 11, 2022, the Company&#8217;s entered into option settlement agreement (&#8220;Agreements&#8221;) with certain
consultants of the Company. According to the Agreements, the Company exchanged 27,000 options granted to certain consultants with cash
payments in the aggregate of $96 thousand. The cash payment is deemed as the sole and complete settlement of the promised options. The
Company recorded an additional expense of $23 thousand for such settlement which was recorded in profit and loss. The Company recorded
the settlement agreement as a reduction in share premium and capital reserve.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 25, 2022 and March 10, 2022, the Company&#8217;s board of directors and shareholders, respectively, approved the compensation
of each of the Company&#8217;s external directors and a newly appointed director. Such compensation included the grant of 72,000 options
to each such director at an exercise price of $1.43 per share (total 216,000 options to three directors), pursuant to the Company&#8217;s
2018 Employee Share Option Plan. One-third of each option award vests one year from the grant date and the remainder vests quarterly
and becomes fully vested three years from the grant date. The options expire 10 years after grant date.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 25, 2022, the Company&#8217;s board of directors approved the grant of aggregate amount of 192,000 options to several employees.
The options have an exercise price of $2.18 per share. The options vest quarterly over three years starting January 25, 2022. The options
expire 10 years after grant date.</span></td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2022, the Company&#8217;s board of directors approved the grant of aggregate amount of 36,000 options to an employee and amount
of 5,000 options consultant of the Company. The options have an exercise price of $3.97 and $2.18, respectively, per share. The options
vest quarterly over three and one years, respectively, from grant date. The options expire 10 years after grant date.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July and August 2022, the Company&#8217;s board of directors approved the grant of aggregate amount of 20,000 options to a consultant
and an amount of 120,000 options to several employees of the Company. The options have an exercise price of $2.18 and $1.99, respectively,
per share. The options vest quarterly over three and one years, respectively, from grant date. The options expire 10 years after grant
date.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2022 the Company issued 85,449 of its ordinary shares to certain consultants in exchange for their services, with fair value of $119
thousand. One of the consultants received 44,000 shares of restricted stock which were issued in 4 equal installments and subject to
2 year lock-up period. Other consultant&#8217;s shares are subject to 6 months restriction period (which ended by December 31, 2022).</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">7.</td><td style="text-align: justify">On&#160;March 20, 2023, the Company&#8217;s board of directors,
approved the following awards:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
of 320,479 RSUs to certain officers, in lieu of cash with respect to the 2022 bonus plan grants in the amount of $161&#160;thousand.
The RSUs vest quarterly over two years with acceleration condition upon meeting certain milestones. The Company met the milestones in
2023 and therefore the vesting was accelerated accordingly.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
bonus for certain employees in the form of 100,000 and 60,000 RSUs. The RSUs vest on a quarterly basis over one year following the grant
and on an annual basis over three years following the grant, respectively.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the grants in accordance with the 2022 bonus plan mentioned above, a raise of additional 30% of the annual 2022 bonus will
be granted to the Company&#8217;s CEO.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
grant of 13,628 options to a consultant of the Company with a total fair value of $22,500. The options have an exercise price of $1.82
per share. The options will vest monthly, over 9 months commencing January 1, 2023. The options expire 10 years after their grant date.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">8.</td><td style="text-align: justify">On May 30, 2023, the Company granted 160,000 RSUs to directors
of the Company. The RSUs have an exercise price of $1.53 per share. The RSUs shall vest entirely on the first anniversary of the vesting
commencement date, provided that no termination of employment of the grantee occurs prior to such anniversary.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">9.</td><td style="text-align: justify">On August 15, 2023, the Company&#8217;s board of directors
approved the grant of aggregate amount of 60,000 options to several employees. The options have an exercise price of $0.96 per share
and vest quarterly over 3 years starting August 15, 2023, and (ii) the grant of 9,000 options to an employee. The options have an exercise
price of $0.96 per share and vest annually over 3 years starting August 15, 2023.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">10.</td><td style="text-align: justify">In May 2024, the Company&#8217;s board of directors, approved
the grant of 24,000 RSUs to a consultant of the Company. 12,000 RSUs vested on grant date, and the remaining 12,000 RSUs will vest monthly
(2,000 RSUs each month), over six months and until November 1, 2024. The fair value of RSUs is estimated by multiplying the number of
RSUs granted by the share price at grant date.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">11.</td><td style="text-align: justify">In May 2024, the Company&#8217;s board of directors, approved
the grant of 24,000 RSUs to a consultant of the Company. 4,000 RSUs vested on grant date, and the remaining 20,000 RSUs will vest monthly
(4,000 RSUs each month), over six months and until October 1, 2024. The fair value of RSUs is estimated by multiplying the number of
RSUs granted by share price at grant date.</td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">12.</td><td style="text-align: justify">In May 2024, the Company&#8217;s board of directors, approved
the grant of 9,000 options to an employee of the Company. The options will vest in equal amount annually over a 3 year period commencing
April 8, 2024. The options have an exercise price of $1.27 per share</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On June 27, 2024, the Company&#8217;s annual general meeting
of shareholders approved the following proposed resolutions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">A grant of 160,000 RSUs to the non-management directors of
the Company. Such RSUs would vest on the one year anniversary of the date of the meeting.</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">To approve an amendment to the Company&#8217;s Articles of
Association to increase the authorized share capital of the Company.</td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">3.</td><td style="text-align: justify">An acceleration of the vesting of the 18,000 unvested options
of a former director, and extending the term of the unexercised options, such that they will expire 10 years from the date of grant</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The weighted average grant date fair value of
options granted during the years ended December&#160;31, 2024, 2023 and 2022 was $0.88, $0.80 and $1.40 per option, respectively. The
weighted average grant date fair value of RSUs granted during the years ended December&#160;31, 2024 and 2023 was $1.08 and $1.75 per
RSU, respectively.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Regarding issuance of 70,964 ordinary shares as
issuance costs in April 2024, see also Note 9A(f).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Stock-based compensation expenses recognized in
profit and loss as an operating expense based on fair value of the option at the grant date by using Binominal option pricing model for
employees and directors and Black and Scholes pricing
model for non-employees. The inputs for the valuation analysis of the share options include several assumptions of which the most significant
are the fair market value of the underlying ordinary share, the expected share price volatility and the expected option term. Expected
volatility was calculated based upon historical volatility of the Company and peer companies in the same industry on weekly basis. Expected
option term represents the period that the Company&#8217;s share options are expected to be outstanding. Risk-free interest rate is based
on the yield from U.S. treasury bonds with an equivalent term. Expected dividend yield assumption is based on the Company&#8217;s historical
experience and expectation of no future dividend payouts. The Company has historically not paid cash dividends and has no foreseeable
plans to pay cash dividends in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The following table lists the inputs used for calculation
of fair value of the options granted to employees and directors for the years ended December 31, 2024, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Expected volatility</td><td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: center">93.72%</td><td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: center">91.80% - 93.51%</td><td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: center">93.63% - 93.79%</td></tr> <tr style="vertical-align: bottom; "> <td>Exercise price</td><td>&#160;</td> <td style="text-align: center">1.27</td><td>&#160;</td> <td style="text-align: center">0.96 - 1.99</td><td>&#160;</td> <td style="text-align: center">1.43 - 3.97</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Share price</td><td>&#160;</td> <td style="text-align: center">1.27</td><td>&#160;</td> <td style="text-align: center">0.96 - 1.99</td><td>&#160;</td> <td style="text-align: center">1.43 - 3.97</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td> <td style="text-align: center">4.61%</td><td>&#160;</td> <td style="text-align: center">3.24% - 4.35%</td><td>&#160;</td> <td style="text-align: center">2.12% - 2.46%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td>&#160;</td> <td style="text-align: center">0</td><td>&#160;</td> <td style="text-align: center">0</td><td>&#160;</td> <td style="text-align: center">0</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected life (years)</td><td>&#160;</td> <td style="text-align: center">10</td><td>&#160;</td> <td style="text-align: center">10</td><td>&#160;</td> <td style="text-align: center">10</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The following table lists the inputs used for
calculation of fair value of the options granted to consultants for the years ended December 31, 2024, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100.540%</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93.64%</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise price</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.82</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.18</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share price </span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.82</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.41 - 1.96</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.64%</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.91% - 2.91%</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td> <td style="width: 1%">&#160;</td> <td style="white-space: nowrap; width: 13%; text-align: center"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="width: 1%">&#160;</td> <td style="white-space: nowrap; width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td> <td style="width: 1%">&#160;</td> <td style="white-space: nowrap; width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (years)</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The following table summarizes the share option activity for employees,
directors, and non-employees for the annual periods ended on December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Number of</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted<br/> Average </b></span></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Weighted<br/> average<br/> remaining</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Intrinsic<br/>
value</b></span></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Share<br/>
Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Exercise<br/> Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">contractual<br/> life (years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">U.S. dollars<br/> in thousands</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Options outstanding at January 1, 2024</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,069,128</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2.26</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;8.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;62</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">1.27</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.96</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif">(*</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 2.5pt">Options outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,069,128</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">6.68</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">936,968</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.34</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">6.52</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">less than $1 thousands</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The income tax benefit for the share options exercised
expense after the valuation allowance is 0.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The following table summarizes the RSUs activity for the annual periods
ended on December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted<br/>
 average<br/>
 grant date<br/>
 fair value</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Number of<br/>
    RSUs</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">U.S. dollars<br/>
 in&#160;thousands</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding at January 1, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">317,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;249</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(325,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">200,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">236</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The income tax benefit for the stock-based compensation
expense after the valuation allowance is 0.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The share-based expense recognized in the statements of operations
were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Share-based compensation expense - Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">193</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">575</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">570</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Share-based compensation expense - General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">364</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">962</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,158</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">557</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,537</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,728</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">As of December 31, 2024, there was $43 thousand
of unrecognized compensation expense related to unvested options and RSUs. Such unrecognized expenses will be recognized over a weighted
average period of approximately 1.25 years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Research and development expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 11 - Research and development expenses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Subcontractors and consultants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,530</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,794</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,612</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">193</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">575</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">570</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salaries and social benefits (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,905</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,405</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,698</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,274</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,587</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 12 - General and Administrative Expenses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professional services</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,998</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,486</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,085</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">364</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">962</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,158</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salaries and social benefits (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">865</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,011</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,014</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">511</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,174</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Traveling abroad</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">534</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">641</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">371</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,204</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,775</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,967</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">During 2024, 2023 and 2022, the Company paid to pension funds
and to insurance companies an amount of $115 thousand, $104 thousand and $85 thousand which are included in Company&#8217;s salary expenses
under research and development and general and administrative expenses, respectively.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Income (Expenses), Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Financing Income Expenses Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">Financing Income (Expenses), Net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 13 - Financing Income (expenses), net</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Finance Income:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Revaluation of warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">46</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,191</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deposit interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rates</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,390</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">91</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(306</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(439</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exchange rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(45</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Bank fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(356</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(448</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total financing income (expanse), net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(308</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,942</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">62</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Balances and Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Parties Balances and Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties Balances and Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 14 - Related Parties Balances and Transactions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 10 and June 21, 2022, the Company&#8217;s board of directors and shareholders, respectively, approved a bonus plan for 2022 for the
Company&#8217;s officers. The bonus plan defined specified millstones (in fields of clinic trial progress, business developments and
raise of money) which their achievements entitled the officers with different percentages out of fix amount of bonus.&#160;As detailed
in the plan, such bonuses (if entitled) will be paid in cash or, if the Company has less than $6 million of cash and cash equivalents
and deposits on December 31, 2022, a number of ordinary shares of the Company with a value equal to the cash bonus amount to which the
officer would otherwise have been entitled, valuing each ordinary share at the closing price of the Company&#8217;s shares on Nasdaq
on December 31, 2022. Since the cash and cash equivalents and deposits on December 31,2022 was more than $6 million, the 2022 bonus should
have been paid in cash. Based on the goals achieved&#160;as of December 31, 2022, the Company recorded a payment liability in the amount
of $370 thousand which has been recorded as salary fee in the year ending December 31, 2022. In March 2023, certain officer&#8217;s 2022
bonus was replaced by issuance of RSUs and an update to 2022 annual bonus of the CEO was approved (see also Note 10).</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
March and May 2023, certain officers and directors were granted with options and RSUs, see also Note 10.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March and May, 2023, the Company&#8217;s board of directors and shareholders, respectively, approved a bonus plan for 2023 for the Company&#8217;s
officers. The bonus plan defined specified millstones (in fields of clinic trail progress, regulatory efforts, business developments
and raise of money) which their achievements entitled the officers with different percentages out of fix amount of bonus.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2024, the Company&#8217;s board of directors approved a change to the 2023 bonuses plan to the Company&#8217;s officers for which
included a change to the bonus calculations previously approved. Following the change, such bonuses will become effective and paid only
after a capital raise, that will allow the initiation of the Company&#8217;s planned phase 3 clinical study, of at least $18 million.
The aggregate amount of the potential bonus payable to the officers after such capital raise will be approximately $0.8 million.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2024, the Company&#8217;s board of directors approved a bonus plan for 2024 for certain Company&#8217;s officers. The bonus plan
defined specified millstones (in fields of clinic trail progress, regulatory affairs, business developments and capital raising).</span></td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">5.</td><td style="text-align: justify">On June 27, 2024, the Company&#8217;s annual general meeting
of shareholders approved the following proposed resolutions, among others:</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in">1.</td> <td style="text-align: justify">An acceleration of the vesting of the 18,000 unvested options of a former director, and extending the term of the unexercised options, such that they will expire 10 years from the date of grant</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>2.</td> <td style="text-align: justify">To approve a 2024 bonus plan for the Company&#8217;s CEO Officer of the Company, based on the achievement of certain Company milestones.</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>3.</td> <td style="text-align: justify">To approve the renewal of Mr. Alon Ben-Noon&#8217;s the Company&#8217;s CEO&#8217;s employment agreement with the Company and in addition, an update to his salary in the event that the Company raises an aggregate of US 25,000,000.</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>4.</td> <td style="text-align: justify">To approve the grant of 160,000 RSUs to the Company&#8217;s directors, see Note 10.</td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 17, 2024, the Company&#8217;s CEO, together with CFO, CMO, CTO, COO, signed a waiver letter with respect to bonuses, that they
were entitled for the years 2022-2024 in their capacity as shareholders. As part of this waiver, the Company recorded an amount of $1,434
thousands within additional paid in capital.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
August and December 2024, the Company entered into a share purchase agreement with certain senior management, see also Note 9A(h) and
9A(l).</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 15 &#8211; Segment Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Segment information is prepared on the same basis
that the chief executive officer, who is the Company&#8217;s chief operating decision maker, manages the business, makes business decisions
and assesses performance. The Company has one reportable segment specializing in the development of treatments for patients suffering
from debilitating neurodegenerative diseases, as described in Note 1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The CODM assesses performance for this segment
and decides how to allocate resources based on net loss. This net loss comprised of research and development expenses related to its product,
general and administrative costs and net financing income or expanses. The CODM performs the assessment of segment performance by using
the reported measure of segment profit or loss to monitor budget versus actual results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net profit or loss report regularly reviewed
by the CODM is identical to the Consolidated Statements of Income and Comprehensive Loss and the related notes in the financial statements
of the company for years ending December 31, 2024, 2023 and 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 16 - Income Taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Israeli taxation: </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The tax rate relevant to the Company
in the years 2024, 2023 and 2022 was 23%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.45pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of December 31, 2024, the Company
has net operating loss carryforwards for Israeli income tax purposes of approximately $24,730, which can be offset against future taxable
income for an indefinite period of time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.45pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company has
final (considered final) tax assessments in Israel through the 2019 tax year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred taxes reflect the net tax effects of carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s net deferred tax assets are as follows:</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-size: 1pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>U.S. dollars<br/>
 in thousands</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net operating loss carryforward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,688</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,315</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Other temporary differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Capitalized research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,282</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,395</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Vacation and convalescence accrual</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">67</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Total deferred tax assets:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,149</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,864</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Deferred tax liability: Operating lease right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(35</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total deferred tax liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(19</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(35</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Net deferred tax assets:</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,130</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,829</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Less: Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,130</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,829</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In assessing the realization of deferred
tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.
The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which
temporary differences are deductible and net operating loss carryforward are available. Based on consideration of these factors, the Company
recorded a valuation allowance as of December 31, 2024 and 2023 for all deferred tax assets not supported by reversing taxable temporary
differences.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.45pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The portion of the valuation allowance
for deferred tax assets for which subsequently recognized tax benefits would be applied directly to contributed capital was $782 thousand
and $693 thousand in 2024 and 2023, respectively.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify">During the years ended December 31, 2024 and 2023, the main reconciling item between the statutory income tax rate in Israel, the country of domicile of the Company (as noted in Note 16A) and the effective tax rate is mainly the recognition of valuation allowance in respect of deferred taxes relating to net operating loss carryforwards and other temporary differences due to the uncertainty of the realization of such deferred taxes.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.25in"> The net change during the year ended December 31, 2024, 2023 and 2022 in the total valuation allowance amounted was $2,301 thousands, $1,813 thousands and $$1,419 thousands, respectively. &#160; </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The movement of the valuation allowance (through income statement) is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt"><b>U.S. dollars in thousands</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">Balance at the beginning of the year</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">4,829</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">3,016</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">1,607</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Addition of valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,301</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,409</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Net change in the valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,301</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,813</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,409</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Balance at the end of the year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">7,130</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">4,829</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">3,016</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 17 - Subsequent Events </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the date hereof, the Company sold 444,216 of it&#8217;s ordinary shares pursuant to the Sales Agreement for aggregate gross proceeds of approximately $509.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 31, 2025, the Company&#8217;s board of directors approved the grant of aggregate amount of 108,000 options to several employees. The options have an exercise price of $0.93 per share. The options vest quarterly over three years and expire 10 years after grant date.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 31, 2025, the Company&#8217;s board of directors approved the grant of an aggregate amount of 355,512 RSUs to several consultants and service providers. </span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 31, 2025, the Company&#8217;s board of directors approved the grant of an aggregate amount of 20,000 options to several consultants. The options have an exercise price of $0.93 per share. The options vest over one year and expire 10 years after grant date.</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (10,210)<span></span>
</td>
<td class="num">$ (10,107)<span></span>
</td>
<td class="num">$ (10,492)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our current cybersecurity
risk assessment and protection program consists of various cybersecurity software features designed to protect our systems and data and
alert us of any cybersecurity incidents, such as software to strengthen protection against forms of malware, including ransomware, spyware,
keyloggers and adware and various measures which limit the ability of different sectors within our organization to access certain types
of information. We also maintain backups to our systems and data which would help us in recovery and mitigation in the event of a cybersecurity
incident. Additionally, we work with external service providers that provide us with information technology services, including the assessment
and identification of risks from cybersecurity threats and to help manage our risk assessment program.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The oversight of cybersecurity
threats is undertaken by our CFO, who has experience in various leadership and consultancy roles. In the event of a material incident
or threat, our CEO is notified as well. The CEO would then be expected to report the threat to the audit committee of the Board of Directors,
which is responsible for oversight of strategic, financial and other major risks to the Company, which could include those posed by cybersecurity
threats. The level of each risk would be determined by considering the impact of the risk itself and the likelihood of the risk materializing
and high scoring risks are actioned upon. The Company&#8217;s risk assessment occurs annually, or as business needs change, and covers identification
of risks that could act against the company&#8217;s objectives as well as specific risks related to a compromise to the security of data.&#160;See
&#8220;Item 3.D Risk Factors&#8212;Risks Related to Our Business and Strategy&#8212;Our internal computer systems, or those of our CROs
or other contractors or consultants, may fail or suffer security breaches, which could result in a disruption of our drug development
programs.&#8221;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of the date of this report,
we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially
affect us, including our business strategy, results of operations or financial condition.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">The oversight of cybersecurity
threats is undertaken by our CFO, who has experience in various leadership and consultancy roles. In the event of a material incident
or threat, our CEO is notified as well. The CEO would then be expected to report the threat to the audit committee of the Board of Directors,
which is responsible for oversight of strategic, financial and other major risks to the Company, which could include those posed by cybersecurity
threats.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">The CEO would then be expected to report the threat to the audit committee of the Board of Directors<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially
affect us, including our business strategy, results of operations or financial condition.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policy [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of presentation</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
consolidated financial statements have been prepared in accordance accounting principles generally accepted in the United States of America
(&#8220;US GAAP&#8221;)</span> assuming the Company will continue as a going concern.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates in preparation of consolidated financial statements</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates in preparation of consolidated financial statements</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts
reported in the consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including
those related to fair value of financial instruments and share based compensation. The Company&#8217;s management believes that the estimates,
judgment, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and
assumptions can affect the reported amounts of assets and liabilities and disclosure of liabilities at the dates of the consolidated financial
statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Functional currency</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The functional currency of the Company and its subsidiaries, all of which are primarily direct and integral component of the Company&#8217;s
operation, is the U.S. dollar (&#8220;$&#8221; or &#8220;dollar&#8221;), as the dollar is primary currency of the economic environment
in which the Company and its subsidiaries have operated and expects to continue to operate in foreseeable future.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In accordance with ASC 830, &#8220;Foreign
Currency Matters&#8221;, balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing
at the applicable balance sheet date. For foreign currency transactions included in the consolidated statement of operations and comprehensive
loss, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates
used in the translation of such transactions are presented within financing income or expenses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principles of Consolidation</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The consolidated financial statements
include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated upon
consolidation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash and cash equivalents</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Cash and cash equivalents include highly
liquid investments, including short-term bank deposits (with original maturity dates of up to three months from date of deposit) that
are not restricted as to withdrawal or use.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_ShortTermDepositsPolicyTextBlock', window );">Short-term deposits</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Short-term deposits</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Short-term deposits in banking institutions
for periods in excess of three months following the date of deposit. The deposits are presented in accordance with the terms of their
deposit.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_RestrictedDepositsPolicyTextBlock', window );">Restricted deposits</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restricted deposits</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Restricted deposits consist of deposits
held in restricted deposit bank accounts including deposits held as collateral for guarantees to third parties, classified as current
or non-current based on expected timing of the disbursement.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property and equipment</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets. When an asset is disposed of, the related cost and accumulated depreciation are removed from the respective accounts and the net
difference less any amount realized from disposition is reflected in the consolidated statements of operations and comprehensive loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s long-lived assets are
reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment&#8221;, whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.
To date, the Company has not incurred any impairment losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The lives used in computing straight-line
depreciation for financial reporting purposes are as follows:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="width: 80%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and peripherals and equipment</span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office furniture and equipment</span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7 - 15</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-55">The shorter of the lease term and the useful life</span></span></td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research and Development</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Research and development costs are
expensed as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>J.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurements</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company measures and discloses
fair value in accordance with the ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; which defines fair value, establishes
a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements.
Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined
based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions
there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 1 - unadjusted quoted prices
are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 2 - pricing inputs are other
than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Level 3 - pricing inputs are unobservable
for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability
at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Level
3 inputs are considered as the lowest priority within the fair value hierarchy. The valuation of certain financial instruments classified
under fair value through profit or loss category falls under this category.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">This hierarchy requires the Company
to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of the reported periods, the fair
values of the Company&#8217;s cash, cash equivalents, short-term bank deposits, current and non-current restricted deposits, other current
assets, trade payables and other current liabilities approximated the carrying values of these instruments presented in the Company&#8217;s
consolidated balance sheets because of their nature.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>K.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations of credit risk</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Financial instruments that potentially
subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents as well as certain other current assets
that do not amount to a significant amount. Cash and cash equivalents, which are primarily held in dollar and New Israeli Shekels (NIS),
are deposited with major bank in Israel. Management believes that such financial institutions are financially sound and, accordingly,
minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration
of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>L.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company entered into non-cancelable
lease agreements for offices for use in its operations, which are classified as operating leases (see below).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company applies ASC 842, &#8220;Leases&#8221;
under which the Company determines if an arrangement is a lease at inception. The Company&#8217;s assessment is based on: (i) whether
the contract involves the use of an identified asset, (ii) whether the Company obtains the right to substantially all of the economic
benefits from the use of the asset throughout the period of use, and (iii) whether the Company has the right to direct the use of the
asset.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Leases are classified as either finance
leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers
ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain
to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset, (iv) the present value of the lease
payments equals or exceeds substantially all of the fair value of the asset, or (v) the underlying asset is of such a specialized nature
that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if
it does not meet any one of these criteria. Since all the Company&#8217;s lease contracts for premises do not meet any of the criteria
above, the Company concluded that all its lease contracts should be classified as operating leases.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Right of Use (&#8220;ROU&#8221;) assets
and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For
this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company&#8217;s
leases do not provide an implicit rate, the Company uses its Incremental Borrowing Rate (&#8220;IBR&#8221;) based on the information available
on the commencement date in determining the present value of lease payments. The Company&#8217;s IBR is estimated to approximate the interest
rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The
ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover,
the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease
had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, &#8220;Property, Plant, and Equipment
- Overall&#8221;, to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases
include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset
and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless
it is reasonably certain that the Company will not exercise the option.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitment and contingencies</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>M.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commitment and contingencies</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies under which a provision is recorded when it is both probable that liability has
been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted
to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events
pertaining to a particular matter.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPPolicy', window );">Employee benefit plans</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N.</b></span></td> <td style="padding-bottom: 6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employee benefit plans </b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s liability for severance
pay to its Israeli employees is subject to Section 14 of the Israeli Severance Compensation Act, 1963 (&#8220;Section 14&#8221;), pursuant
to which all of the Company&#8217;s employees are entitled to monthly deposits by the Company, at a rate of 8.33% of their monthly salary,
made in the employee&#8217;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release
the Company from any future severance payments in respect of those employees. The fund is made available to the employee at the time the
employer-employee relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section
14 are not reflected in the balance sheets as the severance pay risks have been irrevocably transferred to the severance funds. All deposits
required through December 31, 2024 have been made.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>O.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income taxes</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company accounts for income taxes
in accordance with ASC 740, &#8220;Income Taxes&#8221;. Accordingly, deferred income taxes are determined utilizing the asset and liability
method based on the estimated future tax effects of differences between the financial statement carrying amount and the tax bases of assets
and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax rates expected to be in effect
when these differences reverse. A valuation allowance in respect of deferred tax assets is provided for, if necessary, to reduce deferred
tax assets to the amounts more likely than not to be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company implements a&#160;two-step&#160;approach
to recognize and measure tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by
determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits,
the tax position will be sustained on examination, including resolution of any related appeals or litigation processes. The second step
is to measure the tax benefit as the largest amount that is greater than&#160;50% likely to be realized upon settlement. The Company&#8217;s
accounting policy is to classify interest and penalties relating to income taxes under income taxes, however the Company did not recognize
such items in its consolidated financial statements during the reported periods and did not recognize any liability with respect to an
unrecognized tax benefits in its balance sheets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>P.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-based compensation</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s employees&#8217;
and directors&#8217; share-based payment awards are classified as equity awards. The Company accounts for these awards using the grant-date
fair value method. For employees, the fair value of share-based payment transactions is recognized as an expense over the requisite service
period for each separately vesting tranche of the award as if the award is, in-substance, multiple awards. Forfeitures are recognized
as they occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">For nonemployees, compensation costs
are recognized in the same period and in the same manner the Company would if it had paid cash for those goods or services.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted net loss per share</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Q.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basic and diluted net loss per share</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Basic net loss per share is computed
using the weighted average number of ordinary shares, pre-funded warrants to purchase ordinary shares for an exercise price of $0.0001&#160;which
are exercisable immediately and fully vested restricted share units (RSUs) outstanding during the period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Diluted loss per share gives effect
to all potentially dilutive common shares outstanding during the year using the treasury stock method with respect to options and non-vested
RSUs granted under employee stock compensation plan and certain warrants granted through its Initial Public Offering (IPO) and using the
if-converted method with respect to certain warrants granted through registered direct offering and accounted for as derivative liability.
In computing diluted loss per share, the average share price for the period is used in determining the number of shares assumed to be
purchased from the exercise of share options or warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the reported periods, all outstanding
share options, warrants and non-vested RSUs have been excluded from the calculation of the diluted net loss per share as all such securities
are anti-dilutive for all years presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>R.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segment</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company&#8217;s chief operating
decision maker (&#8220;CODM&#8221;) is its Chief Executive Officer. The CODM reviews financial information on an aggregate basis for the
purposes of evaluating financial performance and allocating the Company&#8217;s resources. Accordingly, the Company has determined that
it operates in one segment.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Share capital</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>S.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share capital</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Ordinary shares are classified as equity.
Incremental costs directly attributable to the issuance of the shares are recognized as a deduction from equity.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_ContractsOverOwnEquityPolicyTextBlock', window );">Contracts over own equity</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><b>T.</b></td><td style="text-align: justify"><b>Contracts over own equity</b></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">When the Company becomes party to freestanding
financial instruments, the Company first analyzes the provisions of ASC&#160;480 in order to determine whether the instrument should be
classified as a liability, with subsequent changes in fair value recognized in the statements of operations in each period. Warrants to
purchase ordinary shares are not within the scope of ASC&#160;480, and as such the Company further analyzes the provisions of ASC&#160;815-40&#160;in
order to determine whether the contract should be classified within equity or classified as a liability, with subsequent changes in fair
value recognized in the statements of operations in each period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company reassesses the classification
of a contract over its own equity under the guidance above at each balance sheet date. If classification changes as a result of events
during the reporting period, the Company reclassifies the contract as of the date of the event that caused the reclassification. When
a contract over own equity is reclassified from a liability to equity, gains or losses recorded to account for the contract at fair value
during the period that the contract was classified as a liability are not reversed, and the contract is marked to fair value immediately
before the reclassification.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
adopted accounting pronouncements</b></span></td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>1.</b></td><td style="text-align: justify">In&#160;August 2020,&#160;the FASB issued ASU&#160;2020-06&#160;&#8220;Debt-
Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging- Contracts in Entity&#8217;s Own Equity (Subtopic&#160;815-40)
(&#8220;ASU&#160;2020-06&#8221;): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221;. This guidance
simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments
and contracts on an entity&#8217;s own equity. Furthermore, ASU&#160;2020-06&#160;requires the application of the if-converted method
for calculating diluted earnings per share. ASU 2020-06 is effective for the Company for annual periods beginning after December 15,
2023,&#160;and interim periods within those fiscal years. The Company adopted this guidance on January 1, 2024, and there was no material
impact on the Company&#8217;s consolidated balance sheet and the consolidated statements of operations and comprehensive loss upon adoption.</td>
</tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b>2.</b></td><td style="text-align: justify">In November 2023, the FASB issued ASU 2023-07 &#8220;Segment
Reporting: Improvements to Reportable Segment Disclosures&#8221; which expands public entities&#8217; segment disclosures primarily by
requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within
each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures
of a reportable segment&#8217;s profit or loss and assets. Public entities with a single reportable segment are required to provide the
new disclosures and all the disclosures required under ASC 280.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The guidance is effective for the Company&#8217;s
annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company
has adopted this standard for the fiscal year 2024 annual financial statements and interim financial statements thereafter and has applied
this standard retrospectively for all prior periods presented in the financial statements. See&#160;Note 15 &#8211; Segment Reporting&#160;for
further information.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recently issued accounting pronouncements, not yet adopted</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>V.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently issued accounting pronouncements, not yet adopted</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As an emerging growth company, the
Jumpstart Our Business Startup Act (&#8220;JOBS Act&#8221;) allows the Company to delay adoption of new or revised accounting pronouncements
applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this
extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">1.</td><td style="text-align: justify">In December 2023, the FASB issued ASU 2023-09 &#8220;Improvements to Income Tax Disclosures&#8221; which
improves the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in
the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain amendments to improve income
tax disclosures effectiveness. The guidance is effective for the Company&#8217;s annual periods beginning January 1, 2026, with early
adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on the consolidated financial
statement disclosures.</td></tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">2.</td><td style="text-align: justify">In November 2024, the FASB issued ASU No. 2024-03 Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense
Disaggregation Disclosures (Subtopic 220-40). The ASU improves the disclosures about a public business entity&#8217;s expenses and provides
more detailed information about the types of expenses in commonly presented expense captions. The amendments require that at each interim
and annual reporting period an entity will, inter alia, disclose amounts of purchases of inventory, employee compensation, depreciation
and amortization included in each relevant expense caption (such as cost of sales, SG&amp;A and research and development). The ASU is
effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027.
Early adoption is permitted. The Company is currently evaluating this ASU to determine its impact on the Company&#8217;s disclosures.</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_ContractsOverOwnEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contracts over own equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_ContractsOverOwnEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recently issued accounting pronouncements, not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_RestrictedDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_RestrictedDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_ShortTermDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_ShortTermDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policy (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policy [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock', window );">Schedule of the Lives Used in Computing Straight-Line Depreciation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The lives used in computing straight-line
depreciation for financial reporting purposes are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="width: 80%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 19%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computers and peripherals and equipment</span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office furniture and equipment</span></td> <td>&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7 - 15</span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-55">The shorter of the lease term and the useful life</span></span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lives used in computing straight-line depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalent (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash And Cash Equivalent</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars<br/> in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Denominated in NIS</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,057</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">107</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Denominated in USD</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">321</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">*2,533</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,378</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,640</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">Including short term bank deposit for a period of 1-2 months
at an interest rate of 5%.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrentAbstract', window );"><strong>Other Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Receivables</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars<br/> in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Advance to suppliers</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;738</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Government agencies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">104</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">137</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">989</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">236</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers<br/> and<br/> peripherals<br/> and <br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Office<br/> furniture <br/> and<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cost:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance at January 1, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;28</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">123</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Purchases during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">95</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">126</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif; font-size: 10pt">(*</span></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif; font-size: 10pt">(*</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif; font-size: 10pt">(*</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">Depreciated cost at December&#160;31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">41</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">22</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">66</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Computers<br/> and<br/> peripherals<br/> and <br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Office<br/> furniture <br/> and<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cost:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Balance at January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;66</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">94</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Purchases during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">29</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">92</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">28</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">123</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Depreciation during the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif; font-size: 10pt">(*</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Balance at December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">34</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif; font-size: 10pt">(*</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">Depreciated cost at December&#160;31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">58</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">24</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">85</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
than $1 thousand.</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_LesseeOperatingLeaseDisclosureTableTextBlock', window );">Schedule of Operating Lease</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars<br/> in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Operating right of use asset</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;84</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="-sec-ix-hidden: hidden-fact-67">Current operating lease liability</span></td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Non-Current operating lease liability</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-68">-</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Total operating lease liability</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity Analysis of Company&#8217;s Lease Liability</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><span style="text-decoration:underline">Maturity analysis of the Company&#8217;s lease liability</span>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,<br/>
2024</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S. dollars<br/>
in thousands</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less than one year</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two years</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total operating lease payments</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: imputed interest</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)<b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of lease liability</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Weighted Average Remaining Lease Terms and Discount Rate</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The following is a summary of weighted average
remaining lease terms and discount rate for Company&#8217;s leases:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Lease term (years)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>Weighted average discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">%</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">Presented hereunder are the lease payments the
Company paid in the year ended December 31, 2024, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Lease payments</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;75</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;75</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;79</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">75</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">75</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">79</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_LesseeOperatingLeaseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_LesseeOperatingLeaseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Current Liabilities</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars<br/> in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Employees and payroll accruals (*)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">498</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,481</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Short term lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">261</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">450</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">832</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">see Note 14 regarding waiver signed of bonus accrual.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability in Respect of Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Liability In Respect of Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Financial Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The Company&#8217;s financial measured
at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars<br/> in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Liability in respect of warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,412</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,412</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value of the Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The fair value of the warrants, as
of it&#8217;s the date of reclassification to equity, was determined by the management using the assistance of external appraiser and
by using the Black-Scholes option pricing model and the following inputs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June&#160;26,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Financial liabilities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86.56-92.52</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%">Share price (in $)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.85</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.44-4.40</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected life (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.98-5.30</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The fair value of the warrants was determined by the management using the assistance of external appraiser and by using Black-Scholes option pricing model and the following inputs:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December&#160;31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Financial liabilities:</td><td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Expected volatility (%)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">93.91</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>Share price (in $)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.785</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.90</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected life (years)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4.47</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield (%)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of the Movement in Warrant Liability</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The following table summarizes the movement in warrant liability during
the year ended December 31, 2023 and December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars<br/> in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Balance as at January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left">Recognition of liability in respect to warrants at the initial date</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,603</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Revaluation of liability in respect to warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,191</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Balance as at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,412</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Revaluation of liability in respect to warrants through finance expanse</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(46</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Revaluation of liability in respect to warrants through equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">329</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Reclassification of warrants into equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,695</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 2.5pt">Balance as at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Shareholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalUnitsTextBlock', window );">Schedule of Share Capital</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share capital</b></span><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares<br/> December 31</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/> outstanding 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Authorized<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issued and<br/> outstanding 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 2.5pt"><div style="-sec-ix-hidden: hidden-fact-78"><div style="-sec-ix-hidden: hidden-fact-79">Ordinary shares of <span style="-sec-ix-hidden: hidden-fact-76"><span style="-sec-ix-hidden: hidden-fact-77">no</span></span> par value</div></div></td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">90,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">23,228,941</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">60,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">15,379,042</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalUnitsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's capital units or capital shares, including the value of capital units or capital shares, units authorized, units outstanding and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalUnitsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share Based Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of the Options Granted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The following table lists the inputs used for calculation
of fair value of the options granted to employees and directors for the years ended December 31, 2024, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Expected volatility</td><td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: center">93.72%</td><td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: center">91.80% - 93.51%</td><td style="width: 1%">&#160;</td> <td style="width: 13%; text-align: center">93.63% - 93.79%</td></tr> <tr style="vertical-align: bottom; "> <td>Exercise price</td><td>&#160;</td> <td style="text-align: center">1.27</td><td>&#160;</td> <td style="text-align: center">0.96 - 1.99</td><td>&#160;</td> <td style="text-align: center">1.43 - 3.97</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Share price</td><td>&#160;</td> <td style="text-align: center">1.27</td><td>&#160;</td> <td style="text-align: center">0.96 - 1.99</td><td>&#160;</td> <td style="text-align: center">1.43 - 3.97</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td> <td style="text-align: center">4.61%</td><td>&#160;</td> <td style="text-align: center">3.24% - 4.35%</td><td>&#160;</td> <td style="text-align: center">2.12% - 2.46%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td>&#160;</td> <td style="text-align: center">0</td><td>&#160;</td> <td style="text-align: center">0</td><td>&#160;</td> <td style="text-align: center">0</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Expected life (years)</td><td>&#160;</td> <td style="text-align: center">10</td><td>&#160;</td> <td style="text-align: center">10</td><td>&#160;</td> <td style="text-align: center">10</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The following table lists the inputs used for
calculation of fair value of the options granted to consultants for the years ended December 31, 2024, 2023 and 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100.540%</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93.64%</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise price</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.82</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.18</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share price </span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.82</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.41 - 1.96</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.64%</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.91% - 2.91%</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 58%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield</span></td> <td style="width: 1%">&#160;</td> <td style="white-space: nowrap; width: 13%; text-align: center"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="width: 1%">&#160;</td> <td style="white-space: nowrap; width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td> <td style="width: 1%">&#160;</td> <td style="white-space: nowrap; width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life (years)</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td> <td>&#160;</td> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share Option Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The following table summarizes the share option activity for employees,
directors, and non-employees for the annual periods ended on December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Number of</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted<br/> Average </b></span></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">Weighted<br/> average<br/> remaining</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Intrinsic<br/>
value</b></span></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Share<br/>
Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Exercise<br/> Price</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">contractual<br/> life (years)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">U.S. dollars<br/> in thousands</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Options outstanding at January 1, 2024</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,069,128</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2.26</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;8.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;62</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,000</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">1.27</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.96</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif">(*</span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 2.5pt">Options outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,069,128</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">6.68</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">936,968</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.34</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">6.52</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Unit (RSU&#8217;s) Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The following table summarizes the RSUs activity for the annual periods
ended on December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted<br/>
 average<br/>
 grant date<br/>
 fair value</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Number of<br/>
    RSUs</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">U.S. dollars<br/>
 in&#160;thousands</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Outstanding at January 1, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">317,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;249</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">224</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(325,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">200,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">236</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock', window );">Schedule of Share-Based Expense Recognized in the Statements of Operation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The share-based expense recognized in the statements of operations
were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Share-based compensation expense - Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">193</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">575</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">570</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Share-based compensation expense - General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">364</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">962</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,158</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">557</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,537</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,728</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedStatementOfComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and Development Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock', window );">Schedule of Research and Development Expenses</a></td>
<td class="text">Research and development expenses<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Subcontractors and consultants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,530</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,794</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,612</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">193</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">575</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">570</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salaries and social benefits (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,975</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,905</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,405</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,698</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,274</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,587</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock', window );">Schedule of General and Administrative Expenses</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Professional services</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,998</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,486</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,085</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">364</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">962</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,158</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salaries and social benefits (*)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">865</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,011</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,014</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Insurance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">511</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,174</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Traveling abroad</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">134</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">165</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">534</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">641</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">371</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,204</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,775</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,967</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(*)</td><td style="text-align: justify">During 2024, 2023 and 2022, the Company paid to pension funds
and to insurance companies an amount of $115 thousand, $104 thousand and $85 thousand which are included in Company&#8217;s salary expenses
under research and development and general and administrative expenses, respectively.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Income (Expenses), Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Financing Income Expenses Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Financing Income (Expenses), Net</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">U.S. dollars in thousands</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Finance Income:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Revaluation of warrants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">46</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,191</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deposit interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">178</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange rates</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,390</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">91</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance Expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(306</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(439</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exchange rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(45</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Bank fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(356</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(448</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total financing income (expanse), net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(308</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,942</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">62</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of the Company&#8217;s Net deferred Tax Assets</a></td>
<td class="text">Significant components of the Company&#8217;s net deferred tax assets are as follows:<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-size: 1pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><b>U.S. dollars<br/>
 in thousands</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Net operating loss carryforward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,688</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,315</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Other temporary differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Capitalized research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,282</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,395</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">17</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">33</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Vacation and convalescence accrual</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">67</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Total deferred tax assets:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,149</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,864</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Deferred tax liability: Operating lease right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(35</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total deferred tax liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(19</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(35</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Net deferred tax assets:</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,130</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,829</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Less: Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,130</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,829</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of the Movement of the Valuation Allowance</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The movement of the valuation allowance (through income statement) is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt"><b>U.S. dollars in thousands</b></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">Balance at the beginning of the year</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">4,829</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">3,016</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">1,607</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Addition of valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,301</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,409</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Net change in the valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,301</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,813</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,409</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Balance at the end of the year</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">7,130</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">4,829</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">3,016</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date</a></td>
<td class="text">Feb. 13,  2017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policy (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 02, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Monthly deposits by company, percentage</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Tax benefit rate realized upon settlement</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Operating segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrsn_PrefundedWarrantMember', window );">Pre-funded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrsn_PrefundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrsn_PrefundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policy - Schedule of the Lives Used in Computing Straight-Line Depreciation (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and peripherals and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems', window );"><strong>Significant Accounting Policy - Schedule of the Lives Used in Computing Straight-Line Depreciation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">33 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems', window );"><strong>Significant Accounting Policy - Schedule of the Lives Used in Computing Straight-Line Depreciation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">The shorter of the lease term and the useful life<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems', window );"><strong>Significant Accounting Policy - Schedule of the Lives Used in Computing Straight-Line Depreciation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems', window );"><strong>Significant Accounting Policy - Schedule of the Lives Used in Computing Straight-Line Depreciation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalent (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalent - Schedule of Cash And Cash Equivalent (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Schedule of Cash And Cash Equivalent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalent</a></td>
<td class="nump">$ 3,378<span></span>
</td>
<td class="nump">$ 2,640<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_ILS', window );">Denominated in NIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Schedule of Cash And Cash Equivalent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalent</a></td>
<td class="nump">3,057<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">Denominated in USD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Schedule of Cash And Cash Equivalent [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalent</a></td>
<td class="nump">$ 321<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Including short term bank deposit for a period of 1-2 months
at an interest rate of 5%.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Receivables - Schedule of Other Receivables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Schedule of Other Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Supplies', window );">Advance to suppliers</a></td>
<td class="nump">$ 738<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government agencies</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesGrossCurrent', window );">Other</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other Receivables</a></td>
<td class="nump">$ 989<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables that are derived from government contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentContractReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment Net [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 123<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Cost, Purchases during the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">126<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1', window );">Accumulated Depreciation during the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Depreciated cost at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers and peripherals and equipment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment Net [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Cost, Purchases during the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">95<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1', window );">Accumulated Depreciation during the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">54<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Depreciated cost at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment Net [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Cost, Purchases during the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1', window );">Accumulated Depreciation during the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Depreciated cost at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment Net [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Cost, Purchases during the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1', window );">Accumulated Depreciation during the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Depreciated cost at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
than $1 thousand.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in accumulated depreciation, depletion and amortization as a result of sale or disposal of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Operating Lease [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Monthly rent</a></td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease period</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Description of operating lease, option to extend</a></td>
<td class="text">option to extend the lease period for additional two periods of 24 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_InitialRecognitionRightofuseAssets', window );">Initial recognition of right-of-use asset</a></td>
<td class="nump">$ 306<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_InitialRecognitionRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of initial recognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_InitialRecognitionRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Lease - Schedule of Operating Lease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Current operating lease liability<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, Noncurrent</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Lease - Schedule of Maturity Analysis of Company&#8217;s Lease Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Maturity Analysis of Company&#8217;s Lease Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Less than one year</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Two years</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease - Schedule of Weighted Average Remaining Lease Terms and Discount Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Schedule of Weighted Average Remaining Lease Terms and Discount Rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Lease term (years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Lease payments</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Total lease payments</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Other Current Liabilities - Schedule of Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Schedule of Other Current Liabilities [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employees and payroll accruals</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 498<span></span>
</td>
<td class="nump">$ 1,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Short term lease liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">73<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">261<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other Current Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 832<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">see Note 14 regarding waiver signed of bonus accrual.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability in Respect of Warrants (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 02, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 26, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 22, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Liability in Respect of Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Issued warrant (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (46)<span></span>
</td>
<td class="num">$ (2,191)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities', window );">Revaluation Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Reclassification of warrants into equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Liability in Respect of Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_NumberOfOrdinaryShares', window );">Number of ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Liability in Respect of Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Issued warrant (in Shares) | shares</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_NumberOfOrdinaryShares', window );">Number of ordinary share</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,366<span></span>
</td>
<td class="nump">$ 3,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Liability in Respect of Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Reclassification of warrants into equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_NumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_NumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized from the revaluation of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481435/852-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liability in Respect of Warrants - Schedule of Financial Measured at Fair Value on a Recurring Basis (Details) - Level 2 [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Liability in respect of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrsn_LiabilityInRespectOfWarrantsMember', window );">Liability in Respect of Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Liability in respect of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrsn_LiabilityInRespectOfWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrsn_LiabilityInRespectOfWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability in Respect of Warrants - Schedule of Fair Value of the Warrants (Details) - Warrant [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 26, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.91%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in $) (in Dollars per share)</a></td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="nump">$ 0.785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (%)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 5 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (%)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (%)</a></td>
<td class="nump">86.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (%)</a></td>
<td class="nump">4.44%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">3 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (%)</a></td>
<td class="nump">92.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (%)</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability in Respect of Warrants - Schedule of the Movement in Warrant Liability (Details) - Warrant Liability [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of the Movement in Warrant Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance</a></td>
<td class="nump">$ 1,412<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse', window );">Revaluation of liability in respect to warrants through finance expanse</a></td>
<td class="num">(46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity', window );">Revaluation of liability in respect to warrants through equity</a></td>
<td class="nump">329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_RevaluationOfLiabilityInRespectToWarrants', window );">Reclassification of warrants into equity</a></td>
<td class="num">(1,695)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate', window );">Recognition of liability in respect to warrants at the initial date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_ReclassificationOfWarrantsIntoEquity', window );">Revaluation of liability in respect to warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,191)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_ReclassificationOfWarrantsIntoEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of reclassification of warrants into equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_ReclassificationOfWarrantsIntoEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognition of liability in respect to warrants at the initial date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_RevaluationOfLiabilityInRespectToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revaluation of liability in respect to warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_RevaluationOfLiabilityInRespectToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represented the amount of revaluation of liability in respect to warrants through equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represented the amount of revaluation of liability in respect to warrants through finance expanse.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrsn_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrsn_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 02, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 16, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 06, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 27, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 26, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 10, 2024 </div>
<div>USD ($) </div>
<div>Number </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 23, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 22, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 14, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise warrant received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants price per share | $ / shares</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_MarketOfferingCost', window );">Market offering cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">444,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds from warrant | $</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,304<span></span>
</td>
<td class="nump">$ 4,334<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="num">$ (2,191)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_RemainingFairValueAmount', window );">Remaining fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_AllocatedAmountToOrdinaryWarrants', window );">Allocated amount to ordinary warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Financial expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Total consideration | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Total issuance expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">additional ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares', window );">Registered capital shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_PurchasePricePerShare', window );">Purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted', window );">Commitment amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Ordinary shares value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Structuring fee | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_NetProceedsFromIssuanceOfWarrants', window );">Net proceeds | $</a></td>
<td class="nump">$ 4,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expire term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise warrant received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">645,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_NumberOfOrdinaryShares', window );">Number of ordinary shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate warrants</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds from warrant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestExpenseOfferingCost', window );">Offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Purchase an aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=nrsn_PrefundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants price per share | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_NumberOfOrdinaryShares', window );">Number of ordinary shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate warrants</a></td>
<td class="nump">1,656,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise warrant received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Reimburse for certain specific expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=nrsn_AllianceGlobalPartnersMember', window );">Alliance Global Partners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Aggregate offering price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember', window );">April 2024 Purchase Agrement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Gross proceeds from warrant | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoninterestExpense', window );">Issuance expenses to placement agent | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Total issuance expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember', window );">April 2024 Purchase Agrement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_NumberOfOrdinaryShares', window );">Number of ordinary shares | Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,980,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember', window );">April 2024 Purchase Agrement [Member] | Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_NumberOfOrdinaryShares', window );">Number of ordinary shares | Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,248,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember', window );">April 2024 Purchase Agrement [Member] | Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,732,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrsn_SalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,105,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_SaleOfOrdinaryShareGrossProceedsPercentage', window );">Sale of ordinary shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Reimburse for certain specific expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrsn_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_NetProceedsFromTheOrdinaryShares', window );">Net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrsn_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,248,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=nrsn_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate of shares</a></td>
<td class="nump">2,343,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Reimburse for certain specific expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member] | April 2024 Purchase Agrement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_AllocatedAmountToOrdinaryWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the allocated amount to ordinary warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_AllocatedAmountToOrdinaryWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_MarketOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent  the at the market offering cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_MarketOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_NetProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of net proceeds from issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_NetProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_NetProceedsFromTheOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the net proceeds from the ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_NetProceedsFromTheOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_NumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_NumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_PurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the combined purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_PurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_RemainingFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the remaining fair value warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_RemainingFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_SaleOfOrdinaryShareGrossProceedsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of  sale of ordinary share gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_SaleOfOrdinaryShareGrossProceedsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Includes offering costs of open-end investment companies, and closed-end funds with a continuous offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoninterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noninterest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoninterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor amount as of the balance sheet date that the entity must expend to satisfy the terms of disclosed arrangements (excluding long-term commitments) in which the entity must commit resources to supply goods or services to one or more customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in number of shares issued and outstanding as a result of capital structure change to a stock dividend, stock split or reserve split occurring after the balance sheet date but prior to the later of the issuance of financial statements or the effective date of registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=nrsn_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=nrsn_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nrsn_AllianceGlobalPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nrsn_AllianceGlobalPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nrsn_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nrsn_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nrsn_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nrsn_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=nrsn_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=nrsn_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity - Schedule of Share Capital (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Schedule of Share Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, Authorized</a></td>
<td class="nump">90,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, Issued</a></td>
<td class="nump">23,228,941<span></span>
</td>
<td class="nump">15,379,042<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity - Schedule of Share Capital (Parentheticals) (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Schedule of Share Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Ordinary shares, par value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, Outstanding</a></td>
<td class="nump">23,228,941<span></span>
</td>
<td class="nump">15,379,042<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payment (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 02, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 27, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 15, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 22, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 20, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 25, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 10, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 16, 2018</div></th>
<th class="th">
<div>May 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_NumberOfSharesPercentage', window );">Total number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_ExpirationDateGrantTerm', window );">Expiration date grant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,628<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Cash payment for options granted (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Additional expense (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Option vested quarterly term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expire grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Shares of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_NumberOfInstallments', window );">Number of installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_InstallmentsLockUpPeriod', window );">Installments lock-up period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of unrecognized expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_ExpirationDateGrantTerm', window );">Expiration date grant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_ExpirationDateGrantTerm', window );">Expiration date grant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember', window );">2018 Employee Share Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,151,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Ordinary shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="nump">192,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember', window );">2018 Employee Share Option Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Option vested quarterly term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember', window );">2018 Employee Share Option Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Option vested quarterly term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nrsn_TwoThousandTwentyTwoBonusPlanMember', window );">2022 Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_RaiseOfAdditionalBonusPercentage', window );">Raise of additional bonus percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Option vested quarterly term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expire grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.88<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax benefit for compensation expense (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested options (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice', window );">RSU's exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Grant shares to non-management directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of RSUs (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax benefit for compensation expense (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to unvested RSUs (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | October 1, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares', window );">Bonus allocated in the form of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares', window );">Bonus allocated in the form of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | 2022 Bonus Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">RSUs grants amount (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Directors [Member] | Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Directors [Member] | RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Directors [Member] | RSUs [Member] | November 1, 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares reserved</a></td>
<td class="nump">2,343,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of ordinary shares as issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Employee [Member] | Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Employee [Member] | RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_ExpirationDateGrantTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the expiration date grant term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_ExpirationDateGrantTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_InstallmentsLockUpPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Installments lock-up period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_InstallmentsLockUpPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_NumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of installments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_NumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_NumberOfSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_NumberOfSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_RaiseOfAdditionalBonusPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of raise of additional bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_RaiseOfAdditionalBonusPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average of exercise price award granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares or units in an ESOP trust that have been assigned to individual participant accounts based on a known formula. IRS rules require allocations to be nondiscriminatory generally based on compensation, length of service, or a combination of both. For any particular participant such shares or units may be vested, unvested, or partially vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480489/718-40-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480513/718-10-30-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480843/718-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nrsn_TwoThousandTwentyTwoBonusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nrsn_TwoThousandTwentyTwoBonusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=nrsn_October12024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=nrsn_October12024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=nrsn_November12024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=nrsn_November12024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payment - Schedule of Fair Value of the Options Granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Fair Value of the Options Granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">100.54%<span></span>
</td>
<td class="nump">93.64%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1.82<span></span>
</td>
<td class="nump">$ 2.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=nrsn_EmployeesAndDirectorsMember', window );">Employees and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Fair Value of the Options Granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">93.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 1.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="nump">$ 1.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Fair Value of the Options Granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.91%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Employees and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Fair Value of the Options Granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.80%<span></span>
</td>
<td class="nump">93.63%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.24%<span></span>
</td>
<td class="nump">2.12%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Fair Value of the Options Granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Employees and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Fair Value of the Options Granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.51%<span></span>
</td>
<td class="nump">93.79%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 3.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 3.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.35%<span></span>
</td>
<td class="nump">2.46%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nrsn_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nrsn_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payment - Schedule of Share Option Activity (Details) - Equity Option [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Share Option Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Share Options, Beginning</a></td>
<td class="nump">1,069,128<span></span>
</td>
<td class="nump">1,069,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning</a></td>
<td class="nump">$ 2.26<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (years) , Beginning</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">6 years 8 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value, Beginning</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Share Options, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">936,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (years), Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Share Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted', window );">Weighted average remaining contractual life (years), Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod', window );">Number of Share Options, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited', window );">Weighted average remaining contractual life (years), Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited', window );">Intrinsic value, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Share Options, Forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of intrinsic value forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payment - Schedule of Restricted Stock Unit (RSU&#8217;s) Activity (Details) - Restricted Stock Units (RSUs) [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Restricted Stock Unit (RSU's) Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding beginning</a></td>
<td class="nump">317,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Weighted average grant date fair value, Outstanding beginning (in Dollars) | $</a></td>
<td class="nump">$ 249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted</a></td>
<td class="nump">208,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted', window );">Granted Weighted average grant date fair value, Granted (in Dollars) | $</a></td>
<td class="nump">$ 224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised</a></td>
<td class="num">(325,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding ending</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Weighted average grant date fair value, ending (in Dollars) | $</a></td>
<td class="nump">$ 236<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of granted award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Payment - Schedule of Share-Based Expense Recognized in the Statements of Operation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Share-Based Expense Recognized in the Statements of Operation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 557<span></span>
</td>
<td class="nump">$ 1,537<span></span>
</td>
<td class="nump">$ 1,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Share-based compensation expense - Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Share-Based Expense Recognized in the Statements of Operation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">575<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Share-based compensation expense - General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Share-Based Expense Recognized in the Statements of Operation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 364<span></span>
</td>
<td class="nump">$ 962<span></span>
</td>
<td class="nump">$ 1,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses - Schedule of Research and Development Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Schedule of Research and Development Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_SubcontractorsAndConsultants', window );">Subcontractors and consultants</a></td>
<td class="nump">$ 3,530<span></span>
</td>
<td class="nump">$ 4,794<span></span>
</td>
<td class="nump">$ 3,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_SharebasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">575<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_SalariesAndSocialBenefits', window );">Salaries and social benefits</a></td>
<td class="nump">1,975<span></span>
</td>
<td class="nump">1,905<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 5,698<span></span>
</td>
<td class="nump">$ 7,274<span></span>
</td>
<td class="nump">$ 5,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_SalariesAndSocialBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Salaries and social benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_SalariesAndSocialBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_SharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_SharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_SubcontractorsAndConsultants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subcontractors and consultants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_SubcontractorsAndConsultants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Pension funds paid</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses - Schedule of General and Administrative Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract', window );"><strong>Schedule of General and Administrative Expenses [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Professional services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,998<span></span>
</td>
<td class="nump">$ 1,486<span></span>
</td>
<td class="nump">$ 1,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">364<span></span>
</td>
<td class="nump">962<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Salaries and social benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">865<span></span>
</td>
<td class="nump">1,011<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralInsuranceExpense', window );">Insurance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">309<span></span>
</td>
<td class="nump">511<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Traveling abroad</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">134<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Others</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">534<span></span>
</td>
<td class="nump">641<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,204<span></span>
</td>
<td class="nump">$ 4,775<span></span>
</td>
<td class="nump">$ 4,967<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">During 2024, 2023 and 2022, the Company paid to pension funds
and to insurance companies an amount of $115 thousand, $104 thousand and $85 thousand which are included in Company&#8217;s salary expenses
under research and development and general and administrative expenses, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralInsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralInsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TravelAndEntertainmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses incurred for travel and entertainment during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TravelAndEntertainmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Income (Expenses), Net - Schedule of Financing Income (Expenses), Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeDisclosureNonoperatingAbstract', window );"><strong>Finance Income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Revaluation of warrants</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 2,191<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions', window );">Deposit interest</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_ExchangeRates', window );">Exchange rates</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Total income</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">2,390<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenseDisclosureNonoperatingAbstract', window );"><strong>Finance Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Issuance costs</a></td>
<td class="num">(306)<span></span>
</td>
<td class="num">(439)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExchangeFees', window );">Exchange rates</a></td>
<td class="num">(45)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks', window );">Bank fees</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Total expenses</a></td>
<td class="num">(356)<span></span>
</td>
<td class="num">(448)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total financing income (expanse), net</a></td>
<td class="num">$ (308)<span></span>
</td>
<td class="nump">$ 1,942<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_ExchangeRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_ExchangeRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExchangeFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense in the period for fees charged by securities exchanges for the privilege of trading securities listed on that exchange. Some fees vary with the related volume, while others are fixed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479035/940-320-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExchangeFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on loans received from another Federal Home Loan Bank (FHLB).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph b<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDepositsWithFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenseDisclosureNonoperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenseDisclosureNonoperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeDisclosureNonoperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeDisclosureNonoperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Balances and Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 17, 2024</div></th>
<th class="th"><div>Jun. 27, 2024</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrentAndNoncurrent', window );">Accrued salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrentAndNoncurrent', window );">Accrued bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_PotentialBonusPayable', window );">Potential bonus payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vesting of unvested options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expiry term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Additional paid in capital.</a></td>
<td class="nump">$ 1,434,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares approved the grant (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Mr. Alon Ben-Noon&#8217;s [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrentAndNoncurrent', window );">Accrued salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Mr. Alon Ben-Noon&#8217;s [Member] | RSU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties Balances and Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares approved the grant (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_PotentialBonusPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of potential bonus payable to the officers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_PotentialBonusPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=nrsn_MrAlonBenNoonsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=nrsn_MrAlonBenNoonsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Israel Tax Authority [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal', window );">Corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 24,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax assets recognized tax benefits</a></td>
<td class="nump">782<span></span>
</td>
<td class="nump">$ 693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net change in total valuation allowance</a></td>
<td class="nump">$ 2,301<span></span>
</td>
<td class="nump">$ 1,813<span></span>
</td>
<td class="nump">$ 1,419<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_IsraelTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_IsraelTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of the Company&#8217;s Net deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 5,688<span></span>
</td>
<td class="nump">$ 3,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsStateTaxes', window );">Other temporary differences</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">1,282<span></span>
</td>
<td class="nump">1,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual', window );">Vacation and convalescence accrual</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets:</a></td>
<td class="nump">7,149<span></span>
</td>
<td class="nump">4,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Deferred tax liability: Operating lease right-of-use assets</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets:</a></td>
<td class="nump">7,130<span></span>
</td>
<td class="nump">4,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(7,130)<span></span>
</td>
<td class="num">(4,829)<span></span>
</td>
<td class="num">$ (3,016)<span></span>
</td>
<td class="num">$ (1,607)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of deferred tax assets operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount represents deferred tax assets vacation and convalescence accrual.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of the Movement of the Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceAbstract', window );"><strong>Schedule of the Movement of the Valuation Allowance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at the beginning of the year</a></td>
<td class="nump">$ 4,829<span></span>
</td>
<td class="nump">$ 3,016<span></span>
</td>
<td class="nump">$ 1,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Addition of valuation allowance</a></td>
<td class="nump">2,301<span></span>
</td>
<td class="nump">1,813<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net change in the valuation allowance</a></td>
<td class="nump">2,301<span></span>
</td>
<td class="nump">1,813<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at the end of the year</a></td>
<td class="nump">$ 7,130<span></span>
</td>
<td class="nump">$ 4,829<span></span>
</td>
<td class="nump">$ 3,016<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 27, 2024</div></th>
<th class="th"><div>Jun. 23, 2023</div></th>
<th class="th"><div>Mar. 20, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued under sale agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">444,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Options granted to employees</a></td>
<td class="nump">108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercise price</a></td>
<td class="nump">$ 0.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options to vest</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options expiry term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Options issued for services</a></td>
<td class="nump">355,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options to vest</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options expiry term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Options issued for services</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options exercise price</a></td>
<td class="nump">$ 0.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=nrsn_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=nrsn_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( $.'AUI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( $.'AUI*K4]J\@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL%.PS ,AE\%Y=XZ[2A#4=<+TTX@(3$)Q"U*
MO"VB::+$J-W;DY:M \$#[!C[S^?/DFOEA7(!GX/S&,A@O!ELVT6A_(H=B+P
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( $.'AUHAK?U!6@<  -\F   8
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M-!? ]PLA].; _$#S3MOX7U!+ P04    " !#AX=:XMNXO\P#  "_"0  &
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;)56;8_:.!#^SJ\8I5+52I2$L+OL
M[0+2PEYU*[6]5=E>/U3WP2038N'8J>W \N]O[$"@53;:DQ#QVSQ^GO%XQI.=
MTAN3(UIX+H0TTR"WMKP)0Y/D6# S4"5*FLF4+IBEKEZ'IM3(4F]4B#".HJNP
M8%P&LXD?>]2SB:JLX!(?-9BJ*)C>SU&HW308!L>!KWR=6S<0SB8E6^,2[;?R
M45,O;%!27J T7$G0F$V#N^'-?.S6^P7_<-R9LS8X)2NE-J[SD$Z#R!%"@8EU
M"(P^6UR@$ Z(:/P\8 ;-EL[PO'U$_^BUDY85,[A0XCM/;3X-K@-(,6.5L%_5
M[B\\Z+ET>(D2QO_#KEX;_Q% 4AFKBH,Q,2BXK+_L^>"',X/KZ 6#^& 0>][U
M1I[E/;-L-M%J!]JM)C37\%*]-9'CTAW*TFJ:Y61G9W=5RBT\R/IXR4^3T!*L
MFPR3 \2\AHA?@!C&\%E)FQOX4Z:8_@H0$I^&5'PD-8\[$>\Q&<!HV(<XBB\Z
M\$:-R)''&W6)5!I^/+&5P'_;)-8 %^T [F;<F)(E. TH] WJ+0:SMV^&5]%M
M![V+AMY%%WI#[PLKL(U;M_52%;C)89$SON&R@\YE0^?R570^<EW PWT;HVZ
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MSK6 >C]G3+[>Z$^P]2?W\;]02P,$%     @ 0X>'6D^851.4 @  I0<  !@
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M9)1K@/I]S53B:K[H![3']9;_ %!+ P04    " !#AX=:!OLO8^$*  #%&@
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M->1G6Z$)Y.2ERAD81@YU(N%R))<UZ8 ."=")3B='PY2ULJT*,Y$@PMH7PKA
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M1E?SSTI)L"@]@/72N=A?T '#EZN+_P!02P,$%     @ 0X>'6N+!_Y>%'@
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M"2?BO.38+@LS_7V1?X@;#W.>^@XR8%V?$.*RC:EYR>[H>3FT(+/Q7,-\/+;
MO#50$5P/F+,>"&'25HR34[1=E1/H[-F5E34A  +K<DABJOJ,1C5M,]>/"E?:
M1JT\3"JD>>T5AY#"<N@<J]@B_P?T%$:K%U6"P.[8F)WY.K'%)#YEZPA%-8;Y
M0ML=MH-@/-HG^5:K&O,Z^01/5Q9UJ0\.SI\S B_$T'/$*OG6$#J@?=P16$CA
M&T:8U5"3O[@+@"839+3(?R%3"V3*G[$2[988#H:L9MZP\BR@W(/>DU0K#-P2
M!96'*_C"@:NT=CQ=#Y6(#9G &P/IJR':;*(8.0%2UO8W/YD09CU'.K.JY;3N
M=3'N2SZ&7<%I=%P37)^#:U4 DIVA2.'.FCVH(CFR-,)V?,XG- G>_OJKZ.V]
MA,SR]S5<%8AYXP4EN/P]469PBO0/;Z!+75-I.V(_[0\FF Q^16ZP-Q&UET77
M<3BB3(28^>/=%@>V74L<2PE)@0>%2NL'0.!# IQ)H^A9T;RF$K!/O-\2UA\0
MFR[IK)B=<*1D]SU:OH<&5E*/D?*A 0['0T8=P(H,F4M4D2F0^+:7%=FY82YR
M5.I\X_&(V:E(HJI,QLH1F4JD.3DP^1F,H(#^M^.=Q? 0GR)V/+&[0!(;:%-)
M;!=CMD7V<\MF>39RQ1LR2C@/LG:P114+?T*AH!013M%>CT+ \X&#AY$1R$;Z
M" &-,"&)-X8.*B[\*KSW<,_SOS!E P HGS<<SVX#4^LF1NWZ.G^W6MD2!]DU
MEL]R_,37^3R_?)K_BQAJ"&E4V%='4A:S ^RQ2<R5?S6>9,<3[$,P7"N3OV7/
M8XJN%+3PFK2C;F6MT0]5\@-LEFBM BWV Y[=B_P'\M$XI']S8/VC''ZDT)^3
M2L4H<"3E2V+R,VZ4X?Y5 O?/+,8;"@&I1_\J<Y6A0S2I.,U@W$EU+8%REQ5D
M'XNM03*7)UJSI*P)*S$QG5D77>5]AG@)%20(B.R-07 ROP8]])]+(F4B=-D.
M?9J,V";;6&3?)QS!KF@.<NT4II4T9V<4=GA:5'_8=.TYUA5]-&QR23V=H5 T
M6 X@H<+R#XQ)$147(7(_\!D@,"+E)[28A@%+T^\!4RE8_$03,3P@H%TPZWOE
M2]B'!CDWCFW++-TM-J6SS 4VI.-X(R35NI/*0)CIZ*HL0(RC5-0IDH07=$*2
M>+,<,Z1L"'MF*@L-[G":WOJQ95#+Z!?,:)\=XAK+2B$(<DY J>,MSF6+&_H,
M73K,5/R(  +//5E(";]M0Q8B6J)3\C,R*O^"/N:79 Z&IJA^'1S,^'^&%O^Q
M9#C&U#$[9'WI09DC.Z-=D>00#O+&/N&#3=-6J7%E*5/Q(+%!<A00(\1$QZ<N
MU"+/ZQFO^P6-+3A(;*2S&&W@!,F29^R,IDP0:"V1X98$0=LE+B,]4'R 3S\>
M0Z?5#NL-G7#7M<M6\$PFL4U\2L6)]E+XO5R?WLO0Q&&9)PBP.'J,$^3!+K0-
M4<;'#Z22BU21_-$#?4UZ;N'M27R4%F8,QOY?%\G.JN3/4?QLHT#":UF(QA,Q
MU&QQ[I*4?9+R]*E%#L0%+3/X9KYEURFW(JKP62@2;AKCM>/@@WS&-I&"H$U"
MO*2#?0Z=H& 1\P*39&X,73("2:JC.JN7!7*H*]O[?$8.(+AN.^)T49/'EF%$
M5?P%5-#'0%7,IR>: ]P$XW-:K 2?1G75Q&>+6AN%3;\9[[DYM$Z$S+.3A_M3
M&]L--F>JFB&-JM'O++ VXV>G>8V VH$B9T?)A-G9!,',QX6\D30P/(Y2Z6&V
M 2&4%%LT@T.J**PN#MBI^//1@^,$\XX.[K,&9R-$.=H9V_\H$*.8_52>=10
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M(?P6JJH"\9(HY9!I;] (.$>#J.))<^>&^ZE9"&)CC@L%5(YVCQL/CUHBO#_
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M-_)RW_BXO"+YQP)( K="5C3T8O'UTP=RE\M_()7D5_TNV[YOM_SGQI!C[O
M_;YJR6KI!RP0WOW\XG\!4$L#!!0    ( $.'AUHZ#G#8BP(  )4%   9
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M.!A=^:!;];:&576CF)6RI+]F6]+ 0^T"Z'RMJ)F=X2[H1VCV&U!+ P04
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M]B9^NOOY?^?<3;9*_S8%HH7'4D@S]0MKJXL@,%F!)3,#5:&DD[72);.TU)O
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MAVN,^._PO&A(0/""5E=QJ^N,X0RJJAI1 !>J E";_Q-&XII@Y:(H&I%S52P
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M0 _:4#B#+&0#JU);TUSN= (9?>X0P78<74>%-@;K#K8DR?^;!D9?KX T/JN
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M!P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6R=5<F.VT80O?,K"O3
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M'U0SYQK%R*6;+3-I:%*Y;4Z_!E36@<[GDCZFC6(3M#^;R2]02P,$%     @
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M"+;BRT))Y(<6X'UN875[0PKZKXO7_P502P,$%     @ 0X>'6AW6QOX"!
MTP@  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&ULC59M;^,V#/Z>7R'X
M@/M4Q(F3WO7:)$!?-NR =5>T>_DP[(-LT[906?)$.6GVZT=*CIO;>L$!02)*
MXD,^)$5FM;/N&1L +UY:;7"=--YWEVF*10.MQ*GMP-!)95TK/8FN3K%S(,N@
MU.HTF\T^I*U4)MFLPMZ#VZQL[[4R\. $]FTKW?X&M-VMDWERV'A4=>-Y(]VL
M.EG#$_C?N@='4CJBE*H%@\H:X:!:)]?SRYLEWP\7?E>PPZ.U8":YM<\L?"[7
MR8P= @V%9P1)/UNX!:T9B-SX>\!,1I.L>+P^H/\8N!.77"+<6OV'*GVS3BX2
M44(E>^T?[>XG&/B<,UYA-89OL8MWLT^)*'KTMAV4R8-6F?@K7X8X'"E<S+ZA
MD T*6? [&@I>WDDO-RMG=\+Q;4+C1: :M,DY93@I3][1J2(]OWF"FD+LQ2-T
MUGEEZE7J"98/TV* N(D0V3<@YIFXM\8W*'XP)91? Z3DS^A4=G#J)CN)> ?%
M5"SF9R*;9<L3>(N1Y"+@+;Z7I/CS.D?OJ"3^>HMO1%N^C<;/Y!([6< ZH7>
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MZVD(AF5#_SK \04ZKRS%8!#8P/@_9O,O4$L#!!0    ( $.'AUJD!F<ZK08
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M/7^?3O+WL]6XD+:-V=.JQNV&.0&_W<N(H>.87'7D.%XOTO\/<O#T^H.0N_'
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M77N.CP#)R<E&S,V;13JQ"IF=>[UZ(K+!@L;(T8Y9IN.N0@!9'4N4FTA)4;M
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MO3II-+!B489R!-)1?F$5Y1=&%B.F^_2<2S>(\N8:M$''>CE#+PDVT-@=D*'
MT:B]QMH<3;0EE=M"4$'$U'JKZMPY7W:WHI&H:;PWBKJC^27+ O^S4=X0"%U7
M;1.G9O?1-A;)NX@CN"N8 V#< 6 =S%EK@<".%C%$Y ..E/ECPZ;)=X&=L[HH
M@@E&5*X,_4#Q)>8(E<]CGN@,,!,#5A3"JCCOL-;-$4/.O:J_P$0$!2%H5L3Z
M1OCB]R%9E2M+1GH6[Q8W);/,&2+&XV@C8!YD)[E&JP!'ER<>3IXEYH=(8E[
M"7$9PE"2(F:#WS-1J22;A*?IW B96'$Q;L$$]EEC(L60XG(T,P=07-,6Y[S%
M'7Q&?3_-1/R  (@R&W UG.\S)9C:8-*'Y*=CG?^%-B-=@EUM2Y7_UEKTA[^W
M%?Z/),-2\!ERY<95DH4YO#/8%4@. $KG-2,^F#B)'WLIDC(1#Q ;+'PA5O/Y
MC?-39VI70*UCO.P7::R0@\!&.(O.!@9(YJI+K25'BTF3-5H=SDA6=>1[XP/%
M#PB.SL? :57M=@<G7-?5NF)@F' 2(#PEX@1[46XOE\-[:<LP+'$$80@47.\
M>6@7JA(HH^-'R)>R5('\P0-- 7IN$#:!^ @MQ!@<^[]=)!E5R5^"^)E2$)G3
M,I_^B\10:F>IC:K040'(%5HH\\=A!T4QQ+?D,N96@&<N[0W"#6.<=IQ<5I%
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M<G*U&M4N9(6S:$?1C(EKEA#_S2GJ[HZ"RN.+ULB!8)9[UCGYSITFJ9C$D<1
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MX/=-!59+/N "_E_:>?4_4$L#!!0    ( $.'AUH6??]KLP(  .(%   9
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M%&HS#N)@MW'/UX5U&^%D5+$U+M ^5'>:O+!%R7F)TG E0>-J'$SCRUG?Q?N
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MES%J9T#?-TK9^XD+T%_OBQ]02P,$%     @ 0X>'6HE?'6&1 P  <PD  !D
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MT>GPEZX.7E!]9^_JF*)>^ NRH;,XE[:X15:SU1W\HKAZ[I87%_@;IA=T/H/
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M&TUB!U0W:#K#R+IM[E0:&A7MMJ#9C,HZT/U:2O-BV #]M$_^ %!+ P04
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M JB= YTOE;*[C;N@^ZW,?@)02P,$%     @ 0X>'6FI@QW3G P  60D  !D
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MUD3],M0#Q4M;7+=<Z5)MN[E^3$&8 +V^XUP]#DR];I_GY"]02P,$%     @
M0X>'6A1@]1^8!0  ]B   !D   !X;"]W;W)K<VAE971S+W-H965T-#@N>&UL
MO9K;;N,V$(;O^Q2$&Q2[P#8R*=NQ7=M 8KOH DD;;+KM1= +1J(M877PDE2\
M>?M2AX@Z4+3D"+E)+&EF]/,7-1]E>7$,Z3?F$,+!#]\+V'+@<'Z8&P:S'.)C
M=AD>2"".[$+J8RXVZ=Y@!TJPG23YGH&&PXGA8S<8K!;)OGNZ6H01]]R W%/
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MT?0E>[K!PT/R%ODIY#STDX\.P3:A<8 XO@M#_KH1GR#_J</J?U!+ P04
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M@I'4Y[V3^2C7&G2B6.4NL\R([+\:MQ8/<<%M&4G@R8 8=#NN\)*!F ):]JX
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MCGN:C-#IR1DZ082AQSDO)&:)[+M*JS+<;EPIN"D5^'L4C""^0$&[A7S/[S3
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M>9T*>9=K_H9\/_Q%OM!"NPJ(A#D%;)C#LA'4X\SNYW]3X['N%K)2#PGSD;
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M1+'"I-A1?)VO5[CG2O$XWUPQNF B*Y"^O^1</>UD%>S6^<S^!5!+ P04
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MQ>ZF5MHM& )Y6!*I;6ZU38M4M=J]+Z:]<. DL6HPLYVD^?:S@9(0$=^F8V\
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MZ9K,OF:Z; 9A)NCQ.>=JW3 +-(5X_!=02P,$%     @ 0X>'6O+T)?*Q&@
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M_G^T5 0ZID*U#-4TI9E1UI3F;Q_:HBPSK_C;.XSL5N<<(S4/U7Q4$Z@F42U
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MHVNEP=O+HYU(5IG^VS"INMD,<W7? M< M9\Q)O<3W=+]#1[_ 5!+ P04
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M=/5 GJ[6>IJF?%HMGS?G5V:54YU; IJP1C4#U4Q4LU#-1C4'U5Q4\U#-1[4
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MGDP,3[B_^X17KO3H[J KQUM7CD%7(K9A,<UB],QH$IO, .,MS*ATIKMFM'R
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M,_GD :8 \ON24K'MJ FZ1U3T!U!+ P04    " !#AX=:@%(L(' "  "@!@
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M&[UQR]+\0D#: +._%$)O#9N@_RFE?P%02P,$%     @ 0X>'6I=<D!DO!
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MKK!PKC\3?#V!T 8XON%</37T!-U[;/X?4$L#!!0    ( $.'AUK0E*0<L@,
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MFM?-43V0;%VU"R],JN:C>DQ50PE<&ZCW2\;D;J 7:%O4\"=02P,$%     @
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M673+1.M_@7KYL0, E&9!:3:4YD!I+HK6-,E6NF6\4*A0-H2R$Y)F06DVE.9
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M=H!Z?\&Y?-S)&J@63TW_!U!+ P04    " !#AX=:A9[&%!@#  "7"0  &0
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M)4DSDHN4Y8B3S<+ZY,ZN75\YE!;W*3F(LV>DNO+ V _5^)HL+$=%1"B)I9+
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MI2!4#*U,RL65;8LD@P*+<[8 JM[,&"^P5$,^M\6" TX-J2"VYSBA7>"<6M'
MS-WQ:,!*27(*=QR)LB@P?QT#8:NAY5KKB?M\GDD]84>#!9[#!.3CXHZKD=VH
MI'D!5.2,(@ZSH35RK^*^QAO 4PXKL?&,M),I8\]Z<),.+4<'! 02J16P^EO"
M-1"BA508OVI-JUE2$S>?U^I?C'?E98H%7#/R/4]E-K0N+)3"#)=$WK/55ZC]
M]+1>PH@POVA58QT+):60K*C)*H(BI]4_?JGSL$%PPST$KR9XNX1@#\&O"?ZQ
MA* F!"8SE163AQA+' TX6R&NT4I-/YAD&K:RGU.][1/)U=M<\61T0Q-6 'K
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 0X>'6D$AT:%Q!0  TS
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MEKUMA]=\-OVA]>894$L! A0#%     @ 0X>'6D;'34B5    S0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !#AX=:
M2JU/:O(    K @  $0              @ '#    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " !#AX=:F5R<(Q &  "<)P  $P              @ 'D
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( $.'AUHAK?U!6@<
M -\F   8              " @24(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " !#AX=:XMNXO\P#  "_"0  &               @(&U
M#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 0X>'6EFS
ME4E'!0  ?A<  !@              ("!MQ,  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( $.'AUI/F%43E (  *4'   8
M  " @309  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !#
MAX=:W7C;A?L#   ,#@  &               @('^&P  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ 0X>'6JRQQ-2M!@  [BP  !@
M         ("!+R   'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( $.'AUIA]X@CYP<  +HG   8              " @1(G  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !#AX=:!OLO8^$*  #%&@
M&               @($O+P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ 0X>'6N+!_Y>%'@  !UH  !@              ("!1CH  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( $.'AUHZ#G#8BP(
M )4%   9              " @0%9  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ 0X>'6M245,AC @  3@4  !D              ("!
MPUL  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !#AX=:
M,C5>M!\#   \"   &0              @(%=7@  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( $.'AUH6DW+]@@0  * *   9
M      " @;-A  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ 0X>'6A[(QI.4 @  G@4  !D              ("!;&8  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !#AX=:[4WU)&@&  "Z$
M&0              @($W:0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( $.'AUIDC?E)6@X  +$K   9              " @=9O  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ 0X>'6L] 4KX
M$0  LS4  !D              ("!9WX  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " !#AX=:#:\5SJX"  #N!0  &0
M@(&>CP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( $.'
MAUJH?K_,6P,  $,'   9              " @8.2  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ 0X>'6K UM__R @  > 8  !D
M         ("!%98  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " !#AX=:KZA!V*8'  !I%   &0              @($^F0  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( $.'AUH=UL;^ @0  -,(
M   9              " @1NA  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ 0X>'6J0&9SJM!@  LA   !D              ("!5*4
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !#AX=:@$-#
MSS,#   5"   &0              @($XK   >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( $.'AUI)CQ,/8P(  (@&   9
M  " @:*O  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M0X>'6CRE,S@1 @  W00  !D              ("!/+(  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " !#AX=:M0#(*.(&  #>%0  &0
M            @(&$M   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( $.'AUHI-E4H3R   '5G   9              " @9V[  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ 0X>'6A9]_VNS @
MX@4  !D              ("!(]P  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " !#AX=:;40I,) "  "(!0  &0              @($-
MWP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( $.'AUKF
MMX3-: (  $@%   9              " @=3A  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ 0X>'6K*,O045 P  Z@<  !D
M     ("!<^0  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $.'AUK4Q!)R5 4  %\.   9              "
M@=GU  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 0X>'
M6L8YS).X @  ^04  !D              ("!9/L  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " !#AX=:J32(TF(#   J!P  &0
M        @(%3_@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( $.'AUINIA9-]P(  &(&   9              " @>P! 0!X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ 0X>'6FI@QW3G P  60D
M !D              ("!&@4! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " !#AX=:QBWZ;@L"  "2!   &0              @($X"0$
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( $.'AUJ@JSV?
M)P,  "\+   9              " @7H+ 0!X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ 0X>'6BB,6O4O P  3@T  !D
M ("!V X! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !#
MAX=:GFGXIND!   '!   &0              @($^$@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( $.'AUH9KF)8,P,  $ ,   9
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M970U,"YX;6Q02P$"% ,4    " !#AX=:Y2=B7L<"  "S"   &0
M    @(%%)@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M $.'AUI\M"$X[P(  /4)   9              " @4,I 0!X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ 0X>'6NSIB_\! P  B @  !D
M             ("!:2P! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    " !#AX=:^X?N.MH%  #S,P  &0              @(&A+P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( $.'AUI9&XESN@(
M .T(   9              " @;(U 0!X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L! A0#%     @ 0X>'6I]?/J\#!   91(  !D              ("!
MHS@! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " !#AX=:
MSJ_=#DD#  "4"P  &0              @('=/ $ >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;%!+ 0(4 Q0    ( $.'AUKR]"7RL1H  "CM 0 9
M      " @5U  0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%
M  @ 0X>'6CO-719* @  S04  !D              ("!15L! 'AL+W=O<FMS
M:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " !#AX=:WR]KM%D"   D!@
M&0              @('&70$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+
M 0(4 Q0    ( $.'AUHK_$TS,!\  ,1Q @ 9              " @59@ 0!X
M;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ 0X>'6HD>U>3B
M!0  ?BP  !D              ("!O7\! 'AL+W=O<FMS:&5E=',O<VAE970V
M,BYX;6Q02P$"% ,4    " !#AX=:UC.-\"@$  #J$@  &0
M@('6A0$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( $.'
MAUH@J"\0'P,  ,8(   9              " @36* 0!X;"]W;W)K<VAE971S
M+W-H965T-C0N>&UL4$L! A0#%     @ 0X>'6GLE7*Q= P  F X  !D
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M=#8Y+GAM;%!+ 0(4 Q0    ( $.'AUHX]%)3W04  $@U   9
M  " @56? 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @
M0X>'6H6>QA08 P  EPD  !D              ("!::4! 'AL+W=O<FMS:&5E
M=',O<VAE970W,2YX;6Q02P$"% ,4    " !#AX=:[01""3,$   '%   &0
M            @(&XJ $ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4
M Q0    ( $.'AUJH&R0O P,  %T)   9              " @2*M 0!X;"]W
M;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ 0X>'6JO8<;9P!0
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M2P$"% ,4    " !#AX=:Q]=S3T<"  #5*P  &@              @ 'VOP$
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !#AX=:'YV%
M;PD"  #8*@  $P              @ %UP@$ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     4@!2 '46  "OQ $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>206</ContextCount>
  <ElementCount>338</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>45</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Consolidated Statements of Financial Position (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Statements of Financial Position (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Consolidated Statements of Income and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Income and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Consolidated Statements of Changes in Equity (deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Equity (deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Significant Accounting Policy</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/SignificantAccountingPolicy</Role>
      <ShortName>Significant Accounting Policy</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Cash and Cash Equivalent</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/CashandCashEquivalent</Role>
      <ShortName>Cash and Cash Equivalent</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/OtherReceivables</Role>
      <ShortName>Other Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Operating Lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/OperatingLease</Role>
      <ShortName>Operating Lease</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/OtherCurrentLiabilities</Role>
      <ShortName>Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Liability in Respect of Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/LiabilityinRespectofWarrants</Role>
      <ShortName>Liability in Respect of Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Share Based Payment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ShareBasedPayment</Role>
      <ShortName>Share Based Payment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Research and Development Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ResearchandDevelopmentExpenses</Role>
      <ShortName>Research and Development Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995317 - Disclosure - General and Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/GeneralandAdministrativeExpenses</Role>
      <ShortName>General and Administrative Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995318 - Disclosure - Financing Income (Expenses), Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/FinancingIncomeExpensesNet</Role>
      <ShortName>Financing Income (Expenses), Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Related Parties Balances and Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactions</Role>
      <ShortName>Related Parties Balances and Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995320 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995321 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995322 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/SignificantAccountingPolicy</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Significant Accounting Policy (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/SignificantAccountingPolicyTables</Role>
      <ShortName>Significant Accounting Policy (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/SignificantAccountingPolicy</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Cash and Cash Equivalent (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/CashandCashEquivalentTables</Role>
      <ShortName>Cash and Cash Equivalent (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/CashandCashEquivalent</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Other Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/OtherReceivablesTables</Role>
      <ShortName>Other Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/OtherReceivables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Operating Lease (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/OperatingLeaseTables</Role>
      <ShortName>Operating Lease (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/OperatingLease</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/OtherCurrentLiabilities</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Liability in Respect of Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsTables</Role>
      <ShortName>Liability in Respect of Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/LiabilityinRespectofWarrants</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/ShareholdersEquity</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Share Based Payment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ShareBasedPaymentTables</Role>
      <ShortName>Share Based Payment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/ShareBasedPayment</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Research and Development Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ResearchandDevelopmentExpensesTables</Role>
      <ShortName>Research and Development Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/ResearchandDevelopmentExpenses</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996011 - Disclosure - General and Administrative Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/GeneralandAdministrativeExpensesTables</Role>
      <ShortName>General and Administrative Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/GeneralandAdministrativeExpenses</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Financing Income (Expenses), Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/FinancingIncomeExpensesNetTables</Role>
      <ShortName>Financing Income (Expenses), Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/FinancingIncomeExpensesNet</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/IncomeTaxes</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996014 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/GeneralandAdministrativeExpensesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Significant Accounting Policy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/SignificantAccountingPolicyDetails</Role>
      <ShortName>Significant Accounting Policy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/SignificantAccountingPolicyTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Significant Accounting Policy - Schedule of the Lives Used in Computing Straight-Line Depreciation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation</Role>
      <ShortName>Significant Accounting Policy - Schedule of the Lives Used in Computing Straight-Line Depreciation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Cash and Cash Equivalent (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/CashandCashEquivalentDetails</Role>
      <ShortName>Cash and Cash Equivalent (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/CashandCashEquivalentTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Cash and Cash Equivalent - Schedule of Cash And Cash Equivalent (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleofCashAndCashEquivalentTable</Role>
      <ShortName>Cash and Cash Equivalent - Schedule of Cash And Cash Equivalent (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Other Receivables - Schedule of Other Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable</Role>
      <ShortName>Other Receivables - Schedule of Other Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/OperatingLeaseDetails</Role>
      <ShortName>Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/OperatingLeaseTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Operating Lease - Schedule of Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/OperatingLeaseDetailsScheduleofOperatingLease</Role>
      <ShortName>Operating Lease - Schedule of Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Operating Lease - Schedule of Maturity Analysis of Company???s Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable</Role>
      <ShortName>Operating Lease - Schedule of Maturity Analysis of Company???s Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Operating Lease - Schedule of Weighted Average Remaining Lease Terms and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable</Role>
      <ShortName>Operating Lease - Schedule of Weighted Average Remaining Lease Terms and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Other Current Liabilities - Schedule of Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleofOtherCurrentLiabilitiesTable</Role>
      <ShortName>Other Current Liabilities - Schedule of Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Liability in Respect of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails</Role>
      <ShortName>Liability in Respect of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Liability in Respect of Warrants - Schedule of Financial Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleofFinancialMeasuredatFairValueonaRecurringBasisTable</Role>
      <ShortName>Liability in Respect of Warrants - Schedule of Financial Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Liability in Respect of Warrants - Schedule of Fair Value of the Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable</Role>
      <ShortName>Liability in Respect of Warrants - Schedule of Fair Value of the Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Liability in Respect of Warrants - Schedule of the Movement in Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleoftheMovementinWarrantLiabilityTable</Role>
      <ShortName>Liability in Respect of Warrants - Schedule of the Movement in Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/ShareholdersEquityTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Shareholders' Equity - Schedule of Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleofShareCapitalTable</Role>
      <ShortName>Shareholders' Equity - Schedule of Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Shareholders' Equity - Schedule of Share Capital (Parentheticals) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleofShareCapitalTable_Parentheticals</Role>
      <ShortName>Shareholders' Equity - Schedule of Share Capital (Parentheticals) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Share Based Payment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ShareBasedPaymentDetails</Role>
      <ShortName>Share Based Payment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/ShareBasedPaymentTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Share Based Payment - Schedule of Fair Value of the Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable</Role>
      <ShortName>Share Based Payment - Schedule of Fair Value of the Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Share Based Payment - Schedule of Share Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable</Role>
      <ShortName>Share Based Payment - Schedule of Share Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Share Based Payment - Schedule of Restricted Stock Unit (RSU???s) Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleofRestrictedStockUnitRSUsActivityTable</Role>
      <ShortName>Share Based Payment - Schedule of Restricted Stock Unit (RSU???s) Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Share Based Payment - Schedule of Share-Based Expense Recognized in the Statements of Operation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleofShareBasedExpenseRecognizedintheStatementsofOperationTable</Role>
      <ShortName>Share Based Payment - Schedule of Share-Based Expense Recognized in the Statements of Operation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Research and Development Expenses - Schedule of Research and Development Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleofResearchandDevelopmentExpensesTable</Role>
      <ShortName>Research and Development Expenses - Schedule of Research and Development Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996039 - Disclosure - General and Administrative Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/GeneralandAdministrativeExpensesDetails</Role>
      <ShortName>General and Administrative Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/GeneralandAdministrativeExpensesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996040 - Disclosure - General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable</Role>
      <ShortName>General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Financing Income (Expenses), Net - Schedule of Financing Income (Expenses), Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable</Role>
      <ShortName>Financing Income (Expenses), Net - Schedule of Financing Income (Expenses), Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/FinancingIncomeExpensesNetTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Related Parties Balances and Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails</Role>
      <ShortName>Related Parties Balances and Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactions</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/IncomeTaxesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Income Taxes - Schedule of the Company???s Net deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable</Role>
      <ShortName>Income Taxes - Schedule of the Company???s Net deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Income Taxes - Schedule of the Movement of the Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/ScheduleoftheMovementoftheValuationAllowanceTable</Role>
      <ShortName>Income Taxes - Schedule of the Movement of the Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ea0237295-20f_neuro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurosensetx.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurosensetx.com/role/SubsequentEvents</ParentRole>
      <Position>74</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isUsgaap="true" original="ea0237295-20f_neuro.htm">ea0237295-20f_neuro.htm</File>
    <File>nrsn-20241231.xsd</File>
    <File>nrsn-20241231_cal.xml</File>
    <File>nrsn-20241231_def.xml</File>
    <File>nrsn-20241231_lab.xml</File>
    <File>nrsn-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="707">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="7">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="50">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>99
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0237295-20f_neuro.htm": {
   "nsprefix": "nrsn",
   "nsuri": "http://www.neurosensetx.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "ea0237295-20f_neuro.htm"
     ]
    },
    "schema": {
     "local": [
      "nrsn-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "nrsn-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nrsn-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "nrsn-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nrsn-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 284,
   "keyCustom": 54,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 25,
   "memberCustom": 18,
   "hidden": {
    "total": 100,
    "http://fasb.org/us-gaap/2024": 73,
    "http://www.neurosensetx.com/20241231": 24,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 206,
   "entityCount": 1,
   "segmentCount": 45,
   "elementCount": 727,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 707,
    "http://xbrl.sec.gov/dei/2024": 50,
    "http://xbrl.sec.gov/cyd/2024": 7,
    "http://xbrl.sec.gov/ecd/2024": 1,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:RestrictedCashAndInvestmentsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Consolidated Statements of Financial Position (Parentheticals)",
     "shortName": "Consolidated Statements of Financial Position (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://www.neurosensetx.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Consolidated Statements of Income and Comprehensive Loss",
     "shortName": "Consolidated Statements of Income and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.neurosensetx.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - Consolidated Statements of Changes in Equity (deficit)",
     "shortName": "Consolidated Statements of Changes in Equity (deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c9",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c9",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.neurosensetx.com/role/ConsolidatedCashFlow",
     "longName": "995305 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.neurosensetx.com/role/General",
     "longName": "995306 - Disclosure - General",
     "shortName": "General",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.neurosensetx.com/role/SignificantAccountingPolicy",
     "longName": "995307 - Disclosure - Significant Accounting Policy",
     "shortName": "Significant Accounting Policy",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.neurosensetx.com/role/CashandCashEquivalent",
     "longName": "995308 - Disclosure - Cash and Cash Equivalent",
     "shortName": "Cash and Cash Equivalent",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.neurosensetx.com/role/OtherReceivables",
     "longName": "995309 - Disclosure - Other Receivables",
     "shortName": "Other Receivables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.neurosensetx.com/role/PropertyandEquipmentNet",
     "longName": "995310 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.neurosensetx.com/role/OperatingLease",
     "longName": "995311 - Disclosure - Operating Lease",
     "shortName": "Operating Lease",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.neurosensetx.com/role/OtherCurrentLiabilities",
     "longName": "995312 - Disclosure - Other Current Liabilities",
     "shortName": "Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.neurosensetx.com/role/LiabilityinRespectofWarrants",
     "longName": "995313 - Disclosure - Liability in Respect of Warrants",
     "shortName": "Liability in Respect of Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "nrsn:LiabilityInRespectOfWarrantsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "nrsn:LiabilityInRespectOfWarrantsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.neurosensetx.com/role/ShareholdersEquity",
     "longName": "995314 - Disclosure - Shareholders' Equity",
     "shortName": "Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.neurosensetx.com/role/ShareBasedPayment",
     "longName": "995315 - Disclosure - Share Based Payment",
     "shortName": "Share Based Payment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.neurosensetx.com/role/ResearchandDevelopmentExpenses",
     "longName": "995316 - Disclosure - Research and Development Expenses",
     "shortName": "Research and Development Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.neurosensetx.com/role/GeneralandAdministrativeExpenses",
     "longName": "995317 - Disclosure - General and Administrative Expenses",
     "shortName": "General and Administrative Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "nrsn:GeneralAndAdministrativeExpensesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "nrsn:GeneralAndAdministrativeExpensesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.neurosensetx.com/role/FinancingIncomeExpensesNet",
     "longName": "995318 - Disclosure - Financing Income (Expenses), Net",
     "shortName": "Financing Income (Expenses), Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactions",
     "longName": "995319 - Disclosure - Related Parties Balances and Transactions",
     "shortName": "Related Parties Balances and Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.neurosensetx.com/role/SegmentReporting",
     "longName": "995320 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.neurosensetx.com/role/IncomeTaxes",
     "longName": "995321 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.neurosensetx.com/role/SubsequentEvents",
     "longName": "995322 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.neurosensetx.com/role/SignificantAccountingPolicyTables",
     "longName": "996001 - Disclosure - Significant Accounting Policy (Tables)",
     "shortName": "Significant Accounting Policy (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "nrsn:ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "nrsn:ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.neurosensetx.com/role/CashandCashEquivalentTables",
     "longName": "996002 - Disclosure - Cash and Cash Equivalent (Tables)",
     "shortName": "Cash and Cash Equivalent (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.neurosensetx.com/role/OtherReceivablesTables",
     "longName": "996003 - Disclosure - Other Receivables (Tables)",
     "shortName": "Other Receivables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.neurosensetx.com/role/PropertyandEquipmentNetTables",
     "longName": "996004 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.neurosensetx.com/role/OperatingLeaseTables",
     "longName": "996005 - Disclosure - Operating Lease (Tables)",
     "shortName": "Operating Lease (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "nrsn:LesseeOperatingLeaseDisclosureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "nrsn:LesseeOperatingLeaseDisclosureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.neurosensetx.com/role/OtherCurrentLiabilitiesTables",
     "longName": "996006 - Disclosure - Other Current Liabilities (Tables)",
     "shortName": "Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsTables",
     "longName": "996007 - Disclosure - Liability in Respect of Warrants (Tables)",
     "shortName": "Liability in Respect of Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "nrsn:LiabilityInRespectOfWarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "nrsn:LiabilityInRespectOfWarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.neurosensetx.com/role/ShareholdersEquityTables",
     "longName": "996008 - Disclosure - Shareholders' Equity (Tables)",
     "shortName": "Shareholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCapitalUnitsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCapitalUnitsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.neurosensetx.com/role/ShareBasedPaymentTables",
     "longName": "996009 - Disclosure - Share Based Payment (Tables)",
     "shortName": "Share Based Payment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.neurosensetx.com/role/ResearchandDevelopmentExpensesTables",
     "longName": "996010 - Disclosure - Research and Development Expenses (Tables)",
     "shortName": "Research and Development Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.neurosensetx.com/role/GeneralandAdministrativeExpensesTables",
     "longName": "996011 - Disclosure - General and Administrative Expenses (Tables)",
     "shortName": "General and Administrative Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "nrsn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "nrsn:GeneralAndAdministrativeExpensesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "nrsn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "nrsn:GeneralAndAdministrativeExpensesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.neurosensetx.com/role/FinancingIncomeExpensesNetTables",
     "longName": "996012 - Disclosure - Financing Income (Expenses), Net (Tables)",
     "shortName": "Financing Income (Expenses), Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.neurosensetx.com/role/IncomeTaxesTables",
     "longName": "996013 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.neurosensetx.com/role/GeneralDetails",
     "longName": "996014 - Disclosure - General (Details)",
     "shortName": "General (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetails",
     "longName": "996015 - Disclosure - Significant Accounting Policy (Details)",
     "shortName": "Significant Accounting Policy (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation",
     "longName": "996016 - Disclosure - Significant Accounting Policy - Schedule of the Lives Used in Computing Straight-Line Depreciation (Details)",
     "shortName": "Significant Accounting Policy - Schedule of the Lives Used in Computing Straight-Line Depreciation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c32",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "nrsn:ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c32",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "nrsn:ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.neurosensetx.com/role/CashandCashEquivalentDetails",
     "longName": "996017 - Disclosure - Cash and Cash Equivalent (Details)",
     "shortName": "Cash and Cash Equivalent (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:InvestmentInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:InvestmentInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.neurosensetx.com/role/ScheduleofCashAndCashEquivalentTable",
     "longName": "996018 - Disclosure - Cash and Cash Equivalent - Schedule of Cash And Cash Equivalent (Details)",
     "shortName": "Cash and Cash Equivalent - Schedule of Cash And Cash Equivalent (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c36",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable",
     "longName": "996019 - Disclosure - Other Receivables - Schedule of Other Receivables (Details)",
     "shortName": "Other Receivables - Schedule of Other Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:Supplies",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:Supplies",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable",
     "longName": "996020 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.neurosensetx.com/role/OperatingLeaseDetails",
     "longName": "996021 - Disclosure - Operating Lease (Details)",
     "shortName": "Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PaymentsForRent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PaymentsForRent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.neurosensetx.com/role/OperatingLeaseDetailsScheduleofOperatingLease",
     "longName": "996022 - Disclosure - Operating Lease - Schedule of Operating Lease (Details)",
     "shortName": "Operating Lease - Schedule of Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "nrsn:LesseeOperatingLeaseDisclosureTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.neurosensetx.com/role/ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable",
     "longName": "996023 - Disclosure - Operating Lease - Schedule of Maturity Analysis of Company\u2019s Lease Liability (Details)",
     "shortName": "Operating Lease - Schedule of Maturity Analysis of Company\u2019s Lease Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.neurosensetx.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable",
     "longName": "996024 - Disclosure - Operating Lease - Schedule of Weighted Average Remaining Lease Terms and Discount Rate (Details)",
     "shortName": "Operating Lease - Schedule of Weighted Average Remaining Lease Terms and Discount Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.neurosensetx.com/role/ScheduleofOtherCurrentLiabilitiesTable",
     "longName": "996025 - Disclosure - Other Current Liabilities - Schedule of Other Current Liabilities (Details)",
     "shortName": "Other Current Liabilities - Schedule of Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:OtherLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails",
     "longName": "996026 - Disclosure - Liability in Respect of Warrants (Details)",
     "shortName": "Liability in Respect of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c53",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "nrsn:LiabilityInRespectOfWarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c57",
      "name": "us-gaap:DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "nrsn:LiabilityInRespectOfWarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.neurosensetx.com/role/ScheduleofFinancialMeasuredatFairValueonaRecurringBasisTable",
     "longName": "996027 - Disclosure - Liability in Respect of Warrants - Schedule of Financial Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Liability in Respect of Warrants - Schedule of Financial Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c61",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "nrsn:LiabilityInRespectOfWarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c61",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "nrsn:LiabilityInRespectOfWarrantsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable",
     "longName": "996028 - Disclosure - Liability in Respect of Warrants - Schedule of Fair Value of the Warrants (Details)",
     "shortName": "Liability in Respect of Warrants - Schedule of Fair Value of the Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c66",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c66",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.neurosensetx.com/role/ScheduleoftheMovementinWarrantLiabilityTable",
     "longName": "996029 - Disclosure - Liability in Respect of Warrants - Schedule of the Movement in Warrant Liability (Details)",
     "shortName": "Liability in Respect of Warrants - Schedule of the Movement in Warrant Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c70",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c71",
      "name": "nrsn:RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.neurosensetx.com/role/ShareholdersEquityDetails",
     "longName": "996030 - Disclosure - Shareholders' Equity (Details)",
     "shortName": "Shareholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c53",
      "name": "nrsn:MarketOfferingCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.neurosensetx.com/role/ScheduleofShareCapitalTable",
     "longName": "996031 - Disclosure - Shareholders' Equity - Schedule of Share Capital (Details)",
     "shortName": "Shareholders' Equity - Schedule of Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R60": {
     "role": "http://www.neurosensetx.com/role/ScheduleofShareCapitalTable_Parentheticals",
     "longName": "996032 - Disclosure - Shareholders' Equity - Schedule of Share Capital (Parentheticals) (Details)",
     "shortName": "Shareholders' Equity - Schedule of Share Capital (Parentheticals) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R61": {
     "role": "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
     "longName": "996033 - Disclosure - Share Based Payment (Details)",
     "shortName": "Share Based Payment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c111",
      "name": "nrsn:NumberOfSharesPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c111",
      "name": "nrsn:NumberOfSharesPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable",
     "longName": "996034 - Disclosure - Share Based Payment - Schedule of Fair Value of the Options Granted (Details)",
     "shortName": "Share Based Payment - Schedule of Fair Value of the Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable",
     "longName": "996035 - Disclosure - Share Based Payment - Schedule of Share Option Activity (Details)",
     "shortName": "Share Based Payment - Schedule of Share Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c181",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c181",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.neurosensetx.com/role/ScheduleofRestrictedStockUnitRSUsActivityTable",
     "longName": "996036 - Disclosure - Share Based Payment - Schedule of Restricted Stock Unit (RSU\u2019s) Activity (Details)",
     "shortName": "Share Based Payment - Schedule of Restricted Stock Unit (RSU\u2019s) Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c185",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c185",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.neurosensetx.com/role/ScheduleofShareBasedExpenseRecognizedintheStatementsofOperationTable",
     "longName": "996037 - Disclosure - Share Based Payment - Schedule of Share-Based Expense Recognized in the Statements of Operation (Details)",
     "shortName": "Share Based Payment - Schedule of Share-Based Expense Recognized in the Statements of Operation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:CondensedStatementOfComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:CondensedStatementOfComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.neurosensetx.com/role/ScheduleofResearchandDevelopmentExpensesTable",
     "longName": "996038 - Disclosure - Research and Development Expenses - Schedule of Research and Development Expenses (Details)",
     "shortName": "Research and Development Expenses - Schedule of Research and Development Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "nrsn:SubcontractorsAndConsultants",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "nrsn:SubcontractorsAndConsultants",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.neurosensetx.com/role/GeneralandAdministrativeExpensesDetails",
     "longName": "996039 - Disclosure - General and Administrative Expenses (Details)",
     "shortName": "General and Administrative Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PensionContributions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "link:footnote",
       "td",
       "tr",
       "table",
       "nrsn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
       "nrsn:GeneralAndAdministrativeExpensesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PensionContributions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "link:footnote",
       "td",
       "tr",
       "table",
       "nrsn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
       "nrsn:GeneralAndAdministrativeExpensesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
     "longName": "996040 - Disclosure - General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)",
     "shortName": "General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProfessionalAndContractServicesExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "nrsn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
       "nrsn:GeneralAndAdministrativeExpensesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProfessionalAndContractServicesExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "nrsn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
       "nrsn:GeneralAndAdministrativeExpensesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable",
     "longName": "996041 - Disclosure - Financing Income (Expenses), Net - Schedule of Financing Income (Expenses), Net (Details)",
     "shortName": "Financing Income (Expenses), Net - Schedule of Financing Income (Expenses), Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InterestIncomeDepositsWithFinancialInstitutions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails",
     "longName": "996042 - Disclosure - Related Parties Balances and Transactions (Details)",
     "shortName": "Related Parties Balances and Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:AccruedSalariesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c18",
      "name": "us-gaap:AccruedSalariesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.neurosensetx.com/role/IncomeTaxesDetails",
     "longName": "996043 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c197",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c197",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable",
     "longName": "996044 - Disclosure - Income Taxes - Schedule of the Company\u2019s Net deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Schedule of the Company\u2019s Net deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.neurosensetx.com/role/ScheduleoftheMovementoftheValuationAllowanceTable",
     "longName": "996045 - Disclosure - Income Taxes - Schedule of the Movement of the Valuation Allowance (Details)",
     "shortName": "Income Taxes - Schedule of the Movement of the Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R74": {
     "role": "http://www.neurosensetx.com/role/SubsequentEventsDetails",
     "longName": "996046 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c84",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c201",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0237295-20f_neuro.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policy [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r38"
     ]
    },
    "us-gaap_AccruedBonusesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedBonusesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued bonus",
        "label": "Accrued Bonuses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Current Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_AccruedSalariesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalariesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued salary",
        "label": "Accrued Salaries",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Accumulated depreciation Balance",
        "periodEndLabel": "Accumulated depreciation Balance",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r116",
      "r418"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Depreciation during the year",
        "label": "Accumulated Depreciation, Depletion and Amortization, Sale or Disposal of Property, Plant and Equipment",
        "documentation": "Amount of decrease in accumulated depreciation, depletion and amortization as a result of sale or disposal of property, plant and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Premium and Capital Reserve",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share premium and capital reserve",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r749",
      "r750",
      "r751",
      "r753",
      "r807",
      "r844"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r635",
      "r651",
      "r686"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r627",
      "r638",
      "r654",
      "r689"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofCashAndCashEquivalentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r639",
      "r655",
      "r681",
      "r690",
      "r694",
      "r702"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "nrsn_AllianceGlobalPartnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "AllianceGlobalPartnersMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alliance Global Partners [Member]",
        "label": "Alliance Global Partners Member"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_AllocatedAmountToOrdinaryWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "AllocatedAmountToOrdinaryWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocated amount to ordinary warrants",
        "documentation": "Represent the allocated amount to ordinary warrants.",
        "label": "Allocated Amount To Ordinary Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareBasedExpenseRecognizedintheStatementsofOperationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r294"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_AprilTwoThousandTwentyFourPurchaseAgrementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "AprilTwoThousandTwentyFourPurchaseAgrementMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2024 Purchase Agrement [Member]",
        "label": "April Two Thousand Twenty Four Purchase Agrement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r89",
      "r117",
      "r140",
      "r168",
      "r176",
      "r187",
      "r190",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r333",
      "r335",
      "r362",
      "r410",
      "r480",
      "r559",
      "r560",
      "r584",
      "r596",
      "r771",
      "r772",
      "r830"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r123",
      "r140",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r333",
      "r335",
      "r362",
      "r584",
      "r771",
      "r772",
      "r830"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r333",
      "r335",
      "r362",
      "r771",
      "r772",
      "r830"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r609",
      "r612",
      "r631"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r609",
      "r612",
      "r631"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r609",
      "r612",
      "r631"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails",
      "http://www.neurosensetx.com/role/ScheduleofRestrictedStockUnitRSUsActivityTable",
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/SubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors [Member]",
        "label": "Board of Directors Chairman [Member]",
        "documentation": "Leader of board of directors."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "nrsn_BonusAccrualReclassificationToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "BonusAccrualReclassificationToEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonus accrual reclassification to equity (See Note 14)",
        "documentation": "The amount of bonus accrual reclassification to equity.",
        "label": "Bonus Accrual Reclassification To Equity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r612",
      "r631"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet",
      "http://www.neurosensetx.com/role/ScheduleofCashAndCashEquivalentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalent",
        "verboseLabel": "Cash and Cash Equivalent",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r114",
      "r546"
     ]
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/CashandCashEquivalent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalent",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r412"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofCashAndCashEquivalentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash And Cash Equivalent [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents and deposits",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents as at the beginning of the year",
        "periodEndLabel": "Cash and cash equivalents as of the end of the year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r63",
      "r137"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Continuing Operations",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from change in exchange rate. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalents include, but are not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r820"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer [Member]",
        "label": "Chief Executive Officer [Member]",
        "documentation": "Person with designation of chief executive officer."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails",
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r118",
      "r119",
      "r120",
      "r140",
      "r160",
      "r161",
      "r163",
      "r165",
      "r170",
      "r171",
      "r199",
      "r213",
      "r215",
      "r216",
      "r217",
      "r220",
      "r221",
      "r224",
      "r225",
      "r228",
      "r231",
      "r238",
      "r362",
      "r437",
      "r438",
      "r439",
      "r440",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r468",
      "r489",
      "r511",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r732",
      "r744",
      "r754"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policy [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r170",
      "r224",
      "r225",
      "r226",
      "r228",
      "r231",
      "r236",
      "r238",
      "r437",
      "r438",
      "r439",
      "r440",
      "r569",
      "r732",
      "r744"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails",
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable",
      "http://www.neurosensetx.com/role/ScheduleofFinancialMeasuredatFairValueonaRecurringBasisTable",
      "http://www.neurosensetx.com/role/ScheduleoftheMovementinWarrantLiabilityTable",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails",
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails",
      "http://www.neurosensetx.com/role/ScheduleofFinancialMeasuredatFairValueonaRecurringBasisTable",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails",
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails",
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in Dollars per share)",
        "verboseLabel": "Warrants price per share",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails",
      "http://www.neurosensetx.com/role/ScheduleoftheMovementinWarrantLiabilityTable",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the Movement in Warrant Liability [Line Items]",
        "terseLabel": "Liability in Respect of Warrants [Line Items]",
        "verboseLabel": "Shareholders' Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued warrant (in Shares)",
        "verboseLabel": "Aggregate warrants",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment and contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r541"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares available for future grant",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Ordinary Shares [Member]",
        "netLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r587",
      "r588",
      "r590",
      "r591",
      "r592",
      "r593",
      "r749",
      "r750",
      "r753",
      "r807",
      "r841",
      "r844"
     ]
    },
    "us-gaap_CommonStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockNoParValue",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.neurosensetx.com/role/ScheduleofShareCapitalTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, par value (in Dollars per share)",
        "verboseLabel": "Ordinary shares, par value",
        "label": "Common Stock, No Par Value",
        "documentation": "Face amount per share of no-par value common stock."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.neurosensetx.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares authorized",
        "verboseLabel": "Ordinary shares, Authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r468"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.neurosensetx.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares issued",
        "verboseLabel": "Ordinary shares, Issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.neurosensetx.com/role/ScheduleofShareCapitalTable_Parentheticals",
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "terseLabel": "Ordinary shares, shares outstanding",
        "verboseLabel": "Ordinary shares, Outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r49",
      "r468",
      "r486",
      "r844",
      "r845"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, no par value: Authorized: 90,000,000 shares at December 31, 2024 and 60,000,000 shares at December 31, 2023; Issued and outstanding: 23,228,941 and 15,379,042 shares at December 31, 2024 and 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r413",
      "r584"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting rights",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable",
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers and peripherals and equipment [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of credit risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r92"
     ]
    },
    "srt_CondensedStatementOfComprehensiveIncomeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedStatementOfComprehensiveIncomeTable",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareBasedExpenseRecognizedintheStatementsofOperationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statement of Comprehensive Income [Table]",
        "documentation": "Disclosure of information about condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r142",
      "r734"
     ]
    },
    "srt_CondensedStatementOfComprehensiveIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedStatementOfComprehensiveIncomeTableTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Expense Recognized in the Statements of Operation",
        "label": "Condensed Statement of Comprehensive Income [Table Text Block]",
        "documentation": "Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r737",
      "r748"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r550"
     ]
    },
    "nrsn_ConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ConsultantsMember",
     "presentation": [
      "http://www.neurosensetx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consultants [Member]",
        "label": "Consultants Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_ContractsOverOwnEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ContractsOverOwnEquityPolicyTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contracts over own equity",
        "documentation": "Disclosure of accounting policy for contracts over own equity.",
        "label": "Contracts Over Own Equity Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofCashAndCashEquivalentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "documentation": "Information by currency."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board of Directors Oversight [Text Block]",
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r710"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r618",
      "r711"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r620",
      "r713"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]",
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r615",
      "r708"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r614",
      "r707"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r614",
      "r707"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r614",
      "r707"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r616",
      "r709"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r616",
      "r709"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]",
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r619",
      "r712"
     ]
    },
    "us-gaap_DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revaluation Income",
        "label": "Debtor Reorganization Items, Revaluation of Assets and Liabilities",
        "documentation": "Amount recognized from the revaluation of assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "nrsn_DecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "DecreaseInOperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in operating lease liability",
        "documentation": "Represent the amount of decrease in operating lease liability.",
        "label": "Decrease In Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_DecreaseInOperatingRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "DecreaseInOperatingRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in operating right of use asset",
        "documentation": "Decrease in operating right of use asset.",
        "label": "Decrease In Operating Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets recognized tax benefits",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r98",
      "r746"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liability",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r81",
      "r311"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering price",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets:",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development costs",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax asset",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net deferred tax assets:",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_DeferredTaxAssetsOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "documentation": "Represent the amount of deferred tax assets operating lease liability.",
        "label": "Deferred Tax Assets Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_DeferredTaxAssetsStateTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsStateTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other temporary differences",
        "label": "Deferred Tax Assets, State Taxes",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "nrsn_DeferredTaxAssetsVacationAndConvalescenceAccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "DeferredTaxAssetsVacationAndConvalescenceAccrual",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vacation and convalescence accrual",
        "documentation": "Amount represents deferred tax assets vacation and convalescence accrual.",
        "label": "Deferred Tax Assets Vacation And Convalescence Accrual"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable",
      "http://www.neurosensetx.com/role/ScheduleoftheMovementoftheValuationAllowanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at the beginning of the year",
        "periodEndLabel": "Balance at the end of the year",
        "negatedLabel": "Less: Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleoftheCompanysNetdeferredTaxAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred tax liability: Operating lease right-of-use assets",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly deposits by company, percentage",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r643",
      "r644",
      "r658"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r21"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r78",
      "r458",
      "r460",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r506",
      "r507",
      "r508",
      "r527",
      "r528",
      "r529",
      "r530",
      "r549",
      "r586",
      "r588",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director [Member]",
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r762",
      "r842"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPayment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Payment",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r254",
      "r285",
      "r286",
      "r289",
      "r574"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureTextBlockAbstract",
     "auth_ref": []
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r643",
      "r644",
      "r658"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r612",
      "r631"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r612",
      "r631",
      "r682"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r612",
      "r631",
      "r682"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net loss per share (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r158",
      "r160",
      "r163",
      "r164",
      "r165",
      "r167",
      "r328",
      "r331",
      "r345",
      "r346",
      "r408",
      "r422",
      "r551"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net loss per share (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r160",
      "r163",
      "r164",
      "r165",
      "r167",
      "r328",
      "r331",
      "r345",
      "r346",
      "r408",
      "r422",
      "r551"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and diluted net loss per share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r166"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effects of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://www.neurosensetx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r576"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "presentation": [
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefit rate realized upon settlement",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements."
       }
      }
     },
     "auth_ref": [
      "r747",
      "r801",
      "r802"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal",
     "presentation": [
      "http://www.neurosensetx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, State and Local, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement."
       }
      }
     },
     "auth_ref": [
      "r747",
      "r801",
      "r802"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Employee Benefits and Share-Based Compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and payroll accruals",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareBasedExpenseRecognizedintheStatementsofOperationTable",
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Expense Recognized in the Statements of Operation [Line Items]",
        "terseLabel": "Share Based Payment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period of unrecognized expenses",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense related to unvested RSUs (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense related to unvested options (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax benefit for compensation expense (in Dollars)",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-Based Payment Arrangement, Option [Member]",
        "netLabel": "Options [Member]",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonus allocated in the form of RSUs",
        "label": "Employee Stock Ownership Plan (ESOP), Number of Allocated Shares",
        "documentation": "The shares or units in an ESOP trust that have been assigned to individual participant accounts based on a known formula. IRS rules require allocations to be nondiscriminatory generally based on compensation, length of service, or a combination of both. For any particular participant such shares or units may be vested, unvested, or partially vested."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOwnershipPlanESOPPolicy",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefit plans",
        "label": "Employee Stock Ownership Plan (ESOP), Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for ESOP transactions, including the method of measuring compensation, the classification of dividends on ESOP shares, and the treatment of ESOP shares for EPS computations. If the employer has both old ESOP shares for which it does not adopt new guidance and new ESOP shares for which new guidance is required, these disclosures are required for both blocks of shares."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "nrsn_EmployeesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "EmployeesAndDirectorsMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and Directors [Member]",
        "label": "Employees And Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://www.neurosensetx.com/role/GeneralDetails",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incorporation date",
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r110",
      "r127",
      "r128",
      "r129",
      "r143",
      "r144",
      "r145",
      "r147",
      "r152",
      "r154",
      "r156",
      "r169",
      "r200",
      "r201",
      "r204",
      "r240",
      "r319",
      "r320",
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r331",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r373",
      "r375",
      "r390",
      "r421",
      "r427",
      "r428",
      "r429",
      "r446",
      "r511"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r624",
      "r635",
      "r651",
      "r686"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r632",
      "r648",
      "r683"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExchangeFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ExchangeFees",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable": {
       "parentTag": "us-gaap_OtherNonoperatingExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exchange rates",
        "label": "Exchange Fees",
        "documentation": "The amount of expense in the period for fees charged by securities exchanges for the privilege of trading securities listed on that exchange. Some fees vary with the related volume, while others are fixed."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "nrsn_ExchangeRates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ExchangeRates",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable": {
       "parentTag": "us-gaap_OtherNonoperatingIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange rates",
        "documentation": "Exchange rates.",
        "label": "Exchange Rates"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "nrsn_ExpirationDateGrantTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ExpirationDateGrantTerm",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration date grant term",
        "documentation": "Represent the expiration date grant term.",
        "label": "Expiration Date Grant Term"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable": {
       "parentTag": "us-gaap_OtherNonoperatingIncome",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails",
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Revaluation of warrants",
        "terseLabel": "Fair value of warrants",
        "verboseLabel": "Fair value",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r4"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r579"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r351",
      "r579"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Warrants",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r579"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFinancialMeasuredatFairValueonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r358",
      "r359",
      "r361",
      "r400",
      "r401",
      "r402",
      "r567",
      "r568",
      "r570",
      "r571",
      "r572",
      "r577",
      "r579"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFinancialMeasuredatFairValueonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r242",
      "r247",
      "r348",
      "r349",
      "r359",
      "r401",
      "r567",
      "r568",
      "r570",
      "r571",
      "r572",
      "r577"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFinancialMeasuredatFairValueonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFinancialMeasuredatFairValueonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r360"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Measured at Fair Value on a Recurring Basis",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r357",
      "r360"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities:",
        "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Functional currency",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r639",
      "r655",
      "r690"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r639",
      "r655",
      "r690"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r639",
      "r655",
      "r690"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r639",
      "r655",
      "r690"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r639",
      "r655",
      "r690"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r611",
      "r642"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedIncomeStatement",
      "http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total general and administrative expenses",
        "negatedLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r491"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareBasedExpenseRecognizedintheStatementsofOperationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense - General and administrative [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "nrsn_GeneralAndAdministrativeExpensesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "GeneralAndAdministrativeExpensesDisclosureTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/GeneralandAdministrativeExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expenses",
        "documentation": "The entire disclosure for general and administrative expenses.",
        "label": "General And Administrative Expenses Disclosure Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralInsuranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralInsuranceExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance",
        "label": "General Insurance Expense",
        "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales)."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_GovernmentContractReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentContractReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable": {
       "parentTag": "us-gaap_OtherReceivablesNetCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government agencies",
        "label": "Government Contract Receivable",
        "documentation": "The amount of receivables that are derived from government contracts."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283"
     ]
    },
    "currency_ILS": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "ILS",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofCashAndCashEquivalentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominated in NIS [Member]",
        "label": "Israel, New Shekels"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r609",
      "r612",
      "r631"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareBasedExpenseRecognizedintheStatementsofOperationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r208",
      "r353",
      "r357",
      "r360",
      "r424",
      "r426",
      "r496",
      "r545",
      "r578",
      "r840"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareBasedExpenseRecognizedintheStatementsofOperationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r208",
      "r353",
      "r357",
      "r360",
      "r424",
      "r426",
      "r496",
      "r545",
      "r578",
      "r840"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r302",
      "r303",
      "r307",
      "r316",
      "r576",
      "r805"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r299",
      "r302",
      "r304",
      "r305",
      "r306",
      "r308",
      "r315",
      "r321",
      "r322",
      "r323",
      "r324",
      "r442",
      "r576"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r300",
      "r301",
      "r308",
      "r309",
      "r314",
      "r318",
      "r436"
     ]
    },
    "nrsn_IncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "IncomeTaxesDetailsTable",
     "presentation": [
      "http://www.neurosensetx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in trade payables",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in other payables",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r639",
      "r655",
      "r681",
      "r690",
      "r694",
      "r702"
     ]
    },
    "nrsn_InitialRecognitionRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "InitialRecognitionRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/OperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial recognition of right-of-use asset",
        "documentation": "The amount of initial recognition.",
        "label": "Initial Recognition Rightofuse Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r613",
      "r706"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r613",
      "r706"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r613",
      "r706"
     ]
    },
    "nrsn_InstallmentsLockUpPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "InstallmentsLockUpPeriod",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installments lock-up period",
        "documentation": "Installments lock-up period.",
        "label": "Installments Lock Up Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseLoansFromOtherFederalHomeLoanBanks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseLoansFromOtherFederalHomeLoanBanks",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable": {
       "parentTag": "us-gaap_OtherNonoperatingExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Bank fees",
        "label": "Interest Expense, Loans from Other Federal Home Loan Banks",
        "documentation": "Amount of interest expense on loans received from another Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeDepositsWithFinancialInstitutions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeDepositsWithFinancialInstitutions",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable": {
       "parentTag": "us-gaap_OtherNonoperatingIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposit interest",
        "label": "Interest Income, Deposits with Financial Institutions",
        "documentation": "Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r99",
      "r100"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r644",
      "r645",
      "r646",
      "r647"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_InvestmentInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentInterestRate",
     "presentation": [
      "http://www.neurosensetx.com/role/CashandCashEquivalentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Investment Interest Rate",
        "documentation": "Rate of interest on investment."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r531",
      "r532",
      "r588",
      "r763",
      "r764"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestorMember",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor [Member]",
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r826"
     ]
    },
    "us-gaap_IsraelTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IsraelTaxAuthorityMember",
     "presentation": [
      "http://www.neurosensetx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Israel Tax Authority [Member]",
        "label": "Israel Tax Authority [Member]",
        "documentation": "Designated tax department of the government of Israel."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted Average Remaining Lease Terms and Discount Rate [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/OperatingLeaseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted Average Remaining Lease Terms and Discount Rate",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable",
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r388"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.neurosensetx.com/role/OperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r389"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "nrsn_LesseeOperatingLeaseDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "LesseeOperatingLeaseDisclosureTableTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/OperatingLeaseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease",
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.",
        "label": "Lessee Operating Lease Disclosure Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/OperatingLeaseTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturity Analysis of Company\u2019s Lease Liability",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than one year",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two years",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.neurosensetx.com/role/OperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of operating lease, option to extend",
        "label": "Lessee, Operating Lease, Option to Extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.neurosensetx.com/role/OperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease period",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/OperatingLease"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r47",
      "r140",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r334",
      "r335",
      "r336",
      "r362",
      "r467",
      "r552",
      "r596",
      "r771",
      "r830",
      "r831"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r84",
      "r415",
      "r584",
      "r745",
      "r765",
      "r819"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Current operating lease liability",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r113",
      "r140",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r334",
      "r335",
      "r336",
      "r362",
      "r584",
      "r771",
      "r830",
      "r831"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r42",
      "r43",
      "r44",
      "r47",
      "r140",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r334",
      "r335",
      "r336",
      "r362",
      "r771",
      "r830",
      "r831"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_LiabilityInRespectOfWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "LiabilityInRespectOfWarrantsMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFinancialMeasuredatFairValueonaRecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability in Respect of Warrants [Member]",
        "label": "Liability In Respect Of Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_LiabilityInRespectOfWarrantsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "LiabilityInRespectOfWarrantsTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability in respect of warrants",
        "documentation": "The entire disclosure for liability in respect of warrants.",
        "label": "Liability In Respect Of Warrants Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_LiabilityinRespectofWarrantsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "LiabilityinRespectofWarrantsDetailsTable",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability in Respect of Warrants (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_LiabilityinRespectofWarrantsScheduleoftheMovementinWarrantLiabilityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "LiabilityinRespectofWarrantsScheduleoftheMovementinWarrantLiabilityDetailsTable",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleoftheMovementinWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability in Respect of Warrants - Schedule of the Movement in Warrant Liability (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/OtherReceivables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r761"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_MarketOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "MarketOfferingCost",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market offering cost",
        "documentation": "Represent  the at the market offering cost.",
        "label": "Market Offering Cost"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails",
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable",
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable",
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r108",
      "r109",
      "r209",
      "r210",
      "r211",
      "r212",
      "r249",
      "r295",
      "r351",
      "r405",
      "r423",
      "r425",
      "r432",
      "r459",
      "r460",
      "r520",
      "r522",
      "r525",
      "r526",
      "r531",
      "r542",
      "r543",
      "r565",
      "r569",
      "r573",
      "r579",
      "r580",
      "r581",
      "r582",
      "r585",
      "r773",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails",
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable",
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable",
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r108",
      "r109",
      "r209",
      "r210",
      "r211",
      "r212",
      "r249",
      "r295",
      "r351",
      "r405",
      "r423",
      "r425",
      "r432",
      "r459",
      "r460",
      "r520",
      "r522",
      "r525",
      "r526",
      "r531",
      "r542",
      "r543",
      "r565",
      "r569",
      "r573",
      "r579",
      "r580",
      "r581",
      "r585",
      "r773",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "nrsn_MrAlonBenNoonsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "MrAlonBenNoonsMember",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Alon Ben-Noon\u2019s [Member]",
        "label": "Mr Alon Ben Noons Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.neurosensetx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow",
      "http://www.neurosensetx.com/role/ConsolidatedIncomeStatement",
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss and comprehensive loss",
        "verboseLabel": "Net loss and comprehensive loss",
        "netLabel": "Net loss for the year",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r65",
      "r86",
      "r111",
      "r124",
      "r125",
      "r129",
      "r140",
      "r146",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r155",
      "r156",
      "r162",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r328",
      "r331",
      "r346",
      "r362",
      "r420",
      "r488",
      "r509",
      "r510",
      "r594",
      "r771"
     ]
    },
    "nrsn_NetProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "NetProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "documentation": "Represents the amount of net proceeds from issuance of warrants.",
        "label": "Net Proceeds From Issuance Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_NetProceedsFromTheOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "NetProceedsFromTheOrdinaryShares",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "documentation": "Represent the net proceeds from the ordinary shares.",
        "label": "Net Proceeds From The Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently adopted accounting pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r644",
      "r645",
      "r646",
      "r647"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r628",
      "r639",
      "r655",
      "r681",
      "r690"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_NoncashOrPartNoncashAcquisitionInterestReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "NoncashOrPartNoncashAcquisitionInterestReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest received",
        "documentation": "Represent then interest received \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash Or Part Noncash Acquisition Interest Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoninterestExpenseOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoninterestExpenseOfferingCost",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering expenses",
        "label": "Noninterest Expense Offering Cost",
        "documentation": "Includes offering costs of open-end investment companies, and closed-end funds with a continuous offering period."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedIncomeStatement",
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financing income (expanse), net",
        "terseLabel": "Financing income (expenses), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "nrsn_November12024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "November12024Member",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "November 1, 2024 [Member]",
        "label": "November12024 Member"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_NumberOfInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "NumberOfInstallments",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of installments",
        "documentation": "Number of installments.",
        "label": "Number Of Installments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r756"
     ]
    },
    "nrsn_NumberOfOrdinaryShares": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "NumberOfOrdinaryShares",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of ordinary share",
        "verboseLabel": "Number of ordinary shares",
        "documentation": "Number of ordinary shares.",
        "label": "Number Of Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_NumberOfSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "NumberOfSharesPercentage",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total number of shares",
        "documentation": "Number of shares percentage.",
        "label": "Number Of Shares Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_October12024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "October12024Member",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "October 1, 2024 [Member]",
        "label": "October12024 Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable",
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and equipment [Member]",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r553",
      "r755",
      "r757",
      "r758",
      "r759",
      "r760"
     ]
    },
    "nrsn_OperatingLeaseDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "OperatingLeaseDetailsTable",
     "presentation": [
      "http://www.neurosensetx.com/role/OperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturity Analysis of Company\u2019s Lease Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.neurosensetx.com/role/ScheduleofOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/OperatingLeaseDetailsScheduleofOperatingLease",
      "http://www.neurosensetx.com/role/ScheduleofMaturityAnalysisofCompanysLeaseLiabilityTable",
      "http://www.neurosensetx.com/role/ScheduleofOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of lease liability",
        "verboseLabel": "Short term lease liability",
        "netLabel": "Operating Lease, Liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/OperatingLeaseDetailsScheduleofOperatingLease"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.neurosensetx.com/role/OperatingLeaseDetailsScheduleofOperatingLease"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet",
      "http://www.neurosensetx.com/role/OperatingLeaseDetailsScheduleofOperatingLease"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability less current maturity",
        "verboseLabel": "Operating Lease, Liability, Noncurrent",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r383"
     ]
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePaymentsUse",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable": {
       "parentTag": "us-gaap_OperatingLeasePayments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease payments",
        "label": "Operating Lease, Payments, Use",
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r383"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet",
      "http://www.neurosensetx.com/role/OperatingLeaseDetailsScheduleofOperatingLease"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use assets",
        "verboseLabel": "Operating Lease, Right-of-Use Asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r583"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofWeightedAverageRemainingLeaseTermsandDiscountRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r583"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "nrsn_OrdinarySharesNoParValuePerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "OrdinarySharesNoParValuePerShareMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares, no par value per share",
        "label": "Ordinary Shares No Par Value Per Share Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/General"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r77",
      "r433",
      "r434"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/OtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Current Liabilities",
        "label": "Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenseDisclosureNonoperatingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenseDisclosureNonoperatingAbstract",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Expenses:",
        "label": "Other Expense, Nonoperating [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial expenses",
        "verboseLabel": "Additional expense (in Dollars)",
        "label": "Other Expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Other General and Administrative Expense",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r843"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Income Expenses Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncomeDisclosureNonoperatingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeDisclosureNonoperatingAbstract",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Income:",
        "label": "Other Income, Nonoperating [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.neurosensetx.com/role/ScheduleofOtherCurrentLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet",
      "http://www.neurosensetx.com/role/ScheduleofOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Current Liabilities",
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r584"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/OtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Liabilities",
        "label": "Other Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for other liabilities."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r43",
      "r769"
     ]
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing expenses, net",
        "label": "Other Noncash Expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_OtherNoninterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoninterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance expenses to placement agent",
        "label": "Other Noninterest Expense",
        "documentation": "Amount of noninterest expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total expenses",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total income",
        "label": "Other Nonoperating Income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeAndExpenseTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/FinancingIncomeExpensesNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Income (Expenses), Net",
        "label": "Other Nonoperating Income and Expense [Text Block]",
        "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_OtherReceivablesGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesGrossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable": {
       "parentTag": "us-gaap_OtherReceivablesNetCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Receivables, Gross, Current",
        "documentation": "Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet",
      "http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Receivables",
        "terseLabel": "Other receivables",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherReceivablesNetCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r626",
      "r637",
      "r653",
      "r688"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r640",
      "r656",
      "r691"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r629",
      "r640",
      "r656",
      "r691"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/OperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly rent",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfOtherEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment in respect of cancellation of options",
        "label": "Payments for Repurchase of Other Equity",
        "documentation": "Amount of cash outflow to reacquire equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Structuring fee",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r741"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_PensionContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionContributions",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/GeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension funds paid",
        "label": "Payment for Pension Benefits",
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "nrsn_PotentialBonusPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "PotentialBonusPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential bonus payable",
        "documentation": "Amount of potential bonus payable to the officers.",
        "label": "Potential Bonus Payable"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "nrsn_PrefundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "PrefundedWarrantMember",
     "presentation": [
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants [Member]",
        "label": "Prefunded Warrant Member"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded Warrants [Member]",
        "label": "Prefunded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable": {
       "parentTag": "us-gaap_OtherReceivablesNetCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r202",
      "r203",
      "r547"
     ]
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable": {
       "parentTag": "us-gaap_OtherNonoperatingExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFinancingIncomeExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Issuance costs",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares, warrants and pre-funded warrants, net",
        "verboseLabel": "Gross proceeds from warrant",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds",
        "label": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r437"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants and options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r10"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total issuance expenses",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalAndContractServicesExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional services",
        "label": "Professional and Contract Services Expense",
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAdditions",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost, Purchases during the year",
        "label": "Property, Plant and Equipment, Additions",
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable",
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r388"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r93",
      "r96",
      "r97"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cost, Balance",
        "periodEndLabel": "Cost, Balance",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r115",
      "r419"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment Net [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet",
      "http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "verboseLabel": "Depreciated cost at December 31",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r388",
      "r409",
      "r419",
      "r584"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r93",
      "r96",
      "r417"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/PropertyandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r388"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Useful Life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "nrsn_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Agreement [Member]",
        "label": "Purchase Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_PurchasePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "PurchasePricePerShare",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share",
        "documentation": "Represent the combined purchase price.",
        "label": "Purchase Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "nrsn_RaiseOfAdditionalBonusPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "RaiseOfAdditionalBonusPercentage",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raise of additional bonus percentage",
        "documentation": "The percentage of raise of additional bonus.",
        "label": "Raise Of Additional Bonus Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails",
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable",
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable",
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r108",
      "r109",
      "r209",
      "r210",
      "r211",
      "r212",
      "r241",
      "r249",
      "r280",
      "r281",
      "r282",
      "r295",
      "r351",
      "r403",
      "r404",
      "r405",
      "r423",
      "r425",
      "r432",
      "r459",
      "r460",
      "r520",
      "r522",
      "r525",
      "r526",
      "r531",
      "r542",
      "r543",
      "r565",
      "r569",
      "r573",
      "r579",
      "r580",
      "r581",
      "r582",
      "r585",
      "r588",
      "r770",
      "r773",
      "r809",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails",
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable",
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable",
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r108",
      "r109",
      "r209",
      "r210",
      "r211",
      "r212",
      "r241",
      "r249",
      "r280",
      "r281",
      "r282",
      "r295",
      "r351",
      "r403",
      "r404",
      "r405",
      "r423",
      "r425",
      "r432",
      "r459",
      "r460",
      "r520",
      "r522",
      "r525",
      "r526",
      "r531",
      "r542",
      "r543",
      "r565",
      "r569",
      "r573",
      "r579",
      "r580",
      "r581",
      "r582",
      "r585",
      "r588",
      "r770",
      "r773",
      "r809",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837"
     ]
    },
    "nrsn_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently issued accounting pronouncements, not yet adopted",
        "documentation": "Disclosure of accounting policy for recently issued accounting pronouncements, not yet adopted.",
        "label": "Recently Issued Accounting Pronouncements Not Yet Adopted Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_ReclassificationOfWarrantsIntoEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ReclassificationOfWarrantsIntoEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow",
      "http://www.neurosensetx.com/role/ScheduleoftheMovementinWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of warrants into equity",
        "verboseLabel": "Revaluation of liability in respect to warrants",
        "documentation": "Represents the amount of reclassification of warrants into equity.",
        "label": "Reclassification Of Warrants Into Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationsOfTemporaryToPermanentEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of warrants into equity",
        "label": "Reclassifications of Temporary to Permanent Equity",
        "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r79"
     ]
    },
    "nrsn_RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleoftheMovementinWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of liability in respect to warrants at the initial date",
        "documentation": "Recognition of liability in respect to warrants at the initial date.",
        "label": "Recognition Of Liability In Respect To Warrants At The Initial Date"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r621",
      "r632",
      "r648",
      "r683"
     ]
    },
    "nrsn_RedemptionOfinvestmentInRestrictedDepositNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "RedemptionOfinvestmentInRestrictedDepositNet",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Redemption of (investment in) restricted deposit, net",
        "documentation": "Represent the redemption of investment in restricted deposit, net.",
        "label": "Redemption Ofinvestment In Restricted Deposit Net"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_RedemptionofinvestmentInShorttermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "RedemptionofinvestmentInShorttermDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption of (investment in) short-term deposits",
        "documentation": "Represent the amount of redemption of (investment in) short-term deposits.",
        "label": "Redemptionofinvestment In Shortterm Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "nrsn_RelatedPartiesBalancesandTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "RelatedPartiesBalancesandTransactionsDetailsTable",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties Balances and Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r248",
      "r394",
      "r395",
      "r411",
      "r416",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r485",
      "r487",
      "r519"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r828"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties Balances and Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r492",
      "r493",
      "r496"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties Balances and Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r248",
      "r394",
      "r395",
      "r411",
      "r416",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r485",
      "r487",
      "r519",
      "r828"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Parties Balances and Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r443",
      "r444",
      "r445",
      "r494",
      "r495",
      "r496",
      "r516",
      "r518"
     ]
    },
    "nrsn_RemainingFairValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "RemainingFairValueAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining fair value",
        "documentation": "Represent the remaining fair value warrants.",
        "label": "Remaining Fair Value Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Research and Development Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.neurosensetx.com/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedIncomeStatement",
      "http://www.neurosensetx.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and development expenses",
        "negatedLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r545",
      "r559",
      "r838"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareBasedExpenseRecognizedintheStatementsofOperationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense - Research and development [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/ResearchandDevelopmentExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r544"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r633",
      "r649",
      "r684"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r623",
      "r634",
      "r650",
      "r685"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r630",
      "r641",
      "r657",
      "r692"
     ]
    },
    "us-gaap_RestrictedCashAndInvestmentsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndInvestmentsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted deposits",
        "label": "Restricted Cash and Investments, Current",
        "documentation": "The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r540",
      "r739"
     ]
    },
    "us-gaap_RestrictedCashAndInvestmentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndInvestmentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted deposit",
        "label": "Restricted Cash and Investments, Noncurrent",
        "documentation": "The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r540"
     ]
    },
    "nrsn_RestrictedDepositsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "RestrictedDepositsPolicyTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted deposits",
        "documentation": "Disclosure of accounting policy for restricted deposits.",
        "label": "Restricted Deposits Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails",
      "http://www.neurosensetx.com/role/ScheduleofRestrictedStockUnitRSUsActivityTable",
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "RSUs [Member]",
        "netLabel": "RSU [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r72",
      "r414",
      "r430",
      "r431",
      "r441",
      "r469",
      "r584"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "verboseLabel": "Retained Earnings [Member]",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r143",
      "r144",
      "r145",
      "r147",
      "r152",
      "r154",
      "r156",
      "r200",
      "r201",
      "r204",
      "r319",
      "r320",
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r331",
      "r337",
      "r339",
      "r340",
      "r342",
      "r344",
      "r373",
      "r375",
      "r427",
      "r429",
      "r446",
      "r844"
     ]
    },
    "nrsn_RevaluationOfLiabilityInRespectToWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "RevaluationOfLiabilityInRespectToWarrants",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow",
      "http://www.neurosensetx.com/role/ScheduleoftheMovementinWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Revaluation of liability in respect to warrants",
        "negatedTerseLabel": "Reclassification of warrants into equity",
        "documentation": "Revaluation of liability in respect to warrants.",
        "label": "Revaluation Of Liability In Respect To Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "RevaluationOfLiabilityInRespectToWarrantsThroughEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleoftheMovementinWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revaluation of liability in respect to warrants through equity",
        "documentation": "Represented the amount of revaluation of liability in respect to warrants through equity.",
        "label": "Revaluation Of Liability In Respect To Warrants Through Equity"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleoftheMovementinWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revaluation of liability in respect to warrants through finance expanse",
        "documentation": "Represented the amount of revaluation of liability in respect to warrants through finance expanse.",
        "label": "Revaluation Of Liability In Respect To Warrants Through Finance Expanse"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of right of use assets",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r583"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "nrsn_SalariesAndSocialBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "SalariesAndSocialBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salaries and social benefits",
        "documentation": "Salaries and social benefits.",
        "label": "Salaries And Social Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalariesWagesAndOfficersCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salaries and social benefits",
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_SaleOfOrdinaryShareGrossProceedsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "SaleOfOrdinaryShareGrossProceedsPercentage",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of ordinary shares percentage",
        "documentation": "Percentage of  sale of ordinary share gross proceeds.",
        "label": "Sale Of Ordinary Share Gross Proceeds Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails",
      "http://www.neurosensetx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total consideration",
        "verboseLabel": "Gross proceeds",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails",
      "http://www.neurosensetx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of ordinary shares",
        "verboseLabel": "Shares issued under sale agreement",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agreement [Member]",
        "label": "Sales Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.neurosensetx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast [Member]",
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r736",
      "r752"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.neurosensetx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r157",
      "r250",
      "r733",
      "r752"
     ]
    },
    "us-gaap_ScheduleOfCapitalUnitsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCapitalUnitsTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Capital",
        "label": "Schedule of Capital Units [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's capital units or capital shares, including the value of capital units or capital shares, units authorized, units outstanding and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_ScheduleOfCashAndCashEquivalentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ScheduleOfCashAndCashEquivalentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cash And Cash Equivalent Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofCashAndCashEquivalentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalent [Table]",
        "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/CashandCashEquivalentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash And Cash Equivalent",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Company\u2019s Net deferred Tax Assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Movement in Warrant Liability",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_ScheduleOfFairValueOfTheOptionsGrantedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ScheduleOfFairValueOfTheOptionsGrantedAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of The Options Granted Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_ScheduleOfFairValueOfTheWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ScheduleOfFairValueOfTheWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of The Warrants Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_ScheduleOfFinancialMeasuredAtFairValueOnARecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ScheduleOfFinancialMeasuredAtFairValueOnARecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Measured at Fair Value on a Recurring Basis [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_ScheduleOfFinancingIncomeExpensesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ScheduleOfFinancingIncomeExpensesNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financing Income Expenses Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/GeneralandAdministrativeExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of General and Administrative Expenses",
        "documentation": "Tabular disclosure of general and administrative expenses.",
        "label": "Schedule Of General And Administrative Expenses Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/OtherReceivablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Receivables",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/FinancingIncomeExpensesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financing Income (Expenses), Net",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/ResearchandDevelopmentExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Research and Development Expenses",
        "label": "Schedule of Other Operating Cost and Expense, by Component [Table Text Block]",
        "documentation": "Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "nrsn_ScheduleOfPropertyAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ScheduleOfPropertyAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r388"
     ]
    },
    "nrsn_ScheduleOfRestrictedStockUnitRsuSActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ScheduleOfRestrictedStockUnitRsuSActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Restricted Stock Unit Rsu SActivity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Unit (RSU\u2019s) Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r74"
     ]
    },
    "nrsn_ScheduleOfShareBasedExpenseRecognizedInTheStatementsOfOperationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ScheduleOfShareBasedExpenseRecognizedInTheStatementsOfOperationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Expense Recognized In The Statements Of Operation Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "nrsn_ScheduleOfShareOptionActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ScheduleOfShareOptionActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Option Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ScheduleOfTheCompanySNetDeferredTaxAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of The Company SNet Deferred Tax Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Lives Used in Computing Straight-Line Depreciation",
        "documentation": "Tabular disclosure of lives used in computing straight-line depreciation.",
        "label": "Schedule Of The Lives Used In Computing Straight Line Depreciation Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_ScheduleOfTheMovementInWarrantLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ScheduleOfTheMovementInWarrantLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the Movement in Warrant Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Purchase Agreement [Member]",
        "label": "Securities Purchase Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r168",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r195",
      "r197",
      "r554",
      "r557",
      "r558",
      "r559",
      "r561",
      "r563",
      "r564"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r193",
      "r196",
      "r555",
      "r556",
      "r562"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of General and Administrative Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "verboseLabel": "Options to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "nrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSU's exercise price (in Dollars per share)",
        "documentation": "Per share or unit weighted-average of exercise price award granted under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails",
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs granted",
        "verboseLabel": "Shares approved the grant (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value of RSUs (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable",
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield (%)",
        "verboseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable",
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility (%)",
        "verboseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable",
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate (%)",
        "verboseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable",
      "http://www.neurosensetx.com/role/ScheduleofRestrictedStockUnitRSUsActivityTable",
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of the Options Granted [Line Items]",
        "terseLabel": "Schedule of Share Option Activity [Line Items]",
        "verboseLabel": "Schedule of Restricted Stock Unit (RSU's) Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "additional ordinary shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Share Options, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable",
      "http://www.neurosensetx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercisable",
        "verboseLabel": "Options exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofRestrictedStockUnitRSUsActivityTable",
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable",
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Share Options, Granted",
        "verboseLabel": "Shares, Granted",
        "netLabel": "Share option granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value, Beginning",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofRestrictedStockUnitRSUsActivityTable",
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Shares, Outstanding beginning",
        "periodEndLabel": "Shares, Outstanding ending",
        "terseLabel": "Number of Share Options, Beginning",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable",
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Beginning",
        "verboseLabel": "Exercise price (in Dollars per share)",
        "netLabel": "Options exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental issuance costs",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant shares to non-management directors",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "nrsn_ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Share Options, Forfeited",
        "documentation": "Number of Share Options, Forfeited.",
        "label": "Share Based Compensation Arrangement By Share Based Payments Award Options Forfeitures In Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails",
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/SubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable",
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "verboseLabel": "Exercise price per share (in Dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r258",
      "r277",
      "r278",
      "r279",
      "r280",
      "r283",
      "r290",
      "r291",
      "r292",
      "r293"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee [Member]",
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283"
     ]
    },
    "nrsn_ShareBasedPaymentDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ShareBasedPaymentDetailsTable",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payment (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ShareBasedPaymentScheduleofFairValueoftheOptionsGrantedDetailsTable",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payment - Schedule of Fair Value of the Options Granted (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_ShareBasedPaymentScheduleofRestrictedStockUnitRSUsActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ShareBasedPaymentScheduleofRestrictedStockUnitRSUsActivityDetailsTable",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofRestrictedStockUnitRSUsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payment - Schedule of Restricted Stock Unit (RSU\u2019s) Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_ShareBasedPaymentScheduleofShareOptionActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ShareBasedPaymentScheduleofShareOptionActivityDetailsTable",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Payment - Schedule of Share Option Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable",
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price (in $) (in Dollars per share)",
        "verboseLabel": "Share price (in Dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_SharebasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "SharebasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "documentation": "Share-based compensation.",
        "label": "Sharebased Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofRestrictedStockUnitRSUsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted Weighted average grant date fair value, Granted (in Dollars)",
        "documentation": "Intrinsic value of granted award under share-based payment arrangement.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofRestrictedStockUnitRSUsActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average grant date fair value, Outstanding beginning (in Dollars)",
        "periodEndLabel": "Weighted average grant date fair value, ending (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails",
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options expire grant date",
        "verboseLabel": "Options expiry term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable",
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable",
      "http://www.neurosensetx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life (years), Exercisable",
        "verboseLabel": "Options expiry term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value, Forfeited",
        "documentation": "Represent the amount of intrinsic value forfeited.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Intrinsic Value Forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of unvested options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life (years) , Beginning",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option vested quarterly term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of unvested options (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life (years), Forfeited",
        "documentation": "The weighted average remaining contractual life forfeited.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Contractual Life Forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life (years), Granted",
        "documentation": "The weighted average remaining contractual life granted.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Remaining Contractual Life Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of purchase price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_ShareholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ShareholdersEquityDetailsTable",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_ShortTermDepositsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "ShortTermDepositsPolicyTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term deposits",
        "documentation": "Disclosure of accounting policy for short-term deposits.",
        "label": "Short Term Deposits Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/SignificantAccountingPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policy",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r138"
     ]
    },
    "nrsn_SignificantAccountingPolicyDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "SignificantAccountingPolicyDetailsTable",
     "presentation": [
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policy (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsLineItems",
     "presentation": [
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policy - Schedule of the Lives Used in Computing Straight-Line Depreciation (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "SignificantAccountingPolicyScheduleoftheLivesUsedinComputingStraightLineDepreciationDetailsTable",
     "presentation": [
      "http://www.neurosensetx.com/role/SignificantAccountingPolicyDetailsScheduleoftheLivesUsedinComputingStraightLineDepreciation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policy - Schedule of the Lives Used in Computing Straight-Line Depreciation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantSupplyCommitmentRemainingMinimumAmountCommitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantSupplyCommitmentRemainingMinimumAmountCommitted",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment amount",
        "label": "Supply Commitment, Remaining Minimum Amount Committed",
        "documentation": "The floor amount as of the balance sheet date that the entity must expend to satisfy the terms of disclosed arrangements (excluding long-term commitments) in which the entity must commit resources to supply goods or services to one or more customers."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r83"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails",
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r118",
      "r119",
      "r120",
      "r140",
      "r160",
      "r161",
      "r163",
      "r165",
      "r170",
      "r171",
      "r199",
      "r213",
      "r215",
      "r216",
      "r217",
      "r220",
      "r221",
      "r224",
      "r225",
      "r228",
      "r231",
      "r238",
      "r362",
      "r437",
      "r438",
      "r439",
      "r440",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r468",
      "r489",
      "r511",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r732",
      "r744",
      "r754"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r49",
      "r52",
      "r53",
      "r110",
      "r127",
      "r128",
      "r129",
      "r143",
      "r144",
      "r145",
      "r147",
      "r152",
      "r154",
      "r156",
      "r169",
      "r200",
      "r201",
      "r204",
      "r240",
      "r319",
      "r320",
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r331",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r344",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r373",
      "r375",
      "r390",
      "r421",
      "r427",
      "r428",
      "r429",
      "r446",
      "r511"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r169",
      "r375",
      "r407",
      "r435",
      "r457",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r468",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r487",
      "r490",
      "r491",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r511",
      "r589"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r157",
      "r250",
      "r733",
      "r735",
      "r752"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r169",
      "r198",
      "r375",
      "r407",
      "r435",
      "r457",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r468",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r487",
      "r490",
      "r491",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r511",
      "r589"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r625",
      "r636",
      "r652",
      "r687"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs grants amount (in Dollars)",
        "label": "Shares Granted, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r29"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.neurosensetx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted to employees",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r48",
      "r49",
      "r72"
     ]
    },
    "nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares and pre-funded warrants, net (in Shares)",
        "documentation": "Represent the shares of issuance of shares and pre-funded warrants, net.",
        "label": "Stock Issued During Period Shares Issuance Of Shares And Prefunded Warrants Net"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares due to SEPA agreement (in Shares)",
        "documentation": "Represent the shares issuance of shares due to SEPA agreement.",
        "label": "Stock Issued During Period Shares Issuance Of Shares Due To SEPAAagreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.neurosensetx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options issued for services",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate of shares",
        "verboseLabel": "Shares reserved",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r48",
      "r49",
      "r72",
      "r437",
      "r511",
      "r534"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase an aggregate shares",
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of restricted stock",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r48",
      "r49",
      "r72"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation (in Shares)",
        "verboseLabel": "Reimburse for certain specific expenses",
        "netLabel": "Issuance of ordinary shares as issuance costs",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r48",
      "r49",
      "r72"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofRestrictedStockUnitRSUsActivityTable",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants and vested RSUs (in Shares)",
        "negatedLabel": "Shares, Exercised",
        "verboseLabel": "Exercise shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r48",
      "r49",
      "r72",
      "r264"
     ]
    },
    "nrsn_StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrants, options and vested RSUs (in Shares)",
        "documentation": "Represent the number of shares exercise of pre-funded warrants.",
        "label": "Stock Issued During Period Shares Stock Options Exercisedof Pre-funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonus accrual reclassification to equity",
        "documentation": "Represent the amount of bonus accrual reclassification to equity.",
        "label": "Stock Issued During Period Value Bonus Accrual Reclassification To Equity"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares and pre-funded warrants, net",
        "documentation": "Represent the amount of issuance of shares and prefunded warrants.",
        "label": "Stock Issued During Period Value Issuance Of Shares And Prefunded Warrants Net"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares due to SEPA agreement",
        "documentation": "Represent the amount of issuance of shares due to SEPA agreement.",
        "label": "Stock Issued During Period Value Issuance Of Shares Due To SEPAAagreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares value",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r48",
      "r49",
      "r72",
      "r446",
      "r511",
      "r534",
      "r595"
     ]
    },
    "nrsn_StockIssuedDuringPeriodValuePre-fundedWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "StockIssuedDuringPeriodValuePre-fundedWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrants, options and vested RSUs",
        "documentation": "Represent the amount of exercise of pre-funded warrants, options and vested RSUs.",
        "label": "Stock Issued During Period Value Pre-funded Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r48",
      "r49",
      "r72"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants and vested RSUs",
        "verboseLabel": "Exercise warrant received",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r49",
      "r52",
      "r53",
      "r72"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofShareOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Option [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of options",
        "terseLabel": "Cash payment for options granted (in Dollars)",
        "label": "Stock Repurchased During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r48",
      "r49",
      "r72",
      "r446",
      "r511",
      "r536",
      "r595"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet",
      "http://www.neurosensetx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity (deficit)",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r52",
      "r53",
      "r67",
      "r470",
      "r486",
      "r512",
      "r513",
      "r584",
      "r596",
      "r745",
      "r765",
      "r819",
      "r844"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registered capital shares",
        "label": "Stockholders' Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares",
        "documentation": "Change in number of shares issued and outstanding as a result of capital structure change to a stock dividend, stock split or reserve split occurring after the balance sheet date but prior to the later of the issuance of financial statements or the effective date of registration statement."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r139",
      "r223",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r237",
      "r240",
      "r343",
      "r514",
      "r517",
      "r538"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r515"
     ]
    },
    "nrsn_SubcontractorsAndConsultants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "SubcontractorsAndConsultants",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subcontractors and consultants",
        "documentation": "Subcontractors and consultants.",
        "label": "Subcontractors And Consultants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.neurosensetx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r398"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.neurosensetx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r399"
     ]
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.neurosensetx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Movement of the Valuation Allowance",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Supplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Supplies",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable": {
       "parentTag": "us-gaap_OtherReceivablesNetCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofOtherReceivablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advance to suppliers",
        "label": "Prepaid Supplies",
        "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r566",
      "r766"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails",
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable",
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails",
      "http://www.neurosensetx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r827"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.neurosensetx.com/role/RelatedPartiesBalancesandTransactionsDetails",
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheOptionsGrantedTable",
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails",
      "http://www.neurosensetx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TravelAndEntertainmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TravelAndEntertainmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Traveling abroad",
        "label": "Travel and Entertainment Expense",
        "documentation": "Expenses incurred for travel and entertainment during the period."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "nrsn_TwoThousandEighteenEmployeeShareOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "TwoThousandEighteenEmployeeShareOptionPlanMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2018 Employee Share Option Plan [Member]",
        "verboseLabel": "Two Thousand Eighteen Employee Share Option Plan [Member]",
        "label": "Two Thousand Eighteen Employee Share Option Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "nrsn_TwoThousandTwentyTwoBonusPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "TwoThousandTwentyTwoBonusPlanMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Bonus Plan [Member]",
        "label": "Two Thousand Twenty Two Bonus Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "USD",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleofCashAndCashEquivalentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominated in USD [Member]",
        "label": "United States of America, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.neurosensetx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates in preparation of consolidated financial statements",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r90",
      "r91",
      "r94",
      "r95"
     ]
    },
    "us-gaap_ValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the Movement of the Valuation Allowance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.neurosensetx.com/role/IncomeTaxesDetails",
      "http://www.neurosensetx.com/role/ScheduleoftheMovementoftheValuationAllowanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Addition of valuation allowance",
        "verboseLabel": "Net change in the valuation allowance",
        "netLabel": "Net change in total valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "nrsn_WarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "WarrantLiabilityMember",
     "presentation": [
      "http://www.neurosensetx.com/role/ScheduleoftheMovementinWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Liability [Member]",
        "label": "Warrant Liability Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.neurosensetx.com/role/LiabilityinRespectofWarrantsDetails",
      "http://www.neurosensetx.com/role/ScheduleofFairValueoftheWarrantsTable",
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r587",
      "r590",
      "r591",
      "r592",
      "r593"
     ]
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability In Respect of Warrants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedBalanceSheet",
      "http://www.neurosensetx.com/role/ScheduleofFinancialMeasuredatFairValueonaRecurringBasisTable",
      "http://www.neurosensetx.com/role/ScheduleoftheMovementinWarrantLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "terseLabel": "Liability in respect of warrants",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r809",
      "r810"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.neurosensetx.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expire term",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r809",
      "r810"
     ]
    },
    "nrsn_WarrantsExercisableForOneOrdinaryShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.neurosensetx.com/20241231",
     "localname": "WarrantsExercisableForOneOrdinaryShareMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, exercisable for one ordinary share",
        "label": "Warrants Exercisable For One Ordinary Share Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares used in computing diluted net loss per share (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r165"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.neurosensetx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares used in computing basic net loss per share (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r165"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480513/718-10-30-3"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "30",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480843/718-30-35-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480489/718-40-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "6",
   "Subsection": "04",
   "Paragraph": "12",
   "Subparagraph": "(b)(1)",
   "Publisher": "SEC"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310-10/tableOfContent"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405/tableOfContent"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-9"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479035/940-320-45-6"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>100
<FILENAME>0001213900-25-029464-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-029464-xbrl.zip
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M^6(]Q,EV.5@ZDYF<J!A]OOOY'JYNL:\^7[CY<CW\?P]5H?(3%?]_U[V^][>
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MB@&'O\7$:C+&Q -ZLX'D6I!A)OS(/UHW>1?6$6^Q^7N0M"H!]8XJ2D\7R"Z
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MV92SMY0+'.L$^]9 YQ?1-X6%$RR @&U8R< _,=%D@.F?"[19$8W LH>2>IW
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MT8@_9D+U M:U-/!<;J\)YPK!FJ (&03,Y)9SY[<,ZRLT"#SYWA !&.X,XC1
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M^/>]?[:G63Q$<:"GWEF''Z!+7YN"]@'))!_ND_<HPJ%",FP5WUK8<O-1"\G
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MUP^I=>I4$N-+'>.Q&*=B'$G6%U9E2<,WJB3"0<IBF<<Z6V+';311%:DQ=M7
MVN2K]? #]CWXZ$Z-%*+2W8%-;8@,!:D+B"2YC+Z9V%9"9)I)X/4.@:5' C%X
M6IHQ'AYG(?-?FQ7&560\M>+^BS-ZP,X B8Z"6N=7?$X[#)Q.=B YU!N"0(KS
MF)HT3-/J(5-==G&4.K;#6">$/PS$4ZU3,!I"OHY^<<. RH#@3OZZ)F]=V$E0
M=_,]O7?!//T&^I1PP@?B:$6A+XZA$IY;@EX;D:YIH%E T^E)JN?Z4;G/GELE
MJ1<;_2O'<7@9TEZ?<;=0B6F ->V%0G%-)6LD),S^)"$O-=8*Q;8C,T:C$M!
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M/0K-D9TK^7UI3V+NTPXN](NG5!\ZQ5$EW)2&Y:18L[+-\JQ:UNO*?-LH:PZ
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M964.:JTGX2>41M"THTFB\JS0S!*V\^F(KL%<YR(1G+(A/ FA^(T:RL#F$@&
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MQ&J;+R22P<AD80.,$JF79RBJQH:('R,<423H1*E"E@F37BNQ&T53*X:!\,-
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M(^%R([&KH$E^H(3QM@*K"#8,TCY4V23<4%KF$94?C\QH'#,B(ZM,3\Z4>CA
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MWZ;%NB9 U2@MWL#O\9OYPCM[W;3R2UB3L!;VU9'1D))-U<*WUZ;7OCUX[0/
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MT<HN21DCT +F3[C2)RP!G[&KR3_B=<1#81^P=WIEW#^(?_D2O(2W):2UL8R
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M50I/./)LVI.IB<C>6C7D2;%05K_0-'GMW=]AU8^[&-,[.?,7P&M?8\N::2$
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M NM!%9*J!A1%.EP#H%UW.>#A@$?-][?'MJ?\-3;M >>3:F:_PW)8$,^]WW)
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M@2'*J\9]'>X^C/@6#8LF]<T+IZI+^52I-Y^95)E/#X)<).L3@M6NNMX/".Q
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M 7#>N'CV/LBX4/"EJ\\*B(8'P'*P,)+U0[MYX\C)B7Z-@"S(1@:OWG=9>@K
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MEM$)^&K99!2T3#2ILFL8#"$*$QW:*/8QPXVKGFDKB8Z<0VB,GX,K/*)C'Z]
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M7 (F-+AJ_4C&HC,V=?7&Y^6+8O4\."8EEO'#_WMX1L2?F>%-1T=/ R<IHBV
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M\)A=QI-<AFEI8H0:]91":LFVIE*+^# POH1H[G%)&BIB&$<,M+GV.:;*?.6
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MS\DD4+X!>HJR8CSF=_@]\%!@N<-N>?K!U9,_X[9[\L&?Y? I.8!,+AZ9^0^
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MAP,QE>\:60YVZQXGK$;6')#64:1E-$.AE2($K!(^$X)&*KY>K  -":L<?KO
M_)IRU\%[@(D' SD053-&BP_433:GEL@U+!PM;E&;(OJ:5O"VN6Y-&P-<S6K7
M&MU$G^2;J%)GPQNC'!I10LZ$WE!2":$=JHX"03AD8\*VW7;E[>S#$+,JC73$
MM1\1T:DWC\!HKLH81@>CA6$371<7>S[1BN'OWL_G697VD!VP1561A0K5W-H3
M0<YZNK LDS\7J$!I'&J1S@XOHBJO5FF-FZ&/DVU@.$Z+N4$Q^0%G6&>VAUU*
MA8OM G4)B0@N3JLJ*R9V="OQ<2#+GA?Y;!3Y+FM]88$SU:74+\?&2!_!G(2]
M<3#J[+\=#_$?L'[WZ:5^-ZW??7"IW_V!MM&]TO[-:>XXB< &\6:6%0%6\V+W
M<T3Q>NA$#WV!+IX-KLO8X@DMM,@5O\@3;QD%[N:,MTUF+\/!ZMV'4Q&Y=^25
MQXZQ>6+Y:<#%<S3UCZA9X>1X OM%@;.4R8J[QX&2%MTZ/@&+L$4W;\IK_">*
MQ5=K!K9K,10%9;1)MEBA(.NUYT\,58_U5*T]<G$2JJ1OO#_:6/F,@W&OLWQ6
MFH5AN"XJ49(T3)Q\S@[-O&T+CZ+A(\4F0-.N*XRN:4H@\ Y#+WOC:<=6/SJG
M-__\YB5<Q/WS^4M-(&5K9J5@(>Z,2@J^?_C3_3YC^!J!W\B<$%;;*57X<6-#
M?1.+KE+J4.I>3A8WX:X3UPMAEDQ%ONOH%"2EF.F=C%@ :_3,L),XL_G@FL%%
M'$D2<MY+3'W7-&J;0V[^*OS$EU[22R_IG2-((JD)1B-I+V.0I3D:"AMPI7^*
MFK92*PS7NFGK,1STW8DOO%6(#7XE'$/AH/]-:88O>^:R9^X< ?"70-ZOQ,QO
MOZK],& _$*C)U%O<1YD+<5G3ES7]7J_ISN_&/BQ7DQZ$F@B%+2KCQS$.GQ;0
MWG]D[%AO/KY-/P>*A$B0,Y(WU8](7*JXKIMVH\@S.0H8K13CV@LQQV43O?>;
M2'%GOOH146U (H )#&Q5QN89W&68AH:V/ %@ M<6)9?Q7U%Y]S/N+?IA;#:Z
M[>1+K'4.>C1(HP.9E*XZ5% 4TC3WA77C'7!0@$8YG\5PFBUCG3!R<,/],;\5
M_ELDV2K BZ@+_88T4/L!\6MI"Y% ZUG:RF"\I31+?8R@>E_MVW9;N*8<>'EA
M(@87C&FQB^5JD20)(T<)7!SS5 G0HE29\(4:A8N5KS!LG8-V NI;5""#6]]5
MW#C&Q?X>R$,1/BMJIN6V/ ZVJ U-S (USNLLF%*#[C%>X1.2.LP.4AT> >A1
M/16[UOF>BD(TKS7F@!1I5"-31W,RL4^4PN7L#WR.Q:KABLPG8*!*W"GOZ(SC
M9EW2?D.\KA1U;^^&_#[0:ORWV"L7^U,Y;Y,"K7?2/(M50M)6AF6/;9IAW;8H
M.B[^=^R!Q-\__^Y;^&NX_%B#EB^5#V_")5A_+V^CI)Z2B8ZF8K-CYX:;UAJ5
ML@9RS@,V>MY%D[9#*K0-4:'1KY+67OI5TE!;(0!>,KX(DU2BF)@I#9^[@5PV
MCL6'1X*$&5S-;MJX62G15:BR(BQPUDC'[4-5WG /1(#2J!3GM"LWWMD3Z((+
MR,?P/=D-7EHUKAQ2S75KCR3,9AW=!//=CCVU#"\M*@+A3\GV6A33B=VZHCIO
MOY6MQ4M..\/-WLU#""GC?;6N4+-KIE4_^'L]NV]*-XS',:3$L4%-VR1HF_5X
MN%$1!XG!N9$?RGKL6!S+DQ"AAE-Q;+BAS?W%I,[#W][P>)$O@)89D6[_M6!Z
MK?I$;5[R4X%<&/SK#?\;N7 V9;^GSX;+ I4)B4^P!&+G >7-3H,CMH$P\H[2
M@Z4E'-<F'4P:CMT&ZG4%X-[@/QC T!69V$9"1 *@7(,?!&:&#];@EAPPMB1&
MYB(6)YU0Q*J,]=:S!$Y;<W<;(H8+;O0I]65/-=(4[JZL$/#.E,K\._,2HIXI
M2DS6)R?$MZ2(C**%X5%P?2A9K=FYX6V- YI=:2@'%@B8?U:D/'K#4<UH0F H
MP5DC?A4Z&RJ4>R6[WQ$!V&5_QS$(J?WTY'7SG*4Y6RDNXR]1=!10?1B*!0O@
M,=,=X4:H1TJ<</&7Y36 <X>$B3\Q$6&7N#E[$LT&LV"0H0C;M1Q[5@-<>_FC
MIYUJGR*Z$(4\]*[M+*-RZ@%#!Q]-$5;9PGDQUOQ!#G!*GD(J)^-VA.-):';*
MF[;: N\>"[Q1W7_C\2@SX$@\H\)FA2D\+8\:^N<\3'O<:6-_ABLE/ NX/8-7
M4TRDL#S16(@>2#9Y.AL*G0VQ]2:<V7#J)M-0./W(+MJA?D5A'#-/0R4:KLW]
MM\D']>OP#>;KJP']#'7(L)"(T <>5QBLPGP'"Q=B2K\FAJ!(2$@7 VJ</EE9
M*'A+,LU:\5G[?5GOE%!G,L]D.%!*LA1N.ODT,R>=N-L7AAH.+Y[ BY$Q8_@&
M3BUMB0S^=!^,>EUV+H\"F,!*NL:SIE<^Q$BU&(^N8/^/GC&0B .J$1@4CN&:
M>WQ16[RP+?=X!$T.!:=-M*E 6K4U> QR.".G&CX2G3WBEAI"3FK5OR:^(X3P
M*X><4%(.?K-O@/CG%.EL'/H&"Z(I'OI-;ZI6YD6UP0$1\ BGDUZXS&0X2)$>
M#%A]Y-P42EK1;0[!(*5H*(2DN--M6XDFN;W,9 <L^SV^F@X>+]P#BIP'_PCO
M20-1YI_@QCU"+(\@#^1J_6;O<9G%B=:A&IH %QEZ?MO5_#[LJ'O!1S]\?(&/
M3N&C'U[@HP_T.+(Q+;/6OA#!>_<R'/)",0 &Z=D&8PSY%9,\/OGTTX_1C?GJ
MQ<MGS^;--;F[?:Q*1#U#<'Z60E]/'-"0S (W=!B0G)E\6OH;X!G9:B+9G9=C
M]&2C-E(8C9QS9VX)GFN8+C33[)5RD(T>#E!UCD>4'$:M+X@6-HGOB[EC^AM?
MSAOW=R:Q"/[3UM>5^$_&VX2YF3Y&3V$NYMTO@=P<)CKI4Y%EV1/9LM\ZKFWK
M>H^YT=?1"8&Y_R*\J_8 (NQ NBZ99/Z>!'Q?O7C]Q?.O8B??P'HO2Q(V6#NB
M#>'$GS =839G%Z%1XI",Z"EUP+_81CWW(9AW=(!R23B-:G(^/<#77H\E4B()
MXP9DA8N8$L9G@8PSXW+3ZT,7)DD'5)@IGDDTPSU;)/= _^6V S[A1NF_\4.7
M=9M7'Y6-BO#6L%I<6DRPX5E2$DC*8@G=O52<^!/&C[7"S\+@60@_? $=[\#%
M"?SQ1+O WCH"/H3A@:XM1JL*2^^F##$-+(N4C+;02$(S?L_W5;T-P]<>V_P4
M$IUVJ3*$%0RMC\Z_W?@C[QA(*HA %0M6\3R1*$;&X/K_E8>C$1YD]38"I3S_
MYE6!?<Z(U\=[2LT3<NZ?>T@1"M\!C14GYJLQS&5ZJ:^^>E4D&P(K6IQ[%V;=
MZ.B+8%6O2<#[25414YL8E%](K@JKT@O](GC*.61XXT"(%AOVD:<K+0J+_8_F
M9SHM]%'#-658NCL3MF&K;#@EPG HVOJ;9*E6TP=89%O-<.!H1]//0DJ\'[J3
M+&\7H:^F P$XUJ"QP^LK@+GPP(.R\#$(!L?Z&J>+C[.9S-C%N&;]M\I3.%.V
MM5G>:<:=Z5OO*$F+/@>E);S<$3$,$!P=" ,$(A)2*)T4BUV*P"@XD<QK=(KK
M"=:Z/!!=CB:;&9FZK?KKMJ/LA-45P:1"U;><]0VN2(^,ULQ;P&S#COA3H+>"
MF)!G[+C9=,O5$BJTJ_^BPPTF8*0&,_A:">1OVPJ??4]]M.#L.E-L]X*T15,W
M@JFK)4F- /;1X-/;Y#2][(6$*[!O#9/VEV%EAF^MGK==-QX']U*R2RK!QDG*
MU6W;U=O;:LM)-BPC=MP_@W9329974@8UYM(<+W *X0G3:?V3 RC)=SDKNR"M
MZ9 Y0QFD/G:GC1V64N"-(QZ'PS5@J:0?%$MC$%4ET<V=VC'RK^"@4%!)>+X9
M5N28I7/CMW!>"+4?T>^,//S.;]Y0IK4#JI+P&IA8IT>,%_B^:*KA3B&,K=N3
MAU?)*UN;^##-"!NO04."6,YUVR%J!8/@:VJE^[\SB4^R*? AR([&OV*Q,F9*
M"P9G1#X)-A>Q&D4=4U@FD>8Z2N$J"XL3>L^42[+@JQ*M=?1EN3V/M_O#W(P"
M;GJAZ?O(OP*KF2DX&"E6GUP/78L+/;O5+I)9TN1FQ)>\)I3@,KCE<IJM3TE9
M)Q7.^EN;],91U<#)5KA >,X+$5$H8I-/CJ4/#K[LR7I$ODK"^R6OKA *BW(#
M\0WZ?6B!A2N>>=F$[W"9<'G"P^$((B?=76>63^3YWYU9*=,62EPKP3C]\][?
M*9P@*C 1,?A<XFQET&R(Y?0-LQ)?A\/E1[%LVQ =;KW,L8]-ZN&)3\(]"AHO
MF!WI89\%;R-]?%<#X]O%8T@\!G@O!W MA\XW*MJ,=#'&X9-PAZ:W[OTM$FXA
MO6T_2'L_QB:@PM1M5\;(].G;(Z*Z^-X "D"-V<MOCMB4'K'KP'X)O<UD4<:@
M<GXY<HE?J&X![,C$7%&K&1TDDHW8FDSM2L).IJ<% ;%*F<%P&E+M3-5-R0JS
MY"G-L!!0FA&-.?LZ:6:<R)_^'WOOVMRVE66!?L>O0*62*JDNI9;D=V<Z56K9
M[G@FMC.6>W+GTRV0!$6T28"-AV3FU]^]]N,\0%"6,K&EQ*R:Z<@2"9S'/OOL
MYUH <TRB,\[5XU@,O'+SOMC@$XH,)H,99VO)/=8@ 7S !T\: /%./JFA.#4=
M7&IA&&ETS=AWQW2#-926+N01]/"60#%R(19!<[8HVS6W@13=+P9(41@ 8Z,?
MP/&KE/ =%WRJ!=B!+-FN=]\Q6A]J^EE92P@$8K9>:>$+8^R3Q7*[P!Q";W29
MT)=4J30>(%_(\:X$8Y/;)K(D'(&'M<>::'G_EIH($&S]K#>6JHYJABBW$%)A
M +1('!0= MN346"4"E*1 $)7KG1Y&H_%]&(OB/]UG8,O "[U\'A7';!9'?!H
M5QWP)SI&MQG#NYB;+3/DU41RUDL.S7&)EOF-!MUO]=D.!<*EB3PL\F:+%1BJ
MFX[;Y?S'W,TD8+$7L)L<6#1=#-D6(VZD<72KZ>JY.)JMJAT"EEHY=-W\N].R
M3L%OT929,RL;Q9J"ZE9:O":9%2 K*-5K&Z/QK[B8'QH[.ZZ?2K!OC1)B&ODG
M@WC:8@)ZO*PPP6S/88@HEP09)3X"9X5HVVS<\ 9!R$@J#VI[L[&W.3ALE^0H
MAHU%-U48P%W)C8I<M\L\?2'9AL(AA[:>KXW=L#]@"=JF<,:%_3<9;S;$F!Q.
M(.FQQ2D&,'31*#9ZW#LVWCZ!_SJ1=ET8"B;4WD4'FZ,^REL[D!YUN;M552:N
M%8V->2LM (G(E"'Q6:"F13/++M4F"A&8&X$.!<>C=W\$5TUY0>%:P'3(5IQ]
MHB7B>*:0(G+9[H*$:[I.O+7.'8KCAE6Z]!YQQY'[@"$F6Y(B6&M/%^_#KI^(
M2,569**Y9O'9](O6G(%9NN0+T)*#4&\?<8Y7J6B\>1I@%U3"$I'5YIQPH'L+
MP&GRFOZ.D8R4Y--7*%TSLVFEY=T%9P*EY%H&98;D"IF2F;280' G6:- KOBH
M1P'GMS2)] 4S(8)/25FEZL@ Z2U:Y/*J(PX2\0A#3+@_O6'XVV^T:VZ/I'=Z
M$?IVM+<SZ2Y-X[:0X0>YP@8@ * 5/&C(5@)3CY1>?!E$L*\-KV( (N*F6!4;
M7[UKG(K/.J3,^;Q6,BG.;M$:RU6Z6F3E7:(8?5VR>W-1O7O)_#U'@+#GR =*
MTZ#V+&R&V@GB3A _KR"R44D^+9?"&3*PUB":][>3PIT4?EXIA#=PX+3A76.@
M[63N:Y"Y4B&?A.B">6$7Y.?6 9(.5^[M<,5N4-E_@Q!)$O/7Q0"Z65B'X?"V
MACU.CH4P$MD!M[0N'6"ZA%H$/5^ K2WN(/5@'.E,7!T2 G)<Z2^(0FDS*:3C
M8Q+@*MDS>UGM:=9F[L)4/S>* 6H&DD<<L.>5%;D<!2IFI.8HZFKX5"@&?XYC
M9@PKUFA/VK9 Z!"H61@G3&[U2G#G":-9&"]#+Q@V4G9(*MPQ\5/LE02I1W%9
M3APOT/U*PI!T;Z/<[LB>V ;I!GYJ,]!/H*-KD$NE14#W%,=\RTH*)H4F 11\
M-XF<NN( ;A5AFJL&],>EXLDX^#1=?Z%V! J&A%1_B<@?#8_*I@L!2YJ.ZT$5
M6 (0&F'=5#]?&@Z:Z_W]M^.16\G(I\H?&"Y/YIYLF?N6PHB@%/U&%5PD*%RS
M>S4\HIXB63(4C P"GU5R['[69B-C@^%H06J0XN\7BQ02[@RJ,U3G^+!RN5@G
M5HF"8G=>SSZ=9X PYB 0\QLRP$N9J^#L!263J<!=>!).MWY?)X[>3P&_>E6'
M<>^@:$L*%)D><$,-\C(SR@3OW#+[ !@AB<_[@H;@7O&%K)L$K9-%GM5:M1<1
M;D;G(OG$N2#QN5*X)M8:(J]:U2$?SZV*<A1'PWMIJ&P&DHKA415-8OKI[FI>
M[X?Q\G(3X#3 # 4;Z[3&4DZUUZR5/6"]?D;W;JU5\5'9,=^ZEH_Y5U<7S=38
M!P*3)+Y %7"577#&]%#2 .773.3I%H[_E.#U<B>>/4[[1_3[0;F3*<Q8'4),
M\VH6DP$EFGP:RCA=:+-FS"6*YBZI]@6B*]<0@3"ED10?/05%#ZLZ;S<27#W2
MH<U7)OK*B/\3QSE>W@'X45=F[*\#$$X)!JL?/P_0L9Q&H_5="(;PFH3?U)H"
M1EWU1):2>49F,R\OVKDN!;VT91'O:XQ/W:2#&N,P\;>[F5JY5H7)0@3HM%$#
MM\>3$?K8>*X1'JWD;/E8S,*>/;J@2A(\WMN$T6WS:8 K&_=4],:=GJ-2V@;'
MYV08=$'-Q%U&:1<2^+W"4$9"7/7H8)9Y.Z^F=\INL9/ KT<"4T'4;BM:9E+>
MN,;NE>C=*XU[)_.]KLCV9%=DNUED^WA79+N[$'87PNWSL]YK\*6S6;U,][2+
M>_]>W0P[&?P3RJ#P%3*>!5T]VL9;*2@W$\Y*[(&\U%+JRJMZ(P:_2^KN1/6+
MJLN(['F7Q/WT&%X@0^; -H2\1YH<$B3'BP77TH-,!KB0'#!UR5'Y =\ SLUP
MC&U6H*6]X*UA#(T>O[BON&?RAU6K:)&>E3@QLO>AV&<3!C\;QW'=R_?HO#9&
M.0J&YQI21IH0'4#\N*.$B\G)E\VTO"N:#TWZSO?6TFE]%6*NI8#V>PNTQ:Q>
M)^< 49=]_X7QH]OFCM(+=YBBZA\RUK2"C\(L1)#JD+@KZ3.VO\F::?9O5U[O
MJ=T7 TQBDMML9.$-?27')]&\;Q3%\LCT+&-$O?0UIP/N>%WND0)\7[E55E8)
M6<!$$45D^3C-6^9R$/KP>-?N4D3UG@(U8=DM28%5S&,Q+HS'!&BB0D1 *N?;
MX\.C(VBSY,$1EQ@P:-%EP,PUA=;<P]LA+"='W[_6)_^=GO@S/_%=M\CYC\??
M[WN> Y#X>B[X% -M.=F0M<Q/TZ;?GAP^HH$N%@C\#[PB>2'?"9]_F+XMT^>D
MJ+F;Y.1XE)X<G3S@55/U/46S204$+B^:/^ER_7='6S5S;8-TW<QFT9O/\1LW
M%QKL^WF>J&"?M]7D@XIU^M-/9PP)AT=QRDS8[7#N?L/>!>QX2K2GY6-^(ZM9
M\NW)Z-'1T>B(=@R4!=<L<IU^^^ 1/L@?5DP<07VD.>G!5:Q:1:SZUA[-@ 50
MN]S,QDNH8^?4GKNC$BN)6>**QN)+FA'SYCS;C QXT@-KND$YT79566MA.P?#
MS@V^US .09-S_0WCV9B6L1V%;"2/'CTZVAOO[QWOIRP?+_-QW0%NY1&+QT,6
M#Z4F\? -O-<H%5MDI;1S7DC';*PI\5&3^4 @#T6GG'(6W-.>)-<\;V2#O\"M
M!2P$7&,"H] H;LG&EWA"_YF5/)_'/)]'/!\DWP!.,77",\^F^GW2*C>=!IWA
M_!*T:-+N>IZO6CE;CX:.5O]@R1K: *;%5(E7\C9\81+KBN_3>765HP]U*@D0
MMU]NLVP:U^Y&_-0=F<,/;\)*,U32T27#'=^)[9"KK.H3>]Y07"QC/KP%UC :
MZCU'>")]NFXD4CO#&I!/),L,^F&9LRP<6N8T)LDG UWE'R63<<B6H;?@G> U
M>62_:"NZ ?:1,9,$RF^<X]FQ/2,'=2=2,">Y.$"M;S,"T:0^M&*N2JW)\P\"
MIR1]U4O.R[,LR'4D!%T?+2FJ<M5_#Q[5U@"Q42N)W.T/]$?:9X>?DP@1HT$U
MRK"$*<:LUMXU:>P)N AJ9K)S!97IO[LJ*+O@^RV^/D>#"\*.'T.-0[&A==_A
M!>;@$I.+EUO-\4I(G%#<-!XJ7NBDU%/E$EJ0#6NWK/B_'):58BPLKA)6,9@6
MPUH!3XN$>X56=5?Z,%:DV:SY8!^>:86@/P8]=YG+A+Q#OE@[QK&IFX ^?D,V
M4#1F'TYT]18%'<>I6H"#W_*EO/81,EUY$_01N=:;,K9>'UA!;U:'U*5?55C=
MA!:$,;X$WD"@J@,5H'C"W!0O"QVP4 Q2# <BI(*C'KZH*8=DD1OA ,HIVX0C
MG48SY3422[;17KO!TV;/0!,P80@G:1Q@A%/%CV>(4SJ]9*<IQ)^#1E4N*8B'
MM^1]YWM2<55S5^K6QYP/@=!;=>O6PTD;#4SM="8EZ!OF?^IXH1N8DY5B3R@Z
M1^*QU0TL0:^MC:+IH1'PJFYU1*/"GY&&9IS;Q;M4"KQ:J<T84N:DN _\BT!&
M3%>QKN".=ON04QF>.!,O?DMB<T"3.CA#03% K[SBZZNR+US9>E=EM;?*=#_8
M9;HW,]U/=IGN/]^QX)>_']"Z Y9&$@8^-_'OT]D",.Z90YX&2+=<::R%>TA%
M:X'N=DIX!U \S/+5<.Q'MX<N%L6)2HPTU6%+W60+H]BU$2>C%P 8\7#0%/QI
M#%":P9T=.3S&*4<3F>&KJ+5;A_L5S$Z5>(U X'"B@2V#S6R$,*/>>O11\#*)
M8[\LG3;JO&_A#4#"C-1(F*DI)K1=ZTI3/%J3\ EVYUW%[B[?^SN-0)1C8.J[
M #[+\D6E;*<3LAB_<*',3N[^Q'*G)-":M ZSU*J2'?&N^-K.KT,B&M>%^AB5
M;U9%6"YO"VC9G:3N)/5WJX@14B*NAE"V(_!*9X!\X1B:A%M=E48@AA:,VTYY
M,F"EW&4YXK7&XM=A"'RBS_+3@'"?61SO_D X,-F@)3+LJN_7+>[D>2?/]UF>
MV:4M/D)N/=Z%IO# L+03X)T WVL!YBR7V--QN:?E;6+@(*XT#1$UAAG$=F*_
M$_M[+?9!^[WC_03NV-)P25# O@2ENQK<XW68[,K*;+$6#.T;! &SVM.] !5:
MO_Q'.22[H_)5'Y4P?H+$=#Z9E\;;3N>GI,O! 74 N\-\V.(R*/P'-RD"\G\8
MH=^)^U<J[E8W*I5Q-Q'X4,B[G8#O!/Q^"_BJ&R^TQ-\JEX(8XZK.';@CRE7M
MY[9VQ-@W ]';G8/=.;C7Y\!<7=;:W%>GB(]9*D<$%8VNB8#>@?+",M_)]4ZN
M[[5<:R?O.&^O\ES22T#91H:(*<))TM6D#V/P,&10<5[.,Y;W : [*^&1XAY7
M+,S<X5I<6@6D\+N#LCLH]_R@.,>VL3(5J=MO:>MS2=V"H",'BWA=7,QCTC2M
M#:P6E[EU8B\*@ZY/QW75T3?8\ZW3#/U:37O'_L'7=0*^UJ*# )\A$G'3WYY$
MT@/1]M@*4<"E;: >2AE!453/J.+7&V-938M9$0#9[O3^3N_?Z_,1Q/Y9P!70
MWJ5MF9;16TDC<@R$$@&8P<4D+YL\BON,@A"1) ^LIVCG!>\.PQ_G, QY"H"5
MKGK0]CN9WLGTO99IKFG(I-\>]GN%KES\PK&2\%]AF7<1CT[4FCG:TN Q"KH[
M+/P9I(:CMLK=4=D=E7M]5 +U_R%? _RHJ<HRW]6M[03W?@LNXR1%2!$WZ<>[
M:QS4G6CO1/N3(]#FV32?5&6U5,8]#=.[3@]%]F3KP[6'^MBDP:)T9>V!(^.&
M5_H!U%P,HK4#:+U)FW, -\-X,25@V;BK&+M27B32%QPT(DL'>IDC)GR)GN5B
M2:>I_6V=T!X.E?'M CA8(*(XI"82@HX&-4W4OG7 * 8(E*ZRIAV1W"T6U95*
M0E%-0RP9TJ@T8K1UCC09RF5=F'&$7B*,0LPGA?!V >JB"#EOLLB:)E'D'A\=
M9^(_X&T!TD1CZ$SI%8+.N$^/P HG3?I&YQ1-GT%P.]H$08P#)QOTDI4VT"(H
M %"2M0PB(P%,+ Y)2':A9)M(886HM'>!,OM9>3:N!6N]%?;(PQWVR";VR-,=
M]L@?\W!<BSM"BDIA0X.N8BG@3J<5@RNPAFSFB?L ITJ ($5:9UQU/=H[8%%P
MW15=!TW3Y71)S[++JA;KCJO.6]P! /FOKLH+P7?[Q.TP\FRKR4TN$U&G"D^U
MPS79@FMB'H9>BPH+EUR[L@Q1PA!W"EUB("!15[K)!V<=M@J82I9*4>?AW!UR
M>L+ :<"M849AE4B^EQ4/)$7G@:(^N@?C.5?]CR^712NI0L,*6\)LO*(+.1A]
M+-F=(/$E-S=C(LG#22BK@8<#-5XF#\1BF[[6''K<>#E+ ?-%<LUAO>E9<B>T
M"I=,SJI8W-M/[ 2P?C9T(:2,EZL_AZ^4//BE, -(]= 6L6%)20)^Z=N:S#N]
MMAVRU!A3XYAWXK&6%N(^3(LZ5_>2,0F!\DB>@>/)EF<9+GH%$$H.GJ/[M6>G
M>T"C3VV<T46K[V%\R[_);7+ZAA$W8UI:074B_P<-Z' +HO<:."?KZ#Y8:KI$
M09!,\X9CR!8-LLHKYBR^Q5R2R 5TCE!6U"&I^B;DYD3@ID8IXUX)6F<[Y[HD
M &O37N6U\A&KU@SP3G=')C8%KMNK9&C/&?ZSKE9](N16<'C;8LDX2=HH'C(4
M]T6@0I)J60#_+$XT.3#H.BN:/-']/DQ/_?5:>KOP1J=%I)JD*]>+,A K?HM)
ME9,D/!]WH^(W)-LG,I0YVQ \C_\JN,  Z&,L7URK;$TYC-0>.I_EL'N[\I5>
ML S+UT]MIF0#D>Z:%ZMT536\3<Y;<)K;:7S!S"U;+0DSO:^0PO1AUC+Z??\M
MAK0%WIQL4"! 13E;B%,\J6HRBP![MT1,IK[#J_I^J)A3MH)>L\GZX-AX#-C9
M^-TV9IR7.3"B^2(@21 \>@4-E(\MU@+R:_\:2?W?1VZ,7JR3D^/OG!KI6H:M
MYQLD/NBD@283_MV% B8WN>86FPV,_5@].A'!UUB_P$'!:J$P1;@P'*/Z*&'4
MXZZ=*"ZB"E.$G#_N<5ML7.2S@+HJC*'[.DF.H3./B=1$Y@M?!HDM&E=9/<4_
M F/)JBV#T2%\ZNH1ECFPR'4+.,:5A8%)#;<:S#G#+N>-7BM8DC$[> W FNET
M8^.3"-%,"Q."B6Y"F/M=,;2I4&/8.Z%7.[W/0#K8U0C_M/."YLSFHM7_ ]0>
M+@_WTDC)G/-!9_0(@Q#'DS90PW^C??\UJO9?<O'82R8)(3N0C,*LF2/L#3ST
M*<..,HL#ZWQG!L9.OT<DHT>LF18)"8WX05;-4L&?SOG(BKFY<ZT&QA!O#&RP
M#$JHJI/MFY3V-JGDL)\PV-Q@@X8><LVN)31$3@^ILFVUUK7.!>P%ANAE1J:F
M? =OL%27NAD.+@.0NYTK*?<8 ?C\15U=M7,[PB[4D9YZC-N1F:NL>^&>:*J'
M]>2VXJN!4-LX]RDNI\:J!1#UD?C!@Y@SR/B8AE8E4HROFCK+%P58#\2.:?J&
ML.XL#V;%:E&WPQNO!DPL-[#M%GW7G@Z-#<7,UTKV\:NU4W_))6/9NWJ,3 .Y
M/;0C)"$VLD]B,]!L+T.ITO_/DA&/SUL)55CD-,CX%;&A0$*,4M<-GDWZD^%:
M" 504H 8@E.Z.[MU8 .N8(=<'R3'Z5&BB>'M4@JD -_;4X'%'*3T(TUEI%L)
MH8"ED2TKV*7,7]$B$(OX5<":! S.JFN,SV)AEHI":V83'/;"NAY1")VO[,B3
MN9UKTERK,U2E^O U:#XP$^6'=$:E"P=K3B!GXP<<5'GCXJ#],4D$/V1PQ3,X
M<]_5<+QY?<[5)GUX]-#Z^L^S>IS1DP_>?ESD:V5D@U*:)2='1R>'Z1FS4>%)
M1DC5IX8J&CZ"W L]E?, L[-;@M<7&0<I<,BC6\1' #SC"BQ]\++(T6,35Q8M
MD8D!1)Y,06>E!':N>0IT+39P(DGB,! :$TDR^;,<A[0DB-8X".E1R*;5E>XY
M.0E'T[+[&9QJ7@*^<TB:+[1^8XN"&1Q!]!*IEL_M<_C[A&:,=_J=#&5$YIS$
M= 4-?="!C<@UYX8V7F_IWAI)A"F3(.-Y"%LU35\83\L9\CU-PU>>7HWG+\[L
M9V-UC"'K97?<=>O9:P(N'HO"#"+KWRX8)0D GZ3\<UN:OVTTMRO<>+0KW-@L
MW'BV*]SX$QVCVXSA+=^V+K;$MD2#J,<T49U/2AOM@5Q36=3+%(PF<BWE9(^4
M%[2@8A](-26LE(QN^O;6=_E(.>A(GXI=RS2?L%<26#X(%V$0ZEGI523\KYQ.
MR.GE!5C,9DP,JE;5?W;+%5TR=<M4D'^W$I1S_*I;-:E8 ^G)T?&)NP7^\^W?
MS_$'9X3E'T$.ES@"L8B9MQ*7-RNW+&2Z92%MP>2JPI+UHH9E)7^K5F1NDUUS
ME8%DC)-G8(6NG??G?LENJG*F<JDBOBYV&FABP=V9:X*>AOUO)CM>\PV_=8%U
M#Z^96-*?F TK="T0EFQ:BSYZ%\01C),5 ;2!#'6<C8/:NZF!V+!4)8-2)2$W
M'A2J%(HHTZ3>%:+):/QKOH*\WPU]8J1/HE2>JY,AJ4B8['(7 MN2*HV\/%(>
M]:1H8!8S)?8,[AN35WM&0N#+0+;%KU[X="*,^M+]6A]E%F2.$XPS]>WCPZ.C
M&Q$D2H#Y^F(E.2J7DIL4W(/\XX0]G'G>'X.>4A>0'G _-M^A97K3*I>[Y,:/
M-^76SLW_!-%5&7^FM^BC^*];1?EKC#V=VKJD?B^055M(N9'D34C"$MP$ @ C
M#J'^98L$X398A$^P76W"O5! [8W<V4ZK;([AG[RB* 6PQ%*P<)KFX 8 =WZL
M/,#7QT;_E%/.Q;MUA>BL/'S[-O<3G/\<>EL2O<T;*")3; FXK[ A)>]BMK>M
M[TJK<K%60!;+;T)TY&(7>PQFDVI1!!F:))NU4O3I7X@_?Z7G_!<V$C6D@L0I
MNE($M8;W&6;8R='W*_SVDJ^IG!X3EI:H.<@?//Z>U_^?A^>'1J", !^2O&WV
M$3$Y9'@YZL<[8,%!^B,'AW#YB8&/; OGV#2W$GZB24*^9:F%T:3IUE<C,J?>
M*XL+?\[W_^PTRV#*;HMH)!+Z$YE(M\L$^TT_OWQU-G(IIFBG<RF1>)Y/<I0_
MRJ2UQ..A"W=&@VCKG,LY,(($C_X_BI*4.5K91%1GP$]'&++C6.\2]=%CSKQH
MA'HF'%9)R]4'T[R9U,68>=L7U14BR"IR7"QRQ?97J%:A4ITAAGS+158[]+3P
MY;9V-L6J'CX5_#$UYZ*< 9E>ZA6]@_75(?*I=-/TG5?OSD4?9Q=UGJ<NU@O<
MMT6'*.CVL1VF_Y"63$RQF/$^LTD0CFP$8W5!SF6;/GDDF\QUI:4+!9!GV31V
M7&FM8ZVC?S -(Q%M>=ZCH^W/2^ RQI9A)!Q[T6:2T<?%&VI7SE!":BU_L ,;
M^XL]U2IMIJDN.?+%J!?-2#61>5S3WQ=K-4;W$\Z0R%=YDRP(KM'Q>4ZJS#9:
MX614%N-58$ERC.03N@=)"ND=OYK&YMW9HH634 L?IC]'3];7%XU]PKAJ.1V.
M+$T>9X]2RQX%25ZKC$'2B6_[NEIG"PF],] ?NS8).@.JJ0^]!\6;+9V'1MHB
M-3?IOS>X@O'Z;,R*2XMM_ [2BE:%/L.=H$BG>L#G-E^B_*Y>A_H,1+.=SL]J
MH*2DB L_IY+WT'".%0\?IC]65_"6="VDN<66 Z9)CB'(@OAN9*L;0I4R "=$
M#BP)E6;"THMNYVZB=+BM]&X$C500*>@:KH.:2DQF<[--$FSN$!W69M:$RD+K
M):I_L#%&Y=L5:?M1++6]+(JVZ6E^3]_$7#BR<_+]F=;BO<X@OB2BD<I*7JK@
MOI+ATI=9H6(RDN11=;#/YF$SZ&U4H9%KM7_.4H@TY"=,AD3+U%>KQ5KR=33I
M8,J'Z3D'Z_39D;5!BQMJ<R7>IF.57TII(NHZHO5;9A_RP/B"&A(3%^I(YYWX
M2COVE=P_48B'2Y)[HH*G2% /AIU\%$$YDFE]'-\$__WBI575V>,:U36^NQIA
MW 5?)Q#$A-_%AV3/4FL8YT%;'5B/@'UB?XM7>)C^,D?>^"H/RF[LEC1;[4<M
M2>2:ZI+;\UNYFB26F/ "?8"\DKXNIIB,7Q3V@/!15DV?O(LM.<K7(L<#-%?Y
MH:RNR%VY<"$2W52G>4?1+1P.U)YIKW3%GE,$4UJ>:8:^\]Y\W;3""?WI8Y&W
M,E25T7Q#86U8(K+H$K*VBQ^VJA9\^R"RW!R:E0T_@=^Q/6"?U1MIS]=OCO/0
M."C*9$$3TPI]OF[H>N LFI;,AE;&5F"MZ/&*09#O:YQ02W%:+O; 4G"^37[R
M4;_$1_W^S[;F8?HBBS4@S+:FK2MD*-*NUMP/%T1 ;^#2)IU*"K)H:&/\ -C>
M(6NMP+.A7WL$##RXNEODOMS.E^%Y+85C(J@(N69]>AK\,'VI?9#AJ1PE#9F\
MO^6"2F]T0=%CS!QYJ6[2*V]6G&DF)?[>H:KDNSU4]^%@WRZ!_WB7P-](X#\\
MVB7P_YQ')@!AR'J:21H7H)!]M"2IKAC!W7G.QT??;;UL6('.S19=IW'AU6U"
M;9\QL';_8JK;NXJ'=RB)=BC5'=KS#49ALY%VP[1U-Q' I/V-O<1UJ59$33:"
ME$&2"[HM&R,;G:BXZ$:' 3:[&./!!XTS%I)A[[3F7EH6$8Z!: 8>T7T+$5IO
MFU76G;T\&VE57')15]TJW9,B]_W#].^Y1'8UGD-_\TZ\R![*D8MI01,:]3N[
MRJH\B#]3Y+XH/I@CC8",-S%'R,9HT/-WI?8D2,PJ5R09+0Q];1_-I%M71AQS
M^IBM:UCS(#4(6MF@]:,Z.:P&&4L)#]Y,+@N, ?:B1K-IFUG3XLSVZ+P;LX7Y
MTN)$MC?Z]XM%->9SVF;E!1M;Y&H<H+Q^VO^&+V3D^DMTG/-P'.$#6;%8MU'J
MURT-UHW+-3^(4S4M2&2+<2>637K*M3 (%W&"&BY1T6P<CW =0]'B]BE>5!^9
M$O?4RF'A/Z$T7J4!ZFB::RQ-6'Q5$EE1T784#M[<0FKV#'[7UG$EP=BQ-H%D
MDZ7IJ8*YB'8=UQ!;B7)83!LV1ERW''%78+*LRISQ-<BCT;B2M5FL:LNTYV+<
M2R$!MVWH2_O'EO5^[WAS#<XV55_GY!J4B3D-[&+Y!)R?*0J4IJ27I!<.%596
M(WT+/QQV-+?<68DM;; Y6J@?OXK=P/B0ISPJ^8 4*LM3XEORQI(H5?=:1Z6/
MG]%2 .M(_[3U0<UF6$!U1)F#;!K;N2DY:0;170I&6SX-%I?=5,1UI1,JD*K#
M!,D-Q/=1FZ=K/!41H/]>=,546M-+$BJ'R^>">G$Q,^/VT"<] YASPZ+Y;(R\
MJ).;#'9C??6H'@3W"+3.@.O9S"43&#B;ZFB&:164;J\J1KF3UJJ>JXFSR7ZF
M=%1L[YX?""\>W@MWZ>[3R=SS8CIV51>7\,<9'JAV-9,KG%BT'(\2N6D0\AO)
MCG/\R[3WO.*6BHZV?QVTQ5^@HD_Z(E9(?A03CI8W;9YQ H9S$U?(Z^L>0T2U
M9C]LX-"RTCI/]/8(;%P; J1,%C2$7\RN&I\(&*5TN_$%9.>JK4;NPORX#H(7
MG%@J%@HL8N^PMH,$%:?:!+-+2&]KJ-HB7,F&<*6?1;BTD=R)F#/KQNNP-^2\
MK28?M#.$;\0IO8[F-@DD2D;.@2F#&X66B08V.!SX"BMIE=<08M27A!LE$7,F
M/@IKM6G$7I'0DW:::2QTL+-%K0FYH-G6HW^T/MO ,"0DP71KJ$G$M<H\NL3?
M(5TYU;H;?<L[.1?^C'(?4[!,J5NA<Q^D>]7FR_3X\3_XW\=DK9ZYO?N'6ZRP
M&,77]";!/;4+H-_R8$FENR],]5I-.ZWX#O>;[)JIN%P^@%H6"@@VE<P@P VO
M:591F<,-@H!86%1-)Z6H/8_3X6PQR7K9J"G^!@E8>N6",?'"IL!PV.!RZ187
M/$0_!>M'EC M-/]/V=4H>?3DT;.#XV?/GKFV@.$/VGT7-=+*%*3&32O;PP&;
M_\JEP$N ]\Z+B_EB[3^$P\JP)XE9DYR5"-VJ<4:&LF8D_9KYNKXQHROYCM%,
M#6TWT,HE)-UY%&DXY%Z) =@5OLE)<DITY2]B:U>,=V3AQP-B%%F&9,C5[4$#
M7:AU'74U*UHNXZ-]5#4DR",0FLQ2S-KAF1P_MD!(*'\]>(_^O@P++=\92$N&
MG:M#_8G>1#]_<8;%G-56]H-DH%C>-&DI58R7=>(DACN#PSH(&:)KJ=@R2#5A
MHG55$\/5H+C.VFB@PP\\3%^3'J@N WL-(A/*<&C>OW.'*'WY?.3\/OC\DU:2
MM8TD:2[SX/PJ((VD5<)T#%++@FUSI8 18#  A&2!Y9M6*W;4@@L[>.BJHIMD
M'7:ITW<,'HP&[@>;O'SN$MV\< XV?I'3;M .YPZMU$$LZK9.)%[33*J55N9[
MYT=.@5V.[$G(DN".Q#7J+V1,+I%6*5+1A;A1"J<C]VH6V K]<[B[O:(Z1;%V
M6+&R]I2K+(FO,E?+!^VVS/Z%EN"UR^-KCZT"@;$]QT>5?HO:)CW_FU_T&%+5
M$-HC^Q=B<=&Q_C67*)1_:,7Q"A!N<PHS)W,K:$**[+HH.I!=5@7/F"-OPW>W
MJ]%[/P]A 1*Y<JVY6SN=Z)F=W=\2.>TY/%FSY5)P*8((K0KW%BX,7TC$R#K]
MH2:!<SC4'A8#"H2J6'2CLBT'VK@JAT>)4QJK0--7V").#$_1I+_@;KEI<#^R
M<:OX*/0('_?@0SJ\]@X P"Z^<%),#+KNQZQ9?=%R)ST=2^9TSFIOBS/05),
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M[T-149B3"7O<$X+<]F9T?'=T[_3HWOR4_KD.Y( O%]8:^8,SG#C<2>U.:N]
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M[F>@#B\K<MTH3LO0J;YV2_?<8>]+222[^[)P$/_*M  I/]@849,BS;?.ET[
M&L$1N9"I!FSW/T*1%OSG_\6,E<O .AW')+U\R(HL>-#YFE29&+YU]N_#)%;E
M#^U@TP+1P#VR)'V_9^[8D78SIH?K@AA46_J&_-"E?W0FC,0S1!* (#JNJP_Y
M%MO#/;>'5$!//5W5Y/KCD?S)WO!K&O:><.T@7J;T5[S8[CAE'$;8]_>"&&ZF
M(!)WI-5"@?*;TP+06$7ETJX9,JM8+O*/>28U6W1X2\>7X')FZK.$!A8N@"D,
M$-JL(K]T%5<:7$,A7=E-%LQTD6<KAMP58AJ]%3@V8.^8=GGP3M;84#5J2H;6
M6+2D<G"D0M8,RM.FR022@ZM;$A$;>HIQN\GZ8\):VN.#.Y +BX[WWAMGPUEJ
M"Q55%M%1*-@COS]R_R?Q_:\(R$CZKKB>B[[F0EKDED])RY![ :<"?YX63=UI
M9)9#K#X5"QQC#A31N#QXJ#=6&3#/D$;I&C5];>\R1HU*:VJ*:@'C7/1.$$93
M-S*0@$YA:"3NLH@\S0""PVWQ)*MK 5KMVL3.>C8%8JY@IZ"4$!'CK)[,1_[
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MJ;GDCRVCY\L[PI2"K_3XF0R%/#U).>\F?^2[Y>>:YGDFOYA5.M;3YXEE=9M
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M,[J5E2M]+I2DCK5-XXH9TLD?6XDB"<&;/O,P_:5'Z.LLP?[;,]QB:K?1KZ:
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MB9\=TOA2UA+/;R1V',FV9>4G2+Q+JP,"WQ4)>M"B;#49.(1D7EF_?*)L[D)
M9/BX^$ITR,=<K*'CQ_,!WVH,XY*N4*-G0SA*Z?>-WP/W61MT@\F2/B+;%0'%
M1HYD=F%01 .%+%$AC=6MT)O.J@OP=J;_$*3:5^7D<!3I@I,3D5>T4Z</3TI\
MN<YS<G6/GY+5\W)1D?.1X.S\;U5_&*7V$YVLX\=/=P'Q$ \\1"8^EN"+]D(E
MD(8"_*^T"7H(N-M$^0)QC-]DS33[=WJF>*6O&9!T%#DP8E%>"0<-F]8E8Y:R
M1]IH=4M=?62V+4,^^?;9X3- <BV0P4FR6<M,Z@ Y<'[5%=P! 2CF@O#&W8S
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M?:"7G;]^,4J06^M<CD:A8$+[P[=72\MEV[#0L<N\DL3H- A^\;0"WGHKRN3
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MYA?N0T&=Y&*%]%IY\;=OCKZY_1"NBFD[QT>/OG/&$]>>K1JR'>PG]Z<&J&[
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M?<Z=9^[B#7#"@DLZ0@Q+-,)TI=R[R.A/N@9F:B_8<?;Z;(/2+" W$:RLTO>
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MTJB""G301P5"4>.U"-E2CPBD6I(!VG#K-F=EKM5I(1:A!TUETUNMSABM76\
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M&*#$E=$#9#XGS@F@L^D:F=QQT0'L&A?ZA)<VO*H18T_RII/\QZ+K,8]+IQ@
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M[KK98EU-\Z/+-T^E2DIH("/ED0T LKNXG1B=&>[>L'5'2C#I"2%%GVES5+\
M9C,)'V8?^C1GMTJW3M#A:$=96 V:*3DOA:V/3D!."PL :AZD+0V,WMXWAJ)=
M3%?=;'#%_F;L:<5=0'_[I.<U8URS&#".)AA6:L%*"J?[BTI;=TA+Y-!>-PS$
MS?WW,0H_!S6,4P_'2389^S=>NRO<9>M5(UP+C?-DW/]C/<,J"GD<3\'M6$O;
MLF-M_J@1^-A,PNI+W,5.)L]CV#>5'%N"PHZ1=O#6NVK519&PNXW$V\/9!F4U
MC+"$<B.GSSRSI5+&5NH9]=(NMI/D:!9=^UVD34$46#N(XV$+N%Q;P VX8M,
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MH]%(>.M:U!DJJ38YP$_=I%B)<TJNO:@)1!8_CL"T):O7??!/S<^X+&P!S.U
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M_\+XSXR]:/TDBXT_-L"DR1"D5T'!=%<IA9/%=(D2KEZ=K@:E)%/I^]X5]20
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MI-@@2B!1$M=D85-<M< >LCP<L4)E#%8^T-K(8JRSA9'&M.7QL!(SVQ'NLQ.
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M8<0G9(/:<.%]/P*;3##EI1N0];=F_"YAP^ 4C/N-'ND3.0^^(AZ91O;ZOA
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MHU6\ ^TD!>_[*Z/-?5M+3YW0CL( !Y&4S9@2'H5\.<.649VW\Q*CM+NFLP'
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M;8%Z#47 >#"[#WP0E-/J6V!RP@REP0?T"WE?"'2B!I1O??9ZXW ]_@#7(S1
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M[0:QP*6L9C-[5:94$-J::^DD)QN"R?$C$M]OL/^Q$XW ]"-4+6X#FX4:[Q*
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MUJN-I!'>56A<[H[=^>C^Z6G>X;F(P94\?PVRZ.@MYG$@EM+ O31.4'MI)J\
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MF(;+3C#?'.L2ME3<DY_GW $N#8 M!"H2M1X#]^^,&1#&W@H]1^0W0(:4%B7
M):\([$H<U(Q64D@IO+E>&E.M-0._\B&UC$*2A6):'Z&8J#5^9T=_ECA^/O6
MEYH@"YK@Y>O;F/:4IU]'>6H8/2X<5FOW\(#$RZW=\U7W4O@ 4NAH\;H@D@ID
M=I3&%?'HI?-1=>$XZ %$30#1=@\@ZM5VK[9O/ ,,VZ,#\>'M(9G33O6A9U%K
MX<(/J+1[V?Q!9=.TP" N@PP_ZE##89Z 2J*'"R:#F$V*N%14%<?&88D3#!]A
M/+*8><05Q"(8SYE!3NCK7%\Q<<6=G5\M#Q)ZW-I@>E3Z\]"?A_LY#PH618ZO
MN5;X"7V+Q*TJV-6$T^YS 9F%F-B=@/V6]Y+92^;]2";L5I@H@)'%\F)9DOM7
M4\O$WLMDW2BQ7;2@O:CVHGH_HGJ1%EXU9EN<(C(I&R7<\)F/B/PA*4J,[O;W
M?2^J]R2JG*!Q9-7F9TJ$?<2F6M+F:HCXBXB5F'PX%+B-BX5QTZY4$!IA_@@)
M!80\YA(L[[RPA*M.I9^9 N5"L.@R'5/5I4P6'S\OTDNL?91']PW?^D-ROZ:'
M0=>B*%OHK"AM+5Q-+013$^5LJJ@F]WB3])=UBT4#(/7D),)A$74B&=%&VO'A
MVLH]&CSDX2#\:!33)T8!/WEL)#WUK^F;3\QTSI#7!W^ZOO:#/OP:& ;>$MA+
M 2X?YM1;!D('3_19U&"*V3.DD-]"%03]ERA_O&+&$XH+2>,(#M0(<'R&B ZA
M^OC^:)@'WGU[ZH[ENGX<DO#X9)/(JJ2RUAI1:N0$U/R+V3KA$6DFG2_:?5:7
M?)4%EJ\@EP/M,C&#/RNQ1'WHK)K+5^J+Z,--R!7#[RF"GSK$R:*QVJ2P1POU
M]O)7S0 NS-@P[':JLK**)Q,I8F-4H4JC:R0GTWF6+Y/$0G8IZX+-<KE[+KF
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MP"X.U5F\8&.^1M]"5G)[E?;U$:0V,OD7F]'^*\OQ$AB2#ZKU<.NSG9J7/+R
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M2@PMX*N@1C<@% 8VYQ5UJ$*/.N"\N*4[XF3\]FXXY'1W*,[^:S:=+"BQ/JK
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M9#FHOPE?5B8<[;Z+O;<"5)>G6$0EQ@3?53^#6_L;FQ,2HRF<\BD./L&-?9'
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M/C^'&T--*EVI*+ 1^1)ND$2"!MYG0+)3\ORQ77O>4<OA$=N5QC*C9NK<4]Q
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MBVY -AI)%>WKNL5<'BI=R4VI=,+UU\@!BX8)NI-TW=FZ53(=+G$!EQU!P4"
MB"V0VXB))YRA93Q63#(;L@HPIL8O[ZT8; 1\ K8(/\X6"B["58):%Z[?ZD(/
M:,"R$(6B0;"(*ZG"7W#P2$"WN+O\+<Q BNQ,P@\G9R#>.]&KO=UPS;.58*M?
M1?N[V\X I%-.SO[C'V=O8?LD.47A-E"HR039?O"^:%P]0O!3GQH()M7OQQF6
MEE=ZY3A/JDUX'86<*.,YK.DNE^4_FLZSG(Y"$",=#OZK)B-7"9MXB6/]"/6/
M7>@76WM;WDF)9;?$.HPDQ89&YE6<2@#0Q;WO]-KM6[7;:EVVM7_0T&66&W.U
M,@OKRBQH*+.-34>9_:IA(F%42#2TC K+RISDWXPU49L2"J2I-T"0\70QK0EY
M$*/^:=Z47R/"!]\@P4$OP7<AP=9[&N68*%>8&&R'(S5&/TH:EG9O9]/?/H>O
M3,@W6L0[<,5[PWZ_+MT[VUN.='^%;&UN[J\4KJ!7C]\03]WLXZG->.IN'T_]
MX>.I'8?1RSMJ[$OP+D&;07G7RG;3<5U4V;I4;)(QNLZ@..C6N%N.POPJC;MM
M Y=!;X_^H'*VM>G+F</OQ9=Z<(V(O5HA85M[WRAA^[V$?7-#G_9 ?A2LI>N8
M_X\V-C;"3V?_X"CI6@J_W7NU2;_-)7R*:8=% ?XU2)SY6P%N$,H>A11H\V+8
M502MHF!@3N(<@RH(#(6OS8N4N;1>; UV#Z)0P\E5'MPHOW*%"(E\4955K"U^
M"$BT*!C"<H:S0%0F\FK",*>$O)?X WT"?P.^#\5HYQ)GS3*4OA0A4LDLX$(,
MDW\?2T\!(K3#Z3( ,9_<6Z+]=E6!CTG(?D\HL.I&P)'YD)5/@O5GACK(Q)JP
M,"B5)DHO=E@.Y]F"XE)9.J*XRC\//RL;L]4>E$:B(23&R" 1"=(ANI0"8[:H
M& -W'$8K?PY>;.YV/<J$O*E<>0Y2R&%VU)6U,<,U)J"V4W+G0KFH?.84-O.0
MZ^HHV>\%K@OC+().1WCGD$2( J*WG,EB3M[]5>XL1^2$[BES F]H=BC4>"<&
M'$N'=LQ[&[]^GYAM"\8:ZC5D'T;3,\-?Y8ML;(*N^$V=;ES:KP7\7+K7.CXB
MSU^O72PD@J[L.8^&KYLTEE5M@O4.][?:%%L4P 1>5A<IAUKEQD'-@60!-#MR
MPXW:8%5!RD,)N(MD&O.5"H^CK_T;[ON*6OM00A1K-3#1@N1.^'?:&:POLRHI
MJ(]=<0VLIU]-B-:MJ^4_(:<;O1&*D<#();"I'U2%MZ(*-UAC/BK^'MX'1*I6
M*\0M([W+5\RAKF*=T+0)AL,HO.",\A:&#(ZEEBW/I2W&1 ]VCEE'T1L2Q2FL
MB">%)CB+O7O2&5HAJCX4T\Z?A_E]9Q/B$1'L8E])M@5]\$GZ9A!PVR7/D$5H
MYA5"&B^3MF-G+ H4M[HU(=EESQC0Q*Y(J)-P.5N82]W&V#''MZ0-IFSP:)1D
M)@>(ZJ^DB2SFF"21D:="6^F@+<F&D,P"I<2IUY-7.3H(?T>H<3DJTF%B+)(
M[0VQ4E#<MC9>6_0>R=_6ZT[+94#?V'P=GO"[DCV/S\)K0*_#EI9<A5NM!HJ<
M<^?H"D1!\F64S/E2&,4+6/<U3($G$\JMRXG6&F4QD"@/9!<4H;#$ABQ[2#T,
M8>ZBL4@ILJI3O407*S[Q8 /.TA+V<0)3XMX-.C<"HYY,1%$Z[^G-'_$AJMC&
M6.VC:N.:5>#\^3S&)KKI'+4G2H6JS0#OTWE>:#X=/ZNOQXJ'I->\(%P#LW!/
MWD4^?[O9D-I>AA6<2(+2S'*N. H(HT_/UQL%;!S"B3K\M-<,;]2:S(F-F60V
MUN_C>HK7A*@AZKL1%UF:% ,1M>#;10T3!5C.SDOJ8Y+&*!-<VG[G^W+@[\M-
MUZIK@KA70>M>A7>Z5YT+9+<ON'[[>C_WXXP(W+<W(JG!]/+LP;5Y]N[TN+6\
MX$O@.1N'&<,KXO%@7LWEC_&H?YB/_0C&G@5O8<?&>3'1[HYM>()FH8\6F[(#
M@:-YV',U-,TL]_Q9-AF&!\C$P7\7._9:@3;P@^Z:)-=;=J,SS*S/&].+*HIJ
M*R8DN"DFY'YE%82#ZR?O2M;"KY8UU7RNHW#317)<M6'B+?AN':.S<CE=TQ'G
M W8MON]B)M>/9P]1G,JIK;=Q+EI)<_IK@<K-)TJ%L<*3^#):9'/C040A_.X$
M/C:=85L<7FP4-0,5)#\C_(@:?<HY;\;V$203?D!+(F,J%A=7/$>[I!(H=R(/
M)686?M92&):13:'N8O#%':A4B/F);CJ*,74LJ^0!8O?8Z+KAGOI=7"#*S9&I
MC3$'ZZ48M"<_+33RJY.5;/\TH!!#3-7N([4XP2L>+YACA2EM<GG5ZV:*9#KX
MYN2A5/$?])3<619\9/M 07T@S]'6-61_ T]&I,/(/.B@P,\E,@FPM4.T"]([
M@2H;>6P#] 0?+TDZ_2A'EJ+@Q .'UD3*)SO$#WS4W@SB<CWP.7S42?^M/NG?
M3/KO]4G_'_Y:HB(J-X@5GH+XC98/VB;G,5S$'QOP?UH'\"R#<5+" &RZ@#4T
MQ?H(\%4Q2B7(;/@5%JV+6AU[:K69T",R-(IQ8=?X$A'Y6(^;$M'M&"TZO#'@
MGJ%2)IH]7A(!-3\@3I=ZX*_C0?9&S?+9^4MTFGFIX8GH<]G" 2FEBL,B+?]P
M:AC@E?,,K%8I%4X0C1F[\8C6D(B_CJ#9\/A@9(0@QKR013+)\)YDBQ,&I(G4
MYDF56%&]+Z=Y8" /-!$$9PF=5P1;2>QLRLA<$$"^6>XA^ZVE9L(KA2$DN_T%
M5F2T1#0,WEMWEB.WV-^$-K/$?JZTN&(=8XP'*\#11I&0HWEW210A!0^VH35\
MDJ9":!27%Z9LS8)IN8*/5\XO]:-Q.)BE@Y$5#^Y =85]RS3D26%*]6L8ON M
M4M>.TR$0T"PU7\1,!XKUF*MG5D^P=X2I4+--'.5D8H^=N/(_H?Y<O3 ,=[@=
M2:!50TBMB156E[85'EK96FP$\C?*YPG'+!T2SC31L@KLMC)<R/=87,CCXSE1
MW9-VU_3EK"Y,-T(\6$R/9C*13G91E N"(N1=9SE25+C]@SE[P\1U2%ME&C\F
MVN!G%V,4>24BLB:2['4/YIJ>XCA$!4+T7 S:0?Y>YN(T'R9-+?O",UJ:ST@E
M*CE)5C>X$!!.T%-?1?/1J/436 R"RA93\\Z?E7["T9KKT75JQ4+^V?_4Z"TM
MB)/4H("$%@X5!6:0N' P/$1I\919D;#2DWV!3?A"2D6P 5DZ^\/"]!M[9BX"
MG++4WM0B'%:Q&7U7+Q,"B2=_=.V6>G:=1 8=-U3Y,,V#C9^0#H:<U.ZYMJA9
MO3/;I.(<F1"Q- <NX[B@N%&O/]\<&C"-W33<C@ ..E66"@:PJ6LH[TG1K0J]
M=2T>F1?)RS*IC+T$5QEF_\FYI^N=@R7&WF#;IN0(7V,J08?BZ=!_K$THN6(;
M.3<UE-X 1NV[=EUMJC$5^>(AS3&]'"1>^>SJTX1A",QWNL-+B*=C:AA6;9V*
M+$'!G)P8O JDAJ_K)8F.4%[41"/UZ>T]-=;(PDOQ^K+DA12=Z:P77!\$OR<T
M.V*OXY!N8QN3530(5,?G+3)N3/I@O2X?\>G$,]$NFWQ7\-DQ5=C7B+MK\"R;
ME[^/S6IN]2#\!T'!MDD[6RD.N@] JVKQ3EY]Y_WCA95HJPZ16R7D3[\C$V:>
M^V^T@5*I8L<O(.Y)?QXA:SA<<KT$D@2NOKVIRK#C:-MF\>TA NLCIE3,B]S&
MS)R ]*0NX)Q&RI:4IK%:$1^M4HW8,MKU&JJ]:KM7B,N+^_;:T92+))E=<!M.
M_BXN$]UNKM/7[228: /;M\T@@@U'\/3RTF#F_!02FKM5D<S.X8$SG8X?0*&B
M2R^(TIQ8X/C)9%X.PN.5.UJ_;Y4)-V?B?,U6F3K]IGR0Y>#8W/BZ18K$VH&"
MO27SPK\53-]BEE9,EXQT%<68SKKP&/(G3)B D$5L"#<?;S_%$W$MAT80I#3Z
MT4E!U'UQS.@4 K_44%9M6^W&N#GL)+ENM0-]O$Z2<: (&4%S'?_+"$]CC_'B
M2+JE\J\(QQU%+PGLX?,"F>TB8<!MZ4\=L>[3!$<9!<0;J.)E/*"Z3]MI__1J
M\TW#=?)V7/2?( M+7SFBB4?$G [&D(%R\SEW;J5%OQ1[._;9;!+#+P-JC(AJ
M5ID&5!+#MB&V+8GIULL$K6@";"CCW/O85@)U!;36?&"X0.%I- >"5!LMX*/=
M./4=\0G!P!,:_X9IV9O$2X*6%*0; "3N?((_\IU4)&D?@>N.P*$_$&@8CD&C
M7D1)& .X.&$%(BA)Z9)92]=5N3?DQ-9\.9Q"(KPFEQY\XI8LM)=KGXCV"7X5
MBR:5CYKYH6@<:UT92_NQHL4U_[M.$)F-C0T*M2NHH)'$]Q^<9&@SXWJ<,C+>
M?O SMV:!I_MT^67X<5%A:!"?QPP*_J/IGBV<Q\@-KE-J7"D$2L9*+5W38-6:
M.HZ# O>;&_Y$\2>WS7AO]QGO9L9[O\]X/X6#,'QS;"T ZA "NF:1D>5Q:/!(
M#Y@"?\37(N;%3=J%XO/RTSBP7C';0LBH1Z4?JE[3PDTU.58799#BD89+:^-C
M0".S4?XZOY#S& [KD8,:2]3TBFO O,L3"Z;,MM(CR\0%GE& 7NMC''.5TB-X
MD7,YMR9)TID4AC'3/UY8?/L&6&U'5THE)C,,.B&><.R[QN"T=$8^CKF<X[)4
MQYS^>LG>%X:I:'UM_P"G1#.+09WBNY=46:1Y![PJX<]H#B?X&&IF @/&^);X
M@2KG*\^6Y!6DC/2B79"MS=ZAF.9JN\(KY5H4+'N!Y\54^Y$C5J4<!"CS::(=
M, 7=;7-W4GK<X75)+NSJ L:]:D4,SCP#WM:[FAW5M[&5& &-:1IO"B4:AHB=
M:@U;$-2H!_(EV16FDQE5_Y5"7=_J3'A%(8%]# R\9*]=-L\5?2T,18GSS!2'
M512^)M6$X-U[R,!/B./X-2;34["!GPA]\(D)$5!$\&@;NG<4AS/LJYN<+[7F
MBL5^LBC(<N7"KKF7,F A,W4:D[!V L)1AF_*E6$465>HB7@F*B16!4B<1 _;
M*"X4P)QBRT@*? K^,Y-6D=HCH=?6'SO\PR():/55=RL*A!6W)/79SV_7X]><
M.(JBT6 MZE73P<:IH2/@R2ZY)I=Q08%1$/#8L$[6\LADSIMSCK*2+RH^3I$0
M56-T:*E%=-J(LK8DD9PBH<)BEZ*U5$D1#50<ZY[+>GQ6[Z?G)(6,'AQ(^_13
M0YC[=-&#3#K?Z!;?VXHXAW\8@]!#_A-#4W[+<@5&Z W=ZRF>3.+4B7,S3''L
M9&<XVN)@BUJR?\'']OB,6W5)U;WS_$IC:_@WPO+A[[5-KJGZQ<N;L#H8>L[\
M4I=&-H0;K]CHO<5:<DE'5_)S#0RUI"@$%X.@(KGI3?4/4T/KW;UHWXMUO$5-
M!%QJDK'@:APOP7]\"?\);SJEM%0> C+%&0FF[4(KV1!-BL*WHHXM<8LF J/@
MQXS,<"X>N:P<#$!]=3F1(MF<UFO0F_$J!$/DAE$=RWMD&EEI999 X'!PYRM>
MB)@ZG]HQ_,MT9)U/Y](41%U 8HGF+QN_&M.:JGOP%>?*@DO:^"I0(,CX5OA9
MDO&9"@1-(9<Z1?$[I(Q)Y9'5!HW9(9+J<_I@MM 23Z=4<M85,M6#CN7&U%,!
MYAQ,--,-O[4]W6;(U&^_2; <=1B80 0LT=(@[; -TSFY%/3'EU1])_8+>2?T
M:7\VDLXE/'(@O:_A->=Y22<I"IG_Q3*D6*A9VVOC<$3XKL8\&O]%:[9_S=DR
MK1[";0L<^$IX6+$?VUT46#\MO"6ZO2B*1?+2_NC.P%)OBZN7%JY)%N#2T2.X
M<DMK%?UR6 2P-I=5-UDHT_R!&'5.Q%0&N<SKV_Z:@9THQ9([7DXRNC2Z<6"[
M%XZ:W?(-5*'M2.O,(B.GW']W)#T*B":HXW7YC5B[.G^ZR,U]TL;HHO 7D>UX
MFLM^^ +N4#S=$S'7SBO#RZ4FP,OK[)"*M6>297/,*,[.__,O&W^Y_62NTG%U
M@1_=^,F$E$?PMO&\3'X.]5_F3^4\1@ $3O[+Z[]@M/.O5:%/O<1X!39E$^.F
MRN=_D8!H-=8/R0/KKU>-K_LD=75V7_#E))ZFV?+GZUZ1/ENF?R:\(OC,@[W]
M VT-W?KL=DOUSF9 "A[%BU__Q..[</J[Q]1)F#6I1RKG,_UW%"KCM0GR?9%D
MY'C"J=M[';IO#?]3W&8/VW9KU0ZN="_NZOE/62Y.7-0^;/MA!JK7ZV'Q/B[^
MJ!7%:P4!AAGN2G#V7^.@O>S\2++C:Y7NSLDW5#+7L"(T969WT"HO_T$WE]QF
M]W2+KO2NK[U:']+%/\)PEZ'(X.3919$BRBP)+)4&NX%<IE*T&3-431$3?5'I
MF'T.U]]SBJ-UD4/<*F._TV?LFQG[5WW&_ED=&<^C0D\=<TW$&MJNB*)F4 C+
M]:;S#..+_YT7F->ZS)ESQ\3P)FU4C9$E<>-@#J@X^*:P=QJVWS;^K:9G[L,/
M7="8CYJDU 2S[UCGE@%IU44^YFIA[N+D9%#PA:3TXB)1N#J,;2A&,8R49POA
MF1/'4SKF=00V)>)7?SOX3%?51K-C&,X!4_PV;!@9+NZ6!:"UZ8@=F:YF;$[8
MQ/:4XKAF.K(N,Z9BG,85>?B(5*^%,'05:)E54N89MC"4W*>L+.&M,79LFPPR
M07S;\J2S4-F5,6V%0,,O2U=T).C1&I:16)7#J6C$O>/>C?@U<,\T7L%MD9H!
MD&"%?/I-7HW@M#/+TMTN,9P('B>A/&(:)TSKI$:,K/$>8?0+YDZI;S.Y@-3.
M/*8_"L6YIQ0IY@7AUZ7 I,&/8&2R-S3>K XE!YVAY*I&AH<_.TH29!Y3]%6X
MM_?7<C%_L_4?VV!BPS],X954XKJ'IDW<8"]%*K-E8(KZ*!F+.QQ*"P>?$Z,K
M:NH4_?F2083D2UX"(;_ 8&-I(4&BS60&0?WU[^I]:R7+V,=S-DJ3%:%R2A,0
MUSI&4N&(JX+2JZMYJ35BM*3SB/(+E^.)PF"[RH>MWBASQQQ ;1FT:\L9C'.+
M8+MEU&_&A-.9*?+.)\XES!N_).)(N ^9O9B88G@D81V/S0<=:N"VE -W=32I
M%+G\N<"^[?.221*\V^U4P[TL%"; FC<-^I#!$"O:&$M7LS#\*_-IBC4#,;1#
M :X>812^/RSA$9&V=Q$F=LFP@:JY%4!IC9^VE@.OUX)TE.^ZB7+I+!%XGQ;N
M?<0V4>UP82->%"^Q)I_8/F2OHZUC0; RF]8"Z*ZT+190:*<#0=5%J[+D<,D6
M=&DR6?:E2?UU?-Y29)@ 4?O">FZ!B1#+![L?2IU%'#2LPXL=Q@OPB JOY*^[
MTIQQ98Y>"LQ%+WE@45]QTTTDT#*7AXK]7_<%?84GRK#N]''!4)_#ZW-X=S(#
M8YS&#1M0A-7 =ZFS0R;>NP==\B/H**7CG,X:P;1C6V2KQ>%JJYC3@X?$>,.F
MNTF1R!_@XY/X$HNZQFEI@/5A/"RE*KE<?PT3^6Z1^OZL/(>STH;<N>$AH:O=
M_06B.FYP2)ABP+;U,=?%.9965\V_FP"7D$UM&2<S/C_'DU.9:%2!O>A*M^:1
MT?(/=(9^M&C(YPNO!Y-AQ#!4[.!L<3Q4KFN&+C&2'3<!(6K\(M*URH"2XEE7
M/RE!3RZ&)>4HJFS)4#RWFYF%RE,SLX"R9<Z#^DB63UB@1PV7E8/UY$&S79E1
M7Q%D\.*?##=WEU%X0\O5,[5?=WT(J<FNL5$-OMB!$S/+BOLZU\SZ=<UTKD\"
MWRC@-TJYJ1Y'S907LJ8T0BF$8^67C*V3@&UA+A*V$;B<S*R3TQZ'6TCQ/&*2
M]G2<(DG?$W;+&^7V?;7 JFJ!*!B9'].9@5N[,'^L>U1)/JND(0;S"=A3(_!X
MSYF%,2,%R#-+DBT?2PTVF"[Z($NYIX7V".1,H0E#AVX86NYE&P#&-I/->'.O
MG]^<UG(Y#MD#YKZFB^R\MMFU"(6S6:P+A8<)@>"&=D*J,>"'?PS.!O!ZR$*1
M* M%Y.R][BV'%=E."\1.Z[#QJ%V<:=S&[%]>[[A:P041&-+P./=L:7DI<''F
M":V059$NRMZD:&.8;55CMNL@O2,"4U'>'F(?S@BMAO:[P'%;EL<M5*C0=)TB
MA]0H2,MR0:EIU.UKJ.X5J^R<A'5.5%*">(ZYV4K/J3,5SL*F,VF.T8H-JGW;
M>2F_#*%#3AK,J781NY>.JU1MO;58[<PJM>36N@NF<IW.>][JKX H[?80I29$
MZ:"'*#VK(X/NI4,R(1K.\CNA^K($788$7 -HGOK37)D+#VFQ.RSEDU/O")-L
MX%F\6'9PLUAV9]NQ/IS=A^CN+40G<"T15].UX_HH-R&^4=BSK!FHLYVW5H3W
M;ACR=L]D*_[$0ZBT#81/@:>FEX9H)6YK@-PUVW7K#+5%W:FOFIC!3GP]LEGV
M*S3;)LC!S4Y\J3-+QF9U^VA\?]2_7S2>Y7JXO#XF/UQ^55C^9@=9@_0W^W0?
MN;]/TXJ<<@G^.!(1.+NO(: 8:5<[_'8RK>:+ MQ.089DF<"#2U;"RL/<ZK\2
MR9/VT.2(JHP5F+XP-;?8&];-]'CNJW7TZTRDYB]1"\AU/<*&5K/2QQX$EB)3
M>Y'G\B+\6^2[\A$3&N]UKBXX6I=I47%O*L:8Q0HC%#CH(#ST0B@IFY.+*;TM
M->GH#+>DSO4MO\+_E.$N$O@73 +@PZ_ML8G=R/6%+CK^V8O;F>O,M-FM=W)V
MAD&$>HUU8Q#^7@LXZ.:KR*QANYE\83<9BP66&+."_6-&D?7(7X6@MF)CY(88
M<V]29GCW-I-O>UZ:K=V;+(T/],&%GN6RL:Z0\)"6:V'7-DY8I:8X)\ V1E(3
M/ G>,0*63!SX!'CL2;9D0\=!/9G 3RV5T-@7MI":*0PCY*H_PU_%;9(S22D;
M2[]O8,SP;]/_!;UB=%\5,S;,+^&@89Q7U[EQO:RZ5V)WYWGGX(V'A/JJ+ 22
M)VS[4*@3B#8=BP.NRG^3$"MXN ]*?:;8*J=9M;+083LQM!E$S%?/H2)_69$(
MTT,;1XKM8?-2?.?6KK^CM!@MID@AB8Q8/L4:4I4%/I8F#TT6CIDR8C0>*PX[
M4KJ7A,U)!]>92WJ'^PE;X6OI^G>TP!UMK-1_U-4Q5BBV*Y:2%'%:/!$<>Y:T
M:TI1M-9SW_RIIMN-^O-O&Z+%=_B@.H&5'-IJ=U\CX>U<X6-HP*#F8D2U$;TG
MRTQ-RL EUF&KO[RUV>]I&6?!M?T(4]::P&&K4=MH* =&6L9PY[(U=@AOC35[
M2?FZ=_*?M'KYKOJEW4^&<XW6V=@U!O.K&8MD;*M#Z8397U*YC-$*'6T6/+]K
M7.,[1=L\/B_B.2@VM//Z&-?3%_\?_7Y=46G2N"2[*%%DF#*>.G6")KNO3HE:
MUFZ@J]5.7O/"$'22UOO8U;6Q*TLE1S+0X/JC7S/:*77@,!;]HAX()H2Q=_P-
MX"_BTN##9LR;2)B6M$JX51-\0R$IN-NKG!#$=!"#8NP2\9L:JC8D2X?LUCQ\
MXM(OIC14%%!3(_25N\*LQFJTQ/1NXV6WB;5&V*[RXH]KJK8P]F,!(U' =XDU
M[HS%U\#MKI7$O<HTT30%16ZJ>8?C-Q>L>:[H\*OOJ49AH-T2\/"ZD1:J2O*N
MNY9S:7L8A/4W:LTHKU/C0>:R=<L[-'Q6&Z C:HZZZ!J:IJC5$?"M?$ED<V,%
M/ (3VA8Z3-C& ,-NF>!125=>I%-5MX0UTCG')=%=7*S4IG4!=O6PON>LY!</
M:L5[?6S&HF%]YN5A$K2Q-3 =BQS9ZQB]D'QYU66H*#^Y# UA1#E-RQ([C- 7
M@]83U(@#UJ]%Y,AWR$9IXJ-\452^1HRX2I]A:]KIW L5.>HY&$F# P3,P4OS
M :_B:@&OLZRU.^1J 2=M #^"Z&.VF$\US'"\X'1XEB_CC*/]7ESTL"/<Q<T#
M*.8U-=S+U$>2[WY[&\$+A^DD<DL>:*DP[#F%"TI]<8L'=U>ZGF3@'W!,N(S&
MTD5;,'CU:6)P?\3M(6Z\7,[Q=%<.\9U5.E]D6O[>!.C( WF!?1?EFD7N5<#M
M,(-[/6:P@1D\V.@Q@\_JR)RTNU@( @J&:( @%@))0"K;UXF21)/DRG#@M-8D
M*,%4F[7#&K1*L<]BI8Q8+1\D@Y2OPZ +D(V9$>J>X%[?M;PN]R8EJEC,#U,W
M$<6AVU1MD<SAR$IOV/K[,"66TT2]VYP7;G'N^,")86GYT/T=LC5-]E4CUAC;
M;LR$X%7)O JN=7TZ@/S^LXCFM+%YM"L4,K!48>UV:]">RL)GF$(M+LTBX<DG
M*U@BVJ1HXJ3:4?# Q+I(AZEI!,UM<S!NWEE_U^AT9:C939+7@@ZLV241$Q*>
MEIEULH<%[YQ""+?IJ%N'0HM!,CWP^ZIV!3U2K\WH7)VD+DL#-L:AJV /?:PM
MONK4'RU91I8QZA?7&Q:?&UI'^_;R(33UH&GI5':D;#$.71I(C""W[N[$<C&2
MPC#C*3+S,K&\C"UHEJ!NXOK]:Z5-@J4$=$1 QV>>R1DU(N!V7I2H%M #?Y,@
MG BC,!69&!1W#EY@#YY;3DKSP9-&G>C<_AX\L/' Y?4BLH+)&!Z[C>G@KG$+
MH.=X^DUT82P5>\Y!"#H6_.=P+9:U(<5BTU7X4'YE<."D1(<[A]?QL=YR,V(6
MAK)++*_J F]JP!)_;\G_X*_3<IDA:P.IFR2+B(J=]#O]M3&UUR0)0X_F,K ,
M7SH;^MHL[P1+R?;5P5+XL1HF""-97KHQHDW4QCTWWZ/PJW?&G$?O&C,7D7\-
M2Q^BH*676QQ:_[$)?*+"-<G/(JR"*,7SPF?A:Y8Y$U(ZI^MQADH</%!DX2.F
M/WINKW ;>$L])@*P#*ZIC61<>3G/J7L?=M%A&J08"_ BJGL?\P^X(1BR3&;C
M&/^DW[(10?_+_N=-&25_B4*:3@M2=(+.<Y(%$L=5!%E5[8T=N3>H4GU8.DTS
MC(N#*X<&4M!]'$ICYZVMO./7>S3/D\@W?G],O=]$UY7%'NC12]Z]2IYMZL@8
MCPG\4Y%,CH6 %-\,2:Y,M3CG-V/QU@KLP0I7S)JM8TIG2 !*4=Z:6)?KO6#W
M@GV?@BTF>7?GH5[4>E&[H^)7[;]=-BIMW*I.]V-.#(-*/XKT$ET\=7CF;C:_
M@Z),O4;!Q:9UWG[!W3DAE$:U1OVQ6!U%>42#?^]R,OT.E!TS[-%%-_74/)FY
ME;M6JWP*U])!,H@Z"7_U+^;2E^]%\*@Y9DIKXT4!B6S]MVY=#\<,8G#KIQ:P
M(AV-L8I-RM6D*4!%[>BU&*@4I N1)N=>N,TVK$BK+(F"V(UPC)T)Z)NW!=#T
M"-7KP_I8@<?,-\MU&Q%=L/KDI^V[9,J[ZE:D"3\YU8O,GD_A.@RWZX\4IIV
M!D$866#JLR0VUWQF0\P:[':6?IM&FV >KG,XI^C268*@N02YJ8)T L[JP=DD
MEU"@G<$9% [!0^$3Y$#SR=FA!'@-8L/'!F*9IK,OA/I0.H1TQLT%KMTL&W/F
MG _F,[BDU,GW7)/HL0C%>)HO$'8XC].QE\M!^9K.#*"#(KE?1HMLKGDTL,9
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M5B)I-L/1Z26WJ2EU?G'K8^CNH):,4H)5[VE#S+@,.Z@]KD?1].?I#E$TE%A
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M4ME=XPG<6.Z_Y.UK4$BP 4884A>&]&R$(;E+[DCF0_#J!Q@@Q/4(AJ.:U^:
MN"K[PU5"L1ZQ@Q=&N,O0P>ZSEHC\1;7KX[7R_ JU@4YIQ*135U;U];OM U5E
M[2YE:RO-;!M!_^EIPBE:S+*=)T\F<96T4% ("F,($KZO7@U>PP'Q5O'T+#E/
MLF)I:E*[3A]AF;VJBBO.7M>'6X"#: FM?9P+\LM6+HC/RTQ7EU<3W+_W-YX*
M?_530<,?U"+)J_T\!:-9,WG%TL+^>-^:#1K&%[ /*MT50T:UO;/S-P^1,30B
M5U/&F8R$\ /4Z,'M ]:M0YK?RM#@!5D3US(_:>DA0^%$A%4ZJ\WYT3?,<<>.
M._8+1^!0UZ#^4P>X'^QJX_%^],6M!+(:LRFKQME"#[%R;93>O[CT2HDV_%G8
MQ2ZUX.SYBV8F-MO,4C"@8H:V^RJ+/#G/B!,K4$TW=J7@]<LRH6UCKS)X?]%G
MI'ZPN27;<FE5-8B"-YL$6>'K@BU,"?Y;39C #*8HC-R.V<6KVY>YC0R]&"K7
MF=+#[KFE *$%5%3O#!C0Q2A\8+=C +@Z8A8$LV":1 V60?7C>+DY=G^BBS,
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M*1[$KK[?,;SE@%123<O4M*S$\)+.MQ.ZZ&[D#J^1MXU,CY\VUQ18-Z #A/]
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MH4OB8BA*-T&OYS7G%,A,<+:()"-=KP&K#I TSW17T0T8K!EJ= T)#[]$PNT
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M&MJ%@;4,CBTE*1R^1-?"V0?TE9 ']&K^4<K#YV,^W+!=1Y!?GX0]7ZDH\B[
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MLI^(S[I0!L0F&1E7?ZJ]^X;<JSZ$]F@BZCEIG8"N($3!G)+ZR%0GDV^.1>^
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M@S-SR.1,VOFH1=+4HCCQYC+HFTMO[G"H-#!_.L \2\XQ L-OT]#/#6<XL&J
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M).C__,XGT_S51?&)"!T(ZRXAQ=R*C@Q31$T;K_6M[&B<H:OY&\T7.9<^X4%
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ML( 56=K1FQ YK#C4*NA^F-8U6.UNM<=TNM*4"L?*8B%DHZ,0L!\H]%\")S,
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M(]/<78*!#$9@8\$BDF@S_P;Q*8^U&U9VW*1M)2QN25@M509WVKT7+RQW]V.
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MNN_FAU'UO]GJ==U<-%J=NFL-?H">HYF#-\OR\HCX1AR,)9@ 76F33*S.Q;S
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M]2@_]>Q*?4K*U-Y\$-)U1W5*FYQ!.]:-R0ES=B&#@ZX>@9G=W $Q*@QRR2=
MF@14!I&/BW-\P81; &;!;B:1^"CGIX=E83&].O]H-^^.YZQO&\_#<,#U(E)5
MK-,^HO@PYT =%6RBICRP?0SG^5LZ6>/;P[@=@(#D/LFA;[(\)PSZK4PI4DS[
MR&X56.7I2NT7U7H>?)/(R?=<>EU^L%*\41*8Y@=]S!*:%W,\6/Y>R>=@,<TW
M4?OG0N2E#5%LLH;H8W4Y=,,S:BM\^=>P$[5!B"Z#GV^UHOBTO!1?SIBGRTX
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M(M(_!Y0K-RJ#VZD3=<@2M[H.ROV<6I#U?O"O..'J-WA$ C?N*.0.8P+'R[U
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MI6^9\./:E8Q1TA[U4ZP$R"5[R9^Z%8)@8@WT.E*%AW69;(!$_PXD61LGU\%
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MD?$:5NPA:W5#[8@PY*1,%TP.RE!L_63$S3/BIC/P_-#U++[&7D#D-8,R"KJ
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M!0]%R=QD!/]9K]1J-?@?>N'\8$\M&OD[:@ \@G%7E:0:(,H=JWLWE6XYU)C
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M1BB#.>8 S]YO7[ATM<+8JC/AC?D(0&1NB0+_QJJ;LRL4.037 U:E0D$<A6B
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MA)UBM$69;AO:#4.[4G5W)!FQCM!3E6Z/X1Z*T>A, "K*.!5\8D#:G1O^0*]
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M!<D]X3C3BN\T]9CD'.WD&K9,^NSNVL=!K/MUX/]!+R__%ELHK%3.<@C;HR,
MFZ/L)DZB?X>=#_[L1E?K]&0^1M&XWX\'%UG<_H'Z+#6OU5=\S;KB2=+=6WY+
M*:X:8#I*<1U\./P@&].;>79SY3DFM[WV<?>7)K?UF]]*TQ%W\HI-_&VAVTE#
MF'FV._,8^ \>7%E0<MH(L:*YTFCL*[NR7F)7YC=HP1(VYWKOS6.M/\MZ0ZGF
M3F5K[Z!2VRYSM>8][=2)G9,MV'5^J6^P6:.=6^:9RY1YG''TV[^8,EUJ"#W*
MO/\M"?O1J(^R=Q@,(P@!G8?8(VRY!>_)H/6Z!_NW(.JT!KPHEK*8S;<_6/NX
M=5!I;#\T<_SRTNZ/M(([-765;5>V%L@_LRB\?;/='O6A:3;2RW2C]H+I95Y)
M(&_]"3EFH,ESV#D.DO_+WILVMXTD^</O\2FPVND->X-2\S[L646H??1HGF[+
MCV5OQ[[J ,FBA#$(<'!(5G_Z?V96%5 @01(@#H(2(G9[+(D$JK*R\LY?XFA<
M3SFP]_R\5!;&,;3PBEV\C"V[P]8P1<--ZE#?ZV=^?OF 9@H^ORYB/;0ZW223
M.M_YU2=*6T3V**ECEP?]]%="TA7 MR]/U)4FZ4@?BP/[0 >53CGWL$]E,&Y
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M-U;(2UM,N5;(X:53Z0V3$,]*MS#8WI11U<@."<^&)T@P&Y*M.F>(;6*M2;O
M?OWGKM'R&"'YSPNKJ;JM=K_X<JIG>V!Y3)#\!X;#;-NMP:!X,[\Q0)K%'-L
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MA<-$2P]>LZAVVIYAK3^6- O[KDX7+K4I%BM/.-#:VO6,F$'5';U,@VJS<H&
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M-]_DM!L9/MB8GN;&T P<B47"1UF'I2P1/%7B/8UN.3_G\+:&:"XJKW]TT +
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MUD7">X*N(!WLFE,J$R-6X,MV?S?\V3WP>NSOS$6I!B( KB=BEW7/0+69?"U
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MYTN&8QT<UD70WPO'FM;.[66TBZN)!;P7S++&*'QVDDC_8I#?LE14.<YCB!.
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M;R)QQ0DO>DY$Z!5#!)GZ/@$>&Q9/WF\7MQ?Z'.^CR^M:>/C?"3Q,>%9+89
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M7OK_GHOX^O.K"9OD\".D:PIN&@_/W02^YP/7 X.G<]8F5 _6V9\MK:0>;+]
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MQK^#A3-41A[A*3Q,.-=>^+@1&C."LXN_Y>7PM)[>*W#E' \51KB!#ZIB*=U
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MFM:\7"S@LK#L3'R>CH?M3 #G4S*<@&H%!(1+5I9;2<)\&H:3L%\1">L;:1#
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M4MI4!85$#M 5.\#?S=<6YLI*H^D9+H-^^!LLP(RXKWV<-Q(UH&FRSI86EOE
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MX)^'IV<')P=OD]^/W[T].!E\WOM^XM;K\QY\G&AX Z#S*!EU:2I!BJ:._"!
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MM35;'2[$NIV"6!,  K%1.PM%V!!N<S3Y19%=D!_@7=8Y%E PE0AJ."_F9N(
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M<9?$EX,OU2X<'!F=GB.8V;ZG8.*)O!#_\-143"X%*/P'-N"<:GJ9P<:0C^5
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MS=8X2RAY3)&!46]WB9W^3  ,ISFD+D^#>U+"<[74SZ76'ZQ0T:=XH<A6BT1
M23!TCY%F*0+!6Q_J *H1W#-AP!(V#W(:R:XE$/.]9%^20RN5'2FW /;?51+8
M<%N;FH:#A%J1()[6+8D9$PK03P;AY>V;7<*C,'O"4$B[W_';>BF"('Y[,U.F
MM/:VUX$=8KO!L*T]MJ-Z6O>HAK@:M$O4ML-F(/PT6!9-/> =%Q:)[K@9L@R0
MC'9F973'DEJ6.(:T183VC2*J=.LLVBF5$8&>R6EVA&?0ZS'-UBQ;JS@2G+O
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MO,#Q35>T'Y%IK78R?8*7*'H#9]GQ55FX./G5?U&.P;.O-#E$X?.BJ9AF@,E
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M3]*IR@UZY9[KE9LCSK[IDDZOG-ZM\D^-]URMZ*+XH%.JU1/47*@CXVZ8I76
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M=L,OT>4I*O:'?E#SQ<OD0/@EAR$  T_J9PT!^.8>0S@"@/D+P '6'_6$)K'
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M\-, .!B,ZI<:U0V;K Q&]5]JXG+OQYR:^J[M:9B>>]ONB-W>$AX),IG<G21
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M'8R^2D)/=*\_8CA0\02UF1F;]G>2HC-ZC]C\X3&L<-BY%16_5K=CH]X=I.S
MG+[ HBUD]EYC\!1;NN)><ABW</-'JNB&8_K;Q-\V*K]KV\O1"K+<($L[#D8$
M=[#$W[TEWBA>#G@+JQB[_RVX4WA'A0@BF[..@1:;REO^^&DX>;[?"-H-^&J;
M:KD1/XV+7 5C3MI]A3A95(, PW^9,(LF_9[SN&#0+%FQM%-<PH&=W(TEC*H]
M<W*H%\ R,=IY'5S )KH3#[0.IFRWBMZ?XR:%1+"BU7 5*9@R745/2TM1F2J-
M/![-L,HKP1;(^.1@=4&69=!IW[E.VRAFEBMTVMG5BHD&&_&4+#SO-8ASKBG
M<#[-R/&P^MFLHZ^OT":LCSY-GXU O>#XB1*.7THY69%0Z;P@#RMX&/OOEMJ@
M.?7(PL35/207(Q>299ZK:CO5+I]"U!!^V#.K%MB;!FP&5FM$A_@1AA(7^>OQ
MN"?\G6R>56Z?]LQ(E\.N5<[C?%F;F;JM<+U.7?E>HZD74NY"%UJ^Y[6L!6S"
MKVH[?8@T)18/#0_W\)N?:I79!@Z_#'?WZZR$RK"WA#?TO[KG G41Q,%9%@R1
M]]K^RE>27/ H(Q/,6[]5I3YDT->5NWRQ6;G+/X*P-$C;M$-G*A*#DO*CXVWG
M)LJ?+^S;*+<UUTO^ZJ!EMGV-RDZ[ 7K\*\78/9%_D-% ^L;2>UYS;KP((F%Z
M6LK*N&:03VC?\UM#<3N'ZC:3A,].#7+\B'X#;1 =+/?.%-&N0<L]']!R-T++
M/1_0<H-]^3+[LGF-"V^.CWY[=_CF#+DH#H_.#DX.3L]>)OOOWY\<_VO_'?[V
MS<')V?[A47)VLG]TNO_F[/#XZ#3Y]^'9[\G)P;O]LX.WR?O]D[/#@X&]XCZ?
MVPUCKSB-$SY1>L>Z+Q$67[GV4N;?JB^USN,8CV(BRP;_.PWQE$CI$[_+,1--
M^J0A98+];%VS'5O.J,C&L9'"4@Y810@_*-?/E36%T35?3/H?F2RI5'#,3([9
MNK-@@3LTR'H:ND#1_NQ:R&@))LR4F@F2>#X\+*!=A@A*"RU'[8IW(%1_-DJ3
M7%DKJP;KQ0&*]LXCVV=)@%5!X8+_6$;;;ZN*Y\PXB/.),726::A)#3:<ENF_
M4N%B;I(?[#U >=$EQL>846;-\5Y?F+)NZ/[8XBF=OI1-<0T^%(@RV7Z9\. 9
M#(W+ F+<>'K<4O(-^"])>_A3%7[, X"C@;EA=L8=*RQLPA]H338WZV+QZ$AC
M%)RG2,*U:$IPCZO6)7%+[%:X&-Q><F2#;OL+^KF$EW+.W9SD_%&(C:F8I<SI
M'&OJUFU)2"!*RYZ7(%MTJ9;14^)^7!0\83K'QY!^76R4594]_':P=D^2V#^:
MNR=<,S.6E1B'@C5YZ_SS<>0B++U253(.D7;<[=/J(T!A$QRI__H"8[2S[8T<
M8P%2T7 H%&/;ZV67[.:F^IE J@YN+UL]-6DS,:A)2FUKF11FP>5A/[%]KIII
M&61$W66J;DIWTKW2"D2<&OB1@! Y0*>R]+28-+AN$'8P$Y;^)+.%\)F9MUJ?
M6\0J=7#^5VV)P8116=7!A&JB*PE7RNWXU.-?X6$=V6/$IX1U+G5:R^A8;K"F
MK<)+]Z_.=9>K"9PNCU0([WQGPL?!4_H,3VG#NF%P%N3!F^.3MZ?)_M';!%SZ
MP[>'9_]!OQY<^<%EO\\'<<-<]K.HLZ2=]+/&/.R5#:RJ,V-V_MVX*#Z,5MAQ
MBW8?7=%A:QDF@FY:E4S@S6)YP[%=D!,K%[%W;E/%O#I\O2C-7*&),QKQ2(E&
M1+X4/4)39O.JX3;0OR]\H\]@'NZW5&X8_=T^^FJ3NF*D()SE,42AZ [R218/
MM-?;8>\Q"@]+^P4[8I.#BVARQ\AB,=M$OH;<0?*A+N'Z%7F&F(ZWM HD(>#G
M(U!SCO*'S6Y6482ERA QXO!GZ&MW5H7IV$H9#HKL399QQ7">(&@NBO5&<;LE
M]5-JHN4.<""$@23\(W52^A&=5"*&+_G0D<O1?H\&)7"?E<"&M<QA%OCWPX/?
MDH/_<_#FS[/#?QV >_C;X9N#D\$]O,=G< /=P] 7[((CHSG/[=Z"RQF3%C/G
M3CC&'13MFX/C#J)'P"0(\M<R7R'0W3N5$*ITES$O4M@+SM-@RX+@K6M3RS0?
ML3N-0Y:$2),X7Q B79CKM(<>F2Z7&;"Q%F0.U\1,0FDF\HOV=;JK1KSYI#1C
M;3.SWES"L]K,JU #<0)6IE!H1E!9ME7</+\8>AX"B%G?]JI%[(2]$?@24H8H
M!4G@MD/O+QPE;4<KLK9B^5UFR";K6P!2=U$Y#KOXL/@+4UZ%]>0)I^0KR.13
M]@_H226G1B_<(>$*>RCI'Y4E_^/HP[CLG_SCMJ %@[:]=6V[86[_I[->DY2
M_@QZY*T^6R;M(1X4[*I<22*6)'(A_>P=4*4X[JZ&-4'*:AW2S-\!<;@&8_-B
MP-C<"&/S8L#8#+KVRW3MYG$@_'%X].?9P>EF3)B_(0/"+7$KV>2JF(C6.,'M
M+4G7>E "U\0E[U3S+#0J\A$>OZQE(!3XM%?D@'MO-FK=R=]G>\O=2#QN&HO
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M<<"B\J7/D"Z3E:/%Y1)'28/R:J^QX2(*:4XAF2/\MRS^8:5JK&FDPV@$!E>
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MMPG1AWS-WQL<@*4/F@E-C([-%)7&-2GR@4GJ@E_M=L8FG<IY\2 X:CXV30)
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M >3*VL50P93[-O/-R;E]44^A=Q@"K:YGX4#21M!5K8  $L^&8@644QP8TP_
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M3?+,5*Y31.M:-OTI_C1%OC?(2P!%IZEV]3@T&N/X<.V"1SN0(H[\:CD;;*%
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M?2=OOD8)W(:*B5)$R"JP1BZL ZWNUZ(2U]5"7ZAX8O2$6&3$<N@J12<MBE1
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M/?XZEY/?9-4\/&SA%:$'\:!>?UNNKH@&/^;=H"-ZQRY_Z8[>S?L/4$L#!!0
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M,CDU,#%E>#(M,5]N975R;RYH=&WM7>MOVT:V_V[ _P-O+QK8 .TX3I/NQMD
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MATL8R"C2S42BX8;CU0!+'Y@$,:SNUW+AIB8CMD!O\\>+M[?XCLN]FR=+M@N
MM&$&'^%BX3SWH[/.D_@WR%;XO3@/\%[@P@TH*4M:$5P86$UJ>!53.]N/?F%6
M1KQI84$[A,.8-QF[&D8\5'\+X7XF\'9X%S*RB!AO!6-6Y+M(Y&4T'^"\N'DX
M[8*LT-K6#=S$!/EC!&INXH9!-\EXK-.6(6!@V)'.)O(.N9.".UW1PO:CXX$M
MP6V$::!V4F<\$?2$B!J!ZG#["'*+<=:0Y4?,&'^$3Z2@U@)K3/& A/]WSPYX
M3A58@?!N' />;\?,!VFV*6CPER2C:"8SXE?BO8'UE_SRXM.<E93_KI>IW6W'
M @?>6!<7AO@";:U%IR*,'H,HR3^@6H_O,Q_G!HX43MM.D*R=X&NI)37PX,SF
M:ZGE[\AAB9$^;RI8&BP8#*R19=&S*;SSEROK1J#G!VY(0QP3+UU@(D;WLO3W
MIC@:Z::.O4V]5])W3(W>CY4PU9_%%TU_C=I! D0'FMW>TJ Q/(=%%JGGW24=
M#3: E8/>C1V9,2P/_:3#;U*2?W(#)WY^_/SUR^CDY>O79^^.3T[?_/M?WQU\
M1_]^=_SBA?[[VK-9V+2>XD\/OE\S%XP"/3U_K\,#\R#33@FO+N;?2:3HZ?D+
M_94,?;!_^,CF[7K.7WSBITR_>Y7]P_ :X/:]>OOFW%_<WB29V6SYY%/+ZXUT
M[W__^?C'?\(T<,1GP[-9>:>^TISF0*6ENOG_%'D6PRH.6!9E<0D_-I:X/#'F
M@8NG-@>9,>B[<28&O*S)1-MWYD8[K6*&MVOEQ(+MAO]YSP1UGVCZV1?ASW>W
M95-N"VFKJ#IB_(RI=O)5J#:F9X:_(S,T134\,TE51_]X]+T:TV):BV;OQP[@
MU]X-#R<,DYEAM"\E8U=43I1HXJ<E?5'U*S+=U[YJ9]34)'3Q/?X7G4=H%:*J
M#:]T%[Y#/W'W"9"M%88_%]."%<V6VV X,P/CHIA,0-,MJR/@*W<<X(X#?*DY
MA??H,R4EF(/-J#*_-VAKHB6.8[#-OU(\6D^4BJ]K2-HB_;>15S+5+SCV',V,
M4<=;X#:0*YC C2F1JX&I!C>5/%2.QSQ^'!W>?W@%/J.>+V( 5[CB^]_\<G[&
M@(-$=E5=6D+_&1BMR3K+0TP)=!XC#R9LQA(.K;Q FD&A4V0V%=.F2C*#=,2>
M7)^9L]S!HR!GXP1&S\$B0O=';B8*OUAY'-%9,_H-B(G<4,! Z\3FX@)%ZRA&
MNKZ2161Y_LRJHQV9* 9*&B%3^%;(B>D7UV-S^9M",+9>[A$-;6_AA;&I)=#*
M+C+^KN. [A"_[5Y9X10J(ND,K$'%N8AQ2-')1<XQ2GQ81/2\-)>V:"JVXR*T
MXT3HQ-$#%+)@ULV*T@S>@K^C:V&=\U;?\3][>]$K:[+T2?0.3.@C& CYUA@Y
M8K2WIQSYQ>FO.AE^Q1X(&OC)X;S6E^Z-BKHN9D^BQ_C9J"B!6MQGSS.82?1@
M_Q',BP@=IO G;ZH"U/SY' Q,AR4$K/?I?5C%P()&I4D^[(T,J$2PZCGM@C_H
MXX%!<>'^$CY[8NV1!]/SCN4^G@L?Q5^=^OX4(V4_D/*DL2W'S0SESAA?0(@R
MAXQ#/VV6D6N=_.9%R<%;.P;>*,X:X4RH0RZ*!GW@YLK,#4$'DPGRJ4O@2,@R
M!GU)XBY.X$-0I 5(T7451>PIPDB9OP1R7<$] T:#QSM68(7/N)'#CW]O;(EL
MJ"$L1&XN@"MA@ F_3"]Q>V0:*U0&U%>:RO2,%-8V$HR1XRL,.<;;G;HL++KB
M[.03AG_E&?[;6Y]C^5>?9T)1Z+$R/ER2+ /8U^TM<DCCF'*,,'/D_NB8AS$Y
MR%DI)&6%GJ7!FP$*P]##&(\LL]747UBE 0-/ 0.A B/YGFPSPQ%&1A9N<;E5
M[=9YZV3-\V<O,S-6>_J%[O)-^[>_$5\;@N/YN#M@<Q@& [U\>RO$G4SDYAAO
M]]I81W0,="IWB T+U?@IHJ\:EKHP9.AYL4"4C('K4*&<$B.B0[!B2KAKQ$\A
M6\SH.CFECD)T%>N4JGIB\ PUTB$.PXN"[31E#M^T-XX1$OBXPYAM;[U.%M_P
M+OPEY-]GQ$$H\L?PO8")%2O9VPSFAOPG+R+!ER2Y:,4,*&6&1Q_GP-#]6"7J
M]7I^VUOMF'+(J; V./S"$GT-G&R$!TO0$?0XS1J%SWRDOX?6(M :YMR@KR/1
MPD3(3H=GM[=<@#UR\77$PCAB5).W>T]""W@(EOL7T/^_%8JA->+Z-S2FFPOJ
MU$SW='O+,:;@AB/8:+GJV&-E1B:@&"$7.#!](5F8465!R)J6F>&#^]$IZCZI
M58P4O&A[Z_K@JE67 Q4S8G,Y;&C[.<QR@EKG93)&DQL&W%E,V4(EXY0_!^4#
M)IXV@D]PJ\&K5@#MPH]-><EP;_W9J@NLOQP9_%__IAIW6=PF]O&UVUN?VH/=
MF-4G?( \.Z2G%8C>&9R/@AR"^\<0*A@!.45'A]+1M[=H^#4[3E%<VO4^Z3&J
M^%K(87FQMRI3SIAUMF?2\JC5'C<]=5RMG# C41'HIS@Z,TO8<RYO$?>T\AL=
M;8==&Y61[^'?HJH2=@*'A\GL*Y(*>7#\V=#!CHPNUMYM3/8Q@CQ!4B*B1'$P
MSBBS0'PP=7)QP>".UKS!)<,)O428#OTZW#]-!XD1_I+# \ :X*]Y455VE"&"
M;A(]8,9+%L1JZG.0'HVVHS9?#L%  G<4_;*WX@W@YB_[2A8>,ETRP7"2<05L
M%'FYDJ[G'(M5[ ;/".--LAX5Q#X*%BX%.;-),,M]F#=EU22YTQ3I*;TE-Z;W
M?2,;Z(7@NFB37EM@V^SM%:#_35M#WX@J_V,$Y@B\HC0D(65;6&\D/!N3!_#&
M5E$;PA);XO.87HC;R _94N%[&.AP9@WPC HQB"MT$C>)%)-=[*AA8YY1;E<
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M8HBMM._?"$J0T$&=?.1$ ?1[8I[?+' M8W-(!0_3ANW!<>YQ.$B[752N9G\
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MD5U/+!12*0_S,!,$,&!\H>1ZD\#!&TF.YGDFI:VHO):[/V<87V*PW_&X1@^
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MPB[WG[]]\5_LN'C_I_.?7S_[?U!+ P04    " !#AX=:R+LVWS=3   *1@(
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M,*9FUCDAN%5;-]JYN[^[_F[=T\O+4SE\@UZ_L]WRRF:ZV7+NCE3ZIBG("?.
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M2%3HO;_9N'PD,>'Q28_Q"'B0 R:9K_+\>F^68<>,&5)H9K7W9J:8K7DGF)2
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ML=&OL8-RZ.B\#4_SL+$:>SG'*#*Y!C0)+$W[VSMOL3"O0G40IE]:0 SLK^R
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MCI*835:2GT#]<?)A:N!9&SJ),F-'X6CT+/W0;*,D^M!FUT0BZ):W00I;X?^
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M[IP'?^QR<ZYA#J,6&1+M$MO!\GXXGN"EO2ORI]25)AY*E.U,-=QR3MT)G%J
M2[!=$2JU0S6'+-)=8"00+QGJ86EX9_,1V%=0XD1R&^DW)(RA(I%&N/*\DK\+
M96^)N $S160#U%-+PX.AC;(<_U8JQ[Q6 ^2[TCU(L_S<V_ /DQ9,1VCU+D6S
M(LN/OX%1'KLJZ'3P3?=I9 ZW#NVXE^(+OQOX.@N> WY$+7)39)U%\45R-(P
MCIN*X1"_S15XQY4%R,(/)SF\LFWBI]BGNBW_']P?D#.[<2'C^D<V;Y_HCC3L
M7UY-\"%CS:EAY6SF*@/)F98?P]M^)%/WB5MSGW7656Z7-SISWO %ATNT^(AG
M%=V9F)B^CY&[]#9(*17L9#N3'MO=D->OY1^D$QESJ8HTX(77CW1%FO99@R94
MMPUNLO4CY!^D1[5=AC^'ZQZ7=T=^3ASXE74:X.:JW]E8T)>;9C):);&$1+(
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MZK/#@9=I><W</OQN2] <(47*;@6/_;T]!! JS%&!++=B&<A ?4%C$PSWE4,
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M$R,"H#+I3.9_1_)EOH>^%(50\>RM?Z?;IMOA-T R85[1S#K-*L0P!*:/%B2
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MK\U,X^*ZR&2Z@59N@ K#XW$R'VDK^W9>3UQ? 9FB1B2KIU)) ;R>EPEL,XD
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M8I@>(-1QJ%1K^$U]D'<;+3=HPA,O(-^Y("(S)J2;1SMG9-O1/(Y4&I-"BK/
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MH8LS*Q\(8&_?0U[^098^EH'RF=;ZS^[W?S< 0!COGT]L#0!+DMGZ7T31 8(
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M0C E>80@)7@ +@(?=.<(M/9 NW70WCOH[(&;X1'YT=Z-J_SR;H$/L#V%,PM
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M>="<_:#N5,9/U_."!ZH+#2/GRMIZS<QY S7C814J3WZO6@:KIFN5O=FUS\*
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MK$C)5'R;K#KR&G%)AS3[$EC\ 1LF\G\ 4$L#!!0    ( $.'AUIRK2R%ZPT
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M#W[^H$IQ:MA*Z!&#!EXV"KYG@&=HG.VXN#P 8/1]SKAO"\)(4Q8QX=$+P32
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M"./JM]RO&X8]H>E-V;*)H/@KB"H*2.;[(%F9AM,*)43+?JE\_P=02P,$%
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MOH9NR!U3):_)*DGS1J-LJ!MF>WPL*Y^(C*UK<WO  >QZ&A3=9FTJ1-DRY^G
MY_!=4MYG,^\1/G!L/32Z(T=&R?I&Z!@4:\5+2;D]\S6$N%7@4@*:T_.]N,W(
M7P6S,=P3F?_2]GS?&A_K?!>1L3[?MP9$.]6%=-R>Y0JQM<YR,50.3_#=P/VC
M)W7&R%>6,'+D96$VG6_GU)3_Q5KRFD3'E#"BBZ/6?C"6XD=6I.XTR\,E?5-
M%WW8&MQAN*B92+9!06JQ<Y:D)+R+R[@FO_W^JXP,45DB!'=3V?/ATO)D)M(>
M6"L[^5@E%C73*G'%*R4UII-2CIFZI0]< ABRP+1HCF?O:6*H[ )D[-WBU:MG
MC>K54KF)^I2J!ME_06B"H6[]8U-[:*LPM94,U*.,X1S3!439^<=2WQ"FO^ >
M9]IDG;Y:S8XT?2C5G8 0HG_:C]4A8G\JBB,2H1: 6/U_SKPPY:V@/Q"/6?0V
M2P=9U=>FZRX:PU"QUT=2IP60K3+O4[)E/<?K,/M\G)(@S-E/\+J\D-+^ZR%:
M>&DT];'/)RQSXW#WF(S2>&0DQ4NC1X_=/EHNP[P,$6;QAYQ9^EP/L45F0'@\
M$C1!4Z.ICU7![N4J2IX(*=LJ/,0DS1;ABBE-IS?3*Q0M18OD6"XW/?S4;7YZ
M.6MQMYZ0S&BLQ6*@T'KU=#<=+_N6T+U^SJ_7\)ZPE9*A;#,;#L:RZZS0Q>GM
M<^JE,>6:%1KG7.'N116UL0A0B9JZGP]$7-<0#SH]FN-16C0Q1.KNLYLIBBP]
M);TQV#4-T-/I]V-L8V:J+>,IF]Z3E&I)&I(3V)GU1MK_W60""UJWGDORT. V
M36+ZHU_6B!WB9#0F/Z:M9HZM3@L="^\.4X6B)];5BP0BCBZ3_ ^23X)DQ<+6
MK=P_O<GLN^H"!J=&+QDGM99G\DJ:7TGP7.F)]1<D*"(RG<\6Y((^)+*RF5J9
M<$NIW-"Q6=$7*@!R0E8I\<.R"P;#T-![#41K%/L'#-A]*\ZLV#S6?HMG4:-Y
M(_5N$K)=TU^#-R,^IFK-IKCN5<EFI!WSG"HW;^3;K-+(6_$,M6>4A)VG-AM7
M:#9!U>F.$51E5FV<0W%FT>"#QT_MA:\$MA#SWN3^MZOI*F^3YU:%N:PEV5%7
MN)&$:/X8,1K0X9H6EURVP$4O0],RGD70'N^#EQ<I_7_4:]R& W?ZKUT9;26B
M2*E!G#BK=8<LP6XJ;BVA.I(2H*-,U<%_@^P6.\?0J)Y/S7,!7JAEE90TG3\[
M+,J>JX%T5_195O4<8WL\K^+G]?CK4.>&C*NHYV!*@?7I"J 7%T\H_A@GMQE)
M^<OU/%X5K!%K$OOT6Z7!$SN^'))%AYJ@11EV7&GI[&'[A56:*>ADY3S3#UPF
M<=J: OM^Q:R_B,._"N2#?!B>W>FK$"L/5YQ(JN_&@'9"TO">%]1L\#_)U],;
MR$AIR,8HEXP]Z!HJ-YZ[>:>7!(8R\4Q:2C2\.:LP]Z*/%'6\TD0*:J-J'Z%"
M;K^:1B $6AS:1K26P0[DDP<O#<H<#1XDOKD]Z0U<+,O?#71;@3#WW)I*0,L.
MR:;;Q683@":;$Y_>T=@F7@"&W)WTPRPC4_DHM6:,A;,I.L%9Y!<87_A[L8I,
MN7-H#QA^31F+3L<&;K+&LC1GH>0!4SPH#W2:;$[E]*GV37]-WPIU#ISI*J*#
M-U80_==F]=C3=5J$ FZ%] !>70O+61,D=6 6>#64<?9"V@HD6OLEV0K:-$LX
M>F++(8D1XT]Z,.*ZN+YE/Z0^T+LLR*SJB(3P-'R&/9$VTE?U]^D5CV\X^/BZ
M(]GCN*\MDC"#BD??*6GKT-SM\%.W]QDPM%B7"8<O"O,&2K9 [T=+#*0]-/+.
M&$W_RYRD*0DH@2[WW6 ^+Q,NG#ZX#-MI6".M>RE9M(M8+KWT:3K?6!ZC*'E@
MS<;P.D=HD'2G<9B*5 M '<,;DHNF6G))=R(57VC0#^+NE"W*.SG/R1*ZT+^*
M6F^SIB0##=%S*::)%B#H15'WGM 4J'$"7]?!EL0Y78&G$3<X_?(R*VNR #D[
MN%FK*L,_>0RUEJ+*3-@<#DN76]!OIGYQ2U[1WS+C6Q(+/,PFJW9MZ&LAHE$#
MTQ!UOQK_3WHT5K3H'7?"SV*)!#+B?W.7W+^NOUY*H?[71@K2X3&M0+4H7@6M
MJ902$2TU!KH<$$V7/@C\?[X90@#(Z).Y5T0Y#/P,$'5PF17\YQ<WD&"SX5S$
MBNOLYA;*?-ZP'8368W^\.8'$E TW"DSYO&'7J?RRG^3'7IH^T7<^C\0;1(?;
MINDR,\)"!=($TEUFQ.9MT%G! /I9P(E4KUU$^^(6!?M&BJM5%(*W)5L/Z]8]
M)9%%^W5;@X!F@7B?W),T9CI^73-NLPZA/3<R4J.0AQPLC:!XV[(#9.6%M8&X
M2O8"%DXW#7=V($V)"*#1BTSO70+F/3W5,QQY2$F-8K/(P=()4P$NTX,LH0:A
MO=\V,I"4O=@P(]K7*I&L1 UH%(.P'@F6P52#8/^R3N(J*ZAV4P59/&>1T':J
M+]YN\ZD*2  +*NRR/7J:T:_K6E<AUFV#(IZ +4RP>GM JS91$U1X ZV2/".N
MM-?"UI?:4$3T\$HMN!8K7:_.5 -,E)1J#<I2NR^B(!U8@O'%J&<SMFY+M2IR
MDJ[)?F@I7W ]J#JIN-7S#8ZCK=Y3W9"A;+;I?![Z!%<\W33<*?F6@A% A;5U
M>*4FEFU[OERER7U9P!Q%/C)*+HW6EG*2 J=;Y@KNUN+O]J&NJY*8TZ RNQ>#
M"CY8!YR2ZB0(.&:#"6Y#<!\+DMJ)K@$B2NKFQ/>+9<%SPYH5Z>G/$:D:CDV6
MK!?2%_Y[(9_ ,@9C:R_/7NE2@),(="JF)8<WGO0E_-;MTE%R-[JS!%P\2CLY
MZ+5Q20:KQ\U([>G[QNZVX-AI&,\',9_7-6LGL1<]96&6\-1A+W[*VK5M59$&
M5D^RSC*ZK/5PE?%\4F E:!B1ME6ZI,6"&X0N*9*S!Q+=DP])G"^@53%K-AQZ
MIRQ6AG:99BGR+BIQ-QCZ@WCI["%QM )JZDY+VPXD^C72>&8-/48<R=KMVWDH
M*>OHU^#"_1@'8<8;DI'@]-&G'Z6J7 '^_++CP7%("*;<Q;CC!9%T<S*(MO(T
M<ED*L=L7W?@3815223"YIXS>D6O"(%FW>R'I,F/E:ZHE=TV?<@HEN5>3!\P>
M,*WQ[8/>6O)4@@=M4C FOP<=++H$*]XB.I BZ:]21II;X(JD/D((G2GYL<NV
M$U*D8MIM1NK#^V,&K9F*Z3A512V$U<((S='637,0H3A] ?80B(ZF-U2:CJ#7
MBE ]L#3RTVDU*U+@-OE1T^NQWD^7JRAY(J2J@KA+!'@R:GIN;Q%MX3;WA0:(
MT'G+A[>0I:Q4#R!PDY282][=PT?99II$1R@_73BQ7+R"+F#0&TY 980"$P+F
MM!;N1F^HJ@IZ4=V Q]OT5$EBK]T/"L,C!]B/:L<WNG_=PRYZY]% ]N]"R+<!
M9\]!7@[FDL1JQ>8VX^<X\K)L6O=.G*:\SQ-"GH^8SAYD]V#MS%8 NQAHO-R?
M3J(H.3\R2GCV :U4'^425XK)H(@3L)3 4WJ4<G)2V E:5%K).[WN\*.G]8__
M".G++/473Q>L)CS"V:E)%%%\>W62ZLJ@7@#0)O UT6IBW)BXRPG*,6M&VW62
MI=ENZ92Q'L985BHC-L#/:F-A.SRY!Q(U?"6_'3;X491QEM^A));)*+ETI5B=
M:YV2[((0O-84;PFQMH.>UWW@UPI!9U:@H(F&QC .DP8TM/AUCPP=0%!29G=Z
M!4_I$LB].*#7/? &DI)R:VD<R@ A1]MMNY.&B7)MCYSG"U+SK*Q#V._\ANU1
MCFZ9Q&*W[P,'H=7[."!T58]]J 7<>6.C2-M!'?AK+[[3+E.D* *_&0M)M39_
M52-NRKIN? -!#;NDE7STM6H="0U0U419$WYGV;70-%"!>^"I]_PT1-11D7<=
M/-%L? >7R(!'CH%[!+HD^L$W<O"-''PCX!8 %)M9>VRW;WQ-<XP %@0EX .=
M_[)8@JE5[?&<Q-L+=,5:#=B:,;3YGY/P'F%!;8VWEZ"V9XP55\I[U1^Q7O7-
M;O83MDGN2%FZ<?.1*E9_\N"E05,E*98K7D.)E6CW<Q+\ED1T&&;W9$DPP(?/
M$!P[-"^[,#P,L@B05!+.V%4:^BCKK!S8:9*3LP51@3J*D^<ZS#Z?I82<QSE)
M29;O^[G3R>]>N!O'>NQTKP!E_+[URKU5\WUK<EQBY%4C,OIU'HE(0M?,8=@/
MY>XDO \#$@?[?L1V\GLX8L%7@++DQP"N[7Q!/E15E,.X>N+KUK\#LX-A.:<5
MQ,R/AW9H2EB'IB3KT!1-8$]([H51ES=9%=@#1!/KF2;NTJTE]]WP'RB,>_MP
M#QX80P\,YEX!2T@Y.%P.#I>#P\61PX6?$-O;W2#:5?!5IYV8#4)<13/'2@(X
M1+::*2) ,:K&.X*%S]Z5F$SGNW'0LV3-4#Y;D'/V22\ZV7E3"C:-_>A[MZ_$
MZF,/"&&S,FIN&/OA//2]DJ6:_'F<)ZQ$^G;!&+'LU .Y*V!M+B0-6$#MD!7=
M^]H6(%\<LT6:%'>+LD %H6]X+]ZN#R<45"\2H]II_<#4*EV&*U^C#6@U]+[E
MW,")<VN72JO7X@D25G9C.D&U :H$])U+6R.WEQY[JS#W(ISDF0J_FSSQ/[-J
MHG2.14IVFGW#/ON$U&SM"\ERF<1\5(Y8-BGR19*&7R@TP!.04-J#.T@EQJV^
MFF+04!(%=RB>9UF!+Z**REX\HGH)J(9+2^$>_&CZ\\IC5=(6)*?::90=3BK%
M%KA,*&#<[86W 1HTG%_1EDN_"1-X)KEPJ^$9>J2DQG]&=5EZW!Y4[53D:>E>
M?L^4/!+ EUJV=H+OZ*RNXQPN;!.*N:*],Z:>0(S=O!!TAL_XA5LEZY<-". 0
MM0B_\LQ=Z-5OEYU[R,\]Y.<^G_Q<-OXLS%EOVW.J6MR'0>%IE]M3X-H]KLN*
M>E@GB !!=9)M;U%]"O,%[S3 .%V$JUER&N<L4$4[!,14B J* VP@P7DD7<9"
M2:D !#776'  <L+9"-'9.8@A1[T2=Q9N@;K;!W/(GX0IBRE+38JDR;[OPNK9
MXY!9Z\M23, -#8=DW4.R[B%9]Y"LV\,Z!VLS>#;IN'"\4ZT\S/#2>W$8=9H;
M-XHEV1(KZFGYG#/#$47=%@UX^ZM#[O<^Y7Z/X,B09G>+P^Z<K\U#TNSS7YOV
M:;&'R@-CJSR N!QQ:PN(0R9?#!>:5-K%)WY.=PI*7O;!TZ_T5'0( M+!KQH>
MT8FS)YY])<!.DKA/2!K>TWG?4Q4JHP,Q DRI0LCCEI+:9R>>YM9HGMQR6'6"
M OH)\Y@N'18'-J/?0DG>EI)R%D5@LJJ[Q=4%G-HD!BTL\!QNI;@<9G!#"DO7
M+6>G1;#0R?(<0"F?NSN^RQ>6SF'24E9WT=DW6W(5?]&(>[TL,.0(SI^[@/ ]
M>V>+)8@6;P[(ZR?",MY(,+DGJ7=']M*-8<BUVRCXO5^=<HGC]$BTMAHHV;\F
M3"+T]_6-4'@1,R>\VQ<K48\9',Q', MA[UQ#NY,YISR'5#'U,3*Z\/@\Q#/H
MBU2C<JJ+1?B^*@!R177K)'B?)MG>&!8E'![N>$U)JNM$H"RZS(C7?5)" 3G_
M"IV1D'+7J:!AX6OHH7UHJ!P7X9Q4R13Z_HGA6'I&*J43B59K\N_ :](0E*PY
MA;,DG9,P9ZG6];XR](P!$GXV"B&B;*HU]/WP9B'5Z=S![IBN9E/V#_=S_Q50
M+>8?1G=)5S/=KVMZP]3S69N.A%HMS!^!GML@LVB;!(9=@2+:AX6F)R+PJ@E0
MS_[J0&9A'WOI.MSE[^ Z5$H0-JL>@=%]T@N!N#[8%'M(O%ZP,B>+"\^A> (B
MA]'>Q)?WF,$S,O,X70CUJI:VNW.]KMLJRQXOWVU&#ZO42*SU8I36_!XB0>*:
M9)0UEKC! ^P^TA&O;SYFFLD2AW0)I'0)A5@@4R=,2.'M\CW)HC#"':!$XK_]
M_+]>O7KQWY\^_/;W__GOW_U5\?A'_-V/P9?O[^_^>(H_GA0/[[]/?_S^UW?_
M^CA[RJ+O[_TO;Z+_S%_G-^0_OWS_[>?'M_Y%_N:?9V?O;GY]??]X=/S'F_O@
M)OTC_?<'/_QK\67Z>C:_G+SYUP^_3Z*3R>_?_S/[V_?O;\B/?WQ8_?K[MQ].
M_K%(;Y;75W>?3W]]5_PM^E?ZY>'^_!_S<.47IS_\'C_\Y]'%R7*17^31FT^?
M@V]_??IW__UOWYX^/7W[P^>S-]G%Q5\7T<W#S9O//]Y^O'[X],>GH[G_]V__
M=G'\U\?T][-IO,R_\W_[\/[QQW_DD??^\_3N[,WBAW^=_KZZ+!9_?/S5._[C
MWXO%T><?XLFW#Z?S^*_?WMR%$?&N/OSP_I^_K4ZGX>?O/I/KO_Q_S..'D]O7
MY_-)\>'IE'Y^_L_T_9LORT\K\O?9/Z_>?G>7WCS^\_9OM[]^/YV=S5:_?8F^
M%&_?^/_UY89R6?S7PYPNMO]Y<7QS_>J5K?K*5Q4+4D9(7FF/O<_9*A8G4_-2
MW0)1RQ(SL -EPV(<7$5>?.DM<9)<4%AT4\].ND=@O!HRL;C*!+!@%CSW!FT5
M.<W:<;*0P*N5ULQV')H9/351TGSDM/;9J=_C1&ZN# 78*/U, &--]]+P?\@9
MVKN<(1O+1-EQ;),'F4WS!4EG"R^N9C&YNTO)G9=O62SP>F XG<H^'X;#FJQ
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M'%*20-+>0NB(-'4=_Z**-17 ,J0R70?@W!"_2'E[A6,OBDAP]+0=*S6$NFW
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M;##8=/0H^POVJF9!TGNJ3@D<4&4T5LC:;%X3/Z'J_Q?*%K^R>7KI#KK0-3"
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M((15A7R7%G@<CT >#F-P>DH#/N2<;=SR:IT$04JH"IE5/VB$6JKO%L706-(
M.Z]TX(%M=\<H-D@HSRFU#'9'PS)B20\D_956 ]\! W@H1B<=Z4%D";B38P<
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M2)8=;ABS!/]TB3"H\<!?"0X'F:0^BKVUP$\E3"/8<3^>.0L'WR3XZ&5Y,Y
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M#N:W;KU*[]H^> 5I^".,'S;8SE@]HJU_@. &;H,X[>[B.YAO:267L[@@D3D
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M=*A78U(\?5J81]J.)J9:T-SGNH;BPPG&P47S1,=DD%^#5T([(?_T%NW#NR7
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M2%AJ;*(C2K^8DM#U#I:XA/9UGCW&$8Q>[=\C"!=I6]1MA4ODT'K&\Q1=,T#
M@\&@CZ6H.=PZR3X6 /,0R-JZ@$$[A<\8<7-^Z'.RX789-XN*_EW5U=_O,J3"
MH67&"41(7*3H]H>768%^[Y?-9T'10U*W_57P4G([4-@@R1M@77X%^BW^-^FR
MV*1CL(Z3KZ)V+KASF&0^$W$F7"]M.R/[%LU@:O<91WWPO&3.WB>>>9!%AV&O
M\H/5F(;(.[%E!1&(;@U6;9L4"((,?2BNZKJIT)@T*OY=;F".JP3CCJ748+/,
M)RP([KMUC9'@,,AK9.0@D8WNKL9^/6C%YZ,B-)](@QK0G$5.N#G0I97C@M)G
MD/ZW=TW5U5-FTM0T +N7..K(\>R/#?H)5\I*ZS9P)+)B*4U2](G>YT+-S3$)
MC&!,+>P]R'F&4)C&[4.#'"&NCD,'#I7O?-1NT-M3@CK%VL<"Q<TP?PX8,RJK
M9\OL<HT)U$>-%#74>'$&]6#P950/?X:9L62W[_&D?^M17"S4N'MCG&_$$)SX
M0C\ -/\]RP*Z#'YDH2;C1RP1\3 F$RZ"!T54EERLO/TPYD&.RY V=O3HB!8A
ML!Q'M !+14=TW,RP;$>T C\H.*)EVV44P'(#([@E4;G9.F[[D5ZDMYLL+Q%A
MMV>TY:I:M+CZ;*Z>Z?70XD9-->.Q>OAE-P5BP&>@P+,<XVF:_K2%%_/7C)ZM
M JFW2;9%9NM'\"4R10@L1V0*L%04F>O68;-HD:G #PHB4[9=IF]W"$X(852\
M1DMQ44-%#L^'QBG%2K=$2ITWX]ON4:9NGP/5-L-8;/:G[^*PV:E<5MF- <R#
M.!1CI!S,?S3D-VFVN6_NXU.:QWJ<S;'MF%.(G)-CQ0J2>Y.3*H3U6'IEU;19
MDEBP19@3<XEPOE[#L+Q:GW\*B7O\)BCA58IO0?P_' '\&"3X7?T&J7)Y')8P
MPG]8I='P%[TO+8N1.3#T4@W9_CIX-R.!5&"!!6M@($?00%B_@" +A(2.8.E%
M_@&[.3U[:F;DQT%-YIF(86[0T!?$SCI/HU;MO"CA=C8[1AFNZY!X9<Q$7<@Q
M<_?<.XC?69;+][XO!6WJ#ZP6K8TR["-[F!W274 7::F3AJ0TD6._CAPC>XEP
M[ETYZH3K>7$4M\1EP3XMS-BI$[AY8DNHKGU\G#8]47%D94/ SY5H)OV=" !K
MJ8BJZ8;N9("#C$+PY2V$X%V&]+ 7O_>3@J5-Q9:W]!(%C9*VAV$&5_>TG\]%
MVJAHK[.\C4FXQ$]QE\WYM:P23<'$?=\G<V3Y=UKVD,:-E!S'LWC.+;/ *(,4
M[XD;."'.[[;:[1)2\"!(L#'Q.LD^7J3K+-^2<S63QJ\*U7U)?S7$>#'&O=$@
MBHLPR8HJ)UZ[L'F\0!=].]WWGC,D]6@_B$?6V"?3XHZU37&57P=Y6?^P"I&8
M+XA@0 H%1#Q0WM3E])5N?=TY'5<IU42/&P)#/QMW&G!]SQN2L+WR3?9CBC#$
MKQTW<(>(NL&Q]J-:!;;%H!3>+$G$:K7E17AQK^UF",D;/G@#\Y49K$+041ZP
M=/4>TEU4\&+9G.3A?!?L29P'SMAOJOH]8,L,1OW>=KZJL\Y/,6.3LV>R7ZU;
MQ>LBO:'F^EVF5892?39;QJ?\W.LAQCW\AIX-]XX-37KVO!LZ6V1/0@PI>"?Q
M)&K@R/90:?H3/U/Z&<L+1OZ"R%>@GJ/"L//=Z09J2&FEJ23D5ZV@\%D77)EF
MHBP5CF5N,27@M,IS=(D3+X'M-VXED.[N)!VT9%R'])M>:@K-"@CI!(?NI.4D
M!C!IK9 6,-X9\TRI:ZHT%G<9L;IR>)WCXUONK]%&EZLTPE[7W;@RZ_2X+77
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M"*R(:&R_^GYS$Q%+9KI.JVI;;;=(N[U:XSI]E!>3)/N('WQF<^ZI@'2>AJ.
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M$RW"7YAYH8(=1(8,UD!*W &\"9%_7\!UE5S&:VA9<*A ].":5D"+IVK6(X\
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M!]Y30(LOY\A(PG:]L9[=9!J4[7.=ZCZ8,EQ;=.4M#(HJAQU#S^S<4(;K^O5
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MJQ\8.I\''C2BOJSICGB;)O> NHR#^S@A67DUT.@JO<&9>GF</I!V[>_3[+Z
M^2.^ZB_2756B/Z/-0*-(J>8YM$7KZ'EB=TOH2T_$$>A!:GI012!+00L,$&A'
MH \/$(!@"'$ACJ*Y.)1YWFS2:0%'<B[5>18472K;<RS \>%DJ_-/^X *U?_9
M:&88Y'2#LRFL13;U9W/T2G4 5O!D&1=E' 9)OZFA;^\:AP)-$-/ANJ;J\<2C
MB'L]B9D/?? N2_,!+^+Q]&J X2:-?ZG@+,]7LZ+JU"2=<R5:C3NIY"V(<=%.
M"+H9EZ8AS<BD3$$\%WV6=5AG5Z+F0M?AT^'<:[%\;)>G.\W,L@Z.[]374!*9
MVF"RCQ'\8H=3&1K?7-'XN;-UN8%O<8(C;@B5UG]N1Y[!,H@3UA7+"32V#=.%
M'3,'XKSWU>9;$&-#A<#I>7\+< SZ+Q ('&C@X1&-D[B;YLL:Z#//U^><#->&
M6L]!HPE-MEG>[KGN-PDPMYXX,3(*+VMROE[.K:)&9NDSR%BBZYK(=W&)7XTO
MTBA^C*,J2'Z,R\T-3&CK\DV\N\O.$<N7&@\A$C-:%Z(+86V %X<AR2Q$K[G.
MBICZ@1AFN&L[W)#,C:UNLC=FF4BCFAB="&ZU(B*-ZV+ ;_!I@)&V2F$#CA.3
MVQ:VPJYJPW+70W6AI\'70K:IPUQ#69:Z8)&!NG*8EK;?>BO?7L&85_MQ.9F/
M01[-I3M80,BA]3L=6P4%1'Y2>!$^7DL7364H>8M@[7TVUY_/8!X_!KAZ1M,O
M;[8072$HQ^E-(EQX]1+:(: 9LXCP(!4*]EE.NG3KBDBO/.4J1(!-7!H3IG?$
M6A/1--8W!O5.FYF%.L:"5 Q%UE#1+%3VUWD!#CORG54%5\X"R['>EWQWGLRJ
M918\',C_PX)WE48X^O==L)WGUIT%1:?IZ#,L@)>QB@< /,)SMJH+_M(Z2J9[
M;-JC3R#G;V!1YG&(S /2&NA]&I<WM^^+.30+'5!NG+\6,396.#H8@  !& KX
M$L%IRL<]>W)ZB %3J>@DNN2P;.$KM'NS<XF^D"@H I8)=EDQX!BVVK)$X>M1
M:WDQK?EMF&UA5_P"?XQPF$7]$,-RJ4<(,9$6-T%,3"< S< C)"03TD75]X.%
M%EV'375E6V(82'J:I1%B;2SVZKFOUIC=<[A!OXX?(86L'#0H*\2K \Z!%U47
M)WX9-CH%&/#A8):&*SU683(E>%O$5W>G)G=TA?EC'$*.)$Z2^AA<K7&(]4,:
M_XH$,<SC#'U7S%<VPS9V+F6K9=P5W@[Z;6?//V$8$'23XG &_)[0<A3)[KS:
MP5R8:N"W*ZI=KF3V4K5('F/++D83K^,0)SR'85;A^*"'ZRR)P_T@>@C7ORC>
M(QSC%&-9X<]NRSQHPCC.(!(0(4U^T+?YYD;"P27C9"&\D]B!!1U<0 $SPN<(
M>(#AXY/98@ :%([)>>PCL;!'<D=,V]F4+NAJ^- S'VJ<J]7](1[>HJ[<.@[6
MLXCS[/U=PCD?NSC7H^M9JX+E/OKY='^/G[-()]O]35Q\>!ND ?5)8- E?-BO
MTNA-]@CS%-N],NNM+6^YC^K*EONH5]32&**3,#)C]'BV7'\N@"<#W6Q'H)GO
MB(1"=E-Z+;0TF2E(0<U)&VF@99H 5+'I[+/SX)99(D/+K@UCIF;=  MG;*9,
MG[ZIUG4PF[:0GR0@182,5)E%/4?I$5%%A["?6$.>:^9R>;%AN*P/RT+ B+'\
M*[5*A&-DR# 6;]I3D?K7TH=+&!106Q )AKMRI_!1X+58; 8 ,D(@7YPW6I02
MHVNX*%ZU]A75,-@E+ H(ZTF+,(]W<U;PD4%S*%8DJ"CRTH*"WQ4IV9<N*GM@
M?CN17"K\/I[K9-II<!,#@.,0]3$&'+ZI/Z0% W%:._T1#V3W7?# 0'QZ]7F&
MLV0S'5F4IVPUH]Y7&)@J3J99\ )=>4DY[<;)ZG-'7TF#P^4IRJS ;RG=?%O7
M<^9LGYAK(WUU=\X"R'T CJ^,,0:R@L<T&F\):4Q\\O!LEBDW1#-?/\295H4)
MNM_<H7\504A2$F=I%*L+W6G-,DWDN#%,"9HWRVGB7&].HJ[T?[XJ-S 'Y2;
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M/5]</<+\ZF-*T:')='?P4_D*L=T''OW.XB),,MS5#],OZ)+Q=C09;YWE(&P
M )QY"[*/Z9B,'JY8I76/2*FQ6Y8C=:2$/(-ACI-\+M)A&ED;IJXH.-OC&-43
MXO#VK$V)2LBODF92?R)4NMX1\11WR+T(92!&8HNNUN\+VDJ3>P"9-,KQ8$S"
M"OTEP.,71::#M:G0B;D=/M23,[B&>0XC[$8D/4ZM'38Z+RB#3Y1DQ3(/G=KR
M&335V3?;FK\^67\(Z/V\2B,D\Q^#!!;("@]A?8WSR$N5,Z2[U%0NF(1]K"<G
MSS-A?_I&^_&HXNANA9S42GOI7NJ>?PHW..H?>]VX5D7S$< %1(JO/%EV8WQ'
MN\Y8C8\MW<6TLB<.?B*QD'<PWZH)0]@.!A$.]WH@35!+--ZOILA9%(,"@L6[
MI\4;F"()FZ!#MXJV<1H7)4WCJ8NT%IWN+E7SL9F&0,5(S8\ZC1\K]P\4"!%D
MP0 ,)B>!X_7,&&S"B*[&&^G!FKM(XS(F5B8.'\)?$<TI6U>UYL05=$-3/*;S
M8".\F<@K'>7K8CSTJ6V%#RWR(BW*($E(!MHE[D>QHV%>/.+TOP>8P8ZK'=B1
M(5]Y#(#D+8-!"]%Z?5" 5L4X*+C2'63L.Y>+Q>"^2H+\4"8F9.JZG\:A$E]\
MA0O%)U4$BR-P7Y4@+D":E4BWW\;86UEF1TAE;,MTX+,HG.\(R5DDD:CNB(0P
MOBY)0G&.I-9'=((10CNT>QML0&1U5T_\(8(1T#;(($P"="80/GG='81\%&\1
M0(31_;Z!5%3A!JFPZ+)&?P"$.?(48T*:*\,T0E,$443.&H(<P?N25IQ;5SG)
M*<7SH.\Q("1F-ED21\&^J'\D\Q4%AGT$,OHQR2#"F.1=>_00WT2/=6Q3E58%
M=A;B#V(R%E"7$\6B\*LYZ##9Z,SH<ZB7<]08;A=-78<V0:J8H%<D_=H*>5=;
M8>RY]U<"0[3B,375]\FUX_!MD'^ "!UDM2$^PY'&<GV=>B^HWKXEXQ%UZ 3H
M]!6E1_J,ES,B!F_%[I7T=["\SK,0PJAXC99P42!IAI;7\8:4%,6!(RE%I-C5
M4P*\+>B&H9-RSH]S DG7/**7XBYY)Q^29\VK' GQ5WRK'),,_[9]K2S(5'YO
M,ME"923C[(QK4?<.+3,H-E<YCB&N?UB%OU1(=<!#+E*D/B$="-D,$*D87'5\
M0+X475%T&+:6R#CP7[]46?DG# 0I=P0*_0WZ LF< C]EEALD/G=9WFAYF.1E
MK^H!5@K1I%5"=#UT"^)9*(1=2;4<_(L=S:8IFD8K8Z/  [/H[?*8=TRHY)R5
M*EP;Y&K=-VUX_$*_I79U][57@YJ%_I@0W#4Z=] WJ(RE"*OZ0+?A(BGJ:\]E
MHE.P5%]<3G% 1CNVOH('*.=TNM]8'M5#O*H<G&5P]YZ]7A\&UG568A,I2$@4
MR76P;\+Z!,]/:/MWS; ZJF9'!]*;!ZN"ZQA9[S[M*.;"1@01+-^#>_6Z]J1<
MYVCW$'<0-E%3\L)L>Q^G2#=HO3$[/(G?FYJYGC$-^*OV0(.;("Z0ZK]J'4V4
M,Z2BZ8YJ1_57Q$6&9R*!2YW3BIP6CZ="MKH1<=2VP_6]@76SM$SVV%2#4:\Z
M?IZEZ)\A+;[V+BO_"<M5E.UP6I^]D+.\ADY,7QP"VOMJ@, 14;/WR/X**!(^
M*3]YR\:\88D*/D[Y09QD9^LC];\7,\G2_KB^D5%(:<\C@JTX1H"I#S:0+IQ%
M:,7=\D/*Y@7N:CWV@]YE#:ZK$LGH^MD./Z'S+]9V0O(^PO(5(UJVE*W]E,V;
M)@XN\!=!9;P;+*)/V5?W5T($MSN*;9P^(@,>?T[0K5O2G\%=ADS\=_QPQZ%*
ME;<S4M.ZF;/F@Z;1?42G/<)^-I]T5U\^@]2Z>^?#5.FPS 98WFZRO,0/DS62
MJBD</;G=)_27 TH_0Y8FFOX8S]^0VF-BA_(>"&BLM'M>!#E..D3ZP^L@SG\(
MD@I2>U/UM-:CP1H-!X]X//,]P@/-V.MBD$BT 7Z.W($ **RJT8<RU/,KA'2U
M#(HI[8_[EZ,;B ] (+^\^4IN.X&*$N2;<(JK91!0:Y^\2$5%#.\V>58];,09
M<:W,Q+% !Y>@%L'1: *.E6RU6/(/MLB<%Q@[[4<XZ^'[.B9]*<\_[8*TD+L5
MK7'(FL+%$;L8L$_E:<J&3>87UOZ[MI)N@R3(8XC[$MQF(?9[PQ2N!3IS,X"$
MPQ5D"+BOQ_@5^MREC @E6;3SQT:$#SQX?WN39T711#3(G<W7 T<S* +:LGWX
M&@D>\*1MZ(>_<Z>^7A;IM+;*^7FJF[E?K65A_,8QOXBNNFD0[BELN UC>D_:
M3P_J68?PW09>XL#A]P6,+E)<>;7"%@_N#=T4\C_#=VM(2R]-X8>$!"A7.'P:
M1^XTH$!1PSI.<+&0J =M*>PQ:9,$W&)A\WTP#[M0;]<MZ-5^5-:9U/ZFJB>.
MF\D)A((T5;K;!.D5C<$__X0$8UR_J0IND?JF0-9XE<8E^ CQ;L'H.'A$AX_>
M+K">BCXH@X 43"?)<Q 'R$?-),?WI/YR'3$&>CV/O!H'CO9XS)LN:>O>P6"R
MO(*LKU[%ZRQ?P[A$$JVX2,7I25W4#RWT7<]P!.HYH.> Q#GVP@H_J6VX#]N5
MH'I_N!IA??=:OH2][WT^I+)7P"8;9Z'.E54F+F,6NM<62:N'AQP^!"6\2,L\
M3HLX).YKVJU&D'98?UQ[Z[&F6]\K]);1O5V6P0/S;Z@BE[FBK'L#VG2Y]:*&
M:VEO$=UWP_B ?]>LZ^C)\*1X;^RQG H-GHQDK!?S8ZTWKZC:W#[D-?6\JB"Y
MC-=R3L-!A(T.#AH=O'O9#+OID VX9G+<4^,WW:VSSHAFM/M,.51R8^OR9WV=
M/\4KVFC??#&G[^LXRTDMFAF"!(31-UZN5_%:&1R@LCG.Q0ENK$[C=L\JG*5,
M#4*:E](EP-*?5VETG<,UUL:CYDU+.8JN3M3!ZE(O4;C^+79HHX^/Z=SMTZ'G
M6#H;FS/F VL[[L'9HX/[607OLMOSZ]4J0*8#$7):G,)@DZ@BF45X4M!.ZO-2
MF;@?TYB#N\%>'#DBS,D?#[R64;:^;D^\7M'M]##[KW5-XXRTL1CQ>U%8V1@]
M3M'<;_>* AMY8@%.J?/-,] -*GXOAU.4=T651S2W>4'2A&!N52OI.7&X6LD3
MD"8Z&Z/%)KH*R6*YQ%@;$7*(3"%9-H-,T$CT]G@QFBI!>WP-MG>D+DM(%(^C
M02D\G&N!_GAS^]YGYJ_ASF@QAG2'W6L<U7WCE,KR@E:(QD5O1$KG<$Q31+L9
MY5E7$*QG3"KIXOL'5*MWT_L"70;$]43\&[BF!?9Q7*U)'<&KG%1 ?5^2B-BW
M$*OMS426NCH9(."V.:$^@IQ>4'?$-"93-(6<:+U^XA0C13G1KRH"CGA=/;>'
M,F>-?N,HP^USV=.K"?F.87%:Y;E LZC_S.^XX+5!_7@=+(+P5NOV5(V*__?0
M$BC_S3#299@./ +H>Y^]A25+8=% :?6.>B,V.%%$5O<%N6>XE8-H9XJ?FN_^
MY97CASBS=IJU*LMFCFA3SP-2^;AHJN&<Q4DE>)9K/@<XHI,,. +U$)\<SED%
M:[^%"W8K8OIG"JV1RCH9?_<&(<'2#F,RO&\A/UZ51-[SML'A@>CJ5&=%<8J,
MB_TZR_$[*5>+;T< / 0,QOCN[<Q?#8L2LK4[%O@WN/]K"J/FR';:%SN/F'X-
M6AGU$QW@^T"PE\':?]&"G?:0-8TH[\H)(+.=UH H;N+BP^L<PK;::5VXA45#
M&GY+I@5]T* '&]?Q[W]7PP<$@2. 40 $!]!#X@A@- #& S2( (R)5^U@]GUF
M,9DCXKKDUZ9EU&NHT/\*?^155^DARU101HMQ>O3;1"<VGW1U*(A[[GT:U['_
MJ[",'Y&!J99MQCS '0NBX]J5[""  (9T!!HH=7-S@ $! NE??B)A9]HWYL&=
M@S0.-*OI-;[8UWU7.^UJ#=HID7@']:3@+@/-M&"%?MQ@X4]KIYWYDOU+JIUF
MO0RS2+(<!!@."Q1?5651!FF$M![$UW'(DQO-)*">!1QD;!6@-],1('/Y%0Q:
MRV8=>X-]L_X:)CC6&E5M7C*/<5?J0^$8+[^B!^.$:FV1&Q=$N(]^/MTC1BH@
M,K@1/EB1>XO$0H[$0[)?K=<07R17^0T,BBQ%%\?^,OX D_U==OC5#7P@*?-I
M^3H)'KB.Z3XPJHQW$X$&'DX/[B ""A*_?X^^!1U8\!,&_"]?IO9L6]GGI)GI
MY=BP/]_NDFP/(8TB^YBB96WBW35BF//;JVL:MLS5X^NQM5K8C@9X./@23_#L
M"- YP$_U?UEJH@_57V'=3)- >;\<$=)B46:.;D=F!G1JT,T-AI,#-#M TX-Z
M?C"BM]]J80LMA#U'>3DNF_#SDKD>H/N1 VAQ:8[C$ C!,EV^YQ 9'S\B53_,
MMO N^(1=,MA*2$.D>-0U23[=PK),H+#73SL3H%.1%TT\&1C.=D3^T$UX!.I2
M25XEK?8V,.6NX68ZT;^+O/SY-$LC7*,(6?P(,8S!U1JS7PXWZ-<]Q%5\,NUD
MH)T-VU6#^1I>$+E?')+;> _ZU)ZXD5[>IG!01VM+U%$2/=1I 4"D]%UGM-78
M^:<2KP-A?QGSVV+V7K)HH]P6Q!&H@1P-F:,%!!I(X*<.%CA/JRVDK>2]*EZV
M-D[\:&:#*"Y]O:U#_RW"O,H)FE1;4$RK[+VU]*90TKY]<('R>EEDUMPLQQ95
M\_Y"Q523 /IC7&Y:KL.E-^*R(L\V@CHI]&F,SG,$FIG 1S15[[3W)_-YL#77
MS2*LT=:Y.*8<FS\-Z!L)*4Q9%!"76\)!1 7N2'Z!;K$R7N_1/U=I1#Y&_[S;
MY#!0:&/-=-(T\$ +D*1+MR"/0 \H;9/>P 4U8*0N,-]I%N"FL;";"GX::S1S
M>3V0W"VD$=4U;>L+#:'81>EP@_#H4-",]1N#)U\',S!/=?E.M/WV$5"4E?D.
M?B1_XM;:ISZSVJM"QP,ZP5']?H*#53_2+[P'+ZFME?E4JK%+;F/^C*,OL+?O
M;1:U*93HNJ)*2)#T9Q)UO9<^NA,7:A_($>B! 7ANS[%4+K;/:M",-MF<2A,:
M?*P@SYM ]O9+W[+A$'.F!&>NSK%FWMH-O3#7VH2(KM(;K";D]>MM\3[-[@N8
M/V(OPT6ZJ\H#5Y.Z/=:9[KBB?@,/9/A1M89('L<13?M  8%ZX. 3Q]KXM>0L
M;JK0Z+-./(=>(^<E&WM!"3,&>E+L0 \]0/ #)4*PJ]S;X@BZ(J#U$>GAN81K
MS1.)N->=5Y9Q>#X&9GZ-=ON[WL%_A2P!1,G;#83EFSRK=CA$6Y:N,729U+,?
M]3PI@WR.&@0@,$ +A)/<X47RVM@LIJBU1P6'O/,F>X1YBI%MZN3A%]KX4=3;
MOAL#FD&@&^59$HD6Q"*;? ,</C5?9R5VI32MPX-]@P7K"FH_!N1K4'_N+RB4
MB?WHG5FP1C<[C9_+7F6X<.3Z+,XAR?@_W2!%:8LLG39AA<7X9!1^-6K'@68@
M*U?'\3NB>$V'#X8J.^#8TKBM=KNDL2V#8O,ZR3Y>I.L,H45N;\E-U1\.\'B
M)P"]&19T#2FNE:G;Z&S34U#3:\WJ!U+\I6FXT%HN+U2\088J>*MD4]BX15#C
M3>Q,4<]Y&3/MJE6M68F";OV4;=I &MW@^//B0$-GQ7*WN1;X#8B.XME87B+Q
M!4MBD5.^!6Y)\@Z66%Y=Y]EC','HU9ZVH&KC#^HT']Q^4"+JT4Q4PC=SX7/^
MY7O:Y>L9Z,) NBG9LM\#%?5W@45;T[UTZITEOF(D*\X@_2_"#UO3==1G7_=C
MO^734>#+9OPS+*"ICZ298ZSU>B&JVDK9K_?J>^30$JD3K7K9642$9.NJ@-0M
MS3-+F@2U?GY;-[8N*>,SJEF^M)'-HKH;KA5F08$Y]H./4)<JZH?5H\:_*'UO
M"]:XU%;7+LMO,KKV;FB\O$KWU*E@)2("OPNA*Z#N\LD-B23BLOX6U!][#64<
MX\Z,2N0MT:%%,Y;-!V+Y+@\BW?OK\.8Z F06W\JEVEK5;C#^+CF\P59)$F-'
MZYLDNP^2ZR O<=J1V,'3C %T$&A& 3K,GVM-M)C1;25?N=LW^C"LME42(-.P
MWU@6_3N!Q+Y,H]4VR\OX5_)[VL<:*;9(E2WW./P QRSA=YD=OG2X[H >&-"'
M0V) *21BU_5A'>$ +]+3]2PN=EF!2)ZM00.;QI.49%0+WZ_Q8'DO.6%C]LGE
M4&BSA(^DZ"1')+<Y [YELV!)' J*=\!I/1:L3VVR)$(BB#ZNRHQ[^M416)5E
M'M]7)8G=*#,LC+EUXGRIF\R%<=5*P38,+0>E L,'?;V)<DH=<4V]E$.$:$%A
M/(Y4"7[Q\NL7I%*PQDSN*C,HX<,I!-R,Q149^HV0N_([S03^.B?I$([1QEVV
M*8Y-T6$24=-4^;W +CE,U6K&'('WG@T4WE*89HIXW4X5K>L<[H(XJJTER9U7
M?]Q8A..[SL/.,Q? VG7!2ET6$$#P8YH<B L2D<Z"N/(VSS/6?4ZJ-P$R . 1
M_@P+SA)&@D>X5*=</JKL_";/"FY"&+.<-1GAV6/,7@:+V44+=EK$'2?^0$ZV
MZ-N@).E":IG:=*HC(,K711K?/42W0AP=@6;VI:1M3]@2%H6-=]:UO]GT??@:
M8;'!]V,>XUXX:/0668Y8):Y++<SXQM_ !@1X71  @:?U=\;%'I[4([]T8ZT^
M\RN2T5GUB%L$,\CC['66PS H2K%SK_EJ'*KE.%"+C?9A@)9H<6[?[1NM%F%R
M W<U#URMB8=>W&VP&4D2;KNQ^!#2=PDZW/-5+%\?4P=5W!57!4IMM#+42[FL
M*R?0Z--Z=G X/2Y^.*;RHGIZ>>L<Z>S!&,N3MW$:;ZNM6$;6'WD7D0-D#R4C
M8R4._<N]6V]4PA0C\S5C6X<:1Y.HS PM\R#_1"MB23[Y#KB]GPZ[#@Q>,-"Y
MBP5]+ ];+GPY?$8BHY\MK/_">'TL*JGNBL.CTW]/XAOLW3>^WUWZN+ M\\/U
MN+3'.2& %RGNHCD( 30,HVQGZH51>CX*ZFMFT4MWQ[S4LJK[::61.&67UO'(
M!QF\/S1UFN]@N$GC7_Y?>5_7W#:NI/U7<+655#E[SLQ>[I43._.Z*A.Y;&6V
M3LW%*4:";.W(I)>DG/C\^D7CBZ#8^" E->A];V9BFVBB&R#0GT_O>9/FC\%Q
ML%0QM<J&MJ191WO.==7GE"*VM0B7C]CI<\6_MV#BB!%%J8/^-RU_:GJXX!C;
M_B,>*+(^229I0M^,#D]=F(FZ&QYL08=R[FTV72;X-7*<A(F] 0 !Q=?-9R$1
MA>>LBC^B':+-0 :R-.C7NOFS'9PW_!3A# ]%)8F#,/&M:Z-BL."24:MMRQH+
MFQ?"HZ:'HXXP-C#2$T5!&Z75?J-E=;GZG_VVYM[<J:A7K:V8IG&8LW8QIZ2U
M=(Y#?K94>>5-;DH$'G4'_ELAMN9_,I/V-%/LT2BK:5E/ :Q1DL/Q]Z+^B[>+
MS8:#VF50J[#34#W)S*-]\##JHV\X[<%9Y^-L/NA^!_V]5$\^53OBUQI2$/\&
MO=9,*T5#? :9@I.$XOVFCA#Q'. "==Y:*8QO"!MN7S@<YDVX<4JD&BE\8LX'
MZR_(NS=<.T6$E*E0<-Z8_,._^P'ZF]9F7OX]:SRH-]_!68IP,Y]CU%^%AM6T
M'U3VF2/SB-*^^9VA1U?WQ05+W6!J=.,.B=,/WH%J5>Q.WQ)%DE=N&'C!&^V1
MTA,2MC].(G?:&]9Z'I6W]@M_X;M?(YDP#LRF&G7!Y#CVZUQZC@>X"KI??4*@
ML KEU?&U>I&O_04J+,++T'LT>XDA,O'!O>AECOAX]+H OG*O/1>LZ@/4\-Q>
MD@!/'L=C1 9ST/03$*:UP]1)(NA#:U+@/_6:[A[@K.;6?,XEUW1;XV2+2)!K
M(!.$BI\)J4[JH?RI3NYD!ZE.0TYH\0^4$I3HU>R4RC0W9B:< Y0G[&L(\T\)
MK6?+_F1ZJ:T4D'9J:>J@/K["1UN5'&IS8@YH4R%I4W&[6@QIILOKT=2&B5/4
MD@Y%_7,<CY-%@YY_1PJ:]LH=).)=[MO'JM[^2_GZ,"T(RT1DW;#,=UV (6RU
MHOQ3QH(D(M1B\TTC0BV^J_2[F_+ZY^H1KL_/5>TI\?&F)P+)#]7FPS<#G,4,
M64"2,81E=OU!*557294[>7&Z6+ E/UK*^;M=]OMY8!]IJ"P.ZV"2O4@:X0U;
MO$2!T!ZB_4G]%X<-QM>7+^*W#_QJVT@L#? "14K5!HMF2#%-BQEBTN.&%)[E
M^4#'\A]?V%094O;PUDW0Q!U^7P$@_T=>\LW6CV)H!C Q@JDAS(S)AQGAXV+@
MJ(GP2^<-XZV;(+5\Y(M:&(=%K<Q(K_@A,]GFB\%()H8R,U;K+1E]91&VAHZS
M)#D0W$WJH%V]_O/FR[W7C&OJ@N]4([W[1_X7W^5*^W9GZ\ITR 5I 9",N"HT
M!&B/^:GFZVT+__('/ITALB_I!5.C] \S3?H)L(KKXQ')D';_W$G8)+[&?5H1
MV,QH?/0023//Y9W&)+968\1#JY AB,C6#"^>MVVQBR&(^9"C.P^'HN/I!S$+
M]$T?SQX_U2B)S:!*27=&.B'HNZ7XAD#? U+ UGFJ+&GA/M=KB9 -R*-;,3N]
M R/ JW:01'SY(+Y6^XTB >DL1VV(+_2$C0N"4FN!*O3%1O>$6-32D?)U#W-9
M;.Y5LV_H$EWL=K"S3.\(_:!749=DP8FL!P"6JAPAU$=)'/[6D6>*/GRYMMF&
M&9&]JN=($:$:T2FD3FDGA_*CX/> *ZS!!\&XO*WY9E^*L\C,/!" #P!).$EJ
M$G[9P#8J\]N^I-LS_6C];. D1LEI:+2?3/AY =G$-&)W.0K+!A?\;#2R$%?8
MEQZ70H9TC"D@3VXEZ_[)%+,]<T@J!\B_<_;C<NJ0G;<K8TNF]_?!$C,F9)Q%
MLMZ,C#.N(^E1D5Z ?Z0Q@$$7S-T8"$AAA#$0E24=@K.!B[M\J+G<JF$;P +U
MV></<R*I;WD/ X.+.\@HZ0=V_?2\JUXY5Y7(/Z#OP^/V&5($K^\7MT;Q[/M^
MO'7ZAIBIU3;D9 (E>P<4W[MJOB4[\,]GR0Z?(@KL0SM"IL17_O:AE#ACX@90
M+0! AP2/LC@$XAE!W6C6#6=F//MS-BE<:7RBE^D("1%:7382?E/>\0:N:&LR
M-M&J?3M87'I,#P<#RMI*LZC=3V)Q<+".$ P5S*(Y#<  L\V3PQ>;'2*MV:YW
M]&'&?X9E"7 S6(PHY]T23.E? <J,H S_@U3VEV('FNRT#A9A6F31[\0))32Q
MD*HN[![YCX[$G/I8)"T@TLDB+AOB:Y0_@ YWQY^ARY&^'Y*!'=1@9D?/-Q,Z
MB4_T%DT7$&6DR5L0(PRCS7[W9;OQ1GLCM4&*  ,*,ZT1ZEC$%BQ9,EF <"2
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M\)P1&9@#;*%99F F,(C>?*ERH?,$W7%A!>T+]6T.H>B6E86B>ZRK_<.CZL/
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MM0LP-PC":'[0-1PG#.*E&CJ/#OU+GQ[A0[PI%7:AS^&&^-8ND&2V"[ .59G
M.Y->__Y" SUF/;7'"@);ZFG"I"U<=+HZ=+5$/E=<O_N%6U:5UX9#F?"%73W<
M4I^)A3S&Y4Q,Q4#/WG/PA[T9W(5*$C7KT=5E'!K:#K'LD/7);*.GYVBQT68<
MVL1D[9,U.>-^H#*3GPURLF4S=EAN/2;$DL>3&1$!8=K>'5]!A8YL<:J\Y\93
M+@S)*HRC<3BVUT,4AL\BOA#G#XDFI J%$F_#4]0:R[<,5OH.4S#G4N+K3<A,
MD\,<DJB/#.,$+;8Y17"FQ6WHHS6J03#B+G LBX$EB#90EC0&);M.W.UPZ?)]
M7V/X'7QKXX755Q&3NOIV5E_1<E40H5(VM\7.I _A77U!.(V0CI3,IFB^2_%H
M>G\#[)Z_\5W;F-_(!L"R^>^H5Y)B7L;G W+&%%TS%)1;.]@FJK$_S?C</61'
MK'+?)Y H&F+;$"V"O6P_"87A57PR85O17RM< "JY(G%H/<ZF1OB 2]283!</
M78VPK3IWX2,2@#><4OX>R :*LD%?\!MC:W"Z)PJ"U&4.G3(%Q[!IKO@+WU52
M5] )!"KMV]^)20V57Y0SN&LZ.<\"_ 26L4\K65*DZS?(_7 J4*-I,.#S=)Z_
M8+_559/=O@^QE)3^,A !94LL&PY9/O(OVQ?>J'X/"FI/G,#WXN8$G(TOVY*[
M@?LT3=C680O37[R R3<PV3WCIF3V)<R\A<%K^ND.\U&53R2KX3E[RC6@56]2
M@ZM?Q227/_CNA?]>E>VC]U.?U/][46;VG4^5PC'A:ERBQ![XKDB]659=3Q)8
M&[%]58=KF0'O37+J","Z.BU:@ :XW365"U6PD/NL3V886]J1TB)>RT$2?+<'
MQ24K%?)-54-27=I%;4H$G$]9T&$]0GD_VQ$<A^[Q9('1'LVZ'9NC7$SI2.<,
MS[M8:>R@G]T(05"WEU4JNJ.?RTI6A7)\7VU:L7O&)'D8@A>N?7.ABX(U^K,A
M&RT#R&CJC!9(R ":*%W*$D,<CLF)M*>%/BTT5;5A;IY!5M]0E+=8##0@D-[G
MFN1,/E"XQ1YIZRTT0Y%4OY7;]J[9WYO$+]RM##2DK_B77__C%^DOGDB5SJ4U
M=FH^)[)CSG64=*M+H,4$,6:IS2!\.'FI$>MLC.QH+Y)NCE)_-/>;U$K& Z:I
MTF!-Q""FS0Z6()UG-%PP4F*4M\% L92Q#?%3HHO,:-YR&)/C<MM- 9:25.M#
M"9#6_\/'_AND=R 0ES++X/MA$G$P+;MAFI@JG^87>+V7FZU=;$!S^US5&[YM
MA:J2^],;+Q$\9#=1L$26L6XE#_@3O'ZZXL\03L2P9?".80#N 0.9&<D&<86,
M]V*$K>$UF"0'ZL:SPGZKC-6M_.G>-"=YJ;G/ZZK:S-^2APWL>PERG$OAT'XK
M4(::45J&'BC5QJ!ZD56W0-D+*Q0!B1"[](*^Y&_E6IB^D#//U]<_5^+1+H-^
MJFO>I<D4T<-"A+FYYWUB&.V;#\N3^//</S_O A'5VYH_@W_=/)=;/33S0#^L
M'B_$<D25D&'=^?<!#M#/YZT"6NUJSL_45[1[U7RP $XA,G0OG'8]Z%/!#A*=
M.H^"3H3J_\)MFR"G;2J]NC8JJ]U^+8XB<>#(,BBHZKZ6C7L5'N)>_$V?5X%.
M[_"N"R3)S''QJ$? D7SPRX,6%JKY 5J19B?+S&QE!3U3\[U@W8Q9-^7<G2_R
M+I@O96X.VXBV4AJMU9U<_0QA'[EW53945E43Y<Q[^'ED0.R>VI9< J[*]KAP
MJ KQ7S\][ZI77O]>M*M'L5]Z?^?B_7[54E-D[A!9\B!N-TV5&;*]A^2!L]))
MS?I1WOQ;(2S4_U3)8;#^^1&2)LK+XQH[2OIO1('2%?B+?=NTXM81'!UT\;[C
M3\6V-)P6JW9?[, ]\>L9P9<L4*8S+:2%NYT:<^8F74%O5#6;OA@G5>*.W1,S
MN+$2(*M,36Z7(*2\QI?[]K&JM__BYX07Z^J?G50L[;7N)O V<6'C@DV_=4^X
MCF\%Z$Y_?;_I.E>E21Y\@/*/5T)YM&UL*$YC-:4.# \YDN4C#&;&NHY!N:,H
MM"MQTLU]S&:@C=X<=]<D7##0<T<'L8)>GN_AO?Y1[_7OPZUN=GJJI@$S,C'&
M?'VS226/A*OH%YXLG<=,HEF(V2U^E IQ(#$P:0<S&,W$< ,/'PA/DF^?)!8'
MJSY",)15NU-/V:X97-/LG]3&!)<%.';^J':"# 0>#)+CF?S+;H>];AK2[RPG
MPKJ9'"!BOK%K-5W:)[U*QRXRX<8U*JR->.F66EY'<F<^=%%",R:SMN7E!5O,
M".-T;0"(KC&=630O#<9.*F^?9.(5R*7)'&P!2GP<7=0F9G 7<!*;Q]BFJAD\
MF!GMIC]K[!1!&2-U0GUK^&)SW;3;)W%]>$]M\93TGYOG4EO&99!ZGR%,Z!C+
ME+J>DP:$05N,S\;V@H#,#@!J'.^Q)*I4Z;T5_UE(S[O:OFS7O%SG5N7-//J*
M_/\5)=Z5,ID*/UQ:REBM4S$5=,?V46EU6KK" \U\XA]R@*9$H%S2]VU"2M;<
MUNW85^TOX$,:V,^H?B_4PSY%$G0FU,>JW#>R!KC8'0)W+AVP3FQUY%BF![,!
MGNER#@BF*?P-C(ITH=#F"Y@<CGM>OVQ7'#^1OU:RFXDP:61Q_;)JBYW[=VA
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MBMGHNK&<,,#=I[.&7;#I#\QH/X^4QE77@OJVV HEYU/QO%4N19/<XTVJZ[J
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M?(ZV!D?T5W'\[_T4 I*&/+V0R4$"2>XK]GR2]<91SKB.=$Z#Y8]J^5CM&Z%
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MF;0*Z[.'1C$3A4*X3C=-7? =U&;NV\>JCN+2J.=5L:H9,9<: Q\OV%*$^<Z
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M%S;AH3CP0^2%*'JB+'Q%/_2*N\8K_7C^<6<%R(M6*,*VY880:)>7U+2+:W+
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MM-^9QI\6</?EX8"J*&!@\Y35PVGF9BLXLTYT %.60\6,SS#I6#^]*J?Z:ZT
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MHLG-3U@;"VMA#:.&HW#$:GE63R@(%G8,;WQ$])[0%]-(UQ](M+%)7CGQBXQ
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MYUF0BD:F6+#A28O<\*1&YG("CZV+C(%;[93HT)^Z6[^ZTA@D)1ZUKS(.M2E
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M+=J6[_H(.Z59 *99"$AO2W9%JS3U'KG/F'.! KPEY-RB0[\<:L]KZ-#0"&J
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MB._MM/# #T*R+-%/8>Q&-*8H]O9O6L#T,1+C#8MI-=(!O+UREUAJATBG88-
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M+-HG?PP4_\'FK/<LZ(EMG 0XAB;-M;@=K:&KB95F)[!W#-[>^MZ6';1B1=C
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MW'1JR-7(?;M6CJ*CLK)D]MDB&6+4FI(9[/P9IV^OA7]H7WAG8>?:2\>8LBU
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M=V5_$P$!ZP64F'N1@MSO+:T(3=O& '.X#=JHV=Q*2E.!E0Q!VKML7Z7_2/,
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M,C!F7VYE=7)O+FAT;5!+ 0(4 Q0    ( $.'AUI#A=E1NX4  "MC!  :
M          "  =$)! !E83 R,S<R.34P,65X,2TQ7VYE=7)O+FAT;5!+ 0(4
M Q0    ( $.'AUI%JB^UY#   *Y& 0 ;              "  <2/! !E83 R
M,S<R.34P,65X,3$M,5]N975R;RYH=&U02P$"% ,4    " !#AX=:<EO :#<'
M   $)P  &P              @ 'AP 0 96$P,C,W,CDU,#%E>#$R+3%?;F5U
M<F\N:'1M4$L! A0#%     @ 0X>'6B3]%JE0!P  HB<  !L
M ( !4<@$ &5A,#(S-S(Y-3 Q97@Q,BTR7VYE=7)O+FAT;5!+ 0(4 Q0    (
M $.'AUK"C?6 QP,  !L-   ;              "  =K/! !E83 R,S<R.34P
M,65X,3,M,5]N975R;RYH=&U02P$"% ,4    " !#AX=:][K/K=8#  " #0
M&P              @ ':TP0 96$P,C,W,CDU,#%E>#$S+3)?;F5U<F\N:'1M
M4$L! A0#%     @ 0X>'6GJ%%4.  @  G0<  !L              ( !Z=<$
M &5A,#(S-S(Y-3 Q97@Q-2TQ7VYE=7)O+FAT;5!+ 0(4 Q0    ( $.'AUH5
M1?J3V"8  "S:   :              "  :+:! !E83 R,S<R.34P,65X,BTQ
M7VYE=7)O+FAT;5!+ 0(4 Q0    ( $.'AUK(NS;?-U,   I& @ :
M      "  ;(!!0!E83 R,S<R.34P,65X-"TR7VYE=7)O+FAT;5!+ 0(4 Q0
M   ( $.'AUK^LNZ?%BX  '(V   -              "  2%5!0!I;6%G95\P
M,#$N:G!G4$L! A0#%     @ 0X>'6B=C[]2L%0  W?(  !$
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L &YR<VXM,C R-#$R,S%?<')E+GAM;%!+!08     $  0 %D$  !7X@8    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>ea0237295-20f_neuro_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nrsn="http://www.neurosensetx.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nrsn-20241231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrsn:OrdinarySharesNoParValuePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nrsn:WarrantsExercisableForOneOrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-26</startDate>
            <endDate>2024-06-26</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2024-06-26</startDate>
            <endDate>2024-06-26</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:LiabilityInRespectOfWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:LiabilityInRespectOfWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-26</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-26</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-26</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrsn:AllianceGlobalPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-14</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-23</startDate>
            <endDate>2023-06-23</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2023-06-23</startDate>
            <endDate>2023-06-23</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:AprilTwoThousandTwentyFourPurchaseAgrementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-10</startDate>
            <endDate>2024-04-10</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:AprilTwoThousandTwentyFourPurchaseAgrementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-10</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:AprilTwoThousandTwentyFourPurchaseAgrementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-10</startDate>
            <endDate>2024-04-10</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:AprilTwoThousandTwentyFourPurchaseAgrementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-10</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:AprilTwoThousandTwentyFourPurchaseAgrementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-10</startDate>
            <endDate>2024-04-10</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:AprilTwoThousandTwentyFourPurchaseAgrementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-10</startDate>
            <endDate>2024-04-10</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:AprilTwoThousandTwentyFourPurchaseAgrementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-10</startDate>
            <endDate>2024-04-10</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2024-06-27</startDate>
            <endDate>2024-06-27</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-06</startDate>
            <endDate>2024-08-06</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-06</startDate>
            <endDate>2024-08-06</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <instant>2024-08-06</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-16</startDate>
            <endDate>2024-08-16</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-16</startDate>
            <endDate>2024-08-16</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">nrsn:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-02</startDate>
            <endDate>2024-12-02</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-02</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">nrsn:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-02</startDate>
            <endDate>2024-12-02</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-02</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-02</startDate>
            <endDate>2024-12-02</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2024-12-02</startDate>
            <endDate>2024-12-02</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <instant>2024-12-02</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2018-12-16</startDate>
            <endDate>2018-12-16</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrsn:TwoThousandEighteenEmployeeShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-31</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrsn:TwoThousandEighteenEmployeeShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrsn:TwoThousandEighteenEmployeeShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2022-01-10</startDate>
            <endDate>2022-01-10</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2022-01-11</startDate>
            <endDate>2022-01-11</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrsn:TwoThousandEighteenEmployeeShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-01-25</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-25</startDate>
            <endDate>2022-01-25</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrsn:TwoThousandEighteenEmployeeShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrsn:TwoThousandEighteenEmployeeShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrsn:TwoThousandEighteenEmployeeShareOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2022-07-31</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2022-08-31</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-31</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-31</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrsn:TwoThousandTwentyTwoBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-20</startDate>
            <endDate>2023-03-20</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-20</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-20</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-20</startDate>
            <endDate>2023-03-20</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-20</startDate>
            <endDate>2023-03-20</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nrsn:TwoThousandTwentyTwoBonusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-20</startDate>
            <endDate>2023-03-20</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2023-03-20</startDate>
            <endDate>2023-03-20</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <instant>2023-03-20</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-20</startDate>
            <endDate>2023-03-20</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-30</startDate>
            <endDate>2023-05-30</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-30</startDate>
            <endDate>2023-05-30</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-15</startDate>
            <endDate>2023-08-15</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-15</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-15</startDate>
            <endDate>2023-08-15</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-15</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">nrsn:November12024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">nrsn:October12024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-27</startDate>
            <endDate>2024-06-27</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <instant>2024-06-27</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-30</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2024-05-31</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrsn:MrAlonBenNoonsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-27</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">nrsn:MrAlonBenNoonsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-27</startDate>
            <endDate>2024-06-27</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
        </entity>
        <period>
            <startDate>2024-12-17</startDate>
            <endDate>2024-12-17</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001875091</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">nrsn:ConsultantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Number">
        <measure>nrsn:Number</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-18771">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0" id="ixv-18772">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-18773">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-18774">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-18775">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-18776">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-18777">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0" id="ixv-18778">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-80">001-41084</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-88">NeuroSense Therapeutics Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-103">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-18779">11 HaMenofim Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-18780">Building B</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-18781">Herzliya</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-18782">4672562</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-18783">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-18784">Or Eisenberg</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-18785">11 HaMenofim Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1" id="ixv-18786">Building B</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-18787">Herzliya</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-18788">4672562</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c1" id="ixv-18789">IL</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c1" id="ixv-18790">+972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-18791">9-7996183</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c2" id="ixv-150">Ordinary Shares, no par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c2" id="ixv-154">NRSN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c2" id="ixv-18792">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c3" id="ixv-161">Warrants, exercisable for one ordinary share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c3" id="ixv-165">NRSNW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c3" id="ixv-18793">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-18794"
      unitRef="shares">23228941</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-18795">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-18796">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-18797">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-18798">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-263">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-270">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0" id="ixv-18799">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-18800">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-18801">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="c0" id="ixv-18802">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c0" id="ixv-18803">false</dei:EntityShellCompany>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c0" id="ixv-18804">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c0" id="ixv-12103">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;Our current cybersecurity
risk assessment and protection program consists of various cybersecurity software features designed to protect our systems and data and
alert us of any cybersecurity incidents, such as software to strengthen protection against forms of malware, including ransomware, spyware,
keyloggers and adware and various measures which limit the ability of different sectors within our organization to access certain types
of information. We also maintain backups to our systems and data which would help us in recovery and mitigation in the event of a cybersecurity
incident. Additionally, we work with external service providers that provide us with information technology services, including the assessment
and identification of risks from cybersecurity threats and to help manage our risk assessment program.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;The oversight of cybersecurity
threats is undertaken by our CFO, who has experience in various leadership and consultancy roles. In the event of a material incident
or threat, our CEO is notified as well. The CEO would then be expected to report the threat to the audit committee of the Board of Directors,
which is responsible for oversight of strategic, financial and other major risks to the Company, which could include those posed by cybersecurity
threats. The level of each risk would be determined by considering the impact of the risk itself and the likelihood of the risk materializing
and high scoring risks are actioned upon. The Company&#x2019;s risk assessment occurs annually, or as business needs change, and covers identification
of risks that could act against the company&#x2019;s objectives as well as specific risks related to a compromise to the security of data.&#160;See
&#x201c;Item 3.D Risk Factors&#x2014;Risks Related to Our Business and Strategy&#x2014;Our internal computer systems, or those of our CROs
or other contractors or consultants, may fail or suffer security breaches, which could result in a disruption of our drug development
programs.&#x201d;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;As of the date of this report,
we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially
affect us, including our business strategy, results of operations or financial condition.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c0" id="ixv-18805">The oversight of cybersecurity
threats is undertaken by our CFO, who has experience in various leadership and consultancy roles. In the event of a material incident
or threat, our CEO is notified as well. The CEO would then be expected to report the threat to the audit committee of the Board of Directors,
which is responsible for oversight of strategic, financial and other major risks to the Company, which could include those posed by cybersecurity
threats.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c0" id="ixv-18806">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c0" id="ixv-18807">The CEO would then be expected to report the threat to the audit committee of the Board of Directors</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c0" id="ixv-18808">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="c0" id="ixv-18809">we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially
affect us, including our business strategy, results of operations or financial condition.</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c0" id="ixv-18810">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <dei:AuditorFirmId contextRef="c0" id="ixv-18811">1057</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="c0" id="ixv-12667">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Opinion on the Consolidated Financial Statements&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;We have audited the accompanying
consolidated statements of financial position of NeuroSense Therapeutics Ltd. and its subsidiaries (the &#x201c;Company&#x201d;) as of December
31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, changes in equity (deficit), and cash flows
for each of the years in the three-year period ended December&#160;31, 2024, and the related notes (collectively, the &#x201c;consolidated
financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in
the three-year period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.&#160;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="c0" id="ixv-18812">Somekh Chaikin</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-18813">Tel-Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" id="ixv-18814" unitRef="usd">3378000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c5" decimals="-3" id="ixv-18815" unitRef="usd">2640000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c4" decimals="-3" id="ixv-18816" unitRef="usd">989000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c5" decimals="-3" id="ixv-18817" unitRef="usd">236000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent contextRef="c4" decimals="-3" id="ixv-18818" unitRef="usd">35000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent contextRef="c5" decimals="-3" id="ixv-18819" unitRef="usd">40000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="-3" id="ixv-18820" unitRef="usd">4402000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c5" decimals="-3" id="ixv-18821" unitRef="usd">2916000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" id="ixv-18822" unitRef="usd">66000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="-3" id="ixv-18823" unitRef="usd">85000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="-3" id="ixv-18824" unitRef="usd">84000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c5" decimals="-3" id="ixv-18825" unitRef="usd">162000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="c4" decimals="-3" id="ixv-18826" unitRef="usd">23000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent contextRef="c5" decimals="-3" id="ixv-18827" unitRef="usd">22000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c4" decimals="-3" id="ixv-18828" unitRef="usd">173000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c5" decimals="-3" id="ixv-18829" unitRef="usd">269000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c4" decimals="-3" id="ixv-18830" unitRef="usd">4575000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c5" decimals="-3" id="ixv-18831" unitRef="usd">3185000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c4" decimals="-3" id="ixv-18832" unitRef="usd">1160000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c5" decimals="-3" id="ixv-18833" unitRef="usd">1459000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-18834" unitRef="usd">832000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-18835" unitRef="usd">2000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-18836" unitRef="usd">1992000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-18837" unitRef="usd">3459000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c5" decimals="-3" id="ixv-18838" unitRef="usd">73000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c5" decimals="-3" id="ixv-18839" unitRef="usd">1412000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:LiabilitiesNoncurrent contextRef="c5" decimals="-3" id="ixv-18840" unitRef="usd">1485000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c4" decimals="-3" id="ixv-18841" unitRef="usd">1992000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c5" decimals="-3" id="ixv-18842" unitRef="usd">4944000</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c4"
      decimals="INF"
      id="ixv-18843"
      unitRef="shares">90000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c5"
      decimals="INF"
      id="ixv-18844"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c4"
      decimals="INF"
      id="ixv-18845"
      unitRef="shares">23228941</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-18846"
      unitRef="shares">23228941</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c5"
      decimals="INF"
      id="ixv-18847"
      unitRef="shares">15379042</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="ixv-18848"
      unitRef="shares">15379042</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c4" decimals="-3" id="ixv-18849" unitRef="usd">39243000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c5" decimals="-3" id="ixv-18850" unitRef="usd">24362000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="-3" id="ixv-18851" unitRef="usd">-36660000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c5" decimals="-3" id="ixv-18852" unitRef="usd">-26121000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-18853" unitRef="usd">2583000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-18854" unitRef="usd">-1759000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="-3" id="ixv-18855" unitRef="usd">4575000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c5" decimals="-3" id="ixv-18856" unitRef="usd">3185000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-18857" unitRef="usd">5698000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-18858" unitRef="usd">7274000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-18859" unitRef="usd">5587000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-18860" unitRef="usd">4204000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-18861" unitRef="usd">4775000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-18862" unitRef="usd">4967000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-18863" unitRef="usd">-9902000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="-3" id="ixv-18864" unitRef="usd">-12049000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="-3" id="ixv-18865" unitRef="usd">-10554000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-18866" unitRef="usd">-308000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c6" decimals="-3" id="ixv-18867" unitRef="usd">1942000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c7" decimals="-3" id="ixv-18868" unitRef="usd">62000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-18869" unitRef="usd">-10210000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-18870" unitRef="usd">-10107000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-18871" unitRef="usd">-10492000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-18872"
      unitRef="usdPershares">-0.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-18873"
      unitRef="usdPershares">-0.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="ixv-18874"
      unitRef="usdPershares">-0.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-18875"
      unitRef="usdPershares">-0.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="ixv-18876"
      unitRef="usdPershares">-0.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-18877"
      unitRef="usdPershares">-0.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="ixv-18878"
      unitRef="shares">18602082</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-18879"
      unitRef="shares">18602082</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="INF"
      id="ixv-18880"
      unitRef="shares">13640168</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="INF"
      id="ixv-18881"
      unitRef="shares">13640168</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="INF"
      id="ixv-18882"
      unitRef="shares">11504521</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="INF"
      id="ixv-18883"
      unitRef="shares">11504521</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c8"
      decimals="INF"
      id="ixv-18884"
      unitRef="shares">10943534</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" id="ixv-18885" unitRef="usd">16356000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" id="ixv-18886" unitRef="usd">-5522000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c11" decimals="-3" id="ixv-18887" unitRef="usd">10834000</us-gaap:StockholdersEquity>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c13" decimals="-3" id="ixv-18888" unitRef="usd">96000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c7" decimals="-3" id="ixv-18889" unitRef="usd">96000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c12"
      decimals="INF"
      id="ixv-18890"
      unitRef="shares">838429</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c13" decimals="-3" id="ixv-18891" unitRef="usd">3870000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c7" decimals="-3" id="ixv-18892" unitRef="usd">3870000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c13" decimals="-3" id="ixv-18893" unitRef="usd">1728000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c7" decimals="-3" id="ixv-18894" unitRef="usd">1728000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss contextRef="c14" decimals="-3" id="ixv-18895" unitRef="usd">-10492000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-18896" unitRef="usd">-10492000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c15"
      decimals="INF"
      id="ixv-18897"
      unitRef="shares">11781963</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" id="ixv-18898" unitRef="usd">21858000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="-3" id="ixv-18899" unitRef="usd">-16014000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" id="ixv-18900" unitRef="usd">5844000</us-gaap:StockholdersEquity>
    <nrsn:StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet
      contextRef="c19"
      decimals="INF"
      id="ixv-18901"
      unitRef="shares">1333600</nrsn:StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet>
    <nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet contextRef="c20" decimals="-3" id="ixv-18902" unitRef="usd">806000</nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet>
    <nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet contextRef="c6" decimals="-3" id="ixv-18903" unitRef="usd">806000</nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet>
    <nrsn:StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants
      contextRef="c19"
      decimals="INF"
      id="ixv-18904"
      unitRef="shares">2263479</nrsn:StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c20" decimals="-3" id="ixv-18905" unitRef="usd">1698000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c6" decimals="-3" id="ixv-18906" unitRef="usd">1698000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss contextRef="c21" decimals="-3" id="ixv-18907" unitRef="usd">-10107000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-18908" unitRef="usd">-10107000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c22"
      decimals="INF"
      id="ixv-18909"
      unitRef="shares">15379042</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="-3" id="ixv-18910" unitRef="usd">24362000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="-3" id="ixv-18911" unitRef="usd">-26121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-18912" unitRef="usd">-1759000</us-gaap:StockholdersEquity>
    <nrsn:StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet
      contextRef="c25"
      decimals="INF"
      id="ixv-18913"
      unitRef="shares">5981238</nrsn:StockIssuedDuringPeriodSharesIssuanceOfSharesAndPrefundedWarrantsNet>
    <nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet contextRef="c26" decimals="-3" id="ixv-18914" unitRef="usd">10806000</nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet>
    <nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet contextRef="c0" decimals="-3" id="ixv-18915" unitRef="usd">10806000</nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet>
    <nrsn:StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants
      contextRef="c25"
      decimals="INF"
      id="ixv-18916"
      unitRef="shares">1573000</nrsn:StockIssuedDuringPeriodSharesStockOptionsExercisedofPre-fundedWarrants>
    <nrsn:StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement
      contextRef="c25"
      decimals="INF"
      id="ixv-18917"
      unitRef="shares">224697</nrsn:StockIssuedDuringPeriodSharesIssuanceOfSharesDueToSEPAAagreement>
    <nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement contextRef="c26" decimals="-3" id="ixv-18918" unitRef="usd">281000</nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement>
    <nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement contextRef="c0" decimals="-3" id="ixv-18919" unitRef="usd">281000</nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="c26" decimals="-3" id="ixv-18920" unitRef="usd">1695000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="c27" decimals="-3" id="ixv-18921" unitRef="usd">-329000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="c0" decimals="-3" id="ixv-18922" unitRef="usd">1366000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <nrsn:StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity contextRef="c26" decimals="-3" id="ixv-18923" unitRef="usd">1434000</nrsn:StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity>
    <nrsn:StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity contextRef="c0" decimals="-3" id="ixv-18924" unitRef="usd">1434000</nrsn:StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c25"
      decimals="INF"
      id="ixv-18925"
      unitRef="shares">70964</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c26" decimals="-3" id="ixv-18926" unitRef="usd">665000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-18927" unitRef="usd">665000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss contextRef="c27" decimals="-3" id="ixv-18928" unitRef="usd">-10210000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-18929" unitRef="usd">-10210000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c28"
      decimals="INF"
      id="ixv-18930"
      unitRef="shares">23228941</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c29" decimals="-3" id="ixv-18931" unitRef="usd">39243000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c30" decimals="-3" id="ixv-18932" unitRef="usd">-36660000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-18933" unitRef="usd">2583000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-18934" unitRef="usd">-10210000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-18935" unitRef="usd">-10107000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-18936" unitRef="usd">-10492000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" id="ixv-18937" unitRef="usd">22000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c6" decimals="-3" id="ixv-18938" unitRef="usd">21000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c7" decimals="-3" id="ixv-18939" unitRef="usd">12000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-18940" unitRef="usd">557000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="-3" id="ixv-18941" unitRef="usd">1537000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="-3" id="ixv-18942" unitRef="usd">1728000</us-gaap:ShareBasedCompensation>
    <nrsn:RevaluationOfLiabilityInRespectToWarrants contextRef="c0" decimals="-3" id="ixv-18943" unitRef="usd">46000</nrsn:RevaluationOfLiabilityInRespectToWarrants>
    <nrsn:RevaluationOfLiabilityInRespectToWarrants contextRef="c6" decimals="-3" id="ixv-18944" unitRef="usd">2191000</nrsn:RevaluationOfLiabilityInRespectToWarrants>
    <us-gaap:OtherNoncashExpense contextRef="c0" decimals="-3" id="ixv-18945" unitRef="usd">323000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense contextRef="c6" decimals="-3" id="ixv-18946" unitRef="usd">473000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense contextRef="c7" decimals="-3" id="ixv-18947" unitRef="usd">41000</us-gaap:OtherNoncashExpense>
    <nrsn:DecreaseInOperatingRightOfUseAsset contextRef="c0" decimals="-3" id="ixv-18948" unitRef="usd">78000</nrsn:DecreaseInOperatingRightOfUseAsset>
    <nrsn:DecreaseInOperatingRightOfUseAsset contextRef="c6" decimals="-3" id="ixv-18949" unitRef="usd">74000</nrsn:DecreaseInOperatingRightOfUseAsset>
    <nrsn:DecreaseInOperatingRightOfUseAsset contextRef="c7" decimals="-3" id="ixv-18950" unitRef="usd">70000</nrsn:DecreaseInOperatingRightOfUseAsset>
    <nrsn:DecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-18951" unitRef="usd">69000</nrsn:DecreaseInOperatingLeaseLiability>
    <nrsn:DecreaseInOperatingLeaseLiability contextRef="c6" decimals="-3" id="ixv-18952" unitRef="usd">69000</nrsn:DecreaseInOperatingLeaseLiability>
    <nrsn:DecreaseInOperatingLeaseLiability contextRef="c7" decimals="-3" id="ixv-18953" unitRef="usd">95000</nrsn:DecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c0" decimals="-3" id="ixv-18954" unitRef="usd">753000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c6" decimals="-3" id="ixv-18955" unitRef="usd">-19000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c7" decimals="-3" id="ixv-18956" unitRef="usd">-55000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c0" decimals="-3" id="ixv-18957" unitRef="usd">-299000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c6" decimals="-3" id="ixv-18958" unitRef="usd">961000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c7" decimals="-3" id="ixv-18959" unitRef="usd">459000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c0" decimals="-3" id="ixv-18960" unitRef="usd">262000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c6" decimals="-3" id="ixv-18961" unitRef="usd">928000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c7" decimals="-3" id="ixv-18962" unitRef="usd">606000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-18963" unitRef="usd">-10135000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c6" decimals="-3" id="ixv-18964" unitRef="usd">-8354000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="-3" id="ixv-18965" unitRef="usd">-7616000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" id="ixv-18966" unitRef="usd">3000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c6" decimals="-3" id="ixv-18967" unitRef="usd">29000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c7" decimals="-3" id="ixv-18968" unitRef="usd">70000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <nrsn:RedemptionofinvestmentInShorttermDeposits contextRef="c6" decimals="-3" id="ixv-18969" unitRef="usd">3500000</nrsn:RedemptionofinvestmentInShorttermDeposits>
    <nrsn:RedemptionofinvestmentInShorttermDeposits contextRef="c7" decimals="-3" id="ixv-18970" unitRef="usd">-3500000</nrsn:RedemptionofinvestmentInShorttermDeposits>
    <nrsn:RedemptionOfinvestmentInRestrictedDepositNet contextRef="c0" decimals="-3" id="ixv-18971" unitRef="usd">-4000</nrsn:RedemptionOfinvestmentInRestrictedDepositNet>
    <nrsn:RedemptionOfinvestmentInRestrictedDepositNet contextRef="c6" decimals="-3" id="ixv-18972" unitRef="usd">3000</nrsn:RedemptionOfinvestmentInRestrictedDepositNet>
    <nrsn:RedemptionOfinvestmentInRestrictedDepositNet contextRef="c7" decimals="-3" id="ixv-18973" unitRef="usd">20000</nrsn:RedemptionOfinvestmentInRestrictedDepositNet>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-18974" unitRef="usd">1000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c6" decimals="-3" id="ixv-18975" unitRef="usd">3468000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c7" decimals="-3" id="ixv-18976" unitRef="usd">-3590000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfOtherEquity contextRef="c7" decimals="-3" id="ixv-18977" unitRef="usd">96000</us-gaap:PaymentsForRepurchaseOfOtherEquity>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c6" decimals="-3" id="ixv-18978" unitRef="usd">5000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c7" decimals="-3" id="ixv-18979" unitRef="usd">3870000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c0" decimals="-3" id="ixv-18980" unitRef="usd">11304000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c6" decimals="-3" id="ixv-18981" unitRef="usd">4334000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c0" decimals="-3" id="ixv-18982" unitRef="usd">391000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c6" decimals="-3" id="ixv-18983" unitRef="usd">364000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-18984" unitRef="usd">10913000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c6" decimals="-3" id="ixv-18985" unitRef="usd">3975000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c7" decimals="-3" id="ixv-18986" unitRef="usd">3774000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c0" decimals="-3" id="ixv-18987" unitRef="usd">-41000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c6" decimals="-3" id="ixv-18988" unitRef="usd">8000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c7" decimals="-3" id="ixv-18989" unitRef="usd">-88000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations contextRef="c0" decimals="-3" id="ixv-18990" unitRef="usd">738000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations contextRef="c6" decimals="-3" id="ixv-18991" unitRef="usd">-903000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations contextRef="c7" decimals="-3" id="ixv-18992" unitRef="usd">-7520000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectContinuingOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="-3" id="ixv-18993" unitRef="usd">2640000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c18" decimals="-3" id="ixv-18994" unitRef="usd">3543000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c11" decimals="-3" id="ixv-18995" unitRef="usd">11063000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" id="ixv-18996" unitRef="usd">3378000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="-3" id="ixv-18997" unitRef="usd">2640000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c18" decimals="-3" id="ixv-18998" unitRef="usd">3543000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <nrsn:ReclassificationOfWarrantsIntoEquity contextRef="c0" decimals="-3" id="ixv-18999" unitRef="usd">1366000</nrsn:ReclassificationOfWarrantsIntoEquity>
    <nrsn:BonusAccrualReclassificationToEquity contextRef="c0" decimals="-3" id="ixv-19000" unitRef="usd">1434000</nrsn:BonusAccrualReclassificationToEquity>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c7" decimals="-3" id="ixv-19001" unitRef="usd">306000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <nrsn:NoncashOrPartNoncashAcquisitionInterestReceived contextRef="c0" decimals="-3" id="ixv-19002" unitRef="usd">2000</nrsn:NoncashOrPartNoncashAcquisitionInterestReceived>
    <nrsn:NoncashOrPartNoncashAcquisitionInterestReceived contextRef="c6" decimals="-3" id="ixv-19003" unitRef="usd">179000</nrsn:NoncashOrPartNoncashAcquisitionInterestReceived>
    <nrsn:NoncashOrPartNoncashAcquisitionInterestReceived contextRef="c7" decimals="-3" id="ixv-19004" unitRef="usd">49000</nrsn:NoncashOrPartNoncashAcquisitionInterestReceived>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0" id="ixv-14807">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 1 - General&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NeuroSense Therapeutics Ltd. (&#x201c;NeuroSense&#x201d; or the &#x201c;Company&#x201d;) was incorporated in Israel on February 13, 2017. NeuroSense is a clinical-stage pharmaceutical company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. The Company&#x2019;s lead product candidate, PrimeC, is a novel oral formulation of a fixed dose combination composed of a specific ratio and doses of two FDA-approved drugs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;In addition to PrimeC, the Company
has initiated research and development efforts in Alzheimer&#x2019;s disease and Parkinson&#x2019;s disease, with a similar strategy of
combined products.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company&#x2019;s ordinary shares
and warrants began trading on the Nasdaq Capital Market on&#160;December 9, 2021&#160;under the ticker symbols &#x201c;NRSN&#x201d; and
&#x201c;NRSNW,&#x201d; respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company currently has no products approved for sale and the Company&#x2019;s operations have been funded primarily by its shareholders. To date, the Company has generated no sales or revenues, has incurred losses and expects to incur significant additional losses due to the continuing focus on the research, development, clinical activities of its product candidates, preclinical programs, business development, organizational structure and to advance the programs within the Company&#x2019;s pipeline. Consequently, its operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in the research and development of pharmaceutical compounds. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Based on current expected level of
operating expenditures, the Company&#x2019;s cash resources as at December 31, 2024 shall not be sufficient to fund the Company&#x2019;s
operations for a period of at least 12 months from the approval of these consolidated financial statements, assuming that the Company
will continue its development plan in accordance with the original pipeline and without delaying or slowing down the progress of its plans.
The Company will require additional cash to fund the execution of its mid and long-term development program. The Company anticipates raising
additional funds through public or private sales of debt or equity securities, collaborative arrangements, or some combination thereof.
Whilst management is progressing with its plans to secure external financing, these still require approval by third parties, and accordingly,
there is no assurance that any such arrangement will be entered into or that financing will be available when needed in order to allow
it to continue its operations, or if available, on terms favorable or acceptable to it.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
the event financing is not obtained, the Company may pursue cost cutting measures or may be required to delay, reduce the scope of,
or eliminate any of its development programs or clinical trials, these events could have a material adverse effect on its business.
These factors&#160;raise substantial doubt&#160;about the Company ability to continue as a going concern. The consolidated financial
statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and
classification of liabilities that might be necessary should the Company be unable to continue as a going concern. &lt;/span&gt;The
going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of
business.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On October 3, 2022, the Company established a US based subsidiary, NeuroSense US Inc. (&#x201c;US Subsidiary&#x201d;). From establishment through December 31, 2024, the US Subsidiary had no activity. The U.S. subsidiary was formed to perform research and development activity and engage in possible collaboration agreements. On July, 2023, the Company established a German based subsidiary, NeuroSense GmbH (&#x201c;NeuroSense GmbH &#x201c;). NeuroSense GmbH was formed to perform research and development activity and engage in possible collaboration agreements. From establishment through December 31, 2024, NeuroSense GmbH had no material activity.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In October 2023, Hamas terrorists infiltrated Israel&#x2019;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Following the attack, Israel&#x2019;s security cabinet declared war against Hamas and commenced a military campaign against Hamas. In addition, since the commencement of these events, there have been continued hostilities along Israel&#x2019;s northern border with Lebanon (with the Hezbollah terror organization), Israel&#x2019;s southern border with the Gaza Strip (with the Hamas terrorist organization) and on other fronts from various extremist groups in region, such as the Houthis in Yemen and various rebel militia groups in Syria and Iraq. Further, on April 13, 2024, and on October 1, 2024, Iran launched a series of drone and missile strikes against Israel. As of December 31, 2024 a ceasefire agreement has been reached between Israel the Hezbollah terror organization in Lebanon. To date the Company&#x2019;s operations and financial results have not been materially affected. Since the war broke out in October 2023, the Company&#x2019;s operations have not been adversely affected by this situation, and it has not experienced disruptions to its clinical studies. As such, its clinical and business development activities remain on track. However, the intensity and duration of Israel&#x2019;s current war against Hamas and Hezbollah is difficult to predict at this stage, as are such war&#x2019;s economic implications on its business and operations and on Israel&#x2019;s economy in general. If the ceasefire declared collapses or a new war commences or hostilities expand to other fronts, its operations may be adversely affected.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <dei:EntityIncorporationDateOfIncorporation contextRef="c0" id="ixv-19005">2017-02-13</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-14880">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 2 - Significant Accounting Policy&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basis of presentation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
consolidated financial statements have been prepared in accordance accounting principles generally accepted in the United States of America
(&#x201c;US GAAP&#x201d;)&lt;/span&gt; assuming the Company will continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Use of estimates in preparation of consolidated financial statements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts
reported in the consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including
those related to fair value of financial instruments and share based compensation. The Company&#x2019;s management believes that the estimates,
judgment, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and
assumptions can affect the reported amounts of assets and liabilities and disclosure of liabilities at the dates of the consolidated financial
statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Functional currency&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The functional currency of the Company and its subsidiaries, all of which are primarily direct and integral component of the Company&#x2019;s
operation, is the U.S. dollar (&#x201c;$&#x201d; or &#x201c;dollar&#x201d;), as the dollar is primary currency of the economic environment
in which the Company and its subsidiaries have operated and expects to continue to operate in foreseeable future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;In accordance with ASC 830, &#x201c;Foreign
Currency Matters&#x201d;, balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing
at the applicable balance sheet date. For foreign currency transactions included in the consolidated statement of operations and comprehensive
loss, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates
used in the translation of such transactions are presented within financing income or expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principles of Consolidation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The consolidated financial statements
include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated upon
consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;E.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cash and cash equivalents&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Cash and cash equivalents include highly
liquid investments, including short-term bank deposits (with original maturity dates of up to three months from date of deposit) that
are not restricted as to withdrawal or use.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;F.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Short-term deposits&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Short-term deposits in banking institutions
for periods in excess of three months following the date of deposit. The deposits are presented in accordance with the terms of their
deposit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;G.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Restricted deposits&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Restricted deposits consist of deposits
held in restricted deposit bank accounts including deposits held as collateral for guarantees to third parties, classified as current
or non-current based on expected timing of the disbursement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;H.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Property and equipment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets. When an asset is disposed of, the related cost and accumulated depreciation are removed from the respective accounts and the net
difference less any amount realized from disposition is reflected in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company&#x2019;s long-lived assets are
reviewed for impairment in accordance with ASC 360, &#x201c;Property, Plant and Equipment&#x201d;, whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.
To date, the Company has not incurred any impairment losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The lives used in computing straight-line
depreciation for financial reporting purposes are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="width: 80%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 19%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computers and peripherals and equipment&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7 - 15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-55"&gt;The shorter of the lease term and the useful life&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;I.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Research and development costs are
expensed as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;J.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company measures and discloses
fair value in accordance with the ASC 820, &#x201c;Fair Value Measurements and Disclosures&#x201d; which defines fair value, establishes
a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements.
Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined
based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions
there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level 1 - unadjusted quoted prices
are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level 2 - pricing inputs are other
than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level 3 - pricing inputs are unobservable
for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability
at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Level
3 inputs are considered as the lowest priority within the fair value hierarchy. The valuation of certain financial instruments classified
under fair value through profit or loss category falls under this category.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;This hierarchy requires the Company
to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;As of the reported periods, the fair
values of the Company&#x2019;s cash, cash equivalents, short-term bank deposits, current and non-current restricted deposits, other current
assets, trade payables and other current liabilities approximated the carrying values of these instruments presented in the Company&#x2019;s
consolidated balance sheets because of their nature.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;K.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Concentrations of credit risk&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Financial instruments that potentially
subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents as well as certain other current assets
that do not amount to a significant amount. Cash and cash equivalents, which are primarily held in dollar and New Israeli Shekels (NIS),
are deposited with major bank in Israel. Management believes that such financial institutions are financially sound and, accordingly,
minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration
of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;L.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company entered into non-cancelable
lease agreements for offices for use in its operations, which are classified as operating leases (see below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company applies ASC 842, &#x201c;Leases&#x201d;
under which the Company determines if an arrangement is a lease at inception. The Company&#x2019;s assessment is based on: (i) whether
the contract involves the use of an identified asset, (ii) whether the Company obtains the right to substantially all of the economic
benefits from the use of the asset throughout the period of use, and (iii) whether the Company has the right to direct the use of the
asset.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Leases are classified as either finance
leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers
ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain
to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset, (iv) the present value of the lease
payments equals or exceeds substantially all of the fair value of the asset, or (v) the underlying asset is of such a specialized nature
that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if
it does not meet any one of these criteria. Since all the Company&#x2019;s lease contracts for premises do not meet any of the criteria
above, the Company concluded that all its lease contracts should be classified as operating leases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Right of Use (&#x201c;ROU&#x201d;) assets
and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For
this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company&#x2019;s
leases do not provide an implicit rate, the Company uses its Incremental Borrowing Rate (&#x201c;IBR&#x201d;) based on the information available
on the commencement date in determining the present value of lease payments. The Company&#x2019;s IBR is estimated to approximate the interest
rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The
ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover,
the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease
had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, &#x201c;Property, Plant, and Equipment
- Overall&#x201d;, to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases
include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset
and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless
it is reasonably certain that the Company will not exercise the option.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;M.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Commitment and contingencies&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies under which a provision is recorded when it is both probable that liability has
been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted
to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events
pertaining to a particular matter.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;N.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 6pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Employee benefit plans &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company&#x2019;s liability for severance
pay to its Israeli employees is subject to Section 14 of the Israeli Severance Compensation Act, 1963 (&#x201c;Section 14&#x201d;), pursuant
to which all of the Company&#x2019;s employees are entitled to monthly deposits by the Company, at a rate of 8.33% of their monthly salary,
made in the employee&#x2019;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release
the Company from any future severance payments in respect of those employees. The fund is made available to the employee at the time the
employer-employee relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section
14 are not reflected in the balance sheets as the severance pay risks have been irrevocably transferred to the severance funds. All deposits
required through December 31, 2024 have been made.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;O.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Income taxes&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company accounts for income taxes
in accordance with ASC 740, &#x201c;Income Taxes&#x201d;. Accordingly, deferred income taxes are determined utilizing the asset and liability
method based on the estimated future tax effects of differences between the financial statement carrying amount and the tax bases of assets
and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax rates expected to be in effect
when these differences reverse. A valuation allowance in respect of deferred tax assets is provided for, if necessary, to reduce deferred
tax assets to the amounts more likely than not to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company implements a&#160;two-step&#160;approach
to recognize and measure tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by
determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits,
the tax position will be sustained on examination, including resolution of any related appeals or litigation processes. The second step
is to measure the tax benefit as the largest amount that is greater than&#160;50% likely to be realized upon settlement. The Company&#x2019;s
accounting policy is to classify interest and penalties relating to income taxes under income taxes, however the Company did not recognize
such items in its consolidated financial statements during the reported periods and did not recognize any liability with respect to an
unrecognized tax benefits in its balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.9pt; "&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;P.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock-based compensation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company&#x2019;s employees&#x2019;
and directors&#x2019; share-based payment awards are classified as equity awards. The Company accounts for these awards using the grant-date
fair value method. For employees, the fair value of share-based payment transactions is recognized as an expense over the requisite service
period for each separately vesting tranche of the award as if the award is, in-substance, multiple awards. Forfeitures are recognized
as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;For nonemployees, compensation costs
are recognized in the same period and in the same manner the Company would if it had paid cash for those goods or services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Q.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basic and diluted net loss per share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Basic net loss per share is computed
using the weighted average number of ordinary shares, pre-funded warrants to purchase ordinary shares for an exercise price of $0.0001&#160;which
are exercisable immediately and fully vested restricted share units (RSUs) outstanding during the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Diluted loss per share gives effect
to all potentially dilutive common shares outstanding during the year using the treasury stock method with respect to options and non-vested
RSUs granted under employee stock compensation plan and certain warrants granted through its Initial Public Offering (IPO) and using the
if-converted method with respect to certain warrants granted through registered direct offering and accounted for as derivative liability.
In computing diluted loss per share, the average share price for the period is used in determining the number of shares assumed to be
purchased from the exercise of share options or warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;During the reported periods, all outstanding
share options, warrants and non-vested RSUs have been excluded from the calculation of the diluted net loss per share as all such securities
are anti-dilutive for all years presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;R.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Segment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company&#x2019;s chief operating
decision maker (&#x201c;CODM&#x201d;) is its Chief Executive Officer. The CODM reviews financial information on an aggregate basis for the
purposes of evaluating financial performance and allocating the Company&#x2019;s resources. Accordingly, the Company has determined that
it operates in one segment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;S.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Share capital&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Ordinary shares are classified as equity.
Incremental costs directly attributable to the issuance of the shares are recognized as a deduction from equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;T.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Contracts over own equity&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;When the Company becomes party to freestanding
financial instruments, the Company first analyzes the provisions of ASC&#160;480 in order to determine whether the instrument should be
classified as a liability, with subsequent changes in fair value recognized in the statements of operations in each period. Warrants to
purchase ordinary shares are not within the scope of ASC&#160;480, and as such the Company further analyzes the provisions of ASC&#160;815-40&#160;in
order to determine whether the contract should be classified within equity or classified as a liability, with subsequent changes in fair
value recognized in the statements of operations in each period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company reassesses the classification
of a contract over its own equity under the guidance above at each balance sheet date. If classification changes as a result of events
during the reporting period, the Company reclassifies the contract as of the date of the event that caused the reclassification. When
a contract over own equity is reclassified from a liability to equity, gains or losses recorded to account for the contract at fair value
during the period that the contract was classified as a liability are not reversed, and the contract is marked to fair value immediately
before the reclassification.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;U.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Recently
adopted accounting pronouncements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;In&#160;August 2020,&#160;the FASB issued ASU&#160;2020-06&#160;&#x201c;Debt-
Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging- Contracts in Entity&#x2019;s Own Equity (Subtopic&#160;815-40)
(&#x201c;ASU&#160;2020-06&#x201d;): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d;. This guidance
simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments
and contracts on an entity&#x2019;s own equity. Furthermore, ASU&#160;2020-06&#160;requires the application of the if-converted method
for calculating diluted earnings per share. ASU 2020-06 is effective for the Company for annual periods beginning after December 15,
2023,&#160;and interim periods within those fiscal years. The Company adopted this guidance on January 1, 2024, and there was no material
impact on the Company&#x2019;s consolidated balance sheet and the consolidated statements of operations and comprehensive loss upon adoption.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;In November 2023, the FASB issued ASU 2023-07 &#x201c;Segment
Reporting: Improvements to Reportable Segment Disclosures&#x201d; which expands public entities&#x2019; segment disclosures primarily by
requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within
each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures
of a reportable segment&#x2019;s profit or loss and assets. Public entities with a single reportable segment are required to provide the
new disclosures and all the disclosures required under ASC 280.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The guidance is effective for the Company&#x2019;s
annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company
has adopted this standard for the fiscal year 2024 annual financial statements and interim financial statements thereafter and has applied
this standard retrospectively for all prior periods presented in the financial statements. See&#160;Note 15 &#x2013; Segment Reporting&#160;for
further information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;V.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Recently issued accounting pronouncements, not yet adopted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;As an emerging growth company, the
Jumpstart Our Business Startup Act (&#x201c;JOBS Act&#x201d;) allows the Company to delay adoption of new or revised accounting pronouncements
applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this
extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-09 &#x201c;Improvements to Income Tax Disclosures&#x201d; which
improves the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in
the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain amendments to improve income
tax disclosures effectiveness. The guidance is effective for the Company&#x2019;s annual periods beginning January 1, 2026, with early
adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on the consolidated financial
statement disclosures.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;In November 2024, the FASB issued ASU No. 2024-03 Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense
Disaggregation Disclosures (Subtopic 220-40). The ASU improves the disclosures about a public business entity&#x2019;s expenses and provides
more detailed information about the types of expenses in commonly presented expense captions. The amendments require that at each interim
and annual reporting period an entity will, inter alia, disclose amounts of purchases of inventory, employee compensation, depreciation
and amortization included in each relevant expense caption (such as cost of sales, SG&amp;amp;A and research and development). The ASU is
effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027.
Early adoption is permitted. The Company is currently evaluating this ASU to determine its impact on the Company&#x2019;s disclosures.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-14884">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basis of presentation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
consolidated financial statements have been prepared in accordance accounting principles generally accepted in the United States of America
(&#x201c;US GAAP&#x201d;)&lt;/span&gt; assuming the Company will continue as a going concern.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-14898">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Use of estimates in preparation of consolidated financial statements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts
reported in the consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including
those related to fair value of financial instruments and share based compensation. The Company&#x2019;s management believes that the estimates,
judgment, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and
assumptions can affect the reported amounts of assets and liabilities and disclosure of liabilities at the dates of the consolidated financial
statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0" id="ixv-14911">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Functional currency&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The functional currency of the Company and its subsidiaries, all of which are primarily direct and integral component of the Company&#x2019;s
operation, is the U.S. dollar (&#x201c;$&#x201d; or &#x201c;dollar&#x201d;), as the dollar is primary currency of the economic environment
in which the Company and its subsidiaries have operated and expects to continue to operate in foreseeable future.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;In accordance with ASC 830, &#x201c;Foreign
Currency Matters&#x201d;, balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing
at the applicable balance sheet date. For foreign currency transactions included in the consolidated statement of operations and comprehensive
loss, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates
used in the translation of such transactions are presented within financing income or expenses.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0" id="ixv-14927">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Principles of Consolidation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The consolidated financial statements
include the accounts of the Company and its wholly owned subsidiaries. Intercompany transactions and balances have been eliminated upon
consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-14940">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;E.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cash and cash equivalents&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Cash and cash equivalents include highly
liquid investments, including short-term bank deposits (with original maturity dates of up to three months from date of deposit) that
are not restricted as to withdrawal or use.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <nrsn:ShortTermDepositsPolicyTextBlock contextRef="c0" id="ixv-14980">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;F.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Short-term deposits&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Short-term deposits in banking institutions
for periods in excess of three months following the date of deposit. The deposits are presented in accordance with the terms of their
deposit.&lt;/p&gt;</nrsn:ShortTermDepositsPolicyTextBlock>
    <nrsn:RestrictedDepositsPolicyTextBlock contextRef="c0" id="ixv-14993">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;G.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Restricted deposits&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Restricted deposits consist of deposits
held in restricted deposit bank accounts including deposits held as collateral for guarantees to third parties, classified as current
or non-current based on expected timing of the disbursement.&lt;/p&gt;</nrsn:RestrictedDepositsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-15006">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;H.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Property and equipment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets. When an asset is disposed of, the related cost and accumulated depreciation are removed from the respective accounts and the net
difference less any amount realized from disposition is reflected in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company&#x2019;s long-lived assets are
reviewed for impairment in accordance with ASC 360, &#x201c;Property, Plant and Equipment&#x201d;, whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.
To date, the Company has not incurred any impairment losses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The lives used in computing straight-line
depreciation for financial reporting purposes are as follows:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="width: 80%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 19%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computers and peripherals and equipment&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7 - 15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-55"&gt;The shorter of the lease term and the useful life&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <nrsn:ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock contextRef="c0" id="ixv-15022">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The lives used in computing straight-line
depreciation for financial reporting purposes are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="width: 80%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 19%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computers and peripherals and equipment&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office furniture and equipment&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7 - 15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="background-color: #CCEEFF"&gt; &lt;td style="vertical-align: top"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt; &lt;td style="vertical-align: bottom"&gt;&#160;&lt;/td&gt; &lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-55"&gt;The shorter of the lease term and the useful life&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</nrsn:ScheduleOfTheLivesUsedInComputingStraightLineDepreciationTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c32" id="ixv-15039">P33Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c33" id="ixv-19006">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c34" id="ixv-19007">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-15055">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;I.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Research and development costs are
expensed as incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-15068">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;J.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company measures and discloses
fair value in accordance with the ASC 820, &#x201c;Fair Value Measurements and Disclosures&#x201d; which defines fair value, establishes
a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements.
Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined
based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions
there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level 1 - unadjusted quoted prices
are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level 2 - pricing inputs are other
than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration
with observable market data.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Level 3 - pricing inputs are unobservable
for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability
at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Level
3 inputs are considered as the lowest priority within the fair value hierarchy. The valuation of certain financial instruments classified
under fair value through profit or loss category falls under this category.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;This hierarchy requires the Company
to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;As of the reported periods, the fair
values of the Company&#x2019;s cash, cash equivalents, short-term bank deposits, current and non-current restricted deposits, other current
assets, trade payables and other current liabilities approximated the carrying values of these instruments presented in the Company&#x2019;s
consolidated balance sheets because of their nature.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-15132">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;K.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Concentrations of credit risk&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Financial instruments that potentially
subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents as well as certain other current assets
that do not amount to a significant amount. Cash and cash equivalents, which are primarily held in dollar and New Israeli Shekels (NIS),
are deposited with major bank in Israel. Management believes that such financial institutions are financially sound and, accordingly,
minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration
of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-15145">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;L.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company entered into non-cancelable
lease agreements for offices for use in its operations, which are classified as operating leases (see below).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company applies ASC 842, &#x201c;Leases&#x201d;
under which the Company determines if an arrangement is a lease at inception. The Company&#x2019;s assessment is based on: (i) whether
the contract involves the use of an identified asset, (ii) whether the Company obtains the right to substantially all of the economic
benefits from the use of the asset throughout the period of use, and (iii) whether the Company has the right to direct the use of the
asset.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Leases are classified as either finance
leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers
ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain
to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset, (iv) the present value of the lease
payments equals or exceeds substantially all of the fair value of the asset, or (v) the underlying asset is of such a specialized nature
that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if
it does not meet any one of these criteria. Since all the Company&#x2019;s lease contracts for premises do not meet any of the criteria
above, the Company concluded that all its lease contracts should be classified as operating leases.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Right of Use (&#x201c;ROU&#x201d;) assets
and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For
this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company&#x2019;s
leases do not provide an implicit rate, the Company uses its Incremental Borrowing Rate (&#x201c;IBR&#x201d;) based on the information available
on the commencement date in determining the present value of lease payments. The Company&#x2019;s IBR is estimated to approximate the interest
rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The
ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover,
the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease
had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, &#x201c;Property, Plant, and Equipment
- Overall&#x201d;, to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases
include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset
and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless
it is reasonably certain that the Company will not exercise the option.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c0" id="ixv-15192">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;M.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Commitment and contingencies&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies under which a provision is recorded when it is both probable that liability has
been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted
to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events
pertaining to a particular matter.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:EmployeeStockOwnershipPlanESOPPolicy contextRef="c0" id="ixv-15205">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;N.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 6pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Employee benefit plans &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company&#x2019;s liability for severance
pay to its Israeli employees is subject to Section 14 of the Israeli Severance Compensation Act, 1963 (&#x201c;Section 14&#x201d;), pursuant
to which all of the Company&#x2019;s employees are entitled to monthly deposits by the Company, at a rate of 8.33% of their monthly salary,
made in the employee&#x2019;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release
the Company from any future severance payments in respect of those employees. The fund is made available to the employee at the time the
employer-employee relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section
14 are not reflected in the balance sheets as the severance pay risks have been irrevocably transferred to the severance funds. All deposits
required through December 31, 2024 have been made.&lt;/p&gt;</us-gaap:EmployeeStockOwnershipPlanESOPPolicy>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="c0" decimals="4" id="ixv-19008" unitRef="pure">0.0833</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-15217">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;O.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Income taxes&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company accounts for income taxes
in accordance with ASC 740, &#x201c;Income Taxes&#x201d;. Accordingly, deferred income taxes are determined utilizing the asset and liability
method based on the estimated future tax effects of differences between the financial statement carrying amount and the tax bases of assets
and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax rates expected to be in effect
when these differences reverse. A valuation allowance in respect of deferred tax assets is provided for, if necessary, to reduce deferred
tax assets to the amounts more likely than not to be realized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company implements a&#160;two-step&#160;approach
to recognize and measure tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by
determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits,
the tax position will be sustained on examination, including resolution of any related appeals or litigation processes. The second step
is to measure the tax benefit as the largest amount that is greater than&#160;50% likely to be realized upon settlement. The Company&#x2019;s
accounting policy is to classify interest and penalties relating to income taxes under income taxes, however the Company did not recognize
such items in its consolidated financial statements during the reported periods and did not recognize any liability with respect to an
unrecognized tax benefits in its balance sheets.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements contextRef="c0" decimals="2" id="ixv-19009" unitRef="pure">0.50</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-15233">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;P.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stock-based compensation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company&#x2019;s employees&#x2019;
and directors&#x2019; share-based payment awards are classified as equity awards. The Company accounts for these awards using the grant-date
fair value method. For employees, the fair value of share-based payment transactions is recognized as an expense over the requisite service
period for each separately vesting tranche of the award as if the award is, in-substance, multiple awards. Forfeitures are recognized
as they occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;For nonemployees, compensation costs
are recognized in the same period and in the same manner the Company would if it had paid cash for those goods or services.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-15249">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Q.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Basic and diluted net loss per share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Basic net loss per share is computed
using the weighted average number of ordinary shares, pre-funded warrants to purchase ordinary shares for an exercise price of $0.0001&#160;which
are exercisable immediately and fully vested restricted share units (RSUs) outstanding during the period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Diluted loss per share gives effect
to all potentially dilutive common shares outstanding during the year using the treasury stock method with respect to options and non-vested
RSUs granted under employee stock compensation plan and certain warrants granted through its Initial Public Offering (IPO) and using the
if-converted method with respect to certain warrants granted through registered direct offering and accounted for as derivative liability.
In computing diluted loss per share, the average share price for the period is used in determining the number of shares assumed to be
purchased from the exercise of share options or warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;During the reported periods, all outstanding
share options, warrants and non-vested RSUs have been excluded from the calculation of the diluted net loss per share as all such securities
are anti-dilutive for all years presented.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c31"
      decimals="4"
      id="ixv-19010"
      unitRef="usdPershares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-15305">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;R.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Segment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company&#x2019;s chief operating
decision maker (&#x201c;CODM&#x201d;) is its Chief Executive Officer. The CODM reviews financial information on an aggregate basis for the
purposes of evaluating financial performance and allocating the Company&#x2019;s resources. Accordingly, the Company has determined that
it operates in one segment.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments contextRef="c0" decimals="0" id="ixv-19011" unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c0" id="ixv-15320">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;S.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Share capital&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Ordinary shares are classified as equity.
Incremental costs directly attributable to the issuance of the shares are recognized as a deduction from equity.&lt;/p&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <nrsn:ContractsOverOwnEquityPolicyTextBlock contextRef="c0" id="ixv-15333">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;T.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Contracts over own equity&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;When the Company becomes party to freestanding
financial instruments, the Company first analyzes the provisions of ASC&#160;480 in order to determine whether the instrument should be
classified as a liability, with subsequent changes in fair value recognized in the statements of operations in each period. Warrants to
purchase ordinary shares are not within the scope of ASC&#160;480, and as such the Company further analyzes the provisions of ASC&#160;815-40&#160;in
order to determine whether the contract should be classified within equity or classified as a liability, with subsequent changes in fair
value recognized in the statements of operations in each period.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company reassesses the classification
of a contract over its own equity under the guidance above at each balance sheet date. If classification changes as a result of events
during the reporting period, the Company reclassifies the contract as of the date of the event that caused the reclassification. When
a contract over own equity is reclassified from a liability to equity, gains or losses recorded to account for the contract at fair value
during the period that the contract was classified as a liability are not reversed, and the contract is marked to fair value immediately
before the reclassification.&lt;/p&gt;</nrsn:ContractsOverOwnEquityPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-15348">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;U.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Recently
adopted accounting pronouncements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;In&#160;August 2020,&#160;the FASB issued ASU&#160;2020-06&#160;&#x201c;Debt-
Debt with Conversion and Other Options (Subtopic&#160;470-20) and Derivatives and Hedging- Contracts in Entity&#x2019;s Own Equity (Subtopic&#160;815-40)
(&#x201c;ASU&#160;2020-06&#x201d;): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d;. This guidance
simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments
and contracts on an entity&#x2019;s own equity. Furthermore, ASU&#160;2020-06&#160;requires the application of the if-converted method
for calculating diluted earnings per share. ASU 2020-06 is effective for the Company for annual periods beginning after December 15,
2023,&#160;and interim periods within those fiscal years. The Company adopted this guidance on January 1, 2024, and there was no material
impact on the Company&#x2019;s consolidated balance sheet and the consolidated statements of operations and comprehensive loss upon adoption.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;In November 2023, the FASB issued ASU 2023-07 &#x201c;Segment
Reporting: Improvements to Reportable Segment Disclosures&#x201d; which expands public entities&#x2019; segment disclosures primarily by
requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within
each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures
of a reportable segment&#x2019;s profit or loss and assets. Public entities with a single reportable segment are required to provide the
new disclosures and all the disclosures required under ASC 280.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The guidance is effective for the Company&#x2019;s
annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025, with early adoption permitted. The Company
has adopted this standard for the fiscal year 2024 annual financial statements and interim financial statements thereafter and has applied
this standard retrospectively for all prior periods presented in the financial statements. See&#160;Note 15 &#x2013; Segment Reporting&#160;for
further information.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <nrsn:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="c0" id="ixv-15416">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;V.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Recently issued accounting pronouncements, not yet adopted&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;As an emerging growth company, the
Jumpstart Our Business Startup Act (&#x201c;JOBS Act&#x201d;) allows the Company to delay adoption of new or revised accounting pronouncements
applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this
extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-09 &#x201c;Improvements to Income Tax Disclosures&#x201d; which
improves the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in
the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain amendments to improve income
tax disclosures effectiveness. The guidance is effective for the Company&#x2019;s annual periods beginning January 1, 2026, with early
adoption permitted. The Company is currently evaluating the potential effect that the updated standard will have on the consolidated financial
statement disclosures.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;In November 2024, the FASB issued ASU No. 2024-03 Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense
Disaggregation Disclosures (Subtopic 220-40). The ASU improves the disclosures about a public business entity&#x2019;s expenses and provides
more detailed information about the types of expenses in commonly presented expense captions. The amendments require that at each interim
and annual reporting period an entity will, inter alia, disclose amounts of purchases of inventory, employee compensation, depreciation
and amortization included in each relevant expense caption (such as cost of sales, SG&amp;amp;A and research and development). The ASU is
effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027.
Early adoption is permitted. The Company is currently evaluating this ASU to determine its impact on the Company&#x2019;s disclosures.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</nrsn:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="c0" id="ixv-15445">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 3 - Cash and cash equivalent &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars&lt;br/&gt; in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Denominated in NIS&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,057&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;107&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Denominated in USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;321&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;*2,533&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,378&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,640&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Including short term bank deposit for a period of 1-2 months
at an interest rate of 5%.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c0" id="ixv-15449">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars&lt;br/&gt; in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Denominated in NIS&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,057&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;107&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Denominated in USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;321&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;*2,533&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,378&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,640&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Including short term bank deposit for a period of 1-2 months
at an interest rate of 5%.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c36" decimals="-3" id="ixv-19012" unitRef="usd">3057000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c37" decimals="-3" id="ixv-19013" unitRef="usd">107000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c38" decimals="-3" id="ixv-19014" unitRef="usd">321000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" id="ixv-19015" unitRef="usd">3378000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c5" decimals="-3" id="ixv-19016" unitRef="usd">2640000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentInterestRate contextRef="c4" decimals="2" id="ixv-19018" unitRef="pure">0.05</us-gaap:InvestmentInterestRate>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c0" id="ixv-15524">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 4 - Other receivables&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars&lt;br/&gt; in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Advance to suppliers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;738&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Government agencies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;104&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;137&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;989&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;236&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c0" id="ixv-15529">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars&lt;br/&gt; in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Advance to suppliers&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;738&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Government agencies&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;104&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;137&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;989&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;236&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:Supplies contextRef="c4" decimals="-3" id="ixv-19019" unitRef="usd">738000</us-gaap:Supplies>
    <us-gaap:GovernmentContractReceivable contextRef="c4" decimals="-3" id="ixv-19020" unitRef="usd">60000</us-gaap:GovernmentContractReceivable>
    <us-gaap:GovernmentContractReceivable contextRef="c5" decimals="-3" id="ixv-19021" unitRef="usd">29000</us-gaap:GovernmentContractReceivable>
    <us-gaap:PrepaidExpenseCurrent contextRef="c4" decimals="-3" id="ixv-19022" unitRef="usd">87000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c5" decimals="-3" id="ixv-19023" unitRef="usd">70000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherReceivablesGrossCurrent contextRef="c4" decimals="-3" id="ixv-19024" unitRef="usd">104000</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:OtherReceivablesGrossCurrent contextRef="c5" decimals="-3" id="ixv-19025" unitRef="usd">137000</us-gaap:OtherReceivablesGrossCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c4" decimals="-3" id="ixv-19026" unitRef="usd">989000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c5" decimals="-3" id="ixv-19027" unitRef="usd">236000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-15601">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 5 - Property and equipment, net&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Balance as of December 31, 2024:&lt;/p&gt;

&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Computers&lt;br/&gt; and&lt;br/&gt; peripherals&lt;br/&gt; and &lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Office&lt;br/&gt; furniture &lt;br/&gt; and&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Leasehold&lt;br/&gt; improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Balance at January 1, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;28&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;123&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Purchases during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;95&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;126&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;54&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Depreciated cost at December&#160;31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;66&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Balance as of December 31, 2023:&lt;/p&gt;

&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Computers&lt;br/&gt; and&lt;br/&gt; peripherals&lt;br/&gt; and &lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Office&lt;br/&gt; furniture &lt;br/&gt; and&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Leasehold&lt;br/&gt; improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;66&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;94&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Purchases during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;92&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;123&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;34&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;38&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Depreciated cost at December&#160;31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;58&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;24&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;85&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less
than $1 thousand.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-15607">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Computers&lt;br/&gt; and&lt;br/&gt; peripherals&lt;br/&gt; and &lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Office&lt;br/&gt; furniture &lt;br/&gt; and&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Leasehold&lt;br/&gt; improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Balance at January 1, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;28&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;123&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Purchases during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;95&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;126&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;54&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Depreciated cost at December&#160;31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;22&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;66&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Computers&lt;br/&gt; and&lt;br/&gt; peripherals&lt;br/&gt; and &lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Office&lt;br/&gt; furniture &lt;br/&gt; and&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Leasehold&lt;br/&gt; improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;66&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;25&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;94&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Purchases during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;92&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;123&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Depreciation during the year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;34&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;38&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Depreciated cost at December&#160;31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;58&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;24&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;85&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less
than $1 thousand.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c40" decimals="-3" id="ixv-19028" unitRef="usd">92000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c41" decimals="-3" id="ixv-19029" unitRef="usd">28000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c42" decimals="-3" id="ixv-19030" unitRef="usd">3000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c5" decimals="-3" id="ixv-19031" unitRef="usd">123000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c43" decimals="-3" id="ixv-19032" unitRef="usd">3000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c0" decimals="-3" id="ixv-19033" unitRef="usd">3000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c32" decimals="-3" id="ixv-19034" unitRef="usd">95000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c46" decimals="-3" id="ixv-19035" unitRef="usd">28000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c35" decimals="-3" id="ixv-19036" unitRef="usd">3000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c4" decimals="-3" id="ixv-19037" unitRef="usd">126000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c40" decimals="-3" id="ixv-19038" unitRef="usd">34000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c41" decimals="-3" id="ixv-19039" unitRef="usd">4000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-19040" unitRef="usd">38000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1 contextRef="c43" decimals="-3" id="ixv-19041" unitRef="usd">20000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1 contextRef="c44" decimals="-3" id="ixv-19042" unitRef="usd">2000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1 contextRef="c0" decimals="-3" id="ixv-19043" unitRef="usd">22000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c32" decimals="-3" id="ixv-19044" unitRef="usd">54000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c46" decimals="-3" id="ixv-19045" unitRef="usd">6000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="-3" id="ixv-19046" unitRef="usd">60000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c32" decimals="-3" id="ixv-19047" unitRef="usd">41000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c46" decimals="-3" id="ixv-19048" unitRef="usd">22000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c35" decimals="-3" id="ixv-19049" unitRef="usd">3000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" id="ixv-19050" unitRef="usd">66000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c47" decimals="-3" id="ixv-19051" unitRef="usd">66000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c48" decimals="-3" id="ixv-19052" unitRef="usd">25000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c49" decimals="-3" id="ixv-19053" unitRef="usd">3000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c18" decimals="-3" id="ixv-19054" unitRef="usd">94000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c50" decimals="-3" id="ixv-19055" unitRef="usd">26000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c51" decimals="-3" id="ixv-19056" unitRef="usd">3000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c6" decimals="-3" id="ixv-19057" unitRef="usd">29000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c40" decimals="-3" id="ixv-19058" unitRef="usd">92000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c41" decimals="-3" id="ixv-19059" unitRef="usd">28000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c42" decimals="-3" id="ixv-19060" unitRef="usd">3000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c5" decimals="-3" id="ixv-19061" unitRef="usd">123000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c47" decimals="-3" id="ixv-19062" unitRef="usd">14000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c48" decimals="-3" id="ixv-19063" unitRef="usd">3000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c18" decimals="-3" id="ixv-19064" unitRef="usd">17000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1 contextRef="c50" decimals="-3" id="ixv-19065" unitRef="usd">20000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1 contextRef="c51" decimals="-3" id="ixv-19066" unitRef="usd">1000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1 contextRef="c6" decimals="-3" id="ixv-19067" unitRef="usd">21000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c40" decimals="-3" id="ixv-19068" unitRef="usd">34000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c41" decimals="-3" id="ixv-19069" unitRef="usd">4000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-19070" unitRef="usd">38000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c40" decimals="-3" id="ixv-19071" unitRef="usd">58000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c41" decimals="-3" id="ixv-19072" unitRef="usd">24000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c42" decimals="-3" id="ixv-19073" unitRef="usd">3000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="-3" id="ixv-19074" unitRef="usd">85000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0" id="ixv-16168">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 6 - Operating lease&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The Company has lease agreements with respect
to offices. In December 2021, the Company entered into an office space lease agreement (which commenced on January 1, 2022). Monthly rent
payments including utilities amount to approximately $7 thousand and indexed to Israeli consumer price index. The lease period is for
24 months with an option to extend the lease period for additional two periods of 24 months each (the first one was exercised by the Company).
Accordingly, the Company recognized in the consolidated balance sheet a right-of-use asset in the amount of $306 thousand concurrently
with the recognition of a lease liability in the same amount.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Operating lease&lt;/span&gt;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars&lt;br/&gt; in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;Operating right of use asset&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;84&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-67"&gt;Current operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Non-Current operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-68"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Total operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Maturity analysis of the Company&#x2019;s lease liability&lt;/span&gt;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;
2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;U.S. dollars&lt;br/&gt;
in thousands&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 89%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Two years&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;75&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Present value of lease liability&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;73&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Additional information on lease&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The following is a summary of weighted average
remaining lease terms and discount rate for Company&#x2019;s leases:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;Lease term (years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;Presented hereunder are the lease payments the
Company paid in the year ended December 31, 2024, 2023 and 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt"&gt;Lease payments&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;75&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;75&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;79&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;79&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:PaymentsForRent contextRef="c0" decimals="-3" id="ixv-19075" unitRef="usd">7000</us-gaap:PaymentsForRent>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c4" id="ixv-19076">P24M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="c0" id="ixv-19077">option to extend the lease period for additional two periods of 24 months</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <nrsn:InitialRecognitionRightofuseAssets contextRef="c0" decimals="-3" id="ixv-19078" unitRef="usd">306000</nrsn:InitialRecognitionRightofuseAssets>
    <nrsn:LesseeOperatingLeaseDisclosureTableTextBlock contextRef="c0" id="ixv-16178">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars&lt;br/&gt; in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;Operating right of use asset&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;84&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-67"&gt;Current operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Non-Current operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-68"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Total operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</nrsn:LesseeOperatingLeaseDisclosureTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="-3" id="ixv-19079" unitRef="usd">84000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="-3" id="ixv-19080" unitRef="usd">73000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c4" decimals="-3" id="ixv-19081" unitRef="usd">73000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-16219">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Maturity analysis of the Company&#x2019;s lease liability&lt;/span&gt;:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;br/&gt;
2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;U.S. dollars&lt;br/&gt;
in thousands&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 89%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Two years&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;75&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Present value of lease liability&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;73&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c4" decimals="-3" id="ixv-19082" unitRef="usd">75000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c4" decimals="-3" id="ixv-19083" unitRef="usd">75000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c4" decimals="-3" id="ixv-19084" unitRef="usd">2000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c4" decimals="-3" id="ixv-19085" unitRef="usd">73000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0" id="ixv-16308">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The following is a summary of weighted average
remaining lease terms and discount rate for Company&#x2019;s leases:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;Lease term (years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;Presented hereunder are the lease payments the
Company paid in the year ended December 31, 2024, 2023 and 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt"&gt;Lease payments&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;75&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;75&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;79&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;79&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c4" id="ixv-19086">P1Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c4" decimals="2" id="ixv-19087" unitRef="pure">0.06</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePaymentsUse contextRef="c0" decimals="-3" id="ixv-19088" unitRef="usd">75000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeasePaymentsUse contextRef="c6" decimals="-3" id="ixv-19089" unitRef="usd">75000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeasePaymentsUse contextRef="c7" decimals="-3" id="ixv-19090" unitRef="usd">79000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="-3" id="ixv-19091" unitRef="usd">75000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c6" decimals="-3" id="ixv-19092" unitRef="usd">75000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c7" decimals="-3" id="ixv-19093" unitRef="usd">79000</us-gaap:OperatingLeasePayments>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="c0" id="ixv-16405">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 7 - Other Current Liabilities&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars&lt;br/&gt; in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Employees and payroll accruals (*)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;498&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,481&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Short term lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;450&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;832&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;see Note 14 regarding waiver signed of bonus accrual.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="c0" id="ixv-16409">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars&lt;br/&gt; in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Employees and payroll accruals (*)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;498&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,481&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Short term lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;450&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;832&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;see Note 14 regarding waiver signed of bonus accrual.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c4" decimals="-3" id="ix_0_fact" unitRef="usd">498000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c5" decimals="-3" id="ix_1_fact" unitRef="usd">1481000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c4" decimals="-3" id="ixv-19096" unitRef="usd">73000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c5" decimals="-3" id="ixv-19097" unitRef="usd">69000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c4" decimals="-3" id="ixv-19098" unitRef="usd">261000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c5" decimals="-3" id="ixv-19099" unitRef="usd">450000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-19100" unitRef="usd">832000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-19101" unitRef="usd">2000000</us-gaap:OtherLiabilitiesCurrent>
    <nrsn:LiabilityInRespectOfWarrantsTextBlock contextRef="c0" id="ixv-16479">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 8 - Liability in respect of warrants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;On June 22, 2023, the Company entered
into a registered direct offering under which, the Company issued to an institutional investor 3,000,000 warrants, each representing the
right to acquire one ordinary share at an exercise price of $1.50 and expiring on the fifth anniversary of the original issuance date.
Due to the warrants&#x2019; terms, with respect to the fundamental transaction provisions, the warrants were accounted as a financial liability
measured at fair-value through profit and losses until their expiration or exercise.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;On June 26, 2024, the Company and the
institutional investor entered into an amendment to the warrant which included revisions to the fundamental transactions provision and
the extension of the termination date from June 26, 2028 to October 12, 2029. The Company concluded that the amended warrants meet equity
classification criteria and thus the warrants should be accounted as equity from the date of amendment. As a result, on June 26, 2024
the Company reclassified the warrant liability into equity according to its fair value for the same date in the amount of $1.366 million.
Revaluation income in the amount of $46 thousands until June 26, 2024 was recorded within the Company&#x2019;s finance expanse and the effect
of the amendment was recorded in the Company&#x2019;s equity in the amount of 329 thousands.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The Company&#x2019;s financial measured
at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars&lt;br/&gt; in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Liability in respect of warrants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,412&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,412&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;As of December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The fair value of the warrants, as
of it&#x2019;s the date of reclassification to equity, was determined by the management using the assistance of external appraiser and
by using the Black-Scholes option pricing model and the following inputs:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June&#160;26,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Financial liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;86.56-92.52&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%"&gt;Share price (in $)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.44-4.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected life (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.98-5.30&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;As of December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The fair value of the warrants was determined by the management using the assistance of external appraiser and by using Black-Scholes option pricing model and the following inputs:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold"&gt;Financial liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;93.91&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;Share price (in $)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.785&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Expected life (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The following table summarizes the movement in warrant liability during
the year ended December 31, 2023 and December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars&lt;br/&gt; in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Balance as at January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left"&gt;Recognition of liability in respect to warrants at the initial date&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,603&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Revaluation of liability in respect to warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,191&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Balance as at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,412&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Revaluation of liability in respect to warrants through finance expanse&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(46&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Revaluation of liability in respect to warrants through equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Reclassification of warrants into equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,695&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 2.5pt"&gt;Balance as at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</nrsn:LiabilityInRespectOfWarrantsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c53"
      decimals="0"
      id="ixv-19103"
      unitRef="shares">3000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <nrsn:NumberOfOrdinaryShares contextRef="c54" decimals="0" id="ixv-19104" unitRef="pure">1</nrsn:NumberOfOrdinaryShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c55"
      decimals="2"
      id="ixv-19105"
      unitRef="usdPershares">1.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c56" decimals="-3" id="ixv-19106" unitRef="usd">1366000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities contextRef="c57" decimals="-3" id="ixv-19107" unitRef="usd">46000</us-gaap:DebtorReorganizationItemsRevaluationOfAssetsAndLiabilities>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="c27" decimals="-3" id="ixv-19108" unitRef="usd">-329000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c0" id="ixv-16487">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The Company&#x2019;s financial measured
at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars&lt;br/&gt; in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Liability in respect of warrants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,412&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,412&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c59" decimals="-3" id="ixv-19109" unitRef="usd">1412000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c61" decimals="-3" id="ixv-19110" unitRef="usd">1412000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c0" id="ixv-16550">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The fair value of the warrants, as
of it&#x2019;s the date of reclassification to equity, was determined by the management using the assistance of external appraiser and
by using the Black-Scholes option pricing model and the following inputs:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June&#160;26,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Financial liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;86.56-92.52&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%"&gt;Share price (in $)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.85&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.44-4.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected life (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.98-5.30&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The fair value of the warrants was determined by the management using the assistance of external appraiser and by using Black-Scholes option pricing model and the following inputs:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold"&gt;Financial liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: left"&gt;Expected volatility (%)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;93.91&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;Share price (in $)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.785&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Risk-free interest rate (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Expected life (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.47&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Dividend yield (%)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c62" decimals="4" id="ixv-19111" unitRef="pure">0.8656</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c63" decimals="4" id="ixv-19112" unitRef="pure">0.9252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharePrice
      contextRef="c64"
      decimals="2"
      id="ixv-19113"
      unitRef="usdPershares">0.85</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c62" decimals="4" id="ixv-19114" unitRef="pure">0.0444</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c63" decimals="4" id="ixv-19115" unitRef="pure">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c62" id="ixv-19116">P3Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c63" id="ixv-19117">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c66" decimals="4" id="ixv-19118" unitRef="pure">0.9391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharePrice
      contextRef="c67"
      decimals="3"
      id="ixv-19119"
      unitRef="usdPershares">0.785</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c66" decimals="4" id="ixv-19120" unitRef="pure">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c66" id="ixv-19121">P4Y5M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="c0" id="ixv-16676">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The following table summarizes the movement in warrant liability during
the year ended December 31, 2023 and December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars&lt;br/&gt; in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Balance as at January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left"&gt;Recognition of liability in respect to warrants at the initial date&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,603&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Revaluation of liability in respect to warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,191&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Balance as at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,412&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Revaluation of liability in respect to warrants through finance expanse&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(46&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;Revaluation of liability in respect to warrants through equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Reclassification of warrants into equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,695&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 2.5pt"&gt;Balance as at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <nrsn:RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate contextRef="c69" decimals="-3" id="ixv-19122" unitRef="usd">3603000</nrsn:RecognitionOfLiabilityInRespectToWarrantsAtTheInitialDate>
    <nrsn:ReclassificationOfWarrantsIntoEquity contextRef="c69" decimals="-3" id="ixv-19123" unitRef="usd">-2191000</nrsn:ReclassificationOfWarrantsIntoEquity>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c70" decimals="-3" id="ixv-19124" unitRef="usd">1412000</us-gaap:WarrantsAndRightsOutstanding>
    <nrsn:RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse contextRef="c71" decimals="-3" id="ixv-19125" unitRef="usd">-46000</nrsn:RevaluationOfLiabilityInRespectToWarrantsThroughFinanceExpanse>
    <nrsn:RevaluationOfLiabilityInRespectToWarrantsThroughEquity contextRef="c71" decimals="-3" id="ixv-19126" unitRef="usd">329000</nrsn:RevaluationOfLiabilityInRespectToWarrantsThroughEquity>
    <nrsn:RevaluationOfLiabilityInRespectToWarrants contextRef="c71" decimals="-3" id="ixv-19127" unitRef="usd">1695000</nrsn:RevaluationOfLiabilityInRespectToWarrants>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-16744">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 9 - Shareholders&#x2019; Equity&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Share capital&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of shares&lt;br/&gt; December 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and&lt;br/&gt; outstanding 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and&lt;br/&gt; outstanding 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; padding-bottom: 2.5pt"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;Ordinary shares of &lt;span style="-sec-ix-hidden: hidden-fact-76"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-77"&gt;no&lt;/span&gt;&lt;/span&gt; par value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;90,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;23,228,941&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;60,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;15,379,042&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2022, the Company received an amount of $3,870 thousand as a result of the exercise of 645,000 warrants at a price per share of
$6.00.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April&#160;14, 2023, the Company entered into a sales agreement with Alliance Global Partners, pursuant to which the Company may offer
and sell, from time to time, to or through the Alliance Global Partners as agent or principal, ordinary shares an at-the-market&#160;offering,
having an aggregate offering price of up to $5,744 thousands. On June&#160;22, 2023, the Company filed a prospectus supplement reflecting
a reduction in the size of the at-the-market&#160;offering to $502 thousand. During the reporting period, the Company sold 3,600 ordinary
shares for gross proceeds of $7 thousand through the at-the-market&#160;offering. Issuance expenses were equal to the proceeds received.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 22, 2023, the Company&#160;entered
into a securities purchase agreement pursuant to which the Company agreed to issue and sell, in a registered direct offering: (i) an
aggregate of 1,330,000 ordinary shares, no par value, and (ii) an aggregate of 1,670,000 pre-funded warrants, each representing the right
to acquire one ordinary share with exercise price of $0.0001, exercisable at any time until exercised in full and (iii) an aggregate
of 3,000,000 warrants. The warrants are exercisable immediately upon issuance at an exercise price of $1.50 per ordinary share and will
expire on the fifth anniversary of the original issuance date. The gross proceeds were approximately $4.5 million before deducting the
placement agent fee and related offering expenses of $455 thousand. The warrant instrument is classified as a liability with an original
fair value in the amount of $3,603 thousand and the remaining amount of $897 thousand was attributed to the ordinary shares and pre-funded
warrants and recognized in equity. The direct incremental issuance costs, amounting to $454 thousand, have been allocated in the same
proportion as the gross proceeds. An amount of $365 thousands was allocated to the ordinary warrants and carried directly to profit or
loss as finance expense and an amount of $91 thousands was allocated to the ordinary shares and the pre-funded warrants and recognized
as a reduction of equity. See also Note 8 regarding the agreement amendment signed on June 26, 2024 and the resulting reclassification
of the warrant liability into equity.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 23, 2023, one of the Company&#x2019;s employees exercised 126,000 options into 126,000 ordinary shares for a total consideration of $5 thousands.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
October 2023, 1,670,000 pre-funded warrants were exercised into 1,670,000 ordinary shares of the Company. See also Note 9(a)(c) above.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 10, 2024, the Company&#160;entered into a securities purchase agreement (the &#x201c;April 2024 Purchase Agreement&#x201d;) with an institutional investor (the &#x201c;April 2024 Purchaser&#x201d;), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the April 2024 Purchaser (i) an aggregate of 1,732,000 ordinary shares,; (ii) an aggregate of 1,248,000 pre-funded warrants, each representing the right to acquire one ordinary share at an exercise price of $0.0001 (either physically or on a net-cash basis at the April 2024 Purchaser&#x2019;s discretion), exercisable at any time upon their issuance until exercised in full and (iii) an aggregate of 2,980,000 warrants, each representing the right to acquire one ordinary share at an exercise price of $1.50 (either physically or on a net-cash basis at the April 2024 Purchaser&#x2019;s discretion) and will expire on the fifth anniversary of the original issuance date. The gross proceeds were approximately $4.47 million. As part of the April 2024 Purchase Agreement, the Company also issued 70,964 ordinary shares valued at 0.1 million as issuance expenses to the placement agent in the registered direct offering. Total issuance expenses in cash amounted to $0.153 million. All consideration in this issuance was classified to equity.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 26, 2024, the Company and the April 2024 Purchaser reached an agreement to amend the terms of the warrants to extend the termination date from April 15, 2029, to October 12, 2029. The impact on the financial statements is immaterial.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 27, 2024, the Company&#x2019;s shareholders approved an amendment to the Company&#x2019;s articles of association to increase the
registered share capital of the Company by an additional 30,000,000 ordinary shares, such that the total registered share capital of
the Company would consist of 90,000,000 ordinary shares, no par value per share.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 6, 2024, the Company entered into a securities purchase agreement with certain investors, which include members of the Company&#x2019;s senior management and existing investors. The Company agreed to sell an aggregate of 800,000 ordinary shares and warrants to purchase an aggregate of 800,000 ordinary shares, at a combined purchase price of $0.75 per share and accompanying warrant. All consideration in this issuance was classified to equity.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Each warrant was immediately exercisable upon issuance and has a five-year term from the issuance date. The exercise price of each warrant is $0.75 per share, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if at the time of exercise thereof there is no effective registration statement registering the ordinary shares underlying the warrants. The gross proceeds were approximately $0.6 million. Total issuance expenses in cash amounted to $0.015 million.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
&lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 16, 2024, the Company entered into
a Capital on Demand Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with JonesTrading Institutional Services LLC, as sales agent
(the &#x201c;Sales Agent&#x201d;), pursuant to which the Company may offer and sell, from time to time, to or through the Sales Agent,
ordinary shares, having an aggregate offering price of up to gross sale proceeds of up to $2,524 thousand. The Company agreed to pay
the Sales Agent a commission equal to 3.0% of the gross proceeds from the sale of the ordinary shares pursuant to the Sales Agreement.
The Company has also agreed to reimburse the Sales Agent for certain specified expenses in connection with entering into the Sales Agreement
in the amount of up to $50 thousand. As of December 31, 2024, the Company sold 1,105,509 ordinary shares for aggregate gross proceeds
of $1,234 thousand (net proceeds of $1,067 thousand) under the Sales Agreement.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2024, the Company issued 1,248,000 and 325,000 ordinary shares following exercise of pre-funded warrants
from the Purchase Agreement (see Note 9f) and vested RSU&#x2019;s, respectively.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 31, 2024,&#160;the &#x201c;Company entered into a standby equity purchase agreement (the &#x201c;SEPA&#x201d;) with&#160;YA II PN, LTD., a Cayman Islands exempt limited partnership (&#x201c;Yorkville&#x201d;).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the SEPA, the Company has the
right, but not the obligation, to sell to Yorkville from time to time (each such occurrence, an &#x201c;Advance&#x201d;) up to $30.0 million
(the &#x201c;Commitment Amount&#x201d;) of the Company&#x2019;s ordinary shares,&#160;during the 36 months following the execution of the&#160;SEPA,
subject to the restrictions and satisfaction of the conditions in the SEPA. At the Company&#x2019;s option, the ordinary shares would
be purchased by Yorkville from time to time at a price equal to 97% of the lowest of the three daily VWAPs (as hereinafter defined) during
a three consecutive trading day period commencing on the date that the Company, subject to certain limitations, delivers a notice to
Yorkville that the Company is committing Yorkville to purchase such ordinary shares (the &#x201c;Advance Shares&#x201d;).&#160;The Company
may also specify a certain minimum acceptable price per share in each Advance.&#160;&#x201c;VWAP&#x201d; means, for any trading day, the
daily volume weighted average price of the Company&#x2019;s ordinary shares for such trading day on the Nasdaq Stock Market during regular
trading hours as reported by Bloomberg L.P. As consideration for Yorkville&#x2019;s irrevocable commitment to purchase the Company&#x2019;s
ordinary shares up to the Commitment Amount, the Company agreed to issue 224,697 ordinary shares valued at $281 thousand to Yorkville
and also paid a $25,000 structuring fee to Yorkville. The fee and shares fair value were recognized as finance expenses.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 2, 2024, the Company&#160;entered
into a securities purchase agreement with a single investor the Company&#x2019;s chief executive officer (together, the &#x201c;December
2024 Purchasers&#x201d;) in a private placement. The Company issued to the December 2024 Purchasers (i) an aggregate of 2,343,729 ordinary
shares, (ii) an aggregate of 1,656,271 pre-funded warrants, each representing the right to acquire one ordinary share, and (iii) an aggregate
of 8,000,000 ordinary warrants, each representing the right to acquire one ordinary share for total gross proceeds to the Company of
$5 million (net proceeds of $4.94 million). The ordinary warrants are exercisable immediately upon issuance at an exercise price of $1.25
per share and expire five years from the date of issuance. The pre-funded warrants are exercisable immediately upon issuance at an exercise
price of $0.0001 per share and may be exercised at any time until the pre-funded warrants are exercised in full. All consideration in
this issuance was classified to equity.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ordinary Shares Right&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Each ordinary share is entitled to one vote. The
holders of ordinary shares are also entitled to receive dividends whenever funds are legally available and when declared by the board
of directors, subject to the prior rights of holders of all classes of shares outstanding.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfCapitalUnitsTextBlock contextRef="c0" id="ixv-16754">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Share capital&lt;/b&gt;&lt;/span&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of shares&lt;br/&gt; December 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and&lt;br/&gt; outstanding 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Authorized&lt;br/&gt; 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Issued and&lt;br/&gt; outstanding 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; padding-bottom: 2.5pt"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;Ordinary shares of &lt;span style="-sec-ix-hidden: hidden-fact-76"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-77"&gt;no&lt;/span&gt;&lt;/span&gt; par value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;90,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;23,228,941&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;60,000,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;15,379,042&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCapitalUnitsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c4"
      decimals="INF"
      id="ixv-19128"
      unitRef="shares">90000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c4"
      decimals="INF"
      id="ixv-19129"
      unitRef="shares">23228941</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c5"
      decimals="INF"
      id="ixv-19130"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c5"
      decimals="INF"
      id="ixv-19131"
      unitRef="shares">15379042</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c73" decimals="-3" id="ixv-19132" unitRef="usd">3870000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c73"
      decimals="0"
      id="ixv-19133"
      unitRef="shares">645000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c74"
      decimals="2"
      id="ixv-19134"
      unitRef="usdPershares">6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DeferredOfferingCosts contextRef="c75" decimals="-3" id="ixv-19135" unitRef="usd">5744000</us-gaap:DeferredOfferingCosts>
    <nrsn:MarketOfferingCost contextRef="c53" decimals="-3" id="ixv-19136" unitRef="usd">502000</nrsn:MarketOfferingCost>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c76"
      decimals="0"
      id="ixv-19137"
      unitRef="shares">3600</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c77" decimals="-3" id="ixv-19138" unitRef="usd">7000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c78"
      decimals="0"
      id="ixv-19139"
      unitRef="shares">1330000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c79"
      decimals="0"
      id="ixv-19140"
      unitRef="shares">1670000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <nrsn:NumberOfOrdinaryShares contextRef="c79" decimals="0" id="ixv-19141" unitRef="pure">1</nrsn:NumberOfOrdinaryShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c80"
      decimals="4"
      id="ixv-19142"
      unitRef="usdPershares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c81"
      decimals="0"
      id="ixv-19143"
      unitRef="shares">3000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c81"
      decimals="2"
      id="ixv-19144"
      unitRef="usdPershares">1.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c82" decimals="-5" id="ixv-19145" unitRef="usd">4500000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:NoninterestExpenseOfferingCost contextRef="c82" decimals="-3" id="ixv-19146" unitRef="usd">455000</us-gaap:NoninterestExpenseOfferingCost>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c82" decimals="-3" id="ixv-19147" unitRef="usd">3603000</us-gaap:FairValueAdjustmentOfWarrants>
    <nrsn:RemainingFairValueAmount contextRef="c77" decimals="-3" id="ixv-19148" unitRef="usd">897000</nrsn:RemainingFairValueAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost contextRef="c77" decimals="-3" id="ixv-19149" unitRef="usd">454000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <nrsn:AllocatedAmountToOrdinaryWarrants contextRef="c77" decimals="-3" id="ixv-19150" unitRef="usd">365000</nrsn:AllocatedAmountToOrdinaryWarrants>
    <us-gaap:OtherExpenses contextRef="c77" decimals="-3" id="ixv-19151" unitRef="usd">91000</us-gaap:OtherExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c83"
      decimals="0"
      id="ixv-19152"
      unitRef="shares">126000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c84"
      decimals="0"
      id="ixv-19153"
      unitRef="shares">126000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c84" decimals="-3" id="ixv-19154" unitRef="usd">5000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c85"
      decimals="0"
      id="ixv-19155"
      unitRef="shares">1670000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c86"
      decimals="0"
      id="ixv-19156"
      unitRef="shares">1670000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c87"
      decimals="0"
      id="ixv-19157"
      unitRef="shares">1732000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c88"
      decimals="0"
      id="ixv-19158"
      unitRef="shares">1248000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <nrsn:NumberOfOrdinaryShares
      contextRef="c89"
      decimals="0"
      id="ixv-19159"
      unitRef="Number">1</nrsn:NumberOfOrdinaryShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c88"
      decimals="4"
      id="ixv-19160"
      unitRef="usdPershares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c90"
      decimals="0"
      id="ixv-19161"
      unitRef="shares">2980000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <nrsn:NumberOfOrdinaryShares
      contextRef="c91"
      decimals="0"
      id="ixv-19162"
      unitRef="Number">1</nrsn:NumberOfOrdinaryShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c90"
      decimals="2"
      id="ixv-19163"
      unitRef="usdPershares">1.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c92" decimals="-4" id="ixv-19164" unitRef="usd">4470000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c93"
      decimals="0"
      id="ixv-19165"
      unitRef="shares">70964</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:OtherNoninterestExpense contextRef="c92" decimals="-5" id="ixv-19166" unitRef="usd">100000</us-gaap:OtherNoninterestExpense>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c92" decimals="-3" id="ixv-19167" unitRef="usd">153000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c94"
      decimals="0"
      id="ixv-19168"
      unitRef="shares">30000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares
      contextRef="c94"
      decimals="0"
      id="ixv-19169"
      unitRef="shares">90000000</us-gaap:StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c95"
      decimals="0"
      id="ixv-19170"
      unitRef="shares">800000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="c96"
      decimals="0"
      id="ixv-19171"
      unitRef="shares">800000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <nrsn:PurchasePricePerShare
      contextRef="c97"
      decimals="2"
      id="ixv-19172"
      unitRef="usdPershares">0.75</nrsn:PurchasePricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c98"
      decimals="2"
      id="ixv-19173"
      unitRef="usdPershares">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c99" decimals="-5" id="ixv-19174" unitRef="usd">600000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c0" decimals="-3" id="ixv-19175" unitRef="usd">15000.000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="c100"
      decimals="-3"
      id="ixv-19176"
      unitRef="usd">2524000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <nrsn:SaleOfOrdinaryShareGrossProceedsPercentage
      contextRef="c100"
      decimals="3"
      id="ixv-19177"
      unitRef="pure">0.03</nrsn:SaleOfOrdinaryShareGrossProceedsPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c100"
      decimals="-3"
      id="ixv-19178"
      unitRef="shares">50000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c100"
      decimals="0"
      id="ixv-19179"
      unitRef="shares">1105509</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c100"
      decimals="-3"
      id="ixv-19180"
      unitRef="usd">1234000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <nrsn:NetProceedsFromTheOrdinaryShares
      contextRef="c101"
      decimals="-3"
      id="ixv-19181"
      unitRef="usd">1067000</nrsn:NetProceedsFromTheOrdinaryShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c102"
      decimals="0"
      id="ixv-19182"
      unitRef="shares">1248000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c103"
      decimals="0"
      id="ixv-19183"
      unitRef="shares">325000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted contextRef="c4" decimals="-5" id="ixv-19184" unitRef="usd">30000000</us-gaap:SignificantSupplyCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="c0" decimals="2" id="ixv-19185" unitRef="pure">0.97</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c0"
      decimals="0"
      id="ixv-19186"
      unitRef="shares">224697</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="-3" id="ixv-19187" unitRef="usd">281000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsForRestructuring contextRef="c0" decimals="-3" id="ixv-19188" unitRef="usd">25000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c104"
      decimals="0"
      id="ixv-19189"
      unitRef="shares">2343729</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c105"
      decimals="0"
      id="ixv-19190"
      unitRef="shares">1656271</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <nrsn:NumberOfOrdinaryShares
      contextRef="c106"
      decimals="0"
      id="ixv-19191"
      unitRef="pure">1</nrsn:NumberOfOrdinaryShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c107"
      decimals="0"
      id="ixv-19192"
      unitRef="shares">8000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <nrsn:NumberOfOrdinaryShares
      contextRef="c108"
      decimals="0"
      id="ixv-19193"
      unitRef="pure">1</nrsn:NumberOfOrdinaryShares>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="c109"
      decimals="-6"
      id="ixv-19194"
      unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <nrsn:NetProceedsFromIssuanceOfWarrants
      contextRef="c109"
      decimals="-4"
      id="ixv-19195"
      unitRef="usd">4940000</nrsn:NetProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c110"
      decimals="2"
      id="ixv-19196"
      unitRef="usdPershares">1.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c110" id="ixv-19197">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c105"
      decimals="4"
      id="ixv-19198"
      unitRef="usdPershares">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockVotingRights contextRef="c25" id="ixv-19199">one</us-gaap:CommonStockVotingRights>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-17021">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Note 10 - Share Based Payment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;On December 16, 2018, the Company&#x2019;s board
of directors approved an employee share option plan (&#x201c;ESOP&#x201d;). According to the provisions of the ESOP, the exercise period,
exercise price and vesting conditions for each option grant will be determined by the board of directors. The number of shares reserved
for issuance is subject to an annual increase to be added as of the first day of the Company&#x2019;s fiscal year, equal to 4% of the total
number of shares issued and outstanding on a fully-diluted basis as of the end of the immediately preceding fiscal year (or such lesser
number of shares, including no shares, determined by the Board in its sole discretion). Ordinary shares subject to options granted under
the 2018 Plan that expire or forfeited or otherwise terminated without having been exercised in full will become available again for future
grant under the 2018 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The expiration date of the options granted to
employees and directors is after 10 years from the grant date. Relating to options granted to services providers, the expiration date
of the options is between 3-10 years from the grant date. In addition, pursuant to the grant letters, the options granted to employees,
directors and service providers shall become vested and exercisable upon any merger or consolidation in which the Company is a constituent
party as described in the grant letters (&#x201c;Exit Event&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;On October&#160;31, 2021, the Company&#x2019;s
board of directors approved an amendment to the Company&#x2019;s 2018 Employee Share Option Plan. The amendment determines that the total
number of underlying shares reserved for future issuance under the plan and any modification thereof, shall be:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;900,000
shares, plus&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
annual increase to be added as of the first&#160;day of the Company&#x2019;s fiscal year, beginning in 2022 and occurring each year thereafter
through 2032, equal to 4% of the total number of ordinary shares issued and outstanding on a fully-diluted basis as of the end of the
Company&#x2019;s immediately preceding fiscal year (or such lesser number of shares, including no shares, determined by the board of directors
in its sole discretion).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;Following this amendment, the number of shares
reserved under this plan was 1,151,130. As of December 31, 2024, 688,705 ordinary shares are available for future grant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 10 and January 11, 2022, the Company&#x2019;s entered into option settlement agreement (&#x201c;Agreements&#x201d;) with certain
consultants of the Company. According to the Agreements, the Company exchanged 27,000 options granted to certain consultants with cash
payments in the aggregate of $96 thousand. The cash payment is deemed as the sole and complete settlement of the promised options. The
Company recorded an additional expense of $23 thousand for such settlement which was recorded in profit and loss. The Company recorded
the settlement agreement as a reduction in share premium and capital reserve.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 25, 2022 and March 10, 2022, the Company&#x2019;s board of directors and shareholders, respectively, approved the compensation
of each of the Company&#x2019;s external directors and a newly appointed director. Such compensation included the grant of 72,000 options
to each such director at an exercise price of $1.43 per share (total 216,000 options to three directors), pursuant to the Company&#x2019;s
2018 Employee Share Option Plan. One-third of each option award vests one year from the grant date and the remainder vests quarterly
and becomes fully vested three years from the grant date. The options expire 10 years after grant date.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 25, 2022, the Company&#x2019;s board of directors approved the grant of aggregate amount of 192,000 options to several employees.
The options have an exercise price of $2.18 per share. The options vest quarterly over three years starting January 25, 2022. The options
expire 10 years after grant date.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2022, the Company&#x2019;s board of directors approved the grant of aggregate amount of 36,000 options to an employee and amount
of 5,000 options consultant of the Company. The options have an exercise price of $3.97 and $2.18, respectively, per share. The options
vest quarterly over three and one years, respectively, from grant date. The options expire 10 years after grant date.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July and August 2022, the Company&#x2019;s board of directors approved the grant of aggregate amount of 20,000 options to a consultant
and an amount of 120,000 options to several employees of the Company. The options have an exercise price of $2.18 and $1.99, respectively,
per share. The options vest quarterly over three and one years, respectively, from grant date. The options expire 10 years after grant
date.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2022 the Company issued 85,449 of its ordinary shares to certain consultants in exchange for their services, with fair value of $119
thousand. One of the consultants received 44,000 shares of restricted stock which were issued in 4 equal installments and subject to
2 year lock-up period. Other consultant&#x2019;s shares are subject to 6 months restriction period (which ended by December 31, 2022).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;7.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On&#160;March 20, 2023, the Company&#x2019;s board of directors,
approved the following awards:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Grant
of 320,479 RSUs to certain officers, in lieu of cash with respect to the 2022 bonus plan grants in the amount of $161&#160;thousand.
The RSUs vest quarterly over two years with acceleration condition upon meeting certain milestones. The Company met the milestones in
2023 and therefore the vesting was accelerated accordingly.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
bonus for certain employees in the form of 100,000 and 60,000 RSUs. The RSUs vest on a quarterly basis over one year following the grant
and on an annual basis over three years following the grant, respectively.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
addition to the grants in accordance with the 2022 bonus plan mentioned above, a raise of additional 30% of the annual 2022 bonus will
be granted to the Company&#x2019;s CEO.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
grant of 13,628 options to a consultant of the Company with a total fair value of $22,500. The options have an exercise price of $1.82
per share. The options will vest monthly, over 9 months commencing January 1, 2023. The options expire 10 years after their grant date.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;8.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On May 30, 2023, the Company granted 160,000 RSUs to directors
of the Company. The RSUs have an exercise price of $1.53 per share. The RSUs shall vest entirely on the first anniversary of the vesting
commencement date, provided that no termination of employment of the grantee occurs prior to such anniversary.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;9.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On August 15, 2023, the Company&#x2019;s board of directors
approved the grant of aggregate amount of 60,000 options to several employees. The options have an exercise price of $0.96 per share
and vest quarterly over 3 years starting August 15, 2023, and (ii) the grant of 9,000 options to an employee. The options have an exercise
price of $0.96 per share and vest annually over 3 years starting August 15, 2023.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;10.&lt;/td&gt;&lt;td style="text-align: justify"&gt;In May 2024, the Company&#x2019;s board of directors, approved
the grant of 24,000 RSUs to a consultant of the Company. 12,000 RSUs vested on grant date, and the remaining 12,000 RSUs will vest monthly
(2,000 RSUs each month), over six months and until November 1, 2024. The fair value of RSUs is estimated by multiplying the number of
RSUs granted by the share price at grant date.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;11.&lt;/td&gt;&lt;td style="text-align: justify"&gt;In May 2024, the Company&#x2019;s board of directors, approved
the grant of 24,000 RSUs to a consultant of the Company. 4,000 RSUs vested on grant date, and the remaining 20,000 RSUs will vest monthly
(4,000 RSUs each month), over six months and until October 1, 2024. The fair value of RSUs is estimated by multiplying the number of
RSUs granted by share price at grant date.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;12.&lt;/td&gt;&lt;td style="text-align: justify"&gt;In May 2024, the Company&#x2019;s board of directors, approved
the grant of 9,000 options to an employee of the Company. The options will vest in equal amount annually over a 3 year period commencing
April 8, 2024. The options have an exercise price of $1.27 per share&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;On June 27, 2024, the Company&#x2019;s annual general meeting
of shareholders approved the following proposed resolutions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;1.&lt;/td&gt;&lt;td style="text-align: justify"&gt;A grant of 160,000 RSUs to the non-management directors of
the Company. Such RSUs would vest on the one year anniversary of the date of the meeting.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;2.&lt;/td&gt;&lt;td style="text-align: justify"&gt;To approve an amendment to the Company&#x2019;s Articles of
Association to increase the authorized share capital of the Company.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.5in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;3.&lt;/td&gt;&lt;td style="text-align: justify"&gt;An acceleration of the vesting of the 18,000 unvested options
of a former director, and extending the term of the unexercised options, such that they will expire 10 years from the date of grant&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The weighted average grant date fair value of
options granted during the years ended December&#160;31, 2024, 2023 and 2022 was $0.88, $0.80 and $1.40 per option, respectively. The
weighted average grant date fair value of RSUs granted during the years ended December&#160;31, 2024 and 2023 was $1.08 and $1.75 per
RSU, respectively.&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;Regarding issuance of 70,964 ordinary shares as
issuance costs in April 2024, see also Note 9A(f).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;Stock-based compensation expenses recognized in
profit and loss as an operating expense based on fair value of the option at the grant date by using Binominal option pricing model for
employees and directors and Black and Scholes pricing
model for non-employees. The inputs for the valuation analysis of the share options include several assumptions of which the most significant
are the fair market value of the underlying ordinary share, the expected share price volatility and the expected option term. Expected
volatility was calculated based upon historical volatility of the Company and peer companies in the same industry on weekly basis. Expected
option term represents the period that the Company&#x2019;s share options are expected to be outstanding. Risk-free interest rate is based
on the yield from U.S. treasury bonds with an equivalent term. Expected dividend yield assumption is based on the Company&#x2019;s historical
experience and expectation of no future dividend payouts. The Company has historically not paid cash dividends and has no foreseeable
plans to pay cash dividends in the future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The following table lists the inputs used for calculation
of fair value of the options granted to employees and directors for the years ended December 31, 2024, 2023 and 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 58%; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 13%; text-align: center"&gt;93.72%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 13%; text-align: center"&gt;91.80% - 93.51%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 13%; text-align: center"&gt;93.63% - 93.79%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;1.27&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0.96 - 1.99&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;1.43 - 3.97&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;1.27&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0.96 - 1.99&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;1.43 - 3.97&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;4.61%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;3.24% - 4.35%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;2.12% - 2.46%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Expected life (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The following table lists the inputs used for
calculation of fair value of the options granted to consultants for the years ended December 31, 2024, 2023 and 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100.540%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;93.64%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise price&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.82&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.18&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share price &lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.82&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.41 - 1.96&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.64%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.91% - 2.91%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="width: 58%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 13%; text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 13%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 13%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The following table summarizes the share option activity for employees,
directors, and non-employees for the annual periods ended on December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Number of&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;br/&gt; Average &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Intrinsic&lt;br/&gt;
value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Share&lt;br/&gt;
Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;contractual&lt;br/&gt; life (years)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;U.S. dollars&lt;br/&gt; in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%"&gt;Options outstanding at January 1, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,069,128&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2.26&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;62&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.96&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif"&gt;(*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 2.5pt"&gt;Options outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,069,128&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;6.68&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;936,968&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.34&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;6.52&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;less than $1 thousands&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The income tax benefit for the share options exercised
expense after the valuation allowance is 0.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The following table summarizes the RSUs activity for the annual periods
ended on December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Weighted&lt;br/&gt;
 average&lt;br/&gt;
 grant date&lt;br/&gt;
 fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Number of&lt;br/&gt;
    RSUs&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;U.S. dollars&lt;br/&gt;
 in&#160;thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Outstanding at January 1, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;317,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;249&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(325,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;200,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;236&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The income tax benefit for the stock-based compensation
expense after the valuation allowance is 0.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The share-based expense recognized in the statements of operations
were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Share-based compensation expense - Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;193&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;575&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;570&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Share-based compensation expense - General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;364&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;962&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,158&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;557&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,537&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,728&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;As of December 31, 2024, there was $43 thousand
of unrecognized compensation expense related to unvested options and RSUs. Such unrecognized expenses will be recognized over a weighted
average period of approximately 1.25 years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <nrsn:NumberOfSharesPercentage
      contextRef="c111"
      decimals="2"
      id="ixv-19200"
      unitRef="pure">0.04</nrsn:NumberOfSharesPercentage>
    <nrsn:ExpirationDateGrantTerm contextRef="c0" id="ixv-19201">P10Y</nrsn:ExpirationDateGrantTerm>
    <nrsn:ExpirationDateGrantTerm contextRef="c112" id="ixv-19202">P3Y</nrsn:ExpirationDateGrantTerm>
    <nrsn:ExpirationDateGrantTerm contextRef="c113" id="ixv-19203">P10Y</nrsn:ExpirationDateGrantTerm>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c114"
      decimals="0"
      id="ixv-19204"
      unitRef="shares">900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <nrsn:NumberOfSharesPercentage contextRef="c0" decimals="2" id="ixv-19205" unitRef="pure">0.04</nrsn:NumberOfSharesPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c115"
      decimals="0"
      id="ixv-19206"
      unitRef="shares">1151130</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c116"
      decimals="0"
      id="ixv-19207"
      unitRef="shares">688705</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c117"
      decimals="0"
      id="ixv-19208"
      unitRef="shares">27000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="c118"
      decimals="-3"
      id="ixv-19209"
      unitRef="usd">96000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherExpenses contextRef="c0" decimals="-3" id="ixv-19210" unitRef="usd">23000</us-gaap:OtherExpenses>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c119"
      decimals="0"
      id="ixv-19211"
      unitRef="shares">72000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-19212"
      unitRef="usdPershares">1.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c120"
      decimals="0"
      id="ixv-19213"
      unitRef="shares">216000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-19214">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c0" id="ixv-19215">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c121"
      decimals="0"
      id="ixv-19216"
      unitRef="shares">192000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c121"
      decimals="2"
      id="ixv-19217"
      unitRef="usdPershares">2.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c122" id="ixv-19218">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c123"
      decimals="0"
      id="ixv-19219"
      unitRef="shares">36000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c124"
      decimals="0"
      id="ixv-19220"
      unitRef="shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c125"
      decimals="2"
      id="ixv-19221"
      unitRef="usdPershares">3.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c126"
      decimals="2"
      id="ixv-19222"
      unitRef="usdPershares">2.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c125" id="ixv-19223">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c126" id="ixv-19224">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c127" id="ixv-19226">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c128"
      decimals="0"
      id="ixv-19227"
      unitRef="shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c129"
      decimals="0"
      id="ixv-19228"
      unitRef="shares">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c128"
      decimals="2"
      id="ixv-19229"
      unitRef="usdPershares">2.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c129"
      decimals="2"
      id="ixv-19230"
      unitRef="usdPershares">1.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c130" id="ixv-19231">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c131" id="ixv-19232">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c131" id="ixv-19234">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c130" id="ixv-19235">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c132"
      decimals="0"
      id="ixv-19236"
      unitRef="shares">85449</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c7" decimals="-3" id="ixv-19237" unitRef="usd">119000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="c7"
      decimals="0"
      id="ixv-19238"
      unitRef="shares">44000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <nrsn:NumberOfInstallments contextRef="c7" decimals="0" id="ixv-19239" unitRef="pure">4</nrsn:NumberOfInstallments>
    <nrsn:InstallmentsLockUpPeriod contextRef="c7" id="ixv-19240">P2Y</nrsn:InstallmentsLockUpPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c133"
      decimals="0"
      id="ixv-19241"
      unitRef="shares">320479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="c133"
      decimals="-3"
      id="ixv-19242"
      unitRef="usd">161000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c133" id="ixv-19243">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares
      contextRef="c134"
      decimals="0"
      id="ixv-19244"
      unitRef="shares">100000</us-gaap:EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares>
    <us-gaap:EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares
      contextRef="c135"
      decimals="0"
      id="ixv-19245"
      unitRef="shares">60000</us-gaap:EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c136" id="ixv-19246">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c137" id="ixv-19247">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <nrsn:RaiseOfAdditionalBonusPercentage
      contextRef="c138"
      decimals="2"
      id="ixv-19248"
      unitRef="pure">0.30</nrsn:RaiseOfAdditionalBonusPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c139"
      decimals="0"
      id="ixv-19249"
      unitRef="shares">13628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c139" decimals="0" id="ixv-19250" unitRef="usd">22500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c140"
      decimals="2"
      id="ixv-19251"
      unitRef="usdPershares">1.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c141" id="ixv-19252">P9M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c141" id="ixv-19253">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c142"
      decimals="0"
      id="ixv-19254"
      unitRef="shares">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <nrsn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice
      contextRef="c143"
      decimals="2"
      id="ixv-19255"
      unitRef="usdPershares">1.53</nrsn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c144"
      decimals="0"
      id="ixv-19256"
      unitRef="shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c145"
      decimals="2"
      id="ixv-19257"
      unitRef="usdPershares">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c144" id="ixv-19258">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c146"
      decimals="0"
      id="ixv-19259"
      unitRef="shares">9000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c147"
      decimals="2"
      id="ixv-19260"
      unitRef="usdPershares">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c146" id="ixv-19261">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c148"
      decimals="0"
      id="ixv-19262"
      unitRef="shares">24000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c149"
      decimals="0"
      id="ixv-19263"
      unitRef="shares">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c149"
      decimals="0"
      id="ixv-19264"
      unitRef="shares">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c150"
      decimals="0"
      id="ixv-19265"
      unitRef="shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c148"
      decimals="0"
      id="ixv-19266"
      unitRef="shares">24000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c151"
      decimals="0"
      id="ixv-19267"
      unitRef="shares">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c148"
      decimals="0"
      id="ixv-19268"
      unitRef="shares">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c152"
      decimals="0"
      id="ixv-19269"
      unitRef="shares">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c153"
      decimals="0"
      id="ixv-19270"
      unitRef="shares">9000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c153" id="ixv-19271">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c154"
      decimals="2"
      id="ixv-19272"
      unitRef="usdPershares">1.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c155"
      decimals="0"
      id="ixv-19273"
      unitRef="shares">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c155" id="ixv-19274">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c156"
      decimals="0"
      id="ixv-19275"
      unitRef="shares">18000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c94" id="ixv-19276">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c157"
      decimals="2"
      id="ixv-19277"
      unitRef="usdPershares">0.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c158"
      decimals="2"
      id="ixv-19278"
      unitRef="usdPershares">0.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c159"
      decimals="2"
      id="ixv-19279"
      unitRef="usdPershares">1.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c160"
      decimals="2"
      id="ixv-19280"
      unitRef="usdPershares">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c161"
      decimals="2"
      id="ixv-19281"
      unitRef="usdPershares">1.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c162"
      decimals="0"
      id="ixv-19282"
      unitRef="shares">70964</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0" id="ixv-17241">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The following table lists the inputs used for calculation
of fair value of the options granted to employees and directors for the years ended December 31, 2024, 2023 and 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 58%; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 13%; text-align: center"&gt;93.72%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 13%; text-align: center"&gt;91.80% - 93.51%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 13%; text-align: center"&gt;93.63% - 93.79%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;1.27&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0.96 - 1.99&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;1.43 - 3.97&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;1.27&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0.96 - 1.99&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;1.43 - 3.97&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;4.61%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;3.24% - 4.35%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;2.12% - 2.46%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;0&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;Expected life (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;10&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The following table lists the inputs used for
calculation of fair value of the options granted to consultants for the years ended December 31, 2024, 2023 and 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100.540%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;93.64%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exercise price&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.82&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.18&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share price &lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.82&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.41 - 1.96&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.64%&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.91% - 2.91%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt; &lt;td style="width: 58%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 13%; text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 13%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 13%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c165"
      decimals="4"
      id="ixv-19283"
      unitRef="pure">0.9372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c166"
      decimals="4"
      id="ixv-19284"
      unitRef="pure">0.918</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c167"
      decimals="4"
      id="ixv-19285"
      unitRef="pure">0.9351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c168"
      decimals="4"
      id="ixv-19286"
      unitRef="pure">0.9363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c169"
      decimals="4"
      id="ixv-19287"
      unitRef="pure">0.9379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c170"
      decimals="2"
      id="ixv-19288"
      unitRef="usdPershares">1.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c171"
      decimals="2"
      id="ixv-19289"
      unitRef="usdPershares">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c172"
      decimals="2"
      id="ixv-19290"
      unitRef="usdPershares">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c173"
      decimals="2"
      id="ixv-19291"
      unitRef="usdPershares">1.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c174"
      decimals="2"
      id="ixv-19292"
      unitRef="usdPershares">3.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharePrice
      contextRef="c170"
      decimals="2"
      id="ixv-19293"
      unitRef="usdPershares">1.27</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c171"
      decimals="2"
      id="ixv-19294"
      unitRef="usdPershares">0.96</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c172"
      decimals="2"
      id="ixv-19295"
      unitRef="usdPershares">1.99</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c173"
      decimals="2"
      id="ixv-19296"
      unitRef="usdPershares">1.43</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c174"
      decimals="2"
      id="ixv-19297"
      unitRef="usdPershares">3.97</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c165"
      decimals="4"
      id="ixv-19298"
      unitRef="pure">0.0461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c166"
      decimals="4"
      id="ixv-19299"
      unitRef="pure">0.0324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c167"
      decimals="4"
      id="ixv-19300"
      unitRef="pure">0.0435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c168"
      decimals="4"
      id="ixv-19301"
      unitRef="pure">0.0212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c169"
      decimals="4"
      id="ixv-19302"
      unitRef="pure">0.0246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c165"
      decimals="2"
      id="ixv-19303"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c175"
      decimals="2"
      id="ixv-19304"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c176"
      decimals="2"
      id="ixv-19305"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c165" id="ixv-19306">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c175" id="ixv-19307">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c176" id="ixv-19308">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c6" decimals="5" id="ixv-19309" unitRef="pure">1.0054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c7" decimals="4" id="ixv-19310" unitRef="pure">0.9364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c5"
      decimals="2"
      id="ixv-19311"
      unitRef="usdPershares">1.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c18"
      decimals="2"
      id="ixv-19312"
      unitRef="usdPershares">2.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharePrice
      contextRef="c5"
      decimals="2"
      id="ixv-19313"
      unitRef="usdPershares">1.82</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c177"
      decimals="2"
      id="ixv-19314"
      unitRef="usdPershares">1.41</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c178"
      decimals="2"
      id="ixv-19315"
      unitRef="usdPershares">1.96</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c6" decimals="4" id="ixv-19316" unitRef="pure">0.0364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c179"
      decimals="4"
      id="ixv-19317"
      unitRef="pure">0.0191</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c180"
      decimals="4"
      id="ixv-19318"
      unitRef="pure">0.0291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c6" decimals="2" id="ixv-19319" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c7" decimals="2" id="ixv-19320" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c6" id="ixv-17387">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c7" id="ixv-19321">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-17419">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The following table summarizes the share option activity for employees,
directors, and non-employees for the annual periods ended on December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Number of&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;br/&gt; Average &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Intrinsic&lt;br/&gt;
value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Share&lt;br/&gt;
Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;contractual&lt;br/&gt; life (years)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;U.S. dollars&lt;br/&gt; in thousands&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 52%"&gt;Options outstanding at January 1, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,069,128&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2.26&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;62&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.96&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif"&gt;(*&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-bottom: 2.5pt"&gt;Options outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,069,128&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;6.68&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;936,968&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2.34&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;6.52&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c181"
      decimals="INF"
      id="ixv-19322"
      unitRef="shares">1069128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c181"
      decimals="2"
      id="ixv-19323"
      unitRef="usdPershares">2.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c182" id="ixv-19324">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c181"
      decimals="-3"
      id="ixv-19325"
      unitRef="usd">62000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c183"
      decimals="INF"
      id="ixv-19326"
      unitRef="shares">9000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c183"
      decimals="2"
      id="ixv-19327"
      unitRef="usdPershares">1.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <nrsn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted contextRef="c183" id="ixv-19328">P10Y</nrsn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeGranted>
    <nrsn:ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod
      contextRef="c183"
      decimals="INF"
      id="ixv-19329"
      unitRef="shares">-9000</nrsn:ShareBasedCompensationArrangementByShareBasedPaymentsAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c183"
      decimals="2"
      id="ixv-19330"
      unitRef="usdPershares">0.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c184"
      decimals="INF"
      id="ixv-19331"
      unitRef="shares">1069128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c184"
      decimals="2"
      id="ixv-19332"
      unitRef="usdPershares">2.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c183" id="ixv-19333">P6Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c184"
      decimals="INF"
      id="ixv-19334"
      unitRef="shares">936968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c184"
      decimals="2"
      id="ixv-19335"
      unitRef="usdPershares">2.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c183" id="ixv-19336">P6Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c157" decimals="0" id="ixv-19337" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c0" id="ixv-17566">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The following table summarizes the RSUs activity for the annual periods
ended on December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Weighted&lt;br/&gt;
 average&lt;br/&gt;
 grant date&lt;br/&gt;
 fair value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Number of&lt;br/&gt;
    RSUs&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;U.S. dollars&lt;br/&gt;
 in&#160;thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Outstanding at January 1, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;317,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;249&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(325,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;200,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;236&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c185"
      decimals="INF"
      id="ixv-19338"
      unitRef="shares">317000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c185"
      decimals="-3"
      id="ixv-19339"
      unitRef="usd">249000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c160"
      decimals="INF"
      id="ixv-19340"
      unitRef="shares">208000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <nrsn:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted
      contextRef="c160"
      decimals="-3"
      id="ixv-19341"
      unitRef="usd">224000</nrsn:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c160"
      decimals="INF"
      id="ixv-19342"
      unitRef="shares">325000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c163"
      decimals="INF"
      id="ixv-19343"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c163"
      decimals="-3"
      id="ixv-19344"
      unitRef="usd">236000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c160" decimals="0" id="ixv-19345" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <srt:CondensedStatementOfComprehensiveIncomeTableTextBlock contextRef="c0" id="ixv-17635">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;The share-based expense recognized in the statements of operations
were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Share-based compensation expense - Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;193&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;575&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;570&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Share-based compensation expense - General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;364&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;962&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,158&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;557&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,537&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,728&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:CondensedStatementOfComprehensiveIncomeTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c186"
      decimals="-3"
      id="ixv-19346"
      unitRef="usd">193000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c187"
      decimals="-3"
      id="ixv-19347"
      unitRef="usd">575000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c188"
      decimals="-3"
      id="ixv-19348"
      unitRef="usd">570000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c189"
      decimals="-3"
      id="ixv-19349"
      unitRef="usd">364000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c190"
      decimals="-3"
      id="ixv-19350"
      unitRef="usd">962000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c191"
      decimals="-3"
      id="ixv-19351"
      unitRef="usd">1158000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" id="ixv-19352" unitRef="usd">557000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c6" decimals="-3" id="ixv-19353" unitRef="usd">1537000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c7" decimals="-3" id="ixv-19354" unitRef="usd">1728000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="c163"
      decimals="-3"
      id="ixv-19355"
      unitRef="usd">43000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="c164"
      decimals="-3"
      id="ixv-19356"
      unitRef="usd">43000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c0" id="ixv-19357">P1Y3M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="c0" id="ixv-17725">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 11 - Research and development expenses&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Subcontractors and consultants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,530&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,794&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,612&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;193&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;575&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;570&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Salaries and social benefits (*)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,905&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,405&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,698&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,274&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,587&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock contextRef="c0" id="ixv-19358">Research and development expenses&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Subcontractors and consultants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,530&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,794&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,612&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;193&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;575&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;570&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Salaries and social benefits (*)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,975&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,905&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,405&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,698&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,274&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,587&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock>
    <nrsn:SubcontractorsAndConsultants contextRef="c0" decimals="-3" id="ixv-19359" unitRef="usd">3530000</nrsn:SubcontractorsAndConsultants>
    <nrsn:SubcontractorsAndConsultants contextRef="c6" decimals="-3" id="ixv-19360" unitRef="usd">4794000</nrsn:SubcontractorsAndConsultants>
    <nrsn:SubcontractorsAndConsultants contextRef="c7" decimals="-3" id="ixv-19361" unitRef="usd">3612000</nrsn:SubcontractorsAndConsultants>
    <nrsn:SharebasedCompensation contextRef="c0" decimals="-3" id="ixv-19362" unitRef="usd">193000</nrsn:SharebasedCompensation>
    <nrsn:SharebasedCompensation contextRef="c6" decimals="-3" id="ixv-19363" unitRef="usd">575000</nrsn:SharebasedCompensation>
    <nrsn:SharebasedCompensation contextRef="c7" decimals="-3" id="ixv-19364" unitRef="usd">570000</nrsn:SharebasedCompensation>
    <nrsn:SalariesAndSocialBenefits contextRef="c0" decimals="-3" id="ixv-19365" unitRef="usd">1975000</nrsn:SalariesAndSocialBenefits>
    <nrsn:SalariesAndSocialBenefits contextRef="c6" decimals="-3" id="ixv-19366" unitRef="usd">1905000</nrsn:SalariesAndSocialBenefits>
    <nrsn:SalariesAndSocialBenefits contextRef="c7" decimals="-3" id="ixv-19367" unitRef="usd">1405000</nrsn:SalariesAndSocialBenefits>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-19368" unitRef="usd">5698000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-19369" unitRef="usd">7274000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-19370" unitRef="usd">5587000</us-gaap:ResearchAndDevelopmentExpense>
    <nrsn:GeneralAndAdministrativeExpensesDisclosureTextBlock contextRef="c0" id="ixv-17825">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 12 - General and Administrative Expenses&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Professional services&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,486&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,085&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;364&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;962&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Salaries and social benefits (*)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;865&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,011&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,014&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;511&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,174&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Traveling abroad&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;164&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;534&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;641&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;371&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,204&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,775&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,967&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;During 2024, 2023 and 2022, the Company paid to pension funds
and to insurance companies an amount of $115 thousand, $104 thousand and $85 thousand which are included in Company&#x2019;s salary expenses
under research and development and general and administrative expenses, respectively.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</nrsn:GeneralAndAdministrativeExpensesDisclosureTextBlock>
    <nrsn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock contextRef="c0" id="ixv-17829">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Professional services&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,486&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,085&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;364&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;962&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,158&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Salaries and social benefits (*)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;865&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,011&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,014&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Insurance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;511&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,174&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Traveling abroad&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;134&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;164&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;165&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;534&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;641&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;371&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,204&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,775&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,967&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;(*)&lt;/td&gt;&lt;td style="text-align: justify"&gt;During 2024, 2023 and 2022, the Company paid to pension funds
and to insurance companies an amount of $115 thousand, $104 thousand and $85 thousand which are included in Company&#x2019;s salary expenses
under research and development and general and administrative expenses, respectively.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</nrsn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock>
    <us-gaap:ProfessionalAndContractServicesExpense contextRef="c0" decimals="-3" id="ixv-19371" unitRef="usd">1998000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense contextRef="c6" decimals="-3" id="ixv-19372" unitRef="usd">1486000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense contextRef="c7" decimals="-3" id="ixv-19373" unitRef="usd">1085000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-19374" unitRef="usd">364000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c6" decimals="-3" id="ixv-19375" unitRef="usd">962000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c7" decimals="-3" id="ixv-19376" unitRef="usd">1158000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="c0" decimals="-3" id="ix_2_fact" unitRef="usd">865000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="c6" decimals="-3" id="ix_3_fact" unitRef="usd">1011000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="c7" decimals="-3" id="ix_4_fact" unitRef="usd">1014000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:GeneralInsuranceExpense contextRef="c0" decimals="-3" id="ixv-19380" unitRef="usd">309000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense contextRef="c6" decimals="-3" id="ixv-19381" unitRef="usd">511000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense contextRef="c7" decimals="-3" id="ixv-19382" unitRef="usd">1174000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:TravelAndEntertainmentExpense contextRef="c0" decimals="-3" id="ixv-19383" unitRef="usd">134000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense contextRef="c6" decimals="-3" id="ixv-19384" unitRef="usd">164000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense contextRef="c7" decimals="-3" id="ixv-19385" unitRef="usd">165000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-19386" unitRef="usd">534000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-19387" unitRef="usd">641000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-19388" unitRef="usd">371000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-19389" unitRef="usd">4204000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-19390" unitRef="usd">4775000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-19391" unitRef="usd">4967000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:PensionContributions contextRef="c0" decimals="-3" id="ixv-19393" unitRef="usd">115000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions contextRef="c6" decimals="-3" id="ixv-19394" unitRef="usd">104000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions contextRef="c7" decimals="-3" id="ixv-19395" unitRef="usd">85000</us-gaap:PensionContributions>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock contextRef="c0" id="ixv-17959">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 13 - Financing Income (expenses), net&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Finance Income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Revaluation of warrants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;46&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,191&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deposit interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;178&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange rates&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,390&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;91&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance Expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(306&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(439&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Exchange rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(45&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(22&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Bank fees&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(356&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(448&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(29&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total financing income (expanse), net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,942&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="c0" id="ixv-17963">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;U.S. dollars in thousands&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Finance Income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Revaluation of warrants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;46&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,191&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deposit interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;178&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange rates&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,390&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;91&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Finance Expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(306&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(439&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Exchange rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(45&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(22&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Bank fees&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(356&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(448&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(29&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total financing income (expanse), net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(308&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,942&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;62&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c0" decimals="-3" id="ixv-19396" unitRef="usd">-46000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c6" decimals="-3" id="ixv-19397" unitRef="usd">-2191000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c0" decimals="-3" id="ixv-19398" unitRef="usd">2000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c6" decimals="-3" id="ixv-19399" unitRef="usd">178000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c7" decimals="-3" id="ixv-19400" unitRef="usd">91000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <nrsn:ExchangeRates contextRef="c6" decimals="-3" id="ixv-19401" unitRef="usd">21000</nrsn:ExchangeRates>
    <us-gaap:OtherNonoperatingIncome contextRef="c0" decimals="-3" id="ixv-19402" unitRef="usd">48000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="c6" decimals="-3" id="ixv-19403" unitRef="usd">2390000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="c7" decimals="-3" id="ixv-19404" unitRef="usd">91000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c0" decimals="-3" id="ixv-19405" unitRef="usd">306000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c6" decimals="-3" id="ixv-19406" unitRef="usd">439000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ExchangeFees contextRef="c0" decimals="-3" id="ixv-19407" unitRef="usd">45000</us-gaap:ExchangeFees>
    <us-gaap:ExchangeFees contextRef="c7" decimals="-3" id="ixv-19408" unitRef="usd">22000</us-gaap:ExchangeFees>
    <us-gaap:InterestExpenseLoansFromOtherFederalHomeLoanBanks contextRef="c0" decimals="-3" id="ixv-19409" unitRef="usd">5000</us-gaap:InterestExpenseLoansFromOtherFederalHomeLoanBanks>
    <us-gaap:InterestExpenseLoansFromOtherFederalHomeLoanBanks contextRef="c6" decimals="-3" id="ixv-19410" unitRef="usd">9000</us-gaap:InterestExpenseLoansFromOtherFederalHomeLoanBanks>
    <us-gaap:InterestExpenseLoansFromOtherFederalHomeLoanBanks contextRef="c7" decimals="-3" id="ixv-19411" unitRef="usd">7000</us-gaap:InterestExpenseLoansFromOtherFederalHomeLoanBanks>
    <us-gaap:OtherNonoperatingExpense contextRef="c0" decimals="-3" id="ixv-19412" unitRef="usd">356000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="c6" decimals="-3" id="ixv-19413" unitRef="usd">448000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="c7" decimals="-3" id="ixv-19414" unitRef="usd">29000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-19415" unitRef="usd">-308000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c6" decimals="-3" id="ixv-19416" unitRef="usd">1942000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c7" decimals="-3" id="ixv-19417" unitRef="usd">62000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-18179">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 14 - Related Parties Balances and Transactions&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 10 and June 21, 2022, the Company&#x2019;s board of directors and shareholders, respectively, approved a bonus plan for 2022 for the
Company&#x2019;s officers. The bonus plan defined specified millstones (in fields of clinic trial progress, business developments and
raise of money) which their achievements entitled the officers with different percentages out of fix amount of bonus.&#160;As detailed
in the plan, such bonuses (if entitled) will be paid in cash or, if the Company has less than $6 million of cash and cash equivalents
and deposits on December 31, 2022, a number of ordinary shares of the Company with a value equal to the cash bonus amount to which the
officer would otherwise have been entitled, valuing each ordinary share at the closing price of the Company&#x2019;s shares on Nasdaq
on December 31, 2022. Since the cash and cash equivalents and deposits on December 31,2022 was more than $6 million, the 2022 bonus should
have been paid in cash. Based on the goals achieved&#160;as of December 31, 2022, the Company recorded a payment liability in the amount
of $370 thousand which has been recorded as salary fee in the year ending December 31, 2022. In March 2023, certain officer&#x2019;s 2022
bonus was replaced by issuance of RSUs and an update to 2022 annual bonus of the CEO was approved (see also Note 10).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
March and May 2023, certain officers and directors were granted with options and RSUs, see also Note 10.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March and May, 2023, the Company&#x2019;s board of directors and shareholders, respectively, approved a bonus plan for 2023 for the Company&#x2019;s
officers. The bonus plan defined specified millstones (in fields of clinic trail progress, regulatory efforts, business developments
and raise of money) which their achievements entitled the officers with different percentages out of fix amount of bonus.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2024, the Company&#x2019;s board of directors approved a change to the 2023 bonuses plan to the Company&#x2019;s officers for which
included a change to the bonus calculations previously approved. Following the change, such bonuses will become effective and paid only
after a capital raise, that will allow the initiation of the Company&#x2019;s planned phase 3 clinical study, of at least $18 million.
The aggregate amount of the potential bonus payable to the officers after such capital raise will be approximately $0.8 million.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2024, the Company&#x2019;s board of directors approved a bonus plan for 2024 for certain Company&#x2019;s officers. The bonus plan
defined specified millstones (in fields of clinic trail progress, regulatory affairs, business developments and capital raising).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;5.&lt;/td&gt;&lt;td style="text-align: justify"&gt;On June 27, 2024, the Company&#x2019;s annual general meeting
of shareholders approved the following proposed resolutions, among others:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;1.&lt;/td&gt; &lt;td style="text-align: justify"&gt;An acceleration of the vesting of the 18,000 unvested options of a former director, and extending the term of the unexercised options, such that they will expire 10 years from the date of grant&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;2.&lt;/td&gt; &lt;td style="text-align: justify"&gt;To approve a 2024 bonus plan for the Company&#x2019;s CEO Officer of the Company, based on the achievement of certain Company milestones.&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;3.&lt;/td&gt; &lt;td style="text-align: justify"&gt;To approve the renewal of Mr. Alon Ben-Noon&#x2019;s the Company&#x2019;s CEO&#x2019;s employment agreement with the Company and in addition, an update to his salary in the event that the Company raises an aggregate of US 25,000,000.&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;4.&lt;/td&gt; &lt;td style="text-align: justify"&gt;To approve the grant of 160,000 RSUs to the Company&#x2019;s directors, see Note 10.&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 17, 2024, the Company&#x2019;s CEO, together with CFO, CMO, CTO, COO, signed a waiver letter with respect to bonuses, that they
were entitled for the years 2022-2024 in their capacity as shareholders. As part of this waiver, the Company recorded an amount of $1,434
thousands within additional paid in capital.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
August and December 2024, the Company entered into a share purchase agreement with certain senior management, see also Note 9A(h) and
9A(l).&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="c177"
      decimals="-6"
      id="ixv-19418"
      unitRef="usd">6000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="c178"
      decimals="-6"
      id="ixv-19419"
      unitRef="usd">6000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AccruedSalariesCurrentAndNoncurrent contextRef="c18" decimals="-3" id="ixv-19420" unitRef="usd">370000</us-gaap:AccruedSalariesCurrentAndNoncurrent>
    <us-gaap:AccruedBonusesCurrentAndNoncurrent
      contextRef="c192"
      decimals="-6"
      id="ixv-19421"
      unitRef="usd">18000000</us-gaap:AccruedBonusesCurrentAndNoncurrent>
    <nrsn:PotentialBonusPayable
      contextRef="c193"
      decimals="-5"
      id="ixv-19422"
      unitRef="usd">800000</nrsn:PotentialBonusPayable>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c94"
      decimals="0"
      id="ixv-19423"
      unitRef="shares">18000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c94" id="ixv-19424">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:AccruedSalariesCurrentAndNoncurrent contextRef="c194" decimals="0" id="ixv-19425" unitRef="usd">25000000</us-gaap:AccruedSalariesCurrentAndNoncurrent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c195"
      decimals="0"
      id="ixv-19426"
      unitRef="shares">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="c196"
      decimals="-3"
      id="ixv-19427"
      unitRef="usd">1434000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0" id="ixv-18307">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 15 &#x2013; Segment Reporting&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Segment information is prepared on the same basis
that the chief executive officer, who is the Company&#x2019;s chief operating decision maker, manages the business, makes business decisions
and assesses performance. The Company has one reportable segment specializing in the development of treatments for patients suffering
from debilitating neurodegenerative diseases, as described in Note 1.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The CODM assesses performance for this segment
and decides how to allocate resources based on net loss. This net loss comprised of research and development expenses related to its product,
general and administrative costs and net financing income or expanses. The CODM performs the assessment of segment performance by using
the reported measure of segment profit or loss to monitor budget versus actual results.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The net profit or loss report regularly reviewed
by the CODM is identical to the Consolidated Statements of Income and Comprehensive Loss and the related notes in the financial statements
of the company for years ending December 31, 2024, 2023 and 2022.&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-18338">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 16 - Income Taxes&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Israeli taxation: &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The tax rate relevant to the Company
in the years 2024, 2023 and 2022 was 23%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.45pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;As of December 31, 2024, the Company
has net operating loss carryforwards for Israeli income tax purposes of approximately $24,730, which can be offset against future taxable
income for an indefinite period of time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.45pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company has
final (considered final) tax assessments in Israel through the 2019 tax year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred taxes reflect the net tax effects of carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#x2019;s net deferred tax assets are as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;U.S. dollars&lt;br/&gt;
 in thousands&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Net operating loss carryforward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,688&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,315&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Other temporary differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Capitalized research and development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,282&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Vacation and convalescence accrual&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;67&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Total deferred tax assets:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,149&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,864&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Deferred tax liability: Operating lease right-of-use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(35&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Total deferred tax liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(35&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Net deferred tax assets:&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,130&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,829&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Less: Valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,130&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,829&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;In assessing the realization of deferred
tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.
The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which
temporary differences are deductible and net operating loss carryforward are available. Based on consideration of these factors, the Company
recorded a valuation allowance as of December 31, 2024 and 2023 for all deferred tax assets not supported by reversing taxable temporary
differences.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 16.45pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The portion of the valuation allowance
for deferred tax assets for which subsequently recognized tax benefits would be applied directly to contributed capital was $782 thousand
and $693 thousand in 2024 and 2023, respectively.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;During the years ended December 31, 2024 and 2023, the main reconciling item between the statutory income tax rate in Israel, the country of domicile of the Company (as noted in Note 16A) and the effective tax rate is mainly the recognition of valuation allowance in respect of deferred taxes relating to net operating loss carryforwards and other temporary differences due to the uncertainty of the realization of such deferred taxes.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.25in"&gt; The net change during the year ended December 31, 2024, 2023 and 2022 in the total valuation allowance amounted was $2,301 thousands, $1,813 thousands and $$1,419 thousands, respectively. &#160; &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;The movement of the valuation allowance (through income statement) is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt"&gt;&lt;b&gt;U.S. dollars in thousands&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Balance at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;4,829&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;3,016&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;1,607&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Addition of valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,301&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Net change in the valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,301&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,813&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,409&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Balance at the end of the year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;7,130&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;4,829&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;3,016&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
      contextRef="c197"
      decimals="2"
      id="ixv-19428"
      unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
      contextRef="c198"
      decimals="2"
      id="ixv-19429"
      unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
      contextRef="c199"
      decimals="2"
      id="ixv-19430"
      unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c200"
      decimals="-3"
      id="ixv-19431"
      unitRef="usd">24730000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-19432">Significant components of the Company&#x2019;s net deferred tax assets are as follows:&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 1pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;U.S. dollars&lt;br/&gt;
 in thousands&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Net operating loss carryforward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,688&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,315&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Other temporary differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Capitalized research and development costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,282&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;17&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;33&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Vacation and convalescence accrual&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;67&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Total deferred tax assets:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,149&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,864&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Deferred tax liability: Operating lease right-of-use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(35&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Total deferred tax liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(35&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Net deferred tax assets:&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,130&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,829&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Less: Valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,130&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,829&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Net deferred tax asset&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c4" decimals="-3" id="ixv-19433" unitRef="usd">5688000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c5" decimals="-3" id="ixv-19434" unitRef="usd">3315000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsStateTaxes contextRef="c4" decimals="-3" id="ixv-19435" unitRef="usd">95000</us-gaap:DeferredTaxAssetsStateTaxes>
    <us-gaap:DeferredTaxAssetsStateTaxes contextRef="c5" decimals="-3" id="ixv-19436" unitRef="usd">71000</us-gaap:DeferredTaxAssetsStateTaxes>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c4" decimals="-3" id="ixv-19437" unitRef="usd">1282000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c5" decimals="-3" id="ixv-19438" unitRef="usd">1395000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <nrsn:DeferredTaxAssetsOperatingLeaseLiability contextRef="c4" decimals="-3" id="ixv-19439" unitRef="usd">17000</nrsn:DeferredTaxAssetsOperatingLeaseLiability>
    <nrsn:DeferredTaxAssetsOperatingLeaseLiability contextRef="c5" decimals="-3" id="ixv-19440" unitRef="usd">33000</nrsn:DeferredTaxAssetsOperatingLeaseLiability>
    <nrsn:DeferredTaxAssetsVacationAndConvalescenceAccrual contextRef="c4" decimals="-3" id="ixv-19441" unitRef="usd">67000</nrsn:DeferredTaxAssetsVacationAndConvalescenceAccrual>
    <nrsn:DeferredTaxAssetsVacationAndConvalescenceAccrual contextRef="c5" decimals="-3" id="ixv-19442" unitRef="usd">50000</nrsn:DeferredTaxAssetsVacationAndConvalescenceAccrual>
    <us-gaap:DeferredTaxAssetsGross contextRef="c4" decimals="-3" id="ixv-19443" unitRef="usd">7149000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c5" decimals="-3" id="ixv-19444" unitRef="usd">4864000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c4" decimals="-3" id="ixv-19445" unitRef="usd">19000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c5" decimals="-3" id="ixv-19446" unitRef="usd">35000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c4" decimals="-3" id="ixv-19447" unitRef="usd">19000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c5" decimals="-3" id="ixv-19448" unitRef="usd">35000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet contextRef="c4" decimals="-3" id="ixv-19449" unitRef="usd">7130000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c5" decimals="-3" id="ixv-19450" unitRef="usd">4829000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="-3" id="ixv-19451" unitRef="usd">7130000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c5" decimals="-3" id="ixv-19452" unitRef="usd">4829000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c197"
      decimals="-3"
      id="ixv-19453"
      unitRef="usd">782000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c198"
      decimals="-3"
      id="ixv-19454"
      unitRef="usd">693000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="c197"
      decimals="-3"
      id="ixv-19455"
      unitRef="usd">2301000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="c198"
      decimals="-3"
      id="ixv-19456"
      unitRef="usd">1813000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="c199"
      decimals="-3"
      id="ixv-19457"
      unitRef="usd">1419000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c0" id="ixv-18598">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;The movement of the valuation allowance (through income statement) is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt"&gt;&lt;b&gt;U.S. dollars in thousands&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Balance at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;4,829&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;3,016&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;1,607&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Addition of valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,301&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,409&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Net change in the valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,301&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,813&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,409&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Balance at the end of the year&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;7,130&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;4,829&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;3,016&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c5" decimals="-3" id="ixv-19458" unitRef="usd">4829000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c18" decimals="-3" id="ixv-19459" unitRef="usd">3016000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c11" decimals="-3" id="ixv-19460" unitRef="usd">1607000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c0" decimals="-3" id="ixv-19461" unitRef="usd">2301000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c6" decimals="-3" id="ixv-19462" unitRef="usd">1813000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c7" decimals="-3" id="ixv-19463" unitRef="usd">1409000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c0" decimals="-3" id="ixv-19464" unitRef="usd">2301000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c6" decimals="-3" id="ixv-19465" unitRef="usd">1813000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c7" decimals="-3" id="ixv-19466" unitRef="usd">1409000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="-3" id="ixv-19467" unitRef="usd">7130000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c5" decimals="-3" id="ixv-19468" unitRef="usd">4829000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c18" decimals="-3" id="ixv-19469" unitRef="usd">3016000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-18722">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Note 17 - Subsequent Events &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of the date hereof, the Company sold 444,216 of it&#x2019;s ordinary shares pursuant to the Sales Agreement for aggregate gross proceeds of approximately $509.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 31, 2025, the Company&#x2019;s board of directors approved the grant of aggregate amount of 108,000 options to several employees. The options have an exercise price of $0.93 per share. The options vest quarterly over three years and expire 10 years after grant date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 31, 2025, the Company&#x2019;s board of directors approved the grant of an aggregate amount of 355,512 RSUs to several consultants and service providers. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 31, 2025, the Company&#x2019;s board of directors approved the grant of an aggregate amount of 20,000 options to several consultants. The options have an exercise price of $0.93 per share. The options vest over one year and expire 10 years after grant date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c0"
      decimals="0"
      id="ixv-19470"
      unitRef="shares">444216</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c0" decimals="-3" id="ixv-19471" unitRef="usd">509000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c201"
      decimals="0"
      id="ixv-19472"
      unitRef="shares">108000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c202"
      decimals="2"
      id="ixv-19473"
      unitRef="usdPershares">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c201" id="ixv-19474">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c201" id="ixv-19475">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c203"
      decimals="0"
      id="ixv-19476"
      unitRef="shares">355512</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c204"
      decimals="0"
      id="ixv-19477"
      unitRef="shares">20000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c205"
      decimals="2"
      id="ixv-19478"
      unitRef="usdPershares">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c204" id="ixv-19479">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c204" id="ixv-19481">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c4"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c4"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="c4"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="c4"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="c5"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="c4"
      id="hidden-fact-5"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="c5"
      id="hidden-fact-6"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c8"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="c12"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="c14"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c12"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c14"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c12"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c14"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c12"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c13"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c15"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet
      contextRef="c19"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet
      contextRef="c21"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:StockIssuedDuringPeriodValuePre-fundedWarrantsExercised
      contextRef="c19"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:StockIssuedDuringPeriodValuePre-fundedWarrantsExercised
      contextRef="c20"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:StockIssuedDuringPeriodValuePre-fundedWarrantsExercised
      contextRef="c21"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:StockIssuedDuringPeriodValuePre-fundedWarrantsExercised
      contextRef="c6"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c19"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c21"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c19"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c20"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c22"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet
      contextRef="c25"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesAndPrefundedWarrantsNet
      contextRef="c27"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:StockIssuedDuringPeriodValuePre-fundedWarrantsExercised
      contextRef="c25"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:StockIssuedDuringPeriodValuePre-fundedWarrantsExercised
      contextRef="c27"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement
      contextRef="c25"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:StockIssuedDuringPeriodValueIssuanceOfSharesDueToSEPAAagreement
      contextRef="c27"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="c25"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity
      contextRef="c25"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:StockIssuedDuringPeriodValueBonusAccrualReclassificationToEquity
      contextRef="c27"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c25"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c27"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c25"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c26"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c28"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:RevaluationOfLiabilityInRespectToWarrants
      contextRef="c7"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:RedemptionofinvestmentInShorttermDeposits
      contextRef="c0"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfOtherEquity
      contextRef="c0"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfOtherEquity
      contextRef="c6"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="c7"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="c7"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:ReclassificationOfWarrantsIntoEquity
      contextRef="c6"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:ReclassificationOfWarrantsIntoEquity
      contextRef="c7"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:BonusAccrualReclassificationToEquity
      contextRef="c6"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:BonusAccrualReclassificationToEquity
      contextRef="c7"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c0"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c6"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration contextRef="c35" id="hidden-fact-55">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c39"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Supplies
      contextRef="c5"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="c44"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="c45"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c42"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
      contextRef="c45"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c35"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="c52"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c49"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1
      contextRef="c52"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c42"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c4" id="hidden-fact-67">http://fasb.org/us-gaap/2024#LiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c4"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="c4"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c58"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c60"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c65"
      id="hidden-fact-72"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c66"
      id="hidden-fact-73"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c68"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c72"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="c4"
      id="hidden-fact-76"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="c5"
      id="hidden-fact-77"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="hidden-fact-78"
      unitRef="shares">15379042</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="hidden-fact-79"
      unitRef="shares">23228941</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c0"
      id="hidden-fact-80"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c4"
      id="hidden-fact-81"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharePrice
      contextRef="c4"
      id="hidden-fact-82"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c0"
      id="hidden-fact-83"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c0"
      id="hidden-fact-84"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0" id="hidden-fact-85" xsi:nil="true"/>
    <nrsn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingContractualLifeForfeited contextRef="c183" id="hidden-fact-86" xsi:nil="true"/>
    <nrsn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIntrinsicValueForfeited
      contextRef="c184"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c184"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c184"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c7"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:ExchangeRates
      contextRef="c0"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <nrsn:ExchangeRates
      contextRef="c7"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="c7"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ExchangeFees
      contextRef="c6"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c4"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c5"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-19581">0001875091</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-19582">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-19583">FY</dei:DocumentFiscalPeriodFocus>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#hidden-fact-56"
          xlink:label="hidden-fact-56"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Including short term bank deposit for a period of 1-2 months
at an interest rate of 5%.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-56"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-60"
          xlink:label="hidden-fact-60"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-61"
          xlink:label="hidden-fact-61"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-65"
          xlink:label="hidden-fact-65"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-66"
          xlink:label="hidden-fact-66"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-62"
          xlink:label="hidden-fact-62"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
than $1 thousand.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-60"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-61"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-65"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-66"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-62"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">see Note 14 regarding waiver signed of bonus accrual.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During 2024, 2023 and 2022, the Company paid to pension funds
and to insurance companies an amount of $115 thousand, $104 thousand and $85 thousand which are included in Company&#x2019;s salary expenses
under research and development and general and administrative expenses, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
